ID   GRIA2_RAT               Reviewed;         883 AA.
AC   P19491; Q9R174;
DT   01-FEB-1991, integrated into UniProtKB/Swiss-Prot.
DT   15-JUL-1998, sequence version 2.
DT   17-FEB-2016, entry version 184.
DE   RecName: Full=Glutamate receptor 2;
DE            Short=GluR-2;
DE   AltName: Full=AMPA-selective glutamate receptor 2;
DE   AltName: Full=GluR-B;
DE   AltName: Full=GluR-K2;
DE   AltName: Full=Glutamate receptor ionotropic, AMPA 2;
DE            Short=GluA2;
DE   Flags: Precursor;
GN   Name=Gria2; Synonyms=Glur2;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS FLIP AND FLOP).
RC   TISSUE=Brain;
RX   PubMed=2166337; DOI=10.1126/science.2166337;
RA   Keinaenen K., Wisden W., Sommer B., Werner P., Herb A., Verdoorn T.A.,
RA   Sakmann B., Seeburg P.H.;
RT   "A family of AMPA-selective glutamate receptors.";
RL   Science 249:556-560(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM FLOP).
RX   PubMed=2168579; DOI=10.1126/science.2168579;
RA   Boulter J., Hollmann M., O'Shea-Greenfield A., Hartley M.,
RA   Deneris E.S., Maron C., Heinemann S.F.;
RT   "Molecular cloning and functional expression of glutamate receptor
RT   subunit genes.";
RL   Science 249:1033-1037(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM FLIP).
RC   TISSUE=Brain cortex, and Hippocampus;
RX   PubMed=1699567; DOI=10.1016/0896-6273(90)90212-X;
RA   Nakanishi N., Schneider N.A., Axel R.;
RT   "A family of glutamate receptor genes: evidence for the formation of
RT   heteromultimeric receptors with distinct channel properties.";
RL   Neuron 5:569-581(1990).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM FLIP), AND FUNCTION.
RC   STRAIN=Sprague-Dawley;
RX   PubMed=9351977; DOI=10.1124/mol.52.5.861;
RA   Everts I., Villmann C., Hollmann M.;
RT   "N-glycosylation is not a prerequisite for glutamate receptor function
RT   but is essential for lectin modulation.";
RL   Mol. Pharmacol. 52:861-873(1997).
RN   [5]
RP   RNA EDITING OF POSITION 607.
RX   PubMed=1717158; DOI=10.1016/0092-8674(91)90568-J;
RA   Sommer B., Koehler M., Sprengel R., Seeburg P.H.;
RT   "RNA editing in brain controls a determinant of ion flow in glutamate-
RT   gated channels.";
RL   Cell 67:11-19(1991).
RN   [6]
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, INTERACTION WITH NSF,
RP   IDENTIFICATION IN A COMPLEX WITH NSF; NAPA AND NAPB, AND MUTAGENESIS
RP   OF 851-ASN-PRO-852.
RX   PubMed=9697855; DOI=10.1016/S0896-6273(00)80518-8;
RA   Osten P., Srivastava S., Inman G.J., Vilim F.S., Khatri L., Lee L.M.,
RA   States B.A., Einheber S., Milner T.A., Hanson P.I., Ziff E.B.;
RT   "The AMPA receptor GluR2 C terminus can mediate a reversible, ATP-
RT   dependent interaction with NSF and alpha- and beta-SNAPs.";
RL   Neuron 21:99-110(1998).
RN   [7]
RP   INTERACTION WITH PRKCABP.
RX   PubMed=10027300; DOI=10.1016/S0896-6273(00)80689-3;
RA   Xia J., Zhang X., Staudinger J., Huganir R.L.;
RT   "Clustering of AMPA receptors by the synaptic PDZ domain-containing
RT   protein PICK1.";
RL   Neuron 22:179-187(1999).
RN   [8]
RP   ALTERNATIVE SPLICING (ISOFORMS FLIP AND FLOP).
RX   PubMed=1699275; DOI=10.1126/science.1699275;
RA   Sommer B., Keinaenen K., Verdoorn T.A., Wisden W., Burnashev N.,
RA   Herb A., Koehler M., Takagi T., Sakmann B., Seeburg P.H.;
RT   "Flip and flop: a cell-specific functional switch in glutamate-
RT   operated channels of the CNS.";
RL   Science 249:1580-1585(1990).
RN   [9]
RP   PHOSPHORYLATION AT SER-683 AND SER-717.
RX   PubMed=8848293; DOI=10.1016/0168-0102(95)00977-9;
RA   Nakazawa K., Tadakuma T., Nokihara K., Ito M.;
RT   "Antibody specific for phosphorylated AMPA-type glutamate receptors at
RT   GluR2 Ser-696.";
RL   Neurosci. Res. 24:75-86(1995).
RN   [10]
RP   INTERACTION WITH GRIP1.
RC   TISSUE=Hippocampus;
RX   PubMed=9069286; DOI=10.1038/386279a0;
RA   Dong H., O'Brien R.J., Fung E.T., Lanahan A.A., Worley P.F.,
RA   Huganir R.L.;
RT   "GRIP: a synaptic PDZ domain-containing protein that interacts with
RT   AMPA receptors.";
RL   Nature 386:279-284(1997).
RN   [11]
RP   INTERACTION WITH GRIP2.
RX   PubMed=10414981;
RA   Wyszynski M., Valtschanoff J.G., Naisbitt S., Dunah A.W., Kim E.,
RA   Standaert D.G., Weinberg R., Sheng M.;
RT   "Association of AMPA receptors with a subset of glutamate receptor-
RT   interacting protein in vivo.";
RL   J. Neurosci. 19:6528-6537(1999).
RN   [12]
RP   IDENTIFICATION OF ISOFORM 3, SUBCELLULAR LOCATION, DEVELOPMENTAL
RP   STAGE, AND TISSUE SPECIFICITY.
RX   PubMed=14687553; DOI=10.1016/S0896-6273(03)00722-0;
RA   Kolleker A., Zhu J.J., Schupp B.J., Qin Y., Mack V., Borchardt T.,
RA   Koehr G., Malinow R., Seeburg P.H., Osten P.;
RT   "Glutamatergic plasticity by synaptic delivery of GluR-B(long)-
RT   containing AMPA receptors.";
RL   Neuron 40:1199-1212(2003).
RN   [13]
RP   PHOSPHORYLATION AT TYR-876, AND TISSUE SPECIFICITY.
RX   PubMed=15240807; DOI=10.1523/JNEUROSCI.0799-04.2004;
RA   Hayashi T., Huganir R.L.;
RT   "Tyrosine phosphorylation and regulation of the AMPA receptor by SRC
RT   family tyrosine kinases.";
RL   J. Neurosci. 24:6152-6160(2004).
RN   [14]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH CACNG2.
RX   PubMed=16793768; DOI=10.1074/jbc.M600679200;
RA   Bedoukian M.A., Weeks A.M., Partin K.M.;
RT   "Different domains of the AMPA receptor direct stargazin-mediated
RT   trafficking and stargazin-mediated modulation of kinetics.";
RL   J. Biol. Chem. 281:23908-23921(2006).
RN   [15]
RP   INTERACTION WITH LRFN1.
RX   PubMed=16630835; DOI=10.1016/j.neuron.2006.04.005;
RA   Ko J., Kim S., Chung H.S., Kim K., Han K., Kim H., Jun H.,
RA   Kaang B.-K., Kim E.;
RT   "SALM synaptic cell adhesion-like molecules regulate the
RT   differentiation of excitatory synapses.";
RL   Neuron 50:233-245(2006).
RN   [16]
RP   INTERACTION WITH CACNG5.
RX   PubMed=18817736; DOI=10.1016/j.neuron.2008.07.034;
RA   Kato A.S., Siuda E.R., Nisenbaum E.S., Bredt D.S.;
RT   "AMPA receptor subunit-specific regulation by a distinct family of
RT   type II TARPs.";
RL   Neuron 59:986-996(2008).
RN   [17]
RP   INTERACTION WITH CACNG5.
RX   PubMed=19234459; DOI=10.1038/nn.2266;
RA   Soto D., Coombs I.D., Renzi M., Zonouzi M., Farrant M.,
RA   Cull-Candy S.G.;
RT   "Selective regulation of long-form calcium-permeable AMPA receptors by
RT   an atypical TARP, gamma-5.";
RL   Nat. Neurosci. 12:277-285(2009).
RN   [18]
RP   ERRATUM.
RX   DOI=10.1038/nn0609-808c;
RA   Soto D., Coombs I.D., Renzi M., Zonouzi M., Farrant M.,
RA   Cull-Candy S.G.;
RL   Nat. Neurosci. 12:808-808(2009).
RN   [19]
RP   FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=19265014; DOI=10.1126/science.1167852;
RA   Schwenk J., Harmel N., Zolles G., Bildl W., Kulik A., Heimrich B.,
RA   Chisaka O., Jonas P., Schulte U., Fakler B., Kloecker N.;
RT   "Functional proteomics identify cornichon proteins as auxiliary
RT   subunits of AMPA receptors.";
RL   Science 323:1313-1319(2009).
RN   [20]
RP   FUNCTION.
RX   PubMed=21172611; DOI=10.1016/j.neuron.2010.11.026;
RA   Kato A.S., Gill M.B., Ho M.T., Yu H., Tu Y., Siuda E.R., Wang H.,
RA   Qian Y.W., Nisenbaum E.S., Tomita S., Bredt D.S.;
RT   "Hippocampal AMPA receptor gating controlled by both TARP and
RT   cornichon proteins.";
RL   Neuron 68:1082-1096(2010).
RN   [21]
RP   INTERACTION WITH ATAD1 AND GRIP1.
RX   PubMed=21496646; DOI=10.1016/j.cell.2011.03.016;
RA   Zhang J., Wang Y., Chi Z., Keuss M.J., Pai Y.M., Kang H.C., Shin J.H.,
RA   Bugayenko A., Wang H., Xiong Y., Pletnikov M.V., Mattson M.P.,
RA   Dawson T.M., Dawson V.L.;
RT   "The AAA+ ATPase Thorase regulates AMPA receptor-dependent synaptic
RT   plasticity and behavior.";
RL   Cell 145:284-299(2011).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 404-796 IN COMPLEX WITH
RP   KAINATE.
RX   PubMed=9804426; DOI=10.1038/27692;
RA   Armstrong N., Sun Y., Chen G.Q., Gouaux E.;
RT   "Structure of a glutamate-receptor ligand-binding core in complex with
RT   kainate.";
RL   Nature 395:913-917(1998).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 413-796 IN COMPLEXES WITH
RP   GLUTAMATE; AMPA; KAINATE; DNQX AND ZINC.
RX   PubMed=11086992; DOI=10.1016/S0896-6273(00)00094-5;
RA   Armstrong N., Gouaux E.;
RT   "Mechanisms for activation and antagonism of an AMPA-sensitive
RT   glutamate receptor: crystal structures of the GluR2 ligand binding
RT   core.";
RL   Neuron 28:165-181(2000).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 413-796 IN COMPLEX WITH
RP   QUISQUALATE, AND FUNCTION.
RX   PubMed=12501192; DOI=10.1021/bi020583k;
RA   Jin R., Horning M., Mayer M.L., Gouaux E.;
RT   "Mechanism of activation and selectivity in a ligand-gated ion
RT   channel: structural and functional studies of GluR2 and quisqualate.";
RL   Biochemistry 41:15635-15643(2002).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (1.46 ANGSTROMS) OF 413-796 IN COMPLEXES WITH
RP   ACPA AND BR-HIBO.
RX   PubMed=12215417; DOI=10.1016/S0022-2836(02)00650-2;
RA   Hogner A., Kastrup J.S., Jin R., Liljefors T., Mayer M.L.,
RA   Egebjerg J., Larsen I.K., Gouaux E.;
RT   "Structural basis for AMPA receptor activation and ligand selectivity:
RT   crystal structures of five agonist complexes with the GluR2 ligand-
RT   binding core.";
RL   J. Mol. Biol. 322:93-109(2002).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 413-796 IN COMPLEXES WITH
RP   AMPA; DNQX AND KAINATE, FUNCTION, SUBUNIT, AND MUTAGENESIS OF LEU-504
RP   AND ASN-775.
RX   PubMed=12015593; DOI=10.1038/417245a;
RA   Sun Y., Olson R., Horning M., Armstrong N., Mayer M., Gouaux E.;
RT   "Mechanism of glutamate receptor desensitization.";
RL   Nature 417:245-253(2002).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 413-796 IN COMPLEXES WITH
RP   ATPA AND ZINC IONS.
RX   PubMed=12593667; DOI=10.1021/jm021020+;
RA   Lunn M.-L., Hogner A., Stensboel T.B., Gouaux E., Egebjerg J.,
RA   Kastrup J.S.;
RT   "Three-dimensional structure of the ligand-binding core of GluR2 in
RT   complex with the agonist (S)-ATPA: implications for receptor subunit
RT   selectivity.";
RL   J. Med. Chem. 46:872-875(2003).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (1.35 ANGSTROMS) OF 413-796 IN COMPLEXES WITH
RP   WILLARDIINES, AND FUNCTION.
RX   PubMed=12872125; DOI=10.1038/nn1091;
RA   Jin R., Banke T.G., Mayer M.L., Traynelis S.F., Gouaux E.;
RT   "Structural basis for partial agonist action at ionotropic glutamate
RT   receptors.";
RL   Nat. Neurosci. 6:803-810(2003).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 413-796 IN COMPLEXES WITH
RP   AMPA; KAINATE AND QUISQUALATE, AND FUNCTION.
RX   PubMed=12730367; DOI=10.1073/pnas.1037393100;
RA   Armstrong N., Mayer M., Gouaux E.;
RT   "Tuning activation of the AMPA-sensitive GluR2 ion channel by genetic
RT   adjustment of agonist-induced conformational changes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:5736-5741(2003).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 413-796 IN COMPLEXES WITH
RP   ANIRACETAM AND CX614, AND FUNCTION.
RX   PubMed=16192394; DOI=10.1523/JNEUROSCI.2567-05.2005;
RA   Jin R., Clark S., Weeks A.M., Dudman J.T., Gouaux E., Partin K.M.;
RT   "Mechanism of positive allosteric modulators acting on AMPA
RT   receptors.";
RL   J. Neurosci. 25:9027-9036(2005).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 413-796 IN COMPLEXES WITH
RP   CPW399 AND KAINATE, AND FUNCTION.
RX   PubMed=15591246; DOI=10.1124/mol.104.002931;
RA   Frandsen A., Pickering D.S., Vestergaard B., Kasper C., Nielsen B.B.,
RA   Greenwood J.R., Campiani G., Fattorusso C., Gajhede M., Schousboe A.,
RA   Kastrup J.S.;
RT   "Tyr702 is an important determinant of agonist binding and domain
RT   closure of the ligand-binding core of GluR2.";
RL   Mol. Pharmacol. 67:703-713(2005).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 413-794, FUNCTION, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=17018279; DOI=10.1016/j.cell.2006.08.037;
RA   Armstrong N., Jasti J., Beich-Frandsen M., Gouaux E.;
RT   "Measurement of conformational changes accompanying desensitization in
RT   an ionotropic glutamate receptor.";
RL   Cell 127:85-97(2006).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (2.65 ANGSTROMS) OF 413-796 IN COMPLEX WITH
RP   GLUTAMATE AND S1209, AND FUNCTION.
RX   PubMed=16483599; DOI=10.1016/j.jmb.2006.01.024;
RA   Kasper C., Pickering D.S., Mirza O., Olsen L., Kristensen A.S.,
RA   Greenwood J.R., Liljefors T., Schousboe A., Waetjen F., Gajhede M.,
RA   Sigurskjold B.W., Kastrup J.S.;
RT   "The structure of a mixed GluR2 ligand-binding core dimer in complex
RT   with (S)-glutamate and the antagonist (S)-NS1209.";
RL   J. Mol. Biol. 357:1184-1201(2006).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (3.6 ANGSTROMS) OF 25-847 IN COMPLEX WITH
RP   GLUTAMATE ANALOG, X-RAY CRYSTALLOGRAPHY (1.55 ANGSTROMS) OF 413-796,
RP   FUNCTION, SUBUNIT, MEMBRANE TOPOLOGY, AND GLYCOSYLATION AT ASN-370.
RX   PubMed=19946266; DOI=10.1038/nature08624;
RA   Sobolevsky A.I., Rosconi M.P., Gouaux E.;
RT   "X-ray structure, symmetry and mechanism of an AMPA-subtype glutamate
RT   receptor.";
RL   Nature 462:745-756(2009).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 25-400, FUNCTION, SUBUNIT,
RP   DISULFIDE BOND, AND GLYCOSYLATION AT ASN-256 AND ASN-370.
RX   PubMed=21317873; DOI=10.1038/emboj.2011.16;
RA   Rossmann M., Sukumaran M., Penn A.C., Veprintsev D.B., Babu M.M.,
RA   Greger I.H.;
RT   "Subunit-selective N-terminal domain associations organize the
RT   formation of AMPA receptor heteromers.";
RL   EMBO J. 30:959-971(2011).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (1.82 ANGSTROMS) OF 414-794 IN COMPLEXES WITH
RP   GLUTAMATE; IODOWILLARDIINE AND KAINATE, FUNCTION, AND DISULFIDE BONDS.
RX   PubMed=21846932; DOI=10.1074/jbc.M111.269001;
RA   Ahmed A.H., Wang S., Chuang H.H., Oswald R.E.;
RT   "Mechanism of AMPA receptor activation by partial agonists: disulfide
RT   trapping of closed lobe conformations.";
RL   J. Biol. Chem. 286:35257-35266(2011).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (3.50 ANGSTROMS) OF 25-850 IN COMPLEXES WITH
RP   KAINATE; FLUORAWILLARDINE AND THE CONE SNAIL TOXIN CON-IKOT-IKOT,
RP   DISULFIDE BOND, GLYCOSYLATION AT ASN-370, AND SITES ARG-474; ILE-654;
RP   ARG-681 AND LYS-773.
RX   PubMed=25103405; DOI=10.1126/science.1258409;
RA   Chen L., Durr K.L., Gouaux E.;
RT   "X-ray structures of AMPA receptor-cone snail toxin complexes
RT   illuminate activation mechanism.";
RL   Science 345:1021-1026(2014).
CC   -!- FUNCTION: Receptor for glutamate that functions as ligand-gated
CC       ion channel in the central nervous system and plays an important
CC       role in excitatory synaptic transmission. L-glutamate acts as an
CC       excitatory neurotransmitter at many synapses in the central
CC       nervous system. Binding of the excitatory neurotransmitter L-
CC       glutamate induces a conformation change, leading to the opening of
CC       the cation channel, and thereby converts the chemical signal to an
CC       electrical impulse. The receptor then desensitizes rapidly and
CC       enters a transient inactive state, characterized by the presence
CC       of bound agonist. In the presence of CACNG4 or CACNG7 or CACNG8,
CC       shows resensitization which is characterized by a delayed
CC       accumulation of current flux upon continued application of
CC       glutamate. {ECO:0000269|PubMed:12015593,
CC       ECO:0000269|PubMed:12501192, ECO:0000269|PubMed:12730367,
CC       ECO:0000269|PubMed:12872125, ECO:0000269|PubMed:15591246,
CC       ECO:0000269|PubMed:16192394, ECO:0000269|PubMed:16483599,
CC       ECO:0000269|PubMed:17018279, ECO:0000269|PubMed:19265014,
CC       ECO:0000269|PubMed:19946266, ECO:0000269|PubMed:21172611,
CC       ECO:0000269|PubMed:21317873, ECO:0000269|PubMed:21846932,
CC       ECO:0000269|PubMed:9351977}.
CC   -!- SUBUNIT: Homotetramer or heterotetramer of pore-forming glutamate
CC       receptor subunits. Tetramers may be formed by the dimerization of
CC       dimers. May interact with MPP4. Forms a ternary complex with GRIP1
CC       and CSPG4 (By similarity). Interacts with ATAD1 in an ATP-
CC       dependent manner. ATAD1-catalyzed ATP hydrolysis disrupts binding
CC       to ATAD1 and to GRIP1 and leads to AMPAR complex disassembly.
CC       Interacts with NSF via its C-terminus. Interacts with CACNG2,
CC       PRKCABP and GRIP2. Part of a complex containing GRIA2, NSF and
CC       NAPA and/or NAPB. Interacts with PICK1 (via PDZ domain) (By
CC       similarity). Interacts with GRIA1 and SYNDIG1. Interacts with
CC       SNX27 (via PDZ domain); the interaction is required for recycling
CC       to the plasma membrane when endocytosed and prevent degradation in
CC       lysosomes (By similarity). Interacts with LRFN1. Found in a
CC       complex with GRIA3, GRIA4, CNIH2, CNIH3, CACNG2, CACNG3, CACNG4,
CC       CACNG5, CACNG7 and CACNG8. Interacts with CACNG5. Interacts with
CC       OLFM2 (By similarity). {ECO:0000250|UniProtKB:P23819,
CC       ECO:0000269|PubMed:10027300, ECO:0000269|PubMed:10414981,
CC       ECO:0000269|PubMed:12015593, ECO:0000269|PubMed:12501192,
CC       ECO:0000269|PubMed:16483599, ECO:0000269|PubMed:16630835,
CC       ECO:0000269|PubMed:16793768, ECO:0000269|PubMed:18817736,
CC       ECO:0000269|PubMed:19234459, ECO:0000269|PubMed:19265014,
CC       ECO:0000269|PubMed:19946266, ECO:0000269|PubMed:21317873,
CC       ECO:0000269|PubMed:21496646, ECO:0000269|PubMed:9069286,
CC       ECO:0000269|PubMed:9697855, ECO:0000269|PubMed:9804426}.
CC   -!- INTERACTION:
CC       Self; NbExp=9; IntAct=EBI-77718, EBI-77718;
CC       Q8CGU4:Agap2; NbExp=4; IntAct=EBI-77718, EBI-4409108;
CC       Q505J9:Atad1; NbExp=3; IntAct=EBI-77718, EBI-4280289;
CC       Q71RJ2:Cacng2; NbExp=2; IntAct=EBI-77718, EBI-8538384;
CC       P19490:Gria1; NbExp=3; IntAct=EBI-77718, EBI-371642;
CC       P97879:Grip1; NbExp=15; IntAct=EBI-77718, EBI-936113;
CC       Q9WTW1-3:Grip2; NbExp=7; IntAct=EBI-77718, EBI-936068;
CC       P49185:Mapk8; NbExp=2; IntAct=EBI-9118256, EBI-7456505;
CC       Q9QUL6:Nsf; NbExp=5; IntAct=EBI-77718, EBI-925794;
CC       Q9EP80:Pick1; NbExp=12; IntAct=EBI-77718, EBI-77728;
CC       Q13136:PPFIA1 (xeno); NbExp=2; IntAct=EBI-77718, EBI-745426;
CC       Q91Z80:Ppfia4; NbExp=3; IntAct=EBI-77718, EBI-8276907;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC       Endoplasmic reticulum membrane; Multi-pass membrane protein. Cell
CC       junction, synapse, postsynaptic cell membrane; Multi-pass membrane
CC       protein. Note=Interaction with CACNG2, CNIH2 and CNIH3 promotes
CC       cell surface expression.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=Flop;
CC         IsoId=P19491-1; Sequence=Displayed;
CC       Name=Flip;
CC         IsoId=P19491-2; Sequence=VSP_000111, VSP_000112, VSP_000113,
CC                                  VSP_000114;
CC       Name=3; Synonyms=Long;
CC         IsoId=P19491-3; Sequence=VSP_029310;
CC   -!- TISSUE SPECIFICITY: Detected in forebrain. Detected in dendrites
CC       of neuronal cells. {ECO:0000269|PubMed:14687553,
CC       ECO:0000269|PubMed:15240807, ECO:0000269|PubMed:9697855}.
CC   -!- DEVELOPMENTAL STAGE: Detected at low levels in newborns. Levels
CC       increase strongly and are highest in hippocampus from 8 to 14 day
CC       old animals. Detected at intermediate levels at day 42 (at protein
CC       level). {ECO:0000269|PubMed:14687553}.
CC   -!- DOMAIN: The M4 transmembrane segment mediates tetramerization and
CC       is required for cell surface expression. {ECO:0000250}.
CC   -!- PTM: Palmitoylated. Depalmitoylated upon glutamate stimulation.
CC       Cys-610 palmitoylation leads to Golgi retention and decreased cell
CC       surface expression. In contrast, Cys-836 palmitoylation does not
CC       affect cell surface expression but regulates stimulation-dependent
CC       endocytosis (By similarity). {ECO:0000250}.
CC   -!- RNA EDITING: Modified_positions=607 {ECO:0000269|PubMed:1717158};
CC       Note=Fully edited in the brain. Heteromerically expressed edited
CC       GLUR2 (R) receptor complexes are impermeable to calcium, whereas
CC       the unedited (Q) forms are highly permeable to divalent ions (By
CC       similarity). {ECO:0000250};
CC   -!- MISCELLANEOUS: The postsynaptic actions of Glu are mediated by a
CC       variety of receptors that are named according to their selective
CC       agonists. This receptor binds AMPA (quisqualate) > glutamate >
CC       kainate.
CC   -!- SIMILARITY: Belongs to the glutamate-gated ion channel
CC       (TC 1.A.10.1) family. GRIA2 subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M36419; AAA41244.1; -; mRNA.
DR   EMBL; M38061; AAC37652.1; -; mRNA.
DR   EMBL; M85035; AAA41240.1; -; mRNA.
DR   EMBL; X54655; CAA38465.1; -; mRNA.
DR   EMBL; AF164344; AAD51284.1; -; mRNA.
DR   PIR; S13677; S13677.
DR   RefSeq; NP_001077280.1; NM_001083811.1.
DR   RefSeq; NP_058957.1; NM_017261.2.
DR   UniGene; Rn.91361; -.
DR   PDB; 1FTJ; X-ray; 1.90 A; A/B/C=413-527, A/B/C=653-796.
DR   PDB; 1FTK; X-ray; 1.60 A; A=404-528, A=653-796.
DR   PDB; 1FTL; X-ray; 1.80 A; A/B=413-527, A/B=653-796.
DR   PDB; 1FTM; X-ray; 1.70 A; A/B/C=413-527, A/B/C=653-796.
DR   PDB; 1FTO; X-ray; 2.00 A; A/B=413-527, A/B=653-796.
DR   PDB; 1FW0; X-ray; 1.90 A; A=413-527, A=653-796.
DR   PDB; 1GR2; X-ray; 1.90 A; A=404-528, A=652-796.
DR   PDB; 1LB8; X-ray; 2.30 A; A/B=413-527, A/B=653-796.
DR   PDB; 1LB9; X-ray; 2.30 A; A/B=413-527, A/B=653-796.
DR   PDB; 1LBB; X-ray; 2.10 A; A=413-527, A=653-796.
DR   PDB; 1LBC; X-ray; 1.80 A; A/B/C=413-527, A/B/C=653-796.
DR   PDB; 1M5B; X-ray; 1.85 A; A/B/C=413-527, A/B/C=653-796.
DR   PDB; 1M5C; X-ray; 1.65 A; A=413-527, A=653-796.
DR   PDB; 1M5D; X-ray; 1.73 A; A=413-527, A=653-796.
DR   PDB; 1M5E; X-ray; 1.46 A; A/B/C=413-527, A/B/C=653-796.
DR   PDB; 1M5F; X-ray; 1.95 A; A/B/C=413-527, A/B/C=653-796.
DR   PDB; 1MM6; X-ray; 2.15 A; A/B=413-527, A/B=653-796.
DR   PDB; 1MM7; X-ray; 1.65 A; A/B/C=413-527, A/B/C=653-796.
DR   PDB; 1MQD; X-ray; 1.46 A; A/B/C/D=413-527, A/B/C/D=653-794.
DR   PDB; 1MQG; X-ray; 2.15 A; A/B=413-527, A/B=653-796.
DR   PDB; 1MQH; X-ray; 1.80 A; A=413-527, A=653-796.
DR   PDB; 1MQI; X-ray; 1.35 A; A=413-527, A=653-796.
DR   PDB; 1MQJ; X-ray; 1.65 A; A=413-527, A=653-796.
DR   PDB; 1MS7; X-ray; 1.97 A; A/B/C=413-527, A/B/C=653-796.
DR   PDB; 1MXU; X-ray; 1.80 A; A/B/C=413-527, A/B/C=653-796.
DR   PDB; 1MXV; X-ray; 1.95 A; A/B/C=413-527, A/B/C=653-796.
DR   PDB; 1MXW; X-ray; 1.90 A; A/B/C=413-527, A/B/C=653-796.
DR   PDB; 1MXX; X-ray; 2.00 A; A/B/C=413-527, A/B/C=653-796.
DR   PDB; 1MXY; X-ray; 1.95 A; A/B/C=413-527, A/B/C=653-796.
DR   PDB; 1MXZ; X-ray; 1.90 A; A/B/C=413-527, A/B/C=653-796.
DR   PDB; 1MY0; X-ray; 1.90 A; A/B/C=413-527, A/B/C=653-796.
DR   PDB; 1MY1; X-ray; 1.90 A; A/B/C=413-527, A/B/C=653-796.
DR   PDB; 1MY2; X-ray; 1.80 A; A/B/C=413-527, A/B/C=653-796.
DR   PDB; 1MY3; X-ray; 1.75 A; A/B/C=413-527, A/B/C=653-796.
DR   PDB; 1MY4; X-ray; 1.90 A; A/B/C=413-527, A/B/C=653-796.
DR   PDB; 1N0T; X-ray; 2.10 A; A/B/C/D=413-527, A/B/C/D=653-796.
DR   PDB; 1NNK; X-ray; 1.85 A; A=413-527, A=653-796.
DR   PDB; 1NNP; X-ray; 1.90 A; A/B=413-527, A/B=653-796.
DR   PDB; 1P1N; X-ray; 1.60 A; A=413-527, A=653-796.
DR   PDB; 1P1O; X-ray; 1.60 A; A=413-527, A=653-796.
DR   PDB; 1P1Q; X-ray; 2.00 A; A/B/C=413-527, A/B/C=653-796.
DR   PDB; 1P1U; X-ray; 2.00 A; A/B=413-527, A/B=653-796.
DR   PDB; 1P1W; X-ray; 1.80 A; A/B=413-527, A/B=653-796.
DR   PDB; 1SYH; X-ray; 1.80 A; A=413-527, A=653-796.
DR   PDB; 1SYI; X-ray; 2.10 A; A/B=413-527, A/B=653-796.
DR   PDB; 1WVJ; X-ray; 1.75 A; A=413-527, A=653-796.
DR   PDB; 1XHY; X-ray; 1.85 A; A=413-527, A=653-796.
DR   PDB; 2AIX; X-ray; 2.17 A; A=413-527, A=653-796.
DR   PDB; 2AL4; X-ray; 1.70 A; A/B/C/D/E/F=413-527, A/B/C/D/E/F=653-796.
DR   PDB; 2AL5; X-ray; 1.65 A; A/B=413-527, A/B=653-796.
DR   PDB; 2ANJ; X-ray; 2.10 A; A=413-527, A=653-796.
DR   PDB; 2CMO; X-ray; 2.65 A; A/B=413-527, A/B=653-796.
DR   PDB; 2GFE; X-ray; 1.54 A; A/B/C=413-527, A/B/C=653-795.
DR   PDB; 2I3V; X-ray; 2.40 A; A/B/C/D=413-527, A/B/C/D=655-794.
DR   PDB; 2I3W; X-ray; 2.30 A; A/B=413-527, A/B=653-794.
DR   PDB; 2P2A; X-ray; 2.26 A; A/B=413-527, A/B=653-796.
DR   PDB; 2UXA; X-ray; 2.38 A; A/B/C=412-795.
DR   PDB; 2XX7; X-ray; 2.20 A; A/B/C=413-527, A/B/C=653-795.
DR   PDB; 2XX8; X-ray; 1.55 A; A/B/C=413-527, A/B/C=653-796.
DR   PDB; 2XX9; X-ray; 1.97 A; A/B/C=413-527, A/B/C=653-796.
DR   PDB; 2XXH; X-ray; 1.50 A; A/B/C=413-527, A/B/C=653-796.
DR   PDB; 2XXI; X-ray; 1.60 A; A/B/C=413-527, A/B/C=653-796.
DR   PDB; 3B6Q; X-ray; 2.00 A; A=413-527, A=653-796.
DR   PDB; 3B6T; X-ray; 2.10 A; A=413-527, A=653-796.
DR   PDB; 3B6W; X-ray; 1.70 A; A/B/C/D=413-527, A/B/C/D=653-796.
DR   PDB; 3B7D; X-ray; 2.50 A; A/B/C/D/E/F/G/H=413-527, A/B/C/D/E/F/G/H=653-794.
DR   PDB; 3BBR; X-ray; 2.25 A; A/B=413-527, A/B=653-796.
DR   PDB; 3BFT; X-ray; 2.27 A; A/B/C=413-527, A/B/C=653-796.
DR   PDB; 3BFU; X-ray; 1.95 A; A/B/C/D=413-527, A/B/C/D=653-796.
DR   PDB; 3BKI; X-ray; 1.87 A; B/C/D/P=413-527, B/C/D/P=653-796.
DR   PDB; 3DP6; X-ray; 1.55 A; A/B/C=413-527, A/B/C=653-794.
DR   PDB; 3H03; X-ray; 1.90 A; A/B/D/G=414-527, A/B/D/G=653-794.
DR   PDB; 3H06; X-ray; 2.80 A; B/E/G/H/J/L/N/P=414-527, B/E/G/H/J/L/N/P=653-794.
DR   PDB; 3H5V; X-ray; 2.33 A; A/B/C=21-404.
DR   PDB; 3H5W; X-ray; 2.69 A; A/B=21-404.
DR   PDB; 3H6T; X-ray; 2.25 A; A/B/C=413-527, A/B/C=653-796.
DR   PDB; 3H6U; X-ray; 1.85 A; A=413-527, A=653-796.
DR   PDB; 3H6V; X-ray; 2.10 A; A/B=413-527, A/B=653-796.
DR   PDB; 3H6W; X-ray; 1.49 A; A/B=413-527, A/B=653-796.
DR   PDB; 3HSY; X-ray; 1.75 A; A/B=25-400.
DR   PDB; 3IJO; X-ray; 2.00 A; B/E/H=414-527, B/E/H=653-794.
DR   PDB; 3IJX; X-ray; 2.88 A; B/D/H=414-527, B/D/H=653-794.
DR   PDB; 3IK6; X-ray; 2.10 A; B/E/H=414-527, B/E/H=653-794.
DR   PDB; 3IL1; X-ray; 2.00 A; B/E/H=414-527, B/E/H=653-794.
DR   PDB; 3ILT; X-ray; 2.11 A; B/E/H=414-527, B/E/H=653-794.
DR   PDB; 3ILU; X-ray; 2.00 A; B/E/H=414-527, B/E/H=653-794.
DR   PDB; 3KG2; X-ray; 3.60 A; A/B/C/D=25-412, A/B/C/D=414-847.
DR   PDB; 3KGC; X-ray; 1.55 A; A/B=414-527, A/B=654-795.
DR   PDB; 3LSF; X-ray; 1.85 A; B/E/H=414-527, B/E/H=653-794.
DR   PDB; 3LSL; X-ray; 2.12 A; A/D/G=414-527, A/D/G=653-794.
DR   PDB; 3M3L; X-ray; 1.85 A; A/D/G=414-794.
DR   PDB; 3N6V; X-ray; 3.20 A; A/B/C/D/E/F=27-400.
DR   PDB; 3O28; X-ray; 2.00 A; A=413-527, A=653-795.
DR   PDB; 3O29; X-ray; 2.02 A; A=413-527, A=653-795.
DR   PDB; 3O2A; X-ray; 1.90 A; A=413-527, A=653-795.
DR   PDB; 3O2J; X-ray; 1.95 A; A/B=22-400.
DR   PDB; 3O6G; X-ray; 1.80 A; A=413-527, A=653-795.
DR   PDB; 3O6H; X-ray; 2.10 A; A=413-527, A=653-795.
DR   PDB; 3O6I; X-ray; 1.80 A; A=413-527, A=653-795.
DR   PDB; 3PD8; X-ray; 2.48 A; A/B/C=413-527, A/B/C=653-795.
DR   PDB; 3PD9; X-ray; 2.10 A; A/B=413-527, A/B=653-795.
DR   PDB; 3PMV; X-ray; 1.80 A; A=413-527, A=653-795.
DR   PDB; 3PMW; X-ray; 2.20 A; A=413-527, A=653-795.
DR   PDB; 3PMX; X-ray; 1.87 A; A=413-527, A=653-795.
DR   PDB; 3RTF; X-ray; 1.70 A; B/D/F=414-527, B/D/F=653-794.
DR   PDB; 3RTW; X-ray; 2.10 A; B/D/F=414-527, B/D/F=653-794.
DR   PDB; 3T93; X-ray; 1.91 A; B/D/F=414-527, B/D/F=653-794.
DR   PDB; 3T96; X-ray; 1.87 A; B/D/F=414-527, B/D/F=653-794.
DR   PDB; 3T9H; X-ray; 2.02 A; B/D/F=414-527, B/D/F=653-794.
DR   PDB; 3T9U; X-ray; 1.97 A; A/B/C=414-527, A/B/C=653-794.
DR   PDB; 3T9V; X-ray; 1.98 A; A/B=414-527, A/B=653-794.
DR   PDB; 3T9X; X-ray; 1.82 A; B/D/F=414-527, B/D/F=653-794.
DR   PDB; 3TDJ; X-ray; 1.95 A; A/B=413-527, A/B=653-796.
DR   PDB; 3TKD; X-ray; 1.45 A; A/B=413-527, A/B=653-795.
DR   PDB; 3TZA; X-ray; 1.90 A; A/B=413-527, A/B=653-796.
DR   PDB; 4FAT; X-ray; 1.40 A; A=413-527, A=653-796.
DR   PDB; 4G8M; X-ray; 2.05 A; A/B=413-527, A/B=653-796.
DR   PDB; 4GXS; X-ray; 1.96 A; B/D=414-527, B/D=653-794.
DR   PDB; 4H8J; X-ray; 1.80 A; A/B/C/D=413-527, A/B/C/D=653-797.
DR   PDB; 4IGT; X-ray; 1.24 A; A=413-527, A=653-796.
DR   PDB; 4ISU; X-ray; 2.30 A; A/B/C/D=413-527, A/B/C/D=653-796.
DR   PDB; 4IY5; X-ray; 2.00 A; A/B=413-527, A/B=653-796.
DR   PDB; 4IY6; X-ray; 1.72 A; A=413-527, A=653-796.
DR   PDB; 4L17; X-ray; 2.80 A; A/C/E/G=413-527, A/C/E/G=653-796.
DR   PDB; 4LZ5; X-ray; 1.50 A; A/B/C=404-527, A/B/C=653-796.
DR   PDB; 4LZ7; X-ray; 2.10 A; A/B/C=404-527, A/B/C=653-796.
DR   PDB; 4LZ8; X-ray; 1.85 A; A/B/C=404-527, A/B/C=653-796.
DR   PDB; 4N07; X-ray; 1.87 A; A/B/C=413-527, A/B/C=653-796.
DR   PDB; 4O3A; X-ray; 1.80 A; A/B/C=413-527, A/B/C=653-796.
DR   PDB; 4O3B; X-ray; 1.91 A; A/B=413-527, A/B=653-796.
DR   PDB; 4O3C; X-ray; 1.50 A; A=413-527, A=653-796.
DR   PDB; 4Q30; X-ray; 2.03 A; B/D/F=414-527, B/D/F=653-794.
DR   PDB; 4U1O; X-ray; 1.85 A; A=413-527, A=653-796.
DR   PDB; 4U1W; X-ray; 3.25 A; A/B/C/D=25-412, A/B/C/D=414-622, A/B/C/D=624-847.
DR   PDB; 4U1X; X-ray; 3.30 A; A/B/C/D=25-412, A/B/C/D=414-555, A/B/C/D=557-602, A/B/C/D=604-622, A/B/C/D=624-847.
DR   PDB; 4U1Y; X-ray; 3.90 A; A/B/C/D=25-412, A/B/C/D=414-555, A/B/C/D=557-602, A/B/C/D=604-622, A/B/C/D=624-847.
DR   PDB; 4U1Z; X-ray; 1.94 A; A=413-527, A=653-796.
DR   PDB; 4U21; X-ray; 1.39 A; A/B=413-527, A/B=654-796.
DR   PDB; 4U22; X-ray; 1.44 A; A=413-527, A=653-796.
DR   PDB; 4U23; X-ray; 1.67 A; A=413-527, A=653-796.
DR   PDB; 4U2P; X-ray; 3.24 A; A/B/C/D=25-412, A/B/C/D=414-622, A/B/C/D=624-847.
DR   PDB; 4U2Q; X-ray; 3.52 A; A/B/C/D=25-412, A/B/C/D=414-622, A/B/C/D=624-847.
DR   PDB; 4U2R; X-ray; 1.41 A; A/B/C/D=413-527, A/B/C/D=653-796.
DR   PDB; 4U4F; X-ray; 4.79 A; A/B/C/D=25-412, A/B/C/D=414-847.
DR   PDB; 4U4G; X-ray; 4.49 A; A/B/C/D=25-412, A/B/C/D=414-847.
DR   PDB; 4U4S; X-ray; 1.90 A; A/B=413-527, A/B=653-796.
DR   PDB; 4U4X; X-ray; 1.56 A; A/B=413-527, A/B=653-796.
DR   PDB; 4U5B; X-ray; 3.50 A; A/B/C/D=25-412, A/B/C/D=414-555, A/B/C/D=557-602, A/B/C/D=604-622, A/B/C/D=624-850.
DR   PDB; 4U5C; X-ray; 3.69 A; A/B/C/D=25-412, A/B/C/D=414-555, A/B/C/D=557-602, A/B/C/D=604-622, A/B/C/D=624-850.
DR   PDB; 4U5D; X-ray; 3.58 A; A/B/C/D=25-412, A/B/C/D=414-555, A/B/C/D=557-602, A/B/C/D=604-622, A/B/C/D=624-850.
DR   PDB; 4U5E; X-ray; 3.51 A; A/B/C/D=25-412, A/B/C/D=414-555, A/B/C/D=557-602, A/B/C/D=604-622, A/B/C/D=624-850.
DR   PDB; 4U5F; X-ray; 3.70 A; A/B/C/D=25-412, A/B/C/D=414-850.
DR   PDB; 4UQ6; EM; 12.80 A; A/B/C/D=22-847.
DR   PDB; 4UQJ; EM; 10.40 A; A/B/C/D=22-847.
DR   PDB; 4UQK; EM; 16.40 A; A/B/C/D=22-847.
DR   PDB; 4X48; X-ray; 1.89 A; A/B/C=413-527, A/B/C=653-796.
DR   PDB; 4YMA; X-ray; 1.90 A; A/B=413-527, A/B=653-797.
DR   PDB; 5CBR; X-ray; 2.00 A; A=413-527, A=653-797.
DR   PDB; 5CBS; X-ray; 1.80 A; A/B/C/D=413-527, A/B/C/D=653-797.
DR   PDBsum; 1FTJ; -.
DR   PDBsum; 1FTK; -.
DR   PDBsum; 1FTL; -.
DR   PDBsum; 1FTM; -.
DR   PDBsum; 1FTO; -.
DR   PDBsum; 1FW0; -.
DR   PDBsum; 1GR2; -.
DR   PDBsum; 1LB8; -.
DR   PDBsum; 1LB9; -.
DR   PDBsum; 1LBB; -.
DR   PDBsum; 1LBC; -.
DR   PDBsum; 1M5B; -.
DR   PDBsum; 1M5C; -.
DR   PDBsum; 1M5D; -.
DR   PDBsum; 1M5E; -.
DR   PDBsum; 1M5F; -.
DR   PDBsum; 1MM6; -.
DR   PDBsum; 1MM7; -.
DR   PDBsum; 1MQD; -.
DR   PDBsum; 1MQG; -.
DR   PDBsum; 1MQH; -.
DR   PDBsum; 1MQI; -.
DR   PDBsum; 1MQJ; -.
DR   PDBsum; 1MS7; -.
DR   PDBsum; 1MXU; -.
DR   PDBsum; 1MXV; -.
DR   PDBsum; 1MXW; -.
DR   PDBsum; 1MXX; -.
DR   PDBsum; 1MXY; -.
DR   PDBsum; 1MXZ; -.
DR   PDBsum; 1MY0; -.
DR   PDBsum; 1MY1; -.
DR   PDBsum; 1MY2; -.
DR   PDBsum; 1MY3; -.
DR   PDBsum; 1MY4; -.
DR   PDBsum; 1N0T; -.
DR   PDBsum; 1NNK; -.
DR   PDBsum; 1NNP; -.
DR   PDBsum; 1P1N; -.
DR   PDBsum; 1P1O; -.
DR   PDBsum; 1P1Q; -.
DR   PDBsum; 1P1U; -.
DR   PDBsum; 1P1W; -.
DR   PDBsum; 1SYH; -.
DR   PDBsum; 1SYI; -.
DR   PDBsum; 1WVJ; -.
DR   PDBsum; 1XHY; -.
DR   PDBsum; 2AIX; -.
DR   PDBsum; 2AL4; -.
DR   PDBsum; 2AL5; -.
DR   PDBsum; 2ANJ; -.
DR   PDBsum; 2CMO; -.
DR   PDBsum; 2GFE; -.
DR   PDBsum; 2I3V; -.
DR   PDBsum; 2I3W; -.
DR   PDBsum; 2P2A; -.
DR   PDBsum; 2UXA; -.
DR   PDBsum; 2XX7; -.
DR   PDBsum; 2XX8; -.
DR   PDBsum; 2XX9; -.
DR   PDBsum; 2XXH; -.
DR   PDBsum; 2XXI; -.
DR   PDBsum; 3B6Q; -.
DR   PDBsum; 3B6T; -.
DR   PDBsum; 3B6W; -.
DR   PDBsum; 3B7D; -.
DR   PDBsum; 3BBR; -.
DR   PDBsum; 3BFT; -.
DR   PDBsum; 3BFU; -.
DR   PDBsum; 3BKI; -.
DR   PDBsum; 3DP6; -.
DR   PDBsum; 3H03; -.
DR   PDBsum; 3H06; -.
DR   PDBsum; 3H5V; -.
DR   PDBsum; 3H5W; -.
DR   PDBsum; 3H6T; -.
DR   PDBsum; 3H6U; -.
DR   PDBsum; 3H6V; -.
DR   PDBsum; 3H6W; -.
DR   PDBsum; 3HSY; -.
DR   PDBsum; 3IJO; -.
DR   PDBsum; 3IJX; -.
DR   PDBsum; 3IK6; -.
DR   PDBsum; 3IL1; -.
DR   PDBsum; 3ILT; -.
DR   PDBsum; 3ILU; -.
DR   PDBsum; 3KG2; -.
DR   PDBsum; 3KGC; -.
DR   PDBsum; 3LSF; -.
DR   PDBsum; 3LSL; -.
DR   PDBsum; 3M3L; -.
DR   PDBsum; 3N6V; -.
DR   PDBsum; 3O28; -.
DR   PDBsum; 3O29; -.
DR   PDBsum; 3O2A; -.
DR   PDBsum; 3O2J; -.
DR   PDBsum; 3O6G; -.
DR   PDBsum; 3O6H; -.
DR   PDBsum; 3O6I; -.
DR   PDBsum; 3PD8; -.
DR   PDBsum; 3PD9; -.
DR   PDBsum; 3PMV; -.
DR   PDBsum; 3PMW; -.
DR   PDBsum; 3PMX; -.
DR   PDBsum; 3RTF; -.
DR   PDBsum; 3RTW; -.
DR   PDBsum; 3T93; -.
DR   PDBsum; 3T96; -.
DR   PDBsum; 3T9H; -.
DR   PDBsum; 3T9U; -.
DR   PDBsum; 3T9V; -.
DR   PDBsum; 3T9X; -.
DR   PDBsum; 3TDJ; -.
DR   PDBsum; 3TKD; -.
DR   PDBsum; 3TZA; -.
DR   PDBsum; 4FAT; -.
DR   PDBsum; 4G8M; -.
DR   PDBsum; 4GXS; -.
DR   PDBsum; 4H8J; -.
DR   PDBsum; 4IGT; -.
DR   PDBsum; 4ISU; -.
DR   PDBsum; 4IY5; -.
DR   PDBsum; 4IY6; -.
DR   PDBsum; 4L17; -.
DR   PDBsum; 4LZ5; -.
DR   PDBsum; 4LZ7; -.
DR   PDBsum; 4LZ8; -.
DR   PDBsum; 4N07; -.
DR   PDBsum; 4O3A; -.
DR   PDBsum; 4O3B; -.
DR   PDBsum; 4O3C; -.
DR   PDBsum; 4Q30; -.
DR   PDBsum; 4U1O; -.
DR   PDBsum; 4U1W; -.
DR   PDBsum; 4U1X; -.
DR   PDBsum; 4U1Y; -.
DR   PDBsum; 4U1Z; -.
DR   PDBsum; 4U21; -.
DR   PDBsum; 4U22; -.
DR   PDBsum; 4U23; -.
DR   PDBsum; 4U2P; -.
DR   PDBsum; 4U2Q; -.
DR   PDBsum; 4U2R; -.
DR   PDBsum; 4U4F; -.
DR   PDBsum; 4U4G; -.
DR   PDBsum; 4U4S; -.
DR   PDBsum; 4U4X; -.
DR   PDBsum; 4U5B; -.
DR   PDBsum; 4U5C; -.
DR   PDBsum; 4U5D; -.
DR   PDBsum; 4U5E; -.
DR   PDBsum; 4U5F; -.
DR   PDBsum; 4UQ6; -.
DR   PDBsum; 4UQJ; -.
DR   PDBsum; 4UQK; -.
DR   PDBsum; 4X48; -.
DR   PDBsum; 4YMA; -.
DR   PDBsum; 5CBR; -.
DR   PDBsum; 5CBS; -.
DR   ProteinModelPortal; P19491; -.
DR   SMR; P19491; 412-527, 655-793.
DR   BioGrid; 248250; 6.
DR   DIP; DIP-30952N; -.
DR   IntAct; P19491; 20.
DR   MINT; MINT-86056; -.
DR   STRING; 10116.ENSRNOP00000062152; -.
DR   BindingDB; P19491; -.
DR   ChEMBL; CHEMBL3503; -.
DR   GuidetoPHARMACOLOGY; 445; -.
DR   iPTMnet; P19491; -.
DR   PhosphoSite; P19491; -.
DR   SwissPalm; P19491; -.
DR   PaxDb; P19491; -.
DR   PRIDE; P19491; -.
DR   GeneID; 29627; -.
DR   KEGG; rno:29627; -.
DR   UCSC; RGD:61862; rat. [P19491-1]
DR   CTD; 2891; -.
DR   RGD; 61862; Gria2.
DR   eggNOG; KOG1054; Eukaryota.
DR   eggNOG; ENOG410XPSH; LUCA.
DR   HOGENOM; HOG000234372; -.
DR   HOVERGEN; HBG051839; -.
DR   InParanoid; P19491; -.
DR   KO; K05198; -.
DR   PhylomeDB; P19491; -.
DR   EvolutionaryTrace; P19491; -.
DR   NextBio; 609842; -.
DR   PRO; PR:P19491; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0032281; C:AMPA glutamate receptor complex; IDA:UniProtKB.
DR   GO; GO:0032279; C:asymmetric synapse; IDA:RGD.
DR   GO; GO:0030054; C:cell junction; IEA:UniProtKB-KW.
DR   GO; GO:0009986; C:cell surface; IDA:RGD.
DR   GO; GO:0030425; C:dendrite; IDA:RGD.
DR   GO; GO:0032839; C:dendrite cytoplasm; IDA:RGD.
DR   GO; GO:0043198; C:dendritic shaft; IDA:UniProtKB.
DR   GO; GO:0043197; C:dendritic spine; IDA:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0030426; C:growth cone; IDA:RGD.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0008328; C:ionotropic glutamate receptor complex; TAS:UniProtKB.
DR   GO; GO:0043025; C:neuronal cell body; IDA:UniProtKB.
DR   GO; GO:0043204; C:perikaryon; IDA:RGD.
DR   GO; GO:0014069; C:postsynaptic density; IDA:RGD.
DR   GO; GO:0045211; C:postsynaptic membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042734; C:presynaptic membrane; IDA:RGD.
DR   GO; GO:0043234; C:protein complex; IPI:UniProtKB.
DR   GO; GO:0045202; C:synapse; IDA:UniProtKB.
DR   GO; GO:0030672; C:synaptic vesicle membrane; IDA:RGD.
DR   GO; GO:0043195; C:terminal bouton; IDA:RGD.
DR   GO; GO:0004971; F:AMPA glutamate receptor activity; IDA:UniProtKB.
DR   GO; GO:0005234; F:extracellular-glutamate-gated ion channel activity; IEA:InterPro.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0004970; F:ionotropic glutamate receptor activity; IDA:UniProtKB.
DR   GO; GO:0015277; F:kainate selective glutamate receptor activity; IDA:UniProtKB.
DR   GO; GO:0030165; F:PDZ domain binding; IDA:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:RGD.
DR   GO; GO:0004872; F:receptor activity; IDA:UniProtKB.
DR   GO; GO:0045184; P:establishment of protein localization; IMP:UniProtKB.
DR   GO; GO:0035235; P:ionotropic glutamate receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0050806; P:positive regulation of synaptic transmission; IMP:UniProtKB.
DR   GO; GO:0051262; P:protein tetramerization; IDA:UniProtKB.
DR   GO; GO:0031623; P:receptor internalization; IDA:UniProtKB.
DR   GO; GO:0001919; P:regulation of receptor recycling; IMP:UniProtKB.
DR   GO; GO:0051966; P:regulation of synaptic transmission, glutamatergic; IMP:UniProtKB.
DR   GO; GO:0060992; P:response to fungicide; IEP:RGD.
DR   GO; GO:0010226; P:response to lithium ion; IEP:UniProtKB.
DR   GO; GO:0007268; P:synaptic transmission; IDA:RGD.
DR   InterPro; IPR001828; ANF_lig-bd_rcpt.
DR   InterPro; IPR019594; Glu/Gly-bd.
DR   InterPro; IPR001508; Iono_rcpt_met.
DR   InterPro; IPR001320; Iontro_rcpt.
DR   InterPro; IPR028082; Peripla_BP_I.
DR   Pfam; PF01094; ANF_receptor; 1.
DR   Pfam; PF00060; Lig_chan; 1.
DR   Pfam; PF10613; Lig_chan-Glu_bd; 1.
DR   PRINTS; PR00177; NMDARECEPTOR.
DR   SMART; SM00918; Lig_chan-Glu_bd; 1.
DR   SMART; SM00079; PBPe; 1.
DR   SUPFAM; SSF53822; SSF53822; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell junction; Cell membrane;
KW   Complete proteome; Disulfide bond; Endoplasmic reticulum;
KW   Glycoprotein; Ion channel; Ion transport; Ligand-gated ion channel;
KW   Lipoprotein; Membrane; Palmitate; Phosphoprotein;
KW   Postsynaptic cell membrane; Receptor; Reference proteome; RNA editing;
KW   Signal; Synapse; Transmembrane; Transmembrane helix; Transport.
FT   SIGNAL        1     21       {ECO:0000255}.
FT   CHAIN        22    883       Glutamate receptor 2.
FT                                /FTId=PRO_0000011535.
FT   TOPO_DOM     22    543       Extracellular.
FT   TRANSMEM    544    564       Helical.
FT   TOPO_DOM    565    591       Cytoplasmic.
FT   INTRAMEM    592    607       Helical; Pore-forming.
FT   INTRAMEM    608    610
FT   TOPO_DOM    611    616       Cytoplasmic.
FT   TRANSMEM    617    637       Helical.
FT   TOPO_DOM    638    812       Extracellular.
FT   TRANSMEM    813    833       Helical; Name=M4.
FT   TOPO_DOM    834    883       Cytoplasmic.
FT   REGION      499    501       Glutamate binding.
FT   REGION      675    676       Glutamate binding.
FT   BINDING     471    471       Glutamate. {ECO:0000269|PubMed:16483599}.
FT   BINDING     501    501       Kainate; via amide nitrogen.
FT                                {ECO:0000269|PubMed:25103405}.
FT   BINDING     506    506       Glutamate. {ECO:0000269|PubMed:16483599}.
FT   BINDING     506    506       Kainate. {ECO:0000269|PubMed:25103405}.
FT   BINDING     675    675       Kainate; via amide nitrogen.
FT                                {ECO:0000269|PubMed:25103405}.
FT   BINDING     676    676       Kainate; via amide nitrogen.
FT                                {ECO:0000269|PubMed:25103405}.
FT   BINDING     726    726       Glutamate. {ECO:0000269|PubMed:16483599}.
FT   BINDING     726    726       Kainate. {ECO:0000269|PubMed:25103405}.
FT   SITE        474    474       Interaction with the cone snail toxin
FT                                Con-ikot-ikot.
FT                                {ECO:0000269|PubMed:25103405}.
FT   SITE        654    654       Crucial to convey clamshell closure to
FT                                channel opening.
FT                                {ECO:0000269|PubMed:25103405}.
FT   SITE        681    681       Interaction with the cone snail toxin
FT                                Con-ikot-ikot.
FT                                {ECO:0000269|PubMed:25103405}.
FT   SITE        773    773       Interaction with the cone snail toxin
FT                                Con-ikot-ikot.
FT                                {ECO:0000269|PubMed:25103405}.
FT   MOD_RES     683    683       Phosphoserine; by PKC.
FT                                {ECO:0000269|PubMed:8848293}.
FT   MOD_RES     717    717       Phosphoserine; by PKG.
FT                                {ECO:0000269|PubMed:8848293}.
FT   MOD_RES     860    860       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P23819}.
FT   MOD_RES     863    863       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P23819}.
FT   MOD_RES     876    876       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:15240807}.
FT   MOD_RES     880    880       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P23819}.
FT   LIPID       610    610       S-palmitoyl cysteine. {ECO:0000250}.
FT   LIPID       836    836       S-palmitoyl cysteine. {ECO:0000250}.
FT   CARBOHYD    256    256       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:21317873}.
FT   CARBOHYD    370    370       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19946266,
FT                                ECO:0000269|PubMed:21317873,
FT                                ECO:0000269|PubMed:25103405}.
FT   CARBOHYD    406    406       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    413    413       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     78    330
FT   DISULFID    739    794
FT   VAR_SEQ     765    766       NA -> TP (in isoform Flip).
FT                                {ECO:0000303|PubMed:1699567,
FT                                ECO:0000303|PubMed:2166337,
FT                                ECO:0000303|PubMed:9351977}.
FT                                /FTId=VSP_000111.
FT   VAR_SEQ     775    775       N -> S (in isoform Flip).
FT                                {ECO:0000303|PubMed:1699567,
FT                                ECO:0000303|PubMed:2166337,
FT                                ECO:0000303|PubMed:9351977}.
FT                                /FTId=VSP_000112.
FT   VAR_SEQ     779    779       L -> V (in isoform Flip).
FT                                {ECO:0000303|PubMed:1699567,
FT                                ECO:0000303|PubMed:2166337,
FT                                ECO:0000303|PubMed:9351977}.
FT                                /FTId=VSP_000113.
FT   VAR_SEQ     796    800       SGGGD -> AKDSG (in isoform Flip).
FT                                {ECO:0000303|PubMed:1699567,
FT                                ECO:0000303|PubMed:2166337,
FT                                ECO:0000303|PubMed:9351977}.
FT                                /FTId=VSP_000114.
FT   VAR_SEQ     848    883       VAKNPQNINPSSSQNSQNFATYKEGYNVYGIESVKI -> M
FT                                TLSDVMRSKARLSITGSTGENGRVMTPEFPKAVHAVPYVSP
FT                                GMGMNVSVTDLS (in isoform 3).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_029310.
FT   VARIANT     607    607       Q -> R (in RNA edited version).
FT   MUTAGEN     504    504       L->Y: Promotes dimerization. Strongly
FT                                reduced desensitization.
FT                                {ECO:0000269|PubMed:12015593}.
FT   MUTAGEN     775    775       N->D: Increases rate of desensitization.
FT                                {ECO:0000269|PubMed:12015593}.
FT   MUTAGEN     851    852       NP->AA: Strongly reduces interaction with
FT                                NSF. {ECO:0000269|PubMed:9697855}.
FT   STRAND       26     34       {ECO:0000244|PDB:3HSY}.
FT   HELIX        38     50       {ECO:0000244|PDB:3HSY}.
FT   STRAND       57     65       {ECO:0000244|PDB:3HSY}.
FT   HELIX        70     82       {ECO:0000244|PDB:3HSY}.
FT   STRAND       86     90       {ECO:0000244|PDB:3HSY}.
FT   TURN         94     96       {ECO:0000244|PDB:3HSY}.
FT   HELIX        97    107       {ECO:0000244|PDB:3HSY}.
FT   STRAND      110    113       {ECO:0000244|PDB:3HSY}.
FT   STRAND      125    127       {ECO:0000244|PDB:3HSY}.
FT   HELIX       133    142       {ECO:0000244|PDB:3HSY}.
FT   STRAND      147    152       {ECO:0000244|PDB:3HSY}.
FT   TURN        154    156       {ECO:0000244|PDB:3N6V}.
FT   HELIX       159    171       {ECO:0000244|PDB:3HSY}.
FT   STRAND      174    179       {ECO:0000244|PDB:3HSY}.
FT   STRAND      182    185       {ECO:0000244|PDB:3O2J}.
FT   HELIX       188    199       {ECO:0000244|PDB:3HSY}.
FT   TURN        201    203       {ECO:0000244|PDB:3H5V}.
FT   STRAND      206    211       {ECO:0000244|PDB:3HSY}.
FT   HELIX       213    226       {ECO:0000244|PDB:3HSY}.
FT   TURN        227    229       {ECO:0000244|PDB:4U1X}.
FT   HELIX       230    232       {ECO:0000244|PDB:3HSY}.
FT   STRAND      234    237       {ECO:0000244|PDB:3HSY}.
FT   STRAND      239    241       {ECO:0000244|PDB:3HSY}.
FT   HELIX       242    244       {ECO:0000244|PDB:3H5V}.
FT   HELIX       247    249       {ECO:0000244|PDB:3HSY}.
FT   STRAND      251    254       {ECO:0000244|PDB:3H5V}.
FT   STRAND      256    262       {ECO:0000244|PDB:3HSY}.
FT   STRAND      265    267       {ECO:0000244|PDB:4U1X}.
FT   HELIX       268    277       {ECO:0000244|PDB:3HSY}.
FT   TURN        282    284       {ECO:0000244|PDB:3HSY}.
FT   STRAND      289    291       {ECO:0000244|PDB:3H5V}.
FT   HELIX       295    316       {ECO:0000244|PDB:3HSY}.
FT   HELIX       339    350       {ECO:0000244|PDB:3HSY}.
FT   STRAND      353    355       {ECO:0000244|PDB:3HSY}.
FT   STRAND      358    360       {ECO:0000244|PDB:3HSY}.
FT   STRAND      366    368       {ECO:0000244|PDB:3HSY}.
FT   STRAND      372    379       {ECO:0000244|PDB:3HSY}.
FT   STRAND      382    390       {ECO:0000244|PDB:3HSY}.
FT   TURN        391    393       {ECO:0000244|PDB:3HSY}.
FT   STRAND      394    397       {ECO:0000244|PDB:3HSY}.
FT   STRAND      416    420       {ECO:0000244|PDB:4IGT}.
FT   TURN        424    426       {ECO:0000244|PDB:4IGT}.
FT   STRAND      427    429       {ECO:0000244|PDB:4IGT}.
FT   HELIX       433    435       {ECO:0000244|PDB:4IGT}.
FT   HELIX       438    441       {ECO:0000244|PDB:4IGT}.
FT   STRAND      442    444       {ECO:0000244|PDB:4IGT}.
FT   HELIX       445    457       {ECO:0000244|PDB:4IGT}.
FT   STRAND      461    465       {ECO:0000244|PDB:4IGT}.
FT   STRAND      467    469       {ECO:0000244|PDB:4U2P}.
FT   STRAND      472    474       {ECO:0000244|PDB:2CMO}.
FT   TURN        476    478       {ECO:0000244|PDB:4IGT}.
FT   HELIX       483    489       {ECO:0000244|PDB:4IGT}.
FT   STRAND      494    496       {ECO:0000244|PDB:4IGT}.
FT   HELIX       504    507       {ECO:0000244|PDB:4IGT}.
FT   STRAND      510    512       {ECO:0000244|PDB:4IGT}.
FT   STRAND      516    519       {ECO:0000244|PDB:4IGT}.
FT   STRAND      521    526       {ECO:0000244|PDB:4IGT}.
FT   TURN        534    538       {ECO:0000244|PDB:4U1W}.
FT   STRAND      539    542       {ECO:0000244|PDB:4U1W}.
FT   HELIX       544    565       {ECO:0000244|PDB:4U2P}.
FT   HELIX       617    622       {ECO:0000244|PDB:4U2P}.
FT   STRAND      644    648       {ECO:0000244|PDB:3M3L}.
FT   HELIX       653    655       {ECO:0000244|PDB:4U1W}.
FT   HELIX       657    661       {ECO:0000244|PDB:4IGT}.
FT   STRAND      664    669       {ECO:0000244|PDB:4IGT}.
FT   STRAND      671    674       {ECO:0000244|PDB:4IGT}.
FT   HELIX       675    682       {ECO:0000244|PDB:4IGT}.
FT   HELIX       686    697       {ECO:0000244|PDB:4IGT}.
FT   STRAND      704    706       {ECO:0000244|PDB:4IGT}.
FT   HELIX       707    716       {ECO:0000244|PDB:4IGT}.
FT   TURN        717    719       {ECO:0000244|PDB:4IGT}.
FT   STRAND      721    726       {ECO:0000244|PDB:4IGT}.
FT   HELIX       727    734       {ECO:0000244|PDB:4IGT}.
FT   STRAND      736    738       {ECO:0000244|PDB:3H06}.
FT   STRAND      741    745       {ECO:0000244|PDB:4IGT}.
FT   STRAND      751    753       {ECO:0000244|PDB:4IGT}.
FT   STRAND      756    758       {ECO:0000244|PDB:4IGT}.
FT   HELIX       763    776       {ECO:0000244|PDB:4IGT}.
FT   HELIX       779    788       {ECO:0000244|PDB:4IGT}.
FT   TURN        789    791       {ECO:0000244|PDB:4IGT}.
FT   STRAND      800    803       {ECO:0000244|PDB:4U2P}.
FT   HELIX       810    813       {ECO:0000244|PDB:4U2P}.
FT   HELIX       815    831       {ECO:0000244|PDB:4U2P}.
FT   HELIX       833    836       {ECO:0000244|PDB:4U2P}.
SQ   SEQUENCE   883 AA;  98688 MW;  DEFA817027C1CCD1 CRC64;
     MQKIMHISVL LSPVLWGLIF GVSSNSIQIG GLFPRGADQE YSAFRVGMVQ FSTSEFRLTP
     HIDNLEVANS FAVTNAFCSQ FSRGVYAIFG FYDKKSVNTI TSFCGTLHVS FITPSFPTDG
     THPFVIQMRP DLKGALLSLI EYYQWDKFAY LYDSDRGLST LQAVLDSAAE KKWQVTAINV
     GNINNDKKDE TYRSLFQDLE LKKERRVILD CERDKVNDIV DQVITIGKHV KGYHYIIANL
     GFTDGDLLKI QFGGANVSGF QIVDYDDSLV SKFIERWSTL EEKEYPGAHT ATIKYTSALT
     YDAVQVMTEA FRNLRKQRIE ISRRGNAGDC LANPAVPWGQ GVEIERALKQ VQVEGLSGNI
     KFDQNGKRIN YTINIMELKT NGPRKIGYWS EVDKMVVTLT ELPSGNDTSG LENKTVVVTT
     ILESPYVMMK KNHEMLEGNE RYEGYCVDLA AEIAKHCGFK YKLTIVGDGK YGARDADTKI
     WNGMVGELVY GKADIAIAPL TITLVREEVI DFSKPFMSLG ISIMIKKPQK SKPGVFSFLD
     PLAYEIWMCI VFAYIGVSVV LFLVSRFSPY EWHTEEFEDG RETQSSESTN EFGIFNSLWF
     SLGAFMQQGC DISPRSLSGR IVGGVWWFFT LIIISSYTAN LAAFLTVERM VSPIESAEDL
     SKQTEIAYGT LDSGSTKEFF RRSKIAVFDK MWTYMRSAEP SVFVRTTAEG VARVRKSKGK
     YAYLLESTMN EYIEQRKPCD TMKVGGNLDS KGYGIATPKG SSLGNAVNLA VLKLNEQGLL
     DKLKNKWWYD KGECGSGGGD SKEKTSALSL SNVAGVFYIL VGGLGLAMLV ALIEFCYKSR
     AEAKRMKVAK NPQNINPSSS QNSQNFATYK EGYNVYGIES VKI
//
ID   SFRP2_MOUSE             Reviewed;         295 AA.
AC   P97299; O08862; O35297;
DT   15-MAR-2005, integrated into UniProtKB/Swiss-Prot.
DT   15-MAR-2005, sequence version 2.
DT   17-FEB-2016, entry version 132.
DE   RecName: Full=Secreted frizzled-related protein 2;
DE            Short=sFRP-2;
DE   AltName: Full=Protein SDF5;
DE   AltName: Full=Secreted apoptosis-related protein 1;
DE            Short=SARP-1;
DE   Flags: Precursor;
GN   Name=Sfrp2; Synonyms=Sarp1, Sdf5;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Bone marrow stroma;
RX   PubMed=8938438; DOI=10.1006/geno.1996.0560;
RA   Shirozu M., Tada H., Tashiro K., Nakamura T., Lopez N.D., Nazarea M.,
RA   Hamada T., Sato T., Nakano T., Honjo T.;
RT   "Characterization of novel secreted and membrane proteins isolated by
RT   the signal sequence trap method.";
RL   Genomics 37:273-280(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   STRAIN=C57BL/6J; TISSUE=Embryonic eye;
RX   PubMed=9096311; DOI=10.1073/pnas.94.7.2859;
RA   Rattner A., Hsieh J.-C., Smallwood P.M., Gilbert D.J., Copeland N.G.,
RA   Jenkins N.A., Nathans J.;
RT   "A family of secreted proteins contains homology to the cysteine-rich
RT   ligand-binding domain of frizzled receptors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:2859-2863(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Pancreas;
RX   PubMed=9391078; DOI=10.1073/pnas.94.25.13636;
RA   Melkonyan H.S., Chang W.C., Shapiro J.P., Mahadevappa M.,
RA   Fitzpatrick P.A., Kiefer M.C., Tomei L.D., Umansky S.R.;
RT   "SARPs: a family of secreted apoptosis-related proteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:13636-13641(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=FVB/N; TISSUE=Mammary tumor;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   DEVELOPMENTAL STAGE.
RX   PubMed=9739103; DOI=10.1016/S0925-4773(98)00072-0;
RA   Leimeister C., Bach A., Gessler M.;
RT   "Developmental expression patterns of mouse sFRP genes encoding
RT   members of the secreted frizzled related protein family.";
RL   Mech. Dev. 75:29-42(1998).
RN   [6]
RP   DEVELOPMENTAL STAGE.
RX   PubMed=15226823; DOI=10.1371/journal.pbio.0020247;
RA   Blackshaw S., Harpavat S., Trimarchi J., Cai L., Huang H., Kuo W.P.,
RA   Weber G., Lee K., Fraioli R.E., Cho S.-H., Yung R., Asch E.,
RA   Ohno-Machado L., Wong W.H., Cepko C.L.;
RT   "Genomic analysis of mouse retinal development.";
RL   PLoS Biol. 2:1411-1431(2004).
CC   -!- FUNCTION: Soluble frizzled-related proteins (sFRPS) function as
CC       modulators of Wnt signaling through direct interaction with Wnts.
CC       They have a role in regulating cell growth and differentiation in
CC       specific cell types. SFRP2 may be important for eye retinal
CC       development and for myogenesis.
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- TISSUE SPECIFICITY: Highly expressed in the eye. Weaker expression
CC       in heart and lung. {ECO:0000269|PubMed:9096311}.
CC   -!- DEVELOPMENTAL STAGE: During kidney development, expressed at E10.5
CC       in the mesonephric tubules, and at E12.5 strongly expressed in the
CC       comma shaped bodies and surrounding ureter stalk. In E14.5 kidney,
CC       expressed in the S-shaped bodies. In the developing nervous
CC       system, expressed in the presumptive hindbrain and the ventral
CC       part of the neural tube from E8.0 onwards. At E9.5, expression is
CC       additionally detected in the mesonephros and the optic vesicle.
CC       E10 expression is found in the second and third branchial cleft,
CC       in the eye, the ventral neural tube and specific rhombomeres and
CC       prosomers. E10.5 brain shows specific expression in the basal and
CC       alar plate. In developing eye, expressed at E9.0 in the optic
CC       placode, and at E9.5 in the optic vesicle. By E10.5, expression
CC       found in the lens vesicle and the inner layer of the invaginating
CC       optic vesicle. Strong expression at E14.5 in the anterior lens
CC       epithelium, decreasing thereafter. Expression also found in the
CC       prospective neural retina. In developing limbs, expression found
CC       at E11.5 in the shoulder and at the distal end of the
CC       cartilaginous condensation. At E12.5, expressed in the foot and
CC       hand paddle extending along the digital rays. Expressed, at E13.5
CC       and E14.5, in the forelimb and hindlimb where the interphalangeal
CC       joints will develop. Also expressed at E14.5 between the sternal
CC       bands and where the ribs contact the sternum. In other developing
CC       structures, expression found at E11.5, in the maxillary and
CC       mandibular component of the first branchial arch, and later, in
CC       the loose mesenchyme surrounding cartilage and epithelia of the
CC       skull as well as in the whisker follicles. Also expressed in
CC       developing teeth, with the highest levels at E15.5 and E16.5 in
CC       the mesenchyme and the dental epithelium of the developing molars.
CC       Expressed in development smooth muscle surrounding the esophagus
CC       at E11.5, the dorsal aorta and the ductus arteriosus at E14.5, and
CC       the ureter stalk at E15.5. {ECO:0000269|PubMed:15226823,
CC       ECO:0000269|PubMed:9739103}.
CC   -!- DOMAIN: The FZ domain is involved in binding with Wnt ligands.
CC       {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the secreted frizzled-related protein
CC       (sFRP) family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 FZ (frizzled) domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00090}.
CC   -!- SIMILARITY: Contains 1 NTR domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00295}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D50462; BAA09053.1; -; mRNA.
DR   EMBL; U88567; AAC53146.1; -; mRNA.
DR   EMBL; AF017989; AAB70795.1; -; mRNA.
DR   EMBL; BC014722; AAH14722.1; -; mRNA.
DR   CCDS; CCDS17434.1; -.
DR   RefSeq; NP_033170.1; NM_009144.2.
DR   UniGene; Mm.19155; -.
DR   ProteinModelPortal; P97299; -.
DR   SMR; P97299; 49-150.
DR   BioGrid; 203142; 9.
DR   DIP; DIP-59486N; -.
DR   STRING; 10090.ENSMUSP00000029625; -.
DR   MEROPS; I93.002; -.
DR   PhosphoSite; P97299; -.
DR   PaxDb; P97299; -.
DR   PRIDE; P97299; -.
DR   Ensembl; ENSMUST00000029625; ENSMUSP00000029625; ENSMUSG00000027996.
DR   GeneID; 20319; -.
DR   KEGG; mmu:20319; -.
DR   UCSC; uc008ppl.2; mouse.
DR   CTD; 6423; -.
DR   MGI; MGI:108078; Sfrp2.
DR   eggNOG; KOG3577; Eukaryota.
DR   eggNOG; ENOG410XRC8; LUCA.
DR   HOGENOM; HOG000231058; -.
DR   HOVERGEN; HBG052928; -.
DR   InParanoid; P97299; -.
DR   KO; K02176; -.
DR   OMA; TSLKRWQ; -.
DR   OrthoDB; EOG789CBZ; -.
DR   PhylomeDB; P97299; -.
DR   TreeFam; TF350133; -.
DR   ChiTaRS; Sfrp2; mouse.
DR   NextBio; 298111; -.
DR   PRO; PR:P97299; -.
DR   Proteomes; UP000000589; Chromosome 3.
DR   Bgee; P97299; -.
DR   CleanEx; MM_SFRP2; -.
DR   ExpressionAtlas; P97299; baseline and differential.
DR   Genevisible; P97299; MM.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IBA:GO_Central.
DR   GO; GO:0061133; F:endopeptidase activator activity; IDA:MGI.
DR   GO; GO:0004930; F:G-protein coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0010577; F:metalloenzyme activator activity; IDA:MGI.
DR   GO; GO:0048018; F:receptor agonist activity; IDA:BHF-UCL.
DR   GO; GO:0042813; F:Wnt-activated receptor activity; IBA:GO_Central.
DR   GO; GO:0017147; F:Wnt-protein binding; IPI:MGI.
DR   GO; GO:0009952; P:anterior/posterior pattern specification; IGI:MGI.
DR   GO; GO:0006915; P:apoptotic process; IMP:MGI.
DR   GO; GO:0060349; P:bone morphogenesis; IMP:MGI.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; IBA:GO_Central.
DR   GO; GO:0003214; P:cardiac left ventricle morphogenesis; ISO:MGI.
DR   GO; GO:0051216; P:cartilage development; IMP:MGI.
DR   GO; GO:0031668; P:cellular response to extracellular stimulus; IDA:MGI.
DR   GO; GO:0071481; P:cellular response to X-ray; IDA:UniProtKB.
DR   GO; GO:0002063; P:chondrocyte development; IMP:MGI.
DR   GO; GO:0030199; P:collagen fibril organization; IMP:MGI.
DR   GO; GO:0060028; P:convergent extension involved in axis elongation; IGI:MGI.
DR   GO; GO:0046546; P:development of primary male sexual characteristics; IGI:MGI.
DR   GO; GO:0048546; P:digestive tract morphogenesis; IGI:MGI.
DR   GO; GO:0042733; P:embryonic digit morphogenesis; IMP:MGI.
DR   GO; GO:0007186; P:G-protein coupled receptor signaling pathway; IBA:GOC.
DR   GO; GO:0071425; P:hematopoietic stem cell proliferation; IDA:UniProtKB.
DR   GO; GO:0008584; P:male gonad development; IGI:MGI.
DR   GO; GO:1904693; P:midbrain morphogenesis; IGI:ParkinsonsUK-UCL.
DR   GO; GO:0030514; P:negative regulation of BMP signaling pathway; IDA:MGI.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IDA:MGI.
DR   GO; GO:0010667; P:negative regulation of cardiac muscle cell apoptotic process; IDA:MGI.
DR   GO; GO:0030308; P:negative regulation of cell growth; ISO:MGI.
DR   GO; GO:0030336; P:negative regulation of cell migration; IDA:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; ISO:MGI.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; IDA:MGI.
DR   GO; GO:0061185; P:negative regulation of dermatome development; IDA:BHF-UCL.
DR   GO; GO:0050680; P:negative regulation of epithelial cell proliferation; ISO:MGI.
DR   GO; GO:0010719; P:negative regulation of epithelial to mesenchymal transition; ISO:MGI.
DR   GO; GO:1902042; P:negative regulation of extrinsic apoptotic signaling pathway via death domain receptors; IDA:BHF-UCL.
DR   GO; GO:0010629; P:negative regulation of gene expression; IDA:UniProtKB.
DR   GO; GO:0043508; P:negative regulation of JUN kinase activity; IGI:MGI.
DR   GO; GO:0042662; P:negative regulation of mesodermal cell fate specification; IGI:MGI.
DR   GO; GO:0050732; P:negative regulation of peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:2000041; P:negative regulation of planar cell polarity pathway involved in axis elongation; IGI:MGI.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; ISO:MGI.
DR   GO; GO:0030178; P:negative regulation of Wnt signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0001843; P:neural tube closure; IGI:MGI.
DR   GO; GO:0021915; P:neural tube development; IGI:MGI.
DR   GO; GO:0003151; P:outflow tract morphogenesis; ISO:MGI.
DR   GO; GO:0001569; P:patterning of blood vessels; IDA:BHF-UCL.
DR   GO; GO:0090179; P:planar cell polarity pathway involved in neural tube closure; IGI:MGI.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IDA:BHF-UCL.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; ISO:MGI.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0035413; P:positive regulation of catenin import into nucleus; IDA:BHF-UCL.
DR   GO; GO:0030307; P:positive regulation of cell growth; IDA:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:UniProtKB.
DR   GO; GO:0010950; P:positive regulation of endopeptidase activity; IDA:MGI.
DR   GO; GO:0045600; P:positive regulation of fat cell differentiation; ISO:MGI.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; IGI:MGI.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0036342; P:post-anal tail morphogenesis; IMP:MGI.
DR   GO; GO:0042981; P:regulation of apoptotic process; IMP:MGI.
DR   GO; GO:0042127; P:regulation of cell proliferation; IMP:MGI.
DR   GO; GO:1904338; P:regulation of dopaminergic neuron differentiation; IGI:ParkinsonsUK-UCL.
DR   GO; GO:0090175; P:regulation of establishment of planar polarity; IGI:MGI.
DR   GO; GO:2000035; P:regulation of stem cell division; IDA:UniProtKB.
DR   GO; GO:0030111; P:regulation of Wnt signaling pathway; IDA:UniProtKB.
DR   GO; GO:0042493; P:response to drug; IDA:UniProtKB.
DR   GO; GO:0007584; P:response to nutrient; IEA:Ensembl.
DR   GO; GO:0061056; P:sclerotome development; IEP:BHF-UCL.
DR   GO; GO:0001756; P:somitogenesis; IGI:MGI.
DR   GO; GO:0090244; P:Wnt signaling pathway involved in somitogenesis; IGI:MGI.
DR   Gene3D; 1.10.2000.10; -; 1.
DR   InterPro; IPR015526; Frizzled/SFRP.
DR   InterPro; IPR020067; Frizzled_dom.
DR   InterPro; IPR001134; Netrin_domain.
DR   InterPro; IPR018933; Netrin_module_non-TIMP.
DR   InterPro; IPR026558; SFRP2.
DR   InterPro; IPR008993; TIMP-like_OB-fold.
DR   PANTHER; PTHR11309; PTHR11309; 1.
DR   PANTHER; PTHR11309:SF45; PTHR11309:SF45; 1.
DR   Pfam; PF01392; Fz; 1.
DR   Pfam; PF01759; NTR; 1.
DR   SMART; SM00643; C345C; 1.
DR   SMART; SM00063; FRI; 1.
DR   SUPFAM; SSF50242; SSF50242; 1.
DR   SUPFAM; SSF63501; SSF63501; 1.
DR   PROSITE; PS50038; FZ; 1.
DR   PROSITE; PS50189; NTR; 1.
PE   2: Evidence at transcript level;
KW   Complete proteome; Developmental protein; Differentiation;
KW   Disulfide bond; Reference proteome; Secreted; Signal;
KW   Wnt signaling pathway.
FT   SIGNAL        1     24       {ECO:0000255}.
FT   CHAIN        25    295       Secreted frizzled-related protein 2.
FT                                /FTId=PRO_0000032543.
FT   DOMAIN       35    155       FZ. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00090}.
FT   DOMAIN      172    295       NTR. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00295}.
FT   DISULFID     40    103       {ECO:0000250}.
FT   DISULFID     50     96       {ECO:0000250}.
FT   DISULFID     87    125       {ECO:0000250}.
FT   DISULFID    114    152       {ECO:0000250}.
FT   DISULFID    118    142       {ECO:0000250}.
FT   DISULFID    172    245       {ECO:0000250}.
FT   DISULFID    175    247       {ECO:0000250}.
FT   DISULFID    190    295       {ECO:0000250}.
FT   CONFLICT     38     38       S -> T (in Ref. 3; AAB70795).
FT                                {ECO:0000305}.
FT   CONFLICT    119    119       V -> M (in Ref. 1; BAA09053).
FT                                {ECO:0000305}.
SQ   SEQUENCE   295 AA;  33469 MW;  2D287C177C974C62 CRC64;
     MPRGPASLLL LVLASHCCLG SARGLFLFGQ PDFSYKRSNC KPIPANLQLC HGIEYQNMRL
     PNLLGHETMK EVLEQAGAWI PLVMKQCHPD TKKFLCSLFA PVCLDDLDET IQPCHSLCVQ
     VKDRCAPVMS AFGFPWPDML ECDRFPQDND LCIPLASSDH LLPATEEAPK VCEACKTKNE
     DDNDIMETLC KNDFALKIKV KEITYINRDT KIILETKSKT IYKLNGVSER DLKKSVLWLK
     DSLQCTCEEM NDINAPYLVM GQKQGGELVI TSVKRWQKGQ REFKRISRSI RKLQC
//
ID   TNR16_RAT               Reviewed;         425 AA.
AC   P07174;
DT   01-APR-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1988, sequence version 1.
DT   17-FEB-2016, entry version 156.
DE   RecName: Full=Tumor necrosis factor receptor superfamily member 16;
DE   AltName: Full=Gp80-LNGFR;
DE   AltName: Full=Low affinity neurotrophin receptor p75NTR;
DE   AltName: Full=Low-affinity nerve growth factor receptor;
DE            Short=NGF receptor;
DE   AltName: Full=p75 ICD;
DE   AltName: CD_antigen=CD271;
DE   Flags: Precursor;
GN   Name=Ngfr; Synonyms=Tnfrsf16;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3027580; DOI=10.1038/325593a0;
RA   Radeke M.J., Misko T.P., Hsu C., Herzenberg L.A., Shooter E.M.;
RT   "Gene transfer and molecular cloning of the rat nerve growth factor
RT   receptor.";
RL   Nature 325:593-597(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-22.
RC   TISSUE=Liver;
RX   PubMed=1446821; DOI=10.1016/0378-1119(92)90128-C;
RA   Metsis M., Timmusk T., Allikmets R., Saarma M., Persson H.;
RT   "Regulatory elements and transcriptional regulation by testosterone
RT   and retinoic acid of the rat nerve growth factor receptor promoter.";
RL   Gene 121:247-254(1992).
RN   [3]
RP   INTERACTION WITH NTRK2.
RX   PubMed=9927421; DOI=10.1093/emboj/18.3.616;
RA   Bibel M., Hoppe E., Barde Y.A.;
RT   "Biochemical and functional interactions between the neurotrophin
RT   receptors trk and p75NTR.";
RL   EMBO J. 18:616-622(1999).
RN   [4]
RP   FUNCTION IN APOPTOSIS, AND INTERACTION WITH MAGED1.
RC   STRAIN=Sprague-Dawley; TISSUE=Neural crest;
RX   PubMed=10985348; DOI=10.1016/S0896-6273(00)00036-2;
RA   Salehi A.H., Roux P.P., Kubu C.J., Zeindler C., Bhakar A.,
RA   Tannis L.-L., Verdi J.M., Barker P.A.;
RT   "NRAGE, a novel MAGE protein, interacts with the p75 neurotrophin
RT   receptor and facilitates nerve growth factor dependent apoptosis.";
RL   Neuron 27:279-288(2000).
RN   [5]
RP   INTERACTION WITH KIDINS220.
RX   PubMed=11150334;
RA   Kong H., Boulter J., Weber J.L., Lai C., Chao M.V.;
RT   "An evolutionarily conserved transmembrane protein that is a novel
RT   downstream target of neurotrophin and ephrin receptors.";
RL   J. Neurosci. 21:176-185(2001).
RN   [6]
RP   INTERACTION WITH NRADD.
RX   PubMed=12095158; DOI=10.1385/NMM:1:3:153;
RA   Frankowski H., Castro-Obregon S., del Rio G., Rao R.V., Bredesen D.E.;
RT   "PLAIDD, a type II death domain protein that interacts with p75
RT   neurotrophin receptor.";
RL   NeuroMolecular Med. 1:153-170(2002).
RN   [7]
RP   INTERACTION WITH NTRK1 AND KIDINS220, AND DOMAIN.
RX   PubMed=15378608; DOI=10.1002/jnr.20262;
RA   Chang M.-S., Arevalo J.C., Chao M.V.;
RT   "Ternary complex with Trk, p75, and an ankyrin-rich membrane spanning
RT   protein.";
RL   J. Neurosci. Res. 78:186-192(2004).
RN   [8]
RP   INTERACTION WITH BEX1.
RX   PubMed=16498402; DOI=10.1038/sj.emboj.7601017;
RA   Vilar M., Murillo-Carretero M., Mira H., Magnusson K., Besset V.,
RA   Ibanez C.F.;
RT   "Bex1, a novel interactor of the p75 neurotrophin receptor, links
RT   neurotrophin signaling to the cell cycle.";
RL   EMBO J. 25:1219-1230(2006).
RN   [9]
RP   STRUCTURE BY NMR OF 334-418.
RX   PubMed=9305641; DOI=10.1093/emboj/16.16.4999;
RA   Liepinsh E., Ilag L.L., Otting G., Ibanez C.F.;
RT   "NMR structure of the death domain of the p75 neurotrophin receptor.";
RL   EMBO J. 16:4999-5005(1997).
CC   -!- FUNCTION: Plays a role in the regulation of the translocation of
CC       GLUT4 to the cell surface in adipocytes and skeletal muscle cells
CC       in response to insulin, probably by regulating RAB31 activity, and
CC       thereby contributes to the regulation of insulin-dependent glucose
CC       uptake. Low affinity receptor which can bind to NGF, BDNF, NT-3,
CC       and NT-4. Can mediate cell survival as well as cell death of
CC       neural cells. Necessary for the circadian oscillation of the clock
CC       genes ARNTL/BMAL1, PER1, PER2 and NR1D1 in the suprachiasmatic
CC       nucleus (SCN) of the brain and in liver and of the genes involved
CC       in glucose and lipid metabolism in the liver.
CC       {ECO:0000269|PubMed:10985348}.
CC   -!- SUBUNIT: Homodimer; disulfide-linked. Interacts with p75NTR-
CC       associated cell death executor. Interacts with RTN4R (By
CC       similarity). Interacts with TRAF2, TRAF4, TRAF6, PTPN13 and
CC       RANBP9. Interacts through TRAF6 with SQSTM1 which bridges NGFR to
CC       NTRK1. Interacts with BEX1 and NGFRAP1/BEX3. Interacts with
CC       KIDINS220 and NTRK1. Can form a ternary complex with NTRK1 and
CC       KIDINS220 and this complex is affected by the expression levels of
CC       KIDINS220. An increase in KIDINS220 expression leads to a
CC       decreased association of NGFR and NTRK1. Interacts (via death
CC       domain) with RAB31. Interacts with NTRK2; may regulate the ligand
CC       specificity of the NTRK2 receptor. Interacts with LINGO1 and
CC       NRADD. Interacts with MAGED1; the interaction antagonizes the
CC       association NGFR:NTRK1. {ECO:0000250|UniProtKB:Q9Z0W1,
CC       ECO:0000269|PubMed:10985348, ECO:0000269|PubMed:11150334,
CC       ECO:0000269|PubMed:12095158, ECO:0000269|PubMed:15378608,
CC       ECO:0000269|PubMed:16498402, ECO:0000269|PubMed:9927421}.
CC   -!- INTERACTION:
CC       P05067:APP (xeno); NbExp=2; IntAct=EBI-1038810, EBI-2431589;
CC       Q3MKQ2:Bex1; NbExp=4; IntAct=EBI-1038810, EBI-8089575;
CC       P01138:NGF (xeno); NbExp=2; IntAct=EBI-1038810, EBI-1028250;
CC       Q12933:TRAF2 (xeno); NbExp=3; IntAct=EBI-1038810, EBI-355744;
CC       Q9BUZ4:TRAF4 (xeno); NbExp=3; IntAct=EBI-1038810, EBI-3650647;
CC       Q9Y4K3:TRAF6 (xeno); NbExp=2; IntAct=EBI-1038810, EBI-359276;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- DOMAIN: Death domain is responsible for interaction with RANBP9.
CC       {ECO:0000269|PubMed:15378608}.
CC   -!- DOMAIN: The extracellular domain is responsible for interaction
CC       with NTRK1. {ECO:0000269|PubMed:15378608}.
CC   -!- PTM: N- and O-glycosylated.
CC   -!- PTM: Phosphorylated on serine residues.
CC   -!- SIMILARITY: Contains 1 death domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00064}.
CC   -!- SIMILARITY: Contains 4 TNFR-Cys repeats. {ECO:0000255|PROSITE-
CC       ProRule:PRU00206}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X05137; CAA28783.1; -; mRNA.
DR   EMBL; X61269; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   PIR; A26431; A26431.
DR   RefSeq; NP_036742.2; NM_012610.2.
DR   UniGene; Rn.10980; -.
DR   PDB; 1NGR; NMR; -; A=334-418.
DR   PDB; 1SG1; X-ray; 2.40 A; X=30-190.
DR   PDB; 2MIC; NMR; -; A/B=245-284.
DR   PDB; 2MJO; NMR; -; A/B=245-284.
DR   PDB; 3BUK; X-ray; 2.60 A; C/D=30-190.
DR   PDB; 3IJ2; X-ray; 3.75 A; X/Y=30-190.
DR   PDB; 4F42; X-ray; 2.38 A; A=334-418.
DR   PDB; 4F44; X-ray; 2.40 A; A/B=334-418.
DR   PDBsum; 1NGR; -.
DR   PDBsum; 1SG1; -.
DR   PDBsum; 2MIC; -.
DR   PDBsum; 2MJO; -.
DR   PDBsum; 3BUK; -.
DR   PDBsum; 3IJ2; -.
DR   PDBsum; 4F42; -.
DR   PDBsum; 4F44; -.
DR   ProteinModelPortal; P07174; -.
DR   SMR; P07174; 31-190, 334-418.
DR   BioGrid; 246737; 11.
DR   DIP; DIP-5715N; -.
DR   IntAct; P07174; 15.
DR   MINT; MINT-128759; -.
DR   STRING; 10116.ENSRNOP00000007268; -.
DR   PhosphoSite; P07174; -.
DR   SwissPalm; P07174; -.
DR   PaxDb; P07174; -.
DR   PRIDE; P07174; -.
DR   GeneID; 24596; -.
DR   KEGG; rno:24596; -.
DR   UCSC; RGD:3177; rat.
DR   CTD; 4804; -.
DR   RGD; 3177; Ngfr.
DR   eggNOG; ENOG410IQFC; Eukaryota.
DR   eggNOG; ENOG4111F3C; LUCA.
DR   HOGENOM; HOG000059587; -.
DR   HOVERGEN; HBG060431; -.
DR   InParanoid; P07174; -.
DR   KO; K02583; -.
DR   PhylomeDB; P07174; -.
DR   EvolutionaryTrace; P07174; -.
DR   NextBio; 603794; -.
DR   PMAP-CutDB; P07174; -.
DR   PRO; PR:P07174; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0045334; C:clathrin-coated endocytic vesicle; IDA:RGD.
DR   GO; GO:0030135; C:coated vesicle; IDA:RGD.
DR   GO; GO:0005737; C:cytoplasm; IDA:RGD.
DR   GO; GO:0032590; C:dendrite membrane; IDA:RGD.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:RGD.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:RGD.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0045121; C:membrane raft; IDA:RGD.
DR   GO; GO:0005739; C:mitochondrion; IDA:RGD.
DR   GO; GO:0032809; C:neuronal cell body membrane; IDA:RGD.
DR   GO; GO:0005635; C:nuclear envelope; IDA:RGD.
DR   GO; GO:0005634; C:nucleus; IDA:RGD.
DR   GO; GO:0043204; C:perikaryon; IDA:RGD.
DR   GO; GO:0005886; C:plasma membrane; IDA:RGD.
DR   GO; GO:0005791; C:rough endoplasmic reticulum; IDA:RGD.
DR   GO; GO:0001540; F:beta-amyloid binding; IPI:RGD.
DR   GO; GO:0048406; F:nerve growth factor binding; IDA:RGD.
DR   GO; GO:0043121; F:neurotrophin binding; IPI:RGD.
DR   GO; GO:0005168; F:neurotrophin TRKA receptor binding; IPI:RGD.
DR   GO; GO:0070678; F:preprotein binding; IPI:RGD.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:RGD.
DR   GO; GO:0017137; F:Rab GTPase binding; ISS:UniProtKB.
DR   GO; GO:0005031; F:tumor necrosis factor-activated receptor activity; IBA:GO_Central.
DR   GO; GO:0097190; P:apoptotic signaling pathway; IBA:GO_Central.
DR   GO; GO:0007411; P:axon guidance; IBA:GO_Central.
DR   GO; GO:0034599; P:cellular response to oxidative stress; IMP:RGD.
DR   GO; GO:0032922; P:circadian regulation of gene expression; ISS:UniProtKB.
DR   GO; GO:0042593; P:glucose homeostasis; ISS:UniProtKB.
DR   GO; GO:0006955; P:immune response; IBA:GO_Central.
DR   GO; GO:0006954; P:inflammatory response; IBA:GO_Central.
DR   GO; GO:0006886; P:intracellular protein transport; ISS:UniProtKB.
DR   GO; GO:0016525; P:negative regulation of angiogenesis; IMP:RGD.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:RGD.
DR   GO; GO:0061000; P:negative regulation of dendritic spine development; IMP:RGD.
DR   GO; GO:0051902; P:negative regulation of mitochondrial depolarization; IMP:RGD.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IMP:RGD.
DR   GO; GO:0010977; P:negative regulation of neuron projection development; IDA:RGD.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IMP:RGD.
DR   GO; GO:2000463; P:positive regulation of excitatory postsynaptic potential; IMP:RGD.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:RGD.
DR   GO; GO:0031643; P:positive regulation of myelination; IMP:RGD.
DR   GO; GO:2000179; P:positive regulation of neural precursor cell proliferation; IMP:RGD.
DR   GO; GO:1901216; P:positive regulation of neuron death; IDA:RGD.
DR   GO; GO:0045666; P:positive regulation of neuron differentiation; IDA:RGD.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IMP:RGD.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IDA:RGD.
DR   GO; GO:0035025; P:positive regulation of Rho protein signal transduction; IDA:RGD.
DR   GO; GO:0032224; P:positive regulation of synaptic transmission, cholinergic; IMP:RGD.
DR   GO; GO:0051968; P:positive regulation of synaptic transmission, glutamatergic; IMP:RGD.
DR   GO; GO:0010941; P:regulation of cell death; IDA:RGD.
DR   GO; GO:0042127; P:regulation of cell proliferation; IBA:GO_Central.
DR   GO; GO:2001273; P:regulation of glucose import in response to insulin stimulus; ISS:UniProtKB.
DR   GO; GO:2000377; P:regulation of reactive oxygen species metabolic process; IMP:RGD.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEP:RGD.
DR   GO; GO:0009611; P:response to wounding; IMP:RGD.
DR   GO; GO:0019233; P:sensory perception of pain; IMP:RGD.
DR   GO; GO:0007165; P:signal transduction; IDA:RGD.
DR   GO; GO:0035914; P:skeletal muscle cell differentiation; IEP:RGD.
DR   GO; GO:0033209; P:tumor necrosis factor-mediated signaling pathway; IBA:GOC.
DR   Gene3D; 1.10.533.10; -; 1.
DR   InterPro; IPR011029; DEATH-like_dom.
DR   InterPro; IPR000488; Death_domain.
DR   InterPro; IPR001368; TNFR/NGFR_Cys_rich_reg.
DR   InterPro; IPR022325; TNFR_16.
DR   Pfam; PF00531; Death; 1.
DR   Pfam; PF00020; TNFR_c6; 3.
DR   PRINTS; PR01966; TNFACTORR16.
DR   SMART; SM00005; DEATH; 1.
DR   SMART; SM00208; TNFR; 4.
DR   SUPFAM; SSF47986; SSF47986; 1.
DR   PROSITE; PS50017; DEATH_DOMAIN; 1.
DR   PROSITE; PS00652; TNFR_NGFR_1; 3.
DR   PROSITE; PS50050; TNFR_NGFR_2; 4.
PE   1: Evidence at protein level;
KW   3D-structure; Apoptosis; Biological rhythms; Complete proteome;
KW   Developmental protein; Differentiation; Disulfide bond; Glycoprotein;
KW   Membrane; Neurogenesis; Phosphoprotein; Receptor; Reference proteome;
KW   Repeat; Signal; Transmembrane; Transmembrane helix.
FT   SIGNAL        1     29
FT   CHAIN        30    425       Tumor necrosis factor receptor
FT                                superfamily member 16.
FT                                /FTId=PRO_0000034593.
FT   TOPO_DOM     30    251       Extracellular. {ECO:0000255}.
FT   TRANSMEM    252    273       Helical. {ECO:0000255}.
FT   TOPO_DOM    274    425       Cytoplasmic. {ECO:0000255}.
FT   REPEAT       32     65       TNFR-Cys 1.
FT   REPEAT       67    108       TNFR-Cys 2.
FT   REPEAT      109    147       TNFR-Cys 3.
FT   REPEAT      149    189       TNFR-Cys 4.
FT   DOMAIN      354    419       Death. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00064}.
FT   REGION      327    342       Mediates interaction with KIDINS220.
FT   COMPBIAS    198    249       Ser/Thr-rich.
FT   MOD_RES     312    312       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P08138}.
FT   CARBOHYD     61     61       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD     71     71       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     33     44       {ECO:0000255|PROSITE-ProRule:PRU00206}.
FT   DISULFID     45     58       {ECO:0000255|PROSITE-ProRule:PRU00206}.
FT   DISULFID     48     65       {ECO:0000255|PROSITE-ProRule:PRU00206}.
FT   DISULFID     68     84       {ECO:0000255|PROSITE-ProRule:PRU00206}.
FT   DISULFID     87    100       {ECO:0000255|PROSITE-ProRule:PRU00206}.
FT   DISULFID     90    108       {ECO:0000255|PROSITE-ProRule:PRU00206}.
FT   DISULFID    110    123       {ECO:0000255|PROSITE-ProRule:PRU00206}.
FT   DISULFID    126    139       {ECO:0000255|PROSITE-ProRule:PRU00206}.
FT   DISULFID    129    147       {ECO:0000255|PROSITE-ProRule:PRU00206}.
FT   DISULFID    150    165       {ECO:0000255|PROSITE-ProRule:PRU00206}.
FT   DISULFID    168    181       {ECO:0000255|PROSITE-ProRule:PRU00206}.
FT   DISULFID    171    189       {ECO:0000255|PROSITE-ProRule:PRU00206}.
FT   STRAND       40     45       {ECO:0000244|PDB:3BUK}.
FT   STRAND       52     56       {ECO:0000244|PDB:1SG1}.
FT   STRAND       58     62       {ECO:0000244|PDB:1SG1}.
FT   STRAND       64     67       {ECO:0000244|PDB:1SG1}.
FT   TURN         70     72       {ECO:0000244|PDB:1SG1}.
FT   STRAND       79     81       {ECO:0000244|PDB:1SG1}.
FT   STRAND       94     98       {ECO:0000244|PDB:1SG1}.
FT   STRAND      107    110       {ECO:0000244|PDB:1SG1}.
FT   STRAND      114    116       {ECO:0000244|PDB:1SG1}.
FT   TURN        118    120       {ECO:0000244|PDB:1SG1}.
FT   STRAND      123    125       {ECO:0000244|PDB:1SG1}.
FT   STRAND      133    137       {ECO:0000244|PDB:1SG1}.
FT   STRAND      146    149       {ECO:0000244|PDB:1SG1}.
FT   STRAND      160    162       {ECO:0000244|PDB:1SG1}.
FT   TURN        246    249       {ECO:0000244|PDB:2MIC}.
FT   STRAND      250    253       {ECO:0000244|PDB:2MIC}.
FT   HELIX       255    275       {ECO:0000244|PDB:2MIC}.
FT   TURN        276    278       {ECO:0000244|PDB:2MIC}.
FT   HELIX       337    339       {ECO:0000244|PDB:4F42}.
FT   HELIX       342    351       {ECO:0000244|PDB:4F42}.
FT   TURN        352    355       {ECO:0000244|PDB:4F42}.
FT   HELIX       356    364       {ECO:0000244|PDB:4F42}.
FT   HELIX       368    373       {ECO:0000244|PDB:4F42}.
FT   HELIX       374    376       {ECO:0000244|PDB:4F42}.
FT   STRAND      377    379       {ECO:0000244|PDB:4F42}.
FT   HELIX       380    388       {ECO:0000244|PDB:4F42}.
FT   STRAND      391    393       {ECO:0000244|PDB:4F44}.
FT   HELIX       396    405       {ECO:0000244|PDB:4F42}.
FT   HELIX       409    416       {ECO:0000244|PDB:4F42}.
SQ   SEQUENCE   425 AA;  45433 MW;  B2E152D94D3827F8 CRC64;
     MRRAGAACSA MDRLRLLLLL ILGVSSGGAK ETCSTGLYTH SGECCKACNL GEGVAQPCGA
     NQTVCEPCLD NVTFSDVVSA TEPCKPCTEC LGLQSMSAPC VEADDAVCRC AYGYYQDEET
     GHCEACSVCE VGSGLVFSCQ DKQNTVCEEC PEGTYSDEAN HVDPCLPCTV CEDTERQLRE
     CTPWADAECE EIPGRWIPRS TPPEGSDSTA PSTQEPEVPP EQDLVPSTVA DMVTTVMGSS
     QPVVTRGTTD NLIPVYCSIL AAVVVGLVAY IAFKRWNSCK QNKQGANSRP VNQTPPPEGE
     KLHSDSGISV DSQSLHDQQT HTQTASGQAL KGDGNLYSSL PLTKREEVEK LLNGDTWRHL
     AGELGYQPEH IDSFTHEACP VRALLASWGA QDSATLDALL AALRRIQRAD IVESLCSEST
     ATSPV
//
ID   BMPR2_HUMAN             Reviewed;        1038 AA.
AC   Q13873; Q13161; Q16569; Q4ZG08; Q53SA5; Q585T8;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2000, sequence version 2.
DT   20-JAN-2016, entry version 180.
DE   RecName: Full=Bone morphogenetic protein receptor type-2;
DE            Short=BMP type-2 receptor;
DE            Short=BMPR-2;
DE            EC=2.7.11.30;
DE   AltName: Full=Bone morphogenetic protein receptor type II;
DE            Short=BMP type II receptor;
DE            Short=BMPR-II;
DE   Flags: Precursor;
GN   Name=BMPR2; Synonyms=PPH1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND ALTERNATIVE SPLICING.
RC   TISSUE=Kidney;
RX   PubMed=7791754;
RA   Liu F., Ventura F., Doody J., Massague J.;
RT   "Human type II receptor for bone morphogenic proteins (BMPs):
RT   extension of the two-kinase receptor model to the BMPs.";
RL   Mol. Cell. Biol. 15:3479-3486(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Substantia nigra;
RX   PubMed=7644468; DOI=10.1073/pnas.92.17.7632;
RA   Rosenzweig B.L., Imamura T., Okadome T., Cox G.N., Yamashita H.,
RA   ten Dijke P., Heldin C., Miyazono K.;
RT   "Cloning and characterization of a human type II receptor for bone
RT   morphogenetic proteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:7632-7636(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Skin fibroblast;
RX   PubMed=7673243; DOI=10.1074/jbc.270.38.22522;
RA   Nohno T., Ishikawa T., Saito T., Hosokawa K., Noji S., Wosing D.H.,
RA   Rosenbaum J.S.;
RT   "Identification of a human type II receptor for bone morphogenetic
RT   protein-4 that forms differential heteromeric complexes with bone
RT   morphogenetic protein type I receptors.";
RL   J. Biol. Chem. 270:22522-22526(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=7890683; DOI=10.1074/jbc.270.10.5625;
RA   Kawabata M., Chytil A., Moses H.L.;
RT   "Cloning of a novel type II serine/threonine kinase receptor through
RT   interaction with the type I transforming growth factor-beta
RT   receptor.";
RL   J. Biol. Chem. 270:5625-5630(1995).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-586, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-379, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [10]
RP   INTERACTION WITH GDF5.
RX   PubMed=21976273; DOI=10.1002/jbmr.532;
RA   Schwaerzer G.K., Hiepen C., Schrewe H., Nickel J., Ploeger F.,
RA   Sebald W., Mueller T., Knaus P.;
RT   "New insights into the molecular mechanism of multiple synostoses
RT   syndrome (SYNS): mutation within the GDF5 knuckle epitope causes
RT   noggin-resistance.";
RL   J. Bone Miner. Res. 27:429-442(2012).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.45 ANGSTROMS) OF 33-131, AND DISULFIDE BONDS.
RX   PubMed=17094948; DOI=10.1016/j.bbrc.2006.10.109;
RA   Mace P.D., Cutfield J.F., Cutfield S.M.;
RT   "High resolution structures of the bone morphogenetic protein type II
RT   receptor in two crystal forms: implications for ligand binding.";
RL   Biochem. Biophys. Res. Commun. 351:831-838(2006).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS) OF 189-517 IN COMPLEX WITH ADP.
RG   Structural genomics consortium (SGC);
RT   "Crystal structure of the BMPR2 kinase domain.";
RL   Submitted (FEB-2009) to the PDB data bank.
RN   [14]
RP   VARIANTS PPH1 GLN-491 AND TRP-491.
RX   PubMed=10903931; DOI=10.1086/303059;
RA   Deng Z., Morse J.H., Slager S.L., Cuervo N., Moore K.J., Venetos G.,
RA   Kalachikov S., Cayanis E., Fischer S.G., Barst R.J., Hodge S.E.,
RA   Knowles J.A.;
RT   "Familial primary pulmonary hypertension (gene PPH1) is caused by
RT   mutations in the bone morphogenetic protein receptor-II gene.";
RL   Am. J. Hum. Genet. 67:737-744(2000).
RN   [15]
RP   VARIANTS PPH1 TYR-60; TYR-117 AND ARG-483.
RX   PubMed=11015450; DOI=10.1136/jmg.37.10.741;
RA   Thomson J.R., Machado R.D., Pauciulo M.W., Morgan N.V., Humbert M.,
RA   Elliott G.C., Ward K., Yacoub M., Mikhail G., Rogers P., Newman J.H.,
RA   Wheeler L., Higenbottam T., Gibbs J.S.R., Egan J., Crozier A.,
RA   Peacock A., Allcock R., Corris P., Loyd J.E., Trembath R.C.,
RA   Nichols W.C.;
RT   "Sporadic primary pulmonary hypertension is associated with germline
RT   mutations of the gene encoding BMPR-II, a receptor member of the TGF-
RT   beta family.";
RL   J. Med. Genet. 37:741-745(2000).
RN   [16]
RP   VARIANTS PPH1 TRP-118; TYR-347 AND GLY-485.
RX   PubMed=10973254; DOI=10.1038/79226;
RA   Lane K.B., Machado R.D., Pauciulo M.W., Thomson J.R.,
RA   Phillips J.A. III, Loyd J.E., Nichols W.C., Trembath R.C., Aldred M.,
RA   Brannon C.A., Conneally P.M., Foroud T., Fretwell N., Gaddipati R.,
RA   Koller D., Loyd E.J., Morgan N.V., Newman J.H., Prince M.A.,
RA   Vilarino Gueell C., Wheeler L.;
RT   "Heterozygous germline mutations in BMPR2, encoding a TGF-beta
RT   receptor, cause familial primary pulmonary hypertension.";
RL   Nat. Genet. 26:81-84(2000).
RN   [17]
RP   VARIANTS PPH1 ARG-123; SER-123; ARG-420 AND THR-512, VARIANT ASP-224,
RP   AND CHARACTERIZATION OF VARIANT PPH1 GLY-485.
RX   PubMed=11115378; DOI=10.1086/316947;
RA   Machado R.D., Pauciulo M.W., Thomson J.R., Lane K.B., Morgan N.V.,
RA   Wheeler L., Phillips J.A. III, Newman J.H., Williams D., Galie N.,
RA   Manes A., McNeil K., Yacoub M., Mikhail G., Rogers P., Corris P.,
RA   Humbert M., Donnai D., Martensson G., Tranebjaerg L., Loyd J.E.,
RA   Trembath R.C., Nichols W.C.;
RT   "BMPR2 haploinsufficiency as the inherited molecular mechanism for
RT   primary pulmonary hypertension.";
RL   Am. J. Hum. Genet. 68:92-102(2001).
RN   [18]
RP   VARIANTS PPH1 HIS-82; ASP-182 AND ARG-483.
RX   PubMed=12358323; DOI=10.1183/09031936.02.01762002;
RA   Humbert M., Deng Z., Simonneau G., Barst R.J., Sitbon O., Wolf M.,
RA   Cuervo N., Moore K.J., Hodge S.E., Knowles J.A., Morse J.H.;
RT   "BMPR2 germline mutations in pulmonary hypertension associated with
RT   fenfluramine derivatives.";
RL   Eur. Respir. J. 20:518-523(2002).
RN   [19]
RP   INVOLVEMENT IN PVOD1.
RX   PubMed=12446270; DOI=10.1164/rccm.200208-861OC;
RA   Runo J.R., Vnencak-Jones C.L., Prince M., Loyd J.E., Wheeler L.,
RA   Robbins I.M., Lane K.B., Newman J.H., Johnson J., Nichols W.C.,
RA   Phillips J.A. III;
RT   "Pulmonary veno-occlusive disease caused by an inherited mutation in
RT   bone morphogenetic protein receptor II.";
RL   Am. J. Respir. Crit. Care Med. 167:889-894(2003).
RN   [20]
RP   VARIANT PPH1 PRO-899, AND CHARACTERIZATION OF VARIANT PPH1 PRO-899.
RX   PubMed=15965979; DOI=10.1002/humu.20200;
RA   Sankelo M., Flanagan J.A., Machado R., Harrison R., Rudarakanchana N.,
RA   Morrell N., Dixon M., Halme M., Puolijoki H., Kere J., Elomaa O.,
RA   Kupari M., Raeisaenen-Sokolowski A., Trembath R.C., Laitinen T.;
RT   "BMPR2 mutations have short lifetime expectancy in primary pulmonary
RT   hypertension.";
RL   Hum. Mutat. 26:119-124(2005).
RN   [21]
RP   INVOLVEMENT IN PVOD1.
RX   PubMed=16429395; DOI=10.1002/humu.20285;
RA   Machado R.D., Aldred M.A., James V., Harrison R.E., Patel B.,
RA   Schwalbe E.C., Gruenig E., Janssen B., Koehler R., Seeger W.,
RA   Eickelberg O., Olschewski H., Elliott C.G., Glissmeyer E.,
RA   Carlquist J., Kim M., Torbicki A., Fijalkowska A., Szewczyk G.,
RA   Parma J., Abramowicz M.J., Galie N., Morisaki H., Kyotani S.,
RA   Nakanishi N., Morisaki T., Humbert M., Simonneau G., Sitbon O.,
RA   Soubrier F., Coulet F., Morrell N.W., Trembath R.C.;
RT   "Mutations of the TGF-beta type II receptor BMPR2 in pulmonary
RT   arterial hypertension.";
RL   Hum. Mutat. 27:121-132(2006).
RN   [22]
RP   VARIANT [LARGE SCALE ANALYSIS] ASN-775.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [23]
RP   VARIANTS PPH1 CYS-67 AND ASN-863, CHARACTERIZATION OF VARIANTS PPH1
RP   CYS-67 AND ASN-863, AND SUBCELLULAR LOCATION.
RX   PubMed=25187962; DOI=10.1371/journal.pone.0106703;
RA   Wang H., Ji R., Meng J., Cui Q., Zou W., Li L., Wang G., Sun L.,
RA   Li Z., Huo L., Fan Y., Penny D.J.;
RT   "Functional changes in pulmonary arterial endothelial cells associated
RT   with BMPR2 mutations.";
RL   PLoS ONE 9:E106703-E106703(2014).
CC   -!- FUNCTION: On ligand binding, forms a receptor complex consisting
CC       of two type II and two type I transmembrane serine/threonine
CC       kinases. Type II receptors phosphorylate and activate type I
CC       receptors which autophosphorylate, then bind and activate SMAD
CC       transcriptional regulators. Binds to BMP-7, BMP-2 and, less
CC       efficiently, BMP-4. Binding is weak but enhanced by the presence
CC       of type I receptors for BMPs.
CC   -!- CATALYTIC ACTIVITY: ATP + [receptor-protein] = ADP + [receptor-
CC       protein] phosphate.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250};
CC   -!- SUBUNIT: Interacts with GDF5. {ECO:0000269|PubMed:21976273}.
CC   -!- INTERACTION:
CC       P08607:C4bpa (xeno); NbExp=3; IntAct=EBI-527196, EBI-527325;
CC       P43026:GDF5; NbExp=4; IntAct=EBI-527196, EBI-8571476;
CC       P68404:Prkcb (xeno); NbExp=4; IntAct=EBI-527196, EBI-397048;
CC       Q13976:PRKG1; NbExp=2; IntAct=EBI-527196, EBI-3952014;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:25187962};
CC       Single-pass type I membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q13873-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q13873-2; Sequence=VSP_054441, VSP_054442;
CC   -!- TISSUE SPECIFICITY: Highly expressed in heart and liver.
CC   -!- DISEASE: Pulmonary hypertension, primary, 1 (PPH1) [MIM:178600]: A
CC       rare disorder characterized by plexiform lesions of proliferating
CC       endothelial cells in pulmonary arterioles. The lesions lead to
CC       elevated pulmonary arterial pression, right ventricular failure,
CC       and death. The disease can occur from infancy throughout life and
CC       it has a mean age at onset of 36 years. Penetrance is reduced.
CC       Although familial pulmonary hypertension is rare, cases secondary
CC       to known etiologies are more common and include those associated
CC       with the appetite-suppressant drugs. {ECO:0000269|PubMed:10903931,
CC       ECO:0000269|PubMed:10973254, ECO:0000269|PubMed:11015450,
CC       ECO:0000269|PubMed:11115378, ECO:0000269|PubMed:12358323,
CC       ECO:0000269|PubMed:15965979, ECO:0000269|PubMed:25187962}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Pulmonary venoocclusive disease 1, autosomal dominant
CC       (PVOD1) [MIM:265450]: A disease characterized by widespread
CC       fibrous obstruction and intimal thickening of septal veins and
CC       preseptal venules, a low diffusing capacity for carbon monoxide,
CC       occult alveolar hemorrhage, and nodular ground-glass opacities,
CC       septal lines and lymph node enlargement showed by high-resolution
CC       computed tomography of the chest. It is frequently associated with
CC       pulmonary capillary dilatation and proliferation, and is a rare
CC       and devastating cause of pulmonary hypertension.
CC       {ECO:0000269|PubMed:12446270, ECO:0000269|PubMed:16429395}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. TGFB receptor subfamily. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U25110; AAA86519.1; -; mRNA.
DR   EMBL; Z48923; CAA88759.1; -; mRNA.
DR   EMBL; D50516; BAA09094.1; -; mRNA.
DR   EMBL; U20165; AAC50105.1; -; mRNA.
DR   EMBL; AC009960; AAX76517.1; -; Genomic_DNA.
DR   EMBL; AC073410; AAX88941.1; -; Genomic_DNA.
DR   EMBL; AC064836; AAY24146.1; -; Genomic_DNA.
DR   EMBL; CH471063; EAW70309.1; -; Genomic_DNA.
DR   EMBL; BC052985; AAH52985.1; -; mRNA.
DR   CCDS; CCDS33361.1; -. [Q13873-1]
DR   PIR; I38935; I38935.
DR   RefSeq; NP_001195.2; NM_001204.6. [Q13873-1]
DR   RefSeq; XP_011509990.1; XM_011511688.1. [Q13873-2]
DR   UniGene; Hs.471119; -.
DR   PDB; 2HLQ; X-ray; 1.45 A; A=33-131.
DR   PDB; 3G2F; X-ray; 2.35 A; A/B=189-517.
DR   PDBsum; 2HLQ; -.
DR   PDBsum; 3G2F; -.
DR   ProteinModelPortal; Q13873; -.
DR   SMR; Q13873; 33-131, 197-510.
DR   BioGrid; 107127; 56.
DR   DIP; DIP-5794N; -.
DR   IntAct; Q13873; 34.
DR   MINT; MINT-124272; -.
DR   STRING; 9606.ENSP00000363708; -.
DR   BindingDB; Q13873; -.
DR   ChEMBL; CHEMBL5467; -.
DR   GuidetoPHARMACOLOGY; 1794; -.
DR   iPTMnet; Q13873; -.
DR   PhosphoSite; Q13873; -.
DR   BioMuta; BMPR2; -.
DR   DMDM; 12643724; -.
DR   MaxQB; Q13873; -.
DR   PaxDb; Q13873; -.
DR   PRIDE; Q13873; -.
DR   DNASU; 659; -.
DR   Ensembl; ENST00000374574; ENSP00000363702; ENSG00000204217. [Q13873-2]
DR   Ensembl; ENST00000374580; ENSP00000363708; ENSG00000204217. [Q13873-1]
DR   GeneID; 659; -.
DR   KEGG; hsa:659; -.
DR   UCSC; uc002uzf.4; human. [Q13873-1]
DR   UCSC; uc010ftr.3; human.
DR   CTD; 659; -.
DR   GeneCards; BMPR2; -.
DR   GeneReviews; BMPR2; -.
DR   HGNC; HGNC:1078; BMPR2.
DR   HPA; HPA017385; -.
DR   HPA; HPA049014; -.
DR   MalaCards; BMPR2; -.
DR   MIM; 178600; phenotype.
DR   MIM; 265450; phenotype.
DR   MIM; 600799; gene.
DR   neXtProt; NX_Q13873; -.
DR   Orphanet; 275777; Heritable pulmonary arterial hypertension.
DR   Orphanet; 275766; Idiopathic pulmonary arterial hypertension.
DR   Orphanet; 31837; Pulmonary venoocclusive disease.
DR   PharmGKB; PA25388; -.
DR   eggNOG; KOG3653; Eukaryota.
DR   eggNOG; ENOG410XS2Z; LUCA.
DR   GeneTree; ENSGT00760000118876; -.
DR   HOGENOM; HOG000043088; -.
DR   HOVERGEN; HBG050705; -.
DR   InParanoid; Q13873; -.
DR   KO; K04671; -.
DR   OMA; HATNVAQ; -.
DR   OrthoDB; EOG7JHM5B; -.
DR   PhylomeDB; Q13873; -.
DR   TreeFam; TF314724; -.
DR   Reactome; R-HSA-201451; Signaling by BMP.
DR   SignaLink; Q13873; -.
DR   ChiTaRS; BMPR2; human.
DR   EvolutionaryTrace; Q13873; -.
DR   GeneWiki; BMPR2; -.
DR   GenomeRNAi; 659; -.
DR   NextBio; 2680; -.
DR   PRO; PR:Q13873; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; Q13873; -.
DR   CleanEx; HS_BMPR2; -.
DR   Genevisible; Q13873; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl.
DR   GO; GO:0009925; C:basal plasma membrane; IEA:Ensembl.
DR   GO; GO:0005901; C:caveola; IEA:Ensembl.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0097481; C:neuronal postsynaptic density; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0044214; C:spanning component of plasma membrane; TAS:AgBase.
DR   GO; GO:0016362; F:activin receptor activity, type II; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0036122; F:BMP binding; IPI:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004702; F:receptor signaling protein serine/threonine kinase activity; IEA:InterPro.
DR   GO; GO:0032924; P:activin receptor signaling pathway; TAS:GOC.
DR   GO; GO:0009952; P:anterior/posterior pattern specification; ISS:BHF-UCL.
DR   GO; GO:0060840; P:artery development; ISS:BHF-UCL.
DR   GO; GO:0001974; P:blood vessel remodeling; ISS:BHF-UCL.
DR   GO; GO:0030509; P:BMP signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0007420; P:brain development; IEA:Ensembl.
DR   GO; GO:0071773; P:cellular response to BMP stimulus; IMP:BHF-UCL.
DR   GO; GO:0009267; P:cellular response to starvation; IEP:BHF-UCL.
DR   GO; GO:0002063; P:chondrocyte development; IMP:AgBase.
DR   GO; GO:0060350; P:endochondral bone morphogenesis; ISS:AgBase.
DR   GO; GO:0072577; P:endothelial cell apoptotic process; IMP:UniProtKB.
DR   GO; GO:0001935; P:endothelial cell proliferation; IMP:UniProtKB.
DR   GO; GO:0060173; P:limb development; IEA:Ensembl.
DR   GO; GO:0048286; P:lung alveolus development; ISS:BHF-UCL.
DR   GO; GO:0001946; P:lymphangiogenesis; ISS:BHF-UCL.
DR   GO; GO:0060836; P:lymphatic endothelial cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0001893; P:maternal placenta development; IEA:Ensembl.
DR   GO; GO:0001707; P:mesoderm formation; ISS:BHF-UCL.
DR   GO; GO:0030308; P:negative regulation of cell growth; IDA:UniProtKB.
DR   GO; GO:1902731; P:negative regulation of chondrocyte proliferation; IMP:AgBase.
DR   GO; GO:2000279; P:negative regulation of DNA biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0003085; P:negative regulation of systemic arterial blood pressure; IMP:BHF-UCL.
DR   GO; GO:0045906; P:negative regulation of vasoconstriction; ISS:BHF-UCL.
DR   GO; GO:0048842; P:positive regulation of axon extension involved in axon guidance; IEA:Ensembl.
DR   GO; GO:0030513; P:positive regulation of BMP signaling pathway; IMP:UniProtKB.
DR   GO; GO:0030501; P:positive regulation of bone mineralization; IMP:BHF-UCL.
DR   GO; GO:0061036; P:positive regulation of cartilage development; ISS:AgBase.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; IMP:UniProtKB.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IMP:UniProtKB.
DR   GO; GO:0010634; P:positive regulation of epithelial cell migration; IDA:UniProtKB.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; IMP:BHF-UCL.
DR   GO; GO:0010862; P:positive regulation of pathway-restricted SMAD protein phosphorylation; IMP:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IMP:BHF-UCL.
DR   GO; GO:0030166; P:proteoglycan biosynthetic process; ISS:AgBase.
DR   GO; GO:0042127; P:regulation of cell proliferation; IMP:HGNC.
DR   GO; GO:0014916; P:regulation of lung blood pressure; IMP:BHF-UCL.
DR   GO; GO:0061298; P:retina vasculature development in camera-type eye; ISS:BHF-UCL.
DR   GO; GO:0006366; P:transcription from RNA polymerase II promoter; IMP:BHF-UCL.
DR   GO; GO:0007178; P:transmembrane receptor protein serine/threonine kinase signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0060841; P:venous blood vessel development; ISS:BHF-UCL.
DR   InterPro; IPR000472; Activin_recp.
DR   InterPro; IPR015770; BMPR2.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR000333; TGFB_receptor.
DR   PANTHER; PTHR23255; PTHR23255; 1.
DR   PANTHER; PTHR23255:SF63; PTHR23255:SF63; 1.
DR   Pfam; PF01064; Activin_recp; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Complete proteome; Disease mutation; Disulfide bond; Glycoprotein;
KW   Kinase; Magnesium; Manganese; Membrane; Metal-binding;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Receptor;
KW   Reference proteome; Serine/threonine-protein kinase; Signal;
KW   Transferase; Transmembrane; Transmembrane helix.
FT   SIGNAL        1     26       {ECO:0000255}.
FT   CHAIN        27   1038       Bone morphogenetic protein receptor type-
FT                                2.
FT                                /FTId=PRO_0000024415.
FT   TOPO_DOM     27    150       Extracellular. {ECO:0000255}.
FT   TRANSMEM    151    171       Helical. {ECO:0000255}.
FT   TOPO_DOM    172   1038       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      203    504       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     209    217       ATP. {ECO:0000305|Ref.13}.
FT   NP_BIND     280    282       ATP. {ECO:0000305|Ref.13}.
FT   NP_BIND     337    338       ATP. {ECO:0000305|Ref.13}.
FT   COMPBIAS    547    550       Poly-Ser.
FT   COMPBIAS    610    618       Poly-Thr.
FT   COMPBIAS    901    908       Poly-Asn.
FT   ACT_SITE    333    333       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   BINDING     230    230       ATP. {ECO:0000305|Ref.13}.
FT   BINDING     351    351       ATP. {ECO:0000305|Ref.13}.
FT   MOD_RES     379    379       Phosphothreonine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     586    586       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES     680    680       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O35607}.
FT   MOD_RES     681    681       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O35607}.
FT   CARBOHYD     55     55       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    110    110       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    126    126       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     34     66       {ECO:0000244|PDB:2HLQ,
FT                                ECO:0000269|PubMed:17094948}.
FT   DISULFID     60     84       {ECO:0000244|PDB:2HLQ,
FT                                ECO:0000269|PubMed:17094948}.
FT   DISULFID     94    117       {ECO:0000244|PDB:2HLQ,
FT                                ECO:0000269|PubMed:17094948}.
FT   DISULFID     99    116       {ECO:0000244|PDB:2HLQ,
FT                                ECO:0000269|PubMed:17094948}.
FT   DISULFID    118    123       {ECO:0000244|PDB:2HLQ,
FT                                ECO:0000269|PubMed:17094948}.
FT   VAR_SEQ     530    530       N -> R (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:7791754}.
FT                                /FTId=VSP_054441.
FT   VAR_SEQ     531   1038       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:7791754}.
FT                                /FTId=VSP_054442.
FT   VARIANT      60     60       C -> Y (in PPH1).
FT                                {ECO:0000269|PubMed:11015450}.
FT                                /FTId=VAR_013670.
FT   VARIANT      67     67       Y -> C (in PPH1; significant decrease in
FT                                nitric oxide synthesis by endothelial
FT                                cells). {ECO:0000269|PubMed:25187962}.
FT                                /FTId=VAR_073041.
FT   VARIANT      82     82       Q -> H (in PPH1).
FT                                {ECO:0000269|PubMed:12358323}.
FT                                /FTId=VAR_033109.
FT   VARIANT     117    117       C -> Y (in PPH1).
FT                                {ECO:0000269|PubMed:11015450}.
FT                                /FTId=VAR_013671.
FT   VARIANT     118    118       C -> W (in PPH1).
FT                                {ECO:0000269|PubMed:10973254}.
FT                                /FTId=VAR_013672.
FT   VARIANT     123    123       C -> R (in PPH1).
FT                                {ECO:0000269|PubMed:11115378}.
FT                                /FTId=VAR_013673.
FT   VARIANT     123    123       C -> S (in PPH1).
FT                                {ECO:0000269|PubMed:11115378}.
FT                                /FTId=VAR_013674.
FT   VARIANT     182    182       G -> D (in PPH1).
FT                                {ECO:0000269|PubMed:12358323}.
FT                                /FTId=VAR_033110.
FT   VARIANT     224    224       E -> D. {ECO:0000269|PubMed:11115378}.
FT                                /FTId=VAR_013675.
FT   VARIANT     347    347       C -> Y (in PPH1).
FT                                {ECO:0000269|PubMed:10973254}.
FT                                /FTId=VAR_013676.
FT   VARIANT     420    420       C -> R (in PPH1).
FT                                {ECO:0000269|PubMed:11115378}.
FT                                /FTId=VAR_013677.
FT   VARIANT     483    483       C -> R (in PPH1; sporadic).
FT                                {ECO:0000269|PubMed:11015450,
FT                                ECO:0000269|PubMed:12358323}.
FT                                /FTId=VAR_013678.
FT   VARIANT     485    485       D -> G (in PPH1; complete loss of
FT                                function). {ECO:0000269|PubMed:10973254,
FT                                ECO:0000269|PubMed:11115378}.
FT                                /FTId=VAR_013679.
FT   VARIANT     491    491       R -> Q (in PPH1; sporadic).
FT                                {ECO:0000269|PubMed:10903931}.
FT                                /FTId=VAR_013680.
FT   VARIANT     491    491       R -> W (in PPH1).
FT                                {ECO:0000269|PubMed:10903931}.
FT                                /FTId=VAR_013681.
FT   VARIANT     512    512       K -> T (in PPH1).
FT                                {ECO:0000269|PubMed:11115378}.
FT                                /FTId=VAR_013682.
FT   VARIANT     519    519       N -> K (in PPH1).
FT                                /FTId=VAR_013683.
FT   VARIANT     775    775       S -> N (in dbSNP:rs2228545).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_019996.
FT   VARIANT     863    863       S -> N (in PPH1; abnormal subcellular
FT                                localization; significant increase in
FT                                apoptosis of endothelial cells;
FT                                significant decrease in proliferation of
FT                                endothelial cells; significant decrease
FT                                in nitric oxide synthesis by endothelial
FT                                cells; significant increase in endothelin
FT                                1 synthesis by endothelial cells).
FT                                {ECO:0000269|PubMed:25187962}.
FT                                /FTId=VAR_073042.
FT   VARIANT     899    899       R -> P (in PPH1; leads to constitutive
FT                                activation of the MAPK14 pathway;
FT                                dbSNP:rs137852752).
FT                                {ECO:0000269|PubMed:15965979}.
FT                                /FTId=VAR_033111.
FT   CONFLICT    828    828       G -> R (in Ref. 2; CAA88759).
FT                                {ECO:0000305}.
FT   STRAND       33     35       {ECO:0000244|PDB:2HLQ}.
FT   TURN         42     47       {ECO:0000244|PDB:2HLQ}.
FT   HELIX        48     50       {ECO:0000244|PDB:2HLQ}.
FT   TURN         53     56       {ECO:0000244|PDB:2HLQ}.
FT   STRAND       57     59       {ECO:0000244|PDB:2HLQ}.
FT   STRAND       66     73       {ECO:0000244|PDB:2HLQ}.
FT   STRAND       76     84       {ECO:0000244|PDB:2HLQ}.
FT   STRAND       90     92       {ECO:0000244|PDB:2HLQ}.
FT   TURN        105    109       {ECO:0000244|PDB:2HLQ}.
FT   STRAND      113    118       {ECO:0000244|PDB:2HLQ}.
FT   HELIX       123    125       {ECO:0000244|PDB:2HLQ}.
FT   STRAND      202    211       {ECO:0000244|PDB:3G2F}.
FT   STRAND      213    222       {ECO:0000244|PDB:3G2F}.
FT   STRAND      225    233       {ECO:0000244|PDB:3G2F}.
FT   HELIX       234    236       {ECO:0000244|PDB:3G2F}.
FT   HELIX       237    247       {ECO:0000244|PDB:3G2F}.
FT   STRAND      260    267       {ECO:0000244|PDB:3G2F}.
FT   STRAND      273    279       {ECO:0000244|PDB:3G2F}.
FT   HELIX       287    293       {ECO:0000244|PDB:3G2F}.
FT   HELIX       298    316       {ECO:0000244|PDB:3G2F}.
FT   HELIX       322    324       {ECO:0000244|PDB:3G2F}.
FT   STRAND      338    341       {ECO:0000244|PDB:3G2F}.
FT   STRAND      347    349       {ECO:0000244|PDB:3G2F}.
FT   STRAND      359    362       {ECO:0000244|PDB:3G2F}.
FT   HELIX       380    382       {ECO:0000244|PDB:3G2F}.
FT   HELIX       385    388       {ECO:0000244|PDB:3G2F}.
FT   HELIX       394    396       {ECO:0000244|PDB:3G2F}.
FT   HELIX       397    417       {ECO:0000244|PDB:3G2F}.
FT   HELIX       421    423       {ECO:0000244|PDB:3G2F}.
FT   HELIX       437    440       {ECO:0000244|PDB:3G2F}.
FT   HELIX       446    453       {ECO:0000244|PDB:3G2F}.
FT   HELIX       471    483       {ECO:0000244|PDB:3G2F}.
FT   HELIX       488    490       {ECO:0000244|PDB:3G2F}.
FT   HELIX       494    506       {ECO:0000244|PDB:3G2F}.
SQ   SEQUENCE   1038 AA;  115201 MW;  1389923CE574B913 CRC64;
     MTSSLQRPWR VPWLPWTILL VSTAAASQNQ ERLCAFKDPY QQDLGIGESR ISHENGTILC
     SKGSTCYGLW EKSKGDINLV KQGCWSHIGD PQECHYEECV VTTTPPSIQN GTYRFCCCST
     DLCNVNFTEN FPPPDTTPLS PPHSFNRDET IIIALASVSV LAVLIVALCF GYRMLTGDRK
     QGLHSMNMME AAASEPSLDL DNLKLLELIG RGRYGAVYKG SLDERPVAVK VFSFANRQNF
     INEKNIYRVP LMEHDNIARF IVGDERVTAD GRMEYLLVME YYPNGSLCKY LSLHTSDWVS
     SCRLAHSVTR GLAYLHTELP RGDHYKPAIS HRDLNSRNVL VKNDGTCVIS DFGLSMRLTG
     NRLVRPGEED NAAISEVGTI RYMAPEVLEG AVNLRDCESA LKQVDMYALG LIYWEIFMRC
     TDLFPGESVP EYQMAFQTEV GNHPTFEDMQ VLVSREKQRP KFPEAWKENS LAVRSLKETI
     EDCWDQDAEA RLTAQCAEER MAELMMIWER NKSVSPTVNP MSTAMQNERN LSHNRRVPKI
     GPYPDYSSSS YIEDSIHHTD SIVKNISSEH SMSSTPLTIG EKNRNSINYE RQQAQARIPS
     PETSVTSLST NTTTTNTTGL TPSTGMTTIS EMPYPDETNL HTTNVAQSIG PTPVCLQLTE
     EDLETNKLDP KEVDKNLKES SDENLMEHSL KQFSGPDPLS STSSSLLYPL IKLAVEATGQ
     QDFTQTANGQ ACLIPDVLPT QIYPLPKQQN LPKRPTSLPL NTKNSTKEPR LKFGSKHKSN
     LKQVETGVAK MNTINAAEPH VVTVTMNGVA GRNHSVNSHA ATTQYANGTV LSGQTTNIVT
     HRAQEMLQNQ FIGEDTRLNI NSSPDEHEPL LRREQQAGHD EGVLDRLVDR RERPLEGGRT
     NSNNNNSNPC SEQDVLAQGV PSTAADPGPS KPRRAQRPNS LDLSATNVLD GSSIQIGEST
     QDGKSGSGEK IKKRVKTPYS LKRWRPSTWV ISTESLDCEV NNNGSNRAVH SKSSTAVYLA
     EGGTATTMVS KDIGMNCL
//
ID   NODAL_MOUSE             Reviewed;         354 AA.
AC   P43021; Q8BH87;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   27-JUL-2011, sequence version 2.
DT   17-FEB-2016, entry version 130.
DE   RecName: Full=Nodal;
DE   Flags: Precursor;
GN   Name=Nodal;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND DEVELOPMENTAL STAGE.
RC   TISSUE=Embryo;
RX   PubMed=8429908; DOI=10.1038/361543a0;
RA   Zhou X., Sasaki H., Lowe L., Hogan B.L., Kuehn M.R.;
RT   "Nodal is a novel TGF-beta-like gene expressed in the mouse node
RT   during gastrulation.";
RL   Nature 361:543-547(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M.,
RA   Davis M.J., Wilming L.G., Aidinis V., Allen J.E.,
RA   Ambesi-Impiombato A., Apweiler R., Aturaliya R.N., Bailey T.L.,
RA   Bansal M., Baxter L., Beisel K.W., Bersano T., Bono H., Chalk A.M.,
RA   Chiu K.P., Choudhary V., Christoffels A., Clutterbuck D.R.,
RA   Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., Della Gatta G.,
RA   di Bernardo D., Down T., Engstrom P., Fagiolini M., Faulkner G.,
RA   Fletcher C.F., Fukushima T., Furuno M., Futaki S., Gariboldi M.,
RA   Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N.,
RA   Hill D., Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T.,
RA   Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H.,
RA   Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K.,
RA   Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J.,
RA   Liuni S., McWilliam S., Madan Babu M., Madera M., Marchionni L.,
RA   Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K.,
RA   Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P.,
RA   Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O.,
RA   Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., Pesole G.,
RA   Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., Ringwald M.,
RA   Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B.,
RA   Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K.,
RA   Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A.,
RA   Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K.,
RA   Yamanishi H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C.,
RA   Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J.,
RA   Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y.,
RA   Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T.,
RA   Iida J., Imamura K., Itoh M., Kato T., Kawaji H., Kawagashira N.,
RA   Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N.,
RA   Nishio T., Okada M., Plessy C., Shibata K., Shiraki T., Suzuki S.,
RA   Tagami M., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J.,
RA   Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Adams M.D., Myers E.W., Smith H.O., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   FUNCTION.
RX   PubMed=8582278;
RA   Jones C.M., Kuehn M.R., Hogan B.L.M., Smith J.C., Wright C.V.E.;
RT   "Nodal-related signals induce axial mesoderm and dorsalize mesoderm
RT   during gastrulation.";
RL   Development 121:3651-3662(1995).
CC   -!- FUNCTION: Essential for mesoderm formation and axial patterning
CC       during embryonic development. {ECO:0000269|PubMed:8429908,
CC       ECO:0000269|PubMed:8582278}.
CC   -!- SUBUNIT: Homodimer; disulfide-linked. {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000250}.
CC   -!- DEVELOPMENTAL STAGE: Expressed in the node during gastrulation.
CC       Expression is first detected in primitive streak-stage embryos at
CC       about the time of mesoderm formation. It then becomes highly
CC       localized in the node at the anterior of the primitive streak.
CC       {ECO:0000269|PubMed:8429908}.
CC   -!- SIMILARITY: Belongs to the TGF-beta family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X70514; CAA49914.1; -; mRNA.
DR   EMBL; AK049290; BAC33661.1; -; mRNA.
DR   EMBL; AK082823; BAC38637.1; -; mRNA.
DR   EMBL; CH466553; EDL32144.1; -; Genomic_DNA.
DR   CCDS; CCDS23878.1; -.
DR   PIR; S29718; S29718.
DR   RefSeq; NP_038639.2; NM_013611.4.
DR   UniGene; Mm.57195; -.
DR   ProteinModelPortal; P43021; -.
DR   SMR; P43021; 253-353.
DR   BioGrid; 201801; 2.
DR   STRING; 10090.ENSMUSP00000039653; -.
DR   PaxDb; P43021; -.
DR   PRIDE; P43021; -.
DR   Ensembl; ENSMUST00000049339; ENSMUSP00000039653; ENSMUSG00000037171.
DR   GeneID; 18119; -.
DR   KEGG; mmu:18119; -.
DR   UCSC; uc007ffy.2; mouse.
DR   CTD; 4838; -.
DR   MGI; MGI:97359; Nodal.
DR   eggNOG; KOG3900; Eukaryota.
DR   eggNOG; ENOG410XT8Z; LUCA.
DR   GeneTree; ENSGT00740000114888; -.
DR   HOGENOM; HOG000113815; -.
DR   HOVERGEN; HBG108195; -.
DR   InParanoid; P43021; -.
DR   KO; K04666; -.
DR   OMA; EVDGQNW; -.
DR   OrthoDB; EOG7DFXD1; -.
DR   TreeFam; TF316134; -.
DR   NextBio; 293328; -.
DR   PRO; PR:P43021; -.
DR   Proteomes; UP000000589; Chromosome 10.
DR   Bgee; P43021; -.
DR   CleanEx; MM_NODAL; -.
DR   Genevisible; P43021; MM.
DR   GO; GO:0005576; C:extracellular region; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; TAS:BHF-UCL.
DR   GO; GO:0005125; F:cytokine activity; IBA:GO_Central.
DR   GO; GO:0048018; F:receptor agonist activity; IDA:UniProtKB.
DR   GO; GO:0005160; F:transforming growth factor beta receptor binding; IBA:GO_Central.
DR   GO; GO:0070698; F:type I activin receptor binding; ISO:MGI.
DR   GO; GO:0048646; P:anatomical structure formation involved in morphogenesis; IMP:MGI.
DR   GO; GO:0009948; P:anterior/posterior axis specification; IMP:MGI.
DR   GO; GO:0009952; P:anterior/posterior pattern specification; IMP:MGI.
DR   GO; GO:0048327; P:axial mesodermal cell fate specification; IMP:MGI.
DR   GO; GO:0030509; P:BMP signaling pathway; IBA:GO_Central.
DR   GO; GO:0007420; P:brain development; IMP:MGI.
DR   GO; GO:0045165; P:cell fate commitment; IMP:MGI.
DR   GO; GO:0016477; P:cell migration; IMP:MGI.
DR   GO; GO:0042074; P:cell migration involved in gastrulation; IDA:MGI.
DR   GO; GO:0007368; P:determination of left/right symmetry; TAS:BHF-UCL.
DR   GO; GO:0055123; P:digestive system development; IMP:MGI.
DR   GO; GO:0048546; P:digestive tract morphogenesis; IMP:MGI.
DR   GO; GO:0048701; P:embryonic cranial skeleton morphogenesis; IMP:MGI.
DR   GO; GO:0035050; P:embryonic heart tube development; IMP:MGI.
DR   GO; GO:0009880; P:embryonic pattern specification; IMP:MGI.
DR   GO; GO:0001892; P:embryonic placenta development; IMP:MGI.
DR   GO; GO:0060136; P:embryonic process involved in female pregnancy; IMP:MGI.
DR   GO; GO:0007492; P:endoderm development; IMP:MGI.
DR   GO; GO:0035987; P:endodermal cell differentiation; ISO:MGI.
DR   GO; GO:0060802; P:epiblast cell-extraembryonic ectoderm cell signaling involved in anterior/posterior axis specification; IMP:MGI.
DR   GO; GO:0033505; P:floor plate morphogenesis; IMP:MGI.
DR   GO; GO:0048859; P:formation of anatomical boundary; IMP:MGI.
DR   GO; GO:0007369; P:gastrulation; IMP:MGI.
DR   GO; GO:0001702; P:gastrulation with mouth forming second; IMP:MGI.
DR   GO; GO:0007507; P:heart development; IMP:MGI.
DR   GO; GO:0001947; P:heart looping; IGI:MGI.
DR   GO; GO:0001701; P:in utero embryonic development; IMP:MGI.
DR   GO; GO:0002085; P:inhibition of neuroepithelial cell differentiation; IMP:MGI.
DR   GO; GO:0060460; P:left lung morphogenesis; IMP:MGI.
DR   GO; GO:0001889; P:liver development; IMP:MGI.
DR   GO; GO:0030324; P:lung development; IMP:MGI.
DR   GO; GO:0001893; P:maternal placenta development; IMP:MGI.
DR   GO; GO:0060137; P:maternal process involved in parturition; IMP:MGI.
DR   GO; GO:0048382; P:mesendoderm development; IMP:MGI.
DR   GO; GO:0001707; P:mesoderm formation; TAS:BHF-UCL.
DR   GO; GO:0060766; P:negative regulation of androgen receptor signaling pathway; ISO:MGI.
DR   GO; GO:0010721; P:negative regulation of cell development; IMP:MGI.
DR   GO; GO:0045596; P:negative regulation of cell differentiation; IDA:MGI.
DR   GO; GO:1901383; P:negative regulation of chorionic trophoblast cell proliferation; ISO:MGI.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:MGI.
DR   GO; GO:1901164; P:negative regulation of trophoblast cell migration; ISO:MGI.
DR   GO; GO:0007399; P:nervous system development; IMP:MGI.
DR   GO; GO:0001842; P:neural fold formation; IMP:MGI.
DR   GO; GO:0038092; P:nodal signaling pathway; IMP:UniProtKB.
DR   GO; GO:1900164; P:nodal signaling pathway involved in determination of lateral mesoderm left/right asymmetry; IMP:BHF-UCL.
DR   GO; GO:0001890; P:placenta development; ISO:MGI.
DR   GO; GO:0010085; P:polarity specification of proximal/distal axis; IMP:MGI.
DR   GO; GO:0032927; P:positive regulation of activin receptor signaling pathway; ISO:MGI.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IMP:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:MGI.
DR   GO; GO:0022409; P:positive regulation of cell-cell adhesion; ISO:MGI.
DR   GO; GO:0043280; P:positive regulation of cysteine-type endopeptidase activity involved in apoptotic process; ISO:MGI.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; ISO:MGI.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; ISO:MGI.
DR   GO; GO:0010862; P:positive regulation of pathway-restricted SMAD protein phosphorylation; ISO:MGI.
DR   GO; GO:0051091; P:positive regulation of sequence-specific DNA binding transcription factor activity; ISO:MGI.
DR   GO; GO:0060391; P:positive regulation of SMAD protein import into nucleus; ISO:MGI.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0010575; P:positive regulation of vascular endothelial growth factor production; ISO:MGI.
DR   GO; GO:0090009; P:primitive streak formation; IGI:MGI.
DR   GO; GO:0042981; P:regulation of apoptotic process; IBA:GO_Central.
DR   GO; GO:0010470; P:regulation of gastrulation; IGI:MGI.
DR   GO; GO:0043408; P:regulation of MAPK cascade; IBA:GO_Central.
DR   GO; GO:0009966; P:regulation of signal transduction; IDA:MGI.
DR   GO; GO:0060395; P:SMAD protein signal transduction; IDA:MGI.
DR   GO; GO:0019827; P:stem cell population maintenance; IMP:MGI.
DR   GO; GO:0048729; P:tissue morphogenesis; IMP:MGI.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; ISA:MGI.
DR   GO; GO:0090010; P:transforming growth factor beta receptor signaling pathway involved in primitive streak formation; IMP:MGI.
DR   GO; GO:0001829; P:trophectodermal cell differentiation; IDA:MGI.
DR   GO; GO:0001831; P:trophectodermal cellular morphogenesis; IMP:MGI.
DR   GO; GO:0001944; P:vasculature development; IMP:MGI.
DR   Gene3D; 2.10.90.10; -; 1.
DR   InterPro; IPR029034; Cystine-knot_cytokine.
DR   InterPro; IPR001839; TGF-b_C.
DR   InterPro; IPR015615; TGF-beta-rel.
DR   InterPro; IPR017948; TGFb_CS.
DR   PANTHER; PTHR11848; PTHR11848; 1.
DR   Pfam; PF00019; TGF_beta; 1.
DR   SMART; SM00204; TGFB; 1.
DR   SUPFAM; SSF57501; SSF57501; 1.
DR   PROSITE; PS00250; TGF_BETA_1; 1.
DR   PROSITE; PS51362; TGF_BETA_2; 1.
PE   2: Evidence at transcript level;
KW   Cleavage on pair of basic residues; Complete proteome; Cytokine;
KW   Developmental protein; Disulfide bond; Glycoprotein; Growth factor;
KW   Reference proteome; Secreted; Signal.
FT   SIGNAL        1     26       {ECO:0000255}.
FT   PROPEP       27    244       {ECO:0000255}.
FT                                /FTId=PRO_0000034000.
FT   CHAIN       245    354       Nodal.
FT                                /FTId=PRO_0000034001.
FT   CARBOHYD     73     73       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    254    320       {ECO:0000250}.
FT   DISULFID    283    351       {ECO:0000250}.
FT   DISULFID    287    353       {ECO:0000250}.
FT   DISULFID    319    319       Interchain. {ECO:0000250}.
FT   CONFLICT     93     94       EL -> DV (in Ref. 1; CAA49914).
FT                                {ECO:0000305}.
SQ   SEQUENCE   354 AA;  40476 MW;  40ECFC6785BB5826 CRC64;
     MSAHSLRILL LQACWALLHP RAPTAAALPL WTRGQPSSPS PLAYMLSLYR DPLPRADIIR
     SLQAQDVDVT GQNWTFTFDF SFLSQEEDLV WAELRLQLPG PMDIPTEGPL TIDIFHQAKG
     DPERDPADCL ERIWMETFTV IPSQVTFASG STVLEVTKPL SKWLKDPRAL EKQVSSRAEK
     CWHQPYTPPV PVASTNVLML YSNRPQEQRQ LGGATLLWEA ESSWRAQEGQ LSVERGGWGR
     RQRRHHLPDR SQLCRRVKFQ VDFNLIGWGS WIIYPKQYNA YRCEGECPNP VGEEFHPTNH
     AYIQSLLKRY QPHRVPSTCC APVKTKPLSM LYVDNGRVLL EHHKDMIVEE CGCL
//
ID   FIBG_HUMAN              Reviewed;         453 AA.
AC   P02679; A8K057; P04469; P04470; Q53Y18; Q96A14; Q96KJ3; Q9UC62;
AC   Q9UC63; Q9UCF3;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   16-APR-2002, sequence version 3.
DT   20-JAN-2016, entry version 205.
DE   RecName: Full=Fibrinogen gamma chain;
DE   Flags: Precursor;
GN   Name=FGG; ORFNames=PRO2061;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
RX   PubMed=6688357; DOI=10.1021/bi00282a033;
RA   Chung D.W., Chan W.-Y., Davie E.W.;
RT   "Characterization of a complementary deoxyribonucleic acid coding for
RT   the gamma chain of human fibrinogen.";
RL   Biochemistry 22:3250-3256(1983).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS GAMMA-A AND
RP   GAMMA-B).
RX   PubMed=2990550; DOI=10.1021/bi00329a041;
RA   Rixon M.W., Chung D.W., Davie E.W.;
RT   "Nucleotide sequence of the gene for the gamma chain of human
RT   fibrinogen.";
RL   Biochemistry 24:2077-2086(1985).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS GAMMA-A AND GAMMA-B).
RC   TISSUE=Liver;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM GAMMA-A).
RC   TISSUE=Fetal liver;
RA   Zhang C., Yu Y., Zhang S., Wei H., Zhou G., Bi J., Zhang Y., Liu M.,
RA   He F.;
RT   "Functional prediction of the coding sequences of 33 new genes deduced
RT   by analysis of cDNA clones from human fetal liver.";
RL   Submitted (JAN-1999) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM GAMMA-A).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS HIS-140 AND ARG-191.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JUN-2001) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM GAMMA-A).
RC   TISSUE=Skeletal muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   PROTEIN SEQUENCE OF 27-437.
RA   Henschen A., Lottspeich F., Southan C., Topfer-Petersen E.;
RT   "Human fibrinogen: sequence, sulfur bridges, glycosylation and some
RT   structural variants.";
RL   (In) Peeters H. (eds.);
RL   Protides of the biological fluids, Proc. 28th colloquium, pp.51-56,
RL   Pergamon Press, Oxford (1980).
RN   [10]
RP   PROTEIN SEQUENCE OF 27-41.
RC   TISSUE=Platelet;
RX   PubMed=8509453; DOI=10.1083/jcb.121.6.1329;
RA   Bertagnolli M.E., Beckerle M.C.;
RT   "Evidence for the selective association of a subpopulation of GPIIb-
RT   IIIa with the actin cytoskeletons of thrombin-activated platelets.";
RL   J. Cell Biol. 121:1329-1342(1993).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 75-286.
RC   TISSUE=Liver;
RX   PubMed=1685103;
RA   Marchetti L., Zanelli T., Malcovati M., Tenchini M.L.;
RT   "Polymorphism of the human gamma chain fibrinogen gene.";
RL   DNA Seq. 1:419-422(1991).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 209-270.
RX   PubMed=6689067; DOI=10.1093/nar/11.21.7427;
RA   Imam A.M.A., Eaton M.A.W., Williamson R., Humphries S.;
RT   "Isolation and characterisation of cDNA clones for the A alpha- and
RT   gamma-chains of human fibrinogen.";
RL   Nucleic Acids Res. 11:7427-7434(1983).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 285-437 (ISOFORMS GAMMA-A AND
RP   GAMMA-B).
RX   PubMed=6092346;
RA   Fornace A.J. Jr., Cummings D.E., Comeau C.M., Kant J.A.,
RA   Crabtree G.R.;
RT   "Structure of the human gamma-fibrinogen gene. Alternate mRNA splicing
RT   near the 3' end of the gene produces gamma A and gamma B forms of
RT   gamma-fibrinogen.";
RL   J. Biol. Chem. 259:12826-12830(1984).
RN   [14]
RP   PROTEIN SEQUENCE OF 291-310, AND VARIANTS BARCELONA-3/BARCELONA-4
RP   HIS-301 AND VILLAJOYOSA CYS-301.
RC   TISSUE=Blood;
RX   PubMed=7654933;
RA   Borrell M., Gari M., Coll I., Vallve C., Tirado I., Soria J.M.,
RA   Sala N., Munoz C., Oliver A., Garcia A.;
RT   "Abnormal polymerization and normal binding of plasminogen and t-PA in
RT   three new dysfibrinogenaemias: Barcelona III and IV (gamma Arg
RT   275-->His) and Villajoyosa (gamma Arg 275-->Cys).";
RL   Blood Coagul. Fibrinolysis 6:198-206(1995).
RN   [15]
RP   PROTEIN SEQUENCE OF 411-453 (ISOFORM GAMMA-B).
RX   PubMed=7306501; DOI=10.1021/bi00524a036;
RA   Wolfenstein-Todel C., Mosesson M.W.;
RT   "Carboxy-terminal amino acid sequence of a human fibrinogen gamma-
RT   chain variant (gamma').";
RL   Biochemistry 20:6146-6149(1981).
RN   [16]
RP   REVIEW, AND DISULFIDE BONDS.
RX   PubMed=6575689; DOI=10.1111/j.1749-6632.1983.tb23232.x;
RA   Henschen A., Lottspeich F., Kehl M., Southan C.;
RT   "Covalent structure of fibrinogen.";
RL   Ann. N. Y. Acad. Sci. 408:28-43(1983).
RN   [17]
RP   DISULFIDE BONDS.
RA   Doolittle R.F., Takagi T., Watt K.W.K., Bouma H. III, Cottrell B.A.,
RA   Cassman K.G., Goldbaum D.M., Doolittle L.R., Friezner S.J.;
RT   "The structures of fibrinogen and fibrin.";
RL   (In) Magnusson S., Ottesen M., Foltmann B., Dano K., Neurath H.
RL   (eds.);
RL   Regulatory proteolytic enzymes and their inhibitors, pp.163-172,
RL   Pergamon Press, New York (1978).
RN   [18]
RP   DISULFIDE BONDS.
RX   PubMed=936108; DOI=10.1016/0049-3848(76)90245-0;
RA   Blombaeck B., Hessel B., Hogg D.;
RT   "Disulfide bridges in NH2-terminal part of human fibrinogen.";
RL   Thromb. Res. 8:639-658(1976).
RN   [19]
RP   QUATERNARY STRUCTURE, AND DISULFIDE BONDS.
RX   PubMed=6860649; DOI=10.1021/bi00278a003;
RA   Hoeprich P.D., Doolittle R.F.;
RT   "Dimeric half-molecules of human fibrinogen are joined through
RT   disulfide bonds in an antiparallel orientation.";
RL   Biochemistry 22:2049-2055(1983).
RN   [20]
RP   SULFATION.
RX   PubMed=1892842; DOI=10.1021/bi00103a004;
RA   Farrel D.H., Mulvihill E.R., Huang S., Chung D.W., Davie E.W.;
RT   "Recombinant human fibrinogen and sulfation of the gamma' chain.";
RL   Biochemistry 30:9414-9420(1991).
RN   [21]
RP   SULFATION AT TYR-444 AND TYR-448.
RX   PubMed=11307817;
RA   Meh D.A., Siebenlist K.R., Brennan S.O., Holyst T., Mosesson M.W.;
RT   "The amino acid sequence in fibrin responsible for high affinity
RT   thrombin binding.";
RL   Thromb. Haemost. 85:470-474(2001).
RN   [22]
RP   REVIEW, ELECTRON MICROSCOPY, POLYMERIZATION, AND LIGANDS.
RX   PubMed=6383194;
RA   Doolittle R.F.;
RT   "Fibrinogen and fibrin.";
RL   Annu. Rev. Biochem. 53:195-229(1984).
RN   [23]
RP   POLYMERIZATION SITE.
RX   PubMed=6592597; DOI=10.1073/pnas.81.19.5980;
RA   Horwitz B.H., Varadi A., Scheraga H.A.;
RT   "Localization of a fibrin gamma-chain polymerization site within
RT   segment Thr-374 to Glu-396 of human fibrinogen.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:5980-5984(1984).
RN   [24]
RP   POLYMERIZATION SITE.
RX   PubMed=6451630;
RA   Olexa S.A., Budzynski A.Z.;
RT   "Localization of a fibrin polymerization site.";
RL   J. Biol. Chem. 256:3544-3549(1981).
RN   [25]
RP   PLATELET AGGREGATION SITE.
RX   PubMed=6326808; DOI=10.1021/bi00303a028;
RA   Kloczewiak M., Timmons S., Lukas T.J., Hawiger J.;
RT   "Platelet receptor recognition site on human fibrinogen. Synthesis and
RT   structure-function relationship of peptides corresponding to the
RT   carboxy-terminal segment of the gamma chain.";
RL   Biochemistry 23:1767-1774(1984).
RN   [26]
RP   PLATELET AGGREGATION SITE.
RX   PubMed=6325435;
RA   Plow E.F., Srouji A.H., Meyer D., Marguerie G., Ginsberg M.H.;
RT   "Evidence that three adhesive proteins interact with a common
RT   recognition site on activated platelets.";
RL   J. Biol. Chem. 259:5388-5391(1984).
RN   [27]
RP   CALCIUM-BINDING SITE.
RX   PubMed=3160702;
RA   Dang C.V., Ebert R.F., Bell W.R.;
RT   "Localization of a fibrinogen calcium binding site between gamma-
RT   subunit positions 311 and 336 by terbium fluorescence.";
RL   J. Biol. Chem. 260:9713-9719(1985).
RN   [28]
RP   CHROMATOGRAPHIC COMPARISON OF GAMMA-A AND GAMMA-B CHAINS.
RX   PubMed=6933547; DOI=10.1073/pnas.77.9.5069;
RA   Wolfenstein-Todel C., Mosesson M.W.;
RT   "Human plasma fibrinogen heterogeneity: evidence for an extended
RT   carboxyl-terminal sequence in a normal gamma chain variant (gamma').";
RL   Proc. Natl. Acad. Sci. U.S.A. 77:5069-5073(1980).
RN   [29]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-78.
RC   TISSUE=Plasma;
RX   PubMed=14760718; DOI=10.1002/pmic.200300556;
RA   Bunkenborg J., Pilch B.J., Podtelejnikov A.V., Wisniewski J.R.;
RT   "Screening for N-glycosylated proteins by liquid chromatography mass
RT   spectrometry.";
RL   Proteomics 4:454-465(2004).
RN   [30]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-78.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [31]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-78.
RC   TISSUE=Platelet;
RX   PubMed=16263699; DOI=10.1074/mcp.M500324-MCP200;
RA   Lewandrowski U., Moebius J., Walter U., Sickmann A.;
RT   "Elucidation of N-glycosylation sites on human platelet proteins: a
RT   glycoproteomic approach.";
RL   Mol. Cell. Proteomics 5:226-233(2006).
RN   [32]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-78.
RC   TISSUE=Milk;
RX   PubMed=18780401; DOI=10.1002/pmic.200701057;
RA   Picariello G., Ferranti P., Mamone G., Roepstorff P., Addeo F.;
RT   "Identification of N-linked glycoproteins in human milk by hydrophilic
RT   interaction liquid chromatography and mass spectrometry.";
RL   Proteomics 8:3833-3847(2008).
RN   [33]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-78.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [34]
RP   GLYCOSYLATION AT ASN-78.
RX   PubMed=19139490; DOI=10.1074/mcp.M800504-MCP200;
RA   Jia W., Lu Z., Fu Y., Wang H.P., Wang L.H., Chi H., Yuan Z.F.,
RA   Zheng Z.B., Song L.N., Han H.H., Liang Y.M., Wang J.L., Cai Y.,
RA   Zhang Y.K., Deng Y.L., Ying W.T., He S.M., Qian X.H.;
RT   "A strategy for precise and large scale identification of core
RT   fucosylated glycoproteins.";
RL   Mol. Cell. Proteomics 8:913-923(2009).
RN   [35]
RP   CLEAVAGE BY HEMENTIN AND PLASMIN.
RX   PubMed=2143188;
RA   Kirschbaum N.E., Budzynski A.Z.;
RT   "A unique proteolytic fragment of human fibrinogen containing the A
RT   alpha COOH-terminal domain of the native molecule.";
RL   J. Biol. Chem. 265:13669-13676(1990).
RN   [36]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [37]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [38]
RP   PHOSPHORYLATION AT SER-68.
RX   PubMed=26091039; DOI=10.1016/j.cell.2015.05.028;
RA   Tagliabracci V.S., Wiley S.E., Guo X., Kinch L.N., Durrant E., Wen J.,
RA   Xiao J., Cui J., Nguyen K.B., Engel J.L., Coon J.J., Grishin N.,
RA   Pinna L.A., Pagliarini D.J., Dixon J.E.;
RT   "A single kinase generates the majority of the secreted
RT   phosphoproteome.";
RL   Cell 161:1619-1632(2015).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 169-433 IN COMPLEX WITH
RP   CALCIUM, DISULFIDE BONDS, AND SUBUNIT.
RX   PubMed=9016719; DOI=10.1016/S0969-2126(97)00171-8;
RA   Yee V.C., Pratt K.P., Cote H.C.F., le Trong I., Chung D.W.,
RA   Davie E.W., Stenkamp R.E., Teller D.C.;
RT   "Crystal structure of a 30 kDa C-terminal fragment from the gamma
RT   chain of human fibrinogen.";
RL   Structure 5:125-138(1997).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (2.01 ANGSTROMS) OF 169-433 IN COMPLEX WITH
RP   CALCIUM, DISULFIDE BONDS, AND SUBUNIT.
RX   PubMed=9207064; DOI=10.1073/pnas.94.14.7176;
RA   Pratt K.P., Cote H.C.F., Chung D.W., Stenkamp R.E., Davie E.W.;
RT   "The primary fibrin polymerization pocket: three-dimensional structure
RT   of a 30-kDa C-terminal gamma chain fragment complexed with the peptide
RT   Gly-Pro-Arg-Pro.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:7176-7181(1997).
RN   [41]
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 114-432 IN COMPLEX WITH
RP   CALCIUM, DISULFIDE BONDS, AND SUBUNIT.
RX   PubMed=9333233; DOI=10.1038/38947;
RA   Spraggon G., Everse S.J., Doolittle R.F.;
RT   "Crystal structures of fragment D from human fibrinogen and its
RT   crosslinked counterpart from fibrin.";
RL   Nature 389:455-462(1997).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 114-432 IN COMPLEX WITH
RP   CALCIUM, DISULFIDE BONDS, SUBUNIT, DOMAIN, SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=9628725; DOI=10.1021/bi9804129;
RA   Everse S.J., Spraggon G., Veerapandian L., Riley M., Doolittle R.F.;
RT   "Crystal structure of fragment double-D from human fibrin with two
RT   different bound ligands.";
RL   Biochemistry 37:8637-8642(1998).
RN   [43]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 114-432 IN COMPLEX WITH
RP   CALCIUM, DISULFIDE BONDS, SUBUNIT, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=10074346; DOI=10.1021/bi982626w;
RA   Everse S.J., Spraggon G., Veerapandian L., Doolittle R.F.;
RT   "Conformational changes in fragments D and double-D from human
RT   fibrin(ogen) upon binding the peptide ligand Gly-His-Arg-Pro-amide.";
RL   Biochemistry 38:2941-2946(1999).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 27-433 IN COMPLEX WITH
RP   CALCIUM, DISULFIDE BONDS, SUBUNIT, DOMAIN, SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=19296670; DOI=10.1021/bi802205g;
RA   Kollman J.M., Pandi L., Sawaya M.R., Riley M., Doolittle R.F.;
RT   "Crystal structure of human fibrinogen.";
RL   Biochemistry 48:3877-3886(2009).
RN   [45]
RP   VARIANT ASAHI THR-336.
RX   PubMed=2496144; DOI=10.1172/JCI114056;
RA   Yamazumi K., Shimura K., Terukina S., Takahashi N., Matsuda M.;
RT   "A gamma methionine-310 to threonine substitution and consequent N-
RT   glycosylation at gamma asparagine-308 identified in a congenital
RT   dysfibrinogenemia associated with posttraumatic bleeding, fibrinogen
RT   Asahi.";
RL   J. Clin. Invest. 83:1590-1597(1989).
RN   [46]
RP   VARIANTS OSAKA-2 CYS-301; KYOTO-1 LYS-334; ASAHI THR-336 AND KYOTO-3
RP   TYR-356.
RX   PubMed=1421174;
RA   Mimuro J., Muramatsu S., Maekawa H., Sakata Y., Kaneko M.,
RA   Yoshitake S., Okuma M., Ito Y., Takeda Y., Matsuda M.;
RT   "Gene analyses of abnormal fibrinogens with a mutation in the gamma
RT   chain.";
RL   Int. J. Hematol. 56:129-134(1992).
RN   [47]
RP   INVOLVEMENT IN DYSFIBRIN, AND VARIANT DYSFIBRIN VAL-318.
RX   PubMed=2257302;
RA   Bantia S., Mane S.M., Bell W.R., Dang C.V.;
RT   "Fibrinogen Baltimore I: polymerization defect associated with a gamma
RT   292Gly-->Val (GGC-->GTC) mutation.";
RL   Blood 76:2279-2283(1990).
RN   [48]
RP   VARIANT BALTIMORE-3 ILE-334.
RX   PubMed=2328317;
RA   Bantia S., Bell W.R., Dang C.V.;
RT   "Polymerization defect of fibrinogen Baltimore III due to a gamma
RT   Asn308-->Ile mutation.";
RL   Blood 75:1659-1663(1990).
RN   [49]
RP   VARIANT BERN-1 LYS-363.
RX   PubMed=8400260;
RA   Steinmann C., Reber P., Jungo M., Laemmle B., Heinemann G.,
RA   Wermuth B., Furlan M.;
RT   "Fibrinogen Bern I: substitution gamma 337 Asn-->Lys is responsible
RT   for defective fibrin monomer polymerization.";
RL   Blood 82:2104-2108(1993).
RN   [50]
RP   VARIANT KYOTO-1 LYS-334.
RX   PubMed=2971046;
RA   Yoshida N., Terukina S., Okuma M., Moroi M., Aoki N., Matsuda M.;
RT   "Characterization of an apparently lower molecular weight gamma-chain
RT   variant in fibrinogen Kyoto I. The replacement of gamma-asparagine 308
RT   by lysine which causes accelerated cleavage of fragment D1 by plasmin
RT   and the generation of a new plasmin cleavage site.";
RL   J. Biol. Chem. 263:13848-13856(1988).
RN   [51]
RP   VARIANT KYOTO-3 TYR-356.
RX   PubMed=2819242;
RA   Terukina S., Yamazumi K., Okamoto K., Yamashita H., Ito Y.,
RA   Matsuda M.;
RT   "Fibrinogen Kyoto III: a congenital dysfibrinogen with a gamma
RT   aspartic acid-330 to tyrosine substitution manifesting impaired fibrin
RT   monomer polymerization.";
RL   Blood 74:2681-2687(1989).
RN   [52]
RP   VARIANT DYSFIBRIN VAL-356.
RX   PubMed=3708159;
RA   Reber P., Furlan M., Rupp C., Kehl M., Henschen A., Mannucci P.M.,
RA   Beck E.A.;
RT   "Characterization of fibrinogen Milano I: amino acid exchange gamma
RT   330 Asp-->Val impairs fibrin polymerization.";
RL   Blood 67:1751-1756(1986).
RN   [53]
RP   VARIANT MILANO-5 CYS-301.
RX   PubMed=7841300;
RA   Steinmann C., Boegli C., Jungo M., Laemmle B., Heinemann G.,
RA   Wermuth B., Redaelli R., Baudo F., Furlan M.;
RT   "Fibrinogen Milano V: a congenital dysfibrinogenaemia with a gamma 275
RT   Arg-->Cys substitution.";
RL   Blood Coagul. Fibrinolysis 5:463-471(1994).
RN   [54]
RP   VARIANT MILANO-7 CYS-384.
RX   PubMed=8080993;
RA   Steinmann C., Boegli C., Jungo M., Laemmle B., Heinemann G.,
RA   Wermuth B., Redaelli R., Baudo F., Furlan M.;
RT   "A new substitution, gamma 358 Ser-->Cys, in fibrinogen Milano VII
RT   causes defective fibrin polymerization.";
RL   Blood 84:1874-1880(1994).
RN   [55]
RP   VARIANT NAGOYA-1 ARG-355.
RX   PubMed=2738036;
RA   Miyata T., Furukawa K., Iwanaga S., Takamatsu J., Saito H.;
RT   "Fibrinogen Nagoya, a replacement of glutamine-329 by arginine in the
RT   gamma-chain that impairs the polymerization of fibrin monomer.";
RL   J. Biochem. 105:10-14(1989).
RN   [56]
RP   VARIANT OSAKA-2 CYS-301.
RX   PubMed=2971042;
RA   Terukina S., Matsuda M., Hirata H., Takeda Y., Miyata T., Takao T.,
RA   Shimonishi Y.;
RT   "Substitution of gamma Arg-275 by Cys in an abnormal fibrinogen,
RT   'fibrinogen Osaka II'. Evidence for a unique solitary cystine
RT   structure at the mutation site.";
RL   J. Biol. Chem. 263:13579-13587(1988).
RN   [57]
RP   VARIANT OSAKA-3 HIS-301.
RX   PubMed=1455400;
RA   Yoshida N., Imoka S., Hirata H., Matsuda M., Asakura S.;
RT   "Heterozygous abnormal fibrinogen Osaka III with the replacement of
RT   gamma arginine-275 by histidine has an apparently higher molecular
RT   weight gamma-chain variant.";
RL   Thromb. Haemost. 68:534-538(1992).
RN   [58]
RP   VARIANT OSAKA-5 GLY-401.
RX   PubMed=1733971;
RA   Yoshida N., Hirata H., Morigami Y., Imaoka S., Matsuda M.,
RA   Yamazumi K., Asakura S.;
RT   "Characterization of an abnormal fibrinogen Osaka V with the
RT   replacement of gamma-arginine 375 by glycine. The lack of high
RT   affinity calcium binding to D-domains and the lack of protective
RT   effect of calcium on fibrinolysis.";
RL   J. Biol. Chem. 267:2753-2759(1992).
RN   [59]
RP   VARIANT PARIS-1 GLY-377 DELINS
RP   VAL-MET-CYS-GLY-GLU-ALA-LEU-PRO-MET-LEU-LYS-ASP-PRO-CYS-TYR-SER.
RX   PubMed=8470043;
RA   Rosenberg J.B., Newman P.J., Mosesson M.W., Guillin M.-C.,
RA   Amrani D.L.;
RT   "Paris I dysfibrinogenemia: a point mutation in intron 8 results in
RT   insertion of a 15 amino acid sequence in the fibrinogen gamma-chain.";
RL   Thromb. Haemost. 69:217-220(1993).
RN   [60]
RP   VARIANT TOCHIGI CYS-301.
RX   PubMed=3337908;
RA   Yoshida N., Ota K., Moroi M., Matsuda M.;
RT   "An apparently higher molecular weight gamma-chain variant in a new
RT   congenital abnormal fibrinogen Tochigi characterized by the
RT   replacement of gamma arginine-275 by cysteine.";
RL   Blood 71:480-487(1988).
RN   [61]
RP   VARIANT VLISSINGEN 345-ASN-ASP-346 DEL.
RX   PubMed=2071611;
RA   Koopman J., Haverkate F., Briet E., Lord S.T.;
RT   "A congenitally abnormal fibrinogen (Vlissingen) with a 6-base
RT   deletion in the gamma-chain gene, causing defective calcium binding
RT   and impaired fibrin polymerization.";
RL   J. Biol. Chem. 266:13456-13461(1991).
RN   [62]
RP   VARIANT BERGAMO-2/ESSEN/HAIFA/PERUGIA HIS-301.
RX   PubMed=3563970;
RA   Reber P., Furlan M., Henschen A., Kaudewitz H., Barbui T., Hilgard P.,
RA   Nenci G.G., Berrettini M., Beck E.A.;
RT   "Three abnormal fibrinogen variants with the same amino acid
RT   substitution (gamma 275 Arg-->His): fibrinogens Bergamo II, Essen and
RT   Perugia.";
RL   Thromb. Haemost. 56:401-406(1986).
RN   [63]
RP   INVOLVEMENT IN DYSFIBRIN, AND VARIANT DYSFIBRIN HIS-301.
RX   PubMed=2976995;
RA   Yamazumi K., Terukina S., Onohara S., Matsuda M.;
RT   "Normal plasmic cleavage of the gamma-chain variant of 'fibrinogen
RT   Saga' with an Arg-275 to His substitution.";
RL   Thromb. Haemost. 60:476-480(1988).
RN   [64]
RP   VARIANT MILANO-12 ARG-191.
RX   PubMed=11435303; DOI=10.1182/blood.V98.2.351;
RA   Bolliger-Stucki B., Lord S.T., Furlan M.;
RT   "Fibrinogen Milano XII: a dysfunctional variant containing 2 amino
RT   acid substitutions, A-alpha R16C and gamma G165R.";
RL   Blood 98:351-357(2001).
RN   [65]
RP   VARIANTS ARG-191 AND VAL-410.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions
RT   of human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [66]
RP   ERRATUM.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
RN   [67]
RP   VARIANT HILLSBOROUGH ASP-335.
RX   PubMed=11986213; DOI=10.1182/blood.V99.10.3597;
RA   Mullin J.L., Brennan S.O., Ganly P.S., George P.M.;
RT   "Fibrinogen Hillsborough: a novel gamma-gly309asp dysfibrinogen with
RT   impaired clotting.";
RL   Blood 99:3597-3601(2002).
RN   [68]
RP   VARIANT DYSFIBRIN PRO-404.
RX   PubMed=15632207; DOI=10.1182/blood-2004-04-1621;
RA   Keller M.A., Martinez J., Baradet T.C., Nagaswami C., Chernysh I.N.,
RA   Borowski M.K., Surrey S., Weisel J.W.;
RT   "Fibrinogen Philadelphia, a hypodysfibrinogenemia characterized by
RT   abnormal polymerization and fibrinogen hypercatabolism due to gamma
RT   S378P mutation.";
RL   Blood 105:3162-3168(2005).
RN   [69]
RP   INVOLVEMENT IN CAFBN; VARIANTS CAFBN PRO-303; HIS-327; ASP-345 AND
RP   TRP-401, AND CHARACTERIZATION OF VARIANTS CAFBN PRO-303; HIS-327 AND
RP   ASP-345.
RX   PubMed=25427968; DOI=10.1160/TH14-07-0629;
RA   Asselta R., Plate M., Robusto M., Borhany M., Guella I., Solda G.,
RA   Afrasiabi A., Menegatti M., Shamsi T., Peyvandi F., Duga S.;
RT   "Clinical and molecular characterisation of 21 patients affected by
RT   quantitative fibrinogen deficiency.";
RL   Thromb. Haemost. 113:567-576(2015).
CC   -!- FUNCTION: Together with fibrinogen alpha (FGA) and fibrinogen beta
CC       (FGB), polymerizes to form an insoluble fibrin matrix. Has a major
CC       function in hemostasis as one of the primary components of blood
CC       clots. In addition, functions during the early stages of wound
CC       repair to stabilize the lesion and guide cell migration during re-
CC       epithelialization. Was originally thought to be essential for
CC       platelet aggregation, based on in vitro studies using
CC       anticoagulated blood. However, subsequent studies have shown that
CC       it is not absolutely required for thrombus formation in vivo.
CC       Enhances expression of SELP in activated platelets via an ITGB3-
CC       dependent pathway. Maternal fibrinogen is essential for successful
CC       pregnancy. Fibrin deposition is also associated with infection,
CC       where it protects against IFNG-mediated hemorrhage. May also
CC       facilitate the antibacterial immune response via both innate and
CC       T-cell mediated pathways. {ECO:0000250|UniProtKB:E9PV24}.
CC   -!- SUBUNIT: Heterohexamer; disulfide linked. Contains 2 sets of 3
CC       non-identical chains (alpha, beta and gamma). The 2 heterotrimers
CC       are in head to head conformation with the N-termini in a small
CC       central domain. {ECO:0000269|PubMed:10074346,
CC       ECO:0000269|PubMed:19296670, ECO:0000269|PubMed:6860649,
CC       ECO:0000269|PubMed:9016719, ECO:0000269|PubMed:9207064,
CC       ECO:0000269|PubMed:9333233, ECO:0000269|PubMed:9628725}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:10074346,
CC       ECO:0000269|PubMed:19296670, ECO:0000269|PubMed:9628725}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Gamma-B; Synonyms=Gamma';
CC         IsoId=P02679-1; Sequence=Displayed;
CC         Note=Present in about 10% of the fibrinogen molecules in plasma
CC         but absent from those in the platelets.;
CC       Name=Gamma-A;
CC         IsoId=P02679-2; Sequence=VSP_001537;
CC   -!- TISSUE SPECIFICITY: Detected in blood plasma (at protein level).
CC       {ECO:0000269|PubMed:10074346, ECO:0000269|PubMed:19296670,
CC       ECO:0000269|PubMed:9628725}.
CC   -!- DOMAIN: A long coiled coil structure formed by 3 polypeptide
CC       chains connects the central nodule to the C-terminal domains
CC       (distal nodules). The long C-terminal ends of the alpha chains
CC       fold back, contributing a fourth strand to the coiled coil
CC       structure. {ECO:0000269|PubMed:19296670,
CC       ECO:0000269|PubMed:9628725}.
CC   -!- PTM: Conversion of fibrinogen to fibrin is triggered by thrombin,
CC       which cleaves fibrinopeptides A and B from alpha and beta chains,
CC       and thus exposes the N-terminal polymerization sites responsible
CC       for the formation of the soft clot. The soft clot is converted
CC       into the hard clot by factor XIIIA which catalyzes the epsilon-
CC       (gamma-glutamyl)lysine cross-linking between gamma chains
CC       (stronger) and between alpha chains (weaker) of different
CC       monomers. {ECO:0000269|PubMed:2143188}.
CC   -!- PTM: Sulfation of C-terminal tyrosines increases affinity for
CC       thrombin. {ECO:0000269|PubMed:11307817,
CC       ECO:0000269|PubMed:1892842}.
CC   -!- DISEASE: Congenital afibrinogenemia (CAFBN) [MIM:202400]: Rare
CC       autosomal recessive disorder is characterized by bleeding that
CC       varies from mild to severe and by complete absence or extremely
CC       low levels of plasma and platelet fibrinogen.
CC       {ECO:0000269|PubMed:25427968}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry. Patients
CC       with congenital fibrinogen abnormalities can manifest different
CC       clinical pictures. Some cases are clinically silent, some show a
CC       tendency toward bleeding and some show a predisposition for
CC       thrombosis with or without bleeding.
CC   -!- DISEASE: Dysfibrinogenemia, congenital (DYSFIBRIN) [MIM:616004]: A
CC       disorder characterized by qualitative abnormalities
CC       (dysfibrinogenemia) of the circulating fibrinogen. Affected
CC       individuals are frequently asymptomatic, but some patients have
CC       bleeding diathesis, thromboembolic complications, or both. In some
CC       cases, dysfibrinogenemia is associated with low circulating
CC       fibrinogen levels (hypodysfibrinogenemia).
CC       {ECO:0000269|PubMed:15632207, ECO:0000269|PubMed:2257302,
CC       ECO:0000269|PubMed:2976995, ECO:0000269|PubMed:3708159}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- MISCELLANEOUS: The gamma-chain carries the main binding site for
CC       the platelet receptor.
CC   -!- SIMILARITY: Contains 1 fibrinogen C-terminal domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00739}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Fibrinogen entry;
CC       URL="https://en.wikipedia.org/wiki/Fibrinogen";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/fgg/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M10014; AAB59530.1; -; Genomic_DNA.
DR   EMBL; M10014; AAB59531.1; -; Genomic_DNA.
DR   EMBL; AF118092; AAF22036.1; -; mRNA.
DR   EMBL; AF350254; AAK19751.2; -; Genomic_DNA.
DR   EMBL; AF350254; AAK19752.2; -; Genomic_DNA.
DR   EMBL; AK289422; BAF82111.1; -; mRNA.
DR   EMBL; AK290824; BAF83513.1; -; mRNA.
DR   EMBL; BT007081; AAP35744.1; -; mRNA.
DR   EMBL; CH471056; EAX04917.1; -; Genomic_DNA.
DR   EMBL; CH471056; EAX04919.1; -; Genomic_DNA.
DR   EMBL; BC007044; AAH07044.1; -; mRNA.
DR   EMBL; BC021674; AAH21674.1; -; mRNA.
DR   EMBL; X51473; CAA35837.1; -; mRNA.
DR   EMBL; X00086; CAA24944.1; -; mRNA.
DR   EMBL; K02569; AAA52430.1; -; Genomic_DNA.
DR   EMBL; K02569; AAA52431.1; -; Genomic_DNA.
DR   CCDS; CCDS3788.1; -. [P02679-1]
DR   CCDS; CCDS47153.1; -. [P02679-2]
DR   PIR; A90470; FGHUG.
DR   PIR; A90494; FGHUGB.
DR   RefSeq; NP_000500.2; NM_000509.5. [P02679-2]
DR   RefSeq; NP_068656.2; NM_021870.2. [P02679-1]
DR   UniGene; Hs.727584; -.
DR   PDB; 1DUG; X-ray; 1.80 A; A/B=424-433.
DR   PDB; 1FIB; X-ray; 2.10 A; A=169-433.
DR   PDB; 1FIC; X-ray; 2.50 A; A/B=169-433.
DR   PDB; 1FID; X-ray; 2.10 A; A=169-433.
DR   PDB; 1FZA; X-ray; 2.90 A; C/F=114-432.
DR   PDB; 1FZB; X-ray; 2.90 A; C/F=114-432.
DR   PDB; 1FZC; X-ray; 2.30 A; C/F=114-432.
DR   PDB; 1FZE; X-ray; 3.00 A; C/F=114-432.
DR   PDB; 1FZF; X-ray; 2.70 A; C/F=114-432.
DR   PDB; 1FZG; X-ray; 2.50 A; C/F=114-432.
DR   PDB; 1LT9; X-ray; 2.80 A; C/F=122-432.
DR   PDB; 1LTJ; X-ray; 2.80 A; C/F=122-432.
DR   PDB; 1N86; X-ray; 3.20 A; C/F=114-433.
DR   PDB; 1N8E; X-ray; 4.50 A; C/F=114-433.
DR   PDB; 1RE3; X-ray; 2.45 A; C/F=122-432.
DR   PDB; 1RE4; X-ray; 2.70 A; C/F=122-432.
DR   PDB; 1RF0; X-ray; 2.81 A; C/F=122-432.
DR   PDB; 1RF1; X-ray; 2.53 A; C/F=122-432.
DR   PDB; 2A45; X-ray; 3.65 A; I/L=27-71.
DR   PDB; 2FFD; X-ray; 2.89 A; C/F=122-432.
DR   PDB; 2FIB; X-ray; 2.01 A; A=169-433.
DR   PDB; 2H43; X-ray; 2.70 A; C/F=115-433.
DR   PDB; 2HLO; X-ray; 2.60 A; C/F=114-433.
DR   PDB; 2HOD; X-ray; 2.90 A; C/F/I/L=115-433.
DR   PDB; 2HPC; X-ray; 2.90 A; C/F/I/L=115-433.
DR   PDB; 2HWL; X-ray; 2.40 A; P=439-452.
DR   PDB; 2OYH; X-ray; 2.40 A; C/F=122-432.
DR   PDB; 2OYI; X-ray; 2.70 A; C/F=122-432.
DR   PDB; 2Q9I; X-ray; 2.80 A; C/F=114-433.
DR   PDB; 2VDO; X-ray; 2.51 A; C=426-433.
DR   PDB; 2VDP; X-ray; 2.80 A; C=428-433.
DR   PDB; 2VDQ; X-ray; 2.59 A; C=426-435.
DR   PDB; 2VDR; X-ray; 2.40 A; C=428-452.
DR   PDB; 2VR3; X-ray; 1.95 A; C/D=425-436.
DR   PDB; 2XNX; X-ray; 3.30 A; C/F/I/L=114-432.
DR   PDB; 2XNY; X-ray; 7.50 A; C/F=114-432.
DR   PDB; 2Y7L; X-ray; 1.49 A; B=421-433.
DR   PDB; 2Z4E; X-ray; 2.70 A; C/F=114-433.
DR   PDB; 3BVH; X-ray; 2.60 A; C/F=128-420.
DR   PDB; 3E1I; X-ray; 2.30 A; C/F=114-432.
DR   PDB; 3FIB; X-ray; 2.10 A; A=170-418.
DR   PDB; 3GHG; X-ray; 2.90 A; C/F/I/L=27-433.
DR   PDB; 3H32; X-ray; 3.60 A; C/F=121-433.
DR   PDB; 3HUS; X-ray; 3.04 A; C/F=122-432.
DR   PDB; 4B60; X-ray; 1.83 A; C/D=421-433.
DR   PDBsum; 1DUG; -.
DR   PDBsum; 1FIB; -.
DR   PDBsum; 1FIC; -.
DR   PDBsum; 1FID; -.
DR   PDBsum; 1FZA; -.
DR   PDBsum; 1FZB; -.
DR   PDBsum; 1FZC; -.
DR   PDBsum; 1FZE; -.
DR   PDBsum; 1FZF; -.
DR   PDBsum; 1FZG; -.
DR   PDBsum; 1LT9; -.
DR   PDBsum; 1LTJ; -.
DR   PDBsum; 1N86; -.
DR   PDBsum; 1N8E; -.
DR   PDBsum; 1RE3; -.
DR   PDBsum; 1RE4; -.
DR   PDBsum; 1RF0; -.
DR   PDBsum; 1RF1; -.
DR   PDBsum; 2A45; -.
DR   PDBsum; 2FFD; -.
DR   PDBsum; 2FIB; -.
DR   PDBsum; 2H43; -.
DR   PDBsum; 2HLO; -.
DR   PDBsum; 2HOD; -.
DR   PDBsum; 2HPC; -.
DR   PDBsum; 2HWL; -.
DR   PDBsum; 2OYH; -.
DR   PDBsum; 2OYI; -.
DR   PDBsum; 2Q9I; -.
DR   PDBsum; 2VDO; -.
DR   PDBsum; 2VDP; -.
DR   PDBsum; 2VDQ; -.
DR   PDBsum; 2VDR; -.
DR   PDBsum; 2VR3; -.
DR   PDBsum; 2XNX; -.
DR   PDBsum; 2XNY; -.
DR   PDBsum; 2Y7L; -.
DR   PDBsum; 2Z4E; -.
DR   PDBsum; 3BVH; -.
DR   PDBsum; 3E1I; -.
DR   PDBsum; 3FIB; -.
DR   PDBsum; 3GHG; -.
DR   PDBsum; 3H32; -.
DR   PDBsum; 3HUS; -.
DR   PDBsum; 4B60; -.
DR   ProteinModelPortal; P02679; -.
DR   SMR; P02679; 28-421.
DR   BioGrid; 108557; 22.
DR   DIP; DIP-29644N; -.
DR   IntAct; P02679; 4.
DR   MINT; MINT-5004002; -.
DR   STRING; 9606.ENSP00000336829; -.
DR   ChEMBL; CHEMBL2364709; -.
DR   DrugBank; DB00364; Sucralfate.
DR   iPTMnet; P02679; -.
DR   PhosphoSite; P02679; -.
DR   UniCarbKB; P02679; -.
DR   BioMuta; FGG; -.
DR   DMDM; 20178280; -.
DR   DOSAC-COBS-2DPAGE; P02679; -.
DR   OGP; P02679; -.
DR   REPRODUCTION-2DPAGE; IPI00219713; -.
DR   REPRODUCTION-2DPAGE; P02679; -.
DR   SWISS-2DPAGE; P02679; -.
DR   MaxQB; P02679; -.
DR   PaxDb; P02679; -.
DR   PeptideAtlas; P02679; -.
DR   PRIDE; P02679; -.
DR   DNASU; 2266; -.
DR   Ensembl; ENST00000336098; ENSP00000336829; ENSG00000171557. [P02679-1]
DR   Ensembl; ENST00000404648; ENSP00000384860; ENSG00000171557. [P02679-2]
DR   GeneID; 2266; -.
DR   KEGG; hsa:2266; -.
DR   UCSC; uc003iog.3; human. [P02679-2]
DR   UCSC; uc003ioj.3; human. [P02679-1]
DR   CTD; 2266; -.
DR   GeneCards; FGG; -.
DR   HGNC; HGNC:3694; FGG.
DR   HPA; HPA027529; -.
DR   MalaCards; FGG; -.
DR   MIM; 134850; gene.
DR   MIM; 202400; phenotype.
DR   MIM; 616004; phenotype.
DR   neXtProt; NX_P02679; -.
DR   Orphanet; 98880; Familial afibrinogenemia.
DR   Orphanet; 98881; Familial dysfibrinogenemia.
DR   Orphanet; 248408; Familial hypodysfibrinogenemia.
DR   Orphanet; 101041; Familial hypofibrinogenemia.
DR   PharmGKB; PA430; -.
DR   eggNOG; KOG2579; Eukaryota.
DR   eggNOG; ENOG410ZYS4; LUCA.
DR   GeneTree; ENSGT00760000118809; -.
DR   HOVERGEN; HBG099783; -.
DR   InParanoid; P02679; -.
DR   KO; K03905; -.
DR   OrthoDB; EOG7X9G60; -.
DR   PhylomeDB; P02679; -.
DR   TreeFam; TF336658; -.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-140875; Common Pathway of Fibrin Clot Formation.
DR   Reactome; R-HSA-216083; Integrin cell surface interactions.
DR   Reactome; R-HSA-354192; Integrin alphaIIb beta3 signaling.
DR   Reactome; R-HSA-354194; GRB2:SOS provides linkage to MAPK signaling for Integrins.
DR   Reactome; R-HSA-372708; p130Cas linkage to MAPK signaling for integrins.
DR   Reactome; R-HSA-5674135; MAP2K and MAPK activation.
DR   ChiTaRS; FGG; human.
DR   EvolutionaryTrace; P02679; -.
DR   GeneWiki; FGG; -.
DR   GenomeRNAi; 2266; -.
DR   NextBio; 9205; -.
DR   PMAP-CutDB; P02679; -.
DR   PRO; PR:P02679; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; P02679; -.
DR   CleanEx; HS_FGG; -.
DR   ExpressionAtlas; P02679; baseline and differential.
DR   Genevisible; P02679; HS.
DR   GO; GO:0072562; C:blood microparticle; IDA:UniProtKB.
DR   GO; GO:0005938; C:cell cortex; IEA:Ensembl.
DR   GO; GO:0009986; C:cell surface; IDA:BHF-UCL.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005577; C:fibrinogen complex; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0031091; C:platelet alpha granule; IDA:BHF-UCL.
DR   GO; GO:0031093; C:platelet alpha granule lumen; TAS:Reactome.
DR   GO; GO:0050839; F:cell adhesion molecule binding; IPI:BHF-UCL.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005102; F:receptor binding; IPI:BHF-UCL.
DR   GO; GO:0005198; F:structural molecule activity; IDA:BHF-UCL.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0072378; P:blood coagulation, fibrin clot formation; IDA:UniProtKB.
DR   GO; GO:0007160; P:cell-matrix adhesion; IDA:BHF-UCL.
DR   GO; GO:0043623; P:cellular protein complex assembly; IDA:BHF-UCL.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0042730; P:fibrinolysis; IDA:UniProtKB.
DR   GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; IDA:BHF-UCL.
DR   GO; GO:1902042; P:negative regulation of extrinsic apoptotic signaling pathway via death domain receptors; IDA:BHF-UCL.
DR   GO; GO:0031639; P:plasminogen activation; IDA:UniProtKB.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0070527; P:platelet aggregation; IDA:BHF-UCL.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:BHF-UCL.
DR   GO; GO:0045921; P:positive regulation of exocytosis; IDA:BHF-UCL.
DR   GO; GO:0034116; P:positive regulation of heterotypic cell-cell adhesion; IDA:BHF-UCL.
DR   GO; GO:0090277; P:positive regulation of peptide hormone secretion; IDA:BHF-UCL.
DR   GO; GO:0050714; P:positive regulation of protein secretion; IDA:BHF-UCL.
DR   GO; GO:1900026; P:positive regulation of substrate adhesion-dependent cell spreading; NAS:BHF-UCL.
DR   GO; GO:0045907; P:positive regulation of vasoconstriction; IDA:BHF-UCL.
DR   GO; GO:0051258; P:protein polymerization; IMP:BHF-UCL.
DR   GO; GO:0009306; P:protein secretion; IMP:UniProtKB.
DR   GO; GO:0051592; P:response to calcium ion; IDA:BHF-UCL.
DR   GO; GO:0007165; P:signal transduction; IEA:InterPro.
DR   Gene3D; 3.90.215.10; -; 1.
DR   Gene3D; 4.10.530.10; -; 1.
DR   InterPro; IPR014716; Fibrinogen_a/b/g_C_1.
DR   InterPro; IPR014715; Fibrinogen_a/b/g_C_2.
DR   InterPro; IPR002181; Fibrinogen_a/b/g_C_dom.
DR   InterPro; IPR012290; Fibrinogen_a/b/g_coil_dom.
DR   InterPro; IPR020837; Fibrinogen_CS.
DR   Pfam; PF08702; Fib_alpha; 1.
DR   Pfam; PF00147; Fibrinogen_C; 1.
DR   SMART; SM00186; FBG; 1.
DR   SUPFAM; SSF56496; SSF56496; 1.
DR   PROSITE; PS00514; FIBRINOGEN_C_1; 1.
DR   PROSITE; PS51406; FIBRINOGEN_C_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Blood coagulation; Calcium;
KW   Coiled coil; Complete proteome; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; Glycoprotein; Hemostasis;
KW   Isopeptide bond; Metal-binding; Phosphoprotein; Polymorphism;
KW   Reference proteome; Secreted; Signal; Sulfation.
FT   SIGNAL        1     26       {ECO:0000269|PubMed:8509453,
FT                                ECO:0000269|Ref.9}.
FT   CHAIN        27    453       Fibrinogen gamma chain.
FT                                /FTId=PRO_0000009099.
FT   DOMAIN      170    416       Fibrinogen C-terminal.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00739}.
FT   REGION      400    422       Gamma-chain polymerization, binding amino
FT                                end of another fibrin alpha chain.
FT   REGION      423    437       Platelet aggregation and Staphylococcus
FT                                clumping.
FT   METAL       344    344       Calcium. {ECO:0000244|PDB:1FID,
FT                                ECO:0000269|PubMed:10074346,
FT                                ECO:0000269|PubMed:19296670,
FT                                ECO:0000269|PubMed:9016719,
FT                                ECO:0000269|PubMed:9207064,
FT                                ECO:0000269|PubMed:9333233,
FT                                ECO:0000269|PubMed:9628725}.
FT   METAL       346    346       Calcium. {ECO:0000244|PDB:1FID,
FT                                ECO:0000269|PubMed:10074346,
FT                                ECO:0000269|PubMed:19296670,
FT                                ECO:0000269|PubMed:9016719,
FT                                ECO:0000269|PubMed:9207064,
FT                                ECO:0000269|PubMed:9333233,
FT                                ECO:0000269|PubMed:9628725}.
FT   METAL       348    348       Calcium; via carbonyl oxygen.
FT                                {ECO:0000244|PDB:1FID,
FT                                ECO:0000269|PubMed:10074346,
FT                                ECO:0000269|PubMed:19296670,
FT                                ECO:0000269|PubMed:9016719,
FT                                ECO:0000269|PubMed:9207064,
FT                                ECO:0000269|PubMed:9333233,
FT                                ECO:0000269|PubMed:9628725}.
FT   METAL       350    350       Calcium; via carbonyl oxygen.
FT                                {ECO:0000244|PDB:1FID,
FT                                ECO:0000269|PubMed:10074346,
FT                                ECO:0000269|PubMed:19296670,
FT                                ECO:0000269|PubMed:9016719,
FT                                ECO:0000269|PubMed:9207064,
FT                                ECO:0000269|PubMed:9333233,
FT                                ECO:0000269|PubMed:9628725}.
FT   SITE         84     85       Cleavage; by plasmin; to break down
FT                                fibrin clots.
FT   SITE         88     89       Cleavage; by plasmin; to break down
FT                                fibrin clots.
FT   SITE        102    103       Cleavage; by hementin; to prevent blood
FT                                coagulation.
FT   MOD_RES      68     68       Phosphoserine; by FAM20C.
FT                                {ECO:0000269|PubMed:26091039}.
FT   MOD_RES     444    444       Sulfotyrosine.
FT                                {ECO:0000269|PubMed:11307817}.
FT   MOD_RES     448    448       Sulfotyrosine.
FT                                {ECO:0000269|PubMed:11307817}.
FT   CARBOHYD     78     78       N-linked (GlcNAc...) (complex).
FT                                {ECO:0000269|PubMed:14760718,
FT                                ECO:0000269|PubMed:16263699,
FT                                ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:18780401,
FT                                ECO:0000269|PubMed:19139490,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    334    334       N-linked (GlcNAc...); in variant Asahi.
FT   DISULFID     34     34       Interchain (with C-35).
FT                                {ECO:0000244|PDB:3GHG,
FT                                ECO:0000269|PubMed:19296670}.
FT   DISULFID     35     35       Interchain (with C-34).
FT                                {ECO:0000244|PDB:3GHG,
FT                                ECO:0000269|PubMed:19296670}.
FT   DISULFID     45     45       Interchain (with C-110 in beta chain).
FT                                {ECO:0000305|PubMed:6575689}.
FT   DISULFID     49     49       Interchain (with C-64 in alpha chain).
FT                                {ECO:0000305|PubMed:6575689}.
FT   DISULFID    161    161       Interchain (with C-227 in beta chain).
FT                                {ECO:0000305|PubMed:6575689}.
FT   DISULFID    165    165       Interchain (with C-180 in alpha chain).
FT                                {ECO:0000305|PubMed:6575689}.
FT   DISULFID    179    208       {ECO:0000244|PDB:1FID,
FT                                ECO:0000269|PubMed:10074346,
FT                                ECO:0000269|PubMed:19296670,
FT                                ECO:0000269|PubMed:9016719,
FT                                ECO:0000269|PubMed:9207064,
FT                                ECO:0000269|PubMed:9333233,
FT                                ECO:0000269|PubMed:9628725}.
FT   DISULFID    352    365       {ECO:0000244|PDB:1FID,
FT                                ECO:0000269|PubMed:10074346,
FT                                ECO:0000269|PubMed:19296670,
FT                                ECO:0000269|PubMed:9016719,
FT                                ECO:0000269|PubMed:9207064,
FT                                ECO:0000269|PubMed:9333233,
FT                                ECO:0000269|PubMed:9628725}.
FT   CROSSLNK    424    424       Isoglutamyl lysine isopeptide (Gln-Lys)
FT                                (interchain with K-432).
FT   CROSSLNK    432    432       Isoglutamyl lysine isopeptide (Lys-Gln)
FT                                (interchain with Q-424).
FT   VAR_SEQ     434    453       VRPEHPAETEYDSLYPEDDL -> AGDV (in isoform
FT                                Gamma-A). {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:2990550,
FT                                ECO:0000303|Ref.4, ECO:0000303|Ref.5}.
FT                                /FTId=VSP_001537.
FT   VARIANT      77     77       E -> G (in dbSNP:rs11551835).
FT                                /FTId=VAR_049066.
FT   VARIANT     140    140       Y -> H (in dbSNP:rs2066870).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_033930.
FT   VARIANT     191    191       G -> R (in Milano-12; dbSNP:rs6063).
FT                                {ECO:0000269|PubMed:10391209,
FT                                ECO:0000269|PubMed:11435303,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_014170.
FT   VARIANT     301    301       R -> C (in Tochigi/Osaka-2/Milano-5/
FT                                Villajoyosa).
FT                                {ECO:0000269|PubMed:1421174,
FT                                ECO:0000269|PubMed:2971042,
FT                                ECO:0000269|PubMed:3337908,
FT                                ECO:0000269|PubMed:7654933,
FT                                ECO:0000269|PubMed:7841300}.
FT                                /FTId=VAR_002409.
FT   VARIANT     301    301       R -> H (in DYSFIBRIN; fibrinogen Bergamo-
FT                                2/Essen/Haifa/Osaka-3/Perugia/Saga/
FT                                Barcelona-3/Barcelona-4).
FT                                {ECO:0000269|PubMed:1455400,
FT                                ECO:0000269|PubMed:2976995,
FT                                ECO:0000269|PubMed:3563970,
FT                                ECO:0000269|PubMed:7654933}.
FT                                /FTId=VAR_002410.
FT   VARIANT     303    303       T -> P (in CAFBN; hypofibrinogenemia;
FT                                heterozygous; no effect on fibrinogen
FT                                complex assembly; impaired fibrinogen
FT                                complex secretion).
FT                                {ECO:0000269|PubMed:25427968}.
FT                                /FTId=VAR_072726.
FT   VARIANT     318    318       G -> V (in DYSFIBRIN; fibrinogen
FT                                Baltimore-1; impaired polymerization).
FT                                {ECO:0000269|PubMed:2257302}.
FT                                /FTId=VAR_002411.
FT   VARIANT     327    327       D -> H (in CAFBN; hypofibrinogenemia;
FT                                heterozygous; no effect on fibrinogen
FT                                complex assembly; no effect on fibrinogen
FT                                complex secretion).
FT                                {ECO:0000269|PubMed:25427968}.
FT                                /FTId=VAR_072727.
FT   VARIANT     334    334       N -> I (in Baltimore-3; impaired
FT                                polymerization; dbSNP:rs121913090).
FT                                {ECO:0000269|PubMed:2328317}.
FT                                /FTId=VAR_002413.
FT   VARIANT     334    334       N -> K (in Kyoto-1; causes accelerated
FT                                cleavage by plasmin).
FT                                {ECO:0000269|PubMed:1421174,
FT                                ECO:0000269|PubMed:2971046}.
FT                                /FTId=VAR_002412.
FT   VARIANT     335    335       G -> D (in Hillsborough; prolonged
FT                                thrombin clotting time).
FT                                {ECO:0000269|PubMed:11986213}.
FT                                /FTId=VAR_015853.
FT   VARIANT     336    336       M -> T (in Asahi; impaired
FT                                polymerization).
FT                                {ECO:0000269|PubMed:1421174,
FT                                ECO:0000269|PubMed:2496144}.
FT                                /FTId=VAR_002414.
FT   VARIANT     345    346       Missing (in Vlissingen; defective calcium
FT                                binding and impaired polymerization).
FT                                {ECO:0000269|PubMed:2071611}.
FT                                /FTId=VAR_002415.
FT   VARIANT     345    345       N -> D (in CAFBN; hypofibrinogenemia;
FT                                heterozygous; no effect on fibrinogen
FT                                complex assembly; decreased fibrinogen
FT                                complex secretion).
FT                                {ECO:0000269|PubMed:25427968}.
FT                                /FTId=VAR_072728.
FT   VARIANT     355    355       Q -> R (in Nagoya-1; impaired
FT                                polymerization).
FT                                {ECO:0000269|PubMed:2738036}.
FT                                /FTId=VAR_002416.
FT   VARIANT     356    356       D -> V (in DYSFIBRIN; fibrinogen Milano-
FT                                1; impaired polymerization).
FT                                {ECO:0000269|PubMed:3708159}.
FT                                /FTId=VAR_002418.
FT   VARIANT     356    356       D -> Y (in Kyoto-3; impaired
FT                                polymerization).
FT                                {ECO:0000269|PubMed:1421174,
FT                                ECO:0000269|PubMed:2819242}.
FT                                /FTId=VAR_002417.
FT   VARIANT     363    363       N -> K (in Bern-1; impaired
FT                                polymerization).
FT                                {ECO:0000269|PubMed:8400260}.
FT                                /FTId=VAR_002419.
FT   VARIANT     377    377       G -> VMCGEALPMLKDPCYS (in Paris-1;
FT                                impaired polymerization).
FT                                {ECO:0000269|PubMed:8470043}.
FT                                /FTId=VAR_002420.
FT   VARIANT     384    384       S -> C (in Milano-7; impaired
FT                                polymerization).
FT                                {ECO:0000269|PubMed:8080993}.
FT                                /FTId=VAR_002421.
FT   VARIANT     401    401       R -> G (in Osaka-5).
FT                                {ECO:0000269|PubMed:1733971}.
FT                                /FTId=VAR_002422.
FT   VARIANT     401    401       R -> W (in CAFBN; hypofibrinogenemia;
FT                                heterozygous).
FT                                {ECO:0000269|PubMed:25427968}.
FT                                /FTId=VAR_072729.
FT   VARIANT     404    404       S -> P (in DYSFIBRIN; fibrinogen
FT                                Philadelphia).
FT                                {ECO:0000269|PubMed:15632207}.
FT                                /FTId=VAR_072621.
FT   VARIANT     410    410       M -> V (in dbSNP:rs6061).
FT                                {ECO:0000269|PubMed:10391209}.
FT                                /FTId=VAR_014171.
FT   CONFLICT    114    114       K -> I (in Ref. 2; AAB59530/AAB59531).
FT                                {ECO:0000305}.
FT   CONFLICT    435    435       R -> Y (in Ref. 15; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    448    448       Y -> R (in Ref. 15; AA sequence).
FT                                {ECO:0000305}.
FT   HELIX        31     33       {ECO:0000244|PDB:3GHG}.
FT   STRAND       34     36       {ECO:0000244|PDB:3GHG}.
FT   STRAND       44     46       {ECO:0000244|PDB:3GHG}.
FT   HELIX        49     94       {ECO:0000244|PDB:3GHG}.
FT   TURN         96     98       {ECO:0000244|PDB:3GHG}.
FT   TURN        115    118       {ECO:0000244|PDB:1FZA}.
FT   TURN        119    122       {ECO:0000244|PDB:1FZB}.
FT   TURN        124    128       {ECO:0000244|PDB:1FZC}.
FT   HELIX       129    160       {ECO:0000244|PDB:1FZC}.
FT   STRAND      161    163       {ECO:0000244|PDB:2HLO}.
FT   STRAND      166    168       {ECO:0000244|PDB:1FZC}.
FT   STRAND      171    178       {ECO:0000244|PDB:2FIB}.
FT   HELIX       179    184       {ECO:0000244|PDB:2FIB}.
FT   STRAND      191    195       {ECO:0000244|PDB:2FIB}.
FT   TURN        198    200       {ECO:0000244|PDB:1FID}.
FT   STRAND      204    210       {ECO:0000244|PDB:2FIB}.
FT   STRAND      212    214       {ECO:0000244|PDB:2HOD}.
FT   STRAND      216    226       {ECO:0000244|PDB:2FIB}.
FT   HELIX       234    239       {ECO:0000244|PDB:2FIB}.
FT   STRAND      241    244       {ECO:0000244|PDB:1FZC}.
FT   STRAND      246    248       {ECO:0000244|PDB:1FZA}.
FT   STRAND      252    254       {ECO:0000244|PDB:1RE3}.
FT   HELIX       256    263       {ECO:0000244|PDB:2FIB}.
FT   HELIX       265    267       {ECO:0000244|PDB:2FIB}.
FT   STRAND      270    277       {ECO:0000244|PDB:2FIB}.
FT   STRAND      279    281       {ECO:0000244|PDB:2OYI}.
FT   STRAND      283    290       {ECO:0000244|PDB:2FIB}.
FT   HELIX       296    298       {ECO:0000244|PDB:2FIB}.
FT   STRAND      301    303       {ECO:0000244|PDB:3HUS}.
FT   STRAND      305    309       {ECO:0000244|PDB:2FIB}.
FT   HELIX       315    317       {ECO:0000244|PDB:2FIB}.
FT   STRAND      322    324       {ECO:0000244|PDB:1FIB}.
FT   HELIX       327    331       {ECO:0000244|PDB:2FIB}.
FT   STRAND      341    343       {ECO:0000244|PDB:1FZA}.
FT   STRAND      346    350       {ECO:0000244|PDB:2FIB}.
FT   HELIX       352    356       {ECO:0000244|PDB:2FIB}.
FT   STRAND      358    360       {ECO:0000244|PDB:2H43}.
FT   STRAND      363    365       {ECO:0000244|PDB:2FIB}.
FT   STRAND      367    369       {ECO:0000244|PDB:2FIB}.
FT   STRAND      370    373       {ECO:0000244|PDB:2HOD}.
FT   STRAND      376    379       {ECO:0000244|PDB:2H43}.
FT   HELIX       382    384       {ECO:0000244|PDB:2FIB}.
FT   STRAND      385    387       {ECO:0000244|PDB:1FIB}.
FT   STRAND      392    395       {ECO:0000244|PDB:2FIB}.
FT   TURN        396    398       {ECO:0000244|PDB:2FIB}.
FT   STRAND      406    414       {ECO:0000244|PDB:2FIB}.
FT   HELIX       415    417       {ECO:0000244|PDB:2FIB}.
FT   STRAND      420    424       {ECO:0000244|PDB:1FID}.
FT   STRAND      426    433       {ECO:0000244|PDB:4B60}.
SQ   SEQUENCE   453 AA;  51512 MW;  1787204904E0D4BB CRC64;
     MSWSLHPRNL ILYFYALLFL SSTCVAYVAT RDNCCILDER FGSYCPTTCG IADFLSTYQT
     KVDKDLQSLE DILHQVENKT SEVKQLIKAI QLTYNPDESS KPNMIDAATL KSRKMLEEIM
     KYEASILTHD SSIRYLQEIY NSNNQKIVNL KEKVAQLEAQ CQEPCKDTVQ IHDITGKDCQ
     DIANKGAKQS GLYFIKPLKA NQQFLVYCEI DGSGNGWTVF QKRLDGSVDF KKNWIQYKEG
     FGHLSPTGTT EFWLGNEKIH LISTQSAIPY ALRVELEDWN GRTSTADYAM FKVGPEADKY
     RLTYAYFAGG DAGDAFDGFD FGDDPSDKFF TSHNGMQFST WDNDNDKFEG NCAEQDGSGW
     WMNKCHAGHL NGVYYQGGTY SKASTPNGYD NGIIWATWKT RWYSMKKTTM KIIPFNRLTI
     GEGQQHHLGG AKQVRPEHPA ETEYDSLYPE DDL
//
ID   AGRIN_HUMAN             Reviewed;        2067 AA.
AC   O00468; Q5SVA1; Q5SVA2; Q60FE1; Q7KYS8; Q8N4J5; Q96IC1; Q9BTD4;
DT   25-OCT-2004, integrated into UniProtKB/Swiss-Prot.
DT   06-MAR-2013, sequence version 5.
DT   17-FEB-2016, entry version 155.
DE   RecName: Full=Agrin;
DE   Contains:
DE     RecName: Full=Agrin N-terminal 110 kDa subunit;
DE   Contains:
DE     RecName: Full=Agrin C-terminal 110 kDa subunit;
DE   Contains:
DE     RecName: Full=Agrin C-terminal 90 kDa fragment;
DE              Short=C90;
DE   Contains:
DE     RecName: Full=Agrin C-terminal 22 kDa fragment;
DE              Short=C22;
DE   Flags: Precursor;
GN   Name=AGRN; Synonyms=AGRIN;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND TISSUE SPECIFICITY.
RX   PubMed=9652404; DOI=10.1046/j.1432-1327.1998.2540123.x;
RA   Groffen A.J.A., Buskens C.A.F., Van Kuppevelt T.H., Veerkamp J.H.,
RA   Monnens L.A.H., Van den Heuvel L.P.W.J.;
RT   "Primary structure and high expression of human agrin in basement
RT   membranes of adult lung and kidney.";
RL   Eur. J. Biochem. 254:123-128(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RC   TISSUE=Retinal pigment epithelium;
RA   Kato S.;
RL   Submitted (SEP-2004) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] (ISOFORM 3), AND
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] OF 1703-1949 (ISOFORM
RP   6).
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 20-172, AND INTERACTION WITH LAMININ.
RX   PubMed=9151673; DOI=10.1083/jcb.137.3.671;
RA   Denzer A.J., Brandenberger R., Gesemann M., Chiquet M., Ruegg M.A.;
RT   "Agrin binds to the nerve-muscle basal lamina via laminin.";
RL   J. Cell Biol. 137:671-683(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1558-2045.
RC   TISSUE=Brain, Colon, and Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   IDENTIFICATION OF TRANSMEMBRANE ISOFORM (ISOFORM 2).
RX   PubMed=11161480; DOI=10.1006/mcne.2000.0932;
RA   Neumann F.R., Bittcher G., Annies M., Schumacher B., Kroger S.,
RA   Ruegg M.A.;
RT   "An alternative amino-terminus expressed in the central nervous system
RT   converts agrin to a type II transmembrane protein.";
RL   Mol. Cell. Neurosci. 17:208-225(2001).
RN   [7]
RP   IDENTIFICATION OF TRANSMEMBRANE ISOFORM (ISOFORM 2), ALTERNATIVE
RP   SPLICING, AND TISSUE SPECIFICITY.
RX   PubMed=16487930; DOI=10.1016/j.bbrc.2006.01.161;
RA   Kumar P., Ferns M.J., Meizel S.;
RT   "Identification of agrinSN isoform and muscle-specific receptor
RT   tyrosine kinase (MuSK) in sperm.";
RL   Biochem. Biophys. Res. Commun. 342:522-528(2006).
RN   [8]
RP   ERRATUM.
RA   Kumar P., Ferns M.J., Meizel S.;
RL   Biochem. Biophys. Res. Commun. 344:453-453(2006).
RN   [9]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-135.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY, TISSUE SPECIFICITY, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=20551380; DOI=10.1074/mcp.M110.001693;
RA   Didangelos A., Yin X., Mandal K., Baumert M., Jahangiri M., Mayr M.;
RT   "Proteomics characterization of extracellular space components in the
RT   human aorta.";
RL   Mol. Cell. Proteomics 9:2048-2062(2010).
RN   [11]
RP   INTERACTION WITH LRP4, AND FUNCTION.
RX   PubMed=21969364; DOI=10.1074/jbc.M111.279307;
RA   Zhang W., Coldefy A.S., Hubbard S.R., Burden S.J.;
RT   "Agrin binds to the N-terminal region of Lrp4 protein and stimulates
RT   association between Lrp4 and the first immunoglobulin-like domain in
RT   muscle-specific kinase (MuSK).";
RL   J. Biol. Chem. 286:40624-40630(2011).
RN   [12]
RP   POTENTIAL USAGE AS A BIOMARKER FOR SARCOPENIA.
RX   PubMed=22683512; DOI=10.1016/j.exger.2012.05.021;
RA   Drey M., Sieber C.C., Bauer J.M., Uter W., Dahinden P., Fariello R.G.,
RA   Vrijbloed J.W.;
RT   "C-terminal Agrin Fragment as a potential marker for sarcopenia caused
RT   by degeneration of the neuromuscular junction.";
RL   Exp. Gerontol. 48:76-80(2013).
RN   [13]
RP   INVOLVEMENT IN CMS8, VARIANT CMS8 ARG-1709, VARIANTS LEU-23; ASN-58;
RP   ILE-105; MET-267; SER-375; VAL-728; ARG-852; MET-984; PHE-1088;
RP   LYS-1118; ARG-1135; LEU-1240; ARG-1341; LEU-1451; THR-1514; HIS-1565;
RP   ILE-1666; GLN-1671; PRO-1698; HIS-1734; ASN-1789 AND VAL-2045,
RP   FUNCTION, AND CHARACTERIZATION OF VARIANT CMS8 ARG-1709.
RX   PubMed=19631309; DOI=10.1016/j.ajhg.2009.06.015;
RA   Huze C., Bauche S., Richard P., Chevessier F., Goillot E., Gaudon K.,
RA   Ben Ammar A., Chaboud A., Grosjean I., Lecuyer H.A., Bernard V.,
RA   Rouche A., Alexandri N., Kuntzer T., Fardeau M., Fournier E.,
RA   Brancaccio A., Ruegg M.A., Koenig J., Eymard B., Schaeffer L.,
RA   Hantai D.;
RT   "Identification of an agrin mutation that causes congenital myasthenia
RT   and affects synapse function.";
RL   Am. J. Hum. Genet. 85:155-167(2009).
RN   [14]
RP   ERRATUM.
RA   Huze C., Bauche S., Richard P., Chevessier F., Goillot E., Gaudon K.,
RA   Ben Ammar A., Chaboud A., Grosjean I., Lecuyer H.A., Bernard V.,
RA   Rouche A., Alexandri N., Kuntzer T., Fardeau M., Fournier E.,
RA   Brancaccio A., Ruegg M.A., Koenig J., Eymard B., Schaeffer L.,
RA   Hantai D.;
RL   Am. J. Hum. Genet. 85:536-536(2009).
RN   [15]
RP   VARIANT CMS8 PHE-1727, INTERACTION WITH DAG1, AND CHARACTERIZATION OF
RP   VARIANT CMS8 PHE-1727.
RX   PubMed=22205389; DOI=10.1007/s00439-011-1132-4;
RA   Maselli R.A., Fernandez J.M., Arredondo J., Navarro C., Ngo M.,
RA   Beeson D., Cagney O., Williams D.C., Wollmann R.L., Yarov-Yarovoy V.,
RA   Ferns M.J.;
RT   "LG2 agrin mutation causing severe congenital myasthenic syndrome
RT   mimics functional characteristics of non-neural (z-) agrin.";
RL   Hum. Genet. 131:1123-1135(2012).
RN   [16]
RP   VARIANT VAL-745, VARIANTS CMS8 SER-76; ILE-105 AND ARG-1875, AND
RP   CHARACTERIZATION OF VARIANTS CMS8 SER-76 AND ILE-105.
RX   PubMed=24951643; DOI=10.1093/brain/awu160;
RA   Nicole S., Chaouch A., Torbergsen T., Bauche S., de Bruyckere E.,
RA   Fontenille M.J., Horn M.A., van Ghelue M., Loeseth S., Issop Y.,
RA   Cox D., Mueller J.S., Evangelista T., Staalberg E., Ioos C.,
RA   Barois A., Brochier G., Sternberg D., Fournier E., Hantai D.,
RA   Abicht A., Dusl M., Laval S.H., Griffin H., Eymard B., Lochmueller H.;
RT   "Agrin mutations lead to a congenital myasthenic syndrome with distal
RT   muscle weakness and atrophy.";
RL   Brain 137:2429-2443(2014).
CC   -!- FUNCTION: Isoform 1: heparan sulfate basal lamina glycoprotein
CC       that plays a central role in the formation and the maintenance of
CC       the neuromuscular junction (NMJ) and directs key events in
CC       postsynaptic differentiation. Component of the AGRN-LRP4 receptor
CC       complex that induces the phosphorylation and activation of MUSK.
CC       The activation of MUSK in myotubes induces the formation of NMJ by
CC       regulating different processes including the transcription of
CC       specific genes and the clustering of AChR in the postsynaptic
CC       membrane. Calcium ions are required for maximal AChR clustering.
CC       AGRN function in neurons is highly regulated by alternative
CC       splicing, glycan binding and proteolytic processing. Modulates
CC       calcium ion homeostasis in neurons, specifically by inducing an
CC       increase in cytoplasmic calcium ions. Functions differentially in
CC       the central nervous system (CNS) by inhibiting the alpha(3)-
CC       subtype of Na+/K+-ATPase and evoking depolarization at CNS
CC       synapses. This secreted isoform forms a bridge, after release from
CC       motor neurons, to basal lamina through binding laminin via the NtA
CC       domain.
CC   -!- FUNCTION: Isoform 2: transmembrane form that is the predominate
CC       form in neurons of the brain, induces dendritic filopodia and
CC       synapse formation in mature hippocampal neurons in large part due
CC       to the attached glycosaminoglycan chains and the action of Rho-
CC       family GTPases.
CC   -!- FUNCTION: Isoform 1, isoform 4 and isoform 5: neuron-specific (z+)
CC       isoforms that contain C-terminal insertions of 8-19 AA are potent
CC       activators of AChR clustering. Isoform 5, agrin (z+8), containing
CC       the 8-AA insert, forms a receptor complex in myotubules containing
CC       the neuronal AGRN, the muscle-specific kinase MUSK and LRP4, a
CC       member of the LDL receptor family. The splicing factors, NOVA1 and
CC       NOVA2, regulate AGRN splicing and production of the 'z' isoforms.
CC   -!- FUNCTION: Isoform 3 and isoform 6: lack any 'z' insert, are
CC       muscle-specific and may be involved in endothelial cell
CC       differentiation.
CC   -!- FUNCTION: Agrin N-terminal 110 kDa subunit: is involved in
CC       regulation of neurite outgrowth probably due to the presence of
CC       the glycosaminoglcan (GAG) side chains of heparan and chondroitin
CC       sulfate attached to the Ser/Thr- and Gly/Ser-rich regions. Also
CC       involved in modulation of growth factor signaling (By similarity).
CC       {ECO:0000250, ECO:0000269|PubMed:19631309,
CC       ECO:0000269|PubMed:21969364}.
CC   -!- FUNCTION: Agrin C-terminal 22 kDa fragment: this released fragment
CC       is important for agrin signaling and to exert a maximal dendritic
CC       filopodia-inducing effect. All 'z' splice variants (z+) of this
CC       fragment also show an increase in the number of filopodia.
CC   -!- SUBUNIT: Monomer (By similarity). Interacts (N-terminal subunit)
CC       with TGF-beta family members, BMP2 AND BMP4; the interactions
CC       inhibit the activity of these growth factors. Interacts with
CC       TGFB1; the interaction enhances the activity of TGFB1 (By
CC       similarity). Component of the AGRN-LRP4 complex that consists of a
CC       tetramer of two AGRN-LRP4 heterodimers. Interacts (via the laminin
CC       G-like 3 domain) directly with LRP4; the interaction is required
CC       for activation of MUSK and clustering of AChR and requires the
CC       'z8' insert present in the z(+8) isoforms. Interacts with DAG1;
CC       the interaction is influenced by cell surface glycosaminoglycans
CC       and by alternative splicing of AGRN. {ECO:0000250,
CC       ECO:0000269|PubMed:21969364, ECO:0000269|PubMed:22205389,
CC       ECO:0000269|PubMed:9151673}.
CC   -!- INTERACTION:
CC       O15265:ATXN7; NbExp=2; IntAct=EBI-947482, EBI-708350;
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Secreted, extracellular space,
CC       extracellular matrix {ECO:0000269|PubMed:20551380}. Note=Synaptic
CC       basal lamina at the neuromuscular junction.
CC       {ECO:0000250|UniProtKB:P31696}.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Cell junction, synapse
CC       {ECO:0000250|UniProtKB:A2ASQ1}. Cell membrane
CC       {ECO:0000250|UniProtKB:A2ASQ1}; Single-pass type II membrane
CC       protein {ECO:0000250|UniProtKB:A2ASQ1}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=7;
CC         Comment=Many isoforms may exist depending on the occurrence and
CC         length of inserts at the x, y or z splice site. Four 'z'
CC         isoforms can be produced with inserts of 0, 8, 11 or 19 AA.
CC         Isoforms differ in their acetylcholine receptor clustering
CC         activity and tissue specificity.;
CC       Name=1; Synonyms=Secreted agrin, LN-agrin;
CC         IsoId=O00468-1; Sequence=Displayed;
CC       Name=2; Synonyms=Transmembrane agrin, TM-agrin;
CC         IsoId=O00468-2; Sequence=VSP_045753, VSP_045754;
CC         Note=Produced by usage of an alternative first exon.;
CC       Name=3; Synonyms=Agrin z(0);
CC         IsoId=O00468-3; Sequence=VSP_045756;
CC       Name=4; Synonyms=Agrin z(+11);
CC         IsoId=O00468-4; Sequence=VSP_045757;
CC       Name=5; Synonyms=Agrin z(+8);
CC         IsoId=O00468-5; Sequence=VSP_045758;
CC       Name=6; Synonyms=Agrin y(0)z(0);
CC         IsoId=O00468-6; Sequence=VSP_045755, VSP_045756;
CC       Name=7; Synonyms=y(0);
CC         IsoId=O00468-7; Sequence=VSP_045755;
CC   -!- TISSUE SPECIFICITY: Expressed in basement membranes of lung and
CC       kidney. Muscle- and neuron-specific isoforms are found. Isoforms
CC       (y+) with the 4 AA insert and (z+8) isoforms with the 8 AA insert
CC       are all neuron-specific. Isoforms (z+11) are found in both
CC       neuronal and non-neuronal tissues. {ECO:0000269|PubMed:16487930,
CC       ECO:0000269|PubMed:20551380, ECO:0000269|PubMed:9652404}.
CC   -!- DOMAIN: The NtA domain, absent in TM-agrin, is required for
CC       binding laminin and connecting to basal lamina.
CC   -!- DOMAIN: Both laminin G-like 2 (G2) and laminin G-like 3 (G3)
CC       domains are required for alpha-dystroglycan/DAG1 binding. G3
CC       domain is required for C-terminal heparin, heparan sulfate and
CC       sialic acid binding (By similarity). {ECO:0000250}.
CC   -!- PTM: Contains heparan and chondroitin sulfate chains and alpha-
CC       dystroglycan as well as N-linked and O-linked oligosaccharides.
CC       Glycosaminoglycans (GAGs), present in the N-terminal 110 kDa
CC       fragment, are required for induction of filopodia in hippocampal
CC       neurons. The first cluster (Gly/Ser-rich) for GAG attachment
CC       contains heparan sulfate (HS) chains and the second cluster
CC       (Ser/Thr-rich), contains chondroitin sulfate (CS) chains. Heparin
CC       and heparin sulfate binding in the G3 domain is independent of
CC       calcium ions. Binds heparin with a stoichiometry of 2:1. Binds
CC       sialic acid with a stoichiometry of 1:1 and binding requires
CC       calcium ions (By similarity). {ECO:0000250}.
CC   -!- PTM: At synaptic junctions, cleaved at two conserved sites, alpha
CC       and beta, by neurotrypsin. Cleavage at the alpha-site produces the
CC       agrin N-terminal 110-kDa subunit and the agrin C-terminal 110-kDa
CC       subunit. Further cleavage of agrin C-terminal 110-kDa subunit at
CC       the beta site produces the C-terminal fragments, agrin C-terminal
CC       90 kDa fragment and agrin C-terminal 22 kDa fragment. Excessive
CC       cleavage at the beta-site releases large amounts of the agrin C-
CC       terminal 22 kDa fragment leading to destabilization at the
CC       neuromuscular junction (NMJ).
CC   -!- DISEASE: Myasthenic syndrome, congenital, 8 (CMS8) [MIM:615120]: A
CC       form of congenital myasthenic syndrome, a group of disorders
CC       characterized by failure of neuromuscular transmission, including
CC       pre-synaptic, synaptic, and post-synaptic disorders that are not
CC       of autoimmune origin. Clinical features are easy fatigability and
CC       muscle weakness. CMS8 is an autosomal recessive disease
CC       characterized by prominent defects of both the pre- and
CC       postsynaptic regions. Affected individuals have onset of muscle
CC       weakness in early childhood; the severity of the weakness and
CC       muscles affected is variable. {ECO:0000269|PubMed:19631309,
CC       ECO:0000269|PubMed:22205389, ECO:0000269|PubMed:24951643}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- MISCELLANEOUS: Cleaved C-terminal fragments may be used as a
CC       biomarker for sarcopenia, age-related progressive loss of skeletal
CC       muscle. {ECO:0000305|PubMed:22683512}.
CC   -!- SIMILARITY: Contains 4 EGF-like domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00076}.
CC   -!- SIMILARITY: Contains 9 Kazal-like domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00798}.
CC   -!- SIMILARITY: Contains 2 laminin EGF-like domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00460}.
CC   -!- SIMILARITY: Contains 3 laminin G-like domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00122}.
CC   -!- SIMILARITY: Contains 1 NtA (N-terminal agrin) domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00443}.
CC   -!- SIMILARITY: Contains 1 SEA domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00188}.
CC   -!- CAUTION: The unknown residue 'x' in the transmembrane isoform is
CC       probably a proline residue by similarity to mouse and rat
CC       sequences. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=The Leiden Muscular Dystrophy pages, Agrin
CC       (AGRN); Note=Leiden Open Variation Database (LOVD);
CC       URL="http://www.lovd.nl/AGRN";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U84406; AAB52917.1; -; mRNA.
DR   EMBL; AB191264; BAD52440.1; -; mRNA.
DR   EMBL; AL645608; CAI15575.2; -; Genomic_DNA.
DR   EMBL; AL645608; CAI15576.1; -; Genomic_DNA.
DR   EMBL; AF016903; AAC39776.1; -; mRNA.
DR   EMBL; BC004220; AAH04220.2; -; mRNA.
DR   EMBL; BC007649; AAH07649.1; -; mRNA.
DR   EMBL; BC034009; AAH34009.1; -; mRNA.
DR   EMBL; BC063620; AAH63620.1; -; mRNA.
DR   CCDS; CCDS30551.1; -. [O00468-6]
DR   RefSeq; NP_940978.2; NM_198576.3. [O00468-6]
DR   RefSeq; XP_005244806.1; XM_005244749.2. [O00468-3]
DR   UniGene; Hs.273330; -.
DR   UniGene; Hs.602356; -.
DR   ProteinModelPortal; O00468; -.
DR   SMR; O00468; 36-146, 170-751, 793-921, 934-969, 1320-2067.
DR   BioGrid; 132000; 14.
DR   IntAct; O00468; 8.
DR   MINT; MINT-4053526; -.
DR   STRING; 9606.ENSP00000368678; -.
DR   iPTMnet; O00468; -.
DR   PhosphoSite; O00468; -.
DR   BioMuta; AGRN; -.
DR   MaxQB; O00468; -.
DR   PaxDb; O00468; -.
DR   PRIDE; O00468; -.
DR   Ensembl; ENST00000379370; ENSP00000368678; ENSG00000188157. [O00468-6]
DR   GeneID; 375790; -.
DR   UCSC; uc001ack.2; human. [O00468-1]
DR   CTD; 375790; -.
DR   GeneCards; AGRN; -.
DR   GeneReviews; AGRN; -.
DR   HGNC; HGNC:329; AGRN.
DR   HPA; HPA040090; -.
DR   MalaCards; AGRN; -.
DR   MIM; 103320; gene.
DR   MIM; 615120; phenotype.
DR   neXtProt; NX_O00468; -.
DR   Orphanet; 98913; Postsynaptic congenital myasthenic syndromes.
DR   Orphanet; 98914; Presynaptic congenital myasthenic syndromes.
DR   PharmGKB; PA24626; -.
DR   eggNOG; ENOG410ITSI; Eukaryota.
DR   eggNOG; ENOG410YKSA; LUCA.
DR   GeneTree; ENSGT00530000063501; -.
DR   HOGENOM; HOG000033860; -.
DR   HOVERGEN; HBG080471; -.
DR   InParanoid; O00468; -.
DR   OMA; PRCSCDR; -.
DR   OrthoDB; EOG7BGHJZ; -.
DR   TreeFam; TF326548; -.
DR   Reactome; R-HSA-1971475; A tetrasaccharide linker sequence is required for GAG synthesis.
DR   Reactome; R-HSA-2022928; HS-GAG biosynthesis.
DR   Reactome; R-HSA-2024096; HS-GAG degradation.
DR   Reactome; R-HSA-216083; Integrin cell surface interactions.
DR   Reactome; R-HSA-3000171; Non-integrin membrane-ECM interactions.
DR   Reactome; R-HSA-3000178; ECM proteoglycans.
DR   Reactome; R-HSA-3560783; Defective B4GALT7 causes EDS, progeroid type.
DR   Reactome; R-HSA-3560801; Defective B3GAT3 causes JDSSDHD.
DR   Reactome; R-HSA-3656237; Defective EXT2 causes exostoses 2.
DR   Reactome; R-HSA-3656253; Defective EXT1 causes exostoses 1, TRPS2 and CHDS.
DR   Reactome; R-HSA-419037; NCAM1 interactions.
DR   Reactome; R-HSA-4420332; Defective B3GALT6 causes EDSP2 and SEMDJL1.
DR   Reactome; R-HSA-975634; Retinoid metabolism and transport.
DR   SignaLink; O00468; -.
DR   ChiTaRS; AGRN; human.
DR   GeneWiki; Agrin; -.
DR   GenomeRNAi; 375790; -.
DR   NextBio; 100617; -.
DR   PRO; PR:O00468; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; O00468; -.
DR   CleanEx; HS_AGRN; -.
DR   ExpressionAtlas; O00468; baseline and differential.
DR   Genevisible; O00468; HS.
DR   GO; GO:0005605; C:basal lamina; IDA:UniProtKB.
DR   GO; GO:0030054; C:cell junction; IEA:UniProtKB-KW.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0031012; C:extracellular matrix; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005796; C:Golgi lumen; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0045202; C:synapse; ISS:UniProtKB.
DR   GO; GO:0030548; F:acetylcholine receptor regulator activity; IEA:Ensembl.
DR   GO; GO:0005509; F:calcium ion binding; ISS:UniProtKB.
DR   GO; GO:0035374; F:chondroitin sulfate binding; ISS:UniProtKB.
DR   GO; GO:0002162; F:dystroglycan binding; ISS:UniProtKB.
DR   GO; GO:0043395; F:heparan sulfate proteoglycan binding; ISS:UniProtKB.
DR   GO; GO:0043236; F:laminin binding; TAS:UniProtKB.
DR   GO; GO:0033691; F:sialic acid binding; ISS:UniProtKB.
DR   GO; GO:0005200; F:structural constituent of cytoskeleton; TAS:UniProtKB.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0005975; P:carbohydrate metabolic process; TAS:Reactome.
DR   GO; GO:0030204; P:chondroitin sulfate metabolic process; TAS:Reactome.
DR   GO; GO:0045162; P:clustering of voltage-gated sodium channels; TAS:UniProtKB.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0007213; P:G-protein coupled acetylcholine receptor signaling pathway; TAS:UniProtKB.
DR   GO; GO:0006024; P:glycosaminoglycan biosynthetic process; TAS:Reactome.
DR   GO; GO:0006027; P:glycosaminoglycan catabolic process; TAS:Reactome.
DR   GO; GO:0030203; P:glycosaminoglycan metabolic process; TAS:Reactome.
DR   GO; GO:0007528; P:neuromuscular junction development; IEA:Ensembl.
DR   GO; GO:0045213; P:neurotransmitter receptor metabolic process; IEA:Ensembl.
DR   GO; GO:0007603; P:phototransduction, visible light; TAS:Reactome.
DR   GO; GO:0007009; P:plasma membrane organization; IEA:Ensembl.
DR   GO; GO:0051491; P:positive regulation of filopodium assembly; ISS:UniProtKB.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; ISS:UniProtKB.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0045887; P:positive regulation of synaptic growth at neuromuscular junction; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; ISS:UniProtKB.
DR   GO; GO:0043113; P:receptor clustering; IDA:UniProtKB.
DR   GO; GO:0001523; P:retinoid metabolic process; TAS:Reactome.
DR   GO; GO:0007165; P:signal transduction; TAS:UniProtKB.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0050808; P:synapse organization; TAS:UniProtKB.
DR   GO; GO:0007268; P:synaptic transmission; IEA:Ensembl.
DR   Gene3D; 2.60.120.200; -; 3.
DR   Gene3D; 3.30.70.960; -; 1.
DR   InterPro; IPR013320; ConA-like_dom.
DR   InterPro; IPR013032; EGF-like_CS.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR003645; Fol_N.
DR   InterPro; IPR002350; Kazal_dom.
DR   InterPro; IPR002049; Laminin_EGF.
DR   InterPro; IPR001791; Laminin_G.
DR   InterPro; IPR004850; NtA_dom.
DR   InterPro; IPR000082; SEA_dom.
DR   InterPro; IPR008993; TIMP-like_OB-fold.
DR   Pfam; PF00008; EGF; 2.
DR   Pfam; PF00050; Kazal_1; 1.
DR   Pfam; PF07648; Kazal_2; 8.
DR   Pfam; PF00053; Laminin_EGF; 2.
DR   Pfam; PF00054; Laminin_G_1; 3.
DR   Pfam; PF03146; NtA; 1.
DR   Pfam; PF01390; SEA; 1.
DR   SMART; SM00181; EGF; 4.
DR   SMART; SM00180; EGF_Lam; 2.
DR   SMART; SM00274; FOLN; 5.
DR   SMART; SM00280; KAZAL; 9.
DR   SMART; SM00282; LamG; 3.
DR   SMART; SM00200; SEA; 1.
DR   SUPFAM; SSF49899; SSF49899; 4.
DR   SUPFAM; SSF50242; SSF50242; 1.
DR   SUPFAM; SSF82671; SSF82671; 1.
DR   PROSITE; PS00022; EGF_1; 6.
DR   PROSITE; PS01186; EGF_2; 1.
DR   PROSITE; PS50026; EGF_3; 4.
DR   PROSITE; PS01248; EGF_LAM_1; 1.
DR   PROSITE; PS50027; EGF_LAM_2; 2.
DR   PROSITE; PS51465; KAZAL_2; 9.
DR   PROSITE; PS50025; LAM_G_DOMAIN; 3.
DR   PROSITE; PS51121; NTA; 1.
DR   PROSITE; PS50024; SEA; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Calcium; Cell junction; Cell membrane;
KW   Complete proteome; Congenital myasthenic syndrome;
KW   Developmental protein; Differentiation; Disease mutation;
KW   Disulfide bond; EGF-like domain; Extracellular matrix; Glycoprotein;
KW   Heparan sulfate; Laminin EGF-like domain; Membrane; Phosphoprotein;
KW   Polymorphism; Proteoglycan; Reference proteome; Repeat; Secreted;
KW   Signal; Synapse; Transmembrane; Transmembrane helix.
FT   SIGNAL        1     29       {ECO:0000255}.
FT   CHAIN        30   2067       Agrin.
FT                                /FTId=PRO_0000007471.
FT   CHAIN        30   1102       Agrin N-terminal 110 kDa subunit.
FT                                {ECO:0000250}.
FT                                /FTId=PRO_0000421613.
FT   CHAIN      1103   2067       Agrin C-terminal 110 kDa subunit.
FT                                {ECO:0000250}.
FT                                /FTId=PRO_0000421614.
FT   CHAIN      1103   1863       Agrin C-terminal 90 kDa fragment.
FT                                {ECO:0000250}.
FT                                /FTId=PRO_0000421615.
FT   CHAIN      1864   2067       Agrin C-terminal 22 kDa fragment.
FT                                {ECO:0000250}.
FT                                /FTId=PRO_0000421616.
FT   DOMAIN       30    157       NtA. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00443}.
FT   DOMAIN      191    244       Kazal-like 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00798}.
FT   DOMAIN      264    319       Kazal-like 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00798}.
FT   DOMAIN      337    391       Kazal-like 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00798}.
FT   DOMAIN      408    463       Kazal-like 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00798}.
FT   DOMAIN      484    536       Kazal-like 5. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00798}.
FT   DOMAIN      540    601       Kazal-like 6. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00798}.
FT   DOMAIN      607    666       Kazal-like 7. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00798}.
FT   DOMAIN      699    752       Kazal-like 8. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00798}.
FT   DOMAIN      793    846       Laminin EGF-like 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00460}.
FT   DOMAIN      847    893       Laminin EGF-like 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00460}.
FT   DOMAIN      917    971       Kazal-like 9. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00798}.
FT   DOMAIN     1130   1252       SEA. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00188}.
FT   DOMAIN     1329   1367       EGF-like 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1372   1548       Laminin G-like 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00122}.
FT   DOMAIN     1549   1586       EGF-like 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1588   1625       EGF-like 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1635   1822       Laminin G-like 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00122}.
FT   DOMAIN     1818   1857       EGF-like 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1868   2064       Laminin G-like 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00122}.
FT   CA_BIND    1940   2008       {ECO:0000250}.
FT   COMPBIAS    671    677       Gly/Ser-rich.
FT   COMPBIAS    974   1099       Ser/Thr-rich.
FT   COMPBIAS   1058   1097       Gly/Ser-rich.
FT   COMPBIAS   1254   1324       Ser/Thr-rich.
FT   SITE       1102   1103       Cleavage, alpha site; by neurotrypsin.
FT                                {ECO:0000250}.
FT   SITE       1250   1250       Alternative splice site to produce 'x'
FT                                isoforms. {ECO:0000250}.
FT   SITE       1751   1751       Alternative splice site to produce 'y'
FT                                isoforms. {ECO:0000250}.
FT   SITE       1862   1862       Critical for cleavage by neurotrypsin.
FT                                {ECO:0000250}.
FT   SITE       1863   1864       Cleavage, beta site; by neurotrypsin.
FT                                {ECO:0000250}.
FT   SITE       1888   1888       Alternative splice site to produce 'z'
FT                                isoforms. {ECO:0000250}.
FT   SITE       1892   1892       Highly important for the agrin receptor
FT                                complex activity of the 'z(8)' insert.
FT                                {ECO:0000250}.
FT   MOD_RES     674    674       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:A2ASQ1}.
FT   MOD_RES     676    676       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:A2ASQ1}.
FT   CARBOHYD    135    135       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    250    250       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    777    777       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    932    932       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1835   1835       O-linked (Fuc...). {ECO:0000250}.
FT   DISULFID     31    103       {ECO:0000250}.
FT   DISULFID    152    177       Or C-152 with C-183.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076,
FT                                ECO:0000255|PROSITE-ProRule:PRU00122,
FT                                ECO:0000255|PROSITE-ProRule:PRU00443,
FT                                ECO:0000255|PROSITE-ProRule:PRU00460,
FT                                ECO:0000255|PROSITE-ProRule:PRU00798}.
FT   DISULFID    793    805       {ECO:0000250}.
FT   DISULFID    795    812       {ECO:0000250}.
FT   DISULFID    814    823       {ECO:0000250}.
FT   DISULFID    826    844       {ECO:0000250}.
FT   DISULFID    847    859       {ECO:0000250}.
FT   DISULFID    849    866       {ECO:0000250}.
FT   DISULFID    868    877       {ECO:0000250}.
FT   DISULFID    880    891       {ECO:0000250}.
FT   DISULFID   1333   1344       {ECO:0000250}.
FT   DISULFID   1338   1355       {ECO:0000250}.
FT   DISULFID   1357   1366       {ECO:0000250}.
FT   DISULFID   1519   1548       {ECO:0000250}.
FT   DISULFID   1553   1564       {ECO:0000250}.
FT   DISULFID   1558   1574       {ECO:0000250}.
FT   DISULFID   1576   1585       {ECO:0000250}.
FT   DISULFID   1592   1603       {ECO:0000250}.
FT   DISULFID   1597   1613       {ECO:0000250}.
FT   DISULFID   1615   1624       {ECO:0000250}.
FT   DISULFID   1822   1836       {ECO:0000250}.
FT   DISULFID   1830   1845       {ECO:0000250}.
FT   DISULFID   1847   1856       {ECO:0000250}.
FT   DISULFID   2038   2064       {ECO:0000250}.
FT   VAR_SEQ       1    104       Missing (in isoform 2). {ECO:0000305}.
FT                                /FTId=VSP_045753.
FT   VAR_SEQ     105    154       NQVSTGDTRIFFVNPAPPYLWPAHKNELMLNSSLMRITLRN
FT                                LEEVEFCVE -> MPXLAVARDTRQPAGASLLVRGFMVPCN
FT                                ACLILLATATLGFAVLLFLNNY (in isoform 2).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_045754.
FT   VAR_SEQ    1752   1755       Missing (in isoform 6 and isoform 7).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_045755.
FT   VAR_SEQ    1889   1906       Missing (in isoform 3 and isoform 6).
FT                                {ECO:0000303|PubMed:9652404,
FT                                ECO:0000303|Ref.2}.
FT                                /FTId=VSP_045756.
FT   VAR_SEQ    1889   1896       Missing (in isoform 4). {ECO:0000305}.
FT                                /FTId=VSP_045757.
FT   VAR_SEQ    1897   1906       Missing (in isoform 5). {ECO:0000305}.
FT                                /FTId=VSP_045758.
FT   VARIANT      23     23       V -> L. {ECO:0000269|PubMed:19631309}.
FT                                /FTId=VAR_068724.
FT   VARIANT      58     58       D -> N. {ECO:0000269|PubMed:19631309}.
FT                                /FTId=VAR_068725.
FT   VARIANT      76     76       G -> S (in CMS8; results in decreased
FT                                AChR clustering).
FT                                {ECO:0000269|PubMed:24951643}.
FT                                /FTId=VAR_071367.
FT   VARIANT     105    105       N -> I (in CMS8; results in decreased
FT                                AChR clustering).
FT                                {ECO:0000269|PubMed:19631309,
FT                                ECO:0000269|PubMed:24951643}.
FT                                /FTId=VAR_068726.
FT   VARIANT     267    267       T -> M. {ECO:0000269|PubMed:19631309}.
FT                                /FTId=VAR_068727.
FT   VARIANT     375    375       A -> S (in dbSNP:rs138031468).
FT                                {ECO:0000269|PubMed:19631309}.
FT                                /FTId=VAR_068728.
FT   VARIANT     728    728       E -> V (in dbSNP:rs113288277).
FT                                {ECO:0000269|PubMed:19631309}.
FT                                /FTId=VAR_068729.
FT   VARIANT     745    745       A -> V. {ECO:0000269|PubMed:24951643}.
FT                                /FTId=VAR_071368.
FT   VARIANT     852    852       Q -> R (in dbSNP:rs9697293).
FT                                {ECO:0000269|PubMed:19631309}.
FT                                /FTId=VAR_068730.
FT   VARIANT     984    984       V -> M. {ECO:0000269|PubMed:19631309}.
FT                                /FTId=VAR_068731.
FT   VARIANT    1088   1088       L -> F (in dbSNP:rs150132566).
FT                                {ECO:0000269|PubMed:19631309}.
FT                                /FTId=VAR_068732.
FT   VARIANT    1118   1118       T -> K (in dbSNP:rs149159118).
FT                                {ECO:0000269|PubMed:19631309}.
FT                                /FTId=VAR_068733.
FT   VARIANT    1135   1135       Q -> R (in dbSNP:rs142416636).
FT                                {ECO:0000269|PubMed:19631309}.
FT                                /FTId=VAR_068734.
FT   VARIANT    1240   1240       P -> L (in dbSNP:rs142620337).
FT                                {ECO:0000269|PubMed:19631309}.
FT                                /FTId=VAR_068735.
FT   VARIANT    1341   1341       G -> R. {ECO:0000269|PubMed:19631309}.
FT                                /FTId=VAR_068736.
FT   VARIANT    1451   1451       P -> L. {ECO:0000269|PubMed:19631309}.
FT                                /FTId=VAR_068737.
FT   VARIANT    1514   1514       A -> T (in dbSNP:rs111818381).
FT                                {ECO:0000269|PubMed:19631309}.
FT                                /FTId=VAR_068738.
FT   VARIANT    1565   1565       Q -> H (in dbSNP:rs199876002).
FT                                {ECO:0000269|PubMed:19631309}.
FT                                /FTId=VAR_068739.
FT   VARIANT    1666   1666       V -> I (in dbSNP:rs17160775).
FT                                {ECO:0000269|PubMed:19631309}.
FT                                /FTId=VAR_048966.
FT   VARIANT    1671   1671       R -> Q. {ECO:0000269|PubMed:19631309}.
FT                                /FTId=VAR_068740.
FT   VARIANT    1698   1698       R -> P. {ECO:0000269|PubMed:19631309}.
FT                                /FTId=VAR_068741.
FT   VARIANT    1709   1709       G -> R (in CMS8; results in disruption of
FT                                the neuromuscular junction architecture;
FT                                does not affect phosphorylation of MUSK;
FT                                does not affect AChR clustering).
FT                                {ECO:0000269|PubMed:19631309}.
FT                                /FTId=VAR_068742.
FT   VARIANT    1727   1727       V -> F (in CMS8; decreased AGRN-induced
FT                                clustering of AChR by >100-fold and
FT                                decreased phosphorylation of the MUSK
FT                                receptor and AChR beta subunit by about
FT                                10-fold. Increased binding to alpha-
FT                                dystroglycan).
FT                                {ECO:0000269|PubMed:22205389}.
FT                                /FTId=VAR_069066.
FT   VARIANT    1734   1734       R -> H (in dbSNP:rs145444272).
FT                                {ECO:0000269|PubMed:19631309}.
FT                                /FTId=VAR_068743.
FT   VARIANT    1789   1789       D -> N. {ECO:0000269|PubMed:19631309}.
FT                                /FTId=VAR_068744.
FT   VARIANT    1875   1875       G -> R (in CMS8).
FT                                {ECO:0000269|PubMed:24951643}.
FT                                /FTId=VAR_071369.
FT   VARIANT    2045   2045       G -> V. {ECO:0000269|PubMed:19631309}.
FT                                /FTId=VAR_068745.
FT   CONFLICT    343    343       L -> R (in Ref. 1; AAB52917).
FT                                {ECO:0000305}.
SQ   SEQUENCE   2067 AA;  217232 MW;  E7FAAB9AFB7B8039 CRC64;
     MAGRSHPGPL RPLLPLLVVA ACVLPGAGGT CPERALERRE EEANVVLTGT VEEILNVDPV
     QHTYSCKVRV WRYLKGKDLV ARESLLDGGN KVVISGFGDP LICDNQVSTG DTRIFFVNPA
     PPYLWPAHKN ELMLNSSLMR ITLRNLEEVE FCVEDKPGTH FTPVPPTPPD ACRGMLCGFG
     AVCEPNAEGP GRASCVCKKS PCPSVVAPVC GSDASTYSNE CELQRAQCSQ QRRIRLLSRG
     PCGSRDPCSN VTCSFGSTCA RSADGLTASC LCPATCRGAP EGTVCGSDGA DYPGECQLLR
     RACARQENVF KKFDGPCDPC QGALPDPSRS CRVNPRTRRP EMLLRPESCP ARQAPVCGDD
     GVTYENDCVM GRSGAARGLL LQKVRSGQCQ GRDQCPEPCR FNAVCLSRRG RPRCSCDRVT
     CDGAYRPVCA QDGRTYDSDC WRQQAECRQQ RAIPSKHQGP CDQAPSPCLG VQCAFGATCA
     VKNGQAACEC LQACSSLYDP VCGSDGVTYG SACELEATAC TLGREIQVAR KGPCDRCGQC
     RFGALCEAET GRCVCPSECV ALAQPVCGSD GHTYPSECML HVHACTHQIS LHVASAGPCE
     TCGDAVCAFG AVCSAGQCVC PRCEHPPPGP VCGSDGVTYG SACELREAAC LQQTQIEEAR
     AGPCEQAECG SGGSGSGEDG DCEQELCRQR GGIWDEDSED GPCVCDFSCQ SVPGSPVCGS
     DGVTYSTECE LKKARCESQR GLYVAAQGAC RGPTFAPLPP VAPLHCAQTP YGCCQDNITA
     ARGVGLAGCP SACQCNPHGS YGGTCDPATG QCSCRPGVGG LRCDRCEPGF WNFRGIVTDG
     RSGCTPCSCD PQGAVRDDCE QMTGLCSCKP GVAGPKCGQC PDGRALGPAG CEADASAPAT
     CAEMRCEFGA RCVEESGSAH CVCPMLTCPE ANATKVCGSD GVTYGNECQL KTIACRQGLQ
     ISIQSLGPCQ EAVAPSTHPT SASVTVTTPG LLLSQALPAP PGALPLAPSS TAHSQTTPPP
     SSRPRTTASV PRTTVWPVLT VPPTAPSPAP SLVASAFGES GSTDGSSDEE LSGDQEASGG
     GSGGLEPLEG SSVATPGPPV ERASCYNSAL GCCSDGKTPS LDAEGSNCPA TKVFQGVLEL
     EGVEGQELFY TPEMADPKSE LFGETARSIE STLDDLFRNS DVKKDFRSVR LRDLGPGKSV
     RAIVDVHFDP TTAFRAPDVA RALLRQIQVS RRRSLGVRRP LQEHVRFMDF DWFPAFITGA
     TSGAIAAGAT ARATTASRLP SSAVTPRAPH PSHTSQPVAK TTAAPTTRRP PTTAPSRVPG
     RRPPAPQQPP KPCDSQPCFH GGTCQDWALG GGFTCSCPAG RGGAVCEKVL GAPVPAFEGR
     SFLAFPTLRA YHTLRLALEF RALEPQGLLL YNGNARGKDF LALALLDGRV QLRFDTGSGP
     AVLTSAVPVE PGQWHRLELS RHWRRGTLSV DGETPVLGES PSGTDGLNLD TDLFVGGVPE
     DQAAVALERT FVGAGLRGCI RLLDVNNQRL ELGIGPGAAT RGSGVGECGD HPCLPNPCHG
     GAPCQNLEAG RFHCQCPPGR VGPTCADEKS PCQPNPCHGA APCRVLPEGG AQCECPLGRE
     GTFCQTASGQ DGSGPFLADF NGFSHLELRG LHTFARDLGE KMALEVVFLA RGPSGLLLYN
     GQKTDGKGDF VSLALRDRRL EFRYDLGKGA AVIRSREPVT LGAWTRVSLE RNGRKGALRV
     GDGPRVLGES PKSRKVPHTV LNLKEPLYVG GAPDFSKLAR AAAVSSGFDG AIQLVSLGGR
     QLLTPEHVLR QVDVTSFAGH PCTRASGHPC LNGASCVPRE AAYVCLCPGG FSGPHCEKGL
     VEKSAGDVDT LAFDGRTFVE YLNAVTESEL ANEIPVPETL DSGALHEKAL QSNHFELSLR
     TEATQGLVLW SGKATERADY VALAIVDGHL QLSYNLGSQP VVLRSTVPVN TNRWLRVVAH
     REQREGSLQV GNEAPVTGSS PLGATQLDTD GALWLGGLPE LPVGPALPKA YGTGFVGCLR
     DVVVGRHPLH LLEDAVTKPE LRPCPTP
//
ID   BMP4_RAT                Reviewed;         408 AA.
AC   Q06826;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 1.
DT   11-NOV-2015, entry version 119.
DE   RecName: Full=Bone morphogenetic protein 4;
DE            Short=BMP-4;
DE   AltName: Full=Bone morphogenetic protein 2B;
DE            Short=BMP-2B;
DE   Flags: Precursor;
GN   Name=Bmp4; Synonyms=Bmp-4, Dvr-4;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8373807; DOI=10.1016/0167-4781(93)90200-W;
RA   Chen D., Feng J.Q., Feng M., Harris M.A., Mundy G.R., Harris S.E.;
RT   "Cloning and sequence of bone morphogenetic protein 4 cDNA from fetal
RT   rat calvarial cell.";
RL   Biochim. Biophys. Acta 1174:289-292(1993).
CC   -!- FUNCTION: Induces cartilage and bone formation. Acts in concert
CC       with PTHLH/PTHRP to stimulate ductal outgrowth during embryonic
CC       mammary development and to inhibit hair follicle induction (By
CC       similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Homodimer; disulfide-linked. Interacts with SOSTDC1,
CC       GREM2, RGMA, RGMB and RGMC. Part of a complex consisting of TWSG1
CC       and CHRD. Interacts with the serine proteases, HTRA1 and HTRA3;
CC       the interaction with either inhibits BMP4-mediated signaling. The
CC       HTRA protease activity is required for this inhibition (By
CC       similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular
CC       matrix.
CC   -!- SIMILARITY: Belongs to the TGF-beta family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Z22607; CAA80329.1; -; mRNA.
DR   PIR; S38343; S38343.
DR   UniGene; Rn.10318; -.
DR   ProteinModelPortal; Q06826; -.
DR   SMR; Q06826; 307-408.
DR   STRING; 10116.ENSRNOP00000012957; -.
DR   PhosphoSite; Q06826; -.
DR   PaxDb; Q06826; -.
DR   UCSC; RGD:2213; rat.
DR   RGD; 2213; Bmp4.
DR   eggNOG; KOG3900; Eukaryota.
DR   eggNOG; ENOG410XT8Z; LUCA.
DR   HOGENOM; HOG000249478; -.
DR   HOVERGEN; HBG004860; -.
DR   InParanoid; Q06826; -.
DR   PhylomeDB; Q06826; -.
DR   PRO; PR:Q06826; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0005737; C:cytoplasm; IDA:RGD.
DR   GO; GO:0005615; C:extracellular space; IDA:RGD.
DR   GO; GO:0031988; C:membrane-bounded vesicle; IDA:RGD.
DR   GO; GO:0005578; C:proteinaceous extracellular matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0070700; F:BMP receptor binding; ISS:UniProtKB.
DR   GO; GO:0042056; F:chemoattractant activity; ISS:UniProtKB.
DR   GO; GO:0005125; F:cytokine activity; IBA:GO_Central.
DR   GO; GO:0008083; F:growth factor activity; IDA:RGD.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:RGD.
DR   GO; GO:0005160; F:transforming growth factor beta receptor binding; IBA:GO_Central.
DR   GO; GO:0000186; P:activation of MAPKK activity; ISS:UniProtKB.
DR   GO; GO:0060033; P:anatomical structure regression; IEP:RGD.
DR   GO; GO:0002043; P:blood vessel endothelial cell proliferation involved in sprouting angiogenesis; ISS:UniProtKB.
DR   GO; GO:0030509; P:BMP signaling pathway; ISS:UniProtKB.
DR   GO; GO:0003130; P:BMP signaling pathway involved in heart induction; ISS:UniProtKB.
DR   GO; GO:0071893; P:BMP signaling pathway involved in nephric duct formation; ISS:UniProtKB.
DR   GO; GO:0061151; P:BMP signaling pathway involved in renal system segmentation; ISS:UniProtKB.
DR   GO; GO:0061149; P:BMP signaling pathway involved in ureter morphogenesis; ISS:UniProtKB.
DR   GO; GO:0007420; P:brain development; IEP:RGD.
DR   GO; GO:0001658; P:branching involved in ureteric bud morphogenesis; ISS:UniProtKB.
DR   GO; GO:0048754; P:branching morphogenesis of an epithelial tube; ISS:UniProtKB.
DR   GO; GO:0048468; P:cell development; IBA:GO_Central.
DR   GO; GO:0008283; P:cell proliferation; NAS:RGD.
DR   GO; GO:0071773; P:cellular response to BMP stimulus; IEP:RGD.
DR   GO; GO:0071549; P:cellular response to dexamethasone stimulus; IDA:UniProtKB.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEP:RGD.
DR   GO; GO:0034599; P:cellular response to oxidative stress; IDA:RGD.
DR   GO; GO:0097067; P:cellular response to thyroid hormone stimulus; IEP:RGD.
DR   GO; GO:0002062; P:chondrocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0007182; P:common-partner SMAD protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0035993; P:deltoid tuberosity development; ISS:UniProtKB.
DR   GO; GO:0001958; P:endochondral ossification; ISS:UniProtKB.
DR   GO; GO:0060441; P:epithelial tube branching involved in lung morphogenesis; IEP:RGD.
DR   GO; GO:0072104; P:glomerular capillary formation; ISS:UniProtKB.
DR   GO; GO:0040007; P:growth; IEA:InterPro.
DR   GO; GO:0002244; P:hematopoietic progenitor cell differentiation; ISS:UniProtKB.
DR   GO; GO:0048392; P:intermediate mesodermal cell differentiation; ISS:UniProtKB.
DR   GO; GO:0001822; P:kidney development; ISS:UniProtKB.
DR   GO; GO:0060462; P:lung lobe development; IEP:RGD.
DR   GO; GO:0002320; P:lymphoid progenitor cell differentiation; ISS:UniProtKB.
DR   GO; GO:0003337; P:mesenchymal to epithelial transition involved in metanephros morphogenesis; ISS:UniProtKB.
DR   GO; GO:0007498; P:mesoderm development; NAS:RGD.
DR   GO; GO:0001823; P:mesonephros development; ISS:UniProtKB.
DR   GO; GO:0072205; P:metanephric collecting duct development; ISS:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; ISS:UniProtKB.
DR   GO; GO:0072097; P:negative regulation of branch elongation involved in ureteric bud branching by BMP signaling pathway; ISS:UniProtKB.
DR   GO; GO:0090191; P:negative regulation of branching involved in ureteric bud morphogenesis; ISS:UniProtKB.
DR   GO; GO:0045786; P:negative regulation of cell cycle; ISS:UniProtKB.
DR   GO; GO:0060548; P:negative regulation of cell death; ISS:UniProtKB.
DR   GO; GO:2000137; P:negative regulation of cell proliferation involved in heart morphogenesis; ISS:UniProtKB.
DR   GO; GO:0072125; P:negative regulation of glomerular mesangial cell proliferation; ISS:UniProtKB.
DR   GO; GO:0090194; P:negative regulation of glomerulus development; ISS:UniProtKB.
DR   GO; GO:0033088; P:negative regulation of immature T cell proliferation in thymus; ISS:UniProtKB.
DR   GO; GO:0043407; P:negative regulation of MAP kinase activity; ISS:UniProtKB.
DR   GO; GO:0072200; P:negative regulation of mesenchymal cell proliferation involved in ureter development; ISS:UniProtKB.
DR   GO; GO:2000007; P:negative regulation of metanephric comma-shaped body morphogenesis; ISS:UniProtKB.
DR   GO; GO:2000005; P:negative regulation of metanephric S-shaped body morphogenesis; ISS:UniProtKB.
DR   GO; GO:0045839; P:negative regulation of mitotic nuclear division; ISS:UniProtKB.
DR   GO; GO:0048715; P:negative regulation of oligodendrocyte differentiation; IMP:RGD.
DR   GO; GO:0042326; P:negative regulation of phosphorylation; ISS:UniProtKB.
DR   GO; GO:0070244; P:negative regulation of thymocyte apoptotic process; ISS:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IBA:GO_Central.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0042476; P:odontogenesis; ISS:UniProtKB.
DR   GO; GO:0001649; P:osteoblast differentiation; ISS:UniProtKB.
DR   GO; GO:0001541; P:ovarian follicle development; IMP:RGD.
DR   GO; GO:0050918; P:positive chemotaxis; ISS:GOC.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; ISS:UniProtKB.
DR   GO; GO:0030513; P:positive regulation of BMP signaling pathway; ISS:UniProtKB.
DR   GO; GO:0030501; P:positive regulation of bone mineralization; ISS:UniProtKB.
DR   GO; GO:0061047; P:positive regulation of branching involved in lung morphogenesis; ISS:UniProtKB.
DR   GO; GO:0090190; P:positive regulation of branching involved in ureteric bud morphogenesis; IMP:UniProtKB.
DR   GO; GO:0010524; P:positive regulation of calcium ion transport into cytosol; IMP:RGD.
DR   GO; GO:0055020; P:positive regulation of cardiac muscle fiber development; ISS:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:RGD.
DR   GO; GO:0032967; P:positive regulation of collagen biosynthetic process; ISS:UniProtKB.
DR   GO; GO:2000105; P:positive regulation of DNA-dependent DNA replication; ISS:UniProtKB.
DR   GO; GO:2000353; P:positive regulation of endothelial cell apoptotic process; IMP:RGD.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; ISS:UniProtKB.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; ISS:UniProtKB.
DR   GO; GO:0045606; P:positive regulation of epidermal cell differentiation; ISS:UniProtKB.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; ISS:BHF-UCL.
DR   GO; GO:0070368; P:positive regulation of hepatocyte differentiation; IMP:RGD.
DR   GO; GO:0090184; P:positive regulation of kidney development; ISS:UniProtKB.
DR   GO; GO:1902462; P:positive regulation of mesenchymal stem cell proliferation; IMP:RGD.
DR   GO; GO:0045666; P:positive regulation of neuron differentiation; IMP:RGD.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IDA:RGD.
DR   GO; GO:0045778; P:positive regulation of ossification; IDA:MGI.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; ISS:UniProtKB.
DR   GO; GO:0010862; P:positive regulation of pathway-restricted SMAD protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0060391; P:positive regulation of SMAD protein import into nucleus; ISS:UniProtKB.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; ISS:UniProtKB.
DR   GO; GO:1901341; P:positive regulation of store-operated calcium channel activity; IMP:RGD.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:MGI.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0034504; P:protein localization to nucleus; ISS:UniProtKB.
DR   GO; GO:0061155; P:pulmonary artery endothelial tube morphogenesis; ISS:UniProtKB.
DR   GO; GO:0045595; P:regulation of cell differentiation; IDA:RGD.
DR   GO; GO:0010453; P:regulation of cell fate commitment; ISS:UniProtKB.
DR   GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; IDA:RGD.
DR   GO; GO:0060393; P:regulation of pathway-restricted SMAD protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0032355; P:response to estradiol; IEP:RGD.
DR   GO; GO:0051384; P:response to glucocorticoid; IEP:RGD.
DR   GO; GO:0009612; P:response to mechanical stimulus; IEP:RGD.
DR   GO; GO:0071731; P:response to nitric oxide; IEP:RGD.
DR   GO; GO:0014070; P:response to organic cyclic compound; IEP:RGD.
DR   GO; GO:0032526; P:response to retinoic acid; IEP:RGD.
DR   GO; GO:0033574; P:response to testosterone; IEP:RGD.
DR   GO; GO:0060041; P:retina development in camera-type eye; IEP:RGD.
DR   GO; GO:0003139; P:secondary heart field specification; ISS:UniProtKB.
DR   GO; GO:0060395; P:SMAD protein signal transduction; ISS:UniProtKB.
DR   GO; GO:0048745; P:smooth muscle tissue development; ISS:UniProtKB.
DR   GO; GO:0072101; P:specification of ureteric bud anterior/posterior symmetry by BMP signaling pathway; ISS:UniProtKB.
DR   GO; GO:0043401; P:steroid hormone mediated signaling pathway; ISS:UniProtKB.
DR   GO; GO:0035990; P:tendon cell differentiation; ISS:UniProtKB.
DR   GO; GO:0043587; P:tongue morphogenesis; IEP:RGD.
DR   GO; GO:0003323; P:type B pancreatic cell development; ISS:UniProtKB.
DR   GO; GO:0072192; P:ureter epithelial cell differentiation; ISS:UniProtKB.
DR   GO; GO:0072193; P:ureter smooth muscle cell differentiation; ISS:UniProtKB.
DR   GO; GO:0042060; P:wound healing; IEP:RGD.
DR   Gene3D; 2.10.90.10; -; 1.
DR   InterPro; IPR029034; Cystine-knot_cytokine.
DR   InterPro; IPR001839; TGF-b_C.
DR   InterPro; IPR001111; TGF-b_N.
DR   InterPro; IPR015615; TGF-beta-rel.
DR   InterPro; IPR017948; TGFb_CS.
DR   PANTHER; PTHR11848; PTHR11848; 1.
DR   Pfam; PF00019; TGF_beta; 1.
DR   Pfam; PF00688; TGFb_propeptide; 1.
DR   SMART; SM00204; TGFB; 1.
DR   SUPFAM; SSF57501; SSF57501; 1.
DR   PROSITE; PS00250; TGF_BETA_1; 1.
DR   PROSITE; PS51362; TGF_BETA_2; 1.
PE   2: Evidence at transcript level;
KW   Chondrogenesis; Cleavage on pair of basic residues; Complete proteome;
KW   Cytokine; Developmental protein; Differentiation; Disulfide bond;
KW   Extracellular matrix; Glycoprotein; Growth factor; Osteogenesis;
KW   Phosphoprotein; Reference proteome; Secreted; Signal.
FT   SIGNAL        1     19       {ECO:0000255}.
FT   PROPEP       20    292
FT                                /FTId=PRO_0000033862.
FT   CHAIN       293    408       Bone morphogenetic protein 4.
FT                                /FTId=PRO_0000033863.
FT   MOD_RES      91     91       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P12644}.
FT   CARBOHYD    144    144       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    209    209       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    350    350       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    365    365       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    308    373       {ECO:0000250}.
FT   DISULFID    337    405       {ECO:0000250}.
FT   DISULFID    341    407       {ECO:0000250}.
FT   DISULFID    372    372       Interchain. {ECO:0000250}.
SQ   SEQUENCE   408 AA;  46541 MW;  61E92B4B8D5624F3 CRC64;
     MIPGNRMLMV VLLCQVLLGG ATDASLIPET GKKKVAEIQG HAGGRRSGQS HELLRDFEAT
     LLQMFGLRRR PQPSKSAVIP DYMRDLYRLQ SGEEEEEEQS QGTGLEYPER PASRANTVRS
     FHHEEHLENI PGTSESSAFR FFFNLSSIPE NEVISSAELR LFREQVDQGP DWEQGFHRIN
     IYEVMKPPAE MVPGHLITRL LDTRLVRHNV TRWETFDVSP AVLRWTREKQ PNYGLAIEVT
     HLHQTRTHQG QHVRISRSLP QGSGNWAQLR PLLVTFGHDG RGHTLTRRRA KRSPKHHPQR
     SRKKNKNCRR HSLYVDFSDV GWNDWIVAPP GYQAFYCHGD CPFPLADHLN STNHAIVQTL
     VNSVNSSIPK ACCVPTELSA ISMLYLDEYD KVVLKNYQEM VVEGCGCR
//
ID   APOE_MOUSE              Reviewed;         311 AA.
AC   P08226;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1990, sequence version 2.
DT   17-FEB-2016, entry version 151.
DE   RecName: Full=Apolipoprotein E;
DE            Short=Apo-E;
DE   Flags: Precursor;
GN   Name=Apoe;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2550421;
RA   Horiuchi K., Tajima S., Menju M., Yamamoto A.;
RT   "Structure and expression of mouse apolipoprotein E gene.";
RL   J. Biochem. 106:98-103(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3865219; DOI=10.1073/pnas.82.23.8085;
RA   Rajavashisth T.B., Kaptein J.S., Reue K.L., Lusis A.J.;
RT   "Evolution of apolipoprotein E: mouse sequence and evidence for an 11-
RT   nucleotide ancestral unit.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:8085-8089(1985).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J; TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 26-311.
RX   PubMed=1870200;
RA   Diedrich J.F., Minnigan M., Carp R.I., Whitaker J.N., Race R.,
RA   Frey W. II, Haase A.T.;
RT   "Neuropathological changes in scrapie and Alzheimer's disease are
RT   associated with increased expression of apolipoprotein E and cathepsin
RT   D in astrocytes.";
RL   J. Virol. 65:4759-4768(1991).
RN   [5]
RP   PROTEIN SEQUENCE OF 43-48; 87-100; 114-122; 130-144; 183-188; 191-198;
RP   202-214; 226-236 AND 253-284, IDENTIFICATION BY MASS SPECTROMETRY, AND
RP   OXIDATION AT MET-135.
RX   PubMed=16876491; DOI=10.1016/j.bbapap.2006.06.001;
RA   Puppione D.L., Yam L.M., Bassilian S., Souda P., Castellani L.W.,
RA   Schumaker V.N., Whitelegge J.P.;
RT   "Mass spectral analysis of the apolipoproteins on mouse high density
RT   lipoproteins. Detection of post-translational modifications.";
RL   Biochim. Biophys. Acta 1764:1363-1371(2006).
RN   [6]
RP   PROTEIN SEQUENCE OF 114-122, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   STRAIN=C57BL/6J; TISSUE=Brain;
RA   Lubec G., Kang S.U.;
RL   Submitted (APR-2007) to UniProtKB.
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-139, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain, Brown adipose tissue, Heart, Kidney, Liver, Lung,
RC   Pancreas, Spleen, and Testis;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and
RT   expression.";
RL   Cell 143:1174-1189(2010).
RN   [8]
RP   DISRUPTION PHENOTYPE.
RX   PubMed=20037584; DOI=10.1038/ni.1836;
RA   Stewart C.R., Stuart L.M., Wilkinson K., van Gils J.M., Deng J.,
RA   Halle A., Rayner K.J., Boyer L., Zhong R., Frazier W.A.,
RA   Lacy-Hulbert A., El Khoury J., Golenbock D.T., Moore K.J.;
RT   "CD36 ligands promote sterile inflammation through assembly of a Toll-
RT   like receptor 4 and 6 heterodimer.";
RL   Nat. Immunol. 11:155-161(2010).
RN   [9]
RP   DISRUPTION PHENOTYPE.
RX   PubMed=23812099; DOI=10.1038/ni.2639;
RA   Sheedy F.J., Grebe A., Rayner K.J., Kalantari P., Ramkhelawon B.,
RA   Carpenter S.B., Becker C.E., Ediriweera H.N., Mullick A.E.,
RA   Golenbock D.T., Stuart L.M., Latz E., Fitzgerald K.A., Moore K.J.;
RT   "CD36 coordinates NLRP3 inflammasome activation by facilitating
RT   intracellular nucleation of soluble ligands into particulate ligands
RT   in sterile inflammation.";
RL   Nat. Immunol. 14:812-820(2013).
CC   -!- FUNCTION: Mediates the binding, internalization, and catabolism of
CC       lipoprotein particles. It can serve as a ligand for the LDL (apo
CC       B/E) receptor and for the specific apo-E receptor (chylomicron
CC       remnant) of hepatic tissues. {ECO:0000250|UniProtKB:P02649}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000250|UniProtKB:P02649}.
CC   -!- TISSUE SPECIFICITY: Secreted in plasma.
CC   -!- PTM: Phosphorylated by FAM20C in the extracellular medium.
CC       {ECO:0000250|UniProtKB:P02649}.
CC   -!- DISRUPTION PHENOTYPE: APOE single knockout mice are
CC       atherosclerosis-prone. Animals with a double knockout of APOE and
CC       CD36, fed a Western diet for 12 weeks, exhibit much lower levels
CC       of CXCL1, CXCL2 and CCL5 mRNA expression in the descending aorta
CC       and a corresponding decrease in atherosclerotic lesion formation,
CC       compared to APOE single knockout mice. Animals with a double
CC       knockout of APOE and TLR4 or TLR6 also have less aortic plaque
CC       formation than single knockout mice. All 3 double knockout show
CC       lower serum concentrations of IL1A, ILB and IL18.
CC       {ECO:0000269|PubMed:20037584, ECO:0000269|PubMed:23812099}.
CC   -!- SIMILARITY: Belongs to the apolipoprotein A1/A4/E family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D00466; BAA00361.1; -; Genomic_DNA.
DR   EMBL; M12414; AAA37251.1; -; mRNA.
DR   EMBL; BC083351; AAH83351.1; -; mRNA.
DR   EMBL; M73490; AAA37252.1; -; mRNA.
DR   CCDS; CCDS20912.1; -.
DR   PIR; JU0036; JU0036.
DR   RefSeq; NP_001292748.1; NM_001305819.1.
DR   RefSeq; NP_001292772.1; NM_001305843.1.
DR   RefSeq; NP_001292773.1; NM_001305844.1.
DR   RefSeq; NP_033826.2; NM_009696.4.
DR   UniGene; Mm.305152; -.
DR   PDB; 1YA9; X-ray; 2.09 A; A=20-200.
DR   PDBsum; 1YA9; -.
DR   ProteinModelPortal; P08226; -.
DR   SMR; P08226; 19-305.
DR   BioGrid; 198164; 5.
DR   IntAct; P08226; 5.
DR   MINT; MINT-242645; -.
DR   STRING; 10090.ENSMUSP00000003066; -.
DR   iPTMnet; P08226; -.
DR   PhosphoSite; P08226; -.
DR   MaxQB; P08226; -.
DR   PaxDb; P08226; -.
DR   PRIDE; P08226; -.
DR   Ensembl; ENSMUST00000003066; ENSMUSP00000003066; ENSMUSG00000002985.
DR   Ensembl; ENSMUST00000173739; ENSMUSP00000133371; ENSMUSG00000002985.
DR   Ensembl; ENSMUST00000174064; ENSMUSP00000133302; ENSMUSG00000002985.
DR   Ensembl; ENSMUST00000174355; ENSMUSP00000134160; ENSMUSG00000002985.
DR   GeneID; 11816; -.
DR   KEGG; mmu:11816; -.
DR   UCSC; uc009fmy.3; mouse.
DR   CTD; 348; -.
DR   MGI; MGI:88057; Apoe.
DR   eggNOG; ENOG410IVK0; Eukaryota.
DR   eggNOG; ENOG4111MYC; LUCA.
DR   HOGENOM; HOG000034006; -.
DR   HOVERGEN; HBG010582; -.
DR   InParanoid; P08226; -.
DR   KO; K04524; -.
DR   OMA; FEPIVED; -.
DR   OrthoDB; EOG793B87; -.
DR   PhylomeDB; P08226; -.
DR   TreeFam; TF334458; -.
DR   Reactome; R-MMU-174800; Chylomicron-mediated lipid transport.
DR   Reactome; R-MMU-194223; HDL-mediated lipid transport.
DR   Reactome; R-MMU-3000480; Scavenging by Class A Receptors.
DR   Reactome; R-MMU-975634; Retinoid metabolism and transport.
DR   ChiTaRS; Apoe; mouse.
DR   EvolutionaryTrace; P08226; -.
DR   NextBio; 279703; -.
DR   PRO; PR:P08226; -.
DR   Proteomes; UP000000589; Chromosome 7.
DR   Bgee; P08226; -.
DR   CleanEx; MM_APOE; -.
DR   ExpressionAtlas; P08226; baseline and differential.
DR   Genevisible; P08226; MM.
DR   GO; GO:0072562; C:blood microparticle; ISO:MGI.
DR   GO; GO:0042627; C:chylomicron; ISO:MGI.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISO:MGI.
DR   GO; GO:0070062; C:extracellular exosome; ISO:MGI.
DR   GO; GO:0031012; C:extracellular matrix; ISO:MGI.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:MGI.
DR   GO; GO:1903561; C:extracellular vesicle; ISO:MGI.
DR   GO; GO:0005794; C:Golgi apparatus; ISO:MGI.
DR   GO; GO:0034364; C:high-density lipoprotein particle; ISO:MGI.
DR   GO; GO:0034363; C:intermediate-density lipoprotein particle; ISO:MGI.
DR   GO; GO:0034362; C:low-density lipoprotein particle; IDA:BHF-UCL.
DR   GO; GO:0016020; C:membrane; ISO:MGI.
DR   GO; GO:0005634; C:nucleus; ISO:MGI.
DR   GO; GO:0034361; C:very-low-density lipoprotein particle; ISO:MGI.
DR   GO; GO:0016209; F:antioxidant activity; ISO:MGI.
DR   GO; GO:0001540; F:beta-amyloid binding; ISS:UniProtKB.
DR   GO; GO:0015485; F:cholesterol binding; IBA:GO_Central.
DR   GO; GO:0017127; F:cholesterol transporter activity; IDA:MGI.
DR   GO; GO:0008201; F:heparin binding; ISO:MGI.
DR   GO; GO:0042802; F:identical protein binding; ISO:MGI.
DR   GO; GO:0008289; F:lipid binding; ISO:MGI.
DR   GO; GO:0005319; F:lipid transporter activity; ISO:MGI.
DR   GO; GO:0071813; F:lipoprotein particle binding; IDA:MGI.
DR   GO; GO:0050750; F:low-density lipoprotein particle receptor binding; ISO:MGI.
DR   GO; GO:0046911; F:metal chelating activity; ISO:MGI.
DR   GO; GO:0060228; F:phosphatidylcholine-sterol O-acyltransferase activator activity; IMP:BHF-UCL.
DR   GO; GO:0005543; F:phospholipid binding; ISO:MGI.
DR   GO; GO:0042803; F:protein homodimerization activity; ISO:MGI.
DR   GO; GO:0048156; F:tau protein binding; ISO:MGI.
DR   GO; GO:0070326; F:very-low-density lipoprotein particle receptor binding; ISO:MGI.
DR   GO; GO:0097113; P:AMPA glutamate receptor clustering; ISO:MGI.
DR   GO; GO:0048844; P:artery morphogenesis; IGI:MGI.
DR   GO; GO:0072358; P:cardiovascular system development; IMP:MGI.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; IDA:MGI.
DR   GO; GO:0098869; P:cellular oxidant detoxification; ISO:GOC.
DR   GO; GO:0019934; P:cGMP-mediated signaling; ISO:MGI.
DR   GO; GO:0006695; P:cholesterol biosynthetic process; IBA:GO_Central.
DR   GO; GO:0006707; P:cholesterol catabolic process; IMP:MGI.
DR   GO; GO:0033344; P:cholesterol efflux; IDA:MGI.
DR   GO; GO:0042632; P:cholesterol homeostasis; IMP:MGI.
DR   GO; GO:0008203; P:cholesterol metabolic process; IMP:MGI.
DR   GO; GO:0034382; P:chylomicron remnant clearance; ISO:MGI.
DR   GO; GO:0055089; P:fatty acid homeostasis; ISO:MGI.
DR   GO; GO:0007186; P:G-protein coupled receptor signaling pathway; ISO:MGI.
DR   GO; GO:0034380; P:high-density lipoprotein particle assembly; ISO:MGI.
DR   GO; GO:0034384; P:high-density lipoprotein particle clearance; ISO:MGI.
DR   GO; GO:0034375; P:high-density lipoprotein particle remodeling; ISO:MGI.
DR   GO; GO:0055088; P:lipid homeostasis; IMP:MGI.
DR   GO; GO:0006629; P:lipid metabolic process; IGI:MGI.
DR   GO; GO:0042158; P:lipoprotein biosynthetic process; IGI:MGI.
DR   GO; GO:0042159; P:lipoprotein catabolic process; IMP:MGI.
DR   GO; GO:0042157; P:lipoprotein metabolic process; IMP:MGI.
DR   GO; GO:0015909; P:long-chain fatty acid transport; ISO:MGI.
DR   GO; GO:0034374; P:low-density lipoprotein particle remodeling; IMP:BHF-UCL.
DR   GO; GO:0051651; P:maintenance of location in cell; IMP:MGI.
DR   GO; GO:1902430; P:negative regulation of beta-amyloid formation; ISO:MGI.
DR   GO; GO:0030195; P:negative regulation of blood coagulation; ISO:MGI.
DR   GO; GO:0043537; P:negative regulation of blood vessel endothelial cell migration; ISO:MGI.
DR   GO; GO:0045541; P:negative regulation of cholesterol biosynthetic process; ISO:MGI.
DR   GO; GO:0090370; P:negative regulation of cholesterol efflux; ISO:MGI.
DR   GO; GO:0061000; P:negative regulation of dendritic spine development; ISO:MGI.
DR   GO; GO:1902951; P:negative regulation of dendritic spine maintenance; ISO:MGI.
DR   GO; GO:0001937; P:negative regulation of endothelial cell proliferation; ISO:MGI.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; IGI:UniProtKB.
DR   GO; GO:0051055; P:negative regulation of lipid biosynthetic process; ISO:MGI.
DR   GO; GO:1903001; P:negative regulation of lipid transport across blood brain barrier; ISO:MGI.
DR   GO; GO:0043407; P:negative regulation of MAP kinase activity; ISO:MGI.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IBA:GO_Central.
DR   GO; GO:1901215; P:negative regulation of neuron death; ISO:MGI.
DR   GO; GO:1902999; P:negative regulation of phospholipid efflux; ISO:MGI.
DR   GO; GO:0010544; P:negative regulation of platelet activation; ISO:MGI.
DR   GO; GO:1901627; P:negative regulation of postsynaptic membrane organization; ISO:MGI.
DR   GO; GO:1901630; P:negative regulation of presynaptic membrane organization; ISO:MGI.
DR   GO; GO:0007263; P:nitric oxide mediated signal transduction; ISO:MGI.
DR   GO; GO:0097114; P:NMDA glutamate receptor clustering; ISO:MGI.
DR   GO; GO:0033700; P:phospholipid efflux; ISO:MGI.
DR   GO; GO:0044794; P:positive regulation by host of viral process; ISO:MGI.
DR   GO; GO:1902004; P:positive regulation of beta-amyloid formation; ISO:MGI.
DR   GO; GO:0030828; P:positive regulation of cGMP biosynthetic process; ISO:MGI.
DR   GO; GO:0010875; P:positive regulation of cholesterol efflux; ISO:MGI.
DR   GO; GO:0010873; P:positive regulation of cholesterol esterification; IMP:BHF-UCL.
DR   GO; GO:0060999; P:positive regulation of dendritic spine development; ISO:MGI.
DR   GO; GO:1902952; P:positive regulation of dendritic spine maintenance; ISO:MGI.
DR   GO; GO:0046889; P:positive regulation of lipid biosynthetic process; ISO:MGI.
DR   GO; GO:1903002; P:positive regulation of lipid transport across blood brain barrier; ISO:MGI.
DR   GO; GO:0032805; P:positive regulation of low-density lipoprotein particle receptor catabolic process; ISO:MGI.
DR   GO; GO:0051044; P:positive regulation of membrane protein ectodomain proteolysis; ISO:MGI.
DR   GO; GO:1902998; P:positive regulation of neurofibrillary tangle assembly; ISO:MGI.
DR   GO; GO:1901216; P:positive regulation of neuron death; ISO:MGI.
DR   GO; GO:0051000; P:positive regulation of nitric-oxide synthase activity; ISO:MGI.
DR   GO; GO:1902995; P:positive regulation of phospholipid efflux; ISO:MGI.
DR   GO; GO:1901628; P:positive regulation of postsynaptic membrane organization; ISO:MGI.
DR   GO; GO:1901631; P:positive regulation of presynaptic membrane organization; ISO:MGI.
DR   GO; GO:0017038; P:protein import; ISO:MGI.
DR   GO; GO:0006898; P:receptor-mediated endocytosis; ISO:MGI.
DR   GO; GO:0030516; P:regulation of axon extension; IBA:GO_Central.
DR   GO; GO:1900221; P:regulation of beta-amyloid clearance; ISO:MGI.
DR   GO; GO:0032489; P:regulation of Cdc42 protein signal transduction; ISO:MGI.
DR   GO; GO:0032374; P:regulation of cholesterol transport; IBA:GO_Central.
DR   GO; GO:0010468; P:regulation of gene expression; IMP:MGI.
DR   GO; GO:1901214; P:regulation of neuron death; ISO:MGI.
DR   GO; GO:1902947; P:regulation of tau-protein kinase activity; ISO:MGI.
DR   GO; GO:0002021; P:response to dietary excess; IMP:MGI.
DR   GO; GO:0006979; P:response to oxidative stress; IMP:MGI.
DR   GO; GO:0043691; P:reverse cholesterol transport; ISO:MGI.
DR   GO; GO:0019433; P:triglyceride catabolic process; IBA:GO_Central.
DR   GO; GO:0006641; P:triglyceride metabolic process; ISO:MGI.
DR   GO; GO:0042311; P:vasodilation; IMP:MGI.
DR   GO; GO:0034447; P:very-low-density lipoprotein particle clearance; ISO:MGI.
DR   GO; GO:0034372; P:very-low-density lipoprotein particle remodeling; IMP:BHF-UCL.
DR   GO; GO:0019068; P:virion assembly; ISO:MGI.
DR   InterPro; IPR000074; ApoA_E.
DR   Pfam; PF01442; Apolipoprotein; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Chylomicron; Complete proteome;
KW   Direct protein sequencing; Glycoprotein; HDL; Heparin-binding;
KW   Lipid transport; Oxidation; Phosphoprotein; Reference proteome;
KW   Repeat; Secreted; Signal; Transport; VLDL.
FT   SIGNAL        1     18
FT   CHAIN        19    311       Apolipoprotein E.
FT                                /FTId=PRO_0000001990.
FT   REPEAT       72     93       1.
FT   REPEAT       94    115       2.
FT   REPEAT      116    137       3.
FT   REPEAT      138    159       4.
FT   REPEAT      160    181       5.
FT   REPEAT      182    203       6.
FT   REPEAT      204    225       7.
FT   REPEAT      226    247       8.
FT   REGION       72    247       8 X 22 AA approximate tandem repeats.
FT   REGION      150    160       LDL receptor binding.
FT                                {ECO:0000250|UniProtKB:P02649}.
FT   REGION      154    157       Heparin-binding.
FT                                {ECO:0000250|UniProtKB:P02649}.
FT   REGION      221    228       Heparin-binding.
FT                                {ECO:0000250|UniProtKB:P02649}.
FT   MOD_RES     135    135       Methionine sulfoxide.
FT                                {ECO:0000269|PubMed:16876491}.
FT   MOD_RES     139    139       Phosphoserine.
FT                                {ECO:0000244|PubMed:21183079}.
FT   CARBOHYD     25     25       O-linked (GalNAc...).
FT                                {ECO:0000250|UniProtKB:Q03247}.
FT   CARBOHYD    304    304       O-linked (GalNAc...).
FT                                {ECO:0000250|UniProtKB:Q03247}.
FT   CONFLICT    163    163       E -> D (in Ref. 2; AAA37251).
FT                                {ECO:0000305}.
FT   HELIX        29     31       {ECO:0000244|PDB:1YA9}.
FT   HELIX        34     50       {ECO:0000244|PDB:1YA9}.
FT   HELIX        55     62       {ECO:0000244|PDB:1YA9}.
FT   HELIX        65     90       {ECO:0000244|PDB:1YA9}.
FT   HELIX        97    134       {ECO:0000244|PDB:1YA9}.
FT   TURN        135    137       {ECO:0000244|PDB:1YA9}.
FT   HELIX       141    172       {ECO:0000244|PDB:1YA9}.
FT   HELIX       184    191       {ECO:0000244|PDB:1YA9}.
SQ   SEQUENCE   311 AA;  35867 MW;  3B36FA897CC34170 CRC64;
     MKALWAVLLV TLLTGCLAEG EPEVTDQLEW QSNQPWEQAL NRFWDYLRWV QTLSDQVQEE
     LQSSQVTQEL TALMEDTMTE VKAYKKELEE QLGPVAEETR ARLGKEVQAA QARLGADMED
     LRNRLGQYRN EVHTMLGQST EEIRARLSTH LRKMRKRLMR DAEDLQKRLA VYKAGAREGA
     ERGVSAIRER LGPLVEQGRQ RTANLGAGAA QPLRDRAQAF GDRIRGRLEE VGNQARDRLE
     EVREHMEEVR SKMEEQTQQI RLQAEIFQAR LKGWFEPIVE DMHRQWANLM EKIQASVATN
     PIITPVAQEN Q
//
ID   TGFR1_MOUSE             Reviewed;         503 AA.
AC   Q64729; A2AJN0;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   20-JAN-2016, entry version 158.
DE   RecName: Full=TGF-beta receptor type-1;
DE            Short=TGFR-1;
DE            EC=2.7.11.30;
DE   AltName: Full=ESK2;
DE   AltName: Full=Transforming growth factor-beta receptor type I;
DE            Short=TGF-beta receptor type I;
DE            Short=TbetaR-I;
DE   Flags: Precursor;
GN   Name=Tgfbr1;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain, and Testis;
RX   PubMed=8117261; DOI=10.1006/bbrc.1994.1150;
RA   Tomoda T., Kudoh T., Noma T., Nakazawa A., Muramatsu M.-A., Arai K.;
RT   "Molecular cloning of a mouse counterpart for human TGF-beta type I
RT   receptor.";
RL   Biochem. Biophys. Res. Commun. 198:1054-1062(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=8117262; DOI=10.1006/bbrc.1994.1151;
RA   Suzuki A., Shioda N., Maeda T., Tada M., Ueno N.;
RT   "A mouse TGF-beta type I receptor that requires type II receptor for
RT   ligand binding.";
RL   Biochem. Biophys. Res. Commun. 198:1063-1069(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=C57BL/6J;
RX   PubMed=19468303; DOI=10.1371/journal.pbio.1000112;
RA   Church D.M., Goodstadt L., Hillier L.W., Zody M.C., Goldstein S.,
RA   She X., Bult C.J., Agarwala R., Cherry J.L., DiCuccio M., Hlavina W.,
RA   Kapustin Y., Meric P., Maglott D., Birtle Z., Marques A.C., Graves T.,
RA   Zhou S., Teague B., Potamousis K., Churas C., Place M., Herschleb J.,
RA   Runnheim R., Forrest D., Amos-Landgraf J., Schwartz D.C., Cheng Z.,
RA   Lindblad-Toh K., Eichler E.E., Ponting C.P.;
RT   "Lineage-specific biology revealed by a finished genome assembly of
RT   the mouse.";
RL   PLoS Biol. 7:E1000112-E1000112(2009).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   STRAIN=C57BL/6J; TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   -!- FUNCTION: Transmembrane serine/threonine kinase forming with the
CC       TGF-beta type II serine/threonine kinase receptor, TGFBR2, the
CC       non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2
CC       and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the
CC       cell surface to the cytoplasm and is thus regulating a plethora of
CC       physiological and pathological processes including cell cycle
CC       arrest in epithelial and hematopoietic cells, control of
CC       mesenchymal cell proliferation and differentiation, wound healing,
CC       extracellular matrix production, immunosuppression and
CC       carcinogenesis. The formation of the receptor complex composed of
CC       2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the
CC       cytokine dimer results in the phosphorylation and the activation
CC       of TGFBR1 by the constitutively active TGFBR2. Activated TGFBR1
CC       phosphorylates SMAD2 which dissociates from the receptor and
CC       interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently
CC       translocated to the nucleus where it modulates the transcription
CC       of the TGF-beta-regulated genes. This constitutes the canonical
CC       SMAD-dependent TGF-beta signaling cascade. Also involved in non-
CC       canonical, SMAD-independent TGF-beta signaling pathways. For
CC       instance, TGFBR1 induces TRAF6 autoubiquitination which in turn
CC       results in MAP3K7 ubiquitination and activation to trigger
CC       apoptosis. Also regulates epithelial to mesenchymal transition
CC       through a SMAD-independent signaling pathway through PARD6A
CC       phosphorylation and activation (By similarity). {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY: ATP + [receptor-protein] = ADP + [receptor-
CC       protein] phosphate.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250};
CC   -!- ENZYME REGULATION: Kept in an inactive conformation by FKBP1A
CC       preventing receptor activation in absence of ligand. CD109 is
CC       another inhibitor of the receptor (By similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Homodimer; in the endoplasmic reticulum but also at the
CC       cell membrane. Heterohexamer; TGFB1, TGFB2 and TGFB3 homodimeric
CC       ligands assemble a functional receptor composed of two TGFBR1 and
CC       TGFBR2 heterodimers to form a ligand-receptor heterohexamer. The
CC       respective affinity of TGBRB1 and TGFBR2 for the ligands may
CC       modulate the kinetics of assembly of the receptor and may explain
CC       the different biological activities of TGFB1, TGFB2 and TGFB3.
CC       Interacts with CD109; inhibits TGF-beta receptor activation in
CC       keratinocytes. Interacts with RBPMS. Interacts (unphosphorylated)
CC       with FKBP1A; prevents TGFBR1 phosphorylation by TGFBR2 and
CC       stabilizes it in the inactive conformation. Interacts with SMAD2,
CC       SMAD3 and ZFYVE9; ZFYVE9 recruits SMAD2 and SMAD3 to the TGF-beta
CC       receptor. Interacts with TRAF6 and MAP3K7; induces MAP3K7
CC       activation by TRAF6. Interacts with PARD6A; involved in TGF-beta
CC       induced epithelial to mesenchymal transition. Interacts with
CC       SMAD7, NEDD4L, SMURF1 and SMURF2; SMAD7 recruits NEDD4L, SMURF1
CC       and SMURF2 to the TGF-beta receptor (By similarity). Interacts
CC       with USP15 and VPS39 (By similarity). {ECO:0000250}.
CC   -!- INTERACTION:
CC       P15379:Cd44; NbExp=4; IntAct=EBI-2899393, EBI-7565891;
CC       P55284:Cdh5; NbExp=2; IntAct=EBI-2899393, EBI-7087433;
CC       Q8TDM6:DLG5 (xeno); NbExp=3; IntAct=EBI-2899393, EBI-715138;
CC       P98083-2:Shc1; NbExp=3; IntAct=EBI-2899393, EBI-1019301;
CC   -!- SUBCELLULAR LOCATION: Cell membrane
CC       {ECO:0000250|UniProtKB:P36897}; Single-pass type I membrane
CC       protein {ECO:0000250|UniProtKB:P36897}. Cell junction, tight
CC       junction {ECO:0000250|UniProtKB:P36897}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q64729-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q64729-2; Sequence=VSP_021593;
CC         Note=May be due to a competing donnor splice site.;
CC   -!- PTM: Phosphorylated at basal levels in the absence of ligand.
CC       Activated upon phosphorylation by TGFBR2, mainly in the GS domain.
CC       Phosphorylation in the GS domain abrogates FKBP1A-binding (By
CC       similarity). {ECO:0000250}.
CC   -!- PTM: N-Glycosylated. {ECO:0000250}.
CC   -!- PTM: Ubiquitinated; undergoes ubiquitination catalyzed by several
CC       E3 ubiquitin ligases including SMURF1, SMURF2 and NEDD4L2. Results
CC       in the proteasomal and/or lysosomal degradation of the receptor
CC       thereby negatively regulating its activity. Deubiquitinated by
CC       USP15, leading to stabilization of the protein and enhanced TGF-
CC       beta signal (By similarity). {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. TGFB receptor subfamily. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 GS domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00585}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D28526; BAA05878.1; -; mRNA.
DR   EMBL; D25540; BAA05023.1; -; mRNA.
DR   EMBL; AL772232; CAM13897.1; -; Genomic_DNA.
DR   EMBL; AL772150; CAM13897.1; JOINED; Genomic_DNA.
DR   EMBL; AL772150; CAM24923.1; -; Genomic_DNA.
DR   EMBL; AL772232; CAM24923.1; JOINED; Genomic_DNA.
DR   EMBL; BC063260; AAH63260.1; -; mRNA.
DR   CCDS; CCDS18160.1; -. [Q64729-1]
DR   PIR; JC2061; JC2061.
DR   PIR; JC2062; JC2062.
DR   RefSeq; NP_001299797.1; NM_001312868.1. [Q64729-2]
DR   RefSeq; NP_001299798.1; NM_001312869.1.
DR   RefSeq; NP_033396.1; NM_009370.3. [Q64729-1]
DR   UniGene; Mm.197552; -.
DR   ProteinModelPortal; Q64729; -.
DR   SMR; Q64729; 27-110, 175-500.
DR   BioGrid; 204163; 10.
DR   DIP; DIP-42262N; -.
DR   IntAct; Q64729; 25.
DR   MINT; MINT-1341331; -.
DR   STRING; 10090.ENSMUSP00000007757; -.
DR   BindingDB; Q64729; -.
DR   ChEMBL; CHEMBL2021750; -.
DR   iPTMnet; Q64729; -.
DR   PhosphoSite; Q64729; -.
DR   MaxQB; Q64729; -.
DR   PaxDb; Q64729; -.
DR   PRIDE; Q64729; -.
DR   Ensembl; ENSMUST00000007757; ENSMUSP00000007757; ENSMUSG00000007613. [Q64729-1]
DR   Ensembl; ENSMUST00000044234; ENSMUSP00000048501; ENSMUSG00000007613. [Q64729-2]
DR   GeneID; 21812; -.
DR   KEGG; mmu:21812; -.
DR   UCSC; uc008sun.1; mouse. [Q64729-1]
DR   UCSC; uc008suo.1; mouse. [Q64729-2]
DR   CTD; 7046; -.
DR   MGI; MGI:98728; Tgfbr1.
DR   eggNOG; KOG2052; Eukaryota.
DR   eggNOG; ENOG410XQT0; LUCA.
DR   GeneTree; ENSGT00760000118876; -.
DR   HOGENOM; HOG000230587; -.
DR   HOVERGEN; HBG054502; -.
DR   InParanoid; Q64729; -.
DR   KO; K04674; -.
DR   OMA; GATALQC; -.
DR   OrthoDB; EOG7Q8CN3; -.
DR   PhylomeDB; Q64729; -.
DR   TreeFam; TF314724; -.
DR   BRENDA; 2.7.10.2; 3474.
DR   Reactome; R-MMU-2173788; Downregulation of TGF-beta receptor signaling.
DR   Reactome; R-MMU-2173789; TGF-beta receptor signaling activates SMADs.
DR   Reactome; R-MMU-2173791; TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition).
DR   ChiTaRS; Tgfbr1; mouse.
DR   NextBio; 301202; -.
DR   PRO; PR:Q64729; -.
DR   Proteomes; UP000000589; Chromosome 4.
DR   Bgee; Q64729; -.
DR   CleanEx; MM_TGFBR1; -.
DR   ExpressionAtlas; Q64729; baseline and differential.
DR   Genevisible; Q64729; MM.
DR   GO; GO:0005923; C:bicellular tight junction; ISO:MGI.
DR   GO; GO:0005901; C:caveola; ISO:MGI.
DR   GO; GO:0005623; C:cell; ISS:AgBase.
DR   GO; GO:0005768; C:endosome; IDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005622; C:intracellular; ISS:GOC.
DR   GO; GO:0016020; C:membrane; ISS:AgBase.
DR   GO; GO:0045121; C:membrane raft; ISO:MGI.
DR   GO; GO:0005886; C:plasma membrane; ISO:MGI.
DR   GO; GO:0043235; C:receptor complex; ISO:MGI.
DR   GO; GO:0005524; F:ATP binding; ISO:MGI.
DR   GO; GO:0070411; F:I-SMAD binding; ISO:MGI.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004672; F:protein kinase activity; ISO:MGI.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; ISO:MGI.
DR   GO; GO:0005102; F:receptor binding; IPI:UniProtKB.
DR   GO; GO:0005057; F:receptor signaling protein activity; ISS:AgBase.
DR   GO; GO:0004702; F:receptor signaling protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0046332; F:SMAD binding; IDA:BHF-UCL.
DR   GO; GO:0050431; F:transforming growth factor beta binding; IPI:MGI.
DR   GO; GO:0005025; F:transforming growth factor beta receptor activity, type I; ISS:AgBase.
DR   GO; GO:0005024; F:transforming growth factor beta-activated receptor activity; IDA:MGI.
DR   GO; GO:0005114; F:type II transforming growth factor beta receptor binding; ISO:MGI.
DR   GO; GO:0000186; P:activation of MAPKK activity; ISO:MGI.
DR   GO; GO:0032924; P:activin receptor signaling pathway; ISS:AgBase.
DR   GO; GO:0001525; P:angiogenesis; IMP:MGI.
DR   GO; GO:0009952; P:anterior/posterior pattern specification; IGI:MGI.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0048844; P:artery morphogenesis; IMP:MGI.
DR   GO; GO:0001824; P:blastocyst development; IDA:MGI.
DR   GO; GO:0060317; P:cardiac epithelial to mesenchymal transition; ISS:AgBase.
DR   GO; GO:0048870; P:cell motility; ISO:MGI.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IDA:BHF-UCL.
DR   GO; GO:0030199; P:collagen fibril organization; IMP:MGI.
DR   GO; GO:0048701; P:embryonic cranial skeleton morphogenesis; IMP:MGI.
DR   GO; GO:0042118; P:endothelial cell activation; ISS:AgBase.
DR   GO; GO:0043542; P:endothelial cell migration; IMP:MGI.
DR   GO; GO:0001837; P:epithelial to mesenchymal transition; ISO:MGI.
DR   GO; GO:0008354; P:germ cell migration; IMP:MGI.
DR   GO; GO:0007507; P:heart development; ISS:AgBase.
DR   GO; GO:0001701; P:in utero embryonic development; IMP:MGI.
DR   GO; GO:0035556; P:intracellular signal transduction; ISS:AgBase.
DR   GO; GO:0001822; P:kidney development; IGI:MGI.
DR   GO; GO:0002088; P:lens development in camera-type eye; IMP:MGI.
DR   GO; GO:0008584; P:male gonad development; IMP:MGI.
DR   GO; GO:0048762; P:mesenchymal cell differentiation; ISS:AgBase.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:MGI.
DR   GO; GO:0032331; P:negative regulation of chondrocyte differentiation; IMP:BHF-UCL.
DR   GO; GO:0001937; P:negative regulation of endothelial cell proliferation; IGI:MGI.
DR   GO; GO:2001237; P:negative regulation of extrinsic apoptotic signaling pathway; ISO:MGI.
DR   GO; GO:0048663; P:neuron fate commitment; IMP:MGI.
DR   GO; GO:0060021; P:palate development; IMP:MGI.
DR   GO; GO:0060017; P:parathyroid gland development; IMP:MGI.
DR   GO; GO:0060389; P:pathway-restricted SMAD protein phosphorylation; ISO:MGI.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; ISO:MGI.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; ISO:MGI.
DR   GO; GO:0060037; P:pharyngeal system development; IMP:MGI.
DR   GO; GO:2001235; P:positive regulation of apoptotic signaling pathway; ISO:MGI.
DR   GO; GO:0030307; P:positive regulation of cell growth; ISO:MGI.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; ISO:MGI.
DR   GO; GO:0051272; P:positive regulation of cellular component movement; ISO:MGI.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; ISS:AgBase.
DR   GO; GO:0051491; P:positive regulation of filopodium assembly; IMP:MGI.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISS:AgBase.
DR   GO; GO:0010862; P:positive regulation of pathway-restricted SMAD protein phosphorylation; ISO:MGI.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; ISO:MGI.
DR   GO; GO:0060391; P:positive regulation of SMAD protein import into nucleus; ISO:MGI.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; ISS:AgBase.
DR   GO; GO:0009791; P:post-embryonic development; IMP:MGI.
DR   GO; GO:0006468; P:protein phosphorylation; ISO:MGI.
DR   GO; GO:0010717; P:regulation of epithelial to mesenchymal transition; ISS:AgBase.
DR   GO; GO:0010468; P:regulation of gene expression; ISS:AgBase.
DR   GO; GO:0043393; P:regulation of protein binding; IMP:MGI.
DR   GO; GO:0031396; P:regulation of protein ubiquitination; ISO:MGI.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; ISO:MGI.
DR   GO; GO:0070723; P:response to cholesterol; IDA:BHF-UCL.
DR   GO; GO:0007165; P:signal transduction; ISO:MGI.
DR   GO; GO:0023014; P:signal transduction by protein phosphorylation; IDA:GOC.
DR   GO; GO:0001501; P:skeletal system development; IGI:MGI.
DR   GO; GO:0048705; P:skeletal system morphogenesis; IGI:MGI.
DR   GO; GO:0048538; P:thymus development; IMP:MGI.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IDA:MGI.
DR   InterPro; IPR000472; Activin_recp.
DR   InterPro; IPR003605; GS_dom.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR000333; TGFB_receptor.
DR   PANTHER; PTHR23255; PTHR23255; 1.
DR   Pfam; PF01064; Activin_recp; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF08515; TGF_beta_GS; 1.
DR   SMART; SM00467; GS; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51256; GS; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Apoptosis; ATP-binding; Cell junction;
KW   Cell membrane; Complete proteome; Differentiation; Disulfide bond;
KW   Glycoprotein; Growth regulation; Isopeptide bond; Kinase; Magnesium;
KW   Manganese; Membrane; Metal-binding; Nucleotide-binding;
KW   Phosphoprotein; Receptor; Reference proteome;
KW   Serine/threonine-protein kinase; Signal; Tight junction; Transferase;
KW   Transmembrane; Transmembrane helix; Ubl conjugation.
FT   SIGNAL        1     29       {ECO:0000250}.
FT   CHAIN        30    503       TGF-beta receptor type-1.
FT                                /FTId=PRO_0000024424.
FT   TOPO_DOM     30    126       Extracellular. {ECO:0000255}.
FT   TRANSMEM    127    147       Helical. {ECO:0000255}.
FT   TOPO_DOM    148    503       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      175    204       GS. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00585}.
FT   DOMAIN      205    495       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     211    219       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOTIF       193    194       FKBP1A-binding.
FT   ACT_SITE    333    333       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     232    232       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     165    165       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P36897}.
FT   MOD_RES     185    185       Phosphothreonine; by TGFBR2.
FT                                {ECO:0000250}.
FT   MOD_RES     186    186       Phosphothreonine; by TGFBR2.
FT                                {ECO:0000250}.
FT   MOD_RES     187    187       Phosphoserine; by TGFBR2. {ECO:0000250}.
FT   MOD_RES     189    189       Phosphoserine; by TGFBR2. {ECO:0000250}.
FT   MOD_RES     191    191       Phosphoserine; by TGFBR2. {ECO:0000250}.
FT   CARBOHYD     41     41       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     32     50       {ECO:0000250|UniProtKB:P36897}.
FT   DISULFID     34     37       {ECO:0000250|UniProtKB:P36897}.
FT   DISULFID     44     67       {ECO:0000250|UniProtKB:P36897}.
FT   DISULFID     82     96       {ECO:0000250|UniProtKB:P36897}.
FT   DISULFID     97    102       {ECO:0000250|UniProtKB:P36897}.
FT   CROSSLNK    391    391       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000250}.
FT   VAR_SEQ     111    114       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:8117262}.
FT                                /FTId=VSP_021593.
SQ   SEQUENCE   503 AA;  56179 MW;  BB8BB6D2261793AF CRC64;
     MEAAAAAPRR PQLLIVLVAA ATLLPGAKAL QCFCHLCTKD NFTCETDGLC FVSVTETTDK
     VIHNSMCIAE IDLIPRDRPF VCAPSSKTGA VTTTYCCNQD HCNKIELPTT GPFSEKQSAG
     LGPVELAAVI AGPVCFVCIA LMLMVYICHN RTVIHHRVPN EEDPSLDRPF ISEGTTLKDL
     IYDMTTSGSG SGLPLLVQRT IARTIVLQES IGKGRFGEVW RGKWRGEEVA VKIFSSREER
     SWFREAEIYQ TVMLRHENIL GFIAADNKDN GTWTQLWLVS DYHEHGSLFD YLNRYTVTVE
     GMIKLALSTA SGLAHLHMEI VGTQGKPAIA HRDLKSKNIL VKKNGTCCIA DLGLAVRHDS
     ATDTIDIAPN HRVGTKRYMA PEVLDDSINM KHFESFKRAD IYAMGLVFWE IARRCSIGGI
     HEDYQLPYYD LVPSDPSVEE MRKVVCEQKL RPNIPNRWQS CEALRVMAKI MRECWYANGA
     ARLTALRIKK TLSQLSQQEG IKM
//
ID   CD24_MOUSE              Reviewed;          76 AA.
AC   P24807; P26691;
DT   01-MAR-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-1992, sequence version 1.
DT   09-DEC-2015, entry version 131.
DE   RecName: Full=Signal transducer CD24;
DE   AltName: Full=Lymphocyte antigen 52;
DE            Short=Ly-52;
DE   AltName: Full=M1/69-J11D heat stable antigen;
DE            Short=HSA;
DE   AltName: Full=Nectadrin;
DE   AltName: Full=R13-Ag;
DE   AltName: Full=X62 heat stable antigen;
DE   AltName: CD_antigen=CD24;
DE   Flags: Precursor;
GN   Name=Cd24; Synonyms=Cd24a, Ly-52;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2118158;
RA   Kay R., Takei F., Humphries R.K.;
RT   "Expression cloning of a cDNA encoding M1/69-J11d heat-stable
RT   antigens.";
RL   J. Immunol. 145:1952-1959(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=C57BL/6 X CBA, and Swiss albino X BALB/c; TISSUE=Spleen;
RX   PubMed=2019286; DOI=10.1002/eji.1830210427;
RA   Wenger R.H., Ayane M., Bose R., Koehler G., Nielsen P.J.;
RT   "The genes for a mouse hematopoietic differentiation marker called the
RT   heat-stable antigen.";
RL   Eur. J. Immunol. 21:1039-1046(1991).
RN   [3]
RP   SEQUENCE REVISION.
RA   Nielsen P.J.;
RL   Submitted (JUL-1992) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=C57BL/6 X CBA; TISSUE=Spleen;
RX   PubMed=8226859;
RA   Wenger R.H., Rochelle J.M., Seldin M.F., Koehler G., Nielsen P.J.;
RT   "The heat stable antigen (mouse CD24) gene is differentially regulated
RT   but has a housekeeping promoter.";
RL   J. Biol. Chem. 268:23345-23352(1993).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J; TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 27-53, AND GLYCOSYLATION AT ASN-27; SER-30;
RP   ASN-39; SER-41; SER-43; ASN-48 AND THR-51.
RC   STRAIN=C57BL/6J;
RX   PubMed=1530634; DOI=10.1016/0006-291X(92)91262-O;
RA   Hitsumoto Y., Nakano A., Ohnishi H., Hamada F., Saheki S.,
RA   Takeuchi N.;
RT   "Purification of the murine heat-stable antigen from erythrocytes.";
RL   Biochem. Biophys. Res. Commun. 187:773-777(1992).
CC   -!- FUNCTION: May have a specific role to play in early thymocyte
CC       development.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Lipid-anchor, GPI-anchor.
CC   -!- TISSUE SPECIFICITY: In lymphoid, myeloid, and erythroid cells.
CC   -!- PTM: The identity of the N- and O-linked polysaccharides are not
CC       reported in PubMed:1530634. The O-linked polysaccharides on Ser-
CC       30, Ser-41, Ser-43, and Thr-51 are probably the mucin type linked
CC       to GalNAc. {ECO:0000269|PubMed:1530634}.
CC   -!- SIMILARITY: Belongs to the CD24 family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M58661; AAA39481.1; -; mRNA.
DR   EMBL; X56469; CAA39841.1; -; Genomic_DNA.
DR   EMBL; X72910; CAA51415.1; -; Genomic_DNA.
DR   EMBL; X53825; CAA37822.1; -; mRNA.
DR   EMBL; BC075622; AAH75622.1; -; mRNA.
DR   CCDS; CCDS23821.1; -.
DR   PIR; A43537; A43537.
DR   RefSeq; NP_033976.1; NM_009846.2.
DR   UniGene; Mm.29742; -.
DR   STRING; 10090.ENSMUSP00000057983; -.
DR   PaxDb; P24807; -.
DR   Ensembl; ENSMUST00000058714; ENSMUSP00000057983; ENSMUSG00000047139.
DR   GeneID; 12484; -.
DR   KEGG; mmu:12484; -.
DR   UCSC; uc007ezl.1; mouse.
DR   CTD; 12484; -.
DR   MGI; MGI:88323; Cd24a.
DR   eggNOG; ENOG410JF9E; Eukaryota.
DR   eggNOG; ENOG4111B8V; LUCA.
DR   HOVERGEN; HBG005274; -.
DR   InParanoid; P24807; -.
DR   KO; K06469; -.
DR   OMA; QTSVAPF; -.
DR   OrthoDB; EOG7F515H; -.
DR   PhylomeDB; P24807; -.
DR   TreeFam; TF338512; -.
DR   NextBio; 281392; -.
DR   PRO; PR:P24807; -.
DR   Proteomes; UP000000589; Chromosome 10.
DR   Bgee; P24807; -.
DR   CleanEx; MM_CD24A; -.
DR   ExpressionAtlas; P24807; baseline and differential.
DR   Genevisible; P24807; MM.
DR   GO; GO:0031362; C:anchored component of external side of plasma membrane; IDA:MGI.
DR   GO; GO:0009986; C:cell surface; IDA:MGI.
DR   GO; GO:0060170; C:ciliary membrane; IDA:MGI.
DR   GO; GO:0005829; C:cytosol; ISS:GOC.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:MGI.
DR   GO; GO:0005622; C:intracellular; IMP:GOC.
DR   GO; GO:0016020; C:membrane; ISS:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IDA:UniProtKB.
DR   GO; GO:0031528; C:microvillus membrane; IDA:MGI.
DR   GO; GO:0005886; C:plasma membrane; IDA:MGI.
DR   GO; GO:0030246; F:carbohydrate binding; IDA:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; ISS:UniProtKB.
DR   GO; GO:0030296; F:protein tyrosine kinase activator activity; ISS:UniProtKB.
DR   GO; GO:0008637; P:apoptotic mitochondrial changes; IDA:MGI.
DR   GO; GO:0030262; P:apoptotic nuclear changes; IDA:MGI.
DR   GO; GO:0097190; P:apoptotic signaling pathway; IDA:MGI.
DR   GO; GO:0032597; P:B cell receptor transport into membrane raft; ISS:UniProtKB.
DR   GO; GO:0001775; P:cell activation; ISS:UniProtKB.
DR   GO; GO:0016477; P:cell migration; IMP:UniProtKB.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IDA:MGI.
DR   GO; GO:0032600; P:chemokine receptor transport out of membrane raft; IMP:UniProtKB.
DR   GO; GO:0042632; P:cholesterol homeostasis; IMP:UniProtKB.
DR   GO; GO:0072139; P:glomerular parietal epithelial cell differentiation; ISS:UniProtKB.
DR   GO; GO:0072112; P:glomerular visceral epithelial cell differentiation; ISS:UniProtKB.
DR   GO; GO:0007157; P:heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules; IDA:MGI.
DR   GO; GO:0034109; P:homotypic cell-cell adhesion; IMP:MGI.
DR   GO; GO:0006955; P:immune response; IEA:Ensembl.
DR   GO; GO:0007159; P:leukocyte cell-cell adhesion; IDA:MGI.
DR   GO; GO:0002523; P:leukocyte migration involved in inflammatory response; IMP:MGI.
DR   GO; GO:0030889; P:negative regulation of B cell proliferation; IDA:MGI.
DR   GO; GO:0034119; P:negative regulation of erythrocyte aggregation; IMP:MGI.
DR   GO; GO:0034107; P:negative regulation of erythrocyte clearance; IMP:MGI.
DR   GO; GO:0007406; P:negative regulation of neuroblast proliferation; IMP:MGI.
DR   GO; GO:0050768; P:negative regulation of neurogenesis; IMP:MGI.
DR   GO; GO:0045665; P:negative regulation of neuron differentiation; IMP:MGI.
DR   GO; GO:0046014; P:negative regulation of T cell homeostatic proliferation; IMP:MGI.
DR   GO; GO:0032913; P:negative regulation of transforming growth factor beta3 production; ISS:UniProtKB.
DR   GO; GO:0007274; P:neuromuscular synaptic transmission; IMP:MGI.
DR   GO; GO:0031175; P:neuron projection development; IDA:MGI.
DR   GO; GO:0042104; P:positive regulation of activated T cell proliferation; ISS:UniProtKB.
DR   GO; GO:0046641; P:positive regulation of alpha-beta T cell proliferation; IDA:MGI.
DR   GO; GO:0002904; P:positive regulation of B cell apoptotic process; IDA:MGI.
DR   GO; GO:0050850; P:positive regulation of calcium-mediated signaling; IDA:MGI.
DR   GO; GO:0033630; P:positive regulation of cell adhesion mediated by integrin; IDA:MGI.
DR   GO; GO:0022409; P:positive regulation of cell-cell adhesion; IDA:MGI.
DR   GO; GO:0033634; P:positive regulation of cell-cell adhesion mediated by integrin; IDA:MGI.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; ISS:UniProtKB.
DR   GO; GO:0002863; P:positive regulation of inflammatory response to antigenic stimulus; IMP:MGI.
DR   GO; GO:0033625; P:positive regulation of integrin activation; IDA:MGI.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; ISS:UniProtKB.
DR   GO; GO:2000768; P:positive regulation of nephron tubule epithelial cell differentiation; ISS:UniProtKB.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IDA:MGI.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IDA:MGI.
DR   GO; GO:0061098; P:positive regulation of protein tyrosine kinase activity; ISS:GOC.
DR   GO; GO:0042103; P:positive regulation of T cell homeostatic proliferation; IMP:MGI.
DR   GO; GO:0002842; P:positive regulation of T cell mediated immune response to tumor cell; IDA:MGI.
DR   GO; GO:0002329; P:pre-B cell differentiation; IMP:MGI.
DR   GO; GO:0045577; P:regulation of B cell differentiation; IMP:MGI.
DR   GO; GO:0022407; P:regulation of cell-cell adhesion; IDA:MGI.
DR   GO; GO:0033632; P:regulation of cell-cell adhesion mediated by integrin; IDA:MGI.
DR   GO; GO:0001959; P:regulation of cytokine-mediated signaling pathway; IMP:UniProtKB.
DR   GO; GO:0043408; P:regulation of MAPK cascade; ISS:UniProtKB.
DR   GO; GO:0042325; P:regulation of phosphorylation; ISS:UniProtKB.
DR   GO; GO:0045730; P:respiratory burst; ISS:UniProtKB.
DR   GO; GO:0043627; P:response to estrogen; ISS:UniProtKB.
DR   GO; GO:0001666; P:response to hypoxia; ISS:UniProtKB.
DR   GO; GO:0002237; P:response to molecule of bacterial origin; IDA:UniProtKB.
DR   GO; GO:0048488; P:synaptic vesicle endocytosis; IMP:MGI.
DR   GO; GO:0031295; P:T cell costimulation; ISS:UniProtKB.
DR   InterPro; IPR028029; CD24.
DR   Pfam; PF14984; CD24; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Complete proteome; Direct protein sequencing;
KW   Glycoprotein; GPI-anchor; Lipoprotein; Membrane; Reference proteome;
KW   Signal.
FT   SIGNAL        1     26       {ECO:0000269|PubMed:1530634}.
FT   PEPTIDE      27     53       Signal transducer CD24.
FT                                /FTId=PRO_0000020895.
FT   PROPEP       54     76       Removed in mature form. {ECO:0000255}.
FT                                /FTId=PRO_0000020896.
FT   SITE         45     45       Not glycosylated.
FT   LIPID        53     53       GPI-anchor amidated glycine.
FT                                {ECO:0000255}.
FT   CARBOHYD     27     27       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:1530634}.
FT   CARBOHYD     30     30       O-linked (GalNAc...).
FT                                {ECO:0000269|PubMed:1530634}.
FT   CARBOHYD     39     39       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:1530634}.
FT   CARBOHYD     41     41       O-linked (GalNAc...); partial.
FT                                {ECO:0000269|PubMed:1530634}.
FT   CARBOHYD     43     43       O-linked (GalNAc...); partial.
FT                                {ECO:0000269|PubMed:1530634}.
FT   CARBOHYD     48     48       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:1530634}.
FT   CARBOHYD     51     51       O-linked (GalNAc...); partial.
FT                                {ECO:0000269|PubMed:1530634}.
SQ   SEQUENCE   76 AA;  7797 MW;  6853F121B33625EB CRC64;
     MGRAMVARLG LGLLLLALLL PTQIYCNQTS VAPFPGNQNI SASPNPSNAT TRGGGSSLQS
     TAGLLALSLS LLHLYC
//
ID   TGFR2_MOUSE             Reviewed;         592 AA.
AC   Q62312; Q63947;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   20-JAN-2016, entry version 155.
DE   RecName: Full=TGF-beta receptor type-2;
DE            Short=TGFR-2;
DE            EC=2.7.11.30;
DE   AltName: Full=TGF-beta type II receptor;
DE   AltName: Full=Transforming growth factor-beta receptor type II;
DE            Short=TGF-beta receptor type II;
DE            Short=TbetaR-II;
DE   Flags: Precursor;
GN   Name=Tgfbr2;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND ALTERNATIVE SPLICING.
RC   TISSUE=Brain;
RX   PubMed=7957954; DOI=10.1016/0014-5793(94)01156-7;
RA   Suzuki A., Shioda N., Maeda T., Tada M., Ueno N.;
RT   "Cloning of an isoform of mouse TGF-beta type II receptor gene.";
RL   FEBS Lett. 355:19-22(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8119124;
RA   Lawler S., Candia A.F., Ebner R., Shum L., Lopez A.R., Moses H.L.,
RA   Wright C.V., Derynck R.;
RT   "The murine type II TGF-beta receptor has a coincident embryonic
RT   expression and binding preference for TGF-beta 1.";
RL   Development 120:165-175(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM RII-2).
RC   TISSUE=Olfactory epithelium;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-578, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19144319; DOI=10.1016/j.immuni.2008.11.006;
RA   Trost M., English L., Lemieux S., Courcelles M., Desjardins M.,
RA   Thibault P.;
RT   "The phagosomal proteome in interferon-gamma-activated macrophages.";
RL   Immunity 30:143-154(2009).
RN   [5]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-434 AND SER-578, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brown adipose tissue, Kidney, Lung, and Spleen;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and
RT   expression.";
RL   Cell 143:1174-1189(2010).
CC   -!- FUNCTION: Transmembrane serine/threonine kinase forming with the
CC       TGF-beta type I serine/threonine kinase receptor, TGFBR1, the non-
CC       promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and
CC       TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell
CC       surface to the cytoplasm and is thus regulating a plethora of
CC       physiological and pathological processes including cell cycle
CC       arrest in epithelial and hematopoietic cells, control of
CC       mesenchymal cell proliferation and differentiation, wound healing,
CC       extracellular matrix production, immunosuppression and
CC       carcinogenesis. The formation of the receptor complex composed of
CC       2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the
CC       cytokine dimer results in the phosphorylation and the activation
CC       of TGFRB1 by the constitutively active TGFBR2. Activated TGFBR1
CC       phosphorylates SMAD2 which dissociates from the receptor and
CC       interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently
CC       translocated to the nucleus where it modulates the transcription
CC       of the TGF-beta-regulated genes. This constitutes the canonical
CC       SMAD-dependent TGF-beta signaling cascade. Also involved in non-
CC       canonical, SMAD-independent TGF-beta signaling pathways (By
CC       similarity). {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY: ATP + [receptor-protein] = ADP + [receptor-
CC       protein] phosphate.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250};
CC   -!- SUBUNIT: Homodimer. Heterohexamer; TGFB1, TGFB2 and TGFB3
CC       homodimeric ligands assemble a functional receptor composed of two
CC       TGFBR1 and TGFBR2 heterodimers to form a ligand-receptor
CC       heterohexamer. The respective affinity of TGFRB1 and TGFRB2 for
CC       the ligands may modulate the kinetics of assembly of the receptor
CC       and may explain the different biological activities of TGFB1,
CC       TGFB2 and TGFB3. Interacts with DAXX. Interacts with TCTEX1D4.
CC       Interacts with ZFYVE9; ZFYVE9 recruits SMAD2 and SMAD3 to the TGF-
CC       beta receptor (By similarity). Interacts with and is activated by
CC       SCUBE3; this interaction does not affect TGFB1-binding to TGFBR2
CC       (By similarity). Interacts with VPS39; this interaction is
CC       independent of the receptor kinase activity and of the presence of
CC       TGF-beta (By similarity). {ECO:0000250}.
CC   -!- INTERACTION:
CC       P55284:Cdh5; NbExp=4; IntAct=EBI-2899332, EBI-7087433;
CC       Q8TDM6:DLG5 (xeno); NbExp=3; IntAct=EBI-2899332, EBI-715138;
CC       P98083-1:Shc1; NbExp=2; IntAct=EBI-2899332, EBI-7533258;
CC       P98083-2:Shc1; NbExp=3; IntAct=EBI-2899332, EBI-1019301;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=RII-2;
CC         IsoId=Q62312-1; Sequence=Displayed;
CC       Name=RII-1;
CC         IsoId=Q62312-2; Sequence=VSP_004955, VSP_004956;
CC   -!- TISSUE SPECIFICITY: Widely expressed in adult. Expressed primarily
CC       in mesenchyme and epidermis of the midgestational fetus.
CC   -!- PTM: Phosphorylated on a Ser/Thr residue in the cytoplasmic
CC       domain. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. TGFB receptor subfamily. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D32072; BAA06840.1; -; mRNA.
DR   EMBL; S69114; AAB30100.2; -; mRNA.
DR   EMBL; BC052629; -; NOT_ANNOTATED_CDS; mRNA.
DR   CCDS; CCDS23601.1; -. [Q62312-1]
DR   CCDS; CCDS23602.1; -. [Q62312-2]
DR   PIR; S51371; S51371.
DR   RefSeq; NP_033397.3; NM_009371.3. [Q62312-1]
DR   UniGene; Mm.172346; -.
DR   ProteinModelPortal; Q62312; -.
DR   SMR; Q62312; 73-178, 269-564.
DR   BioGrid; 204164; 3.
DR   DIP; DIP-44605N; -.
DR   IntAct; Q62312; 8.
DR   MINT; MINT-5181700; -.
DR   STRING; 10090.ENSMUSP00000062333; -.
DR   iPTMnet; Q62312; -.
DR   PhosphoSite; Q62312; -.
DR   MaxQB; Q62312; -.
DR   PaxDb; Q62312; -.
DR   PRIDE; Q62312; -.
DR   Ensembl; ENSMUST00000035014; ENSMUSP00000035014; ENSMUSG00000032440. [Q62312-2]
DR   Ensembl; ENSMUST00000061101; ENSMUSP00000062333; ENSMUSG00000032440. [Q62312-1]
DR   GeneID; 21813; -.
DR   KEGG; mmu:21813; -.
DR   UCSC; uc009rys.2; mouse. [Q62312-1]
DR   UCSC; uc009ryt.2; mouse. [Q62312-2]
DR   CTD; 7048; -.
DR   MGI; MGI:98729; Tgfbr2.
DR   eggNOG; KOG3653; Eukaryota.
DR   eggNOG; ENOG410XS2Z; LUCA.
DR   GeneTree; ENSGT00760000118876; -.
DR   HOGENOM; HOG000231495; -.
DR   HOVERGEN; HBG104975; -.
DR   InParanoid; Q62312; -.
DR   KO; K04388; -.
DR   OMA; TRHIISW; -.
DR   OrthoDB; EOG7JHM5B; -.
DR   PhylomeDB; Q62312; -.
DR   TreeFam; TF314724; -.
DR   BRENDA; 2.7.10.2; 3474.
DR   Reactome; R-MMU-2173788; Downregulation of TGF-beta receptor signaling.
DR   Reactome; R-MMU-2173789; TGF-beta receptor signaling activates SMADs.
DR   Reactome; R-MMU-2173791; TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition).
DR   ChiTaRS; Tgfbr2; mouse.
DR   NextBio; 301206; -.
DR   PRO; PR:Q62312; -.
DR   Proteomes; UP000000589; Chromosome 9.
DR   Bgee; Q62312; -.
DR   CleanEx; MM_TGFBR2; -.
DR   ExpressionAtlas; Q62312; baseline and differential.
DR   Genevisible; Q62312; MM.
DR   GO; GO:0005901; C:caveola; ISO:MGI.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:MGI.
DR   GO; GO:0016021; C:integral component of membrane; ISO:MGI.
DR   GO; GO:0005887; C:integral component of plasma membrane; IEA:Ensembl.
DR   GO; GO:0045121; C:membrane raft; ISO:MGI.
DR   GO; GO:0043235; C:receptor complex; ISO:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005539; F:glycosaminoglycan binding; ISO:MGI.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004702; F:receptor signaling protein serine/threonine kinase activity; IEA:InterPro.
DR   GO; GO:0046332; F:SMAD binding; IDA:BHF-UCL.
DR   GO; GO:0050431; F:transforming growth factor beta binding; IPI:MGI.
DR   GO; GO:0005026; F:transforming growth factor beta receptor activity, type II; IEA:InterPro.
DR   GO; GO:0005024; F:transforming growth factor beta-activated receptor activity; IGI:MGI.
DR   GO; GO:0004675; F:transmembrane receptor protein serine/threonine kinase activity; ISO:MGI.
DR   GO; GO:0034713; F:type I transforming growth factor beta receptor binding; ISO:MGI.
DR   GO; GO:0034714; F:type III transforming growth factor beta receptor binding; ISO:MGI.
DR   GO; GO:0032147; P:activation of protein kinase activity; IDA:MGI.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0006915; P:apoptotic process; ISO:MGI.
DR   GO; GO:0007420; P:brain development; IMP:BHF-UCL.
DR   GO; GO:0060433; P:bronchus development; IMP:MGI.
DR   GO; GO:0060434; P:bronchus morphogenesis; IMP:MGI.
DR   GO; GO:0051216; P:cartilage development; IMP:UniProtKB.
DR   GO; GO:0007182; P:common-partner SMAD protein phosphorylation; IEA:Ensembl.
DR   GO; GO:0048565; P:digestive tract development; IEA:Ensembl.
DR   GO; GO:0007566; P:embryo implantation; IEA:Ensembl.
DR   GO; GO:0048701; P:embryonic cranial skeleton morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0035162; P:embryonic hemopoiesis; IMP:BHF-UCL.
DR   GO; GO:0007369; P:gastrulation; IMP:MGI.
DR   GO; GO:0003430; P:growth plate cartilage chondrocyte growth; IMP:MGI.
DR   GO; GO:0003417; P:growth plate cartilage development; IGI:MGI.
DR   GO; GO:0007507; P:heart development; IMP:MGI.
DR   GO; GO:0001701; P:in utero embryonic development; IMP:MGI.
DR   GO; GO:0002088; P:lens development in camera-type eye; IMP:MGI.
DR   GO; GO:1990086; P:lens fiber cell apoptotic process; IDA:MGI.
DR   GO; GO:0030324; P:lung development; IMP:MGI.
DR   GO; GO:0060463; P:lung lobe morphogenesis; IMP:MGI.
DR   GO; GO:0060425; P:lung morphogenesis; IMP:MGI.
DR   GO; GO:0060443; P:mammary gland morphogenesis; IMP:MGI.
DR   GO; GO:0043011; P:myeloid dendritic cell differentiation; IMP:MGI.
DR   GO; GO:0060044; P:negative regulation of cardiac muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0007219; P:Notch signaling pathway; IDA:MGI.
DR   GO; GO:0031100; P:organ regeneration; IEA:Ensembl.
DR   GO; GO:0060021; P:palate development; IMP:BHF-UCL.
DR   GO; GO:0060389; P:pathway-restricted SMAD protein phosphorylation; ISO:MGI.
DR   GO; GO:0001569; P:patterning of blood vessels; IMP:MGI.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; ISO:MGI.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; ISO:MGI.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IGI:MGI.
DR   GO; GO:0002663; P:positive regulation of B cell tolerance induction; IMP:MGI.
DR   GO; GO:0010634; P:positive regulation of epithelial cell migration; IMP:MGI.
DR   GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; IMP:BHF-UCL.
DR   GO; GO:0051138; P:positive regulation of NK T cell differentiation; IMP:MGI.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; ISO:MGI.
DR   GO; GO:0043415; P:positive regulation of skeletal muscle tissue regeneration; IEA:Ensembl.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0002666; P:positive regulation of T cell tolerance induction; IMP:MGI.
DR   GO; GO:0002651; P:positive regulation of tolerance induction to self antigen; IMP:MGI.
DR   GO; GO:0006468; P:protein phosphorylation; ISO:MGI.
DR   GO; GO:0006898; P:receptor-mediated endocytosis; IEA:Ensembl.
DR   GO; GO:0042127; P:regulation of cell proliferation; IMP:MGI.
DR   GO; GO:0010468; P:regulation of gene expression; IMP:MGI.
DR   GO; GO:0070723; P:response to cholesterol; IDA:BHF-UCL.
DR   GO; GO:0042493; P:response to drug; ISO:MGI.
DR   GO; GO:0043627; P:response to estrogen; IEA:Ensembl.
DR   GO; GO:0009749; P:response to glucose; IEA:Ensembl.
DR   GO; GO:0009612; P:response to mechanical stimulus; IEA:Ensembl.
DR   GO; GO:0007584; P:response to nutrient; IEA:Ensembl.
DR   GO; GO:0007224; P:smoothened signaling pathway; IMP:MGI.
DR   GO; GO:0060440; P:trachea formation; IMP:MGI.
DR   GO; GO:0060439; P:trachea morphogenesis; IMP:MGI.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IMP:MGI.
DR   GO; GO:0001570; P:vasculogenesis; IMP:BHF-UCL.
DR   GO; GO:0042060; P:wound healing; IEA:Ensembl.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR000333; TGFB_receptor.
DR   InterPro; IPR017194; Transform_growth_fac-b_typ-2.
DR   InterPro; IPR015013; Transforming_GF_b_rcpt_2_ecto.
DR   PANTHER; PTHR23255; PTHR23255; 2.
DR   Pfam; PF08917; ecTbetaR2; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PIRSF; PIRSF037393; TGFRII; 1.
DR   PRINTS; PR00653; ACTIVIN2R.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Apoptosis; ATP-binding; Cell membrane;
KW   Complete proteome; Differentiation; Disulfide bond; Glycoprotein;
KW   Growth regulation; Kinase; Magnesium; Manganese; Membrane;
KW   Metal-binding; Nucleotide-binding; Phosphoprotein; Receptor;
KW   Reference proteome; Serine/threonine-protein kinase; Signal;
KW   Transferase; Transmembrane; Transmembrane helix.
FT   SIGNAL        1     23       {ECO:0000255}.
FT   CHAIN        24    592       TGF-beta receptor type-2.
FT                                /FTId=PRO_0000024427.
FT   TOPO_DOM     24    184       Extracellular. {ECO:0000255}.
FT   TRANSMEM    185    214       Helical. {ECO:0000255}.
FT   TOPO_DOM    215    592       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      269    569       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     275    283       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    404    404       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     302    302       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     434    434       Phosphoserine.
FT                                {ECO:0000244|PubMed:21183079}.
FT   MOD_RES     573    573       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P37173}.
FT   MOD_RES     578    578       Phosphoserine.
FT                                {ECO:0000244|PubMed:19144319,
FT                                ECO:0000244|PubMed:21183079}.
FT   CARBOHYD     48     48       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD     95     95       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    119    119       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     76    109       {ECO:0000250|UniProtKB:P37173}.
FT   DISULFID     79     96       {ECO:0000250|UniProtKB:P37173}.
FT   DISULFID     86     92       {ECO:0000250|UniProtKB:P37173}.
FT   DISULFID    102    126       {ECO:0000250|UniProtKB:P37173}.
FT   DISULFID    146    161       {ECO:0000250|UniProtKB:P37173}.
FT   DISULFID    163    168       {ECO:0000250|UniProtKB:P37173}.
FT   VAR_SEQ      32     56       Missing (in isoform RII-1).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_004955.
FT   VAR_SEQ      57     57       F -> V (in isoform RII-1). {ECO:0000305}.
FT                                /FTId=VSP_004956.
FT   CONFLICT      8      8       G -> A (in Ref. 2; AAB30100).
FT                                {ECO:0000305}.
FT   CONFLICT    117    117       D -> N (in Ref. 2; AAB30100).
FT                                {ECO:0000305}.
FT   CONFLICT    354    354       A -> R (in Ref. 2; AAB30100).
FT                                {ECO:0000305}.
FT   CONFLICT    440    443       NSGQ -> KQRE (in Ref. 2; AAB30100).
FT                                {ECO:0000305}.
FT   CONFLICT    486    486       C -> W (in Ref. 2; AAB30100).
FT                                {ECO:0000305}.
FT   CONFLICT    506    506       H -> P (in Ref. 2; AAB30100).
FT                                {ECO:0000305}.
FT   CONFLICT    569    570       PE -> MD (in Ref. 2; AAB30100).
FT                                {ECO:0000305}.
SQ   SEQUENCE   592 AA;  67122 MW;  1A12D58550921F5E CRC64;
     MGRGLLRGLW PLHIVLWTRI ASTIPPHVPK SDVEMEAQKD ASIHLSCNRT IHPLKHFNSD
     VMASDNGGAV KLPQLCKFCD VRLSTCDNQK SCMSNCSITA ICEKPHEVCV AVWRKNDKNI
     TLETVCHDPK LTYHGFTLED AASPKCVMKE KKRAGETFFM CACNMEECND YIIFSEEYTT
     SSPDLLLVII QVTGVSLLPP LGIAIAVIII FYCYRVHRQQ KLSPSWESSK PRKLMDFSDN
     CAIILEDDRS DISSTCANNI NHNTELLPIE LDTLVGKGRF AEVYKAKLKQ NTSEQFETVA
     VKIFPYEEYS SWKTEKDIFS DINLKHENIL QFLTAEERKT ELGKQYWLIT AFHAKGNLQE
     YLTRHVISWE DLRKLGSSLA RGIAHLHSDH TPCGRPKMPI VHRDLKSSNI LVKNDLTCCL
     CDFGLSLRLD PTLSVDDLAN SGQVGTARYM APEVLESRMN LENVESFKQT DVYSMALVLW
     EMTSRCNAVG EVKDYEPPFG SKVREHPCVE SMKDSVLRDR GRPEIPSFWL NHQGIQIVCE
     TLTECWDHDP EARLTAQCVA ERFSELEHPE RLSGRSCSQE KIPEDGSLNT TK
//
ID   FURIN_HUMAN             Reviewed;         794 AA.
AC   P09958; Q14336; Q6LBS3; Q9UCZ5;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1990, sequence version 2.
DT   17-FEB-2016, entry version 194.
DE   RecName: Full=Furin;
DE            EC=3.4.21.75;
DE   AltName: Full=Dibasic-processing enzyme;
DE   AltName: Full=Paired basic amino acid residue-cleaving enzyme;
DE            Short=PACE;
DE   Flags: Precursor;
GN   Name=FURIN; Synonyms=FUR, PACE, PCSK3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Blood;
RX   PubMed=2408021; DOI=10.1093/nar/18.3.664;
RA   van den Ouweland A.M.W., van Duijnhoven H.L.P., Keizer G.D.,
RA   Dorssers L.C.J., van de Ven W.J.M.;
RT   "Structural homology between the human fur gene product and the
RT   subtilisin-like protease encoded by yeast KEX2.";
RL   Nucleic Acids Res. 18:664-664(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2251280; DOI=10.1073/pnas.87.23.9378;
RA   Wise R.J., Barr P.J., Wong P.A., Kiefer M.C., Brake A.J.,
RA   Kaufman R.J.;
RT   "Expression of a human proprotein processing enzyme: correct cleavage
RT   of the von Willebrand factor precursor at a paired basic amino acid
RT   site.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:9378-9382(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=1713771; DOI=10.1089/dna.1991.10.319;
RA   Barr P.J., Mason O.B., Landsberg K.E., Wong P.A., Kiefer M.C.,
RA   Brake A.J.;
RT   "cDNA and gene structure for a human subtilisin-like protease with
RT   cleavage specificity for paired basic amino acid residues.";
RL   DNA Cell Biol. 10:319-328(1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-280.
RX   PubMed=2674906; DOI=10.1093/nar/17.17.7101;
RA   Van den Ouweland A.M.W., van Groningen J.J.M., Roebrock A.J.M.,
RA   Onnekink C., Van de Ven W.J.M.;
RT   "Nucleotide sequence analysis of the human fur gene.";
RL   Nucleic Acids Res. 17:7101-7102(1989).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 296-794.
RX   PubMed=3023061;
RA   Roebroek A.J.M., Schalken J.A., Leunissen J.A.M., Onnekink C.,
RA   Bloemers H.P.J., van de Ven W.J.M.;
RT   "Evolutionary conserved close linkage of the c-fes/fps proto-oncogene
RT   and genetic sequences encoding a receptor-like protein.";
RL   EMBO J. 5:2197-2202(1986).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 402-428, AND FUNCTION.
RC   TISSUE=Colon carcinoma;
RX   PubMed=7690548; DOI=10.1006/bbrc.1993.2146;
RA   Takahashi S., Kasai K., Hatsuzawa K., Kitamura N., Misumi Y.,
RA   Ikehara Y., Murakami K., Nakayama K.;
RT   "A mutation of furin causes the lack of precursor-processing activity
RT   in human colon carcinoma LoVo cells.";
RL   Biochem. Biophys. Res. Commun. 195:1019-1026(1993).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 527-553, AND VARIANT ARG-547.
RC   TISSUE=Colon carcinoma;
RX   PubMed=7592877; DOI=10.1074/jbc.270.44.26565;
RA   Takahashi S., Nakagawa T., Kasai K., Banno T., Duguay S.J.,
RA   Van de Ven W.J.M., Murakami K., Nakayama K.;
RT   "A second mutant allele of furin in the processing-incompetent cell
RT   line, LoVo. Evidence for involvement of the homo B domain in
RT   autocatalytic activation.";
RL   J. Biol. Chem. 270:26565-26569(1995).
RN   [9]
RP   PROTEOLYTIC PROCESSING.
RX   PubMed=1629222;
RA   Leduc R., Molloy S.S., Thorne B.A., Thomas G.;
RT   "Activation of human furin precursor processing endoprotease occurs by
RT   an intramolecular autoproteolytic cleavage.";
RL   J. Biol. Chem. 267:14304-14308(1992).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [11]
RP   3D-STRUCTURE MODELING OF CATALYTIC DOMAIN.
RX   PubMed=8020465; DOI=10.1111/j.1432-1033.1994.tb18864.x;
RA   Siezen R.J., Creemers J.W.M., van de Ven W.J.M.;
RT   "Homology modelling of the catalytic domain of human furin. A model
RT   for the eukaryotic subtilisin-like proprotein convertases.";
RL   Eur. J. Biochem. 222:255-266(1994).
RN   [12]
RP   PHOSPHORYLATION AT SER-773 AND SER-775.
RX   PubMed=8846780;
RA   Jones B.G., Thomas L., Molloy S.S., Thulin C.D., Fry M.D., Walsh K.A.,
RA   Thomas G.;
RT   "Intracellular trafficking of furin is modulated by the
RT   phosphorylation state of a casein kinase II site in its cytoplasmic
RT   tail.";
RL   EMBO J. 14:5869-5883(1995).
RN   [13]
RP   INTERACTION WITH PACS1.
RX   PubMed=11331585; DOI=10.1093/emboj/20.9.2191;
RA   Crump C.M., Xiang Y., Thomas L., Gu F., Austin C., Tooze S.A.,
RA   Thomas G.;
RT   "PACS-1 binding to adaptors is required for acidic cluster motif-
RT   mediated protein traffic.";
RL   EMBO J. 20:2191-2201(2001).
CC   -!- FUNCTION: Furin is likely to represent the ubiquitous endoprotease
CC       activity within constitutive secretory pathways and capable of
CC       cleavage at the RX(K/R)R consensus motif.
CC       {ECO:0000269|PubMed:7690548}.
CC   -!- CATALYTIC ACTIVITY: Release of mature proteins from their
CC       proproteins by cleavage of -Arg-Xaa-Yaa-Arg-|-Zaa- bonds, where
CC       Xaa can be any amino acid and Yaa is Arg or Lys. Releases albumin,
CC       complement component C3 and von Willebrand factor from their
CC       respective precursors.
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC   -!- ENZYME REGULATION: Could be inhibited by the not secondly cleaved
CC       propeptide.
CC   -!- SUBUNIT: Interacts with FLNA (By similarity). Binds to PACS1 which
CC       mediates TGN localization and connection to clathrin adapters.
CC       {ECO:0000250, ECO:0000269|PubMed:11331585}.
CC   -!- INTERACTION:
CC       O14793:MSTN; NbExp=2; IntAct=EBI-1056807, EBI-8542977;
CC   -!- SUBCELLULAR LOCATION: Golgi apparatus, trans-Golgi network
CC       membrane; Single-pass type I membrane protein. Cell membrane;
CC       Single-pass type I membrane protein. Note=Shuttles between the
CC       trans-Golgi network and the cell surface. Propeptide cleavage is a
CC       prerequisite for exit of furin molecules out of the endoplasmic
CC       reticulum (ER). A second cleavage within the propeptide occurs in
CC       the trans Golgi network (TGN), followed by the release of the
CC       propeptide and the activation of furin.
CC   -!- TISSUE SPECIFICITY: Seems to be expressed ubiquitously.
CC   -!- DOMAIN: Contains a cytoplasmic domain responsible for its TGN
CC       localization and recycling from the cell surface.
CC   -!- PTM: The inhibition peptide, which plays the role of an
CC       intramolecular chaperone, is autocatalytically removed in the
CC       endoplasmic reticulum (ER) and remains non-covalently bound to
CC       furin as a potent autoinhibitor. Following transport to the trans
CC       Golgi, a second cleavage within the inhibition propeptide results
CC       in propeptide dissociation and furin activation.
CC       {ECO:0000269|PubMed:1629222}.
CC   -!- PTM: Phosphorylation is required for TGN localization of the
CC       endoprotease. In vivo, exists as di-, mono- and non-phosphorylated
CC       forms. {ECO:0000269|PubMed:8846780}.
CC   -!- SIMILARITY: Belongs to the peptidase S8 family. Furin subfamily.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 peptidase S8 domain. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/FURINID40646ch15q26.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X17094; CAA34948.1; -; mRNA.
DR   EMBL; BC012181; AAH12181.1; -; mRNA.
DR   EMBL; X15723; CAA33745.1; -; Genomic_DNA.
DR   EMBL; X04329; CAA27860.1; -; Genomic_DNA.
DR   CCDS; CCDS10364.1; -.
DR   PIR; A39552; KXHUF.
DR   RefSeq; NP_001276752.1; NM_001289823.1.
DR   RefSeq; NP_001276753.1; NM_001289824.1.
DR   RefSeq; NP_002560.1; NM_002569.3.
DR   UniGene; Hs.513153; -.
DR   PDB; 4OMC; X-ray; 2.30 A; A/B/C/D/E/F=108-574.
DR   PDB; 4OMD; X-ray; 2.70 A; A/B/C/D/E/F=108-574.
DR   PDB; 4RYD; X-ray; 2.15 A; A/B/C/D/E/F=108-574.
DR   PDBsum; 4OMC; -.
DR   PDBsum; 4OMD; -.
DR   PDBsum; 4RYD; -.
DR   ProteinModelPortal; P09958; -.
DR   SMR; P09958; 30-99, 109-574.
DR   BioGrid; 111082; 11.
DR   DIP; DIP-29904N; -.
DR   IntAct; P09958; 11.
DR   MINT; MINT-1209355; -.
DR   STRING; 9606.ENSP00000268171; -.
DR   BindingDB; P09958; -.
DR   ChEMBL; CHEMBL2611; -.
DR   GuidetoPHARMACOLOGY; 2366; -.
DR   MEROPS; S08.071; -.
DR   iPTMnet; P09958; -.
DR   PhosphoSite; P09958; -.
DR   BioMuta; FURIN; -.
DR   DMDM; 120611; -.
DR   OGP; P09958; -.
DR   MaxQB; P09958; -.
DR   PaxDb; P09958; -.
DR   PeptideAtlas; P09958; -.
DR   PRIDE; P09958; -.
DR   Ensembl; ENST00000268171; ENSP00000268171; ENSG00000140564.
DR   Ensembl; ENST00000610579; ENSP00000484952; ENSG00000140564.
DR   Ensembl; ENST00000618099; ENSP00000483552; ENSG00000140564.
DR   GeneID; 5045; -.
DR   KEGG; hsa:5045; -.
DR   UCSC; uc002bpu.1; human.
DR   CTD; 5045; -.
DR   GeneCards; FURIN; -.
DR   HGNC; HGNC:8568; FURIN.
DR   HPA; CAB009499; -.
DR   MIM; 136950; gene.
DR   neXtProt; NX_P09958; -.
DR   PharmGKB; PA32894; -.
DR   eggNOG; KOG3525; Eukaryota.
DR   eggNOG; COG1404; LUCA.
DR   eggNOG; COG4935; LUCA.
DR   GeneTree; ENSGT00750000117358; -.
DR   HOGENOM; HOG000192536; -.
DR   HOVERGEN; HBG008705; -.
DR   InParanoid; P09958; -.
DR   KO; K01349; -.
DR   OMA; ESIGCKT; -.
DR   OrthoDB; EOG7BW0JD; -.
DR   PhylomeDB; P09958; -.
DR   TreeFam; TF314277; -.
DR   Reactome; R-HSA-1181150; Signaling by NODAL.
DR   Reactome; R-HSA-1442490; Collagen degradation.
DR   Reactome; R-HSA-1566948; Elastic fibre formation.
DR   Reactome; R-HSA-1592389; Activation of Matrix Metalloproteinases.
DR   Reactome; R-HSA-159782; Removal of aminoterminal propeptides from gamma-carboxylated proteins.
DR   Reactome; R-HSA-167060; NGF processing.
DR   Reactome; R-HSA-171286; Synthesis and processing of ENV and VPU.
DR   Reactome; R-HSA-186797; Signaling by PDGF.
DR   Reactome; R-HSA-1912420; Pre-NOTCH Processing in Golgi.
DR   Reactome; R-HSA-2173789; TGF-beta receptor signaling activates SMADs.
DR   Reactome; R-HSA-5210891; Uptake and function of anthrax toxins.
DR   Reactome; R-HSA-977225; Amyloid fiber formation.
DR   SignaLink; P09958; -.
DR   ChiTaRS; FURIN; human.
DR   GeneWiki; Furin; -.
DR   GenomeRNAi; 5045; -.
DR   NextBio; 19422; -.
DR   PMAP-CutDB; P09958; -.
DR   PRO; PR:P09958; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   Bgee; P09958; -.
DR   CleanEx; HS_FURIN; -.
DR   ExpressionAtlas; P09958; baseline and differential.
DR   Genevisible; P09958; HS.
DR   GO; GO:0009986; C:cell surface; IDA:BHF-UCL.
DR   GO; GO:0005783; C:endoplasmic reticulum; IGI:BHF-UCL.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:Ensembl.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0031985; C:Golgi cisterna; IEA:Ensembl.
DR   GO; GO:0005796; C:Golgi lumen; TAS:Reactome.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005802; C:trans-Golgi network; IDA:BHF-UCL.
DR   GO; GO:0030140; C:trans-Golgi network transport vesicle; IDA:MGI.
DR   GO; GO:0004175; F:endopeptidase activity; IDA:BHF-UCL.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0048406; F:nerve growth factor binding; IDA:BHF-UCL.
DR   GO; GO:0008233; F:peptidase activity; IDA:UniProtKB.
DR   GO; GO:0042277; F:peptide binding; IDA:BHF-UCL.
DR   GO; GO:0002020; F:protease binding; IPI:BHF-UCL.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IDA:BHF-UCL.
DR   GO; GO:0004867; F:serine-type endopeptidase inhibitor activity; IDA:BHF-UCL.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0008283; P:cell proliferation; IMP:BHF-UCL.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0030574; P:collagen catabolic process; TAS:Reactome.
DR   GO; GO:0022617; P:extracellular matrix disassembly; TAS:Reactome.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0010951; P:negative regulation of endopeptidase activity; IDA:GOC.
DR   GO; GO:0032804; P:negative regulation of low-density lipoprotein particle receptor catabolic process; IDA:HGNC.
DR   GO; GO:0032911; P:negative regulation of transforming growth factor beta1 production; IMP:BHF-UCL.
DR   GO; GO:0032455; P:nerve growth factor processing; TAS:Reactome.
DR   GO; GO:0032902; P:nerve growth factor production; IDA:BHF-UCL.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007219; P:Notch signaling pathway; TAS:Reactome.
DR   GO; GO:0043043; P:peptide biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0016486; P:peptide hormone processing; IDA:BHF-UCL.
DR   GO; GO:0017187; P:peptidyl-glutamic acid carboxylation; TAS:Reactome.
DR   GO; GO:0030335; P:positive regulation of cell migration; IEA:Ensembl.
DR   GO; GO:0051044; P:positive regulation of membrane protein ectodomain proteolysis; IC:BHF-UCL.
DR   GO; GO:0030511; P:positive regulation of transforming growth factor beta receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0043687; P:post-translational protein modification; TAS:Reactome.
DR   GO; GO:0016485; P:protein processing; IDA:UniProtKB.
DR   GO; GO:0006508; P:proteolysis; TAS:Reactome.
DR   GO; GO:0052548; P:regulation of endopeptidase activity; IDA:BHF-UCL.
DR   GO; GO:0045714; P:regulation of low-density lipoprotein particle receptor biosynthetic process; IEA:Ensembl.
DR   GO; GO:0042176; P:regulation of protein catabolic process; IMP:BHF-UCL.
DR   GO; GO:0032940; P:secretion by cell; IDA:BHF-UCL.
DR   GO; GO:0006465; P:signal peptide processing; IDA:HGNC.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0019058; P:viral life cycle; IEP:BHF-UCL.
DR   GO; GO:0016032; P:viral process; TAS:Reactome.
DR   GO; GO:0019082; P:viral protein processing; TAS:Reactome.
DR   GO; GO:0019068; P:virion assembly; TAS:Reactome.
DR   Gene3D; 2.60.120.260; -; 1.
DR   Gene3D; 3.30.70.850; -; 1.
DR   Gene3D; 3.40.50.200; -; 1.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR008979; Galactose-bd-like.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR000209; Peptidase_S8/S53_dom.
DR   InterPro; IPR023827; Peptidase_S8_Asp-AS.
DR   InterPro; IPR022398; Peptidase_S8_His-AS.
DR   InterPro; IPR023828; Peptidase_S8_Ser-AS.
DR   InterPro; IPR015500; Peptidase_S8_subtilisin-rel.
DR   InterPro; IPR009020; Prot_inh_propept.
DR   InterPro; IPR002884; PrprotnconvertsP.
DR   InterPro; IPR032815; S8_pro-domain.
DR   Pfam; PF01483; P_proprotein; 1.
DR   Pfam; PF00082; Peptidase_S8; 1.
DR   Pfam; PF16470; S8_pro-domain; 1.
DR   PRINTS; PR00723; SUBTILISIN.
DR   SMART; SM00261; FU; 2.
DR   SUPFAM; SSF49785; SSF49785; 1.
DR   SUPFAM; SSF52743; SSF52743; 1.
DR   SUPFAM; SSF54897; SSF54897; 1.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   PROSITE; PS00136; SUBTILASE_ASP; 1.
DR   PROSITE; PS00137; SUBTILASE_HIS; 1.
DR   PROSITE; PS00138; SUBTILASE_SER; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Autocatalytic cleavage; Calcium; Cell membrane;
KW   Cleavage on pair of basic residues; Complete proteome; Disulfide bond;
KW   Glycoprotein; Golgi apparatus; Hydrolase; Membrane; Metal-binding;
KW   Phosphoprotein; Polymorphism; Protease; Reference proteome;
KW   Serine protease; Signal; Transmembrane; Transmembrane helix; Zymogen.
FT   SIGNAL        1     24       {ECO:0000255}.
FT   PROPEP       25    107       Inhibition peptide.
FT                                /FTId=PRO_0000027028.
FT   CHAIN       108    794       Furin.
FT                                /FTId=PRO_0000027029.
FT   TRANSMEM    716    738       Helical. {ECO:0000255}.
FT   DOMAIN      148    435       Peptidase S8.
FT   REGION      759    762       Cell surface signal.
FT   MOTIF       498    500       Cell attachment site. {ECO:0000255}.
FT   MOTIF       773    779       Trans Golgi network signal.
FT   ACT_SITE    153    153       Charge relay system. {ECO:0000250}.
FT   ACT_SITE    194    194       Charge relay system. {ECO:0000250}.
FT   ACT_SITE    368    368       Charge relay system. {ECO:0000250}.
FT   METAL       115    115       Calcium 1. {ECO:0000250}.
FT   METAL       162    162       Calcium 1. {ECO:0000250}.
FT   METAL       208    208       Calcium 1. {ECO:0000250}.
FT   METAL       258    258       Calcium 2. {ECO:0000250}.
FT   METAL       301    301       Calcium 2. {ECO:0000250}.
FT   METAL       331    331       Calcium 2. {ECO:0000250}.
FT   SITE         75     76       Cleavage, second; by autolysis.
FT   SITE        107    108       Cleavage, first; by autolysis.
FT   MOD_RES     773    773       Phosphoserine; by CK2.
FT                                {ECO:0000269|PubMed:8846780}.
FT   MOD_RES     775    775       Phosphoserine; by CK2.
FT                                {ECO:0000269|PubMed:8846780}.
FT   CARBOHYD    387    387       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    440    440       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    553    553       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    211    360       {ECO:0000250}.
FT   DISULFID    303    333       {ECO:0000250}.
FT   DISULFID    450    474       {ECO:0000250}.
FT   VARIANT      43     43       A -> V (in dbSNP:rs16944971).
FT                                /FTId=VAR_051821.
FT   VARIANT     547    547       W -> R (in cell line LoVo; does not
FT                                undergo autocatalytic activation and is
FT                                not transported to the Golgi apparatus).
FT                                {ECO:0000269|PubMed:7592877}.
FT                                /FTId=VAR_055343.
FT   HELIX       118    120       {ECO:0000244|PDB:4RYD}.
FT   TURN        122    124       {ECO:0000244|PDB:4RYD}.
FT   HELIX       134    139       {ECO:0000244|PDB:4RYD}.
FT   STRAND      148    154       {ECO:0000244|PDB:4RYD}.
FT   TURN        161    166       {ECO:0000244|PDB:4RYD}.
FT   HELIX       169    171       {ECO:0000244|PDB:4RYD}.
FT   TURN        175    178       {ECO:0000244|PDB:4RYD}.
FT   HELIX       191    193       {ECO:0000244|PDB:4RYD}.
FT   HELIX       194    203       {ECO:0000244|PDB:4RYD}.
FT   STRAND      206    211       {ECO:0000244|PDB:4RYD}.
FT   TURN        215    218       {ECO:0000244|PDB:4RYD}.
FT   STRAND      219    225       {ECO:0000244|PDB:4RYD}.
FT   STRAND      227    229       {ECO:0000244|PDB:4RYD}.
FT   HELIX       233    240       {ECO:0000244|PDB:4RYD}.
FT   TURN        244    246       {ECO:0000244|PDB:4RYD}.
FT   STRAND      249    252       {ECO:0000244|PDB:4RYD}.
FT   STRAND      259    261       {ECO:0000244|PDB:4RYD}.
FT   HELIX       268    280       {ECO:0000244|PDB:4RYD}.
FT   HELIX       282    284       {ECO:0000244|PDB:4RYD}.
FT   STRAND      288    292       {ECO:0000244|PDB:4RYD}.
FT   HELIX       297    299       {ECO:0000244|PDB:4RYD}.
FT   HELIX       303    305       {ECO:0000244|PDB:4RYD}.
FT   TURN        307    309       {ECO:0000244|PDB:4RYD}.
FT   STRAND      314    320       {ECO:0000244|PDB:4RYD}.
FT   STRAND      338    341       {ECO:0000244|PDB:4RYD}.
FT   STRAND      351    355       {ECO:0000244|PDB:4RYD}.
FT   TURN        356    358       {ECO:0000244|PDB:4RYD}.
FT   STRAND      359    364       {ECO:0000244|PDB:4RYD}.
FT   HELIX       367    384       {ECO:0000244|PDB:4RYD}.
FT   HELIX       390    400       {ECO:0000244|PDB:4RYD}.
FT   STRAND      419    421       {ECO:0000244|PDB:4RYD}.
FT   TURN        422    424       {ECO:0000244|PDB:4RYD}.
FT   HELIX       431    440       {ECO:0000244|PDB:4RYD}.
FT   STRAND      448    453       {ECO:0000244|PDB:4RYD}.
FT   STRAND      464    471       {ECO:0000244|PDB:4RYD}.
FT   STRAND      482    496       {ECO:0000244|PDB:4RYD}.
FT   HELIX       498    500       {ECO:0000244|PDB:4RYD}.
FT   STRAND      501    506       {ECO:0000244|PDB:4RYD}.
FT   STRAND      512    516       {ECO:0000244|PDB:4RYD}.
FT   STRAND      528    535       {ECO:0000244|PDB:4RYD}.
FT   TURN        537    540       {ECO:0000244|PDB:4RYD}.
FT   STRAND      545    553       {ECO:0000244|PDB:4RYD}.
FT   STRAND      555    557       {ECO:0000244|PDB:4RYD}.
FT   STRAND      561    573       {ECO:0000244|PDB:4RYD}.
SQ   SEQUENCE   794 AA;  86678 MW;  10C44DD5892EF85D CRC64;
     MELRPWLLWV VAATGTLVLL AADAQGQKVF TNTWAVRIPG GPAVANSVAR KHGFLNLGQI
     FGDYYHFWHR GVTKRSLSPH RPRHSRLQRE PQVQWLEQQV AKRRTKRDVY QEPTDPKFPQ
     QWYLSGVTQR DLNVKAAWAQ GYTGHGIVVS ILDDGIEKNH PDLAGNYDPG ASFDVNDQDP
     DPQPRYTQMN DNRHGTRCAG EVAAVANNGV CGVGVAYNAR IGGVRMLDGE VTDAVEARSL
     GLNPNHIHIY SASWGPEDDG KTVDGPARLA EEAFFRGVSQ GRGGLGSIFV WASGNGGREH
     DSCNCDGYTN SIYTLSISSA TQFGNVPWYS EACSSTLATT YSSGNQNEKQ IVTTDLRQKC
     TESHTGTSAS APLAAGIIAL TLEANKNLTW RDMQHLVVQT SKPAHLNAND WATNGVGRKV
     SHSYGYGLLD AGAMVALAQN WTTVAPQRKC IIDILTEPKD IGKRLEVRKT VTACLGEPNH
     ITRLEHAQAR LTLSYNRRGD LAIHLVSPMG TRSTLLAARP HDYSADGFND WAFMTTHSWD
     EDPSGEWVLE IENTSEANNY GTLTKFTLVL YGTAPEGLPV PPESSGCKTL TSSQACVVCE
     EGFSLHQKSC VQHCPPGFAP QVLDTHYSTE NDVETIRASV CAPCHASCAT CQGPALTDCL
     SCPSHASLDP VEQTCSRQSQ SSRESPPQQQ PPRLPPEVEA GQRLRAGLLP SHLPEVVAGL
     SCAFIVLVFV TVFLVLQLRS GFSFRGVKVY TMDRGLISYK GLPPEAWQEE CPSDSEEDEG
     RGERTAFIKD QSAL
//
ID   EGF_HUMAN               Reviewed;        1207 AA.
AC   P01133; B4DRK7; E7EVD2; E9PBF0; Q52LZ6;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   07-JUL-2009, sequence version 2.
DT   17-FEB-2016, entry version 186.
DE   RecName: Full=Pro-epidermal growth factor;
DE            Short=EGF;
DE   Contains:
DE     RecName: Full=Epidermal growth factor;
DE     AltName: Full=Urogastrone;
DE   Flags: Precursor;
GN   Name=EGF;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Kidney;
RX   PubMed=3491360; DOI=10.1093/nar/14.21.8427;
RA   Bell G.I., Fong N.M., Stempien M.M., Wormsted M.A., Caput D., Ku L.,
RA   Urdea M.S., Rall L.B., Sanchez-Pescador R.;
RT   "Human epidermal growth factor precursor: cDNA sequence, expression in
RT   vitro and gene organization.";
RL   Nucleic Acids Res. 14:8427-8446(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ARG-16; HIS-257;
RP   LYS-431; ARG-638; ILE-708; VAL-784; THR-842; VAL-920; GLU-981;
RP   PHE-1043 AND GLY-1084.
RG   NIEHS SNPs program;
RL   Submitted (DEC-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT
RP   VAL-920.
RC   TISSUE=Teratocarcinoma;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 971-1023.
RX   PubMed=300079;
RA   Gregory H., Preston B.M.;
RT   "The primary structure of human urogastrone.";
RL   Int. J. Pept. Protein Res. 9:107-118(1977).
RN   [7]
RP   PROTEIN SEQUENCE OF 971-1023.
RX   PubMed=2789514; DOI=10.1016/0006-291X(89)92334-6;
RA   Furuya M., Akashi S., Hirayama K.;
RT   "The primary structure of human EGF produced by genetic engineering,
RT   studied by high-performance tandem mass spectrometry.";
RL   Biochem. Biophys. Res. Commun. 163:1100-1106(1989).
RN   [8]
RP   GLYCOSYLATION AT SER-954 AND THR-955, STRUCTURE OF CARBOHYDRATES, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=22171320; DOI=10.1074/mcp.M111.013649;
RA   Halim A., Nilsson J., Ruetschi U., Hesse C., Larson G.;
RT   "Human urinary glycoproteomics; attachment site specific analysis of
RT   N-and O-linked glycosylations by CID and ECD.";
RL   Mol. Cell. Proteomics 0:0-0(2011).
RN   [9]
RP   STRUCTURE BY NMR OF EGF.
RX   PubMed=1522591; DOI=10.1016/0022-2836(92)90697-I;
RA   Hommel U., Harvey T.S., Driscoll P.C., Campbell I.D.;
RT   "Human epidermal growth factor. High resolution solution structure and
RT   comparison with human transforming growth factor alpha.";
RL   J. Mol. Biol. 227:271-282(1992).
RN   [10]
RP   FUNCTION.
RX   PubMed=10964941;
RA   Hermann P.M., van Kesteren R.E., Wildering W.C., Painter S.D.,
RA   Reno J.M., Smith J.S., Kumar S.B., Geraerts W.P., Ericsson L.H.,
RA   Smit A.B., Bulloch A.G., Nagle G.T.;
RT   "Neurotrophic actions of a novel molluscan epidermal growth factor.";
RL   J. Neurosci. 20:6355-6364(2000).
RN   [11]
RP   FUNCTION, TISSUE SPECIFICITY, VARIANT HOMG4 LEU-1070, AND
RP   CHARACTERIZATION OF VARIANT HOMG4 LEU-1070.
RX   PubMed=17671655; DOI=10.1172/JCI31680;
RA   Groenestege W.M.T., Thebault S., van der Wijst J., van den Berg D.,
RA   Janssen R., Tejpar S., van den Heuvel L.P., van Cutsem E.,
RA   Hoenderop J.G., Knoers N.V., Bindels R.J.;
RT   "Impaired basolateral sorting of pro-EGF causes isolated recessive
RT   renal hypomagnesemia.";
RL   J. Clin. Invest. 117:2260-2267(2007).
RN   [12]
RP   INTERACTION WITH RHBDF1.
RX   PubMed=21439629; DOI=10.1016/j.cell.2011.02.047;
RA   Zettl M., Adrain C., Strisovsky K., Lastun V., Freeman M.;
RT   "Rhomboid family pseudoproteases use the ER quality control machinery
RT   to regulate intercellular signaling.";
RL   Cell 145:79-91(2011).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 971-1021, AND DISULFIDE
RP   BONDS.
RX   PubMed=11438527; DOI=10.1074/jbc.M102874200;
RA   Lu H.S., Chai J.J., Li M., Huang B.R., He C.H., Bi R.C.;
RT   "Crystal structure of human epidermal growth factor and its
RT   dimerization.";
RL   J. Biol. Chem. 276:34913-34917(2001).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (3.3 ANGSTROMS) OF 971-1023 IN COMPLEX WITH
RP   EGFR, AND DISULFIDE BONDS.
RX   PubMed=12297050; DOI=10.1016/S0092-8674(02)00963-7;
RA   Ogiso H., Ishitani R., Nureki O., Fukai S., Yamanaka M., Kim J.H.,
RA   Saito K., Sakamoto A., Inoue M., Shirouzu M., Yokoyama S.;
RT   "Crystal structure of the complex of human epidermal growth factor and
RT   receptor extracellular domains.";
RL   Cell 110:775-787(2002).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 971-1023 IN COMPLEX WITH
RP   EGFR, AND DISULFIDE BONDS.
RX   PubMed=12620237; DOI=10.1016/S1097-2765(03)00047-9;
RA   Ferguson K.M., Berger M.B., Mendrola J.M., Cho H.S., Leahy D.J.,
RA   Lemmon M.A.;
RT   "EGF activates its receptor by removing interactions that autoinhibit
RT   ectodomain dimerization.";
RL   Mol. Cell 11:507-517(2003).
RN   [16]
RP   STRUCTURE BY NMR OF 971-1023 IN COMPLEX WITH SURAMIN.
RX   PubMed=21029725; DOI=10.1016/j.bbrc.2010.10.089;
RA   Huang H.W., Mohan S.K., Yu C.;
RT   "The NMR solution structure of human epidermal growth factor (hEGF) at
RT   physiological pH and its interactions with suramin.";
RL   Biochem. Biophys. Res. Commun. 402:705-710(2010).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (3.3 ANGSTROMS) OF 975-1021 IN COMPLEX WITH
RP   EGFR, AND DISULFIDE BONDS.
RX   PubMed=20837704; DOI=10.1128/MCB.00742-10;
RA   Lu C., Mi L.Z., Grey M.J., Zhu J., Graef E., Yokoyama S.,
RA   Springer T.A.;
RT   "Structural evidence for loose linkage between ligand binding and
RT   kinase activation in the epidermal growth factor receptor.";
RL   Mol. Cell. Biol. 30:5432-5443(2010).
CC   -!- FUNCTION: EGF stimulates the growth of various epidermal and
CC       epithelial tissues in vivo and in vitro and of some fibroblasts in
CC       cell culture. Magnesiotropic hormone that stimulates magnesium
CC       reabsorption in the renal distal convoluted tubule via engagement
CC       of EGFR and activation of the magnesium channel TRPM6. Can induce
CC       neurite outgrowth in motoneurons of the pond snail Lymnaea
CC       stagnalis in vitro (PubMed:10964941).
CC       {ECO:0000269|PubMed:10964941, ECO:0000269|PubMed:17671655}.
CC   -!- SUBUNIT: Interacts with EGFR and promotes EGFR dimerization.
CC       Interacts with RHBDF2 (By similarity). Interacts with RHBDF1; may
CC       retain EGF in the endoplasmic reticulum and regulates its
CC       degradation through the endoplasmic reticulum-associated
CC       degradation (ERAD). {ECO:0000250, ECO:0000269|PubMed:12297050,
CC       ECO:0000269|PubMed:12620237, ECO:0000269|PubMed:20837704,
CC       ECO:0000269|PubMed:21029725, ECO:0000269|PubMed:21439629}.
CC   -!- INTERACTION:
CC       P00533:EGFR; NbExp=16; IntAct=EBI-640857, EBI-297353;
CC       Q01279:Egfr (xeno); NbExp=3; IntAct=EBI-640857, EBI-6296235;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P01133-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P01133-2; Sequence=VSP_041586;
CC       Name=3;
CC         IsoId=P01133-3; Sequence=VSP_047190;
CC         Note=No experimental confirmation available. Gene prediction
CC         based on cDNA data.;
CC   -!- TISSUE SPECIFICITY: Expressed in kidney, salivary gland, cerebrum
CC       and prostate. {ECO:0000269|PubMed:17671655}.
CC   -!- PTM: O-glycosylated with core 1-like and core 2-like glycans. It
CC       is uncertain if Ser-954 or Thr-955 is O-glycosylated. The
CC       modification here shows glycan heterogeneity: HexHexNAc (major)
CC       and Hex2HexNAc2 (minor). {ECO:0000269|PubMed:22171320}.
CC   -!- DISEASE: Hypomagnesemia 4 (HOMG4) [MIM:611718]: A disorder
CC       characterized by massive renal hypomagnesemia and normal levels of
CC       serum calcium and calcium excretion. Clinical features include
CC       seizures, mild-to moderate psychomotor retardation, and brisk
CC       tendon reflexes. {ECO:0000269|PubMed:17671655}. Note=The disease
CC       is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Contains 9 EGF-like domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00076}.
CC   -!- SIMILARITY: Contains 9 LDL-receptor class B repeats.
CC       {ECO:0000255|PROSITE-ProRule:PRU00461}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAR84237.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/egf/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Epidermal growth factor entry;
CC       URL="https://en.wikipedia.org/wiki/Epidermal_growth_factor";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X04571; CAA28240.1; -; mRNA.
DR   EMBL; AY506357; AAR84237.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AK299306; BAG61319.1; -; mRNA.
DR   EMBL; AC004050; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC005509; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC093731; AAH93731.1; -; mRNA.
DR   EMBL; BC113461; AAI13462.1; -; mRNA.
DR   CCDS; CCDS3689.1; -. [P01133-1]
DR   CCDS; CCDS54794.1; -. [P01133-3]
DR   CCDS; CCDS54795.1; -. [P01133-2]
DR   PIR; A25531; EGHU.
DR   RefSeq; NP_001171601.1; NM_001178130.1. [P01133-3]
DR   RefSeq; NP_001171602.1; NM_001178131.1. [P01133-2]
DR   RefSeq; NP_001954.2; NM_001963.4. [P01133-1]
DR   UniGene; Hs.419815; -.
DR   PDB; 1IVO; X-ray; 3.30 A; C/D=971-1023.
DR   PDB; 1JL9; X-ray; 3.00 A; A/B=971-1021.
DR   PDB; 1NQL; X-ray; 2.80 A; B=971-1023.
DR   PDB; 1P9J; NMR; -; A=976-1022.
DR   PDB; 2KV4; NMR; -; A=971-1023.
DR   PDB; 3NJP; X-ray; 3.30 A; C/D=975-1021.
DR   PDBsum; 1IVO; -.
DR   PDBsum; 1JL9; -.
DR   PDBsum; 1NQL; -.
DR   PDBsum; 1P9J; -.
DR   PDBsum; 2KV4; -.
DR   PDBsum; 3NJP; -.
DR   ProteinModelPortal; P01133; -.
DR   SMR; P01133; 973-1020.
DR   BioGrid; 108270; 16.
DR   DIP; DIP-5767N; -.
DR   IntAct; P01133; 7.
DR   MINT; MINT-260489; -.
DR   STRING; 9606.ENSP00000265171; -.
DR   ChEMBL; CHEMBL5734; -.
DR   DrugBank; DB00364; Sucralfate.
DR   iPTMnet; P01133; -.
DR   PhosphoSite; P01133; -.
DR   UniCarbKB; P01133; -.
DR   BioMuta; EGF; -.
DR   DMDM; 251757262; -.
DR   PaxDb; P01133; -.
DR   PRIDE; P01133; -.
DR   Ensembl; ENST00000265171; ENSP00000265171; ENSG00000138798. [P01133-1]
DR   Ensembl; ENST00000503392; ENSP00000421384; ENSG00000138798. [P01133-3]
DR   Ensembl; ENST00000509793; ENSP00000424316; ENSG00000138798. [P01133-2]
DR   GeneID; 1950; -.
DR   KEGG; hsa:1950; -.
DR   UCSC; uc003hzy.4; human. [P01133-1]
DR   UCSC; uc011cfu.2; human. [P01133-2]
DR   CTD; 1950; -.
DR   GeneCards; EGF; -.
DR   HGNC; HGNC:3229; EGF.
DR   HPA; CAB017843; -.
DR   MalaCards; EGF; -.
DR   MIM; 131530; gene.
DR   MIM; 611718; phenotype.
DR   neXtProt; NX_P01133; -.
DR   Orphanet; 210159; Adult hepatocellular carcinoma.
DR   Orphanet; 34527; Familial primary hypomagnesemia with normocalciuria and normocalcemia.
DR   PharmGKB; PA27664; -.
DR   eggNOG; ENOG410IPSY; Eukaryota.
DR   eggNOG; ENOG410ZVIM; LUCA.
DR   GeneTree; ENSGT00760000118968; -.
DR   HOGENOM; HOG000112345; -.
DR   HOVERGEN; HBG003858; -.
DR   InParanoid; P01133; -.
DR   KO; K04357; -.
DR   OMA; KIYFAHT; -.
DR   OrthoDB; EOG7Q2N4J; -.
DR   PhylomeDB; P01133; -.
DR   TreeFam; TF315253; -.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-1227986; Signaling by ERBB2.
DR   Reactome; R-HSA-1236382; Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants.
DR   Reactome; R-HSA-1236394; Signaling by ERBB4.
DR   Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling.
DR   Reactome; R-HSA-1251932; PLCG1 events in ERBB2 signaling.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-177929; Signaling by EGFR.
DR   Reactome; R-HSA-179812; GRB2 events in EGFR signaling.
DR   Reactome; R-HSA-180292; GAB1 signalosome.
DR   Reactome; R-HSA-180336; SHC1 events in EGFR signaling.
DR   Reactome; R-HSA-182971; EGFR downregulation.
DR   Reactome; R-HSA-1963640; GRB2 events in ERBB2 signaling.
DR   Reactome; R-HSA-1963642; PI3K events in ERBB2 signaling.
DR   Reactome; R-HSA-212718; EGFR interacts with phospholipase C-gamma.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-5637810; Constitutive Signaling by EGFRvIII.
DR   Reactome; R-HSA-5638303; Inhibition of Signaling by Overexpressed EGFR.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   SignaLink; P01133; -.
DR   ChiTaRS; EGF; human.
DR   EvolutionaryTrace; P01133; -.
DR   GeneWiki; Epidermal_growth_factor; -.
DR   GenomeRNAi; 1950; -.
DR   NextBio; 7903; -.
DR   PMAP-CutDB; P01133; -.
DR   PRO; PR:P01133; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; P01133; -.
DR   CleanEx; HS_EGF; -.
DR   Genevisible; P01133; HS.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; IC:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005765; C:lysosomal membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:ProtInc.
DR   GO; GO:0031093; C:platelet alpha granule lumen; TAS:Reactome.
DR   GO; GO:0043235; C:receptor complex; IBA:GO_Central.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0005154; F:epidermal growth factor receptor binding; TAS:UniProtKB.
DR   GO; GO:0008083; F:growth factor activity; IDA:HGNC.
DR   GO; GO:0030297; F:transmembrane receptor protein tyrosine kinase activator activity; TAS:UniProtKB.
DR   GO; GO:0042813; F:Wnt-activated receptor activity; IBA:GO_Central.
DR   GO; GO:0017147; F:Wnt-protein binding; IBA:GO_Central.
DR   GO; GO:0000186; P:activation of MAPKK activity; TAS:Reactome.
DR   GO; GO:0007171; P:activation of transmembrane receptor protein tyrosine kinase activity; TAS:GOC.
DR   GO; GO:0001525; P:angiogenesis; IDA:HGNC.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0048754; P:branching morphogenesis of an epithelial tube; IEA:Ensembl.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; IBA:GO_Central.
DR   GO; GO:0006260; P:DNA replication; TAS:ProtInc.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0070371; P:ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0045087; P:innate immune response; TAS:Reactome.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0060749; P:mammary gland alveolus development; IEA:Ensembl.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0090370; P:negative regulation of cholesterol efflux; IEA:Ensembl.
DR   GO; GO:0042059; P:negative regulation of epidermal growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0051048; P:negative regulation of secretion; IDA:BHF-UCL.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IEA:Ensembl.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:Reactome.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   GO; GO:0035413; P:positive regulation of catenin import into nucleus; IDA:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:HGNC.
DR   GO; GO:0021940; P:positive regulation of cerebellar granule cell precursor proliferation; IEA:Ensembl.
DR   GO; GO:0043388; P:positive regulation of DNA binding; ISS:UniProtKB.
DR   GO; GO:0045741; P:positive regulation of epidermal growth factor-activated receptor activity; TAS:UniProtKB.
DR   GO; GO:1900127; P:positive regulation of hyaluronan biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IDA:HGNC.
DR   GO; GO:0045840; P:positive regulation of mitotic nuclear division; IDA:HGNC.
DR   GO; GO:0010800; P:positive regulation of peptidyl-threonine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0042327; P:positive regulation of phosphorylation; IDA:HGNC.
DR   GO; GO:2000060; P:positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process; IEA:Ensembl.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0007265; P:Ras protein signal transduction; TAS:Reactome.
DR   GO; GO:0090279; P:regulation of calcium ion import; IDA:BHF-UCL.
DR   GO; GO:2000008; P:regulation of protein localization to cell surface; IDA:BHF-UCL.
DR   GO; GO:0007165; P:signal transduction; TAS:Reactome.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; TAS:Reactome.
DR   GO; GO:0007262; P:STAT protein import into nucleus; ISS:UniProtKB.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0044332; P:Wnt signaling pathway involved in dorsal/ventral axis specification; IBA:GO_Central.
DR   Gene3D; 2.120.10.30; -; 2.
DR   Gene3D; 2.40.155.10; -; 1.
DR   InterPro; IPR011042; 6-blade_b-propeller_TolB-like.
DR   InterPro; IPR001881; EGF-like_Ca-bd_dom.
DR   InterPro; IPR013032; EGF-like_CS.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR000152; EGF-type_Asp/Asn_hydroxyl_site.
DR   InterPro; IPR018097; EGF_Ca-bd_CS.
DR   InterPro; IPR023413; GFP-like.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR000033; LDLR_classB_rpt.
DR   InterPro; IPR016317; Pro-epidermal_GF.
DR   Pfam; PF00008; EGF; 1.
DR   Pfam; PF07645; EGF_CA; 3.
DR   Pfam; PF00058; Ldl_recept_b; 4.
DR   PIRSF; PIRSF001778; Pro-epidermal_growth_factor; 1.
DR   SMART; SM00181; EGF; 6.
DR   SMART; SM00179; EGF_CA; 2.
DR   SMART; SM00135; LY; 9.
DR   SUPFAM; SSF57184; SSF57184; 4.
DR   PROSITE; PS00010; ASX_HYDROXYL; 3.
DR   PROSITE; PS00022; EGF_1; 1.
DR   PROSITE; PS01186; EGF_2; 7.
DR   PROSITE; PS50026; EGF_3; 5.
DR   PROSITE; PS01187; EGF_CA; 3.
DR   PROSITE; PS51120; LDLRB; 9.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   EGF-like domain; Glycoprotein; Growth factor; Membrane; Polymorphism;
KW   Primary hypomagnesemia; Reference proteome; Repeat; Signal;
KW   Transmembrane; Transmembrane helix.
FT   SIGNAL        1     22       {ECO:0000255}.
FT   CHAIN        23   1207       Pro-epidermal growth factor.
FT                                /FTId=PRO_0000007540.
FT   CHAIN       971   1023       Epidermal growth factor.
FT                                /FTId=PRO_0000007541.
FT   TOPO_DOM     23   1032       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1033   1053       Helical. {ECO:0000255}.
FT   TOPO_DOM   1054   1207       Cytoplasmic. {ECO:0000255}.
FT   REPEAT       86    127       LDL-receptor class B 1.
FT   REPEAT      128    169       LDL-receptor class B 2.
FT   REPEAT      170    211       LDL-receptor class B 3.
FT   REPEAT      212    258       LDL-receptor class B 4.
FT   DOMAIN      314    355       EGF-like 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      356    396       EGF-like 2; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      397    437       EGF-like 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      435    477       EGF-like 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   REPEAT      483    523       LDL-receptor class B 5.
FT   REPEAT      524    566       LDL-receptor class B 6.
FT   REPEAT      567    609       LDL-receptor class B 7.
FT   REPEAT      610    653       LDL-receptor class B 8.
FT   REPEAT      654    696       LDL-receptor class B 9.
FT   DOMAIN      741    781       EGF-like 5. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      831    869       EGF-like 6. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      870    911       EGF-like 7; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      912    952       EGF-like 8; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      972   1013       EGF-like 9. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   REGION      801    807       O-glycosylated at one site.
FT   CARBOHYD     38     38       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    104    104       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    117    117       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    148    148       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    324    324       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    404    404       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    596    596       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    815    815       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    926    926       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    954    954       O-linked (GalNAc...); or Thr-955.
FT                                {ECO:0000269|PubMed:22171320}.
FT   CARBOHYD    955    955       O-linked (GalNAc...); or Ser-954.
FT                                {ECO:0000269|PubMed:22171320}.
FT   DISULFID    318    330       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    325    339       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    341    354       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    360    371       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    367    380       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    382    395       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    401    412       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    408    421       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    423    436       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    439    451       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    447    461       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    463    476       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    745    756       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    752    765       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    767    780       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    835    846       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    840    855       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    857    868       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    874    888       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    881    897       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    899    910       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    916    929       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    923    938       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    940    951       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    976    990
FT   DISULFID    984   1001
FT   DISULFID   1003   1012
FT   VAR_SEQ     314    355       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_041586.
FT   VAR_SEQ     912    952       Missing (in isoform 3). {ECO:0000305}.
FT                                /FTId=VSP_047190.
FT   VARIANT      16     16       S -> R (in dbSNP:rs11568849).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_020161.
FT   VARIANT     151    151       H -> Y (in dbSNP:rs9991664).
FT                                /FTId=VAR_033825.
FT   VARIANT     257    257       D -> H (in dbSNP:rs11568911).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_020968.
FT   VARIANT     292    292       L -> H (in dbSNP:rs35191533).
FT                                /FTId=VAR_033826.
FT   VARIANT     431    431       R -> K (in dbSNP:rs11568943).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_020162.
FT   VARIANT     638    638       S -> R (in dbSNP:rs11568992).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_020969.
FT   VARIANT     708    708       M -> I (in dbSNP:rs2237051).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_002275.
FT   VARIANT     723    723       G -> R (in dbSNP:rs6413481).
FT                                /FTId=VAR_020163.
FT   VARIANT     784    784       D -> V (in dbSNP:rs11569017).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_020164.
FT   VARIANT     842    842       M -> T (in dbSNP:rs11569046).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_020165.
FT   VARIANT     920    920       E -> V (in dbSNP:rs4698803).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|Ref.2}.
FT                                /FTId=VAR_020970.
FT   VARIANT     981    981       D -> E (in dbSNP:rs11569086).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_020971.
FT   VARIANT    1043   1043       L -> F (in dbSNP:rs11569098).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_020166.
FT   VARIANT    1070   1070       P -> L (in HOMG4; affects basolateral
FT                                sorting of pro-EGF preventing the hormone
FT                                to stimulate EGFR; lack of TRPM6
FT                                activation).
FT                                {ECO:0000269|PubMed:17671655}.
FT                                /FTId=VAR_039474.
FT   VARIANT    1084   1084       A -> G (in dbSNP:rs11569111).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_020972.
FT   CONFLICT    302    302       A -> T (in Ref. 3; BAG61319).
FT                                {ECO:0000305}.
FT   STRAND      979    981       {ECO:0000244|PDB:1JL9}.
FT   STRAND      982    984       {ECO:0000244|PDB:1P9J}.
FT   TURN        985    987       {ECO:0000244|PDB:1JL9}.
FT   STRAND      989    993       {ECO:0000244|PDB:1NQL}.
FT   TURN        994    997       {ECO:0000244|PDB:1NQL}.
FT   STRAND      998   1003       {ECO:0000244|PDB:1NQL}.
FT   STRAND     1007   1009       {ECO:0000244|PDB:1NQL}.
FT   TURN       1018   1021       {ECO:0000244|PDB:1P9J}.
SQ   SEQUENCE   1207 AA;  133994 MW;  3C787F1D405CFAF1 CRC64;
     MLLTLIILLP VVSKFSFVSL SAPQHWSCPE GTLAGNGNST CVGPAPFLIF SHGNSIFRID
     TEGTNYEQLV VDAGVSVIMD FHYNEKRIYW VDLERQLLQR VFLNGSRQER VCNIEKNVSG
     MAINWINEEV IWSNQQEGII TVTDMKGNNS HILLSALKYP ANVAVDPVER FIFWSSEVAG
     SLYRADLDGV GVKALLETSE KITAVSLDVL DKRLFWIQYN REGSNSLICS CDYDGGSVHI
     SKHPTQHNLF AMSLFGDRIF YSTWKMKTIW IANKHTGKDM VRINLHSSFV PLGELKVVHP
     LAQPKAEDDT WEPEQKLCKL RKGNCSSTVC GQDLQSHLCM CAEGYALSRD RKYCEDVNEC
     AFWNHGCTLG CKNTPGSYYC TCPVGFVLLP DGKRCHQLVS CPRNVSECSH DCVLTSEGPL
     CFCPEGSVLE RDGKTCSGCS SPDNGGCSQL CVPLSPVSWE CDCFPGYDLQ LDEKSCAASG
     PQPFLLFANS QDIRHMHFDG TDYGTLLSQQ MGMVYALDHD PVENKIYFAH TALKWIERAN
     MDGSQRERLI EEGVDVPEGL AVDWIGRRFY WTDRGKSLIG RSDLNGKRSK IITKENISQP
     RGIAVHPMAK RLFWTDTGIN PRIESSSLQG LGRLVIASSD LIWPSGITID FLTDKLYWCD
     AKQSVIEMAN LDGSKRRRLT QNDVGHPFAV AVFEDYVWFS DWAMPSVMRV NKRTGKDRVR
     LQGSMLKPSS LVVVHPLAKP GADPCLYQNG GCEHICKKRL GTAWCSCREG FMKASDGKTC
     LALDGHQLLA GGEVDLKNQV TPLDILSKTR VSEDNITESQ HMLVAEIMVS DQDDCAPVGC
     SMYARCISEG EDATCQCLKG FAGDGKLCSD IDECEMGVPV CPPASSKCIN TEGGYVCRCS
     EGYQGDGIHC LDIDECQLGE HSCGENASCT NTEGGYTCMC AGRLSEPGLI CPDSTPPPHL
     REDDHHYSVR NSDSECPLSH DGYCLHDGVC MYIEALDKYA CNCVVGYIGE RCQYRDLKWW
     ELRHAGHGQQ QKVIVVAVCV VVLVMLLLLS LWGAHYYRTQ KLLSKNPKNP YEESSRDVRS
     RRPADTEDGM SSCPQPWFVV IKEHQDLKNG GQPVAGEDGQ AADGSMQPTS WRQEPQLCGM
     GTEQGCWIPV SSDKGSCPQV MERSFHMPSY GTQTLEGGVE KPHSLLSANP LWQQRALDPP
     HQMELTQ
//
ID   PGH2_RAT                Reviewed;         604 AA.
AC   P35355; Q64379; Q925V4;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 1.
DT   11-NOV-2015, entry version 154.
DE   RecName: Full=Prostaglandin G/H synthase 2;
DE            EC=1.14.99.1;
DE   AltName: Full=Cyclooxygenase-2;
DE            Short=COX-2;
DE   AltName: Full=PHS II;
DE   AltName: Full=Prostaglandin H2 synthase 2;
DE            Short=PGH synthase 2;
DE            Short=PGHS-2;
DE   AltName: Full=Prostaglandin-endoperoxide synthase 2;
DE   Flags: Precursor;
GN   Name=Ptgs2; Synonyms=Cox-2, Cox2;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=7916614; DOI=10.1006/bbrc.1993.2506;
RA   Kennedy B.P., Chan C.C., Culp S.A., Cromlish W.A.;
RT   "Cloning and expression of rat prostaglandin endoperoxide synthase
RT   (cyclooxygenase)-2 cDNA.";
RL   Biochem. Biophys. Res. Commun. 197:494-500(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8352945; DOI=10.1016/0896-6273(93)90192-T;
RA   Yamagata K., Andreasson K.I., Kaufmann W.E., Barnes C.A., Worley P.F.;
RT   "Expression of a mitogen-inducible cyclooxygenase in brain neurons:
RT   regulation by synaptic activity and glucocorticoids.";
RL   Neuron 11:371-386(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Wistar; TISSUE=Intestine;
RX   PubMed=8203528;
RA   Dubois R.N., Tsujii M., Bishop P., Awad J.A., Makita K., Lanahan A.;
RT   "Cloning and characterization of a growth factor-inducible
RT   cyclooxygenase gene from rat intestinal epithelial cells.";
RL   Am. J. Physiol. 266:G822-G827(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Fischer 344;
RX   PubMed=8274023; DOI=10.1006/abbi.1993.1601;
RA   Feng L., Sun W., Xia Y., Tang W.W., Chanmugam P., Soyoola E.,
RA   Wilson C.B., Hwang D.;
RT   "Cloning two isoforms of rat cyclooxygenase: differential regulation
RT   of their expression.";
RL   Arch. Biochem. Biophys. 307:361-368(1993).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=10816563; DOI=10.1074/jbc.M001611200;
RA   Xu K., Robida A.M., Murphy T.J.;
RT   "Immediate-early MEK-1-dependent stabilization of rat smooth muscle
RT   cell cyclooxygenase-2 mRNA by Galpha(q)-coupled receptor signaling.";
RL   J. Biol. Chem. 275:23012-23019(2000).
RN   [6]
RP   PROTEIN SEQUENCE OF 18-43.
RX   PubMed=1556140;
RA   Sirois J., Richards J.S.;
RT   "Purification and characterization of a novel, distinct isoform of
RT   prostaglandin endoperoxide synthase induced by human chorionic
RT   gonadotropin in granulosa cells of rat preovulatory follicles.";
RL   J. Biol. Chem. 267:6382-6388(1992).
RN   [7]
RP   REVIEW ON FUNCTION; TISSUE SPECIFICITY AND INHIBITION BY NSAIDS.
RX   PubMed=10966456; DOI=10.1146/annurev.biochem.69.1.145;
RA   Smith W.L., DeWitt D.L., Garavito R.M.;
RT   "Cyclooxygenases: structural, cellular, and molecular biology.";
RL   Annu. Rev. Biochem. 69:145-182(2000).
RN   [8]
RP   REVIEW ON FUNCTION; INHIBITION BY ASPIRIN AND INVOLVEMENT IN
RP   COLORECTAL CANCER.
RX   PubMed=24605250; DOI=10.4292/wjgpt.v5.i1.40;
RA   Sostres C., Gargallo C.J., Lanas A.;
RT   "Aspirin, cyclooxygenase inhibition and colorectal cancer.";
RL   World J. Gastrointest. Pharmacol. Ther. 5:40-49(2014).
CC   -!- FUNCTION: Converts arachidonate to prostaglandin H2 (PGH2), a
CC       committed step in prostanoid synthesis. Constitutively expressed
CC       in some tissues in physiological conditions, such as the
CC       endothelium, kidney and brain, and in pathological conditions,
CC       such as in cancer. PTGS2 is responsible for production of
CC       inflammatory prostaglandins. Up-regulation of PTGS2 is also
CC       associated with increased cell adhesion, phenotypic changes,
CC       resistance to apoptosis and tumor angiogenesis. In cancer cells,
CC       PTGS2 is a key step in the production of prostaglandin E2 (PGE2),
CC       which plays important roles in modulating motility, proliferation
CC       and resistance to apoptosis.
CC   -!- CATALYTIC ACTIVITY: Arachidonate + AH(2) + 2 O(2) = prostaglandin
CC       H(2) + A + H(2)O.
CC   -!- COFACTOR:
CC       Name=heme b; Xref=ChEBI:CHEBI:60344; Evidence={ECO:0000250};
CC       Note=Binds 1 heme b (iron(II)-protoporphyrin IX) group per
CC       subunit. {ECO:0000250};
CC   -!- PATHWAY: Lipid metabolism; prostaglandin biosynthesis.
CC   -!- SUBUNIT: Homodimer. {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Microsome membrane; Peripheral membrane
CC       protein. Endoplasmic reticulum membrane; Peripheral membrane
CC       protein.
CC   -!- TISSUE SPECIFICITY: Expressed throughout the forebrain in discrete
CC       populations of neurons and is enriched in the cortex and
CC       hippocampus.
CC   -!- INDUCTION: By cytokines and mitogens.
CC   -!- PTM: S-nitrosylation by NOS2 (iNOS) activates enzyme activity. S-
CC       nitrosylation may take place on different Cys residues in addition
CC       to Cys-526 (By similarity). {ECO:0000250}.
CC   -!- MISCELLANEOUS: The conversion of arachidonate to prostaglandin H2
CC       is a 2 step reaction: a cyclooxygenase (COX) reaction which
CC       converts arachidonate to prostaglandin G2 (PGG2) and a peroxidase
CC       reaction in which PGG2 is reduced to prostaglandin H2 (PGH2). The
CC       cyclooxygenase reaction occurs in a hydrophobic channel in the
CC       core of the enzyme. The peroxidase reaction occurs at a heme-
CC       containing active site located near the protein surface. The
CC       nonsteroidal anti-inflammatory drugs (NSAIDs) binding site
CC       corresponds to the cyclooxygenase active site.
CC   -!- MISCELLANEOUS: Conversion of arachidonate to prostaglandin H2 is
CC       mediated by 2 different isozymes: the constitutive PTGS1 and the
CC       inducible PTGS2. PGHS1 is expressed constitutively and generally
CC       produces prostanoids acutely in response to hormonal stimuli to
CC       fine-tune physiological processes requiring instantaneous,
CC       continuous regulation (e.g. hemostasis). PGHS2 is inducible and
CC       typically produces prostanoids that mediate responses to
CC       physiological stresses such as infection and inflammation.
CC   -!- MISCELLANEOUS: PTGS1 and PTGS2 are the targets of nonsteroidal
CC       anti-inflammatory drugs (NSAIDs) including aspirin and ibuprofen.
CC       Aspirin is able to produce an irreversible inactivation of the
CC       enzyme through a serine acetylation. Inhibition of the PGHSs with
CC       NSAIDs acutely reduces inflammation, pain, and fever, and long-
CC       term use of these drugs reduces fatal thrombotic events, as well
CC       as the development of colon cancer and Alzheimer's disease. PTGS2
CC       is the principal isozyme responsible for production of
CC       inflammatory prostaglandins. New generation PTGSs inhibitors
CC       strive to be selective for PTGS2, to avoid side effects such as
CC       gastrointestinal complications and ulceration.
CC   -!- SIMILARITY: Belongs to the prostaglandin G/H synthase family.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 EGF-like domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00076}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L25925; AAA16477.1; -; mRNA.
DR   EMBL; U04300; AAA20246.1; -; mRNA.
DR   EMBL; U03389; AAA03466.1; -; mRNA.
DR   EMBL; S67722; AAB29401.1; -; mRNA.
DR   EMBL; AF233596; AAF36986.1; -; mRNA.
DR   PIR; JC2030; JC2030.
DR   RefSeq; NP_058928.3; NM_017232.3.
DR   UniGene; Rn.217585; -.
DR   UniGene; Rn.44369; -.
DR   ProteinModelPortal; P35355; -.
DR   SMR; P35355; 18-569.
DR   BioGrid; 248163; 2.
DR   STRING; 10116.ENSRNOP00000003567; -.
DR   BindingDB; P35355; -.
DR   ChEMBL; CHEMBL2977; -.
DR   PeroxiBase; 3975; RnoPGHS02-A.
DR   PhosphoSite; P35355; -.
DR   PaxDb; P35355; -.
DR   PRIDE; P35355; -.
DR   Ensembl; ENSRNOT00000003567; ENSRNOP00000003567; ENSRNOG00000002525.
DR   GeneID; 29527; -.
DR   KEGG; rno:29527; -.
DR   UCSC; RGD:620349; rat.
DR   CTD; 5743; -.
DR   RGD; 620349; Ptgs2.
DR   eggNOG; KOG2408; Eukaryota.
DR   eggNOG; ENOG410XPZ3; LUCA.
DR   GeneTree; ENSGT00390000010743; -.
DR   HOGENOM; HOG000013149; -.
DR   HOVERGEN; HBG000366; -.
DR   InParanoid; P35355; -.
DR   KO; K11987; -.
DR   OMA; CNNVKGC; -.
DR   OrthoDB; EOG7RFTHC; -.
DR   PhylomeDB; P35355; -.
DR   TreeFam; TF329675; -.
DR   BRENDA; 1.14.99.1; 5301.
DR   Reactome; R-RNO-197264; Nicotinamide salvaging.
DR   Reactome; R-RNO-2142770; Synthesis of 15-eicosatetraenoic acid derivatives.
DR   Reactome; R-RNO-2162123; Synthesis of Prostaglandins (PG) and Thromboxanes (TX).
DR   UniPathway; UPA00662; -.
DR   NextBio; 609492; -.
DR   PRO; PR:P35355; -.
DR   Proteomes; UP000002494; Chromosome 13.
DR   Genevisible; P35355; RN.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0043005; C:neuron projection; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0043234; C:protein complex; IDA:RGD.
DR   GO; GO:0020037; F:heme binding; ISS:UniProtKB.
DR   GO; GO:0008289; F:lipid binding; IMP:RGD.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0016702; F:oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen; IDA:RGD.
DR   GO; GO:0004601; F:peroxidase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004666; F:prostaglandin-endoperoxide synthase activity; ISS:UniProtKB.
DR   GO; GO:0001525; P:angiogenesis; IMP:RGD.
DR   GO; GO:0030282; P:bone mineralization; IMP:MGI.
DR   GO; GO:0050873; P:brown fat cell differentiation; IEA:Ensembl.
DR   GO; GO:0071318; P:cellular response to ATP; IEP:RGD.
DR   GO; GO:0071498; P:cellular response to fluid shear stress; IEA:Ensembl.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEA:Ensembl.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEP:RGD.
DR   GO; GO:0034644; P:cellular response to UV; IEP:RGD.
DR   GO; GO:0019371; P:cyclooxygenase pathway; ISS:UniProtKB.
DR   GO; GO:0046697; P:decidualization; IMP:RGD.
DR   GO; GO:0007566; P:embryo implantation; IMP:RGD.
DR   GO; GO:0042633; P:hair cycle; IEP:RGD.
DR   GO; GO:0006954; P:inflammatory response; IMP:RGD.
DR   GO; GO:0007612; P:learning; IMP:RGD.
DR   GO; GO:0035633; P:maintenance of blood-brain barrier; IMP:RGD.
DR   GO; GO:0007613; P:memory; IMP:RGD.
DR   GO; GO:0051926; P:negative regulation of calcium ion transport; IMP:RGD.
DR   GO; GO:0045786; P:negative regulation of cell cycle; IGI:RGD.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IDA:RGD.
DR   GO; GO:0045986; P:negative regulation of smooth muscle contraction; IMP:RGD.
DR   GO; GO:0032227; P:negative regulation of synaptic transmission, dopaminergic; IMP:RGD.
DR   GO; GO:0030728; P:ovulation; IMP:RGD.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IMP:RGD.
DR   GO; GO:0090336; P:positive regulation of brown fat cell differentiation; IEA:Ensembl.
DR   GO; GO:0010942; P:positive regulation of cell death; IMP:RGD.
DR   GO; GO:0090050; P:positive regulation of cell migration involved in sprouting angiogenesis; IMP:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:RGD.
DR   GO; GO:0031622; P:positive regulation of fever generation; IDA:BHF-UCL.
DR   GO; GO:0090271; P:positive regulation of fibroblast growth factor production; IMP:BHF-UCL.
DR   GO; GO:0042346; P:positive regulation of NF-kappaB import into nucleus; IMP:RGD.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0090362; P:positive regulation of platelet-derived growth factor production; IMP:BHF-UCL.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IMP:RGD.
DR   GO; GO:0045987; P:positive regulation of smooth muscle contraction; IMP:RGD.
DR   GO; GO:0031915; P:positive regulation of synaptic plasticity; IMP:RGD.
DR   GO; GO:0051968; P:positive regulation of synaptic transmission, glutamatergic; IMP:RGD.
DR   GO; GO:0071636; P:positive regulation of transforming growth factor beta production; IMP:BHF-UCL.
DR   GO; GO:0010575; P:positive regulation of vascular endothelial growth factor production; IMP:BHF-UCL.
DR   GO; GO:0045907; P:positive regulation of vasoconstriction; IMP:RGD.
DR   GO; GO:0001516; P:prostaglandin biosynthetic process; IMP:RGD.
DR   GO; GO:0008217; P:regulation of blood pressure; ISS:UniProtKB.
DR   GO; GO:0034097; P:response to cytokine; IMP:RGD.
DR   GO; GO:0042493; P:response to drug; IEP:RGD.
DR   GO; GO:0032355; P:response to estradiol; IEP:RGD.
DR   GO; GO:0070542; P:response to fatty acid; IEP:RGD.
DR   GO; GO:0009750; P:response to fructose; IEP:RGD.
DR   GO; GO:0051384; P:response to glucocorticoid; IEP:RGD.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IMP:RGD.
DR   GO; GO:0010226; P:response to lithium ion; IEP:RGD.
DR   GO; GO:0010042; P:response to manganese ion; IEP:RGD.
DR   GO; GO:0014070; P:response to organic cyclic compound; IEP:RGD.
DR   GO; GO:0010033; P:response to organic substance; IEP:RGD.
DR   GO; GO:0010243; P:response to organonitrogen compound; IEP:RGD.
DR   GO; GO:0006979; P:response to oxidative stress; IEA:InterPro.
DR   GO; GO:0009314; P:response to radiation; IEP:RGD.
DR   GO; GO:0034612; P:response to tumor necrosis factor; IEP:RGD.
DR   GO; GO:0033280; P:response to vitamin D; IEP:RGD.
DR   GO; GO:0019233; P:sensory perception of pain; IMP:RGD.
DR   Gene3D; 1.10.640.10; -; 1.
DR   InterPro; IPR029576; COX-2.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR010255; Haem_peroxidase.
DR   InterPro; IPR019791; Haem_peroxidase_animal.
DR   PANTHER; PTHR11903:SF8; PTHR11903:SF8; 1.
DR   Pfam; PF03098; An_peroxidase; 1.
DR   Pfam; PF00008; EGF; 1.
DR   PRINTS; PR00457; ANPEROXIDASE.
DR   SMART; SM00181; EGF; 1.
DR   SUPFAM; SSF48113; SSF48113; 1.
DR   PROSITE; PS50026; EGF_3; 1.
DR   PROSITE; PS50292; PEROXIDASE_3; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Dioxygenase; Direct protein sequencing;
KW   Disulfide bond; Endoplasmic reticulum; Fatty acid biosynthesis;
KW   Fatty acid metabolism; Glycoprotein; Heme; Iron; Lipid biosynthesis;
KW   Lipid metabolism; Membrane; Metal-binding; Microsome; Oxidoreductase;
KW   Peroxidase; Prostaglandin biosynthesis; Prostaglandin metabolism;
KW   Reference proteome; S-nitrosylation; Signal.
FT   SIGNAL        1     17       {ECO:0000269|PubMed:1556140}.
FT   CHAIN        18    604       Prostaglandin G/H synthase 2.
FT                                /FTId=PRO_0000023879.
FT   DOMAIN       18     55       EGF-like. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   ACT_SITE    193    193       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00298}.
FT   ACT_SITE    371    371       For cyclooxygenase activity.
FT                                {ECO:0000250}.
FT   METAL       374    374       Iron (heme axial ligand).
FT                                {ECO:0000255|PROSITE-ProRule:PRU00298}.
FT   BINDING     106    106       Substrate. {ECO:0000250}.
FT   BINDING     341    341       Substrate. {ECO:0000250}.
FT   BINDING     371    371       Substrate. {ECO:0000250}.
FT   SITE        516    516       Aspirin-acetylated serine. {ECO:0000250}.
FT   CARBOHYD     53     53       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    130    130       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    396    396       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    580    580       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     21     32       {ECO:0000250}.
FT   DISULFID     22    145       {ECO:0000250}.
FT   DISULFID     26     42       {ECO:0000250}.
FT   DISULFID     44     54       {ECO:0000250}.
FT   DISULFID    555    561       {ECO:0000250}.
FT   CONFLICT     11     13       ALA -> CPG (in Ref. 4 and 5).
FT                                {ECO:0000305}.
FT   CONFLICT     58     58       E -> R (in Ref. 4 and 5). {ECO:0000305}.
FT   CONFLICT     66     66       L -> P (in Ref. 4 and 5). {ECO:0000305}.
FT   CONFLICT     96     98       NSI -> IQS (in Ref. 4 and 5).
FT                                {ECO:0000305}.
FT   CONFLICT    339    339       S -> R (in Ref. 4 and 5). {ECO:0000305}.
FT   CONFLICT    344    344       K -> Q (in Ref. 4 and 5). {ECO:0000305}.
FT   CONFLICT    350    350       E -> D (in Ref. 4 and 5). {ECO:0000305}.
FT   CONFLICT    368    368       N -> K (in Ref. 4 and 5). {ECO:0000305}.
FT   CONFLICT    573    573       P -> A (in Ref. 4 and 5). {ECO:0000305}.
SQ   SEQUENCE   604 AA;  69164 MW;  98E418825D98FF0C CRC64;
     MLFRAVLLCA ALALSHAANP CCSNPCQNRG ECMSIGFDQY KCDCTRTGFY GENCTTPEFL
     TRIKLLLKPT PNTVHYILTH FKGVWNIVNN IPFLRNSIMR YVLTSRSHLI DSPPTYNVHY
     GYKSWEAFSN LSYYTRALPP VADDCPTPMG VKGNKELPDS KEVLEKVLLR REFIPDPQGT
     NMMFAFFAQH FTHQFFKTDQ KRGPGFTRGL GHGVDLNHVY GETLDRQHKL RLFQDGKLKY
     QVIGGEVYPP TVKDTQVDMI YPPHVPEHLR FAVGQEVFGL VPGLMMYATI WLREHNRVCD
     ILKQEHPEWD DERLFQTSRL ILIGETIKIV IEDYVQHLSG YHFKLKFDPE LLFNQQFQYQ
     NRIASEFNTL YHWHPLLPDT FNIEDQEYTF KQFLYNNSIL LEHGLAHFVE SFTRQIAGRV
     AGGRNVPIAV QAVAKASIDQ SREMKYQSLN EYRKRFSLKP YTSFEELTGE KEMAAELKAL
     YHDIDAMELY PALLVEKPRP DAIFGETMVE LGAPFSLKGL MGNPICSPQY WKPSTFGGEV
     GFRIINTASI QSLICNNVKG CPFASFNVQD PQPTKTATIN ASASHSRLDD INPTVLIKRR
     STEL
//
ID   SLIT2_HUMAN             Reviewed;        1529 AA.
AC   O94813; B7ZLR5; O95710; Q17RU3; Q9Y5Q7;
DT   19-JUL-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1999, sequence version 1.
DT   20-JAN-2016, entry version 163.
DE   RecName: Full=Slit homolog 2 protein;
DE            Short=Slit-2;
DE   Contains:
DE     RecName: Full=Slit homolog 2 protein N-product;
DE   Contains:
DE     RecName: Full=Slit homolog 2 protein C-product;
DE   Flags: Precursor;
GN   Name=SLIT2; Synonyms=SLIL3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000312|EMBL:BAA35185.1};
RN   [1] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), TISSUE SPECIFICITY, AND
RP   VARIANTS PRO-636 AND PHE-1277.
RC   TISSUE=Fetal lung;
RX   PubMed=9813312; DOI=10.1016/S0169-328X(98)00224-1;
RA   Itoh A., Miyabayashi T., Ohno M., Sakano S.;
RT   "Cloning and expressions of three mammalian homologues of Drosophila
RT   slit suggest possible roles for Slit in the formation and maintenance
RT   of the nervous system.";
RL   Brain Res. Mol. Brain Res. 62:175-186(1998).
RN   [2] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND TISSUE SPECIFICITY.
RC   TISSUE=Fetal brain, and Fetal kidney;
RX   PubMed=10349621; DOI=10.1016/S0925-4773(98)00174-9;
RA   Holmes G.P., Negus K., Burridge L., Raman S., Algar E., Yamada T.,
RA   Little M.H.;
RT   "Distinct but overlapping expression patterns of two vertebrate slit
RT   homologs implies functional roles in CNS development and
RT   organogenesis.";
RL   Mech. Dev. 79:57-72(1998).
RN   [3] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), PROTEIN SEQUENCE OF 1122-1129,
RP   FUNCTION, INTERACTION WITH ROBO1 AND ROBO2, AND SUBCELLULAR LOCATION.
RC   TISSUE=Fetal brain;
RX   PubMed=10102268; DOI=10.1016/S0092-8674(00)80590-5;
RA   Brose K., Bland K.S., Wang K.H., Arnott D., Henzel W., Goodman C.S.,
RA   Tessier-Lavigne M., Kidd T.;
RT   "Slit proteins bind Robo receptors and have an evolutionarily
RT   conserved role in repulsive axon guidance.";
RL   Cell 96:795-806(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   FUNCTION.
RX   PubMed=10975526; DOI=10.1016/S0092-8674(00)00041-6;
RA   Zou Y., Stoeckli E., Chen H., Tessier-Lavigne M.;
RT   "Squeezing axons out of the gray matter: a role for slit and
RT   semaphorin proteins from midline and ventral spinal cord.";
RL   Cell 102:363-375(2000).
RN   [7]
RP   FUNCTION.
RX   PubMed=10864954;
RA   Niclou S.P., Jia L., Raper J.A.;
RT   "Slit2 is a repellent for retinal ganglion cell axons.";
RL   J. Neurosci. 20:4962-4974(2000).
RN   [8]
RP   FUNCTION.
RX   PubMed=11309622; DOI=10.1038/35073616;
RA   Wu J.Y., Feng L., Park H.T., Havlioglu N., Wen L., Tang H.,
RA   Bacon K.B., Jiang Z.H., Zhang X.C., Rao Y.;
RT   "The neuronal repellent Slit inhibits leukocyte chemotaxis induced by
RT   chemotactic factors.";
RL   Nature 410:948-952(2001).
RN   [9]
RP   DOMAIN.
RX   PubMed=11222645;
RA   Chen J.H., Wen L., Dupuis S., Wu J.Y., Rao Y.;
RT   "The N-terminal leucine-rich regions in Slit are sufficient to repel
RT   olfactory bulb axons and subventricular zone neurons.";
RL   J. Neurosci. 21:1548-1556(2001).
RN   [10]
RP   FUNCTION, AND INTERACTION WITH ROBO1 AND ROBO2.
RX   PubMed=11404413;
RA   Nguyen-Ba-Charvet K.T., Brose K., Ma L., Wang K.H., Marillat V.,
RA   Sotelo C., Tessier-Lavigne M., Chedotal A.;
RT   "Diversity and specificity of actions of Slit2 proteolytic fragments
RT   in axon guidance.";
RL   J. Neurosci. 21:4281-4289(2001).
RN   [11]
RP   FUNCTION.
RX   PubMed=11239147; DOI=10.1126/science.1058445;
RA   Stein E., Tessier-Lavigne M.;
RT   "Hierarchical organization of guidance receptors: silencing of netrin
RT   attraction by slit through a Robo/DCC receptor complex.";
RL   Science 291:1928-1938(2001).
RN   [12]
RP   REVIEW.
RX   PubMed=12200164; DOI=10.1016/S0959-437X(02)00343-X;
RA   Wong K., Park H.T., Wu J.Y., Rao Y.;
RT   "Slit proteins: molecular guidance cues for cells ranging from neurons
RT   to leukocytes.";
RL   Curr. Opin. Genet. Dev. 12:583-591(2002).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (3.01 ANGSTROMS) OF 504-716, AND DISULFIDE
RP   BONDS.
RX   PubMed=17704564; DOI=10.1107/S0907444907035470;
RA   Morlot C., Hemrika W., Romijn R.A., Gros P., Cusack S., McCarthy A.A.;
RT   "Production of Slit2 LRR domains in mammalian cells for structural
RT   studies and the structure of human Slit2 domain 3.";
RL   Acta Crystallogr. D 63:961-968(2007).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 271-480 IN COMPLEX WITH
RP   ROBO1, AND DISULFIDE BONDS.
RX   PubMed=17848514; DOI=10.1073/pnas.0705310104;
RA   Morlot C., Thielens N.M., Ravelli R.B., Hemrika W., Romijn R.A.,
RA   Gros P., Cusack S., McCarthy A.A.;
RT   "Structural insights into the Slit-Robo complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:14923-14928(2007).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 726-907, SUBUNIT, DISULFIDE
RP   BONDS, AND HEPARIN-BINDING.
RX   PubMed=19498462; DOI=10.1038/embor.2009.95;
RA   Seiradake E., von Philipsborn A.C., Henry M., Fritz M.,
RA   Lortat-Jacob H., Jamin M., Hemrika W., Bastmeyer M., Cusack S.,
RA   McCarthy A.A.;
RT   "Structure and functional relevance of the Slit2 homodimerization
RT   domain.";
RL   EMBO Rep. 10:736-741(2009).
CC   -!- FUNCTION: Thought to act as molecular guidance cue in cellular
CC       migration, and function appears to be mediated by interaction with
CC       roundabout homolog receptors. During neural development involved
CC       in axonal navigation at the ventral midline of the neural tube and
CC       projection of axons to different regions. SLIT1 and SLIT2 seem to
CC       be essential for midline guidance in the forebrain by acting as
CC       repulsive signal preventing inappropriate midline crossing by
CC       axons projecting from the olfactory bulb. In spinal chord
CC       development may play a role in guiding commissural axons once they
CC       reached the floor plate by modulating the response to netrin. In
CC       vitro, silences the attractive effect of NTN1 but not its growth-
CC       stimulatory effect and silencing requires the formation of a
CC       ROBO1-DCC complex. May be implicated in spinal chord midline post-
CC       crossing axon repulsion. In vitro, only commissural axons that
CC       crossed the midline responded to SLIT2. In the developing visual
CC       system appears to function as repellent for retinal ganglion axons
CC       by providing a repulsion that directs these axons along their
CC       appropriate paths prior to, and after passage through, the optic
CC       chiasm. In vitro, collapses and repels retinal ganglion cell
CC       growth cones. Seems to play a role in branching and arborization
CC       of CNS sensory axons, and in neuronal cell migration. In vitro,
CC       Slit homolog 2 protein N-product, but not Slit homolog 2 protein
CC       C-product, repels olfactory bulb (OB) but not dorsal root ganglia
CC       (DRG) axons, induces OB growth cones collapse and induces
CC       branching of DRG axons. Seems to be involved in regulating
CC       leukocyte migration. {ECO:0000269|PubMed:10102268,
CC       ECO:0000269|PubMed:10864954, ECO:0000269|PubMed:10975526,
CC       ECO:0000269|PubMed:11239147, ECO:0000269|PubMed:11309622,
CC       ECO:0000269|PubMed:11404413}.
CC   -!- SUBUNIT: Interacts with GREM1 (By similarity). Homodimer. Binds
CC       ROBO1 and ROBO2 with high affinity. {ECO:0000250,
CC       ECO:0000269|PubMed:10102268, ECO:0000269|PubMed:11404413,
CC       ECO:0000269|PubMed:17848514, ECO:0000269|PubMed:19498462}.
CC   -!- INTERACTION:
CC       Self; NbExp=2; IntAct=EBI-1236865, EBI-1236865;
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:10102268}.
CC       Note=The C-terminal cleavage protein is more diffusible than the
CC       larger N-terminal protein that is more tightly cell associated.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1 {ECO:0000305};
CC         IsoId=O94813-1; Sequence=Displayed;
CC       Name=2 {ECO:0000305};
CC         IsoId=O94813-2; Sequence=VSP_050035, VSP_050036;
CC       Name=3 {ECO:0000305};
CC         IsoId=O94813-3; Sequence=VSP_050036;
CC   -!- TISSUE SPECIFICITY: Fetal lung and kidney, and adult spinal cord.
CC       Weak expression in adult adrenal gland, thyroid, trachea and other
CC       tissues examined. {ECO:0000269|PubMed:10349621,
CC       ECO:0000269|PubMed:9813312}.
CC   -!- DOMAIN: The leucine-rich repeat domain is sufficient for guiding
CC       both axon projection and neuronal migration, in vitro.
CC       {ECO:0000269|PubMed:11222645}.
CC   -!- SIMILARITY: Contains 1 CTCK (C-terminal cystine knot-like) domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00039}.
CC   -!- SIMILARITY: Contains 7 EGF-like domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00076, ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 laminin G-like domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00122}.
CC   -!- SIMILARITY: Contains 20 LRR (leucine-rich) repeats. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 4 LRRCT domains. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 4 LRRNT domains. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/SLIT2ID42328ch4p15.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB017168; BAA35185.1; -; mRNA.
DR   EMBL; AF055585; AAD04309.1; -; mRNA.
DR   EMBL; AF133270; AAD25539.1; -; mRNA.
DR   EMBL; CH471069; EAW92793.1; -; Genomic_DNA.
DR   EMBL; BC117190; AAI17191.1; -; mRNA.
DR   EMBL; BC143978; AAI43979.1; -; mRNA.
DR   CCDS; CCDS3426.1; -. [O94813-1]
DR   CCDS; CCDS75110.1; -. [O94813-2]
DR   CCDS; CCDS75111.1; -. [O94813-3]
DR   RefSeq; NP_001276064.1; NM_001289135.2. [O94813-2]
DR   RefSeq; NP_001276065.1; NM_001289136.2. [O94813-3]
DR   RefSeq; NP_004778.1; NM_004787.3. [O94813-1]
DR   UniGene; Hs.29802; -.
DR   PDB; 2V70; X-ray; 3.01 A; A/B/C/D=504-714.
DR   PDB; 2V9S; X-ray; 2.00 A; A/B/C/D=271-480.
DR   PDB; 2V9T; X-ray; 1.70 A; B=271-479.
DR   PDB; 2WFH; X-ray; 1.80 A; A/B=726-907.
DR   PDBsum; 2V70; -.
DR   PDBsum; 2V9S; -.
DR   PDBsum; 2V9T; -.
DR   PDBsum; 2WFH; -.
DR   ProteinModelPortal; O94813; -.
DR   SMR; O94813; 271-478, 505-714, 727-907.
DR   BioGrid; 114756; 11.
DR   DIP; DIP-38198N; -.
DR   IntAct; O94813; 7.
DR   MINT; MINT-6768470; -.
DR   STRING; 9606.ENSP00000422591; -.
DR   iPTMnet; O94813; -.
DR   PhosphoSite; O94813; -.
DR   BioMuta; SLIT2; -.
DR   MaxQB; O94813; -.
DR   PaxDb; O94813; -.
DR   PRIDE; O94813; -.
DR   Ensembl; ENST00000503823; ENSP00000427548; ENSG00000145147. [O94813-3]
DR   Ensembl; ENST00000503837; ENSP00000422261; ENSG00000145147. [O94813-2]
DR   Ensembl; ENST00000504154; ENSP00000422591; ENSG00000145147. [O94813-1]
DR   GeneID; 9353; -.
DR   KEGG; hsa:9353; -.
DR   UCSC; uc003gpr.1; human. [O94813-1]
DR   UCSC; uc003gps.1; human. [O94813-3]
DR   CTD; 9353; -.
DR   GeneCards; SLIT2; -.
DR   HGNC; HGNC:11086; SLIT2.
DR   HPA; CAB007590; -.
DR   HPA; HPA019511; -.
DR   HPA; HPA023088; -.
DR   MIM; 603746; gene.
DR   neXtProt; NX_O94813; -.
DR   PharmGKB; PA35939; -.
DR   eggNOG; KOG4237; Eukaryota.
DR   eggNOG; COG4886; LUCA.
DR   GeneTree; ENSGT00790000122942; -.
DR   HOGENOM; HOG000116120; -.
DR   HOVERGEN; HBG057959; -.
DR   InParanoid; O94813; -.
DR   KO; K06839; -.
DR   OrthoDB; EOG78WKQW; -.
DR   PhylomeDB; O94813; -.
DR   TreeFam; TF332887; -.
DR   Reactome; R-HSA-373752; Netrin-1 signaling.
DR   Reactome; R-HSA-376176; Signaling by Robo receptor.
DR   Reactome; R-HSA-428540; Activation of Rac.
DR   Reactome; R-HSA-428542; Regulation of Commissural axon pathfinding by Slit and Robo.
DR   Reactome; R-HSA-428543; Inactivation of Cdc42 and Rac.
DR   Reactome; R-HSA-428890; Role of Abl in Robo-Slit signaling.
DR   ChiTaRS; SLIT2; human.
DR   EvolutionaryTrace; O94813; -.
DR   GeneWiki; SLIT2; -.
DR   GenomeRNAi; 9353; -.
DR   NextBio; 35025; -.
DR   PRO; PR:O94813; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; O94813; -.
DR   CleanEx; HS_SLIT2; -.
DR   ExpressionAtlas; O94813; baseline and differential.
DR   Genevisible; O94813; HS.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; NAS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005578; C:proteinaceous extracellular matrix; IBA:GO_Central.
DR   GO; GO:0005509; F:calcium ion binding; NAS:UniProtKB.
DR   GO; GO:0045499; F:chemorepellent activity; IEA:Ensembl.
DR   GO; GO:0005095; F:GTPase inhibitor activity; IDA:UniProtKB.
DR   GO; GO:0008201; F:heparin binding; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0043237; F:laminin-1 binding; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0043394; F:proteoglycan binding; IPI:UniProtKB.
DR   GO; GO:0048495; F:Roundabout binding; IPI:UniProtKB.
DR   GO; GO:0061364; P:apoptotic process involved in luteolysis; IEP:UniProtKB.
DR   GO; GO:0048846; P:axon extension involved in axon guidance; IDA:UniProtKB.
DR   GO; GO:0007411; P:axon guidance; IDA:UniProtKB.
DR   GO; GO:0048754; P:branching morphogenesis of an epithelial tube; IDA:UniProtKB.
DR   GO; GO:0002042; P:cell migration involved in sprouting angiogenesis; IMP:BHF-UCL.
DR   GO; GO:0071504; P:cellular response to heparin; IDA:UniProtKB.
DR   GO; GO:0032870; P:cellular response to hormone stimulus; IEP:UniProtKB.
DR   GO; GO:0021836; P:chemorepulsion involved in postnatal olfactory bulb interneuron migration; IDA:UniProtKB.
DR   GO; GO:0021972; P:corticospinal neuron axon guidance through spinal cord; IMP:BHF-UCL.
DR   GO; GO:0033563; P:dorsal/ventral axon guidance; IEA:Ensembl.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0050929; P:induction of negative chemotaxis; IDA:UniProtKB.
DR   GO; GO:0060763; P:mammary duct terminal end bud growth; IEA:Ensembl.
DR   GO; GO:0001656; P:metanephros development; IEA:Ensembl.
DR   GO; GO:0008045; P:motor neuron axon guidance; IDA:UniProtKB.
DR   GO; GO:0050919; P:negative chemotaxis; IDA:UniProtKB.
DR   GO; GO:0030837; P:negative regulation of actin filament polymerization; IDA:UniProtKB.
DR   GO; GO:0030517; P:negative regulation of axon extension; IEA:Ensembl.
DR   GO; GO:0030308; P:negative regulation of cell growth; IMP:BHF-UCL.
DR   GO; GO:0030336; P:negative regulation of cell migration; IDA:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0090288; P:negative regulation of cellular response to growth factor stimulus; IDA:BHF-UCL.
DR   GO; GO:0070100; P:negative regulation of chemokine-mediated signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0010596; P:negative regulation of endothelial cell migration; IDA:UniProtKB.
DR   GO; GO:0010629; P:negative regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0034260; P:negative regulation of GTPase activity; IDA:GOC.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; IEA:Ensembl.
DR   GO; GO:0010593; P:negative regulation of lamellipodium assembly; IDA:UniProtKB.
DR   GO; GO:0002689; P:negative regulation of leukocyte chemotaxis; IDA:UniProtKB.
DR   GO; GO:0090027; P:negative regulation of monocyte chemotaxis; ISS:BHF-UCL.
DR   GO; GO:0071676; P:negative regulation of mononuclear cell migration; IDA:BHF-UCL.
DR   GO; GO:0090024; P:negative regulation of neutrophil chemotaxis; IDA:UniProtKB.
DR   GO; GO:0001933; P:negative regulation of protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0090260; P:negative regulation of retinal ganglion cell axon guidance; IDA:UniProtKB.
DR   GO; GO:0051058; P:negative regulation of small GTPase mediated signal transduction; IDA:UniProtKB.
DR   GO; GO:0071672; P:negative regulation of smooth muscle cell chemotaxis; IDA:BHF-UCL.
DR   GO; GO:0014912; P:negative regulation of smooth muscle cell migration; IDA:BHF-UCL.
DR   GO; GO:0043116; P:negative regulation of vascular permeability; IDA:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0050772; P:positive regulation of axonogenesis; TAS:UniProtKB.
DR   GO; GO:0051414; P:response to cortisol; IEP:UniProtKB.
DR   GO; GO:0031667; P:response to nutrient levels; IEA:Ensembl.
DR   GO; GO:0031290; P:retinal ganglion cell axon guidance; IDA:UniProtKB.
DR   GO; GO:0035385; P:Roundabout signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0016337; P:single organismal cell-cell adhesion; IEA:Ensembl.
DR   GO; GO:0021510; P:spinal cord development; IEA:Ensembl.
DR   GO; GO:0001657; P:ureteric bud development; IMP:UniProtKB.
DR   Gene3D; 2.60.120.200; -; 1.
DR   Gene3D; 3.80.10.10; -; 6.
DR   InterPro; IPR013320; ConA-like_dom.
DR   InterPro; IPR000483; Cys-rich_flank_reg_C.
DR   InterPro; IPR006207; Cys_knot_C.
DR   InterPro; IPR001881; EGF-like_Ca-bd_dom.
DR   InterPro; IPR013032; EGF-like_CS.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR000152; EGF-type_Asp/Asn_hydroxyl_site.
DR   InterPro; IPR018097; EGF_Ca-bd_CS.
DR   InterPro; IPR003645; Fol_N.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR001791; Laminin_G.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR003591; Leu-rich_rpt_typical-subtyp.
DR   InterPro; IPR000372; LRRNT.
DR   Pfam; PF00008; EGF; 6.
DR   Pfam; PF00054; Laminin_G_1; 1.
DR   Pfam; PF13855; LRR_8; 7.
DR   Pfam; PF01463; LRRCT; 4.
DR   Pfam; PF01462; LRRNT; 4.
DR   SMART; SM00041; CT; 1.
DR   SMART; SM00181; EGF; 7.
DR   SMART; SM00179; EGF_CA; 2.
DR   SMART; SM00274; FOLN; 3.
DR   SMART; SM00282; LamG; 1.
DR   SMART; SM00369; LRR_TYP; 8.
DR   SMART; SM00082; LRRCT; 4.
DR   SMART; SM00013; LRRNT; 4.
DR   SUPFAM; SSF49899; SSF49899; 1.
DR   SUPFAM; SSF52058; SSF52058; 4.
DR   PROSITE; PS00010; ASX_HYDROXYL; 2.
DR   PROSITE; PS01185; CTCK_1; 1.
DR   PROSITE; PS01225; CTCK_2; 1.
DR   PROSITE; PS00022; EGF_1; 9.
DR   PROSITE; PS01186; EGF_2; 7.
DR   PROSITE; PS50026; EGF_3; 9.
DR   PROSITE; PS01187; EGF_CA; 2.
DR   PROSITE; PS50025; LAM_G_DOMAIN; 1.
DR   PROSITE; PS51450; LRR; 20.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Chemotaxis; Complete proteome;
KW   Developmental protein; Differentiation; Direct protein sequencing;
KW   Disulfide bond; EGF-like domain; Glycoprotein; Heparin-binding;
KW   Leucine-rich repeat; Neurogenesis; Polymorphism; Reference proteome;
KW   Repeat; Secreted; Signal.
FT   SIGNAL        1     30       {ECO:0000255}.
FT   CHAIN        31   1529       Slit homolog 2 protein.
FT                                /FTId=PRO_0000007725.
FT   CHAIN        31   1121       Slit homolog 2 protein N-product.
FT                                /FTId=PRO_0000007726.
FT   CHAIN      1122   1529       Slit homolog 2 protein C-product.
FT                                /FTId=PRO_0000007727.
FT   DOMAIN       31     55       LRRNT.
FT   REPEAT       56     77       LRR 1.
FT   REPEAT       80    101       LRR 2.
FT   REPEAT      104    125       LRR 3.
FT   REPEAT      128    149       LRR 4.
FT   REPEAT      152    173       LRR 5.
FT   REPEAT      176    197       LRR 6.
FT   DOMAIN      209    259       LRRCT 1.
FT   DOMAIN      264    300       LRRNT 2.
FT   REPEAT      301    322       LRR 7.
FT   REPEAT      325    346       LRR 8.
FT   REPEAT      349    370       LRR 9.
FT   REPEAT      373    394       LRR 10.
FT   REPEAT      397    418       LRR 11.
FT   DOMAIN      430    480       LRRCT 2.
FT   DOMAIN      497    533       LRRNT 3.
FT   REPEAT      534    555       LRR 12.
FT   REPEAT      559    580       LRR 13.
FT   REPEAT      583    604       LRR 14.
FT   REPEAT      607    628       LRR 15.
FT   REPEAT      631    652       LRR 16.
FT   DOMAIN      664    714       LRRCT 3.
FT   DOMAIN      718    754       LRRNT 4.
FT   REPEAT      755    777       LRR 17.
FT   REPEAT      778    799       LRR 18.
FT   REPEAT      802    823       LRR 19.
FT   REPEAT      826    847       LRR 20.
FT   DOMAIN      859    909       LRRCT 4.
FT   DOMAIN      918    955       EGF-like 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      957    996       EGF-like 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      998   1034       EGF-like 3; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1036   1074       EGF-like 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1076   1112       EGF-like 5; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1121   1157       EGF-like 6. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1160   1333       Laminin G-like. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00122}.
FT   DOMAIN     1332   1368       EGF-like 7. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1453   1528       CTCK. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00039, ECO:0000305}.
FT   SITE       1121   1122       Cleavage.
FT   CARBOHYD     66     66       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    186    186       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    564    564       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    623    623       N-linked (GlcNAc...).
FT   CARBOHYD    794    794       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    799    799       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1009   1009       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1010   1010       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1019   1019       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1183   1183       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1266   1266       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1300   1300       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    277    286
FT   DISULFID    434    457
FT   DISULFID    436    478
FT   DISULFID    506    512
FT   DISULFID    510    519
FT   DISULFID    668    691
FT   DISULFID    670    712
FT   DISULFID    727    733
FT   DISULFID    731    740
FT   DISULFID    863    886
FT   DISULFID    865    907
FT   DISULFID    922    933       {ECO:0000250}.
FT   DISULFID    927    943       {ECO:0000250}.
FT   DISULFID    945    954       {ECO:0000250}.
FT   DISULFID    961    972       {ECO:0000250}.
FT   DISULFID    966    984       {ECO:0000250}.
FT   DISULFID    986    995       {ECO:0000250}.
FT   DISULFID   1002   1013       {ECO:0000250}.
FT   DISULFID   1007   1022       {ECO:0000250}.
FT   DISULFID   1024   1033       {ECO:0000250}.
FT   DISULFID   1040   1053       {ECO:0000250}.
FT   DISULFID   1047   1062       {ECO:0000250}.
FT   DISULFID   1064   1073       {ECO:0000250}.
FT   DISULFID   1080   1091       {ECO:0000250}.
FT   DISULFID   1085   1100       {ECO:0000250}.
FT   DISULFID   1102   1111       {ECO:0000250}.
FT   DISULFID   1125   1136       {ECO:0000250}.
FT   DISULFID   1130   1145       {ECO:0000250}.
FT   DISULFID   1147   1156       {ECO:0000250}.
FT   DISULFID   1307   1333       {ECO:0000250}.
FT   DISULFID   1336   1346       {ECO:0000250}.
FT   DISULFID   1341   1356       {ECO:0000250}.
FT   DISULFID   1358   1367       {ECO:0000250}.
FT   DISULFID   1375   1385       {ECO:0000250}.
FT   DISULFID   1380   1395       {ECO:0000250}.
FT   DISULFID   1397   1406       {ECO:0000250}.
FT   DISULFID   1416   1426       {ECO:0000250}.
FT   DISULFID   1421   1436       {ECO:0000250}.
FT   DISULFID   1438   1447       {ECO:0000250}.
FT   DISULFID   1453   1492       {ECO:0000250}.
FT   DISULFID   1471   1506       {ECO:0000250}.
FT   DISULFID   1482   1522       {ECO:0000250}.
FT   DISULFID   1486   1524       {ECO:0000250}.
FT   VAR_SEQ     258    258       S -> SDEEE (in isoform 2).
FT                                {ECO:0000303|PubMed:10102268,
FT                                ECO:0000303|PubMed:9813312}.
FT                                /FTId=VSP_050035.
FT   VAR_SEQ     480    487       Missing (in isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:10102268,
FT                                ECO:0000303|PubMed:10349621,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:9813312}.
FT                                /FTId=VSP_050036.
FT   VARIANT     636    636       S -> P. {ECO:0000269|PubMed:9813312}.
FT                                /FTId=VAR_018098.
FT   VARIANT    1277   1277       S -> F. {ECO:0000269|PubMed:9813312}.
FT                                /FTId=VAR_018099.
FT   CONFLICT    226    226       Q -> K (in Ref. 2; AAD25539).
FT                                {ECO:0000305}.
FT   CONFLICT    607    610       SLKT -> KPQN (in Ref. 3; AAD04309).
FT                                {ECO:0000305}.
FT   CONFLICT    634    634       L -> M (in Ref. 3; AAD04309).
FT                                {ECO:0000305}.
FT   STRAND      277    280       {ECO:0000244|PDB:2V9T}.
FT   STRAND      283    285       {ECO:0000244|PDB:2V9T}.
FT   STRAND      304    306       {ECO:0000244|PDB:2V9T}.
FT   TURN        317    322       {ECO:0000244|PDB:2V9S}.
FT   STRAND      328    330       {ECO:0000244|PDB:2V9T}.
FT   TURN        341    346       {ECO:0000244|PDB:2V9T}.
FT   STRAND      352    354       {ECO:0000244|PDB:2V9T}.
FT   TURN        365    370       {ECO:0000244|PDB:2V9T}.
FT   STRAND      376    378       {ECO:0000244|PDB:2V9T}.
FT   TURN        389    394       {ECO:0000244|PDB:2V9T}.
FT   STRAND      400    402       {ECO:0000244|PDB:2V9T}.
FT   TURN        413    418       {ECO:0000244|PDB:2V9T}.
FT   STRAND      424    426       {ECO:0000244|PDB:2V9T}.
FT   HELIX       436    438       {ECO:0000244|PDB:2V9T}.
FT   HELIX       439    447       {ECO:0000244|PDB:2V9T}.
FT   STRAND      456    460       {ECO:0000244|PDB:2V9T}.
FT   HELIX       461    463       {ECO:0000244|PDB:2V9T}.
FT   HELIX       468    470       {ECO:0000244|PDB:2V9T}.
FT   HELIX       473    475       {ECO:0000244|PDB:2V9T}.
FT   STRAND      511    513       {ECO:0000244|PDB:2V70}.
FT   STRAND      516    518       {ECO:0000244|PDB:2V70}.
FT   STRAND      536    539       {ECO:0000244|PDB:2V70}.
FT   HELIX       554    556       {ECO:0000244|PDB:2V70}.
FT   STRAND      562    564       {ECO:0000244|PDB:2V70}.
FT   TURN        575    580       {ECO:0000244|PDB:2V70}.
FT   STRAND      586    588       {ECO:0000244|PDB:2V70}.
FT   HELIX       599    602       {ECO:0000244|PDB:2V70}.
FT   STRAND      610    612       {ECO:0000244|PDB:2V70}.
FT   STRAND      633    636       {ECO:0000244|PDB:2V70}.
FT   TURN        647    652       {ECO:0000244|PDB:2V70}.
FT   STRAND      658    660       {ECO:0000244|PDB:2V70}.
FT   HELIX       670    672       {ECO:0000244|PDB:2V70}.
FT   HELIX       673    681       {ECO:0000244|PDB:2V70}.
FT   STRAND      690    694       {ECO:0000244|PDB:2V70}.
FT   HELIX       695    697       {ECO:0000244|PDB:2V70}.
FT   HELIX       702    704       {ECO:0000244|PDB:2V70}.
FT   HELIX       707    709       {ECO:0000244|PDB:2V70}.
FT   STRAND      732    734       {ECO:0000244|PDB:2WFH}.
FT   STRAND      737    739       {ECO:0000244|PDB:2WFH}.
FT   STRAND      758    760       {ECO:0000244|PDB:2WFH}.
FT   HELIX       771    775       {ECO:0000244|PDB:2WFH}.
FT   STRAND      781    783       {ECO:0000244|PDB:2WFH}.
FT   TURN        794    799       {ECO:0000244|PDB:2WFH}.
FT   STRAND      805    807       {ECO:0000244|PDB:2WFH}.
FT   TURN        818    823       {ECO:0000244|PDB:2WFH}.
FT   STRAND      829    831       {ECO:0000244|PDB:2WFH}.
FT   TURN        842    847       {ECO:0000244|PDB:2WFH}.
FT   STRAND      853    855       {ECO:0000244|PDB:2WFH}.
FT   HELIX       865    867       {ECO:0000244|PDB:2WFH}.
FT   HELIX       868    876       {ECO:0000244|PDB:2WFH}.
FT   STRAND      885    889       {ECO:0000244|PDB:2WFH}.
FT   HELIX       890    892       {ECO:0000244|PDB:2WFH}.
FT   TURN        897    899       {ECO:0000244|PDB:2WFH}.
FT   HELIX       902    904       {ECO:0000244|PDB:2WFH}.
SQ   SEQUENCE   1529 AA;  169870 MW;  5D19CC5E7FD461BA CRC64;
     MRGVGWQMLS LSLGLVLAIL NKVAPQACPA QCSCSGSTVD CHGLALRSVP RNIPRNTERL
     DLNGNNITRI TKTDFAGLRH LRVLQLMENK ISTIERGAFQ DLKELERLRL NRNHLQLFPE
     LLFLGTAKLY RLDLSENQIQ AIPRKAFRGA VDIKNLQLDY NQISCIEDGA FRALRDLEVL
     TLNNNNITRL SVASFNHMPK LRTFRLHSNN LYCDCHLAWL SDWLRQRPRV GLYTQCMGPS
     HLRGHNVAEV QKREFVCSGH QSFMAPSCSV LHCPAACTCS NNIVDCRGKG LTEIPTNLPE
     TITEIRLEQN TIKVIPPGAF SPYKKLRRID LSNNQISELA PDAFQGLRSL NSLVLYGNKI
     TELPKSLFEG LFSLQLLLLN ANKINCLRVD AFQDLHNLNL LSLYDNKLQT IAKGTFSPLR
     AIQTMHLAQN PFICDCHLKW LADYLHTNPI ETSGARCTSP RRLANKRIGQ IKSKKFRCSA
     KEQYFIPGTE DYRSKLSGDC FADLACPEKC RCEGTTVDCS NQKLNKIPEH IPQYTAELRL
     NNNEFTVLEA TGIFKKLPQL RKINFSNNKI TDIEEGAFEG ASGVNEILLT SNRLENVQHK
     MFKGLESLKT LMLRSNRITC VGNDSFIGLS SVRLLSLYDN QITTVAPGAF DTLHSLSTLN
     LLANPFNCNC YLAWLGEWLR KKRIVTGNPR CQKPYFLKEI PIQDVAIQDF TCDDGNDDNS
     CSPLSRCPTE CTCLDTVVRC SNKGLKVLPK GIPRDVTELY LDGNQFTLVP KELSNYKHLT
     LIDLSNNRIS TLSNQSFSNM TQLLTLILSY NRLRCIPPRT FDGLKSLRLL SLHGNDISVV
     PEGAFNDLSA LSHLAIGANP LYCDCNMQWL SDWVKSEYKE PGIARCAGPG EMADKLLLTT
     PSKKFTCQGP VDVNILAKCN PCLSNPCKND GTCNSDPVDF YRCTCPYGFK GQDCDVPIHA
     CISNPCKHGG TCHLKEGEED GFWCICADGF EGENCEVNVD DCEDNDCENN STCVDGINNY
     TCLCPPEYTG ELCEEKLDFC AQDLNPCQHD SKCILTPKGF KCDCTPGYVG EHCDIDFDDC
     QDNKCKNGAH CTDAVNGYTC ICPEGYSGLF CEFSPPMVLP RTSPCDNFDC QNGAQCIVRI
     NEPICQCLPG YQGEKCEKLV SVNFINKESY LQIPSAKVRP QTNITLQIAT DEDSGILLYK
     GDKDHIAVEL YRGRVRASYD TGSHPASAIY SVETINDGNF HIVELLALDQ SLSLSVDGGN
     PKIITNLSKQ STLNFDSPLY VGGMPGKSNV ASLRQAPGQN GTSFHGCIRN LYINSELQDF
     QKVPMQTGIL PGCEPCHKKV CAHGTCQPSS QAGFTCECQE GWMGPLCDQR TNDPCLGNKC
     VHGTCLPINA FSYSCKCLEG HGGVLCDEEE DLFNPCQAIK CKHGKCRLSG LGQPYCECSS
     GYTGDSCDRE ISCRGERIRD YYQKQQGYAA CQTTKKVSRL ECRGGCAGGQ CCGPLRSKRR
     KYSFECTDGS SFVDEVEKVV KCGCTRCVS
//
ID   TGFB2_MOUSE             Reviewed;         414 AA.
AC   P27090; Q91VP5;
DT   01-AUG-1992, integrated into UniProtKB/Swiss-Prot.
DT   27-JUL-2011, sequence version 2.
DT   17-FEB-2016, entry version 143.
DE   RecName: Full=Transforming growth factor beta-2;
DE            Short=TGF-beta-2;
DE   Contains:
DE     RecName: Full=Latency-associated peptide;
DE              Short=LAP;
DE   Flags: Precursor;
GN   Name=Tgfb2;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2797004; DOI=10.1210/mend-3-7-1108;
RA   Miller D.A., Lee A., Pelton R.W., Chen E.Y., Moses H.L., Derynck R.;
RT   "Murine transforming growth factor-beta 2 cDNA sequence and expression
RT   in adult tissues and embryos.";
RL   Mol. Endocrinol. 3:1108-1114(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Mammary tumor;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   INTERACTION WITH NREP.
RX   PubMed=14985127; DOI=10.1016/j.bbrc.2004.01.171;
RA   Paliwal S., Shi J., Dhru U., Zhou Y., Schuger L.;
RT   "P311 binds to the latency associated protein and downregulates the
RT   expression of TGF-beta1 and TGF-beta2.";
RL   Biochem. Biophys. Res. Commun. 315:1104-1109(2004).
RN   [4]
RP   INTERACTION WITH HTRA3.
RX   PubMed=15206957; DOI=10.1111/j.1440-169X.2004.00743.x;
RA   Tocharus J., Tsuchiya A., Kajikawa M., Ueta Y., Oka C., Kawaichi M.;
RT   "Developmentally regulated expression of mouse HtrA3 and its role as
RT   an inhibitor of TGF-beta signaling.";
RL   Dev. Growth Differ. 46:257-274(2004).
RN   [5]
RP   INTERACTION WITH HTRA1.
RX   PubMed=14973287; DOI=10.1242/dev.00999;
RA   Oka C., Tsujimoto R., Kajikawa M., Koshiba-Takeuchi K., Ina J.,
RA   Yano M., Tsuchiya A., Ueta Y., Soma A., Kanda H., Matsumoto M.,
RA   Kawaichi M.;
RT   "HtrA1 serine protease inhibits signaling mediated by Tgfbeta family
RT   proteins.";
RL   Development 131:1041-1053(2004).
RN   [6]
RP   INTERACTION WITH MFAP5.
RX   PubMed=23963447; DOI=10.1074/jbc.M113.497727;
RA   Combs M.D., Knutsen R.H., Broekelmann T.J., Toennies H.M., Brett T.J.,
RA   Miller C.A., Kober D.L., Craft C.S., Atkinson J.J., Shipley J.M.,
RA   Trask B.C., Mecham R.P.;
RT   "Microfibril-associated glycoprotein 2 (MAGP2) loss of function has
RT   pleiotropic effects in vivo.";
RL   J. Biol. Chem. 288:28869-28880(2013).
CC   -!- FUNCTION: TGF-beta 2 has suppressive effects on interleukin-2
CC       dependent T-cell growth.
CC   -!- SUBUNIT: Homodimer; disulfide-linked (By similarity). Heterodimers
CC       with TGFB1 and with TGFB3 have been found in bone (By similarity).
CC       Interacts with ASPN (By similarity). Interacts with the serine
CC       proteases HTRA1 and HTRA3. Latency-associated peptide interacts
CC       with NREP; the interaction results in a decrease in TGFB2
CC       autoinduction. Interacts with MFAP5.
CC       {ECO:0000250|UniProtKB:P16812, ECO:0000269|PubMed:14973287,
CC       ECO:0000269|PubMed:14985127, ECO:0000269|PubMed:15206957,
CC       ECO:0000269|PubMed:23963447}.
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- PTM: The precursor is cleaved into mature TGF-beta-2 and LAP,
CC       which remains non-covalently linked to mature TGF-beta-2 rendering
CC       it inactive. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the TGF-beta family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X57413; CAA40672.1; -; mRNA.
DR   EMBL; BC011170; AAH11170.1; -; mRNA.
DR   CCDS; CCDS15601.1; -.
DR   PIR; A40148; WFMSB2.
DR   RefSeq; NP_033393.2; NM_009367.3.
DR   UniGene; Mm.18213; -.
DR   ProteinModelPortal; P27090; -.
DR   SMR; P27090; 21-414.
DR   BioGrid; 204160; 2.
DR   IntAct; P27090; 1.
DR   MINT; MINT-4121010; -.
DR   STRING; 10090.ENSMUSP00000043849; -.
DR   PhosphoSite; P27090; -.
DR   MaxQB; P27090; -.
DR   PaxDb; P27090; -.
DR   PRIDE; P27090; -.
DR   Ensembl; ENSMUST00000045288; ENSMUSP00000043849; ENSMUSG00000039239.
DR   GeneID; 21808; -.
DR   KEGG; mmu:21808; -.
DR   UCSC; uc007dzo.2; mouse.
DR   CTD; 7042; -.
DR   MGI; MGI:98726; Tgfb2.
DR   eggNOG; KOG3900; Eukaryota.
DR   eggNOG; ENOG410XT8Z; LUCA.
DR   GeneTree; ENSGT00760000119112; -.
DR   HOGENOM; HOG000290198; -.
DR   HOVERGEN; HBG074115; -.
DR   InParanoid; P27090; -.
DR   KO; K13376; -.
DR   OrthoDB; EOG70GMFT; -.
DR   TreeFam; TF318514; -.
DR   Reactome; R-MMU-114608; Platelet degranulation.
DR   Reactome; R-MMU-2129379; Molecules associated with elastic fibres.
DR   ChiTaRS; Tgfb2; mouse.
DR   NextBio; 301190; -.
DR   PRO; PR:P27090; -.
DR   Proteomes; UP000000589; Chromosome 1.
DR   Bgee; P27090; -.
DR   CleanEx; MM_TGFB2; -.
DR   ExpressionAtlas; P27090; baseline and differential.
DR   Genevisible; P27090; MM.
DR   GO; GO:0030424; C:axon; IDA:UniProtKB.
DR   GO; GO:0005768; C:endosome; IDA:UniProtKB.
DR   GO; GO:0031012; C:extracellular matrix; ISS:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; ISS:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:MGI.
DR   GO; GO:0043025; C:neuronal cell body; IDA:UniProtKB.
DR   GO; GO:0001540; F:beta-amyloid binding; ISS:UniProtKB.
DR   GO; GO:0005125; F:cytokine activity; IBA:GO_Central.
DR   GO; GO:0008083; F:growth factor activity; TAS:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; ISS:UniProtKB.
DR   GO; GO:0005102; F:receptor binding; ISS:UniProtKB.
DR   GO; GO:0004702; F:receptor signaling protein serine/threonine kinase activity; ISS:UniProtKB.
DR   GO; GO:0005160; F:transforming growth factor beta receptor binding; ISS:UniProtKB.
DR   GO; GO:0005114; F:type II transforming growth factor beta receptor binding; ISS:UniProtKB.
DR   GO; GO:0034714; F:type III transforming growth factor beta receptor binding; ISS:AgBase.
DR   GO; GO:0032147; P:activation of protein kinase activity; ISS:UniProtKB.
DR   GO; GO:0007411; P:axon guidance; IMP:MGI.
DR   GO; GO:0001568; P:blood vessel development; IMP:MGI.
DR   GO; GO:0001974; P:blood vessel remodeling; IMP:MGI.
DR   GO; GO:0060317; P:cardiac epithelial to mesenchymal transition; ISS:UniProtKB.
DR   GO; GO:0003214; P:cardiac left ventricle morphogenesis; TAS:DFLAT.
DR   GO; GO:0060038; P:cardiac muscle cell proliferation; ISS:UniProtKB.
DR   GO; GO:0003215; P:cardiac right ventricle morphogenesis; TAS:DFLAT.
DR   GO; GO:0010002; P:cardioblast differentiation; ISS:UniProtKB.
DR   GO; GO:0001502; P:cartilage condensation; IGI:MGI.
DR   GO; GO:0042637; P:catagen; ISS:UniProtKB.
DR   GO; GO:0007050; P:cell cycle arrest; ISS:UniProtKB.
DR   GO; GO:0008219; P:cell death; ISS:UniProtKB.
DR   GO; GO:0016049; P:cell growth; IEA:InterPro.
DR   GO; GO:0016477; P:cell migration; ISS:UniProtKB.
DR   GO; GO:0000902; P:cell morphogenesis; ISS:UniProtKB.
DR   GO; GO:0045216; P:cell-cell junction organization; ISS:UniProtKB.
DR   GO; GO:0030199; P:collagen fibril organization; ISS:UniProtKB.
DR   GO; GO:0042416; P:dopamine biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0048566; P:embryonic digestive tract development; ISS:AgBase.
DR   GO; GO:0001837; P:epithelial to mesenchymal transition; ISS:UniProtKB.
DR   GO; GO:0030198; P:extracellular matrix organization; IMP:MGI.
DR   GO; GO:0097191; P:extrinsic apoptotic signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0001654; P:eye development; ISS:UniProtKB.
DR   GO; GO:0060325; P:face morphogenesis; IEP:UniProtKB.
DR   GO; GO:0008347; P:glial cell migration; ISS:UniProtKB.
DR   GO; GO:0001942; P:hair follicle development; IMP:UniProtKB.
DR   GO; GO:0031069; P:hair follicle morphogenesis; IMP:UniProtKB.
DR   GO; GO:0007507; P:heart development; ISS:UniProtKB.
DR   GO; GO:0003007; P:heart morphogenesis; ISS:UniProtKB.
DR   GO; GO:0003179; P:heart valve morphogenesis; IMP:MGI.
DR   GO; GO:0030097; P:hemopoiesis; IMP:UniProtKB.
DR   GO; GO:0010693; P:negative regulation of alkaline phosphatase activity; ISS:UniProtKB.
DR   GO; GO:0061037; P:negative regulation of cartilage development; IMP:MGI.
DR   GO; GO:0030308; P:negative regulation of cell growth; ISS:AgBase.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; ISS:UniProtKB.
DR   GO; GO:0050680; P:negative regulation of epithelial cell proliferation; ISS:UniProtKB.
DR   GO; GO:0010629; P:negative regulation of gene expression; IDA:UniProtKB.
DR   GO; GO:0045617; P:negative regulation of keratinocyte differentiation; NAS:UniProtKB.
DR   GO; GO:0010936; P:negative regulation of macrophage cytokine production; ISS:UniProtKB.
DR   GO; GO:0048666; P:neuron development; IMP:UniProtKB.
DR   GO; GO:0048663; P:neuron fate commitment; IDA:MGI.
DR   GO; GO:0030593; P:neutrophil chemotaxis; ISS:UniProtKB.
DR   GO; GO:0003151; P:outflow tract morphogenesis; TAS:DFLAT.
DR   GO; GO:0060389; P:pathway-restricted SMAD protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0070237; P:positive regulation of activation-induced cell death of T cells; IDA:MGI.
DR   GO; GO:0051891; P:positive regulation of cardioblast differentiation; ISS:UniProtKB.
DR   GO; GO:0051795; P:positive regulation of catagen; ISS:UniProtKB.
DR   GO; GO:0033630; P:positive regulation of cell adhesion mediated by integrin; ISS:UniProtKB.
DR   GO; GO:0045787; P:positive regulation of cell cycle; IMP:UniProtKB.
DR   GO; GO:0051781; P:positive regulation of cell division; IEA:UniProtKB-KW.
DR   GO; GO:0030307; P:positive regulation of cell growth; ISS:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; ISS:UniProtKB.
DR   GO; GO:0010634; P:positive regulation of epithelial cell migration; ISS:UniProtKB.
DR   GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; ISS:UniProtKB.
DR   GO; GO:0090091; P:positive regulation of extracellular matrix disassembly; IDA:UniProtKB.
DR   GO; GO:2001241; P:positive regulation of extrinsic apoptotic signaling pathway in absence of ligand; IDA:MGI.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:UniProtKB.
DR   GO; GO:1904426; P:positive regulation of GTP binding; IDA:UniProtKB.
DR   GO; GO:0045823; P:positive regulation of heart contraction; ISS:UniProtKB.
DR   GO; GO:0050778; P:positive regulation of immune response; ISS:UniProtKB.
DR   GO; GO:0045726; P:positive regulation of integrin biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; ISS:UniProtKB.
DR   GO; GO:0045778; P:positive regulation of ossification; ISS:AgBase.
DR   GO; GO:0010862; P:positive regulation of pathway-restricted SMAD protein phosphorylation; IBA:GO_Central.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; ISS:UniProtKB.
DR   GO; GO:1900182; P:positive regulation of protein localization to nucleus; IDA:UniProtKB.
DR   GO; GO:0050714; P:positive regulation of protein secretion; ISS:UniProtKB.
DR   GO; GO:0032874; P:positive regulation of stress-activated MAPK cascade; ISS:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0032956; P:regulation of actin cytoskeleton organization; IDA:UniProtKB.
DR   GO; GO:0042981; P:regulation of apoptotic process; IMP:MGI.
DR   GO; GO:0042127; P:regulation of cell proliferation; IBA:GO_Central.
DR   GO; GO:1903053; P:regulation of extracellular matrix organization; IMP:MGI.
DR   GO; GO:0043408; P:regulation of MAPK cascade; IBA:GO_Central.
DR   GO; GO:0032909; P:regulation of transforming growth factor beta2 production; ISS:UniProtKB.
DR   GO; GO:0042493; P:response to drug; ISS:UniProtKB.
DR   GO; GO:0001666; P:response to hypoxia; ISS:UniProtKB.
DR   GO; GO:0032570; P:response to progesterone; ISS:UniProtKB.
DR   GO; GO:0009611; P:response to wounding; ISS:AgBase.
DR   GO; GO:0007435; P:salivary gland morphogenesis; ISS:AgBase.
DR   GO; GO:0023014; P:signal transduction by protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0001501; P:skeletal system development; IMP:MGI.
DR   GO; GO:0007184; P:SMAD protein import into nucleus; ISS:UniProtKB.
DR   GO; GO:0060395; P:SMAD protein signal transduction; IBA:GO_Central.
DR   GO; GO:0048103; P:somatic stem cell division; IDA:UniProtKB.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0060412; P:ventricular septum morphogenesis; TAS:DFLAT.
DR   GO; GO:0042060; P:wound healing; ISS:UniProtKB.
DR   Gene3D; 2.10.90.10; -; 1.
DR   InterPro; IPR029034; Cystine-knot_cytokine.
DR   InterPro; IPR001839; TGF-b_C.
DR   InterPro; IPR001111; TGF-b_N.
DR   InterPro; IPR016319; TGF-beta.
DR   InterPro; IPR015615; TGF-beta-rel.
DR   InterPro; IPR003940; TGFb2.
DR   InterPro; IPR017948; TGFb_CS.
DR   PANTHER; PTHR11848; PTHR11848; 2.
DR   PANTHER; PTHR11848:SF141; PTHR11848:SF141; 2.
DR   Pfam; PF00019; TGF_beta; 1.
DR   Pfam; PF00688; TGFb_propeptide; 1.
DR   PIRSF; PIRSF001787; TGF-beta; 1.
DR   PRINTS; PR01423; TGFBETA.
DR   PRINTS; PR01425; TGFBETA2.
DR   SMART; SM00204; TGFB; 1.
DR   SUPFAM; SSF57501; SSF57501; 1.
DR   PROSITE; PS00250; TGF_BETA_1; 1.
DR   PROSITE; PS51362; TGF_BETA_2; 1.
PE   1: Evidence at protein level;
KW   Cleavage on pair of basic residues; Complete proteome; Disulfide bond;
KW   Glycoprotein; Growth factor; Mitogen; Reference proteome; Secreted;
KW   Signal.
FT   SIGNAL        1     20       {ECO:0000255}.
FT   CHAIN        21    302       Latency-associated peptide.
FT                                /FTId=PRO_0000033786.
FT   CHAIN       303    414       Transforming growth factor beta-2.
FT                                /FTId=PRO_0000033787.
FT   CARBOHYD     72     72       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    140    140       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    241    241       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    309    318       {ECO:0000250}.
FT   DISULFID    317    380       {ECO:0000250}.
FT   DISULFID    346    411       {ECO:0000250}.
FT   DISULFID    350    413       {ECO:0000250}.
FT   DISULFID    379    379       Interchain. {ECO:0000250}.
FT   CONFLICT     95     96       DE -> EQ (in Ref. 1; CAA40672).
FT                                {ECO:0000305}.
SQ   SEQUENCE   414 AA;  47589 MW;  DB37A7C38881F286 CRC64;
     MHYCVLSTFL LLHLVPVALS LSTCSTLDMD QFMRKRIEAI RGQILSKLKL TSPPEDYPEP
     DEVPPEVISI YNSTRDLLQE KASRRAAACE RERSDEEYYA KEVYKIDMPS HLPSENAIPP
     TFYRPYFRIV RFDVSTMEKN ASNLVKAEFR VFRLQNPKAR VAEQRIELYQ ILKSKDLTSP
     TQRYIDSKVV KTRAEGEWLS FDVTDAVQEW LHHKDRNLGF KISLHCPCCT FVPSNNYIIP
     NKSEELEARF AGIDGTSTYA SGDQKTIKST RKKTSGKTPH LLLMLLPSYR LESQQSSRRK
     KRALDAAYCF RNVQDNCCLR PLYIDFKRDL GWKWIHEPKG YNANFCAGAC PYLWSSDTQH
     TKVLSLYNTI NPEASASPCC VSQDLEPLTI LYYIGNTPKI EQLSNMIVKS CKCS
//
ID   ITBX_DROME              Reviewed;         846 AA.
AC   P11584; Q8MYX9; Q9W3L2;
DT   01-OCT-1989, integrated into UniProtKB/Swiss-Prot.
DT   20-JUN-2003, sequence version 3.
DT   17-FEB-2016, entry version 175.
DE   RecName: Full=Integrin beta-PS;
DE   AltName: Full=Position-specific antigen beta subunit;
DE   AltName: Full=Protein myospheroid;
DE   AltName: Full=Protein olfactory C;
DE   Flags: Precursor;
GN   Name=mys; Synonyms=l(1)mys, olfC; ORFNames=CG1560;
OS   Drosophila melanogaster (Fruit fly).
OC   Eukaryota; Metazoa; Ecdysozoa; Arthropoda; Hexapoda; Insecta;
OC   Pterygota; Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC   Ephydroidea; Drosophilidae; Drosophila; Sophophora.
OX   NCBI_TaxID=7227;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3128792; DOI=10.1073/pnas.85.8.2633;
RA   Mackrell A.J., Blumberg B., Haynes S.R., Fessler J.H.;
RT   "The lethal myospheroid gene of Drosophila encodes a membrane protein
RT   homologous to vertebrate integrin beta subunits.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:2633-2637(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE, FUNCTION, TISSUE SPECIFICITY, AND MUTAGENESIS OF
RP   ASP-807; PHE-811; PHE-814; GLU-817; TYR-831 AND TYR-843.
RC   TISSUE=Embryo, and Imaginal disk;
RX   PubMed=8119134;
RA   Grinblat Y., Zusman S., Yee G., Hynes R.O., Kafatos F.C.;
RT   "Functions of the cytoplasmic domain of the beta PS integrin subunit
RT   during Drosophila development.";
RL   Development 120:91-102(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Berkeley;
RX   PubMed=10731132; DOI=10.1126/science.287.5461.2185;
RA   Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,
RA   Amanatides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galle R.F.,
RA   George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,
RA   Sutton G.G., Wortman J.R., Yandell M.D., Zhang Q., Chen L.X.,
RA   Brandon R.C., Rogers Y.-H.C., Blazej R.G., Champe M., Pfeiffer B.D.,
RA   Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Miklos G.L.G.,
RA   Abril J.F., Agbayani A., An H.-J., Andrews-Pfannkoch C., Baldwin D.,
RA   Ballew R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,
RA   Beeson K.Y., Benos P.V., Berman B.P., Bhandari D., Bolshakov S.,
RA   Borkova D., Botchan M.R., Bouck J., Brokstein P., Brottier P.,
RA   Burtis K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,
RA   Cherry J.M., Cawley S., Dahlke C., Davenport L.B., Davies P.,
RA   de Pablos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,
RA   Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,
RA   Durbin K.J., Evangelista C.C., Ferraz C., Ferriera S., Fleischmann W.,
RA   Fosler C., Gabrielian A.E., Garg N.S., Gelbart W.M., Glasser K.,
RA   Glodek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,
RA   Harris N.L., Harvey D.A., Heiman T.J., Hernandez J.R., Houck J.,
RA   Hostin D., Houston K.A., Howland T.J., Wei M.-H., Ibegwam C.,
RA   Jalali M., Kalush F., Karpen G.H., Ke Z., Kennison J.A., Ketchum K.A.,
RA   Kimmel B.E., Kodira C.D., Kraft C.L., Kravitz S., Kulp D., Lai Z.,
RA   Lasko P., Lei Y., Levitsky A.A., Li J.H., Li Z., Liang Y., Lin X.,
RA   Liu X., Mattei B., McIntosh T.C., McLeod M.P., McPherson D.,
RA   Merkulov G., Milshina N.V., Mobarry C., Morris J., Moshrefi A.,
RA   Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,
RA   Nelson D.R., Nelson K.A., Nixon K., Nusskern D.R., Pacleb J.M.,
RA   Palazzolo M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,
RA   Reinert K., Remington K., Saunders R.D.C., Scheeler F., Shen H.,
RA   Shue B.C., Siden-Kiamos I., Simpson M., Skupski M.P., Smith T.J.,
RA   Spier E., Spradling A.C., Stapleton M., Strong R., Sun E.,
RA   Svirskas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,
RA   Wang Z.-Y., Wassarman D.A., Weinstock G.M., Weissenbach J.,
RA   Williams S.M., Woodage T., Worley K.C., Wu D., Yang S., Yao Q.A.,
RA   Ye J., Yeh R.-F., Zaveri J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,
RA   Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S.C., Zhu X.,
RA   Smith H.O., Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;
RT   "The genome sequence of Drosophila melanogaster.";
RL   Science 287:2185-2195(2000).
RN   [4]
RP   GENOME REANNOTATION.
RC   STRAIN=Berkeley;
RX   PubMed=12537572; DOI=10.1186/gb-2002-3-12-research0083;
RA   Misra S., Crosby M.A., Mungall C.J., Matthews B.B., Campbell K.S.,
RA   Hradecky P., Huang Y., Kaminker J.S., Millburn G.H., Prochnik S.E.,
RA   Smith C.D., Tupy J.L., Whitfield E.J., Bayraktaroglu L., Berman B.P.,
RA   Bettencourt B.R., Celniker S.E., de Grey A.D.N.J., Drysdale R.A.,
RA   Harris N.L., Richter J., Russo S., Schroeder A.J., Shu S.Q.,
RA   Stapleton M., Yamada C., Ashburner M., Gelbart W.M., Rubin G.M.,
RA   Lewis S.E.;
RT   "Annotation of the Drosophila melanogaster euchromatic genome: a
RT   systematic review.";
RL   Genome Biol. 3:RESEARCH0083.1-RESEARCH0083.22(2002).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=Berkeley; TISSUE=Embryo;
RX   PubMed=12537569; DOI=10.1186/gb-2002-3-12-research0080;
RA   Stapleton M., Carlson J.W., Brokstein P., Yu C., Champe M.,
RA   George R.A., Guarin H., Kronmiller B., Pacleb J.M., Park S., Wan K.H.,
RA   Rubin G.M., Celniker S.E.;
RT   "A Drosophila full-length cDNA resource.";
RL   Genome Biol. 3:RESEARCH0080.1-RESEARCH0080.8(2002).
RN   [6]
RP   FUNCTION.
RX   PubMed=7924982;
RA   Fogerty F.J., Fessler L.I., Bunch T.A., Yaron Y., Parker C.G.,
RA   Nelson R.E., Brower D.L., Gullberg D., Fessler J.H.;
RT   "Tiggrin, a novel Drosophila extracellular matrix protein that
RT   functions as a ligand for Drosophila alpha PS2 beta PS integrins.";
RL   Development 120:1747-1758(1994).
RN   [7]
RP   FUNCTION.
RX   PubMed=7972082; DOI=10.1073/pnas.91.24.11447;
RA   Gotwals P.J., Fessler L.I., Wehrli M., Hynes R.O.;
RT   "Drosophila PS1 integrin is a laminin receptor and differs in ligand
RT   specificity from PS2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:11447-11451(1994).
RN   [8]
RP   FUNCTION.
RX   PubMed=9660786; DOI=10.1074/jbc.273.29.18235;
RA   Graner M.W., Bunch T.A., Baumgartner S., Kerschen A., Brower D.L.;
RT   "Splice variants of the Drosophila PS2 integrins differentially
RT   interact with RGD-containing fragments of the extracellular proteins
RT   tiggrin, ten-m, and D-laminin 2.";
RL   J. Biol. Chem. 273:18235-18241(1998).
RN   [9]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=10821184; DOI=10.1007/s004380051194;
RA   Ayyub C., Rodrigues V., Hasan G., Siddiqi O.;
RT   "Genetic analysis of olfC demonstrates a role for the position-
RT   specific integrins in the olfactory system of Drosophila
RT   melanogaster.";
RL   Mol. Gen. Genet. 263:498-504(2000).
RN   [10]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=15469969; DOI=10.1242/dev.01427;
RA   Devenport D., Brown N.H.;
RT   "Morphogenesis in the absence of integrins: mutation of both
RT   Drosophila beta subunits prevents midgut migration.";
RL   Development 131:5405-5415(2004).
RN   [11]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-403; ASN-557 AND ASN-718,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   STRAIN=Oregon-R; TISSUE=Head;
RX   PubMed=17893096; DOI=10.1093/glycob/cwm097;
RA   Koles K., Lim J.-M., Aoki K., Porterfield M., Tiemeyer M., Wells L.,
RA   Panin V.;
RT   "Identification of N-glycosylated proteins from the central nervous
RT   system of Drosophila melanogaster.";
RL   Glycobiology 17:1388-1403(2007).
RN   [12]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=19035354; DOI=10.1002/dvdy.21802;
RA   Dinkins M.B., Fratto V.M., Lemosy E.K.;
RT   "Integrin alpha chains exhibit distinct temporal and spatial
RT   localization patterns in epithelial cells of the Drosophila ovary.";
RL   Dev. Dyn. 237:3927-3939(2008).
RN   [13]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-266; ASN-403; ASN-557 AND
RP   ASN-718, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=19349973; DOI=10.1038/nbt.1532;
RA   Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M.,
RA   Schiess R., Aebersold R., Watts J.D.;
RT   "Mass-spectrometric identification and relative quantification of N-
RT   linked cell surface glycoproteins.";
RL   Nat. Biotechnol. 27:378-386(2009).
CC   -!- FUNCTION: Integrin alpha-PS1/beta-PS is a receptor for laminin.
CC       Integrin alpha-PS2/beta-PS is a receptor for Tig, wb and Ten-m.
CC       Contributes to endodermal integrity and adhesion between the
CC       midgut epithelium and the surrounding visceral muscle. Essential
CC       for migration of the primordial midgut cells and for maintaining,
CC       but not establishing, cell polarity in the midgut epithelium. The
CC       two beta subunits mediate midgut migration by distinct mechanisms:
CC       beta-PS requires rhea/talin and Itgbn does not. Required for
CC       rhea/talin correct cellular localization in the midgut. Required
CC       for many embryonic (dorsal closure and somatic muscle attachments)
CC       and post-embryonic developmental processes (attachment between
CC       cell layers of imaginal disks, organization of ommatidial arrays
CC       and flight muscle development). Involved in the function and/or
CC       development of the olfactory system. Plays a role in timely border
CC       cell migration during oogenesis. {ECO:0000269|PubMed:10821184,
CC       ECO:0000269|PubMed:15469969, ECO:0000269|PubMed:19035354,
CC       ECO:0000269|PubMed:7924982, ECO:0000269|PubMed:7972082,
CC       ECO:0000269|PubMed:8119134, ECO:0000269|PubMed:9660786}.
CC   -!- SUBUNIT: Heterodimer of an alpha and a beta subunit. Beta-PS
CC       associates with either alpha-PS1, alpha-PS2, alpha-PS3, alpha-PS4
CC       or alpha-PS5.
CC   -!- SUBCELLULAR LOCATION: Apical cell membrane
CC       {ECO:0000269|PubMed:19035354}; Single-pass type I membrane protein
CC       {ECO:0000269|PubMed:19035354}. Lateral cell membrane
CC       {ECO:0000269|PubMed:19035354}; Single-pass type I membrane protein
CC       {ECO:0000269|PubMed:19035354}. Basal cell membrane
CC       {ECO:0000269|PubMed:19035354}; Single-pass type I membrane protein
CC       {ECO:0000269|PubMed:19035354}. Note=In ovary, localizes to the
CC       apical, lateral and basal membranes of follicle cells through
CC       oogenesis stage 10A. Apical membrane expression peaks at oogenesis
CC       stages 9 and 10A in columnar follicle cells overlying the oocyte
CC       but decreases in the most posterior follicle cells. Thereafter, it
CC       is down-regulated. Localization to lateral and basal membranes
CC       persists during dorsal appendage morphogenesis.
CC   -!- TISSUE SPECIFICITY: In ovaries, strongly expressed in follicle
CC       cells. In oocytes, expressed in the forming dorsal appendages (at
CC       protein level). Expressed in the embryonic dorsal cuticle, the
CC       larval eye and the wing imaginal disk.
CC       {ECO:0000269|PubMed:19035354, ECO:0000269|PubMed:8119134}.
CC   -!- DISRUPTION PHENOTYPE: In zygotic mutant embryos, midgut forms
CC       primary constrictions but fails to elongate and the visceral
CC       muscle does not flatten but remains attached to the midgut
CC       epithelium. Embryos lacking maternal and zygotic mys show a delay
CC       in midgut migration. Mutant larvae present an olfatory phenotype,
CC       showing reduced response to isoamyl acetate but normal response to
CC       ethyl acetate. {ECO:0000269|PubMed:10821184,
CC       ECO:0000269|PubMed:15469969}.
CC   -!- MISCELLANEOUS: The absence of the beta-PS subunit results in
CC       detachment and rounding up of the muscles, thus the gene encoding
CC       beta-PS is called myospheroid.
CC   -!- SIMILARITY: Belongs to the integrin beta chain family.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 VWFA domain. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J03251; AAA28714.1; -; mRNA.
DR   EMBL; AE014298; AAF46313.2; -; Genomic_DNA.
DR   EMBL; AY113499; AAM29504.1; -; mRNA.
DR   PIR; A30889; A30889.
DR   RefSeq; NP_001284998.1; NM_001298069.1.
DR   RefSeq; NP_001284999.1; NM_001298070.1.
DR   RefSeq; NP_524793.2; NM_080054.3.
DR   UniGene; Dm.1814; -.
DR   ProteinModelPortal; P11584; -.
DR   SMR; P11584; 149-771, 800-832.
DR   BioGrid; 69357; 18.
DR   IntAct; P11584; 1.
DR   STRING; 7227.FBpp0071061; -.
DR   PaxDb; P11584; -.
DR   PRIDE; P11584; -.
DR   EnsemblMetazoa; FBtr0071105; FBpp0071061; FBgn0004657.
DR   EnsemblMetazoa; FBtr0340136; FBpp0309122; FBgn0004657.
DR   EnsemblMetazoa; FBtr0340137; FBpp0309123; FBgn0004657.
DR   GeneID; 44885; -.
DR   CTD; 44885; -.
DR   FlyBase; FBgn0004657; mys.
DR   eggNOG; KOG1226; Eukaryota.
DR   eggNOG; ENOG410XP60; LUCA.
DR   InParanoid; P11584; -.
DR   OMA; ADENRCL; -.
DR   OrthoDB; EOG7T7GSB; -.
DR   PhylomeDB; P11584; -.
DR   Reactome; R-DME-114608; Platelet degranulation.
DR   Reactome; R-DME-1236973; Cross-presentation of particulate exogenous antigens (phagosomes).
DR   Reactome; R-DME-1566948; Elastic fibre formation.
DR   Reactome; R-DME-210991; Basigin interactions.
DR   Reactome; R-DME-2129379; Molecules associated with elastic fibres.
DR   Reactome; R-DME-216083; Integrin cell surface interactions.
DR   Reactome; R-DME-3000157; Laminin interactions.
DR   Reactome; R-DME-3000170; Syndecan interactions.
DR   Reactome; R-DME-3000178; ECM proteoglycans.
DR   Reactome; R-DME-354192; Integrin alphaIIb beta3 signaling.
DR   Reactome; R-DME-354194; GRB2:SOS provides linkage to MAPK signaling for Integrins.
DR   Reactome; R-DME-372708; p130Cas linkage to MAPK signaling for integrins.
DR   Reactome; R-DME-445144; Signal transduction by L1.
DR   Reactome; R-DME-446343; Localization of the PINCH-ILK-PARVIN complex to focal adhesions.
DR   ChiTaRS; mys; fly.
DR   GenomeRNAi; 44885; -.
DR   NextBio; 837783; -.
DR   PRO; PR:P11584; -.
DR   Proteomes; UP000000803; Chromosome X.
DR   Bgee; P11584; -.
DR   Genevisible; P11584; DM.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0009925; C:basal plasma membrane; IDA:UniProtKB.
DR   GO; GO:0031252; C:cell leading edge; IDA:FlyBase.
DR   GO; GO:0043034; C:costamere; IDA:FlyBase.
DR   GO; GO:0005925; C:focal adhesion; IDA:FlyBase.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:FlyBase.
DR   GO; GO:0008305; C:integrin complex; IDA:FlyBase.
DR   GO; GO:0016328; C:lateral plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005927; C:muscle tendon junction; IDA:FlyBase.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0050839; F:cell adhesion molecule binding; TAS:FlyBase.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:FlyBase.
DR   GO; GO:0004872; F:receptor activity; TAS:FlyBase.
DR   GO; GO:0007015; P:actin filament organization; IMP:FlyBase.
DR   GO; GO:0007475; P:apposition of dorsal and ventral imaginal disc-derived wing surfaces; NAS:FlyBase.
DR   GO; GO:0007411; P:axon guidance; IMP:FlyBase.
DR   GO; GO:0007298; P:border follicle cell migration; IMP:FlyBase.
DR   GO; GO:0016339; P:calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules; TAS:FlyBase.
DR   GO; GO:0016340; P:calcium-dependent cell-matrix adhesion; ISS:FlyBase.
DR   GO; GO:0007155; P:cell adhesion; IMP:FlyBase.
DR   GO; GO:0033627; P:cell adhesion mediated by integrin; IDA:FlyBase.
DR   GO; GO:0016477; P:cell migration; TAS:FlyBase.
DR   GO; GO:0007160; P:cell-matrix adhesion; TAS:FlyBase.
DR   GO; GO:0031589; P:cell-substrate adhesion; IMP:FlyBase.
DR   GO; GO:0007417; P:central nervous system development; IMP:FlyBase.
DR   GO; GO:0021551; P:central nervous system morphogenesis; IMP:FlyBase.
DR   GO; GO:0008340; P:determination of adult lifespan; IMP:FlyBase.
DR   GO; GO:0007391; P:dorsal closure; IMP:FlyBase.
DR   GO; GO:0035001; P:dorsal trunk growth, open tracheal system; IMP:FlyBase.
DR   GO; GO:0007427; P:epithelial cell migration, open tracheal system; TAS:FlyBase.
DR   GO; GO:0007629; P:flight behavior; IEA:UniProtKB-KW.
DR   GO; GO:0007377; P:germ-band extension; IMP:FlyBase.
DR   GO; GO:0030718; P:germ-line stem cell population maintenance; IMP:FlyBase.
DR   GO; GO:0035099; P:hemocyte migration; IGI:FlyBase.
DR   GO; GO:0007157; P:heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules; TAS:FlyBase.
DR   GO; GO:0048803; P:imaginal disc-derived male genitalia morphogenesis; IMP:FlyBase.
DR   GO; GO:0007229; P:integrin-mediated signaling pathway; IEA:UniProtKB-KW.
DR   GO; GO:0007508; P:larval heart development; IMP:FlyBase.
DR   GO; GO:0035160; P:maintenance of epithelial integrity, open tracheal system; IMP:FlyBase.
DR   GO; GO:0007494; P:midgut development; TAS:FlyBase.
DR   GO; GO:0016203; P:muscle attachment; IMP:FlyBase.
DR   GO; GO:0007517; P:muscle organ development; IMP:FlyBase.
DR   GO; GO:0030336; P:negative regulation of cell migration; IMP:UniProtKB.
DR   GO; GO:0003344; P:pericardium morphogenesis; IMP:FlyBase.
DR   GO; GO:0008360; P:regulation of cell shape; IMP:FlyBase.
DR   GO; GO:0051492; P:regulation of stress fiber assembly; IMP:FlyBase.
DR   GO; GO:0007431; P:salivary gland development; IMP:FlyBase.
DR   GO; GO:0045214; P:sarcomere organization; IMP:FlyBase.
DR   GO; GO:0007608; P:sensory perception of smell; IMP:FlyBase.
DR   GO; GO:0034446; P:substrate adhesion-dependent cell spreading; IDA:FlyBase.
DR   GO; GO:0006930; P:substrate-dependent cell migration, cell extension; IGI:FlyBase.
DR   GO; GO:0007426; P:tracheal outgrowth, open tracheal system; TAS:FlyBase.
DR   GO; GO:0007601; P:visual perception; IEA:UniProtKB-KW.
DR   Gene3D; 1.20.5.630; -; 1.
DR   Gene3D; 3.40.50.410; -; 1.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR013111; EGF_extracell.
DR   InterPro; IPR015812; Integrin_bsu.
DR   InterPro; IPR014836; Integrin_bsu_cyt_dom.
DR   InterPro; IPR002369; Integrin_bsu_N.
DR   InterPro; IPR012896; Integrin_bsu_tail.
DR   InterPro; IPR032695; Integrin_dom.
DR   InterPro; IPR016201; Plexin-like_fold.
DR   InterPro; IPR002035; VWF_A.
DR   PANTHER; PTHR10082; PTHR10082; 2.
DR   Pfam; PF07974; EGF_2; 1.
DR   Pfam; PF08725; Integrin_b_cyt; 1.
DR   Pfam; PF07965; Integrin_B_tail; 1.
DR   Pfam; PF00362; Integrin_beta; 1.
DR   PIRSF; PIRSF002512; Integrin_B; 1.
DR   PRINTS; PR01186; INTEGRINB.
DR   SMART; SM00181; EGF; 1.
DR   SMART; SM00187; INB; 1.
DR   SMART; SM00423; PSI; 1.
DR   SMART; SM00327; VWA; 1.
DR   SUPFAM; SSF103575; SSF103575; 1.
DR   SUPFAM; SSF53300; SSF53300; 1.
DR   SUPFAM; SSF69179; SSF69179; 1.
DR   SUPFAM; SSF69687; SSF69687; 1.
DR   PROSITE; PS00022; EGF_1; 2.
DR   PROSITE; PS01186; EGF_2; 1.
DR   PROSITE; PS00243; INTEGRIN_BETA; 3.
PE   1: Evidence at protein level;
KW   Behavior; Cell adhesion; Cell membrane; Complete proteome;
KW   Developmental protein; Disulfide bond; Flight; Glycoprotein; Integrin;
KW   Membrane; Olfaction; Phosphoprotein; Receptor; Reference proteome;
KW   Repeat; Sensory transduction; Signal; Transmembrane;
KW   Transmembrane helix; Vision.
FT   SIGNAL        1     23       {ECO:0000255}.
FT   CHAIN        24    846       Integrin beta-PS.
FT                                /FTId=PRO_0000016356.
FT   TOPO_DOM     24    776       Extracellular. {ECO:0000255}.
FT   TRANSMEM    777    799       Helical. {ECO:0000255}.
FT   TOPO_DOM    800    846       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      186    419       VWFA.
FT   REPEAT      507    560       I.
FT   REPEAT      561    605       II.
FT   REPEAT      606    646       III.
FT   REPEAT      647    687       IV.
FT   REGION      507    687       Cysteine-rich tandem repeats.
FT   COMPBIAS    115    143       Ser-rich.
FT   MOD_RES     831    831       Phosphotyrosine. {ECO:0000250}.
FT   MOD_RES     843    843       Phosphotyrosine. {ECO:0000250}.
FT   CARBOHYD     72     72       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    266    266       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19349973}.
FT   CARBOHYD    277    277       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    403    403       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17893096,
FT                                ECO:0000269|PubMed:19349973}.
FT   CARBOHYD    428    428       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    557    557       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17893096,
FT                                ECO:0000269|PubMed:19349973}.
FT   CARBOHYD    603    603       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    644    644       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    718    718       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17893096,
FT                                ECO:0000269|PubMed:19349973}.
FT   DISULFID     46     55       {ECO:0000250}.
FT   DISULFID    249    252       {ECO:0000250}.
FT   DISULFID    300    341       {ECO:0000250}.
FT   DISULFID    441    453       {ECO:0000250}.
FT   DISULFID    473    741       {ECO:0000250}.
FT   DISULFID    503    507       {ECO:0000250}.
FT   DISULFID    522    533       {ECO:0000250}.
FT   DISULFID    530    571       {ECO:0000250}.
FT   DISULFID    535    544       {ECO:0000250}.
FT   DISULFID    546    561       {ECO:0000250}.
FT   DISULFID    584    599       {ECO:0000250}.
FT   DISULFID    601    606       {ECO:0000250}.
FT   DISULFID    622    627       {ECO:0000250}.
FT   DISULFID    624    656       {ECO:0000250}.
FT   DISULFID    629    638       {ECO:0000250}.
FT   DISULFID    640    647       {ECO:0000250}.
FT   DISULFID    662    667       {ECO:0000250}.
FT   DISULFID    664    715       {ECO:0000250}.
FT   DISULFID    669    682       {ECO:0000250}.
FT   DISULFID    685    688       {ECO:0000250}.
FT   DISULFID    692    701       {ECO:0000250}.
FT   DISULFID    698    771       {ECO:0000250}.
FT   DISULFID    719    749       {ECO:0000250}.
FT   MUTAGEN     807    807       D->A: Rescues dorsal closure defect,
FT                                muscle attachment defect, disorganized
FT                                ommatidial array and loss of cell layer
FT                                attachment in mutants; when associated
FT                                with A-817. {ECO:0000269|PubMed:8119134}.
FT   MUTAGEN     811    811       F->A: Rescues muscle attachment defect
FT                                and loss of cell layer attachment in
FT                                mutants; when associated with A-814.
FT                                {ECO:0000269|PubMed:8119134}.
FT   MUTAGEN     814    814       F->A: Rescues muscle attachment defect
FT                                and loss of cell layer attachment in
FT                                mutants; when associated with A-811.
FT                                {ECO:0000269|PubMed:8119134}.
FT   MUTAGEN     817    817       E->A: Rescues dorsal closure defect,
FT                                muscle attachment defects, disorganized
FT                                ommatidial array and loss of cell layer
FT                                attachment in mutants; when associated
FT                                with A-807. {ECO:0000269|PubMed:8119134}.
FT   MUTAGEN     831    831       Y->A: No effect on lethality; when
FT                                associated with A-843.
FT                                {ECO:0000269|PubMed:8119134}.
FT   MUTAGEN     843    843       Y->A: No effect on lethality; when
FT                                associated with A-831.
FT                                {ECO:0000269|PubMed:8119134}.
FT   CONFLICT     18     18       I -> M (in Ref. 1; AAA28714).
FT                                {ECO:0000305}.
FT   CONFLICT     24     24       G -> A (in Ref. 1; AAA28714).
FT                                {ECO:0000305}.
FT   CONFLICT     27     27       D -> N (in Ref. 1; AAA28714).
FT                                {ECO:0000305}.
SQ   SEQUENCE   846 AA;  92656 MW;  3618C74FA1B99AFB CRC64;
     MILERNRRCQ LALLMIAILA AIAGQTDAQK AAKLTAVSTC ASKEKCHTCI QTEGCAWCMQ
     PDFKGQSRCY QNTSSLCPEE FAYSPITVEQ ILVNNKLTNQ YKAELAAGGG GSAMSGSSSS
     SYSSSSSSSS FYSQSSSGSS SASGYEEYSA GEIVQIQPQS MRLALRVNEK HNIKISYSQA
     EGYPVDLYYL MDLSKSMEDD KAKLSTLGDK LSETMKRITN NFHLGFGSFV DKVLMPYVST
     IPKKLEHPCE NCKAPYGYQN HMPLNNNTES FSNEVKNATV SGNLDAPEGG FDAIMQAIAC
     RSQIGWREQA RRLLVFSTDA GFHYAGDGKL GGVIAPNDGE CHLSPKGEYT HSTLQDYPSI
     SQINQKVKDN AINIIFAVTA SQLSVYEKLV EHIQGSSAAK LDNDSSNVVE LVKEEYRKIS
     SSVEMKDNAT GDVKITYFSS CLSNGPEVQT SKCDNLKEGQ QVSFTAQIQL LKCPEDPRDW
     TQTIHISPVG INEVMQIQLT MLCSCPCENP GSIGYQVQAN SCSGHGTSMC GICNCDDSYF
     GNKCECSATD LTSKFANDTS CRADSTSTTD CSGRGHCVCG ACECHKRPNP IEIISGKHCE
     CDNFSCERNR NQLCSGPDHG TCECGRCKCK PGWTGSNCGC QESNDTCMPP GGGEICSGHG
     TCECGVCKCT VNDQGRFSGR HCEKCPTCSG RCQELKDCVQ CQMYKTGELK NGDDCARNCT
     QFVPVGVEKV EIDETKDEQM CKFFDEDDCK FMFKYSEQGE LHVYAQENKE CPAKVFMLGI
     VMGVIAAIVL VGLAILLLWK LLTTIHDRRE FARFEKERMN AKWDTGENPI YKQATSTFKN
     PMYAGK
//
ID   PTPRC_MOUSE             Reviewed;        1291 AA.
AC   P06800; E9QLT5; Q61812; Q61813; Q61814; Q61815; Q78EF1;
DT   01-JAN-1988, integrated into UniProtKB/Swiss-Prot.
DT   27-JUL-2011, sequence version 3.
DT   17-FEB-2016, entry version 169.
DE   RecName: Full=Receptor-type tyrosine-protein phosphatase C;
DE            EC=3.1.3.48;
DE   AltName: Full=Leukocyte common antigen;
DE            Short=L-CA;
DE   AltName: Full=Lymphocyte antigen 5;
DE            Short=Ly-5;
DE   AltName: Full=T200;
DE   AltName: CD_antigen=CD45;
DE   Flags: Precursor;
GN   Name=Ptprc; Synonyms=Ly-5;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RX   PubMed=2944116; DOI=10.1073/pnas.83.18.6940;
RA   Saga Y., Tung J.-S., Shen F.-W., Boyse E.A.;
RT   "Sequences of Ly-5 cDNA: isoform-related diversity of Ly-5 mRNA.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:6940-6944(1986).
RN   [2]
RP   ERRATUM, AND SEQUENCE REVISION.
RA   Saga Y., Tung J.-S., Shen F.-W., Boyse E.A.;
RL   Proc. Natl. Acad. Sci. U.S.A. 84:1991-1991(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   STRAIN=BALB/cJ;
RX   PubMed=1822988; DOI=10.1155/1991/52686;
RA   Zebedee S.L., Barritt D.S., Raschke W.C.;
RT   "Comparison of mouse Ly5a and Ly5b leucocyte common antigen alleles.";
RL   Dev. Immunol. 1:243-254(1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=C57BL/6J;
RX   PubMed=19468303; DOI=10.1371/journal.pbio.1000112;
RA   Church D.M., Goodstadt L., Hillier L.W., Zody M.C., Goldstein S.,
RA   She X., Bult C.J., Agarwala R., Cherry J.L., DiCuccio M., Hlavina W.,
RA   Kapustin Y., Meric P., Maglott D., Birtle Z., Marques A.C., Graves T.,
RA   Zhou S., Teague B., Potamousis K., Churas C., Place M., Herschleb J.,
RA   Runnheim R., Forrest D., Amos-Landgraf J., Schwartz D.C., Cheng Z.,
RA   Lindblad-Toh K., Eichler E.E., Ponting C.P.;
RT   "Lineage-specific biology revealed by a finished genome assembly of
RT   the mouse.";
RL   PLoS Biol. 7:E1000112-E1000112(2009).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-226 (ISOFORM 2).
RX   PubMed=3037546; DOI=10.1073/pnas.84.15.5364;
RA   Saga Y., Tung J.-S., Shen F.-W.W., Boyse E.A.;
RT   "Alternative use of 5' exons in the specification of Ly-5 isoforms
RT   distinguishing hematopoietic cell lineages.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:5364-5368(1987).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-22.
RX   PubMed=3211131;
RA   Saga Y., Tung J.-S., Shen F.-W.W., Pancoast T.C., Boyse E.A.;
RT   "Organization of the Ly-5 gene.";
RL   Mol. Cell. Biol. 8:4889-4895(1988).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-22.
RX   PubMed=2522930;
RA   Johnson N.A., Meyer C.M., Pingel J.T., Thomas M.L.;
RT   "Sequence conservation in potential regulatory regions of the mouse
RT   and human leukocyte common antigen gene.";
RL   J. Biol. Chem. 264:6220-6229(1989).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 10-263 (ISOFORM 3).
RC   TISSUE=T-cell;
RX   PubMed=3864163; DOI=10.1073/pnas.82.21.7360;
RA   Shen F.-W., Saga Y., Litman G., Freeman G., Tung J.-S., Cantor H.,
RA   Boyse E.A.;
RT   "Cloning of Ly-5 cDNA.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:7360-7363(1985).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 31-73.
RX   PubMed=3417340; DOI=10.1007/BF00345505;
RA   Tung J.-S., Saga Y., Boyse E.A.;
RT   "Structural features of Ly-5 glycoproteins of the mouse and
RT   counterparts in other mammals.";
RL   Immunogenetics 28:271-277(1988).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 730-838.
RX   PubMed=1932742;
RA   Yi T., Cleveland J.L., Ihle J.N.;
RT   "Identification of novel protein tyrosine phosphatases of
RT   hematopoietic cells by polymerase chain reaction amplification.";
RL   Blood 78:2222-2228(1991).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 961-1291.
RX   PubMed=2948186; DOI=10.1073/pnas.84.1.161;
RA   Raschke W.C.;
RT   "Cloned murine T200 (Ly-5) cDNA reveals multiple transcripts within B-
RT   and T-lymphocyte lineages.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:161-165(1987).
RN   [12]
RP   PARTIAL PROTEIN SEQUENCE.
RX   PubMed=3570377; DOI=10.1007/BF00404697;
RA   Gonez L.J., Walker I.D., Sandrin M.S., McKenzie I.F.;
RT   "High sequence conservation between rat (T200) and mouse (Ly-5)
RT   leukocyte common antigens.";
RL   Immunogenetics 25:263-266(1987).
RN   [13]
RP   INTERACTION WITH GANAB AND PRKCSH.
RX   PubMed=9148925; DOI=10.1074/jbc.272.20.13117;
RA   Arendt C.W., Ostergaard H.L.;
RT   "Identification of the CD45-associated 116-kDa and 80-kDa proteins as
RT   the alpha- and beta-subunits of alpha-glucosidase II.";
RL   J. Biol. Chem. 272:13117-13125(1997).
RN   [14]
RP   FUNCTION.
RX   PubMed=10415030;
RA   Katagiri T., Ogimoto M., Hasegawa K., Arimura Y., Mitomo K., Okada M.,
RA   Clark M.R., Mizuno K., Yakura H.;
RT   "CD45 negatively regulates lyn activity by dephosphorylating both
RT   positive and negative regulatory tyrosine residues in immature B
RT   cells.";
RL   J. Immunol. 163:1321-1326(1999).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-962, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19144319; DOI=10.1016/j.immuni.2008.11.006;
RA   Trost M., English L., Lemieux S., Courcelles M., Desjardins M.,
RA   Thibault P.;
RT   "The phagosomal proteome in interferon-gamma-activated macrophages.";
RL   Immunity 30:143-154(2009).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-962; SER-992; THR-1265
RP   AND SER-1284, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Brain, Brown adipose tissue, Heart, Kidney, Liver, Lung,
RC   Pancreas, Spleen, and Testis;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and
RT   expression.";
RL   Cell 143:1174-1189(2010).
CC   -!- FUNCTION: Protein tyrosine-protein phosphatase required for T-cell
CC       activation through the antigen receptor. Acts as a positive
CC       regulator of T-cell coactivation upon binding to DPP4. The first
CC       PTPase domain has enzymatic activity, while the second one seems
CC       to affect the substrate specificity of the first one. Upon T-cell
CC       activation, recruits and dephosphorylates SKAP1 and FYN (By
CC       similarity). Dephosphorylates LYN, and thereby modulates LYN
CC       activity. {ECO:0000250, ECO:0000269|PubMed:10415030}.
CC   -!- CATALYTIC ACTIVITY: Protein tyrosine phosphate + H(2)O = protein
CC       tyrosine + phosphate. {ECO:0000255|PROSITE-ProRule:PRU10044}.
CC   -!- SUBUNIT: Interacts with SKAP1. Interacts with DPP4; the
CC       interaction is enhanced in a interleukin-12-dependent manner in
CC       activated lymphocytes (By similarity). Binds GANAB and PRKCSH.
CC       {ECO:0000250, ECO:0000269|PubMed:9148925}.
CC   -!- INTERACTION:
CC       P06240:Lck; NbExp=3; IntAct=EBI-1672, EBI-1401;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein. Membrane raft {ECO:0000250}. Note=Colocalized with DPP4
CC       in membrane rafts. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=B220;
CC         IsoId=P06800-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P06800-2; Sequence=VSP_012441;
CC       Name=3;
CC         IsoId=P06800-3; Sequence=VSP_012442;
CC   -!- DEVELOPMENTAL STAGE: Expression is restricted to the hematopoietic
CC       compartment of development.
CC   -!- DOMAIN: The first PTPase domain interacts with SKAP1.
CC       {ECO:0000250}.
CC   -!- PTM: Heavily N- and O-glycosylated.
CC   -!- SIMILARITY: Belongs to the protein-tyrosine phosphatase family.
CC       Receptor class 1/6 subfamily. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 2 fibronectin type-III domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00316}.
CC   -!- SIMILARITY: Contains 2 tyrosine-protein phosphatase domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00160}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA39462.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M14342; AAA39458.1; -; mRNA.
DR   EMBL; M92933; AAA39459.1; -; mRNA.
DR   EMBL; AC122903; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC159278; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M17320; AAA60449.1; -; mRNA.
DR   EMBL; M23354; AAA39462.1; ALT_INIT; Genomic_DNA.
DR   EMBL; M22456; AAB46374.1; -; Genomic_DNA.
DR   EMBL; M11934; AAA39461.1; -; mRNA.
DR   EMBL; M23241; AAA39460.1; -; Genomic_DNA.
DR   EMBL; M15174; AAA40161.1; -; mRNA.
DR   PIR; A23329; A23329.
DR   PIR; A28334; A28334.
DR   PIR; A28335; A28335.
DR   PIR; I57644; I57644.
DR   UniGene; Mm.391573; -.
DR   ProteinModelPortal; P06800; -.
DR   SMR; P06800; 612-1216.
DR   IntAct; P06800; 8.
DR   MINT; MINT-188397; -.
DR   STRING; 10090.ENSMUSP00000027645; -.
DR   iPTMnet; P06800; -.
DR   PhosphoSite; P06800; -.
DR   SwissPalm; P06800; -.
DR   MaxQB; P06800; -.
DR   PaxDb; P06800; -.
DR   PRIDE; P06800; -.
DR   DNASU; 19264; -.
DR   UCSC; uc007cvf.3; mouse. [P06800-1]
DR   MGI; MGI:97810; Ptprc.
DR   eggNOG; KOG4228; Eukaryota.
DR   eggNOG; COG5599; LUCA.
DR   HOVERGEN; HBG000066; -.
DR   InParanoid; P06800; -.
DR   OrthoDB; EOG7XSTCW; -.
DR   TreeFam; TF351829; -.
DR   NextBio; 296132; -.
DR   PRO; PR:P06800; -.
DR   Proteomes; UP000000589; Unplaced.
DR   Bgee; P06800; -.
DR   CleanEx; MM_PTPRC; -.
DR   GO; GO:0071944; C:cell periphery; IDA:MGI.
DR   GO; GO:0009986; C:cell surface; IDA:MGI.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:MGI.
DR   GO; GO:0070062; C:extracellular exosome; ISO:MGI.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; ISS:UniProtKB.
DR   GO; GO:0005622; C:intracellular; IDA:GOC.
DR   GO; GO:0016020; C:membrane; ISO:MGI.
DR   GO; GO:0045121; C:membrane raft; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:MGI.
DR   GO; GO:0043395; F:heparan sulfate proteoglycan binding; IDA:MGI.
DR   GO; GO:0008201; F:heparin binding; IDA:MGI.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0004725; F:protein tyrosine phosphatase activity; ISS:UniProtKB.
DR   GO; GO:0000187; P:activation of MAPK activity; IMP:MGI.
DR   GO; GO:0030183; P:B cell differentiation; IMP:MGI.
DR   GO; GO:0042100; P:B cell proliferation; IMP:UniProtKB.
DR   GO; GO:0050853; P:B cell receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0048539; P:bone marrow development; ISO:MGI.
DR   GO; GO:0044770; P:cell cycle phase transition; ISO:MGI.
DR   GO; GO:0051607; P:defense response to virus; IMP:UniProtKB.
DR   GO; GO:0016311; P:dephosphorylation; IDA:UniProtKB.
DR   GO; GO:0002244; P:hematopoietic progenitor cell differentiation; ISO:MGI.
DR   GO; GO:0034113; P:heterotypic cell-cell adhesion; IMP:MGI.
DR   GO; GO:0002378; P:immunoglobulin biosynthetic process; ISO:MGI.
DR   GO; GO:0007159; P:leukocyte cell-cell adhesion; IMP:MGI.
DR   GO; GO:0006933; P:negative regulation of cell adhesion involved in substrate-bound cell migration; ISO:MGI.
DR   GO; GO:0001960; P:negative regulation of cytokine-mediated signaling pathway; IDA:UniProtKB.
DR   GO; GO:0050732; P:negative regulation of peptidyl-tyrosine phosphorylation; IMP:MGI.
DR   GO; GO:0031953; P:negative regulation of protein autophosphorylation; IMP:MGI.
DR   GO; GO:0006469; P:negative regulation of protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0001915; P:negative regulation of T cell mediated cytotoxicity; IMP:UniProtKB.
DR   GO; GO:0045060; P:negative thymic T cell selection; IMP:MGI.
DR   GO; GO:0035335; P:peptidyl-tyrosine dephosphorylation; ISO:MGI.
DR   GO; GO:0046641; P:positive regulation of alpha-beta T cell proliferation; IMP:MGI.
DR   GO; GO:0050857; P:positive regulation of antigen receptor-mediated signaling pathway; IMP:UniProtKB.
DR   GO; GO:0030890; P:positive regulation of B cell proliferation; IMP:MGI.
DR   GO; GO:2001238; P:positive regulation of extrinsic apoptotic signaling pathway; IMP:MGI.
DR   GO; GO:0045588; P:positive regulation of gamma-delta T cell differentiation; IMP:MGI.
DR   GO; GO:2000473; P:positive regulation of hematopoietic stem cell migration; ISO:MGI.
DR   GO; GO:0002925; P:positive regulation of humoral immune response mediated by circulating immunoglobulin; IMP:MGI.
DR   GO; GO:0048304; P:positive regulation of isotype switching to IgG isotypes; IMP:MGI.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IMP:MGI.
DR   GO; GO:2000648; P:positive regulation of stem cell proliferation; ISO:MGI.
DR   GO; GO:0045582; P:positive regulation of T cell differentiation; IMP:MGI.
DR   GO; GO:0001916; P:positive regulation of T cell mediated cytotoxicity; IMP:MGI.
DR   GO; GO:0002711; P:positive regulation of T cell mediated immunity; IMP:MGI.
DR   GO; GO:0042102; P:positive regulation of T cell proliferation; IMP:UniProtKB.
DR   GO; GO:0045059; P:positive thymic T cell selection; IMP:MGI.
DR   GO; GO:0006470; P:protein dephosphorylation; IDA:UniProtKB.
DR   GO; GO:0045577; P:regulation of B cell differentiation; IMP:MGI.
DR   GO; GO:0050855; P:regulation of B cell receptor signaling pathway; IMP:MGI.
DR   GO; GO:0051726; P:regulation of cell cycle; IDA:UniProtKB.
DR   GO; GO:2001236; P:regulation of extrinsic apoptotic signaling pathway; IMP:MGI.
DR   GO; GO:0002923; P:regulation of humoral immune response mediated by circulating immunoglobulin; IMP:MGI.
DR   GO; GO:0051209; P:release of sequestered calcium ion into cytosol; IDA:UniProtKB.
DR   GO; GO:0048864; P:stem cell development; ISO:MGI.
DR   GO; GO:0030217; P:T cell differentiation; IMP:UniProtKB.
DR   GO; GO:0042098; P:T cell proliferation; IMP:MGI.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; ISS:UniProtKB.
DR   Gene3D; 2.60.40.10; -; 2.
DR   Gene3D; 3.90.190.10; -; 2.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR029021; Prot-tyrosine_phosphatase-like.
DR   InterPro; IPR024739; PTP_recept_N.
DR   InterPro; IPR000242; PTPase_domain.
DR   InterPro; IPR016335; Ptprc.
DR   InterPro; IPR016130; Tyr_Pase_AS.
DR   InterPro; IPR000387; TYR_PHOSPHATASE_dom.
DR   Pfam; PF12567; CD45; 1.
DR   Pfam; PF12453; PTP_N; 1.
DR   Pfam; PF00102; Y_phosphatase; 2.
DR   PIRSF; PIRSF002004; Leukocyte_common_antigen; 1.
DR   PRINTS; PR00700; PRTYPHPHTASE.
DR   SMART; SM00060; FN3; 2.
DR   SMART; SM00194; PTPc; 2.
DR   SUPFAM; SSF49265; SSF49265; 2.
DR   SUPFAM; SSF52799; SSF52799; 2.
DR   PROSITE; PS50853; FN3; 2.
DR   PROSITE; PS00383; TYR_PHOSPHATASE_1; 1.
DR   PROSITE; PS50056; TYR_PHOSPHATASE_2; 2.
DR   PROSITE; PS50055; TYR_PHOSPHATASE_PTP; 2.
PE   1: Evidence at protein level;
KW   Alternative splicing; Complete proteome; Direct protein sequencing;
KW   Glycoprotein; Hydrolase; Membrane; Phosphoprotein;
KW   Protein phosphatase; Reference proteome; Repeat; Signal;
KW   Transmembrane; Transmembrane helix.
FT   SIGNAL        1     23
FT   CHAIN        24   1291       Receptor-type tyrosine-protein
FT                                phosphatase C.
FT                                /FTId=PRO_0000025471.
FT   TOPO_DOM     24    564       Extracellular. {ECO:0000255}.
FT   TRANSMEM    565    586       Helical. {ECO:0000255}.
FT   TOPO_DOM    587   1291       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      374    470       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      471    566       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      640    899       Tyrosine-protein phosphatase 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00160}.
FT   DOMAIN      931   1214       Tyrosine-protein phosphatase 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00160}.
FT   REGION      840    846       Substrate binding. {ECO:0000250}.
FT   ACT_SITE    840    840       Phosphocysteine intermediate.
FT                                {ECO:0000250}.
FT   ACT_SITE   1155   1155       Phosphocysteine intermediate.
FT                                {ECO:0000250}.
FT   BINDING     808    808       Substrate. {ECO:0000250}.
FT   BINDING     884    884       Substrate. {ECO:0000250}.
FT   MOD_RES     670    670       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P04157}.
FT   MOD_RES     962    962       Phosphoserine.
FT                                {ECO:0000244|PubMed:19144319,
FT                                ECO:0000244|PubMed:21183079}.
FT   MOD_RES     981    981       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P04157}.
FT   MOD_RES     984    984       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P04157}.
FT   MOD_RES     988    988       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P04157}.
FT   MOD_RES     991    991       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P04157}.
FT   MOD_RES     992    992       Phosphoserine.
FT                                {ECO:0000244|PubMed:21183079}.
FT   MOD_RES     996    996       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P04157}.
FT   MOD_RES    1227   1227       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P04157}.
FT   MOD_RES    1265   1265       Phosphothreonine.
FT                                {ECO:0000244|PubMed:21183079}.
FT   MOD_RES    1284   1284       Phosphoserine.
FT                                {ECO:0000244|PubMed:21183079}.
FT   CARBOHYD     64     64       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    150    150       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    161    161       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    207    207       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    211    211       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    218    218       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    253    253       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    258    258       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    290    290       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    311    311       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    322    322       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    347    347       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    416    416       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    427    427       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    457    457       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    489    489       N-linked (GlcNAc...). {ECO:0000255}.
FT   VAR_SEQ      31    169       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:2944116,
FT                                ECO:0000303|PubMed:3864163}.
FT                                /FTId=VSP_012442.
FT   VAR_SEQ      31     73       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:3037546}.
FT                                /FTId=VSP_012441.
FT   CONFLICT    300    300       K -> E (in Ref. 3; AAA39459).
FT                                {ECO:0000305}.
FT   CONFLICT    398    398       V -> A (in Ref. 3; AAA39459).
FT                                {ECO:0000305}.
FT   CONFLICT    402    403       ES -> DP (in Ref. 3; AAA39459).
FT                                {ECO:0000305}.
FT   CONFLICT    476    476       N -> T (in Ref. 3; AAA39459).
FT                                {ECO:0000305}.
FT   CONFLICT    518    520       KYN -> NTT (in Ref. 1; AAA39458).
FT                                {ECO:0000305}.
FT   CONFLICT    528    528       V -> G (in Ref. 1; AAA39458).
FT                                {ECO:0000305}.
FT   CONFLICT    556    556       N -> S (in Ref. 1; AAA39458).
FT                                {ECO:0000305}.
FT   CONFLICT    588    588       I -> S (in Ref. 1; AAA39458).
FT                                {ECO:0000305}.
FT   CONFLICT    906    906       E -> Q (in Ref. 1; AAA39458).
FT                                {ECO:0000305}.
FT   CONFLICT    931    931       L -> R (in Ref. 1; AAA39458).
FT                                {ECO:0000305}.
FT   CONFLICT    953    953       E -> G (in Ref. 1; AAA39458).
FT                                {ECO:0000305}.
FT   CONFLICT    959    959       N -> K (in Ref. 1; AAA39458).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1291 AA;  144604 MW;  ED752FD195BA9643 CRC64;
     MGLWLKLLAF GFALLDTEVF VTGQTPTPSD ELSTTENALL LPQSDPLPAR TTESTPPSIS
     ERGNGSSETT YHPGVLSTLL PHLSPQPDSQ TPSAGGADTQ TFSSQADNPT LTPAPGGGTD
     PPGVPGERTV PGTIPADTAF PVDTPSLARN SSAASPTHTS NVSTTDISSG ASLTTLTPST
     LGLASTDPPS TTIATTTKQT CAAMFGNITV NYTYESSNQT FKADLKDVQN AKCGNEDCEN
     VLNNLEECSQ IKNISVSNDS CAPATTIDLY VPPGTDKFSL HDCTPKEKAN TSICLEWKTK
     NLDFRKCNSD NISYVLHCEP ENNTKCIRRN TFIPERCQLD NLRAQTNYTC VAEILYRGVK
     LVKNVINVQT DLGIPETPKP SCGDPAARKT LVSWPEPVSK PESASKPHGY VLCYKNNSEK
     CKSLPNNVTS FEVESLKPYK YYEVSLLAYV NGKIQRNGTA EKCNFHTKAD RPDKVNGMKT
     SRPTDNSINV TCGPPYETNG PKTFYILVVR SGGSFVTKYN KTNCQFYVDN LYYSTDYEFL
     VSFHNGVYEG DSVIRNESTN FNAKALIIFL VFLIIVTSIA LLVVLYKIYD LRKKRSSNLD
     EQQELVERDD EKQLMDVEPI HSDILLETYK RKIADEGRLF LAEFQSIPRV FSKFPIKDAR
     KPHNQNKNRY VDILPYDYNR VELSEINGDA GSTYINASYI DGFKEPRKYI AAQGPRDETV
     DDFWRMIWEQ KATVIVMVTR CEEGNRNKCA EYWPSMEEGT RAFKDIVVTI NDHKRCPDYI
     IQKLNVAHKK EKATGREVTH IQFTSWPDHG VPEDPHLLLK LRRRVNAFSN FFSGPIVVHC
     SAGVGRTGTY IGIDAMLEGL EAEGKVDVYG YVVKLRRQRC LMVQVEAQYI LIHQALVEYN
     QFGETEVNLS ELHSCLHNMK KRDPPSDPSP LEAEYQRLPS YRSWRTQHIG NQEENKKKNR
     NSNVVPYDFN RVPLKHELEM SKESEPESDE SSDDDSDSEE TSKYINASFV MSYWKPEMMI
     AAQGPLKETI GDFWQMIFQR KVKVIVMLTE LVNGDQEVCA QYWGEGKQTY GDMEVEMKDT
     NRASAYTLRT FELRHSKRKE PRTVYQYQCT TWKGEELPAE PKDLVSMIQD LKQKLPKASP
     EGMKYHKHAS ILVHCRDGSQ QTGLFCALFN LLESAETEDV VDVFQVVKSL RKARPGVVCS
     YEQYQFLYDI IASIYPAQNG QVKKTNSQDK IEFHNEVDGG KQDANCVRPD GPLNKAQEDS
     RGVGTPEPTN SAEEPEHAAN GSASPAPTQS S
//
ID   EPHB2_MOUSE             Reviewed;         986 AA.
AC   P54763; A3KG00; A3KG01; A3KG02; A3KG89; A3KG90; Q62213; Q6GTQ7;
AC   Q6P5F1; Q9QVY4;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   14-OCT-2015, sequence version 3.
DT   17-FEB-2016, entry version 168.
DE   RecName: Full=Ephrin type-B receptor 2 {ECO:0000305};
DE            EC=2.7.10.1;
DE   AltName: Full=Neural kinase;
DE   AltName: Full=Nuk receptor tyrosine kinase;
DE   AltName: Full=Tyrosine-protein kinase receptor EPH-3;
DE   AltName: Full=Tyrosine-protein kinase receptor SEK-3;
DE   Flags: Precursor;
GN   Name=Ephb2 {ECO:0000312|MGI:MGI:99611};
GN   Synonyms=Epth3, Nuk {ECO:0000303|PubMed:8134103},
GN   Sek3 {ECO:0000312|MGI:MGI:99611};
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=C57BL/6J;
RX   PubMed=19468303; DOI=10.1371/journal.pbio.1000112;
RA   Church D.M., Goodstadt L., Hillier L.W., Zody M.C., Goldstein S.,
RA   She X., Bult C.J., Agarwala R., Cherry J.L., DiCuccio M., Hlavina W.,
RA   Kapustin Y., Meric P., Maglott D., Birtle Z., Marques A.C., Graves T.,
RA   Zhou S., Teague B., Potamousis K., Churas C., Place M., Herschleb J.,
RA   Runnheim R., Forrest D., Amos-Landgraf J., Schwartz D.C., Cheng Z.,
RA   Lindblad-Toh K., Eichler E.E., Ponting C.P.;
RT   "Lineage-specific biology revealed by a finished genome assembly of
RT   the mouse.";
RL   PLoS Biol. 7:E1000112-E1000112(2009).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3 AND 4).
RC   STRAIN=C57BL/6J; TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 10-986 (ISOFORM 3).
RX   PubMed=8134103;
RA   Henkemeyer M., Marengere L.E., McGlade J., Olivier J.P., Conlon R.A.,
RA   Holmyard D.P., Letwin K., Pawson T.;
RT   "Immunolocalization of the Nuk receptor tyrosine kinase suggests roles
RT   in segmental patterning of the brain and axonogenesis.";
RL   Oncogene 9:1001-1014(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 508-986 (ISOFORM 2).
RC   STRAIN=BALB/cJ; TISSUE=Brain;
RX   PubMed=7947319; DOI=10.1016/0925-4773(94)90091-4;
RA   Becker N., Seitanidou T., Murphy P., Mattei M.-G., Topilko P.,
RA   Nieto A., Wilkinson D.G., Charnay P., Gilardi P.;
RT   "Several receptor tyrosine kinase genes of the Eph family are
RT   segmentally expressed in the developing hindbrain.";
RL   Mech. Dev. 47:3-17(1994).
RN   [5]
RP   DISRUPTION PHENOTYPE, FUNCTION IN COMMISSURAL AXON GUIDANCE,
RP   SUBCELLULAR LOCATION, AND DEVELOPMENTAL STAGE.
RX   PubMed=8689685; DOI=10.1016/S0092-8674(00)80075-6;
RA   Henkemeyer M., Orioli D., Henderson J.T., Saxton T.M., Roder J.,
RA   Pawson T., Klein R.;
RT   "Nuk controls pathfinding of commissural axons in the mammalian
RT   central nervous system.";
RL   Cell 86:35-46(1996).
RN   [6]
RP   FUNCTION IN AXON GUIDANCE, AND FUNCTION IN PALATE DEVELOPMENT.
RX   PubMed=8947026;
RA   Orioli D., Henkemeyer M., Lemke G., Klein R., Pawson T.;
RT   "Sek4 and Nuk receptors cooperate in guidance of commissural axons and
RT   in palate formation.";
RL   EMBO J. 15:6035-6049(1996).
RN   [7]
RP   INTERACTION WITH PICK1 AND GRIP1, AND IDENTIFICATION OF PDZ-BINDING
RP   MOTIF.
RX   PubMed=9883737; DOI=10.1016/S0896-6273(00)80663-7;
RA   Torres R., Firestein B.L., Dong H., Staudinger J., Olson E.N.,
RA   Huganir R.L., Bredt D.S., Gale N.W., Yancopoulos G.D.;
RT   "PDZ proteins bind, cluster, and synaptically colocalize with Eph
RT   receptors and their ephrin ligands.";
RL   Neuron 21:1453-1463(1998).
RN   [8]
RP   FUNCTION IN ANGIOGENESIS, AND DEVELOPMENTAL STAGE.
RX   PubMed=9990854; DOI=10.1101/gad.13.3.295;
RA   Adams R.H., Wilkinson G.A., Weiss C., Diella F., Gale N.W.,
RA   Deutsch U., Risau W., Klein R.;
RT   "Roles of ephrinB ligands and EphB receptors in cardiovascular
RT   development: demarcation of arterial/venous domains, vascular
RT   morphogenesis, and sprouting angiogenesis.";
RL   Genes Dev. 13:295-306(1999).
RN   [9]
RP   DEVELOPMENTAL STAGE.
RX   PubMed=10704386;
RA   Imondi R., Wideman C., Kaprielian Z.;
RT   "Complementary expression of transmembrane ephrins and their receptors
RT   in the mouse spinal cord: a possible role in constraining the
RT   orientation of longitudinally projecting axons.";
RL   Development 127:1397-1410(2000).
RN   [10]
RP   DISRUPTION PHENOTYPE, FUNCTION IN AXON GUIDANCE, FUNCTION IN INNER EAR
RP   DEVELOPMENT, INTERACTION WITH AQP1, TISSUE SPECIFICITY, AND
RP   DEVELOPMENTAL STAGE.
RX   PubMed=10839360; DOI=10.1016/S0896-6273(00)81174-5;
RA   Cowan C.A., Yokoyama N., Bianchi L.M., Henkemeyer M., Fritzsch B.;
RT   "EphB2 guides axons at the midline and is necessary for normal
RT   vestibular function.";
RL   Neuron 26:417-430(2000).
RN   [11]
RP   FUNCTION IN DENDRITIC SPINE DEVELOPMENT, FUNCTION IN EXCITATORY
RP   SYNAPSE FORMATION, AND SUBCELLULAR LOCATION.
RX   PubMed=14691139; DOI=10.1083/jcb.200306033;
RA   Henkemeyer M., Itkis O.S., Ngo M., Hickmott P.W., Ethell I.M.;
RT   "Multiple EphB receptor tyrosine kinases shape dendritic spines in the
RT   hippocampus.";
RL   J. Cell Biol. 163:1313-1326(2003).
RN   [12]
RP   FUNCTION IN URORECTAL DEVELOPMENT.
RX   PubMed=15223334; DOI=10.1016/j.ydbio.2004.03.027;
RA   Dravis C., Yokoyama N., Chumley M.J., Cowan C.A., Silvany R.E.,
RA   Shay J., Baker L.A., Henkemeyer M.;
RT   "Bidirectional signaling mediated by ephrin-B2 and EphB2 controls
RT   urorectal development.";
RL   Dev. Biol. 271:272-290(2004).
RN   [13]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-482.
RC   TISSUE=Myoblast;
RX   PubMed=19656770; DOI=10.1074/mcp.M900195-MCP200;
RA   Gundry R.L., Raginski K., Tarasova Y., Tchernyshyov I.,
RA   Bausch-Fluck D., Elliott S.T., Boheler K.R., Van Eyk J.E.,
RA   Wollscheid B.;
RT   "The mouse C2C12 myoblast cell surface N-linked glycoproteome:
RT   identification, glycosite occupancy, and membrane orientation.";
RL   Mol. Cell. Proteomics 8:2555-2569(2009).
RN   [14]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-265.
RX   PubMed=19349973; DOI=10.1038/nbt.1532;
RA   Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M.,
RA   Schiess R., Aebersold R., Watts J.D.;
RT   "Mass-spectrometric identification and relative quantification of N-
RT   linked cell surface glycoproteins.";
RL   Nat. Biotechnol. 27:378-386(2009).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain, and Kidney;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and
RT   expression.";
RL   Cell 143:1174-1189(2010).
RN   [16]
RP   FUNCTION IN EXCITATORY SYNAPSE FORMATION, FUNCTION IN PHOSPHORYLATION
RP   OF ARHGEF15, AND INTERACTION WITH ARHGEF15.
RX   PubMed=21029865; DOI=10.1016/j.cell.2010.09.038;
RA   Margolis S.S., Salogiannis J., Lipton D.M., Mandel-Brehm C.,
RA   Wills Z.P., Mardinly A.R., Hu L., Greer P.L., Bikoff J.B., Ho H.Y.,
RA   Soskis M.J., Sahin M., Greenberg M.E.;
RT   "EphB-mediated degradation of the RhoA GEF Ephexin5 relieves a
RT   developmental brake on excitatory synapse formation.";
RL   Cell 143:442-455(2010).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 21-196.
RX   PubMed=9853759; DOI=10.1038/24904;
RA   Himanen J.-P., Henkemeyer M., Nikolov D.B.;
RT   "Crystal structure of the ligand-binding domain of the receptor
RT   tyrosine kinase EphB2.";
RL   Nature 396:486-491(1998).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 21-200 IN COMPLEX WITH EFNB2,
RP   AND DISULFIDE BOND.
RX   PubMed=11780069; DOI=10.1038/414933a;
RA   Himanen J.-P., Rajashankar K.R., Lackmann M., Cowan C.A.,
RA   Henkemeyer M., Nikolov D.B.;
RT   "Crystal structure of an Eph receptor-ephrin complex.";
RL   Nature 414:933-938(2001).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 19-199 IN COMPLEX WITH EFNA5.
RX   PubMed=15107857; DOI=10.1038/nn1237;
RA   Himanen J.P., Chumley M.J., Lackmann M., Li C., Barton W.A.,
RA   Jeffrey P.D., Vearing C., Geleick D., Feldheim D.A., Boyd A.W.,
RA   Henkemeyer M., Nikolov D.B.;
RT   "Repelling class discrimination: ephrin-A5 binds to and activates
RT   EphB2 receptor signaling.";
RL   Nat. Neurosci. 7:501-509(2004).
CC   -!- FUNCTION: Receptor tyrosine kinase which binds promiscuously
CC       transmembrane ephrin-B family ligands residing on adjacent cells,
CC       leading to contact-dependent bidirectional signaling into
CC       neighboring cells. The signaling pathway downstream of the
CC       receptor is referred to as forward signaling while the signaling
CC       pathway downstream of the ephrin ligand is referred to as reverse
CC       signaling. Functions in axon guidance during development. Involved
CC       in the guidance of commissural axons, that form a major
CC       interhemispheric connection between the 2 temporal lobes of the
CC       cerebral cortex. Also involved in guidance of contralateral inner
CC       ear efferent growth cones at the midline and of retinal ganglion
CC       cell axons to the optic disk. In addition to axon guidance, also
CC       regulates dendritic spines development and maturation and
CC       stimulates the formation of excitatory synapses. Upon activation
CC       by EFNB1, abolishes the ARHGEF15-mediated negative regulation on
CC       excitatory synapse formation. Controls other aspects of
CC       development including angiogenesis, palate development and in
CC       inner ear development through regulation of endolymph production.
CC       Forward and reverse signaling through the EFNB2/EPHB2 complex
CC       regulate movement and adhesion of cells that tubularize the
CC       urethra and septate the cloaca. May function as a tumor
CC       suppressor. {ECO:0000269|PubMed:10839360,
CC       ECO:0000269|PubMed:14691139, ECO:0000269|PubMed:15223334,
CC       ECO:0000269|PubMed:21029865, ECO:0000269|PubMed:8689685,
CC       ECO:0000269|PubMed:8947026, ECO:0000269|PubMed:9990854}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- SUBUNIT: Heterotetramer upon binding of the ligand. The
CC       heterotetramer is composed of an ephrin dimer and a receptor
CC       dimer. Oligomerization is probably required to induce biological
CC       responses (By similarity). Interacts (via PDZ-binding motif) with
CC       GRIP1 and PICK1 (via PDZ domain) (By similarity). Interacts with
CC       ARHGEF15; mediates ARHGEF15 phosphorylation, ubiquitination and
CC       degradation by the proteasome. Interacts with AQP1; involved in
CC       endolymph production in the inner ear. {ECO:0000250,
CC       ECO:0000269|PubMed:10839360, ECO:0000269|PubMed:11780069,
CC       ECO:0000269|PubMed:15107857, ECO:0000269|PubMed:21029865,
CC       ECO:0000269|PubMed:9883737}.
CC   -!- INTERACTION:
CC       Self; NbExp=2; IntAct=EBI-537711, EBI-537711;
CC       Q5FWH6-2:Arhgef15; NbExp=3; IntAct=EBI-537711, EBI-2943608;
CC       Q03137:Epha4; NbExp=3; IntAct=EBI-537711, EBI-1539152;
CC       Q925T6:Grip1; NbExp=2; IntAct=EBI-537711, EBI-537752;
CC       P34152:Ptk2; NbExp=3; IntAct=EBI-537711, EBI-77070;
CC       P05480:Src; NbExp=3; IntAct=EBI-537711, EBI-298680;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein. Cell projection, axon. Cell projection, dendrite.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=3 {ECO:0000305};
CC         IsoId=P54763-3; Sequence=Displayed;
CC       Name=2 {ECO:0000305};
CC         IsoId=P54763-2; Sequence=VSP_057933;
CC         Note=No experimental confirmation available.;
CC       Name=4 {ECO:0000305};
CC         IsoId=P54763-4; Sequence=VSP_057932;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed in the epithelial dark cells of the
CC       inner ear. Expressed in the region of the proximal tubules of the
CC       kidney nephron. {ECO:0000269|PubMed:10839360}.
CC   -!- DEVELOPMENTAL STAGE: Highly expressed in ventral cells of the
CC       neural tube and within axons of the peripheral nervous system
CC       during development. Expressed in the vestibulo-acoustic system and
CC       hindbrain as early as E11.5. Detected in the spinal cord at E12.
CC       Expressed in cells of the developing outer retina. Also expressed
CC       in mesenchyme adjacent to vessels. {ECO:0000269|PubMed:10704386,
CC       ECO:0000269|PubMed:10839360, ECO:0000269|PubMed:8689685,
CC       ECO:0000269|PubMed:9990854}.
CC   -!- DISRUPTION PHENOTYPE: Mice are long-lived and fertile. They
CC       display strain-specific circling behavior, are hyperactive and
CC       exhibit rapid head bobbing and twirled excessively when picked-up
CC       by the tail. This is probably due to abnormal vestibular function.
CC       {ECO:0000269|PubMed:10839360, ECO:0000269|PubMed:8689685}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 1 Eph LBD (Eph ligand-binding) domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00883}.
CC   -!- SIMILARITY: Contains 2 fibronectin type-III domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00316}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 1 SAM (sterile alpha motif) domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00184}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA72411.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=AAH62924.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AL627214; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL627345; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL671173; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC043088; AAH43088.2; -; mRNA.
DR   EMBL; BC062924; AAH62924.1; ALT_INIT; mRNA.
DR   EMBL; L25890; AAA72411.1; ALT_INIT; mRNA.
DR   EMBL; X76011; CAA53598.1; -; mRNA.
DR   RefSeq; NP_001277682.1; NM_001290753.2. [P54763-4]
DR   RefSeq; NP_034272.1; NM_010142.4. [P54763-3]
DR   RefSeq; XP_006538594.1; XM_006538531.2. [P54763-2]
DR   UniGene; Mm.250981; -.
DR   PDB; 1JPA; X-ray; 1.91 A; A/B=587-898.
DR   PDB; 1KGY; X-ray; 2.70 A; A/B/C/D=20-199.
DR   PDB; 1NUK; X-ray; 2.90 A; A=20-202.
DR   PDB; 1SHW; X-ray; 2.20 A; B=19-199.
DR   PDB; 2HEN; X-ray; 2.60 A; A/B/C/D=614-898.
DR   PDB; 3ETP; X-ray; 2.00 A; A=20-199.
DR   PDBsum; 1JPA; -.
DR   PDBsum; 1KGY; -.
DR   PDBsum; 1NUK; -.
DR   PDBsum; 1SHW; -.
DR   PDBsum; 2HEN; -.
DR   PDBsum; 3ETP; -.
DR   ProteinModelPortal; P54763; -.
DR   SMR; P54763; 18-531, 575-985.
DR   DIP; DIP-34917N; -.
DR   IntAct; P54763; 11.
DR   MINT; MINT-3381667; -.
DR   STRING; 10090.ENSMUSP00000101471; -.
DR   BindingDB; P54763; -.
DR   ChEMBL; CHEMBL5961; -.
DR   GuidetoPHARMACOLOGY; 1831; -.
DR   iPTMnet; P54763; -.
DR   PhosphoSite; P54763; -.
DR   SwissPalm; P54763; -.
DR   MaxQB; P54763; -.
DR   PaxDb; P54763; -.
DR   PRIDE; P54763; -.
DR   DNASU; 13844; -.
DR   Ensembl; ENSMUST00000059287; ENSMUSP00000058135; ENSMUSG00000028664. [P54763-4]
DR   Ensembl; ENSMUST00000105845; ENSMUSP00000101471; ENSMUSG00000028664. [P54763-3]
DR   Ensembl; ENSMUST00000105846; ENSMUSP00000101472; ENSMUSG00000028664. [P54763-2]
DR   GeneID; 13844; -.
DR   UCSC; uc008vim.2; mouse.
DR   CTD; 2048; -.
DR   MGI; MGI:99611; Ephb2.
DR   eggNOG; KOG0196; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00740000115264; -.
DR   HOGENOM; HOG000233856; -.
DR   HOVERGEN; HBG062180; -.
DR   InParanoid; P54763; -.
DR   KO; K05111; -.
DR   OMA; FFKEDSH; -.
DR   OrthoDB; EOG7VTDM6; -.
DR   PhylomeDB; P54763; -.
DR   TreeFam; TF315608; -.
DR   ChiTaRS; Ephb2; mouse.
DR   EvolutionaryTrace; P54763; -.
DR   NextBio; 284684; -.
DR   PRO; PR:P54763; -.
DR   Proteomes; UP000000589; Chromosome 4.
DR   Bgee; A3KG00; -.
DR   CleanEx; MM_EPHB2; -.
DR   ExpressionAtlas; P54763; baseline and differential.
DR   GO; GO:0030424; C:axon; IDA:UniProtKB.
DR   GO; GO:0030425; C:dendrite; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043025; C:neuronal cell body; IDA:MGI.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0045202; C:synapse; NAS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0008046; F:axon guidance receptor activity; IDA:MGI.
DR   GO; GO:0005003; F:ephrin receptor activity; IDA:MGI.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004872; F:receptor activity; IDA:MGI.
DR   GO; GO:0005102; F:receptor binding; IPI:MGI.
DR   GO; GO:0005005; F:transmembrane-ephrin receptor activity; IDA:UniProtKB.
DR   GO; GO:0001525; P:angiogenesis; IMP:UniProtKB.
DR   GO; GO:0007411; P:axon guidance; IMP:UniProtKB.
DR   GO; GO:0007413; P:axonal fasciculation; IMP:UniProtKB.
DR   GO; GO:0048593; P:camera-type eye morphogenesis; IMP:MGI.
DR   GO; GO:0000902; P:cell morphogenesis; IGI:MGI.
DR   GO; GO:0021952; P:central nervous system projection neuron axonogenesis; IMP:MGI.
DR   GO; GO:0071679; P:commissural neuron axon guidance; IMP:UniProtKB.
DR   GO; GO:0022038; P:corpus callosum development; IMP:UniProtKB.
DR   GO; GO:0060996; P:dendritic spine development; IMP:UniProtKB.
DR   GO; GO:0060997; P:dendritic spine morphogenesis; IMP:UniProtKB.
DR   GO; GO:0048013; P:ephrin receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0042472; P:inner ear morphogenesis; IMP:UniProtKB.
DR   GO; GO:0007612; P:learning; IMP:MGI.
DR   GO; GO:0050771; P:negative regulation of axonogenesis; IDA:MGI.
DR   GO; GO:0021631; P:optic nerve morphogenesis; IMP:MGI.
DR   GO; GO:0009887; P:organ morphogenesis; IMP:MGI.
DR   GO; GO:0060021; P:palate development; IMP:UniProtKB.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0016310; P:phosphorylation; IDA:UniProtKB.
DR   GO; GO:0048170; P:positive regulation of long-term neuronal synaptic plasticity; IMP:MGI.
DR   GO; GO:0051965; P:positive regulation of synapse assembly; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:MGI.
DR   GO; GO:0050770; P:regulation of axonogenesis; IDA:MGI.
DR   GO; GO:0050878; P:regulation of body fluid levels; IMP:UniProtKB.
DR   GO; GO:0048168; P:regulation of neuronal synaptic plasticity; IMP:MGI.
DR   GO; GO:0031290; P:retinal ganglion cell axon guidance; IDA:MGI.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IDA:MGI.
DR   GO; GO:0001655; P:urogenital system development; IMP:UniProtKB.
DR   Gene3D; 1.10.150.50; -; 1.
DR   Gene3D; 2.60.120.260; -; 1.
DR   Gene3D; 2.60.40.10; -; 2.
DR   InterPro; IPR027936; Eph_TM.
DR   InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR008979; Galactose-bd-like.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001660; SAM.
DR   InterPro; IPR013761; SAM/pointed.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR011641; Tyr-kin_ephrin_A/B_rcpt-like.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016257; Tyr_kinase_ephrin_rcpt.
DR   InterPro; IPR001426; Tyr_kinase_rcpt_V_CS.
DR   Pfam; PF14575; EphA2_TM; 1.
DR   Pfam; PF01404; Ephrin_lbd; 1.
DR   Pfam; PF00041; fn3; 2.
DR   Pfam; PF07699; GCC2_GCC3; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00536; SAM_1; 1.
DR   PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00615; EPH_lbd; 1.
DR   SMART; SM00060; FN3; 2.
DR   SMART; SM00454; SAM; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF47769; SSF47769; 1.
DR   SUPFAM; SSF49265; SSF49265; 1.
DR   SUPFAM; SSF49785; SSF49785; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 2.
DR   PROSITE; PS51550; EPH_LBD; 1.
DR   PROSITE; PS50853; FN3; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1.
DR   PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1.
DR   PROSITE; PS50105; SAM_DOMAIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Cell projection; Complete proteome; Developmental protein;
KW   Disulfide bond; Glycoprotein; Kinase; Membrane; Neurogenesis;
KW   Nucleotide-binding; Phosphoprotein; Receptor; Reference proteome;
KW   Repeat; Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase.
FT   SIGNAL        1     18       {ECO:0000255}.
FT   CHAIN        19    986       Ephrin type-B receptor 2. {ECO:0000255}.
FT                                /FTId=PRO_0000016828.
FT   TOPO_DOM     19    543       Extracellular. {ECO:0000255}.
FT   TRANSMEM    544    564       Helical. {ECO:0000255}.
FT   TOPO_DOM    565    986       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       20    202       Eph LBD. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00883}.
FT   DOMAIN      324    434       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      435    530       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      621    884       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      913    977       SAM. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00184}.
FT   NP_BIND     627    635       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOTIF       984    986       PDZ-binding.
FT   COMPBIAS    184    321       Cys-rich.
FT   ACT_SITE    746    746       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   BINDING     653    653       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     602    602       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P54753}.
FT   CARBOHYD    265    265       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19349973}.
FT   CARBOHYD    336    336       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    428    428       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    482    482       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19656770}.
FT   DISULFID     62    184       {ECO:0000269|PubMed:11780069}.
FT   DISULFID     97    107       {ECO:0000269|PubMed:11780069}.
FT   VAR_SEQ     476    476       K -> KQ (in isoform 4). {ECO:0000305}.
FT                                /FTId=VSP_057932.
FT   VAR_SEQ     566    566       N -> NR (in isoform 2).
FT                                {ECO:0000303|PubMed:7947319}.
FT                                /FTId=VSP_057933.
FT   STRAND       20     25       {ECO:0000244|PDB:3ETP}.
FT   HELIX        26     28       {ECO:0000244|PDB:3ETP}.
FT   STRAND       36     39       {ECO:0000244|PDB:3ETP}.
FT   STRAND       44     49       {ECO:0000244|PDB:3ETP}.
FT   STRAND       55     61       {ECO:0000244|PDB:3ETP}.
FT   STRAND       66     68       {ECO:0000244|PDB:3ETP}.
FT   STRAND       71     74       {ECO:0000244|PDB:3ETP}.
FT   STRAND       84     94       {ECO:0000244|PDB:3ETP}.
FT   HELIX        97     99       {ECO:0000244|PDB:3ETP}.
FT   STRAND      100    102       {ECO:0000244|PDB:1SHW}.
FT   STRAND      110    121       {ECO:0000244|PDB:3ETP}.
FT   STRAND      125    128       {ECO:0000244|PDB:3ETP}.
FT   STRAND      130    132       {ECO:0000244|PDB:3ETP}.
FT   STRAND      135    142       {ECO:0000244|PDB:3ETP}.
FT   STRAND      147    152       {ECO:0000244|PDB:3ETP}.
FT   STRAND      155    166       {ECO:0000244|PDB:3ETP}.
FT   STRAND      171    182       {ECO:0000244|PDB:3ETP}.
FT   STRAND      185    195       {ECO:0000244|PDB:3ETP}.
FT   HELIX       599    601       {ECO:0000244|PDB:1JPA}.
FT   STRAND      602    604       {ECO:0000244|PDB:1JPA}.
FT   HELIX       605    612       {ECO:0000244|PDB:1JPA}.
FT   HELIX       618    620       {ECO:0000244|PDB:1JPA}.
FT   STRAND      621    629       {ECO:0000244|PDB:1JPA}.
FT   STRAND      631    640       {ECO:0000244|PDB:1JPA}.
FT   STRAND      643    645       {ECO:0000244|PDB:2HEN}.
FT   STRAND      648    654       {ECO:0000244|PDB:1JPA}.
FT   HELIX       661    674       {ECO:0000244|PDB:1JPA}.
FT   STRAND      685    689       {ECO:0000244|PDB:1JPA}.
FT   STRAND      691    694       {ECO:0000244|PDB:1JPA}.
FT   STRAND      696    700       {ECO:0000244|PDB:1JPA}.
FT   HELIX       707    712       {ECO:0000244|PDB:1JPA}.
FT   TURN        713    716       {ECO:0000244|PDB:1JPA}.
FT   HELIX       720    739       {ECO:0000244|PDB:1JPA}.
FT   HELIX       749    751       {ECO:0000244|PDB:1JPA}.
FT   STRAND      752    754       {ECO:0000244|PDB:1JPA}.
FT   STRAND      760    762       {ECO:0000244|PDB:1JPA}.
FT   HELIX       790    792       {ECO:0000244|PDB:1JPA}.
FT   HELIX       795    799       {ECO:0000244|PDB:1JPA}.
FT   HELIX       805    820       {ECO:0000244|PDB:1JPA}.
FT   TURN        821    823       {ECO:0000244|PDB:2HEN}.
FT   TURN        826    829       {ECO:0000244|PDB:1JPA}.
FT   HELIX       832    840       {ECO:0000244|PDB:1JPA}.
FT   HELIX       853    862       {ECO:0000244|PDB:1JPA}.
FT   TURN        867    869       {ECO:0000244|PDB:1JPA}.
FT   HELIX       873    885       {ECO:0000244|PDB:1JPA}.
FT   HELIX       887    890       {ECO:0000244|PDB:1JPA}.
SQ   SEQUENCE   986 AA;  109899 MW;  92DB5234F18758A7 CRC64;
     MAVRRLGAAL LLLPLLAAVE ETLMDSTTAT AELGWMVHPP SGWEEVSGYD ENMNTIRTYQ
     VCNVFESSQN NWLRTKFIRR RGAHRIHVEM KFSVRDCSSI PSVPGSCKET FNLYYYEADF
     DLATKTFPNW MENPWVKVDT IAADESFSQV DLGGRVMKIN TEVRSFGPVS RNGFYLAFQD
     YGGCMSLIAV RVFYRKCPRI IQNGAIFQET LSGAESTSLV AARGSCIANA EEVDVPIKLY
     CNGDGEWLVP IGRCMCKAGF EAVENGTVCR GCPSGTFKAN QGDEACTHCP INSRTTSEGA
     TNCVCRNGYY RADLDPLDMP CTTIPSAPQA VISSVNETSL MLEWTPPRDS GGREDLVYNI
     ICKSCGSGRG ACTRCGDNVQ YAPRQLGLTE PRIYISDLLA HTQYTFEIQA VNGVTDQSPF
     SPQFASVNIT TNQAAPSAVS IMHQVSRTVD SITLSWSQPD QPNGVILDYE LQYYEKELSE
     YNATAIKSPT NTVTVQGLKA GAIYVFQVRA RTVAGYGRYS GKMYFQTMTE AEYQTSIKEK
     LPLIVGSSAA GLVFLIAVVV IAIVCNRRGF ERADSEYTDK LQHYTSGHMT PGMKIYIDPF
     TYEDPNEAVR EFAKEIDISC VKIEQVIGAG EFGEVCSGHL KLPGKREIFV AIKTLKSGYT
     EKQRRDFLSE ASIMGQFDHP NVIHLEGVVT KSTPVMIITE FMENGSLDSF LRQNDGQFTV
     IQLVGMLRGI AAGMKYLADM NYVHRDLAAR NILVNSNLVC KVSDFGLSRF LEDDTSDPTY
     TSALGGKIPI RWTAPEAIQY RKFTSASDVW SYGIVMWEVM SYGERPYWDM TNQDVINAIE
     QDYRLPPPMD CPSALHQLML DCWQKDRNHR PKFGQIVNTL DKMIRNPNSL KAMAPLSSGI
     NLPLLDRTIP DYTSFNTVDE WLEAIKMGQY KESFANAGFT SFDVVSQMMM EDILRVGVTL
     AGHQKKILNS IQVMRAQMNQ IQSVEV
//
ID   EPHA2_HUMAN             Reviewed;         976 AA.
AC   P29317; B5A968; Q8N3Z2;
DT   01-DEC-1992, integrated into UniProtKB/Swiss-Prot.
DT   05-MAY-2009, sequence version 2.
DT   17-FEB-2016, entry version 190.
DE   RecName: Full=Ephrin type-A receptor 2;
DE            EC=2.7.10.1;
DE   AltName: Full=Epithelial cell kinase;
DE   AltName: Full=Tyrosine-protein kinase receptor ECK;
DE   Flags: Precursor;
GN   Name=EPHA2; Synonyms=ECK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), CATALYTIC ACTIVITY, AND
RP   AUTOPHOSPHORYLATION.
RC   TISSUE=Epithelium;
RX   PubMed=2174105;
RA   Lindberg R.A., Hunter T.;
RT   "cDNA cloning and characterization of eck, an epithelial cell receptor
RT   protein-tyrosine kinase in the eph/elk family of protein kinases.";
RL   Mol. Cell. Biol. 10:6316-6324(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND ALTERNATIVE SPLICING.
RX   PubMed=18593464; DOI=10.1186/ar2447;
RA   Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D.,
RA   Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.;
RT   "Novel splice variants derived from the receptor tyrosine kinase
RT   superfamily are potential therapeutics for rheumatoid arthritis.";
RL   Arthritis Res. Ther. 10:R73-R73(2008).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NOMENCLATURE.
RX   PubMed=9267020;
RG   Eph nomenclature committee;
RT   "Unified nomenclature for Eph family receptors and their ligands, the
RT   ephrins.";
RL   Cell 90:403-404(1997).
RN   [7]
RP   FUNCTION IN INTEGRIN-MEDIATED CELL ADHESION, FUNCTION IN CELL
RP   MIGRATION, PHOSPHORYLATION, INTERACTION WITH PTK2/FAK1 AND PTPN11, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=10655584; DOI=10.1038/35000008;
RA   Miao H., Burnett E., Kinch M., Simon E., Wang B.;
RT   "Activation of EphA2 kinase suppresses integrin function and causes
RT   focal-adhesion-kinase dephosphorylation.";
RL   Nat. Cell Biol. 2:62-69(2000).
RN   [8]
RP   ONCOGENICITY.
RX   PubMed=11280802;
RA   Zelinski D.P., Zantek N.D., Stewart J.C., Irizarry A.R., Kinch M.S.;
RT   "EphA2 overexpression causes tumorigenesis of mammary epithelial
RT   cells.";
RL   Cancer Res. 61:2301-2306(2001).
RN   [9]
RP   INTERACTION WITH ACP1, AND DEPHOSPHORYLATION BY ACP1.
RX   PubMed=12167657; DOI=10.1074/jbc.M207127200;
RA   Kikawa K.D., Vidale D.R., Van Etten R.L., Kinch M.S.;
RT   "Regulation of the EphA2 kinase by the low molecular weight tyrosine
RT   phosphatase induces transformation.";
RL   J. Biol. Chem. 277:39274-39279(2002).
RN   [10]
RP   FUNCTION IN CELL-CELL INTERACTION, INTERACTION WITH CLDN4, AND
RP   MUTAGENESIS OF LYS-646.
RX   PubMed=16236711; DOI=10.1074/jbc.M503786200;
RA   Tanaka M., Kamata R., Sakai R.;
RT   "EphA2 phosphorylates the cytoplasmic tail of Claudin-4 and mediates
RT   paracellular permeability.";
RL   J. Biol. Chem. 280:42375-42382(2005).
RN   [11]
RP   TISSUE SPECIFICITY.
RX   PubMed=17332925;
RA   Liu D.-P., Wang Y., Koeffler H.P., Xie D.;
RT   "Ephrin-A1 is a negative regulator in glioma through down-regulation
RT   of EphA2 and FAK.";
RL   Int. J. Oncol. 30:865-871(2007).
RN   [12]
RP   INTERACTION WITH INPPL1.
RX   PubMed=17135240; DOI=10.1074/jbc.M608509200;
RA   Zhuang G., Hunter S., Hwang Y., Chen J.;
RT   "Regulation of EphA2 receptor endocytosis by SHIP2 lipid phosphatase
RT   via phosphatidylinositol 3-Kinase-dependent Rac1 activation.";
RL   J. Biol. Chem. 282:2683-2694(2007).
RN   [13]
RP   FUNCTION IN APOPTOSIS, AND INDUCTION BY UV.
RX   PubMed=18339848; DOI=10.1158/0008-5472.CAN-07-2372;
RA   Zhang G., Njauw C.-N., Park J.M., Naruse C., Asano M., Tsao H.;
RT   "EphA2 is an essential mediator of UV radiation-induced apoptosis.";
RL   Cancer Res. 68:1691-1696(2008).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-570; SER-579 AND
RP   THR-647, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [15]
RP   SUBCELLULAR LOCATION, AND PHOSPHORYLATION.
RX   PubMed=18794797; DOI=10.1038/onc.2008.328;
RA   Wykosky J., Palma E., Gibo D.M., Ringler S., Turner C.P., Debinski W.;
RT   "Soluble monomeric EphrinA1 is released from tumor cells and is a
RT   functional ligand for the EphA2 receptor.";
RL   Oncogene 27:7260-7273(2008).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-570; SER-892 AND
RP   SER-901, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [17]
RP   DISEASE, FUNCTION IN CELL MIGRATION, SUBCELLULAR LOCATION, MUTAGENESIS
RP   OF ASP-739 AND SER-897, AND PHOSPHORYLATION AT SER-897 BY PKB.
RX   PubMed=19573808; DOI=10.1016/j.ccr.2009.04.009;
RA   Miao H., Li D.Q., Mukherjee A., Guo H., Petty A., Cutter J.,
RA   Basilion J.P., Sedor J., Wu J., Danielpour D., Sloan A.E., Cohen M.L.,
RA   Wang B.;
RT   "EphA2 mediates ligand-dependent inhibition and ligand-independent
RT   promotion of cell migration and invasion via a reciprocal regulatory
RT   loop with Akt.";
RL   Cancer Cell 16:9-20(2009).
RN   [18]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-435.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [19]
RP   UBIQUITINATION BY STUB1.
RX   PubMed=19567782; DOI=10.1158/1541-7786.MCR-08-0582;
RA   Annamalai B., Liu X., Gopal U., Isaacs J.S.;
RT   "Hsp90 is an essential regulator of EphA2 receptor stability and
RT   signaling: implications for cancer cell migration and metastasis.";
RL   Mol. Cancer Res. 7:1021-1032(2009).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-570; TYR-628; THR-647
RP   AND SER-869, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [21]
RP   FUNCTION IN CELL MIGRATION, AND INTERACTION WITH ARHGEF16; DOCK4 AND
RP   ELMO2.
RX   PubMed=20679435; DOI=10.1083/jcb.201005141;
RA   Hiramoto-Yamaki N., Takeuchi S., Ueda S., Harada K., Fujimoto S.,
RA   Negishi M., Katoh H.;
RT   "Ephexin4 and EphA2 mediate cell migration through a RhoG-dependent
RT   mechanism.";
RL   J. Cell Biol. 190:461-477(2010).
RN   [22]
RP   FUNCTION IN KERATINOCYTE ADHESION AND DIFFERENTIATION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=20861311; DOI=10.1091/mbc.E10-03-0242;
RA   Lin S., Gordon K., Kaplan N., Getsios S.;
RT   "Ligand targeting of EphA2 enhances keratinocyte adhesion and
RT   differentiation via desmoglein 1.";
RL   Mol. Biol. Cell 21:3902-3914(2010).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [25]
RP   INTERACTION WITH ANKS1A.
RX   PubMed=22332920; DOI=10.1021/bi300141h;
RA   Mercurio F.A., Marasco D., Pirone L., Pedone E.M., Pellecchia M.,
RA   Leone M.;
RT   "Solution structure of the first Sam domain of Odin and binding
RT   studies with the EphA2 receptor.";
RL   Biochemistry 51:2136-2145(2012).
RN   [26]
RP   INTERACTION WITH HHV-8 GLYCOPROTEIN L/GLYCOPROTEIN H.
RX   PubMed=22635007; DOI=10.1038/nm.2805;
RA   Hahn A.S., Kaufmann J.K., Wies E., Naschberger E., Panteleev-Ivlev J.,
RA   Schmidt K., Holzer A., Schmidt M., Chen J., Konig S., Ensser A.,
RA   Myoung J., Brockmeyer N.H., Sturzl M., Fleckenstein B., Neipel F.;
RT   "The ephrin receptor tyrosine kinase A2 is a cellular receptor for
RT   Kaposi's sarcoma-associated herpesvirus.";
RL   Nat. Med. 18:961-966(2012).
RN   [27]
RP   FUNCTION IN CELL MIGRATION, PHOSPHORYLATION AT TYR-930,
RP   DEPHOSPHORYLATION AT TYR-930 BY PTPRF, AND INTERACTION WITH NCK1.
RX   PubMed=23358419; DOI=10.1128/MCB.01708-12;
RA   Lee H., Bennett A.M.;
RT   "Receptor protein tyrosine phosphatase-receptor tyrosine kinase
RT   substrate screen identifies EphA2 as a target for LAR in cell
RT   migration.";
RL   Mol. Cell. Biol. 33:1430-1441(2013).
RN   [28]
RP   INTERACTION WITH CEMIP.
RX   PubMed=23936024; DOI=10.1371/journal.pone.0069473;
RA   Tiwari A., Schneider M., Fiorino A., Haider R., Okoniewski M.J.,
RA   Roschitzki B., Uzozie A., Menigatti M., Jiricny J., Marra G.;
RT   "Early insights into the function of KIAA1199, a markedly
RT   overexpressed protein in human colorectal tumors.";
RL   PLoS ONE 8:E69473-E69473(2013).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 596-900.
RX   PubMed=12467573; DOI=10.1016/S0969-2126(02)00907-3;
RA   Nowakowski J., Cronin C.N., McRee D.E., Knuth M.W., Nelson C.G.,
RA   Pavletich N.P., Rogers J., Sang B.C., Scheibe D.N., Swanson R.V.,
RA   Thompson D.A.;
RT   "Structures of the cancer-related Aurora-A, FAK, and EphA2 protein
RT   kinases from nanovolume crystallography.";
RL   Structure 10:1659-1667(2002).
RN   [30]
RP   STRUCTURE BY NMR OF 902-976.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the C-terminal SAM-domain of EPHAA2: ephrin
RT   type-A receptor 2 precursor (EC 2.7.10.1).";
RL   Submitted (JAN-2008) to the PDB data bank.
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (2.52 ANGSTROMS) OF 28-201, X-RAY
RP   CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 28-201 IN COMPLEX WITH EFNA1,
RP   SUBUNIT, DISULFIDE BOND, AND MUTAGENESIS OF ARG-103.
RX   PubMed=19525919; DOI=10.1038/embor.2009.91;
RA   Himanen J.P., Goldgur Y., Miao H., Myshkin E., Guo H., Buck M.,
RA   Nguyen M., Rajashankar K.R., Wang B., Nikolov D.B.;
RT   "Ligand recognition by A-class Eph receptors: crystal structures of
RT   the EphA2 ligand-binding domain and the EphA2/ephrin-A1 complex.";
RL   EMBO Rep. 10:722-728(2009).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 25-202, AND DISULFIDE BOND.
RG   Structural genomics consortium (SGC);
RT   "Ephrin A1 bound to the ligand binding domain of the human ephrin A2
RT   (EPHA2) receptor protein kinase.";
RL   Submitted (FEB-2009) to the PDB data bank.
RN   [33]
RP   STRUCTURE BY NMR OF 523-563.
RA   Mayzel M.L., Bocharov E.V., Volynsky P.E., Arseniev A.S.;
RT   "Left-handed dimer of EPHA2 transmembrane domain helix packing
RT   diversity among receptor tyrosine kinases.";
RL   Submitted (AUG-2009) to the PDB data bank.
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (2.65 ANGSTROMS) OF 23-202 IN COMPLEX WITH
RP   EFNA1, AND SUBUNIT.
RX   PubMed=20505120; DOI=10.1073/pnas.1004148107;
RA   Himanen J.P., Yermekbayeva L., Janes P.W., Walker J.R., Xu K.,
RA   Atapattu L., Rajashankar K.R., Mensinga A., Lackmann M., Nikolov D.B.,
RA   Dhe-Paganon S.;
RT   "Architecture of Eph receptor clusters.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:10860-10865(2010).
RN   [35]
RP   VARIANTS [LARGE SCALE ANALYSIS] ARG-391; MET-511; HIS-568; SER-777 AND
RP   HIS-876.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [36]
RP   VARIANT CTRCT6 TRP-948.
RX   PubMed=19005574;
RA   Shiels A., Bennett T.M., Knopf H.L.S., Maraini G., Li A., Jiao X.,
RA   Hejtmancik J.F.;
RT   "The EPHA2 gene is associated with cataracts linked to chromosome
RT   1p.";
RL   Mol. Vis. 14:2042-2055(2008).
RN   [37]
RP   VARIANT CTRCT6 ILE-940.
RX   PubMed=19306328; DOI=10.1002/humu.20995;
RA   Zhang T., Hua R., Xiao W., Burdon K.P., Bhattacharya S.S., Craig J.E.,
RA   Shang D., Zhao X., Mackey D.A., Moore A.T., Luo Y., Zhang J.,
RA   Zhang X.;
RT   "Mutations of the EPHA2 receptor tyrosine kinase gene cause autosomal
RT   dominant congenital cataract.";
RL   Hum. Mutat. 30:E603-E611(2009).
RN   [38]
RP   VARIANT CTRCT6 GLN-721, AND CHARACTERIZATION OF VARIANT CTRCT6
RP   GLN-721.
RX   PubMed=19649315; DOI=10.1371/journal.pgen.1000584;
RA   Jun G., Guo H., Klein B.E., Klein R., Wang J.J., Mitchell P., Miao H.,
RA   Lee K.E., Joshi T., Buck M., Chugha P., Bardenstein D., Klein A.P.,
RA   Bailey-Wilson J.E., Gong X., Spector T.D., Andrew T., Hammond C.J.,
RA   Elston R.C., Iyengar S.K., Wang B.;
RT   "EPHA2 is associated with age-related cortical cataract in mice and
RT   humans.";
RL   PLoS Genet. 5:E1000584-E1000584(2009).
RN   [39]
RP   CHARACTERIZATION OF VARIANTS CTRCT6 ILE-940 AND CTRCT6 TRP-948.
RX   PubMed=22570727; DOI=10.1371/journal.pone.0036564;
RA   Park J.E., Son A.I., Hua R., Wang L., Zhang X., Zhou R.;
RT   "Human cataract mutations in EPHA2 SAM domain alter receptor stability
RT   and function.";
RL   PLoS ONE 7:E36564-E36564(2012).
CC   -!- FUNCTION: Receptor tyrosine kinase which binds promiscuously
CC       membrane-bound ephrin-A family ligands residing on adjacent cells,
CC       leading to contact-dependent bidirectional signaling into
CC       neighboring cells. The signaling pathway downstream of the
CC       receptor is referred to as forward signaling while the signaling
CC       pathway downstream of the ephrin ligand is referred to as reverse
CC       signaling. Activated by the ligand ephrin-A1/EFNA1 regulates
CC       migration, integrin-mediated adhesion, proliferation and
CC       differentiation of cells. Regulates cell adhesion and
CC       differentiation through DSG1/desmoglein-1 and inhibition of the
CC       ERK1/ERK2 (MAPK3/MAPK1, respectively) signaling pathway. May also
CC       participate in UV radiation-induced apoptosis and have a ligand-
CC       independent stimulatory effect on chemotactic cell migration.
CC       During development, may function in distinctive aspects of pattern
CC       formation and subsequently in development of several fetal
CC       tissues. Involved for instance in angiogenesis, in early hindbrain
CC       development and epithelial proliferation and branching
CC       morphogenesis during mammary gland development. Engaged by the
CC       ligand ephrin-A5/EFNA5 may regulate lens fiber cells shape and
CC       interactions and be important for lens transparency development
CC       and maintenance. With ephrin-A2/EFNA2 may play a role in bone
CC       remodeling through regulation of osteoclastogenesis and
CC       osteoblastogenesis. {ECO:0000269|PubMed:10655584,
CC       ECO:0000269|PubMed:16236711, ECO:0000269|PubMed:18339848,
CC       ECO:0000269|PubMed:19573808, ECO:0000269|PubMed:20679435,
CC       ECO:0000269|PubMed:20861311, ECO:0000269|PubMed:23358419}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:2174105}.
CC   -!- SUBUNIT: Homodimer. Interacts with SLA. Interacts (phosphorylated
CC       form) with VAV2, VAV3 and PI3-kinase p85 subunit (PIK3R1, PIK3R2
CC       or PIK3R3); critical for the EFNA1-induced activation of RAC1
CC       which stimulates cell migration (By similarity). Interacts with
CC       INPPL1; regulates activated EPHA2 endocytosis and degradation.
CC       Interacts (inactivated form) with PTK2/FAK1 and interacts (EFNA1
CC       ligand-activated form) with PTPN11; regulates integrin-mediated
CC       adhesion. Interacts with ARHGEF16, DOCK4 and ELMO2; mediates
CC       ligand-independent activation of RAC1 which stimulates cell
CC       migration. Interacts with CLDN4; phosphorylates CLDN4 and may
CC       regulate tight junctions. Interacts with ACP1. Interacts (via SAM
CC       domain) with ANKS1A (via SAM domain). Interacts with human herpes
CC       virus 8/HHV-8 glycoprotein L/gL and glycoprotein H/gH heterodimer;
CC       this interaction triggers EPHA2 phosphorylation and endocytosis,
CC       allowing virus entry. Interacts with CEMIP. Interacts with NCK1;
CC       may regulate EPHA2 activity in cell migration and adhesion.
CC       {ECO:0000250, ECO:0000269|PubMed:10655584,
CC       ECO:0000269|PubMed:12167657, ECO:0000269|PubMed:16236711,
CC       ECO:0000269|PubMed:17135240, ECO:0000269|PubMed:19525919,
CC       ECO:0000269|PubMed:20505120, ECO:0000269|PubMed:20679435,
CC       ECO:0000269|PubMed:22332920, ECO:0000269|PubMed:22635007,
CC       ECO:0000269|PubMed:23358419, ECO:0000269|PubMed:23936024}.
CC   -!- INTERACTION:
CC       P20827:EFNA1; NbExp=7; IntAct=EBI-702104, EBI-715194;
CC       Q15375:EPHA7; NbExp=3; IntAct=EBI-702104, EBI-1383428;
CC       P08238:HSP90AB1; NbExp=2; IntAct=EBI-702104, EBI-352572;
CC       Q05397:PTK2; NbExp=3; IntAct=EBI-702104, EBI-702142;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:18794797,
CC       ECO:0000269|PubMed:19573808, ECO:0000269|PubMed:20861311}; Single-
CC       pass type I membrane protein {ECO:0000255}. Cell projection,
CC       ruffle membrane {ECO:0000269|PubMed:19573808}; Single-pass type I
CC       membrane protein {ECO:0000255}. Cell projection, lamellipodium
CC       membrane {ECO:0000269|PubMed:19573808}; Single-pass type I
CC       membrane protein {ECO:0000255}. Cell junction, focal adhesion
CC       {ECO:0000269|PubMed:10655584}. Note=Present at regions of cell-
CC       cell contacts but also at the leading edge of migrating cells
CC       (PubMed:19573808, PubMed:20861311). Relocates from the plasma
CC       membrane to the cytoplasmic and perinuclear regions in cancer
CC       cells (PubMed:18794797). {ECO:0000269|PubMed:18794797,
CC       ECO:0000269|PubMed:19573808, ECO:0000269|PubMed:20861311}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P29317-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P29317-2; Sequence=VSP_056014, VSP_056015;
CC   -!- TISSUE SPECIFICITY: Expressed in brain and glioma tissue and
CC       glioma cell lines (at protein level). Expressed most highly in
CC       tissues that contain a high proportion of epithelial cells, e.g.
CC       skin, intestine, lung, and ovary. {ECO:0000269|PubMed:17332925}.
CC   -!- INDUCTION: Up-regulated by UV irradiation via a TP53-independent,
CC       MAPK-dependent mechanism. {ECO:0000269|PubMed:18339848}.
CC   -!- PTM: Autophosphorylates. Phosphorylated on tyrosine upon binding
CC       and activation by EFNA1. Phosphorylated residues Tyr-588 and Tyr-
CC       594 are required for binding VAV2 and VAV3 while phosphorylated
CC       residues Tyr-735 and Tyr-930 are required for binding PI3-kinase
CC       p85 subunit (PIK3R1, PIK3R2 or PIK3R3). These phosphorylated
CC       residues are critical for recruitment of VAV2 and VAV3 and PI3-
CC       kinase p85 subunit which transduce downstream signaling to
CC       activate RAC1 GTPase and cell migration. Dephosphorylation of Tyr-
CC       930 by PTPRF prevents the interaction of EPHA2 with NCK1.
CC       Phosphorylated at Ser-897 by PKB; serum-induced phosphorylation
CC       which targets EPHA2 to the cell leading edge and stimulates cell
CC       migration. Phosphorylation by PKB is inhibited by EFNA1-activated
CC       EPHA2 which regulates PKB activity via a reciprocal regulatory
CC       loop. Dephosphorylated by ACP1. {ECO:0000269|PubMed:10655584,
CC       ECO:0000269|PubMed:18794797, ECO:0000269|PubMed:19573808,
CC       ECO:0000269|PubMed:23358419}.
CC   -!- PTM: Ubiquitinated by CHIP/STUB1. Ubiquitination is regulated by
CC       the HSP90 chaperone and regulates the receptor stability and
CC       activity through proteasomal degradation. ANKS1A prevents
CC       ubiquitination and degradation (By similarity). {ECO:0000250}.
CC   -!- DISEASE: Cataract 6, multiple types (CTRCT6) [MIM:116600]: An
CC       opacification of the crystalline lens of the eye that frequently
CC       results in visual impairment or blindness. Opacities vary in
CC       morphology, are often confined to a portion of the lens, and may
CC       be static or progressive. CTRCT6 includes posterior polar and age-
CC       related cortical cataracts, among others. Posterior polar cataract
CC       is a subcapsular opacity, usually disk-shaped, located at the back
CC       of the lens. Age-related cortical cataract is a developmental
CC       punctate opacity restricted to the cortex. The cataract is white
CC       or cerulean, increases in number with age, but rarely affects
CC       vision. {ECO:0000269|PubMed:19005574, ECO:0000269|PubMed:19306328,
CC       ECO:0000269|PubMed:19649315}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Note=Overexpressed in several cancer types and promotes
CC       malignancy. {ECO:0000269|PubMed:19573808}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 1 Eph LBD (Eph ligand-binding) domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00883}.
CC   -!- SIMILARITY: Contains 2 fibronectin type-III domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00316}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 1 SAM (sterile alpha motif) domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00184}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/EPHA2ID40462ch1p36.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M59371; AAA53375.1; -; mRNA.
DR   EMBL; EU826606; ACF47642.1; -; mRNA.
DR   EMBL; AL451042; CAH71943.1; -; Genomic_DNA.
DR   EMBL; CH471167; EAW51769.1; -; Genomic_DNA.
DR   EMBL; BC037166; AAH37166.1; -; mRNA.
DR   CCDS; CCDS169.1; -. [P29317-1]
DR   PIR; A36355; A36355.
DR   RefSeq; NP_004422.2; NM_004431.3. [P29317-1]
DR   UniGene; Hs.171596; -.
DR   PDB; 1MQB; X-ray; 2.30 A; A/B=596-900.
DR   PDB; 2E8N; NMR; -; A=902-976.
DR   PDB; 2K9Y; NMR; -; A/B=523-563.
DR   PDB; 2KSO; NMR; -; A=908-972.
DR   PDB; 2X10; X-ray; 3.00 A; A=27-534.
DR   PDB; 2X11; X-ray; 4.83 A; A=27-534.
DR   PDB; 3C8X; X-ray; 1.95 A; A=23-202.
DR   PDB; 3CZU; X-ray; 2.65 A; A=23-202.
DR   PDB; 3FL7; X-ray; 2.50 A; A=23-531.
DR   PDB; 3HEI; X-ray; 2.00 A; A/C/E/G/I/K/M/O=28-201.
DR   PDB; 3HPN; X-ray; 2.52 A; A/B/C/D/E/F=28-201.
DR   PDB; 3KKA; X-ray; 2.40 A; C/D/E=903-971.
DR   PDB; 3MBW; X-ray; 2.81 A; A=23-326.
DR   PDB; 3MX0; X-ray; 3.51 A; A/C=27-435.
DR   PDB; 3SKJ; X-ray; 2.50 A; E/F=23-202.
DR   PDB; 4P2K; X-ray; 1.50 A; A=590-876.
DR   PDB; 4PDO; X-ray; 2.10 A; A/B=590-876.
DR   PDB; 4TRL; X-ray; 2.45 A; A=590-876.
DR   PDB; 5EK7; X-ray; 1.90 A; A/B=583-876.
DR   PDBsum; 1MQB; -.
DR   PDBsum; 2E8N; -.
DR   PDBsum; 2K9Y; -.
DR   PDBsum; 2KSO; -.
DR   PDBsum; 2X10; -.
DR   PDBsum; 2X11; -.
DR   PDBsum; 3C8X; -.
DR   PDBsum; 3CZU; -.
DR   PDBsum; 3FL7; -.
DR   PDBsum; 3HEI; -.
DR   PDBsum; 3HPN; -.
DR   PDBsum; 3KKA; -.
DR   PDBsum; 3MBW; -.
DR   PDBsum; 3MX0; -.
DR   PDBsum; 3SKJ; -.
DR   PDBsum; 4P2K; -.
DR   PDBsum; 4PDO; -.
DR   PDBsum; 4TRL; -.
DR   PDBsum; 5EK7; -.
DR   ProteinModelPortal; P29317; -.
DR   SMR; P29317; 25-528, 555-970.
DR   BioGrid; 108288; 53.
DR   DIP; DIP-96N; -.
DR   IntAct; P29317; 30.
DR   MINT; MINT-3972729; -.
DR   STRING; 9606.ENSP00000351209; -.
DR   BindingDB; P29317; -.
DR   ChEMBL; CHEMBL2068; -.
DR   DrugBank; DB01254; Dasatinib.
DR   DrugBank; DB08896; Regorafenib.
DR   GuidetoPHARMACOLOGY; 1822; -.
DR   iPTMnet; P29317; -.
DR   PhosphoSite; P29317; -.
DR   SwissPalm; P29317; -.
DR   UniCarbKB; P29317; -.
DR   BioMuta; EPHA2; -.
DR   DMDM; 229462861; -.
DR   MaxQB; P29317; -.
DR   PaxDb; P29317; -.
DR   PRIDE; P29317; -.
DR   DNASU; 1969; -.
DR   Ensembl; ENST00000358432; ENSP00000351209; ENSG00000142627. [P29317-1]
DR   GeneID; 1969; -.
DR   KEGG; hsa:1969; -.
DR   UCSC; uc001aya.2; human. [P29317-1]
DR   CTD; 1969; -.
DR   GeneCards; EPHA2; -.
DR   HGNC; HGNC:3386; EPHA2.
DR   HPA; CAB010464; -.
DR   MalaCards; EPHA2; -.
DR   MIM; 116600; phenotype.
DR   MIM; 176946; gene.
DR   neXtProt; NX_P29317; -.
DR   Orphanet; 98993; Posterior polar cataract.
DR   Orphanet; 98994; Total congenital cataract.
DR   PharmGKB; PA27818; -.
DR   eggNOG; KOG0196; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118975; -.
DR   HOGENOM; HOG000233856; -.
DR   HOVERGEN; HBG062180; -.
DR   InParanoid; P29317; -.
DR   KO; K05103; -.
DR   OMA; CSPGFFK; -.
DR   OrthoDB; EOG7VTDM6; -.
DR   PhylomeDB; P29317; -.
DR   TreeFam; TF315608; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-2682334; EPH-Ephrin signaling.
DR   Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse.
DR   Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells.
DR   SignaLink; P29317; -.
DR   EvolutionaryTrace; P29317; -.
DR   GeneWiki; EPH_receptor_A2; -.
DR   GenomeRNAi; 1969; -.
DR   NextBio; 35477785; -.
DR   PRO; PR:P29317; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; P29317; -.
DR   CleanEx; HS_EPHA2; -.
DR   ExpressionAtlas; P29317; baseline and differential.
DR   Genevisible; P29317; HS.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005622; C:intracellular; IDA:GOC.
DR   GO; GO:0031258; C:lamellipodium membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0031256; C:leading edge membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0032587; C:ruffle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005003; F:ephrin receptor activity; IEA:InterPro.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0090630; P:activation of GTPase activity; IMP:UniProtKB.
DR   GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0048320; P:axial mesoderm formation; IEA:Ensembl.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0046849; P:bone remodeling; ISS:UniProtKB.
DR   GO; GO:0060444; P:branching involved in mammary gland duct morphogenesis; ISS:UniProtKB.
DR   GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW.
DR   GO; GO:0060326; P:cell chemotaxis; IMP:UniProtKB.
DR   GO; GO:0016477; P:cell migration; IMP:UniProtKB.
DR   GO; GO:0048013; P:ephrin receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IDA:UniProtKB.
DR   GO; GO:0030216; P:keratinocyte differentiation; IMP:UniProtKB.
DR   GO; GO:0070309; P:lens fiber cell morphogenesis; ISS:UniProtKB.
DR   GO; GO:0033598; P:mammary gland epithelial cell proliferation; ISS:UniProtKB.
DR   GO; GO:0007275; P:multicellular organismal development; TAS:ProtInc.
DR   GO; GO:0051898; P:negative regulation of protein kinase B signaling; IDA:UniProtKB.
DR   GO; GO:0021915; P:neural tube development; IEA:Ensembl.
DR   GO; GO:0060035; P:notochord cell development; IEA:Ensembl.
DR   GO; GO:0014028; P:notochord formation; IEA:Ensembl.
DR   GO; GO:0001649; P:osteoblast differentiation; ISS:UniProtKB.
DR   GO; GO:0030316; P:osteoclast differentiation; ISS:UniProtKB.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:GOC.
DR   GO; GO:0090004; P:positive regulation of establishment of protein localization to plasma membrane; IMP:UniProtKB.
DR   GO; GO:0036342; P:post-anal tail morphogenesis; IEA:Ensembl.
DR   GO; GO:0043491; P:protein kinase B signaling; IDA:UniProtKB.
DR   GO; GO:0045765; P:regulation of angiogenesis; ISS:UniProtKB.
DR   GO; GO:0043535; P:regulation of blood vessel endothelial cell migration; ISS:UniProtKB.
DR   GO; GO:0033628; P:regulation of cell adhesion mediated by integrin; IDA:UniProtKB.
DR   GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:0010591; P:regulation of lamellipodium assembly; IMP:UniProtKB.
DR   GO; GO:0070848; P:response to growth factor; IMP:UniProtKB.
DR   GO; GO:0001501; P:skeletal system development; IEA:Ensembl.
DR   GO; GO:0001570; P:vasculogenesis; IEA:Ensembl.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   Gene3D; 1.10.150.50; -; 1.
DR   Gene3D; 2.60.120.260; -; 1.
DR   Gene3D; 2.60.40.10; -; 2.
DR   InterPro; IPR027936; Eph_TM.
DR   InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR008979; Galactose-bd-like.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001660; SAM.
DR   InterPro; IPR013761; SAM/pointed.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016257; Tyr_kinase_ephrin_rcpt.
DR   InterPro; IPR001426; Tyr_kinase_rcpt_V_CS.
DR   Pfam; PF14575; EphA2_TM; 1.
DR   Pfam; PF01404; Ephrin_lbd; 1.
DR   Pfam; PF00041; fn3; 2.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00536; SAM_1; 1.
DR   PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00615; EPH_lbd; 1.
DR   SMART; SM00060; FN3; 2.
DR   SMART; SM00454; SAM; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF47769; SSF47769; 1.
DR   SUPFAM; SSF49265; SSF49265; 1.
DR   SUPFAM; SSF49785; SSF49785; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 2.
DR   PROSITE; PS51550; EPH_LBD; 1.
DR   PROSITE; PS50853; FN3; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1.
DR   PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1.
DR   PROSITE; PS50105; SAM_DOMAIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Angiogenesis; Apoptosis;
KW   ATP-binding; Cataract; Cell adhesion; Cell junction; Cell membrane;
KW   Cell projection; Complete proteome; Differentiation; Disease mutation;
KW   Disulfide bond; Glycoprotein; Host-virus interaction; Kinase;
KW   Membrane; Nucleotide-binding; Phosphoprotein; Polymorphism; Receptor;
KW   Reference proteome; Repeat; Signal; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     23       {ECO:0000255}.
FT   CHAIN        24    976       Ephrin type-A receptor 2.
FT                                /FTId=PRO_0000016800.
FT   TOPO_DOM     24    537       Extracellular. {ECO:0000255}.
FT   TRANSMEM    538    558       Helical. {ECO:0000255}.
FT   TOPO_DOM    559    976       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       28    206       Eph LBD. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00883}.
FT   DOMAIN      328    432       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      438    529       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      613    875       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      904    968       SAM. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00184}.
FT   NP_BIND     619    627       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION        1    206       Mediates interaction with CLDN4.
FT   REGION      606    906       Mediates interaction with ARHGEF16 and
FT                                ELMO2.
FT   REGION      886    976       Negatively regulates interaction with
FT                                ARHGEF16.
FT   MOTIF       974    976       PDZ-binding. {ECO:0000255}.
FT   COMPBIAS    188    325       Cys-rich.
FT   ACT_SITE    739    739       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     646    646       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     570    570       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195}.
FT   MOD_RES     579    579       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES     588    588       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     594    594       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q03145}.
FT   MOD_RES     628    628       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     647    647       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195}.
FT   MOD_RES     735    735       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     772    772       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q03145}.
FT   MOD_RES     869    869       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     892    892       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     897    897       Phosphoserine; by PKB.
FT                                {ECO:0000269|PubMed:19573808}.
FT   MOD_RES     901    901       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     921    921       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000255}.
FT   MOD_RES     930    930       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:23358419}.
FT   CARBOHYD    407    407       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    435    435       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   DISULFID     70    188
FT   DISULFID    105    115
FT   VAR_SEQ     477    497       GDSNSYNVRRTEGFSVTLDDL -> VTPRGAGLALAGPTAG
FT                                DRLVT (in isoform 2).
FT                                {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_056014.
FT   VAR_SEQ     498    976       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_056015.
FT   VARIANT      99     99       K -> N (in dbSNP:rs1058372).
FT                                /FTId=VAR_055989.
FT   VARIANT     391    391       G -> R (in dbSNP:rs34192549).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042121.
FT   VARIANT     511    511       T -> M (in dbSNP:rs55747232).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042122.
FT   VARIANT     568    568       R -> H (in dbSNP:rs56198600).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042123.
FT   VARIANT     631    631       M -> T (in dbSNP:rs34021505).
FT                                /FTId=VAR_055990.
FT   VARIANT     721    721       R -> Q (in CTRCT6; retained in the
FT                                cytoplasm and constitutively active it
FT                                alters EPHA2 signaling;
FT                                dbSNP:rs116506614).
FT                                {ECO:0000269|PubMed:19649315}.
FT                                /FTId=VAR_062532.
FT   VARIANT     777    777       G -> S (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042124.
FT   VARIANT     876    876       R -> H (in dbSNP:rs35903225).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042125.
FT   VARIANT     940    940       T -> I (in CTRCT6; reduced protein
FT                                stability and reduced ability to
FT                                stimulate cell migration in absence of
FT                                its ephrin ligand).
FT                                {ECO:0000269|PubMed:19306328,
FT                                ECO:0000269|PubMed:22570727}.
FT                                /FTId=VAR_058907.
FT   VARIANT     948    948       G -> W (in CTRCT6; reduced protein
FT                                stability and reduced ability to
FT                                stimulate cell migration in absence of
FT                                its ephrin ligand).
FT                                {ECO:0000269|PubMed:19005574,
FT                                ECO:0000269|PubMed:22570727}.
FT                                /FTId=VAR_058908.
FT   MUTAGEN     103    103       R->E: Significantly reduced response to
FT                                EFNA1. {ECO:0000269|PubMed:19525919}.
FT   MUTAGEN     646    646       K->M: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:16236711}.
FT   MUTAGEN     739    739       D->N: Increases serum-induced chemotaxis.
FT                                Loss of EFNA1-dependent regulation of
FT                                cell migration.
FT                                {ECO:0000269|PubMed:19573808}.
FT   MUTAGEN     897    897       S->A,D: Loss of serum-induced
FT                                phosphorylation by PKB. Loss of serum-
FT                                induced chemotaxis.
FT                                {ECO:0000269|PubMed:19573808}.
FT   CONFLICT     94     99       IFIELK -> NNFELN (in Ref. 1; AAA53375).
FT                                {ECO:0000305}.
FT   STRAND       28     33       {ECO:0000244|PDB:3C8X}.
FT   HELIX        34     36       {ECO:0000244|PDB:3C8X}.
FT   TURN         37     40       {ECO:0000244|PDB:3HPN}.
FT   STRAND       44     57       {ECO:0000244|PDB:3C8X}.
FT   STRAND       59     62       {ECO:0000244|PDB:3C8X}.
FT   STRAND       64     69       {ECO:0000244|PDB:3C8X}.
FT   STRAND       73     76       {ECO:0000244|PDB:3C8X}.
FT   STRAND       79     82       {ECO:0000244|PDB:3C8X}.
FT   STRAND       92    103       {ECO:0000244|PDB:3C8X}.
FT   HELIX       105    107       {ECO:0000244|PDB:3C8X}.
FT   STRAND      108    110       {ECO:0000244|PDB:3HEI}.
FT   TURN        112    114       {ECO:0000244|PDB:3SKJ}.
FT   STRAND      119    128       {ECO:0000244|PDB:3C8X}.
FT   HELIX       136    138       {ECO:0000244|PDB:3C8X}.
FT   STRAND      139    145       {ECO:0000244|PDB:3C8X}.
FT   STRAND      148    151       {ECO:0000244|PDB:3MBW}.
FT   HELIX       153    157       {ECO:0000244|PDB:3HEI}.
FT   STRAND      161    170       {ECO:0000244|PDB:3C8X}.
FT   STRAND      175    187       {ECO:0000244|PDB:3C8X}.
FT   STRAND      189    199       {ECO:0000244|PDB:3C8X}.
FT   STRAND      204    206       {ECO:0000244|PDB:3FL7}.
FT   STRAND      209    211       {ECO:0000244|PDB:3FL7}.
FT   STRAND      218    221       {ECO:0000244|PDB:3MBW}.
FT   STRAND      224    227       {ECO:0000244|PDB:3FL7}.
FT   STRAND      238    240       {ECO:0000244|PDB:3MBW}.
FT   STRAND      244    247       {ECO:0000244|PDB:3FL7}.
FT   STRAND      253    257       {ECO:0000244|PDB:3MBW}.
FT   STRAND      266    269       {ECO:0000244|PDB:3FL7}.
FT   STRAND      272    275       {ECO:0000244|PDB:3FL7}.
FT   STRAND      286    288       {ECO:0000244|PDB:3MBW}.
FT   STRAND      295    298       {ECO:0000244|PDB:3FL7}.
FT   STRAND      335    338       {ECO:0000244|PDB:3FL7}.
FT   STRAND      343    348       {ECO:0000244|PDB:3FL7}.
FT   STRAND      361    369       {ECO:0000244|PDB:3FL7}.
FT   STRAND      376    378       {ECO:0000244|PDB:3FL7}.
FT   STRAND      384    387       {ECO:0000244|PDB:3FL7}.
FT   STRAND      389    392       {ECO:0000244|PDB:3FL7}.
FT   STRAND      394    400       {ECO:0000244|PDB:3FL7}.
FT   STRAND      407    415       {ECO:0000244|PDB:3FL7}.
FT   HELIX       419    421       {ECO:0000244|PDB:3FL7}.
FT   STRAND      427    433       {ECO:0000244|PDB:3FL7}.
FT   STRAND      441    446       {ECO:0000244|PDB:3FL7}.
FT   STRAND      453    457       {ECO:0000244|PDB:3FL7}.
FT   TURN        460    465       {ECO:0000244|PDB:3FL7}.
FT   STRAND      467    475       {ECO:0000244|PDB:3FL7}.
FT   STRAND      483    493       {ECO:0000244|PDB:3FL7}.
FT   STRAND      502    510       {ECO:0000244|PDB:3FL7}.
FT   STRAND      522    525       {ECO:0000244|PDB:3FL7}.
FT   HELIX       536    556       {ECO:0000244|PDB:2K9Y}.
FT   STRAND      557    561       {ECO:0000244|PDB:2K9Y}.
FT   HELIX       597    600       {ECO:0000244|PDB:4PDO}.
FT   TURN        601    604       {ECO:0000244|PDB:4PDO}.
FT   HELIX       610    612       {ECO:0000244|PDB:4P2K}.
FT   STRAND      613    621       {ECO:0000244|PDB:4P2K}.
FT   STRAND      623    632       {ECO:0000244|PDB:4P2K}.
FT   STRAND      641    647       {ECO:0000244|PDB:4P2K}.
FT   HELIX       654    667       {ECO:0000244|PDB:4P2K}.
FT   STRAND      678    682       {ECO:0000244|PDB:4P2K}.
FT   STRAND      684    687       {ECO:0000244|PDB:4P2K}.
FT   STRAND      689    693       {ECO:0000244|PDB:4P2K}.
FT   HELIX       700    706       {ECO:0000244|PDB:4P2K}.
FT   TURN        707    709       {ECO:0000244|PDB:4P2K}.
FT   HELIX       713    732       {ECO:0000244|PDB:4P2K}.
FT   HELIX       742    744       {ECO:0000244|PDB:4P2K}.
FT   STRAND      745    747       {ECO:0000244|PDB:4P2K}.
FT   STRAND      753    755       {ECO:0000244|PDB:4P2K}.
FT   HELIX       781    783       {ECO:0000244|PDB:4P2K}.
FT   HELIX       786    791       {ECO:0000244|PDB:4P2K}.
FT   HELIX       796    811       {ECO:0000244|PDB:4P2K}.
FT   TURN        817    820       {ECO:0000244|PDB:4P2K}.
FT   HELIX       823    831       {ECO:0000244|PDB:4P2K}.
FT   HELIX       844    853       {ECO:0000244|PDB:4P2K}.
FT   HELIX       858    860       {ECO:0000244|PDB:4P2K}.
FT   HELIX       864    873       {ECO:0000244|PDB:4P2K}.
FT   HELIX       878    882       {ECO:0000244|PDB:1MQB}.
FT   HELIX       909    915       {ECO:0000244|PDB:3KKA}.
FT   HELIX       919    921       {ECO:0000244|PDB:3KKA}.
FT   HELIX       922    927       {ECO:0000244|PDB:3KKA}.
FT   HELIX       933    937       {ECO:0000244|PDB:3KKA}.
FT   HELIX       941    946       {ECO:0000244|PDB:3KKA}.
FT   HELIX       952    964       {ECO:0000244|PDB:3KKA}.
SQ   SEQUENCE   976 AA;  108266 MW;  845D7E1BBCCAACCC CRC64;
     MELQAARACF ALLWGCALAA AAAAQGKEVV LLDFAAAGGE LGWLTHPYGK GWDLMQNIMN
     DMPIYMYSVC NVMSGDQDNW LRTNWVYRGE AERIFIELKF TVRDCNSFPG GASSCKETFN
     LYYAESDLDY GTNFQKRLFT KIDTIAPDEI TVSSDFEARH VKLNVEERSV GPLTRKGFYL
     AFQDIGACVA LLSVRVYYKK CPELLQGLAH FPETIAGSDA PSLATVAGTC VDHAVVPPGG
     EEPRMHCAVD GEWLVPIGQC LCQAGYEKVE DACQACSPGF FKFEASESPC LECPEHTLPS
     PEGATSCECE EGFFRAPQDP ASMPCTRPPS APHYLTAVGM GAKVELRWTP PQDSGGREDI
     VYSVTCEQCW PESGECGPCE ASVRYSEPPH GLTRTSVTVS DLEPHMNYTF TVEARNGVSG
     LVTSRSFRTA SVSINQTEPP KVRLEGRSTT SLSVSWSIPP PQQSRVWKYE VTYRKKGDSN
     SYNVRRTEGF SVTLDDLAPD TTYLVQVQAL TQEGQGAGSK VHEFQTLSPE GSGNLAVIGG
     VAVGVVLLLV LAGVGFFIHR RRKNQRARQS PEDVYFSKSE QLKPLKTYVD PHTYEDPNQA
     VLKFTTEIHP SCVTRQKVIG AGEFGEVYKG MLKTSSGKKE VPVAIKTLKA GYTEKQRVDF
     LGEAGIMGQF SHHNIIRLEG VISKYKPMMI ITEYMENGAL DKFLREKDGE FSVLQLVGML
     RGIAAGMKYL ANMNYVHRDL AARNILVNSN LVCKVSDFGL SRVLEDDPEA TYTTSGGKIP
     IRWTAPEAIS YRKFTSASDV WSFGIVMWEV MTYGERPYWE LSNHEVMKAI NDGFRLPTPM
     DCPSAIYQLM MQCWQQERAR RPKFADIVSI LDKLIRAPDS LKTLADFDPR VSIRLPSTSG
     SEGVPFRTVS EWLESIKMQQ YTEHFMAAGY TAIEKVVQMT NDDIKRIGVR LPGHQKRIAY
     SLLGLKDQVN TVGIPI
//
ID   FGFR3_MOUSE             Reviewed;         801 AA.
AC   Q61851; Q61564; Q63834;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   17-FEB-2016, entry version 151.
DE   RecName: Full=Fibroblast growth factor receptor 3;
DE            Short=FGFR-3;
DE            EC=2.7.10.1;
DE   AltName: Full=Heparin-binding growth factor receptor;
DE   AltName: CD_antigen=CD333;
DE   Flags: Precursor;
GN   Name=Fgfr3; Synonyms=Mfr3, Sam3;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1379594;
RA   Ornitz D.M., Leder P.;
RT   "Ligand specificity and heparin dependence of fibroblast growth factor
RT   receptors 1 and 3.";
RL   J. Biol. Chem. 267:16305-16311(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=8382556;
RA   Katoh O., Hattori Y., Sasaki H., Sakamoto H., Fujimoto K., Fujii T.,
RA   Sugimura T., Terada M.;
RT   "Isolation of the complementary DNA encoding a mouse heparin-binding
RT   growth factor receptor with the use of a unique kinase insert
RT   sequence.";
RL   Cancer Res. 53:1136-1141(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 242-364 (ISOFORM 2).
RX   PubMed=7512569;
RA   Chellaiah A.T., McEwen D.G., Werner S., Xu J., Ornitz D.M.;
RT   "Fibroblast growth factor receptor (FGFR) 3. Alternative splicing in
RT   immunoglobulin-like domain III creates a receptor highly specific for
RT   acidic FGF/FGF-1.";
RL   J. Biol. Chem. 269:11620-11627(1994).
RN   [4]
RP   DISRUPTION PHENOTYPE, AND FUNCTION.
RX   PubMed=8601314; DOI=10.1016/S0092-8674(00)81069-7;
RA   Deng C., Wynshaw-Boris A., Zhou F., Kuo A., Leder P.;
RT   "Fibroblast growth factor receptor 3 is a negative regulator of bone
RT   growth.";
RL   Cell 84:911-921(1996).
RN   [5]
RP   INTERACTION WITH FGF1; FGF2; FGF4; FGF8 AND FGF9, AND FUNCTION IN CELL
RP   PROLIFERATION.
RX   PubMed=8663044; DOI=10.1074/jbc.271.25.15292;
RA   Ornitz D.M., Xu J., Colvin J.S., McEwen D.G., MacArthur C.A.,
RA   Coulier F., Gao G., Goldfarb M.;
RT   "Receptor specificity of the fibroblast growth factor family.";
RL   J. Biol. Chem. 271:15292-15297(1996).
RN   [6]
RP   DISRUPTION PHENOTYPE, AND FUNCTION.
RX   PubMed=8630492; DOI=10.1038/ng0496-390;
RA   Colvin J.S., Bohne B.A., Harding G.W., McEwen D.G., Ornitz D.M.;
RT   "Skeletal overgrowth and deafness in mice lacking fibroblast growth
RT   factor receptor 3.";
RL   Nat. Genet. 12:390-397(1996).
RN   [7]
RP   DISRUPTION PHENOTYPE, AND FUNCTION.
RX   PubMed=9716527;
RA   Weinstein M., Xu X., Ohyama K., Deng C.X.;
RT   "FGFR-3 and FGFR-4 function cooperatively to direct alveogenesis in
RT   the murine lung.";
RL   Development 125:3615-3623(1998).
RN   [8]
RP   FUNCTION AS FGF2 RECEPTOR AND IN PHOSPHORYLATION OF CBL,
RP   UBIQUITINATION, PHOSPHORYLATION, ENZYME REGULATION, AND MUTAGENESIS OF
RP   644.
RX   PubMed=14699054; DOI=10.1073/pnas.2237184100;
RA   Cho J.Y., Guo C., Torello M., Lunstrum G.P., Iwata T., Deng C.,
RA   Horton W.A.;
RT   "Defective lysosomal targeting of activated fibroblast growth factor
RT   receptor 3 in achondroplasia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:609-614(2004).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-438 AND SER-439, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain, and Lung;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and
RT   expression.";
RL   Cell 143:1174-1189(2010).
RN   [10]
RP   DISRUPTION PHENOTYPE, AND FUNCTION IN VITAMIN D METABOLISM.
RX   PubMed=21561999; DOI=10.1152/ajprenal.00740.2010;
RA   Gattineni J., Twombley K., Goetz R., Mohammadi M., Baum M.;
RT   "Regulation of serum 1,25(OH)2Vitamin D3 levels by fibroblast growth
RT   factor 23 is mediated by FGF receptors 3 and 4.";
RL   Am. J. Physiol. 301:F371-F377(2011).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as cell-surface
CC       receptor for fibroblast growth factors and plays an essential role
CC       in the regulation of cell proliferation, differentiation and
CC       apoptosis. Plays an essential role in the regulation of
CC       chondrocyte differentiation, proliferation and apoptosis, and is
CC       required for normal skeleton development. Regulates both
CC       osteogenesis and postnatal bone mineralization by osteoblasts.
CC       Promotes apoptosis in chondrocytes, but can also promote cancer
CC       cell proliferation. Required for normal development of the inner
CC       ear. Phosphorylates PLCG1, CBL and FRS2. Ligand binding leads to
CC       the activation of several signaling cascades. Activation of PLCG1
CC       leads to the production of the cellular signaling molecules
CC       diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation
CC       of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and
CC       mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP
CC       kinase signaling pathway, as well as of the AKT1 signaling
CC       pathway. Plays a role in the regulation of vitamin D metabolism.
CC       Mutations that lead to constitutive kinase activation or impair
CC       normal FGFR3 maturation, internalization and degradation lead to
CC       aberrant signaling. Over-expressed or constitutively activated
CC       FGFR3 promotes activation of STAT1, STAT5A and STAT5B. Plays a
CC       role in postnatal lung development. {ECO:0000269|PubMed:14699054,
CC       ECO:0000269|PubMed:21561999, ECO:0000269|PubMed:8601314,
CC       ECO:0000269|PubMed:8630492, ECO:0000269|PubMed:8663044,
CC       ECO:0000269|PubMed:9716527}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- ENZYME REGULATION: Present in an inactive conformation in the
CC       absence of bound ligand. Ligand binding leads to dimerization and
CC       activation by autophosphorylation on tyrosine residues (By
CC       similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Monomer. Homodimer after ligand binding. Interacts with
CC       FGF1, FGF2, FGF4, FGF6; FGF8, FGF9, FGF10, FGF17, FGF18, FGF19,
CC       FGF20 and FGF23 (in vitro). Interacts with KLB. Affinity for
CC       fibroblast growth factors (FGFs) is increased by heparan sulfate
CC       glycosaminoglycans that function as coreceptors. Likewise, KLB
CC       increases the affinity for FGF19 and FGF21. Interacts with PIK3R1,
CC       PLCG1, SOCS1 and SOCS3 (By similarity). {ECO:0000250}.
CC   -!- INTERACTION:
CC       Q9JID9:Sh2b2; NbExp=3; IntAct=EBI-6287052, EBI-8100899;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein. Cytoplasmic vesicle {ECO:0000250}. Endoplasmic reticulum
CC       {ECO:0000250}. Note=The activated receptor is rapidly internalized
CC       and degraded. Detected in intracellular vesicles after
CC       internalization of the autophosphorylated receptor (By
CC       similarity). {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=IIIc;
CC         IsoId=Q61851-1; Sequence=Displayed;
CC       Name=2; Synonyms=IIIb;
CC         IsoId=Q61851-2; Sequence=VSP_002990;
CC   -!- TISSUE SPECIFICITY: In embryo, expressed in heart, lung, kidney,
CC       skin, head and liver but not in muscle. In adult, highest levels
CC       in brain. Also expressed in liver, lung, kidney, testis, ovary and
CC       uterus. Very low levels in heart, thymus, spleen and muscle.
CC   -!- DEVELOPMENTAL STAGE: Expressed in embryos from mid-gestation and
CC       in adult.
CC   -!- DOMAIN: The second and third Ig-like domains directly interact
CC       with fibroblast growth factors (FGF) and heparan sulfate
CC       proteoglycans. {ECO:0000250}.
CC   -!- PTM: Autophosphorylated. Binding of FGF family members together
CC       with heparan sulfate proteoglycan or heparin promotes receptor
CC       dimerization and autophosphorylation on tyrosine residues.
CC       Autophosphorylation occurs in trans between the two FGFR molecules
CC       present in the dimer. Phosphorylation at Tyr-719 is essential for
CC       stimulation of cell proliferation and activation of PIK3R1, STAT1
CC       and MAP kinase signaling. Phosphorylation at Tyr-755 is required
CC       for interaction with PIK3R1 and PLCG1 (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: Ubiquitinated. Is rapidly ubiquitinated after ligand binding
CC       and autophosphorylation, leading to receptor internalization and
CC       degradation. Subject to both proteasomal and lysosomal degradation
CC       (By similarity). {ECO:0000250}.
CC   -!- PTM: N-glycosylated in the endoplasmic reticulum. The N-glycan
CC       chains undergo further maturation to an Endo H-resistant form in
CC       the Golgi apparatus (By similarity). {ECO:0000250}.
CC   -!- DISRUPTION PHENOTYPE: Mice exhibit defects in their skeleton,
CC       including kyphosis, scoliosis, crooked tails and curvature and
CC       overgrowth of long bones and vertebrae. This bone dysplasia is due
CC       to defects in the regulation of chondrocyte proliferation and
CC       differentiation in the cartilaginous growth plate. Mice also
CC       display inner ear defects including failure of pillar cell
CC       differentiation and tunnel of Corti formation, resulting in
CC       profound deafness. Mice lacking both FGFR3 and FGFR4 display
CC       pronounced dwarfism, and while their lungs appear normal at birth,
CC       they are completely blocked in alveogenesis and do not form
CC       secondary septae to delimit alveoli. These mice also show elevated
CC       serum levels of 1,25-dihydroxyvitamin D3 and reduced serum
CC       phosphorus levels. {ECO:0000269|PubMed:21561999,
CC       ECO:0000269|PubMed:8601314, ECO:0000269|PubMed:8630492,
CC       ECO:0000269|PubMed:9716527}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Fibroblast growth factor receptor subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 3 Ig-like C2-type (immunoglobulin-like)
CC       domains. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M81342; AAA39535.1; -; mRNA.
DR   EMBL; S56291; AAB25535.1; -; mRNA.
DR   EMBL; L26492; AAA21490.2; -; Genomic_DNA.
DR   PIR; A48991; A48991.
DR   PIR; I55363; I55363.
DR   UniGene; Mm.6904; -.
DR   ProteinModelPortal; Q61851; -.
DR   SMR; Q61851; 17-393, 453-781.
DR   DIP; DIP-6031N; -.
DR   IntAct; Q61851; 2.
DR   MINT; MINT-5181473; -.
DR   STRING; 10090.ENSMUSP00000133064; -.
DR   BindingDB; Q61851; -.
DR   ChEMBL; CHEMBL2111391; -.
DR   iPTMnet; Q61851; -.
DR   PhosphoSite; Q61851; -.
DR   MaxQB; Q61851; -.
DR   PaxDb; Q61851; -.
DR   PRIDE; Q61851; -.
DR   MGI; MGI:95524; Fgfr3.
DR   eggNOG; KOG0200; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   HOGENOM; HOG000263410; -.
DR   HOVERGEN; HBG000345; -.
DR   InParanoid; Q61851; -.
DR   PhylomeDB; Q61851; -.
DR   BRENDA; 2.7.10.1; 3474.
DR   ChiTaRS; Fgfr3; mouse.
DR   PRO; PR:Q61851; -.
DR   Proteomes; UP000000589; Unplaced.
DR   CleanEx; MM_FGFR3; -.
DR   GO; GO:0009898; C:cytoplasmic side of plasma membrane; IDA:MGI.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISO:MGI.
DR   GO; GO:0005794; C:Golgi apparatus; ISO:MGI.
DR   GO; GO:0005887; C:integral component of plasma membrane; ISS:UniProtKB.
DR   GO; GO:0005764; C:lysosome; IDA:MGI.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:MGI.
DR   GO; GO:0005886; C:plasma membrane; ISO:MGI.
DR   GO; GO:0030133; C:transport vesicle; ISO:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0017134; F:fibroblast growth factor binding; ISS:UniProtKB.
DR   GO; GO:0005007; F:fibroblast growth factor-activated receptor activity; ISS:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; ISS:UniProtKB.
DR   GO; GO:0061144; P:alveolar secondary septum development; IGI:MGI.
DR   GO; GO:0060385; P:axonogenesis involved in innervation; IMP:MGI.
DR   GO; GO:0070977; P:bone maturation; IMP:BHF-UCL.
DR   GO; GO:0030282; P:bone mineralization; IMP:BHF-UCL.
DR   GO; GO:0060349; P:bone morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0051216; P:cartilage development; IMP:MGI.
DR   GO; GO:0030154; P:cell differentiation; IMP:MGI.
DR   GO; GO:0022010; P:central nervous system myelination; IMP:MGI.
DR   GO; GO:0090102; P:cochlea development; IMP:MGI.
DR   GO; GO:0048546; P:digestive tract morphogenesis; IMP:MGI.
DR   GO; GO:0072148; P:epithelial cell fate commitment; IMP:MGI.
DR   GO; GO:1902178; P:fibroblast growth factor receptor apoptotic signaling pathway; ISS:UniProtKB.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0030900; P:forebrain development; IMP:MGI.
DR   GO; GO:0048839; P:inner ear development; IMP:MGI.
DR   GO; GO:0060113; P:inner ear receptor cell differentiation; IMP:MGI.
DR   GO; GO:0070307; P:lens fiber cell development; IGI:MGI.
DR   GO; GO:0002089; P:lens morphogenesis in camera-type eye; IMP:MGI.
DR   GO; GO:0000165; P:MAPK cascade; IDA:MGI.
DR   GO; GO:0002009; P:morphogenesis of an epithelium; IMP:MGI.
DR   GO; GO:0048712; P:negative regulation of astrocyte differentiation; IMP:MGI.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IMP:MGI.
DR   GO; GO:0048640; P:negative regulation of developmental growth; IMP:BHF-UCL.
DR   GO; GO:0050680; P:negative regulation of epithelial cell proliferation; IMP:MGI.
DR   GO; GO:0045839; P:negative regulation of mitotic nuclear division; IGI:MGI.
DR   GO; GO:0045879; P:negative regulation of smoothened signaling pathway; IMP:MGI.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IMP:MGI.
DR   GO; GO:0014003; P:oligodendrocyte development; IMP:MGI.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; ISS:UniProtKB.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IMP:MGI.
DR   GO; GO:0045597; P:positive regulation of cell differentiation; IMP:MGI.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; ISS:UniProtKB.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IMP:MGI.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; ISS:UniProtKB.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; ISS:UniProtKB.
DR   GO; GO:0090080; P:positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathway; IGI:MGI.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IMP:MGI.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IDA:MGI.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; ISS:UniProtKB.
DR   GO; GO:0010518; P:positive regulation of phospholipase activity; ISS:UniProtKB.
DR   GO; GO:0031398; P:positive regulation of protein ubiquitination; IDA:MGI.
DR   GO; GO:0042511; P:positive regulation of tyrosine phosphorylation of Stat1 protein; ISS:UniProtKB.
DR   GO; GO:0042517; P:positive regulation of tyrosine phosphorylation of Stat3 protein; ISS:UniProtKB.
DR   GO; GO:0036342; P:post-anal tail morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; ISS:UniProtKB.
DR   GO; GO:0048678; P:response to axon injury; IMP:MGI.
DR   GO; GO:0035019; P:somatic stem cell population maintenance; IMP:MGI.
DR   GO; GO:0021762; P:substantia nigra development; IMP:MGI.
DR   Gene3D; 2.60.40.10; -; 3.
DR   InterPro; IPR016248; FGF_rcpt_fam.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF07679; I-set; 2.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PIRSF; PIRSF000628; FGFR; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00408; IGc2; 3.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 3.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50835; IG_LIKE; 3.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Apoptosis; ATP-binding; Cell membrane;
KW   Complete proteome; Cytoplasmic vesicle; Disulfide bond;
KW   Endoplasmic reticulum; Glycoprotein; Immunoglobulin domain; Kinase;
KW   Membrane; Nucleotide-binding; Phosphoprotein; Receptor;
KW   Reference proteome; Repeat; Signal; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     20       {ECO:0000255}.
FT   CHAIN        21    801       Fibroblast growth factor receptor 3.
FT                                /FTId=PRO_0000016786.
FT   TOPO_DOM     21    369       Extracellular. {ECO:0000255}.
FT   TRANSMEM    370    390       Helical. {ECO:0000255}.
FT   TOPO_DOM    391    801       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       22    124       Ig-like C2-type 1.
FT   DOMAIN      145    238       Ig-like C2-type 2.
FT   DOMAIN      247    349       Ig-like C2-type 3.
FT   DOMAIN      466    756       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     472    480       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    611    611       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     502    502       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     438    438       Phosphoserine.
FT                                {ECO:0000244|PubMed:21183079}.
FT   MOD_RES     439    439       Phosphoserine.
FT                                {ECO:0000244|PubMed:21183079}.
FT   MOD_RES     641    641       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:14699054}.
FT   MOD_RES     642    642       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     719    719       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     755    755       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   CARBOHYD     96     96       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    219    219       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    256    256       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    288    288       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    309    309       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    322    322       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     59    107       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    170    222       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    269    333       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   VAR_SEQ     305    352       TAGANTTDKELEVLSLHNVTFEDAGEYTCLAGNSIGFSHHS
FT                                AWLVVLP -> SWISENVEADARLRLANVSERDGGEYLCRA
FT                                TNFIGVAEKAFWLRVHGPQA (in isoform 2).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_002990.
FT   MUTAGEN     644    644       K->E: Constitutively activated kinase.
FT                                {ECO:0000269|PubMed:14699054}.
FT   CONFLICT    684    684       P -> L (in Ref. 2; AAB25535).
FT                                {ECO:0000305}.
FT   CONFLICT    687    687       Missing (in Ref. 2; AAB25535).
FT                                {ECO:0000305}.
SQ   SEQUENCE   801 AA;  87758 MW;  68BC110212691705 CRC64;
     MVVPACVLVF CVAVVAGATS EPPGPEQRVV RRAAEVPGPE PSQQEQVAFG SGDTVELSCH
     PPGGAPTGPT VWAKDGTGLV ASHRILVGPQ RLQVLNASHE DAGVYSCQHR LTRRVLCHFS
     VRVTDAPSSG DDEDGEDVAE DTGAPYWTRP ERMDKKLLAV PAANTVRFRC PAAGNPTPSI
     SWLKNGKEFR GEHRIGGIKL RHQQWSLVME SVVPSDRGNY TCVVENKFGS IRQTYTLDVL
     ERSPHRPILQ AGLPANQTAI LGSDVEFHCK VYSDAQPHIQ WLKHVEVNGS KVGPDGTPYV
     TVLKTAGANT TDKELEVLSL HNVTFEDAGE YTCLAGNSIG FSHHSAWLVV LPAEEELMET
     DEAGSVYAGV LSYGVVFFLF ILVVAAVILC RLRSPPKKGL GSPTVHKVSR FPLKRQVSLE
     SNSSMNSNTP LVRIARLSSG EGPVLANVSE LELPADPKWE LSRTRLTLGK PLGEGCFGQV
     VMAEAIGIDK DRTAKPVTVA VKMLKDDATD KDLSDLVSEM EMMKMIGKHK NIINLLGACT
     QGGPLYVLVE YAAKGNLREF LRARRPPGMD YSFDACRLPE EQLTCKDLVS CAYQVARGME
     YLASQKCIHR DLAARNVLVT EDNVMKIADF GLARDVHNLD YYKKTTNGRL PVKWMAPEAL
     FDRVYTHQSD VWSFGVLLWE IFTPGGPSPY PGIPVEELFK LLKEGHRMDK PASCTHDLYM
     IMRECWHAVP SQRPTFKQLV EDLDRILTVT STDEYLDLSV PFEQYSPGGQ DTPSSSSSGD
     DSVFTHDLLP PGPPSNGGPR T
//
ID   CO4A1_HUMAN             Reviewed;        1669 AA.
AC   P02462; A7E2W4; B1AM70; Q1P9S9; Q5VWF6; Q86X41; Q8NF88; Q9NYC5;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   06-FEB-2007, sequence version 3.
DT   17-FEB-2016, entry version 180.
DE   RecName: Full=Collagen alpha-1(IV) chain;
DE   Contains:
DE     RecName: Full=Arresten;
DE   Flags: Precursor;
GN   Name=COL4A1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT PRO-555.
RX   PubMed=2701944;
RA   Soininen R., Huotari M., Ganguly A., Prockop D.J., Tryggvason K.;
RT   "Structural organization of the gene for the alpha 1 chain of human
RT   type IV collagen.";
RL   J. Biol. Chem. 264:13565-13571(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057823; DOI=10.1038/nature02379;
RA   Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L.,
RA   Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E.,
RA   Griffiths-Jones S., Jones M.C., Keenan S.J., Oliver K., Scott C.E.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Andrews D.T.,
RA   Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., Bannerjee R.,
RA   Barlow K.F., Bates K., Beasley H., Bird C.P., Bray-Allen S.,
RA   Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M.,
RA   Clegg S.C., Cobley V., Collins J.E., Corby N., Coville G.J.,
RA   Deloukas P., Dhami P., Dunham I., Dunn M., Earthrowl M.E.,
RA   Ellington A.G., Faulkner L., Frankish A.G., Frankland J., French L.,
RA   Garner P., Garnett J., Gilbert J.G.R., Gilson C.J., Ghori J.,
RA   Grafham D.V., Gribble S.M., Griffiths C., Hall R.E., Hammond S.,
RA   Harley J.L., Hart E.A., Heath P.D., Howden P.J., Huckle E.J.,
RA   Hunt P.J., Hunt A.R., Johnson C., Johnson D., Kay M., Kimberley A.M.,
RA   King A., Laird G.K., Langford C.J., Lawlor S., Leongamornlert D.A.,
RA   Lloyd D.M., Lloyd C., Loveland J.E., Lovell J., Martin S.,
RA   Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S.,
RA   Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K.M., Rice C.M., Searle S.,
RA   Sehra H.K., Shownkeen R., Skuce C.D., Smith M., Steward C.A.,
RA   Sycamore N., Tester J., Thomas D.W., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., Whitehead S.L., Willey D.L.,
RA   Wilming L., Wray P.W., Wright M.W., Young L., Coulson A., Durbin R.M.,
RA   Hubbard T., Sulston J.E., Beck S., Bentley D.R., Rogers J., Ross M.T.;
RT   "The DNA sequence and analysis of human chromosome 13.";
RL   Nature 428:522-528(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS
RP   PRO-555 AND HIS-1334.
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-943, AND VARIANT PRO-555.
RC   TISSUE=Placenta;
RX   PubMed=3311751; DOI=10.1111/j.1432-1033.1987.tb13450.x;
RA   Brazel D., Oberbaeumer I., Dieringer H., Babel W., Glanville R.W.,
RA   Deutzmann R., Kuehn K.;
RT   "Completion of the amino acid sequence of the alpha 1 chain of human
RT   basement membrane collagen (type IV) reveals 21 non-triplet
RT   interruptions located within the collagenous domain.";
RL   Eur. J. Biochem. 168:529-536(1987).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-28.
RX   PubMed=3182844;
RA   Soininen R., Huotari M., Hostikka S.L., Prockop D.J., Tryggvason K.;
RT   "The structural genes for alpha 1 and alpha 2 chains of human type IV
RT   collagen are divergently encoded on opposite DNA strands and have an
RT   overlapping promoter region.";
RL   J. Biol. Chem. 263:17217-17220(1988).
RN   [6]
RP   PROTEIN SEQUENCE OF 28-243.
RX   PubMed=4043082; DOI=10.1111/j.1432-1033.1985.tb09186.x;
RA   Glanville R.W., Qian R.Q., Siebold B., Risteli J., Kuehn K.;
RT   "Amino acid sequence of the N-terminal aggregation and cross-linking
RT   region (7S domain) of the alpha 1 (IV) chain of human basement
RT   membrane collagen.";
RL   Eur. J. Biochem. 152:213-219(1985).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 46-1257, AND VARIANT PRO-555.
RC   TISSUE=Placenta;
RX   PubMed=3691802; DOI=10.1016/0014-5793(87)81155-9;
RA   Soininen R., Haka-Risku T., Prockop D.J., Tryggvason K.;
RT   "Complete primary structure of the alpha 1-chain of human basement
RT   membrane (type IV) collagen.";
RL   FEBS Lett. 225:188-194(1987).
RN   [8]
RP   PROTEIN SEQUENCE OF 534-1447.
RX   PubMed=6434307; DOI=10.1111/j.1432-1033.1984.tb08404.x;
RA   Babel W., Glanville R.W.;
RT   "Structure of human-basement-membrane (type IV) collagen. Complete
RT   amino-acid sequence of a 914-residue-long pepsin fragment from the
RT   alpha 1(IV) chain.";
RL   Eur. J. Biochem. 143:545-556(1984).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1256-1669.
RX   PubMed=2581969;
RA   Pihlajaniemi T., Tryggvason K., Myers J.C., Kurkinen M., Lebo R.,
RA   Cheung M.-C., Prockop D.J., Boyd C.D.;
RT   "cDNA clones coding for the pro-alpha1(IV) chain of human type IV
RT   procollagen reveal an unusual homology of amino acid sequences in two
RT   halves of the carboxyl-terminal domain.";
RL   J. Biol. Chem. 260:7681-7687(1985).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1259-1669.
RX   PubMed=2582422; DOI=10.1073/pnas.82.11.3649;
RA   Brinker J.M., Gudas L.J., Loidl H.R., Wang S.-Y., Rosenbloom J.,
RA   Kefalides N.A., Myers J.C.;
RT   "Restricted homology between human alpha 1 type IV and other
RT   procollagen chains.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:3649-3653(1985).
RN   [11]
RP   PROTEIN SEQUENCE OF 1441-1669, AND DISULFIDE BONDS.
RC   TISSUE=Placenta;
RX   PubMed=2844531; DOI=10.1111/j.1432-1033.1988.tb14321.x;
RA   Siebold B., Deutzmann R., Kuehn K.;
RT   "The arrangement of intra- and intermolecular disulfide bonds in the
RT   carboxyterminal, non-collagenous aggregation and cross-linking domain
RT   of basement-membrane type IV collagen.";
RL   Eur. J. Biochem. 176:617-624(1988).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1441-1669, FUNCTION OF ARRESTEN, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=10811134;
RA   Colorado P.C., Torre A., Kamphaus G., Maeshima Y., Hopfer H.,
RA   Takahashi K., Volk R., Zamborsky E.D., Herman S., Sarkar P.K.,
RA   Ericksen M.B., Dhanabal M., Simons M., Post M., Kufe D.W.,
RA   Weichselbaum R.R., Sukhatme V.P., Kalluri R.;
RT   "Anti-angiogenic cues from vascular basement membrane collagen.";
RL   Cancer Res. 60:2520-2526(2000).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1441-1669.
RA   Fu J., Bai X., Wang W., Ruan C.;
RT   "Arresten, a collagen-derived inhibitor of angiogenesis.";
RL   Submitted (MAR-2001) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1441-1669.
RA   Peng X., Yin B., Yuan J., Qiang B.;
RL   Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1441-1669.
RA   Zheng Q.C., Song Z.F., Zheng Y.W., Li Y.Q., Shu X.;
RT   "Molecular cloning and sequencing of human arresten gene.";
RL   Zhonghua Shi Yan Wai Ke Za Zhi 19:46-47(2002).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1441-1669.
RA   He A.B.;
RT   "Cloning and expression of arresten in Escherichia coli and Pachia
RT   pastoris.";
RL   Submitted (AUG-2002) to the EMBL/GenBank/DDBJ databases.
RN   [17]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1441-1669, FUNCTION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Placenta;
RX   PubMed=16481288;
RA   Zheng J.P., Tang H.Y., Chen X.J., Yu B.F., Xie J., Wu T.C.;
RT   "Construction of recombinant plasmid and prokaryotic expression in E.
RT   coli and biological activity analysis of human placenta arresten
RT   gene.";
RL   Hepatobiliary Pancreat. Dis. Int. 5:74-79(2006).
RN   [18]
RP   IDENTIFICATION OF RECEPTOR, AND FUNCTION OF ARRESTEN.
RX   PubMed=16151532; DOI=10.1172/JCI24813;
RA   Sudhakar A., Nyberg P., Keshamouni V.G., Mannam A.P., Li J.,
RA   Sugimoto H., Cosgrove D., Kalluri R.;
RT   "Human alpha1 type IV collagen NC1 domain exhibits distinct
RT   antiangiogenic activity mediated by alpha1beta1 integrin.";
RL   J. Clin. Invest. 115:2801-2810(2005).
RN   [19]
RP   IDENTIFICATION OF RECEPTOR, AND FUNCTION OF ARRESTEN.
RX   PubMed=18775695; DOI=10.1016/j.yexcr.2008.08.011;
RA   Nyberg P., Xie L., Sugimoto H., Colorado P., Sund M., Holthaus K.,
RA   Sudhakar A., Salo T., Kalluri R.;
RT   "Characterization of the anti-angiogenic properties of arresten, an
RT   alpha1beta1 integrin-dependent collagen-derived tumor suppressor.";
RL   Exp. Cell Res. 314:3292-3305(2008).
RN   [20]
RP   INVOLVEMENT IN ICH, VARIANTS ICH LEU-352 AND GLY-538, VARIANTS VAL-144
RP   AND VAL-1531, AND CHARACTERIZATION OF VARIANTS ICH LEU-352 AND
RP   GLY-538.
RX   PubMed=22522439; DOI=10.1002/ana.22682;
RA   Weng Y.C., Sonni A., Labelle-Dumais C., de Leau M., Kauffman W.B.,
RA   Jeanne M., Biffi A., Greenberg S.M., Rosand J., Gould D.B.;
RT   "COL4A1 mutations in patients with sporadic late-onset intracerebral
RT   hemorrhage.";
RL   Ann. Neurol. 71:470-477(2012).
RN   [21]
RP   INVOLVEMENT IN BSVD, AND VARIANTS BSVD ARG-755; ARG-773; ASP-882 AND
RP   ARG-1266.
RX   PubMed=22574627; DOI=10.1111/j.1469-8749.2011.04198.x;
RA   Shah S., Ellard S., Kneen R., Lim M., Osborne N., Rankin J.,
RA   Stoodley N., van der Knaap M., Whitney A., Jardine P.;
RT   "Childhood presentation of COL4A1 mutations.";
RL   Dev. Med. Child. Neurol. 54:569-574(2012).
RN   [22]
RP   INVOLVEMENT IN BSVD, AND VARIANT BSVD LYS-1627.
RX   PubMed=23394911; DOI=10.1016/j.ajo.2012.11.028;
RA   Rodahl E., Knappskog P.M., Majewski J., Johansson S., Telstad W.,
RA   Krakenes J., Boman H.;
RT   "Variants of anterior segment dysgenesis and cerebral involvement in a
RT   large family with a novel COL4A1 mutation.";
RL   Am. J. Ophthalmol. 155:946-953(2013).
RN   [23]
RP   INVOLVEMENT IN SCHZ, AND VARIANTS SCHZC ARG-655; ARG-870; SER-897;
RP   SER-948; GLU-1041; GLU-1082; ARG-1326; ASP-1332 AND LYS-1615.
RX   PubMed=23225343; DOI=10.1002/ana.23736;
RA   Yoneda Y., Haginoya K., Kato M., Osaka H., Yokochi K., Arai H.,
RA   Kakita A., Yamamoto T., Otsuki Y., Shimizu S., Wada T., Koyama N.,
RA   Mino Y., Kondo N., Takahashi S., Hirabayashi S., Takanashi J.,
RA   Okumura A., Kumagai T., Hirai S., Nabetani M., Saitoh S., Hattori A.,
RA   Yamasaki M., Kumakura A., Sugo Y., Nishiyama K., Miyatake S.,
RA   Tsurusaki Y., Doi H., Miyake N., Matsumoto N., Saitsu H.;
RT   "Phenotypic spectrum of COL4A1 mutations: porencephaly to
RT   schizencephaly.";
RL   Ann. Neurol. 73:48-57(2013).
RN   [24]
RP   INVOLVEMENT IN RATOR, AND VARIANT RATOR ARG-510.
RX   PubMed=25228067; DOI=10.1007/s00417-014-2800-6;
RA   Zenteno J.C., Crespi J., Buentello-Volante B., Buil J.A.,
RA   Bassaganyas F., Vela-Segarra J.I., Diaz-Cascajosa J., Marieges M.T.;
RT   "Next generation sequencing uncovers a missense mutation in COL4A1 as
RT   the cause of familial retinal arteriolar tortuosity.";
RL   Graefes Arch. Clin. Exp. Ophthalmol. 252:1789-1794(2014).
RN   [25]
RP   INVOLVEMENT IN BSVD, AND VARIANTS BSVD ARG-708 AND ARG-773.
RX   PubMed=24628545; DOI=10.1111/cge.12379;
RA   Deml B., Reis L.M., Maheshwari M., Griffis C., Bick D., Semina E.V.;
RT   "Whole exome analysis identifies dominant COL4A1 mutations in patients
RT   with complex ocular phenotypes involving microphthalmia.";
RL   Clin. Genet. 86:475-481(2014).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 1441-1669, AND ADDITIONAL
RP   INTERCHAIN LINKS.
RX   PubMed=12011424; DOI=10.1073/pnas.062183499;
RA   Than M.E., Henrich S., Huber R., Ries A., Mann K., Kuhn K., Timpl R.,
RA   Bourenkov G.P., Bartunik H.D., Bode W.;
RT   "The 1.9-A crystal structure of the noncollagenous (NC1) domain of
RT   human placenta collagen IV shows stabilization via a novel type of
RT   covalent Met-Lys cross-link.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:6607-6612(2002).
RN   [28]
RP   VARIANTS POREN1 SER-749 AND ARG-1236.
RX   PubMed=15905400; DOI=10.1126/science.1109418;
RA   Gould D.B., Phalan F.C., Breedveld G.J., van Mil S.E., Smith R.S.,
RA   Schimenti J.C., Aguglia U., van der Knaap M.S., Heutink P.,
RA   John S.W.M.;
RT   "Mutations in Col4a1 cause perinatal cerebral hemorrhage and
RT   porencephaly.";
RL   Science 308:1167-1171(2005).
RN   [29]
RP   VARIANTS POREN1 ASP-1130 AND ARG-1423.
RX   PubMed=16107487; DOI=10.1136/jmg.2005.035584;
RA   Breedveld G., de Coo I.F., Lequin M.H., Arts W.F.M., Heutink P.,
RA   Gould D.B., John S.W.M., Oostra B., Mancini G.M.S.;
RT   "Novel mutations in three families confirm a major role of COL4A1 in
RT   hereditary porencephaly.";
RL   J. Med. Genet. 43:490-495(2006).
RN   [30]
RP   VARIANT BSVD GLU-562.
RX   PubMed=16598045; DOI=10.1056/NEJMoa053727;
RA   Gould D.B., Phalan F.C., van Mil S.E., Sundberg J.P., Vahedi K.,
RA   Massin P., Bousser M.G., Heutink P., Miner J.H., Tournier-Lasserve E.,
RA   John S.W.M.;
RT   "Role of COL4A1 in small-vessel disease and hemorrhagic stroke.";
RL   N. Engl. J. Med. 354:1489-1496(2006).
RN   [31]
RP   VARIANT BSVD ASP-720.
RX   PubMed=17696175; DOI=10.1002/ana.21191;
RA   Sibon I., Coupry I., Menegon P., Bouchet J.P., Gorry P., Burgelin I.,
RA   Calvas P., Orignac I., Dousset V., Lacombe D., Orgogozo J.M.,
RA   Arveiler B., Goizet C.;
RT   "COL4A1 mutation in Axenfeld-Rieger anomaly with leukoencephalopathy
RT   and stroke.";
RL   Ann. Neurol. 62:177-184(2007).
RN   [32]
RP   VARIANTS HANAC VAL-498; ARG-519 AND GLU-528.
RX   PubMed=18160688; DOI=10.1056/NEJMoa071906;
RA   Plaisier E., Gribouval O., Alamowitch S., Mougenot B., Prost C.,
RA   Verpont M.C., Marro B., Desmettre T., Cohen S.Y., Roullet E.,
RA   Dracon M., Fardeau M., Van Agtmael T., Kerjaschki D., Antignac C.,
RA   Ronco P.;
RT   "COL4A1 mutations and hereditary angiopathy, nephropathy, aneurysms,
RT   and muscle cramps.";
RL   N. Engl. J. Med. 357:2687-2695(2007).
RN   [33]
RP   INTERCHAIN SULFILIMINE BONDS.
RX   PubMed=19729652; DOI=10.1126/science.1176811;
RA   Vanacore R., Ham A.-J.L., Voehler M., Sanders C.R., Conrads T.P.,
RA   Veenstra T.D., Sharpless K.B., Dawson P.E., Hudson B.G.;
RT   "A sulfilimine bond identified in collagen IV.";
RL   Science 325:1230-1234(2009).
RN   [34]
RP   VARIANT BSVD ARG-805.
RX   PubMed=17379824; DOI=10.1161/STROKEAHA.106.475194;
RA   Vahedi K., Kubis N., Boukobza M., Arnoult M., Massin P.,
RA   Tournier-Lasserve E., Bousser M.G.;
RT   "COL4A1 mutation in a patient with sporadic, recurrent intracerebral
RT   hemorrhage.";
RL   Stroke 38:1461-1464(2007).
RN   [35]
RP   VARIANT POREN1 ARG-1580.
RX   PubMed=19194877; DOI=10.1002/ana.21525;
RA   de Vries L.S., Koopman C., Groenendaal F., Van Schooneveld M.,
RA   Verheijen F.W., Verbeek E., Witkamp T.D., van der Worp H.B.,
RA   Mancini G.;
RT   "COL4A1 mutation in two preterm siblings with antenatal onset of
RT   parenchymal hemorrhage.";
RL   Ann. Neurol. 65:12-18(2009).
RN   [36]
RP   VARIANTS HANAC ARG-498; ARG-510 AND LEU-525.
RX   PubMed=20818663; DOI=10.1002/ajmg.a.33659;
RA   Plaisier E., Chen Z., Gekeler F., Benhassine S., Dahan K., Marro B.,
RA   Alamowitch S., Paques M., Ronco P.;
RT   "Novel COL4A1 mutations associated with HANAC syndrome: a role for the
RT   triple helical CB3[IV] domain.";
RL   Am. J. Med. Genet. A 152:2550-2555(2010).
RN   [37]
RP   VARIANTS BSVD ASP-720 AND ARG-755.
RX   PubMed=20385946; DOI=10.1001/archophthalmol.2010.42;
RA   Coupry I., Sibon I., Mortemousque B., Rouanet F., Mine M., Goizet C.;
RT   "Ophthalmological features associated with COL4A1 mutations.";
RL   Arch. Ophthalmol. 128:483-489(2010).
RN   [38]
RP   VARIANT BSVD ARG-755.
RX   PubMed=19477666; DOI=10.1016/j.ejpn.2009.04.010;
RA   Shah S., Kumar Y., McLean B., Churchill A., Stoodley N., Rankin J.,
RA   Rizzu P., van der Knaap M., Jardine P.;
RT   "A dominantly inherited mutation in collagen IV A1 (COL4A1) causing
RT   childhood onset stroke without porencephaly.";
RL   Eur. J. Paediatr. Neurol. 14:182-187(2010).
RN   [39]
RP   VARIANTS LEU-7; PRO-555 AND HIS-1334.
RX   PubMed=21527998;
RA   Karolak J.A., Kulinska K., Nowak D.M., Pitarque J.A., Molinari A.,
RA   Rydzanicz M., Bejjani B.A., Gajecka M.;
RT   "Sequence variants in COL4A1 and COL4A2 genes in Ecuadorian families
RT   with keratoconus.";
RL   Mol. Vis. 17:827-843(2011).
CC   -!- FUNCTION: Type IV collagen is the major structural component of
CC       glomerular basement membranes (GBM), forming a 'chicken-wire'
CC       meshwork together with laminins, proteoglycans and
CC       entactin/nidogen.
CC   -!- FUNCTION: Arresten, comprising the C-terminal NC1 domain, inhibits
CC       angiogenesis and tumor formation. The C-terminal half is found to
CC       possess the anti-angiogenic activity. Specifically inhibits
CC       endothelial cell proliferation, migration and tube formation.
CC       Inhibits expression of hypoxia-inducible factor 1alpha and ERK1/2
CC       and p38 MAPK activation. Ligand for alpha1/beta1 integrin.
CC   -!- SUBUNIT: There are six type IV collagen isoforms, alpha 1(IV)-
CC       alpha 6(IV), each of which can form a triple helix structure with
CC       2 other chains to generate type IV collagen network.
CC   -!- INTERACTION:
CC       P08572:COL4A2; NbExp=2; IntAct=EBI-2432478, EBI-2432506;
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular
CC       matrix, basement membrane.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P02462-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P02462-2; Sequence=VSP_034644;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Highly expressed in placenta.
CC       {ECO:0000269|PubMed:10811134, ECO:0000269|PubMed:16481288}.
CC   -!- DOMAIN: Alpha chains of type IV collagen have a non-collagenous
CC       domain (NC1) at their C-terminus, frequent interruptions of the G-
CC       X-Y repeats in the long central triple-helical domain (which may
CC       cause flexibility in the triple helix), and a short N-terminal
CC       triple-helical 7S domain.
CC   -!- PTM: Lysines at the third position of the tripeptide repeating
CC       unit (G-X-Y) are hydroxylated in all cases and bind carbohydrates.
CC   -!- PTM: Prolines at the third position of the tripeptide repeating
CC       unit (G-X-Y) are hydroxylated in some or all of the chains.
CC   -!- PTM: Type IV collagens contain numerous cysteine residues which
CC       are involved in inter- and intramolecular disulfide bonding. 12 of
CC       these, located in the NC1 domain, are conserved in all known type
CC       IV collagens.
CC   -!- PTM: The trimeric structure of the NC1 domains is stabilized by
CC       covalent bonds between Lys and Met residues.
CC   -!- PTM: Proteolytic processing produces the C-terminal NC1 peptide,
CC       arresten.
CC   -!- DISEASE: Brain small vessel disease with or without ocular
CC       anomalies (BSVD) [MIM:607595]: An autosomal dominant disease
CC       characterized by weakening of the blood vessels in the brain and
CC       retinal arteriolar tortuosity. In affected individuals, stroke is
CC       often the first symptom and is usually caused by bleeding in the
CC       brain (hemorrhagic stroke) rather than a lack of blood flow in the
CC       brain (ischemic stroke). Patients also have leukoencephalopathy
CC       and may experience seizures and migraine headaches accompanied by
CC       visual sensations known as auras. {ECO:0000269|PubMed:16598045,
CC       ECO:0000269|PubMed:17379824, ECO:0000269|PubMed:17696175,
CC       ECO:0000269|PubMed:19477666, ECO:0000269|PubMed:20385946,
CC       ECO:0000269|PubMed:22574627, ECO:0000269|PubMed:23394911,
CC       ECO:0000269|PubMed:24628545}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Hereditary angiopathy with nephropathy aneurysms and
CC       muscle cramps (HANAC) [MIM:611773]: The clinical renal
CC       manifestations include hematuria and bilateral large cysts.
CC       Histologic analysis revealed complex basement membrane defects in
CC       kidney and skin. The systemic angiopathy appears to affect both
CC       small vessels and large arteries. {ECO:0000269|PubMed:18160688,
CC       ECO:0000269|PubMed:20818663}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Porencephaly 1 (POREN1) [MIM:175780]: A neurologic
CC       disorder characterized by a fluid-filled cysts or cavities within
CC       the cerebral hemispheres, neurologic manifestations, facial
CC       paresis, and visual defects. Affected individuals typically have
CC       hemiplegia, seizures, and intellectual disability. Porencephaly
CC       type 1 is usually unilateral and results from focal destructive
CC       lesions such as fetal vascular occlusion or birth trauma.
CC       {ECO:0000269|PubMed:15905400, ECO:0000269|PubMed:16107487,
CC       ECO:0000269|PubMed:19194877}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Intracerebral hemorrhage (ICH) [MIM:614519]: A
CC       pathological condition characterized by bleeding into one or both
CC       cerebral hemispheres including the basal ganglia and the cerebral
CC       cortex. It is often associated with hypertension and
CC       craniocerebral trauma. Intracerebral bleeding is a common cause of
CC       stroke. {ECO:0000269|PubMed:22522439}. Note=Disease susceptibility
CC       is associated with variations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Tortuosity of retinal arteries (RATOR) [MIM:180000]: A
CC       disease characterized by marked tortuosity of second- and third-
CC       order retinal arteries with normal first-order arteries and venous
CC       system. Most patients manifest variable degrees of symptomatic
CC       transient vision loss due to retinal hemorrhage following minor
CC       stress or trauma. {ECO:0000269|PubMed:25228067}. Note=The disease
CC       is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Schizencephaly (SCHZC) [MIM:269160]: Extremely rare human
CC       congenital disorder characterized by a full-thickness cleft within
CC       the cerebral hemispheres. These clefts are lined with gray matter
CC       and most commonly involve the parasylvian regions. Large portions
CC       of the cerebral hemispheres may be absent and replaced by cerebro-
CC       spinal fluid. {ECO:0000269|PubMed:23225343}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the type IV collagen family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00736}.
CC   -!- SIMILARITY: Contains 1 collagen IV NC1 (C-terminal non-
CC       collagenous) domain. {ECO:0000255|PROSITE-ProRule:PRU00736}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M26576; AAA53098.1; -; Genomic_DNA.
DR   EMBL; J04217; AAA53098.1; JOINED; Genomic_DNA.
DR   EMBL; M26550; AAA53098.1; JOINED; Genomic_DNA.
DR   EMBL; M26540; AAA53098.1; JOINED; Genomic_DNA.
DR   EMBL; M26542; AAA53098.1; JOINED; Genomic_DNA.
DR   EMBL; M26543; AAA53098.1; JOINED; Genomic_DNA.
DR   EMBL; M26544; AAA53098.1; JOINED; Genomic_DNA.
DR   EMBL; M26545; AAA53098.1; JOINED; Genomic_DNA.
DR   EMBL; M26546; AAA53098.1; JOINED; Genomic_DNA.
DR   EMBL; M26547; AAA53098.1; JOINED; Genomic_DNA.
DR   EMBL; M26537; AAA53098.1; JOINED; Genomic_DNA.
DR   EMBL; M26538; AAA53098.1; JOINED; Genomic_DNA.
DR   EMBL; M26548; AAA53098.1; JOINED; Genomic_DNA.
DR   EMBL; M26549; AAA53098.1; JOINED; Genomic_DNA.
DR   EMBL; M26551; AAA53098.1; JOINED; Genomic_DNA.
DR   EMBL; M26552; AAA53098.1; JOINED; Genomic_DNA.
DR   EMBL; M26553; AAA53098.1; JOINED; Genomic_DNA.
DR   EMBL; M26554; AAA53098.1; JOINED; Genomic_DNA.
DR   EMBL; M26555; AAA53098.1; JOINED; Genomic_DNA.
DR   EMBL; M26556; AAA53098.1; JOINED; Genomic_DNA.
DR   EMBL; M26557; AAA53098.1; JOINED; Genomic_DNA.
DR   EMBL; M26539; AAA53098.1; JOINED; Genomic_DNA.
DR   EMBL; M26558; AAA53098.1; JOINED; Genomic_DNA.
DR   EMBL; M26559; AAA53098.1; JOINED; Genomic_DNA.
DR   EMBL; M26560; AAA53098.1; JOINED; Genomic_DNA.
DR   EMBL; M26561; AAA53098.1; JOINED; Genomic_DNA.
DR   EMBL; M26562; AAA53098.1; JOINED; Genomic_DNA.
DR   EMBL; M26536; AAA53098.1; JOINED; Genomic_DNA.
DR   EMBL; M26563; AAA53098.1; JOINED; Genomic_DNA.
DR   EMBL; M26541; AAA53098.1; JOINED; Genomic_DNA.
DR   EMBL; M26564; AAA53098.1; JOINED; Genomic_DNA.
DR   EMBL; M26565; AAA53098.1; JOINED; Genomic_DNA.
DR   EMBL; M26566; AAA53098.1; JOINED; Genomic_DNA.
DR   EMBL; M26567; AAA53098.1; JOINED; Genomic_DNA.
DR   EMBL; M26568; AAA53098.1; JOINED; Genomic_DNA.
DR   EMBL; M26569; AAA53098.1; JOINED; Genomic_DNA.
DR   EMBL; M26570; AAA53098.1; JOINED; Genomic_DNA.
DR   EMBL; M26571; AAA53098.1; JOINED; Genomic_DNA.
DR   EMBL; M26572; AAA53098.1; JOINED; Genomic_DNA.
DR   EMBL; M26573; AAA53098.1; JOINED; Genomic_DNA.
DR   EMBL; M26574; AAA53098.1; JOINED; Genomic_DNA.
DR   EMBL; M26575; AAA53098.1; JOINED; Genomic_DNA.
DR   EMBL; AL161773; CAH71365.1; -; Genomic_DNA.
DR   EMBL; AL390755; CAH71365.1; JOINED; Genomic_DNA.
DR   EMBL; AL390755; CAH74130.1; -; Genomic_DNA.
DR   EMBL; AL161773; CAH74130.1; JOINED; Genomic_DNA.
DR   EMBL; AL161773; CAM14222.1; -; Genomic_DNA.
DR   EMBL; AL390755; CAM14222.1; JOINED; Genomic_DNA.
DR   EMBL; AL390755; CAM20295.1; -; Genomic_DNA.
DR   EMBL; AL161773; CAM20295.1; JOINED; Genomic_DNA.
DR   EMBL; BC047305; AAH47305.1; -; mRNA.
DR   EMBL; BC151220; AAI51221.1; -; mRNA.
DR   EMBL; X05561; CAA29075.1; -; mRNA.
DR   EMBL; Y00706; CAA68698.1; -; mRNA.
DR   EMBL; M10940; AAA52006.1; -; mRNA.
DR   EMBL; M11315; AAA52042.1; -; mRNA.
DR   EMBL; AF258349; AAF72630.1; -; mRNA.
DR   EMBL; AF363672; AAK53382.1; -; mRNA.
DR   EMBL; AF400431; AAK92480.1; -; mRNA.
DR   EMBL; AY285780; AAP43112.1; -; mRNA.
DR   EMBL; AF536207; AAM97359.1; -; mRNA.
DR   EMBL; DQ464183; ABE73157.1; -; mRNA.
DR   CCDS; CCDS9511.1; -. [P02462-1]
DR   PIR; S16876; CGHU4B.
DR   RefSeq; NP_001290039.1; NM_001303110.1.
DR   RefSeq; NP_001836.3; NM_001845.5.
DR   UniGene; Hs.17441; -.
DR   PDB; 1LI1; X-ray; 1.90 A; A/B/D/E=1441-1669.
DR   PDBsum; 1LI1; -.
DR   ProteinModelPortal; P02462; -.
DR   SMR; P02462; 1442-1669.
DR   BioGrid; 107679; 19.
DR   IntAct; P02462; 26.
DR   MINT; MINT-6743187; -.
DR   STRING; 9606.ENSP00000364979; -.
DR   ChEMBL; CHEMBL2364188; -.
DR   PhosphoSite; P02462; -.
DR   SwissPalm; P02462; -.
DR   BioMuta; COL4A1; -.
DR   DMDM; 125987809; -.
DR   MaxQB; P02462; -.
DR   PaxDb; P02462; -.
DR   PRIDE; P02462; -.
DR   Ensembl; ENST00000375820; ENSP00000364979; ENSG00000187498.
DR   GeneID; 1282; -.
DR   KEGG; hsa:1282; -.
DR   UCSC; uc001vqw.4; human. [P02462-1]
DR   CTD; 1282; -.
DR   GeneCards; COL4A1; -.
DR   GeneReviews; COL4A1; -.
DR   HGNC; HGNC:2202; COL4A1.
DR   HPA; CAB001695; -.
DR   HPA; HPA054039; -.
DR   MalaCards; COL4A1; -.
DR   MIM; 120130; gene.
DR   MIM; 175780; phenotype.
DR   MIM; 180000; phenotype.
DR   MIM; 269160; phenotype.
DR   MIM; 607595; phenotype.
DR   MIM; 611773; phenotype.
DR   MIM; 614519; phenotype.
DR   neXtProt; NX_P02462; -.
DR   Orphanet; 73229; Autosomal dominant familial hematuria - retinal arteriolar tortuosity - contractures.
DR   Orphanet; 99810; Familial porencephaly.
DR   Orphanet; 36383; Familial vascular leukoencephalopathy.
DR   Orphanet; 799; Schizencephaly.
DR   Orphanet; 899; Walker-Warburg syndrome.
DR   PharmGKB; PA26717; -.
DR   eggNOG; KOG3544; Eukaryota.
DR   eggNOG; ENOG410XNMM; LUCA.
DR   HOVERGEN; HBG004933; -.
DR   InParanoid; P02462; -.
DR   KO; K06237; -.
DR   OrthoDB; EOG7RZ5P3; -.
DR   PhylomeDB; P02462; -.
DR   TreeFam; TF316865; -.
DR   Reactome; R-HSA-1442490; Collagen degradation.
DR   Reactome; R-HSA-1474244; Extracellular matrix organization.
DR   Reactome; R-HSA-1650814; Collagen biosynthesis and modifying enzymes.
DR   Reactome; R-HSA-186797; Signaling by PDGF.
DR   Reactome; R-HSA-2022090; Assembly of collagen fibrils and other multimeric structures.
DR   Reactome; R-HSA-216083; Integrin cell surface interactions.
DR   Reactome; R-HSA-2214320; Anchoring fibril formation.
DR   Reactome; R-HSA-3000157; Laminin interactions.
DR   Reactome; R-HSA-3000171; Non-integrin membrane-ECM interactions.
DR   Reactome; R-HSA-3000178; ECM proteoglycans.
DR   Reactome; R-HSA-3000480; Scavenging by Class A Receptors.
DR   Reactome; R-HSA-419037; NCAM1 interactions.
DR   ChiTaRS; COL4A1; human.
DR   EvolutionaryTrace; P02462; -.
DR   GeneWiki; Collagen,_type_IV,_alpha_1; -.
DR   GenomeRNAi; 1282; -.
DR   NextBio; 5181; -.
DR   PRO; PR:P02462; -.
DR   Proteomes; UP000005640; Chromosome 13.
DR   Bgee; P02462; -.
DR   CleanEx; HS_COL4A1; -.
DR   ExpressionAtlas; P02462; baseline and differential.
DR   Genevisible; P02462; HS.
DR   GO; GO:0005604; C:basement membrane; IC:BHF-UCL.
DR   GO; GO:0005587; C:collagen type IV trimer; IMP:BHF-UCL.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0031012; C:extracellular matrix; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; NAS:UniProtKB.
DR   GO; GO:0030023; F:extracellular matrix constituent conferring elasticity; IC:BHF-UCL.
DR   GO; GO:0005201; F:extracellular matrix structural constituent; IMP:BHF-UCL.
DR   GO; GO:0048407; F:platelet-derived growth factor binding; IDA:MGI.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0071711; P:basement membrane organization; IMP:BHF-UCL.
DR   GO; GO:0048514; P:blood vessel morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0007420; P:brain development; IMP:BHF-UCL.
DR   GO; GO:0071230; P:cellular response to amino acid stimulus; IEA:Ensembl.
DR   GO; GO:0030574; P:collagen catabolic process; TAS:Reactome.
DR   GO; GO:0030855; P:epithelial cell differentiation; IEA:Ensembl.
DR   GO; GO:0022617; P:extracellular matrix disassembly; TAS:Reactome.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0007528; P:neuromuscular junction development; IEA:Ensembl.
DR   GO; GO:0001569; P:patterning of blood vessels; IMP:BHF-UCL.
DR   GO; GO:0006898; P:receptor-mediated endocytosis; TAS:Reactome.
DR   GO; GO:0061333; P:renal tubule morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0061304; P:retinal blood vessel morphogenesis; IMP:BHF-UCL.
DR   Gene3D; 2.170.240.10; -; 1.
DR   InterPro; IPR016187; C-type_lectin_fold.
DR   InterPro; IPR008160; Collagen.
DR   InterPro; IPR001442; Collagen_VI_NC.
DR   Pfam; PF01413; C4; 2.
DR   Pfam; PF01391; Collagen; 15.
DR   SMART; SM00111; C4; 2.
DR   SUPFAM; SSF56436; SSF56436; 2.
DR   PROSITE; PS51403; NC1_IV; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Angiogenesis; Basement membrane;
KW   Collagen; Complete proteome; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; Extracellular matrix; Glycoprotein;
KW   Hydroxylation; Polymorphism; Reference proteome; Repeat; Secreted;
KW   Signal.
FT   SIGNAL        1     27       {ECO:0000269|PubMed:4043082}.
FT   PROPEP       28    172       N-terminal propeptide (7S domain).
FT                                /FTId=PRO_0000005748.
FT   CHAIN       173   1669       Collagen alpha-1(IV) chain.
FT                                /FTId=PRO_0000005749.
FT   CHAIN      1445   1669       Arresten.
FT                                /FTId=PRO_0000390482.
FT   DOMAIN     1445   1669       Collagen IV NC1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00736}.
FT   REGION      173   1440       Triple-helical region.
FT   CARBOHYD    126    126       N-linked (GlcNAc...).
FT   DISULFID   1460   1551       {ECO:0000255|PROSITE-ProRule:PRU00736,
FT                                ECO:0000269|PubMed:2844531}.
FT   DISULFID   1493   1548       {ECO:0000255|PROSITE-ProRule:PRU00736,
FT                                ECO:0000269|PubMed:2844531}.
FT   DISULFID   1505   1511       {ECO:0000255|PROSITE-ProRule:PRU00736,
FT                                ECO:0000269|PubMed:2844531}.
FT   DISULFID   1570   1665       {ECO:0000255|PROSITE-ProRule:PRU00736,
FT                                ECO:0000269|PubMed:2844531}.
FT   DISULFID   1604   1662       {ECO:0000255|PROSITE-ProRule:PRU00736,
FT                                ECO:0000269|PubMed:2844531}.
FT   DISULFID   1616   1622       {ECO:0000255|PROSITE-ProRule:PRU00736,
FT                                ECO:0000269|PubMed:2844531}.
FT   CROSSLNK   1533   1533       S-Lysyl-methionine sulfilimine (Met-Lys)
FT                                (interchain with K-1651).
FT   CROSSLNK   1651   1651       S-Lysyl-methionine sulfilimine (Lys-Met)
FT                                (interchain with M-1533).
FT   VAR_SEQ     498    848       Missing (in isoform 2). {ECO:0000305}.
FT                                /FTId=VSP_034644.
FT   VARIANT       7      7       V -> L (in dbSNP:rs9515185).
FT                                {ECO:0000269|PubMed:21527998}.
FT                                /FTId=VAR_030027.
FT   VARIANT     144    144       A -> V. {ECO:0000269|PubMed:22522439}.
FT                                /FTId=VAR_073809.
FT   VARIANT     304    304       P -> L (in dbSNP:rs34843786).
FT                                /FTId=VAR_044158.
FT   VARIANT     352    352       P -> L (in ICH; the mutant protein is
FT                                retained intracellularly and is not
FT                                secreted normally).
FT                                {ECO:0000269|PubMed:22522439}.
FT                                /FTId=VAR_073810.
FT   VARIANT     498    498       G -> R (in HANAC).
FT                                {ECO:0000269|PubMed:20818663}.
FT                                /FTId=VAR_064493.
FT   VARIANT     498    498       G -> V (in HANAC).
FT                                {ECO:0000269|PubMed:18160688}.
FT                                /FTId=VAR_044159.
FT   VARIANT     510    510       G -> R (in HANAC and RATOR).
FT                                {ECO:0000269|PubMed:20818663,
FT                                ECO:0000269|PubMed:25228067}.
FT                                /FTId=VAR_064494.
FT   VARIANT     519    519       G -> R (in HANAC).
FT                                {ECO:0000269|PubMed:18160688}.
FT                                /FTId=VAR_044160.
FT   VARIANT     525    525       G -> L (in HANAC; requires 2 nucleotide
FT                                substitutions).
FT                                {ECO:0000269|PubMed:20818663}.
FT                                /FTId=VAR_064495.
FT   VARIANT     528    528       G -> E (in HANAC).
FT                                {ECO:0000269|PubMed:18160688}.
FT                                /FTId=VAR_044161.
FT   VARIANT     538    538       R -> G (in ICH; the mutant protein is
FT                                retained intracellularly and is not
FT                                secreted normally).
FT                                {ECO:0000269|PubMed:22522439}.
FT                                /FTId=VAR_073811.
FT   VARIANT     555    555       T -> P (in dbSNP:rs536174).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:21527998,
FT                                ECO:0000269|PubMed:2701944,
FT                                ECO:0000269|PubMed:3311751,
FT                                ECO:0000269|PubMed:3691802}.
FT                                /FTId=VAR_030511.
FT   VARIANT     562    562       G -> E (in BSVD).
FT                                {ECO:0000269|PubMed:16598045}.
FT                                /FTId=VAR_030028.
FT   VARIANT     655    655       G -> R (in SCHZC).
FT                                {ECO:0000269|PubMed:23225343}.
FT                                /FTId=VAR_073812.
FT   VARIANT     708    708       G -> R (in BSVD).
FT                                {ECO:0000269|PubMed:24628545}.
FT                                /FTId=VAR_073813.
FT   VARIANT     720    720       G -> D (in BSVD; diffuse small vessel
FT                                disease of the brain associated with
FT                                Axenfeld-Rieger anomaly and
FT                                leukoencephalopathy).
FT                                {ECO:0000269|PubMed:17696175,
FT                                ECO:0000269|PubMed:20385946}.
FT                                /FTId=VAR_064496.
FT   VARIANT     749    749       G -> S (in POREN1).
FT                                {ECO:0000269|PubMed:15905400}.
FT                                /FTId=VAR_030029.
FT   VARIANT     755    755       G -> R (in BSVD; associated with ocular
FT                                anomalies of variable severity in some
FT                                patients). {ECO:0000269|PubMed:19477666,
FT                                ECO:0000269|PubMed:20385946,
FT                                ECO:0000269|PubMed:22574627}.
FT                                /FTId=VAR_064497.
FT   VARIANT     773    773       G -> R (in BSVD).
FT                                {ECO:0000269|PubMed:22574627,
FT                                ECO:0000269|PubMed:24628545}.
FT                                /FTId=VAR_073814.
FT   VARIANT     805    805       G -> R (in BSVD).
FT                                {ECO:0000269|PubMed:17379824}.
FT                                /FTId=VAR_064498.
FT   VARIANT     870    870       G -> R (in SCHZC).
FT                                {ECO:0000269|PubMed:23225343}.
FT                                /FTId=VAR_073815.
FT   VARIANT     882    882       G -> D (in BSVD).
FT                                {ECO:0000269|PubMed:22574627}.
FT                                /FTId=VAR_073816.
FT   VARIANT     897    897       G -> S (in SCHZC).
FT                                {ECO:0000269|PubMed:23225343}.
FT                                /FTId=VAR_073817.
FT   VARIANT     948    948       G -> S (in SCHZC).
FT                                {ECO:0000269|PubMed:23225343}.
FT                                /FTId=VAR_073818.
FT   VARIANT    1041   1041       G -> E (in SCHZC).
FT                                {ECO:0000269|PubMed:23225343}.
FT                                /FTId=VAR_073819.
FT   VARIANT    1082   1082       G -> E (in SCHZC).
FT                                {ECO:0000269|PubMed:23225343}.
FT                                /FTId=VAR_073820.
FT   VARIANT    1130   1130       G -> D (in POREN1).
FT                                {ECO:0000269|PubMed:16107487}.
FT                                /FTId=VAR_030030.
FT   VARIANT    1236   1236       G -> R (in POREN1).
FT                                {ECO:0000269|PubMed:15905400}.
FT                                /FTId=VAR_030031.
FT   VARIANT    1266   1266       G -> R (in BSVD).
FT                                {ECO:0000269|PubMed:22574627}.
FT                                /FTId=VAR_073821.
FT   VARIANT    1326   1326       G -> R (in SCHZC).
FT                                {ECO:0000269|PubMed:23225343}.
FT                                /FTId=VAR_073822.
FT   VARIANT    1332   1332       G -> D (in SCHZC).
FT                                {ECO:0000269|PubMed:23225343}.
FT                                /FTId=VAR_073823.
FT   VARIANT    1334   1334       Q -> H (in dbSNP:rs3742207).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:21527998}.
FT                                /FTId=VAR_020013.
FT   VARIANT    1423   1423       G -> R (in POREN1).
FT                                {ECO:0000269|PubMed:16107487}.
FT                                /FTId=VAR_030032.
FT   VARIANT    1531   1531       M -> V. {ECO:0000269|PubMed:22522439}.
FT                                /FTId=VAR_073824.
FT   VARIANT    1580   1580       G -> R (in POREN1).
FT                                {ECO:0000269|PubMed:19194877}.
FT                                /FTId=VAR_064499.
FT   VARIANT    1615   1615       E -> K (in SCHZC).
FT                                {ECO:0000269|PubMed:23225343}.
FT                                /FTId=VAR_073825.
FT   VARIANT    1627   1627       N -> K (in BSVD).
FT                                {ECO:0000269|PubMed:23394911}.
FT                                /FTId=VAR_073826.
FT   CONFLICT    237    238       SG -> KE (in Ref. 6; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    241    241       G -> K (in Ref. 6; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    319    319       Q -> A (in Ref. 4; CAA29075).
FT                                {ECO:0000305}.
FT   CONFLICT    719    719       N -> D (in Ref. 8; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    837    837       D -> Y (in Ref. 8; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    842    842       K -> P (in Ref. 8; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    896    896       V -> W (in Ref. 7; CAA68698).
FT                                {ECO:0000305}.
FT   CONFLICT    904    904       E -> Q (in Ref. 8; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    914    914       S -> K (in Ref. 8; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    998    998       S -> K (in Ref. 8; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT   1010   1010       K -> P (in Ref. 8; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT   1012   1012       S -> K (in Ref. 8; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT   1358   1358       E -> Q (in Ref. 8; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT   1490   1490       A -> T (in Ref. 17; ABE73157).
FT                                {ECO:0000305}.
FT   CONFLICT   1507   1507       I -> T (in Ref. 17; ABE73157).
FT                                {ECO:0000305}.
FT   CONFLICT   1519   1519       Y -> C (in Ref. 17; ABE73157).
FT                                {ECO:0000305}.
FT   CONFLICT   1570   1570       C -> Y (in Ref. 16; AAM97359).
FT                                {ECO:0000305}.
FT   STRAND     1446   1451       {ECO:0000244|PDB:1LI1}.
FT   STRAND     1453   1456       {ECO:0000244|PDB:1LI1}.
FT   STRAND     1465   1478       {ECO:0000244|PDB:1LI1}.
FT   STRAND     1481   1484       {ECO:0000244|PDB:1LI1}.
FT   HELIX      1490   1492       {ECO:0000244|PDB:1LI1}.
FT   STRAND     1493   1496       {ECO:0000244|PDB:1LI1}.
FT   STRAND     1502   1505       {ECO:0000244|PDB:1LI1}.
FT   STRAND     1509   1514       {ECO:0000244|PDB:1LI1}.
FT   STRAND     1519   1524       {ECO:0000244|PDB:1LI1}.
FT   HELIX      1538   1544       {ECO:0000244|PDB:1LI1}.
FT   STRAND     1547   1555       {ECO:0000244|PDB:1LI1}.
FT   STRAND     1557   1561       {ECO:0000244|PDB:1LI1}.
FT   STRAND     1563   1566       {ECO:0000244|PDB:1LI1}.
FT   STRAND     1574   1587       {ECO:0000244|PDB:1LI1}.
FT   HELIX      1589   1591       {ECO:0000244|PDB:1LI1}.
FT   STRAND     1593   1595       {ECO:0000244|PDB:1LI1}.
FT   HELIX      1601   1603       {ECO:0000244|PDB:1LI1}.
FT   STRAND     1604   1607       {ECO:0000244|PDB:1LI1}.
FT   STRAND     1613   1617       {ECO:0000244|PDB:1LI1}.
FT   STRAND     1620   1623       {ECO:0000244|PDB:1LI1}.
FT   STRAND     1629   1634       {ECO:0000244|PDB:1LI1}.
FT   HELIX      1638   1640       {ECO:0000244|PDB:1LI1}.
FT   STRAND     1648   1651       {ECO:0000244|PDB:1LI1}.
FT   HELIX      1655   1658       {ECO:0000244|PDB:1LI1}.
FT   STRAND     1661   1667       {ECO:0000244|PDB:1LI1}.
SQ   SEQUENCE   1669 AA;  160615 MW;  3C9BCD8E410A9ED1 CRC64;
     MGPRLSVWLL LLPAALLLHE EHSRAAAKGG CAGSGCGKCD CHGVKGQKGE RGLPGLQGVI
     GFPGMQGPEG PQGPPGQKGD TGEPGLPGTK GTRGPPGASG YPGNPGLPGI PGQDGPPGPP
     GIPGCNGTKG ERGPLGPPGL PGFAGNPGPP GLPGMKGDPG EILGHVPGML LKGERGFPGI
     PGTPGPPGLP GLQGPVGPPG FTGPPGPPGP PGPPGEKGQM GLSFQGPKGD KGDQGVSGPP
     GVPGQAQVQE KGDFATKGEK GQKGEPGFQG MPGVGEKGEP GKPGPRGKPG KDGDKGEKGS
     PGFPGEPGYP GLIGRQGPQG EKGEAGPPGP PGIVIGTGPL GEKGERGYPG TPGPRGEPGP
     KGFPGLPGQP GPPGLPVPGQ AGAPGFPGER GEKGDRGFPG TSLPGPSGRD GLPGPPGSPG
     PPGQPGYTNG IVECQPGPPG DQGPPGIPGQ PGFIGEIGEK GQKGESCLIC DIDGYRGPPG
     PQGPPGEIGF PGQPGAKGDR GLPGRDGVAG VPGPQGTPGL IGQPGAKGEP GEFYFDLRLK
     GDKGDPGFPG QPGMTGRAGS PGRDGHPGLP GPKGSPGSVG LKGERGPPGG VGFPGSRGDT
     GPPGPPGYGP AGPIGDKGQA GFPGGPGSPG LPGPKGEPGK IVPLPGPPGA EGLPGSPGFP
     GPQGDRGFPG TPGRPGLPGE KGAVGQPGIG FPGPPGPKGV DGLPGDMGPP GTPGRPGFNG
     LPGNPGVQGQ KGEPGVGLPG LKGLPGLPGI PGTPGEKGSI GVPGVPGEHG AIGPPGLQGI
     RGEPGPPGLP GSVGSPGVPG IGPPGARGPP GGQGPPGLSG PPGIKGEKGF PGFPGLDMPG
     PKGDKGAQGL PGITGQSGLP GLPGQQGAPG IPGFPGSKGE MGVMGTPGQP GSPGPVGAPG
     LPGEKGDHGF PGSSGPRGDP GLKGDKGDVG LPGKPGSMDK VDMGSMKGQK GDQGEKGQIG
     PIGEKGSRGD PGTPGVPGKD GQAGQPGQPG PKGDPGISGT PGAPGLPGPK GSVGGMGLPG
     TPGEKGVPGI PGPQGSPGLP GDKGAKGEKG QAGPPGIGIP GLRGEKGDQG IAGFPGSPGE
     KGEKGSIGIP GMPGSPGLKG SPGSVGYPGS PGLPGEKGDK GLPGLDGIPG VKGEAGLPGT
     PGPTGPAGQK GEPGSDGIPG SAGEKGEPGL PGRGFPGFPG AKGDKGSKGE VGFPGLAGSP
     GIPGSKGEQG FMGPPGPQGQ PGLPGSPGHA TEGPKGDRGP QGQPGLPGLP GPMGPPGLPG
     IDGVKGDKGN PGWPGAPGVP GPKGDPGFQG MPGIGGSPGI TGSKGDMGPP GVPGFQGPKG
     LPGLQGIKGD QGDQGVPGAK GLPGPPGPPG PYDIIKGEPG LPGPEGPPGL KGLQGLPGPK
     GQQGVTGLVG IPGPPGIPGF DGAPGQKGEM GPAGPTGPRG FPGPPGPDGL PGSMGPPGTP
     SVDHGFLVTR HSQTIDDPQC PSGTKILYHG YSLLYVQGNE RAHGQDLGTA GSCLRKFSTM
     PFLFCNINNV CNFASRNDYS YWLSTPEPMP MSMAPITGEN IRPFISRCAV CEAPAMVMAV
     HSQTIQIPPC PSGWSSLWIG YSFVMHTSAG AEGSGQALAS PGSCLEEFRS APFIECHGRG
     TCNYYANAYS FWLATIERSE MFKKPTPSTL KAGELRTHVS RCQVCMRRT
//
ID   COMP_HUMAN              Reviewed;         757 AA.
AC   P49747; B4DKJ3; O14592; Q16388; Q16389; Q2NL86; Q8N4T2;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   14-OCT-2008, sequence version 2.
DT   20-JAN-2016, entry version 165.
DE   RecName: Full=Cartilage oligomeric matrix protein;
DE            Short=COMP;
DE   AltName: Full=Thrombospondin-5;
DE            Short=TSP5;
DE   Flags: Precursor;
GN   Name=COMP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS ASP-50; TRP-51;
RP   GLY-109; GLY-224 AND PRO-285.
RC   TISSUE=Cartilage;
RX   PubMed=7713493; DOI=10.1006/geno.1994.1649;
RA   Newton G., Weremowicz S., Morton C.C., Copeland N.G., Gilbert D.J.,
RA   Jenkins N.A., Lawler J.;
RT   "Characterization of human and mouse cartilage oligomeric matrix
RT   protein.";
RL   Genomics 24:435-439(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS ASP-50; TRP-51;
RP   GLY-109; GLY-224 AND PRO-285.
RA   Hashimoto Y., Mori H.;
RT   "Human comp cDNA with 5 SNIPs.";
RL   Submitted (JUN-2002) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J.,
RA   Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M.,
RA   Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E.,
RA   Caenepeel S., Carrano A.V., Caoile C., Chan Y.M., Christensen M.,
RA   Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C.,
RA   Escobar J., Flowers D., Fotopulos D., Garcia C., Georgescu A.M.,
RA   Glavina T., Gomez M., Gonzales E., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H.,
RA   Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S.,
RA   Malfatti S., Martinez D., McCready P.M., Medina C., Morgan J.,
RA   Nelson K., Nolan M., Ovcharenko I., Pitluck S., Pollard M.,
RA   Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J.,
RA   Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D.,
RA   Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A.,
RA   Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I.,
RA   Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Ovary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 326-344, VARIANT EDM1 TYR-342,
RP   AND VARIANT PSACH ARG-328.
RX   PubMed=7670472; DOI=10.1038/ng0795-330;
RA   Briggs M.D., Hoffman S.M.G., King L.M., Olsen A.S., Mohrenweiser H.,
RA   Leroy J.G., Mortier G.R., Rimoin D.L., Lachman R.S., Gaines E.S.,
RA   Cekleniak J.A., Knowlton R.G., Cohn D.H.;
RT   "Pseudoachondroplasia and multiple epiphyseal dysplasia due to
RT   mutations in the cartilage oligomeric matrix protein gene.";
RL   Nat. Genet. 10:330-336(1995).
RN   [8]
RP   PROTEIN SEQUENCE OF 80-89, SUBUNIT, CALCIUM-BINDING, AND
RP   CHARACTERIZATION OF VARIANT PSACH ASP-469 DEL.
RX   PubMed=10852928; DOI=10.1074/jbc.M909780199;
RA   Chen H., Deere M., Hecht J.T., Lawler J.;
RT   "Cartilage oligomeric matrix protein is a calcium-binding protein, and
RT   a mutation in its type 3 repeats causes conformational changes.";
RL   J. Biol. Chem. 275:26538-26544(2000).
RN   [9]
RP   PROTEIN SEQUENCE, CALCIUM-BINDING, INTERACTION WITH COLLAGEN I;
RP   COLLAGEN II AND COLLAGEN IX, CHARACTERIZATION OF VARIANT PSACH ASP-469
RP   DEL, AND CHARACTERIZATION OF VARIANT EDM1 TYR-361.
RX   PubMed=11084047; DOI=10.1074/jbc.M009512200;
RA   Thur J., Rosenberg K., Nitsche D.P., Pihlajamaa T., Ala-Kokko L.,
RA   Heinegaard D., Paulsson M., Maurer P.;
RT   "Mutations in cartilage oligomeric matrix protein causing
RT   pseudoachondroplasia and multiple epiphyseal dysplasia affect binding
RT   of calcium and collagen I, II, and IX.";
RL   J. Biol. Chem. 276:6083-6092(2001).
RN   [10]
RP   INTERACTION WITH FN1.
RX   PubMed=12225811; DOI=10.1016/S0945-053X(02)00015-X;
RA   Di Cesare P.E., Chen F.S., Moergelin M., Carlson C.S., Leslie M.P.,
RA   Perris R., Fang C.;
RT   "Matrix-matrix interaction of cartilage oligomeric matrix protein and
RT   fibronectin.";
RL   Matrix Biol. 21:461-470(2002).
RN   [11]
RP   INTERACTION WITH MATN1; MATN3 AND MATN4.
RX   PubMed=15075323; DOI=10.1074/jbc.M403778200;
RA   Mann H.H., Oezbek S., Engel J., Paulsson M., Wagener R.;
RT   "Interactions between the cartilage oligomeric matrix protein and
RT   matrilins. Implications for matrix assembly and the pathogenesis of
RT   chondrodysplasias.";
RL   J. Biol. Chem. 279:25294-25298(2004).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH ITGB3 AND ITGA5.
RX   PubMed=16051604; DOI=10.1074/jbc.M504778200;
RA   Chen F.-H., Thomas A.O., Hecht J.T., Goldring M.B., Lawler J.;
RT   "Cartilage oligomeric matrix protein/thrombospondin 5 supports
RT   chondrocyte attachment through interaction with integrins.";
RL   J. Biol. Chem. 280:32655-32661(2005).
RN   [13]
RP   FUNCTION, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.
RX   PubMed=16542502; DOI=10.1186/ar1922;
RA   Koelling S., Clauditz T.S., Kaste M., Miosge N.;
RT   "Cartilage oligomeric matrix protein is involved in human limb
RT   development and in the pathogenesis of osteoarthritis.";
RL   Arthritis Res. Ther. 8:R56-R56(2006).
RN   [14]
RP   INTERACTION WITH ADAMTS12.
RX   PubMed=16611630; DOI=10.1074/jbc.M513433200;
RA   Liu C.-J., Kong W., Xu K., Luan Y., Ilalov K., Sehgal B., Yu S.,
RA   Howell R.D., Di Cesare P.E.;
RT   "ADAMTS-12 associates with and degrades cartilage oligomeric matrix
RT   protein.";
RL   J. Biol. Chem. 281:15800-15808(2006).
RN   [15]
RP   INTERACTION WITH ACAN; HEPARIN; HEPARAN SULFATE AND CHONDROITIN
RP   SULFATE.
RX   PubMed=17588949; DOI=10.1074/jbc.M611390200;
RA   Chen F.-H., Herndon M.E., Patel N., Hecht J.T., Tuan R.S., Lawler J.;
RT   "Interaction of cartilage oligomeric matrix protein/thrombospondin 5
RT   with aggrecan.";
RL   J. Biol. Chem. 282:24591-24598(2007).
RN   [16]
RP   FUNCTION, AND DOMAINS.
RX   PubMed=17993464; DOI=10.1074/jbc.M704035200;
RA   Gagarina V., Carlberg A.L., Pereira-Mouries L., Hall D.J.;
RT   "Cartilage oligomeric matrix protein protects cells against death by
RT   elevating members of the IAP family of survival proteins.";
RL   J. Biol. Chem. 283:648-659(2008).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (3.15 ANGSTROMS) OF 225-757 IN COMPLEX WITH
RP   CALCIUM IONS, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-742.
RX   PubMed=19276170; DOI=10.1096/fj.08-128090;
RA   Tan K., Duquette M., Joachimiak A., Lawler J.;
RT   "The crystal structure of the signature domain of cartilage oligomeric
RT   matrix protein: implications for collagen, glycosaminoglycan and
RT   integrin binding.";
RL   FASEB J. 23:2490-2501(2009).
RN   [19]
RP   VARIANTS PSACH SER-459 DEL; TYR-468 AND TYR-472.
RX   PubMed=7670471; DOI=10.1038/ng0795-325;
RA   Hecht J.T., Nelson L.D., Crowder E., Wang Y., Elder F.F.B.,
RA   Harrison W.R., Francomano C.A., Prange C.K., Lennon G.G., Deere M.,
RA   Lawler J.;
RT   "Mutations in exon 17B of cartilage oligomeric matrix protein (COMP)
RT   cause pseudoachondroplasia.";
RL   Nat. Genet. 10:325-329(1995).
RN   [20]
RP   VARIANT EDM1 LYS-523.
RX   PubMed=9021009;
RX   DOI=10.1002/(SICI)1096-8628(19970211)68:4<396::AID-AJMG4>3.3.CO;2-R;
RA   Ballo R., Briggs M.D., Cohn D.H., Knowlton R.G., Beighton P.H.,
RA   Ramesar R.S.;
RT   "Multiple epiphyseal dysplasia, ribbing type: a novel point mutation
RT   in the COMP gene in a South African family.";
RL   Am. J. Med. Genet. 68:396-400(1997).
RN   [21]
RP   VARIANT EDM1 SER-371, AND VARIANT PSACH 513-VAL--LYS-516 DEL.
RX   PubMed=9184241;
RA   Susic S., McGrory J., Ahier J., Cole W.G.;
RT   "Multiple epiphyseal dysplasia and pseudoachondroplasia due to novel
RT   mutations in the calmodulin-like repeats of cartilage oligomeric
RT   matrix protein.";
RL   Clin. Genet. 51:219-224(1997).
RN   [22]
RP   VARIANTS PSACH, AND VARIANTS EDM1 SER-453 AND ARG-585.
RX   PubMed=9463320; DOI=10.1086/301713;
RA   Briggs M.D., Mortier G.R., Cole W.G., King L.M., Golik S.S.,
RA   Bonaventure J., Nuytinck L., de Paepe A., Leroy J.G., Biesecker L.,
RA   Lipson M., Wilcox W.R., Lachman R.S., Rimoin D.L., Knowlton R.G.,
RA   Cohn D.H.;
RT   "Diverse mutations in the gene for cartilage oligomeric matrix protein
RT   in the pseudoachondroplasia-multiple epiphyseal dysplasia disease
RT   spectrum.";
RL   Am. J. Hum. Genet. 62:311-319(1998).
RN   [23]
RP   VARIANTS PSACH AND EDM1.
RX   PubMed=9921895; DOI=10.1007/s004390050883;
RA   Ikegawa S., Ohashi H., Nishimura G., Kim K.C., Sannohe A.,
RA   Kimizuka M., Fukushima Y., Nagai T., Nakamura Y.;
RT   "Novel and recurrent COMP (cartilage oligomeric matrix protein)
RT   mutations in pseudoachondroplasia and multiple epiphyseal dysplasia.";
RL   Hum. Genet. 103:633-638(1998).
RN   [24]
RP   VARIANTS PSACH ARG-328; ASP-372 DEL; 391-PRO--ASP-394 DELINS VAL;
RP   ARG-440; SER-459 DEL; TYR-468; ASP-469 DEL AND TYR-472, AND VARIANTS
RP   EDM1 TYR-342; TYR-361; 367-ARG-GLY-368 DEL AND TYR-408.
RX   PubMed=9452026;
RA   Loughlin J., Irven C., Mustafa Z., Briggs M.D., Carr A., Lynch S.-A.,
RA   Knowlton R.G., Cohn D.H., Sykes B.;
RT   "Identification of five novel mutations in cartilage oligomeric matrix
RT   protein gene in pseudoachondroplasia and multiple epiphyseal
RT   dysplasia.";
RL   Hum. Mutat. Suppl. 1:S10-S17(1998).
RN   [25]
RP   VARIANT PSACH GLY-482.
RX   PubMed=9452063;
RA   Susic S., Ahier J., Cole W.G.;
RT   "Pseudoachondroplasia due to the substitution of the highly conserved
RT   Asp482 by Gly in the seventh calmodulin-like repeat of cartilage
RT   oligomeric matrix protein.";
RL   Hum. Mutat. Suppl. 1:S125-S127(1998).
RN   [26]
RP   VARIANT PSACH ARG-348.
RX   PubMed=11746045; DOI=10.1002/ajmg.10062;
RA   Unger S., Koerkkoe J., Krakow D., Lachman R.S., Rimoin D.L.,
RA   Cohn D.H.;
RT   "Double heterozygosity for pseudoachondroplasia and spondyloepiphyseal
RT   dysplasia congenita.";
RL   Am. J. Med. Genet. 104:140-146(2001).
RN   [27]
RP   VARIANT PSACH ASP-719.
RX   PubMed=11746044; DOI=10.1002/ajmg.10067;
RA   Mabuchi A., Haga N., Ikeda T., Manabe N., Ohashi H., Takatori Y.,
RA   Nakamura K., Ikegawa S.;
RT   "Novel mutation in exon 18 of the cartilage oligomeric matrix protein
RT   gene causes a severe pseudoachondroplasia.";
RL   Am. J. Med. Genet. 104:135-139(2001).
RN   [28]
RP   VARIANTS EDM1 ARG-276; ALA-420 AND MET-585.
RX   PubMed=11565064; DOI=10.1086/324023;
RA   Czarny-Ratajczak M., Lohiniva J., Rogala P., Kozlowski K.,
RA   Peraelae M., Carter L., Spector T.D., Kolodziej L., Seppaenen U.,
RA   Glazar R., Krolewski J., Latos-Bielenska A., Ala-Kokko L.;
RT   "A mutation in COL9A1 causes multiple epiphyseal dysplasia: further
RT   evidence for locus heterogeneity.";
RL   Am. J. Hum. Genet. 69:969-980(2001).
RN   [29]
RP   VARIANTS PSACH SER-234; GLY-290; ARG-299; TYR-326; 341-GLU-ASP-342
RP   DEL; 350-ASN--ASP-372 DEL; VAL-378; ARG-387; 402-GLY--GLY-404 DELINS
RP   VAL-CYS; ARG-440; ASN-446; SER-448; ASP-473 DEL; HIS-473; ASN-475;
RP   GLY-482; GLY-507; GLY-511; GLY-515; ILE-529; ARG-585 AND SER-719,
RP   VARIANTS EDM1 GLU-167; ARG-276; LEU-298; ASP-311; GLY-317; GLY-326;
RP   PHE-348; SER-371; TYR-371; ASN-374; ASN-376; ASN-385; ASP-385 DEL;
RP   TYR-385; HIS-397; ARG-404; TYR-410; LYS-415; GLU-427; 430-CYS--SER-432
RP   DELINS LEU-TRP-CYS; GLU-457 DEL; ASP-473 INS; ASP-501; LYS-523;
RP   MET-585; PRO-718 AND TRP-718, AND VARIANT ARG-756.
RX   PubMed=21922596; DOI=10.1002/humu.21611;
RA   Jackson G.C., Mittaz-Crettol L., Taylor J.A., Mortier G.R.,
RA   Spranger J., Zabel B., Le Merrer M., Cormier-Daire V., Hall C.M.,
RA   Offiah A., Wright M.J., Savarirayan R., Nishimura G., Ramsden S.C.,
RA   Elles R., Bonafe L., Superti-Furga A., Unger S., Zankl A.,
RA   Briggs M.D.;
RT   "Pseudoachondroplasia and multiple epiphyseal dysplasia: A 7-year
RT   comprehensive analysis of the known disease genes identify novel and
RT   recurrent mutations and provides an accurate assessment of their
RT   relative contribution.";
RL   Hum. Mutat. 33:144-157(2012).
CC   -!- FUNCTION: May play a role in the structural integrity of cartilage
CC       via its interaction with other extracellular matrix proteins such
CC       as the collagens and fibronectin. Can mediate the interaction of
CC       chondrocytes with the cartilage extracellular matrix through
CC       interaction with cell surface integrin receptors. Could play a
CC       role in the pathogenesis of osteoarthritis. Potent suppressor of
CC       apoptosis in both primary chondrocytes and transformed cells.
CC       Suppresses apoptosis by blocking the activation of caspase-3 and
CC       by inducing the IAP family of survival proteins (BIRC3, BIRC2,
CC       BIRC5 and XIAP). Essential for maintaining a vascular smooth
CC       muscle cells (VSMCs) contractile/differentiated phenotype under
CC       physiological and pathological stimuli. Maintains this phenotype
CC       of VSMCs by interacting with ITGA7 (By similarity). {ECO:0000250,
CC       ECO:0000269|PubMed:16051604, ECO:0000269|PubMed:16542502,
CC       ECO:0000269|PubMed:17993464}.
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC       Note=Binds 11-14 calcium ions per subunit.;
CC   -!- SUBUNIT: Pentamer; disulfide-linked. Exists in a more compact
CC       conformation in the presence of calcium and shows a more extended
CC       conformation in the absence of calcium. Interacts with ITGB3,
CC       ITGA5 and FN1. Binding to FN1 requires the presence of divalent
CC       cations (Ca(2+), Mg(2+) or Mn(2+)). The greatest amount of binding
CC       is seen in the presence of Mn(2+). Interacts with MATN1, MATN3,
CC       MATN4 and ACAN. Binds heparin, heparan sulfate and chondroitin
CC       sulfate. EDTA dimishes significantly its binding to ACAN and
CC       abolishes its binding to MATN3, MATN4 and chondroitin sulfate.
CC       Interacts with collagen I, II and IX, and interaction with these
CC       collagens is dependent on the presence of zinc ions. Interacts
CC       with ADAMTS12. Interacts with ITGA7 (By similarity).
CC       {ECO:0000250}.
CC   -!- INTERACTION:
CC       P13608:ACAN (xeno); NbExp=2; IntAct=EBI-2531022, EBI-6259246;
CC       P58397:ADAMTS12; NbExp=3; IntAct=EBI-2531022, EBI-9028051;
CC       P32242:OTX1; NbExp=3; IntAct=EBI-2531022, EBI-740446;
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular
CC       matrix.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P49747-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P49747-2; Sequence=VSP_055758;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Abundantly expressed in the chondrocyte
CC       extracellular matrix, and is also found in bone, tendon, ligament
CC       and synovium and blood vessels. Increased amounts are produced
CC       during late stages of osteoarthritis in the area adjacent to the
CC       main defect. {ECO:0000269|PubMed:16542502}.
CC   -!- DEVELOPMENTAL STAGE: Present during the earliest stages of limb
CC       maturation and is later found in regions where the joints develop.
CC       {ECO:0000269|PubMed:16542502}.
CC   -!- DOMAIN: The cell attachment motif mediates the attachment to
CC       chondrocytes. It mediates the induction of both the IAP family of
CC       survival proteins and the antiapoptotic response.
CC       {ECO:0000269|PubMed:17993464}.
CC   -!- DOMAIN: The TSP C-terminal domain mediates interaction with FN1
CC       and ACAN. {ECO:0000269|PubMed:17993464}.
CC   -!- DOMAIN: Each of the eight TSP type-3 repeats binds two calcium
CC       ions. The TSP C-terminal domain binds three calcium ions.
CC       {ECO:0000269|PubMed:17993464}.
CC   -!- DISEASE: Multiple epiphyseal dysplasia 1 (EDM1) [MIM:132400]: A
CC       generalized skeletal dysplasia associated with significant
CC       morbidity. Joint pain, joint deformity, waddling gait, and short
CC       stature are the main clinical signs and symptoms. Radiological
CC       examination of the skeleton shows delayed, irregular
CC       mineralization of the epiphyseal ossification centers and of the
CC       centers of the carpal and tarsal bones. Multiple epiphyseal
CC       dysplasia is broadly categorized into the more severe Fairbank and
CC       the milder Ribbing types. The Fairbank type is characterized by
CC       shortness of stature, short and stubby fingers, small epiphyses in
CC       several joints, including the knee, ankle, hand, and hip. The
CC       Ribbing type is confined predominantly to the hip joints and is
CC       characterized by hands that are normal and stature that is normal
CC       or near-normal. {ECO:0000269|PubMed:11565064,
CC       ECO:0000269|PubMed:21922596, ECO:0000269|PubMed:7670472,
CC       ECO:0000269|PubMed:9021009, ECO:0000269|PubMed:9184241,
CC       ECO:0000269|PubMed:9452026, ECO:0000269|PubMed:9463320,
CC       ECO:0000269|PubMed:9921895}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Pseudoachondroplasia (PSACH) [MIM:177170]: A skeletal
CC       dysplasia usually manifesting in the second year of life and
CC       characterized by moderate to severe disproportionate short
CC       stature, deformity of the lower limbs, brachydactyly, ligamentous
CC       laxity, and degenerative joint disease.
CC       {ECO:0000269|PubMed:11746044, ECO:0000269|PubMed:11746045,
CC       ECO:0000269|PubMed:21922596, ECO:0000269|PubMed:7670471,
CC       ECO:0000269|PubMed:7670472, ECO:0000269|PubMed:9184241,
CC       ECO:0000269|PubMed:9452026, ECO:0000269|PubMed:9452063,
CC       ECO:0000269|PubMed:9463320}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the thrombospondin family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 4 EGF-like domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00076}.
CC   -!- SIMILARITY: Contains 1 TSP C-terminal (TSPC) domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00635}.
CC   -!- SIMILARITY: Contains 8 TSP type-3 repeats. {ECO:0000255|PROSITE-
CC       ProRule:PRU00634}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB86501.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L32137; AAA57253.1; -; mRNA.
DR   EMBL; AB086984; BAC53888.1; -; mRNA.
DR   EMBL; AK296586; BAG59205.1; -; mRNA.
DR   EMBL; AC003107; AAB86501.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; CH471106; EAW84737.1; -; Genomic_DNA.
DR   EMBL; BC110847; AAI10848.1; -; mRNA.
DR   EMBL; BC125092; AAI25093.1; -; mRNA.
DR   EMBL; S79499; AAB35269.1; -; Genomic_DNA.
DR   EMBL; S79500; AAB35270.1; -; Genomic_DNA.
DR   CCDS; CCDS12385.1; -. [P49747-1]
DR   RefSeq; NP_000086.2; NM_000095.2. [P49747-1]
DR   UniGene; Hs.1584; -.
DR   PDB; 3FBY; X-ray; 3.15 A; A/B/C=225-757.
DR   PDBsum; 3FBY; -.
DR   ProteinModelPortal; P49747; -.
DR   SMR; P49747; 29-72, 91-757.
DR   BioGrid; 107706; 1.
DR   IntAct; P49747; 5.
DR   STRING; 9606.ENSP00000222271; -.
DR   PhosphoSite; P49747; -.
DR   BioMuta; COMP; -.
DR   DMDM; 209572601; -.
DR   MaxQB; P49747; -.
DR   PaxDb; P49747; -.
DR   PRIDE; P49747; -.
DR   DNASU; 1311; -.
DR   Ensembl; ENST00000222271; ENSP00000222271; ENSG00000105664. [P49747-1]
DR   Ensembl; ENST00000425807; ENSP00000403792; ENSG00000105664. [P49747-2]
DR   GeneID; 1311; -.
DR   KEGG; hsa:1311; -.
DR   UCSC; uc002nkd.3; human. [P49747-1]
DR   UCSC; uc010xqj.2; human.
DR   CTD; 1311; -.
DR   GeneCards; COMP; -.
DR   GeneReviews; COMP; -.
DR   H-InvDB; HIX0014925; -.
DR   HGNC; HGNC:2227; COMP.
DR   MalaCards; COMP; -.
DR   MIM; 132400; phenotype.
DR   MIM; 177170; phenotype.
DR   MIM; 600310; gene.
DR   neXtProt; NX_P49747; -.
DR   Orphanet; 93308; Multiple epiphyseal dysplasia type 1.
DR   Orphanet; 750; Pseudoachondroplasia.
DR   PharmGKB; PA26744; -.
DR   eggNOG; ENOG410IFQQ; Eukaryota.
DR   eggNOG; ENOG410XQKE; LUCA.
DR   GeneTree; ENSGT00820000126982; -.
DR   HOGENOM; HOG000007542; -.
DR   HOVERGEN; HBG000636; -.
DR   InParanoid; P49747; -.
DR   KO; K04659; -.
DR   OMA; CDNCPQK; -.
DR   PhylomeDB; P49747; -.
DR   TreeFam; TF324917; -.
DR   Reactome; R-HSA-216083; Integrin cell surface interactions.
DR   Reactome; R-HSA-3000178; ECM proteoglycans.
DR   ChiTaRS; COMP; human.
DR   EvolutionaryTrace; P49747; -.
DR   GeneWiki; Cartilage_oligomeric_matrix_protein; -.
DR   GenomeRNAi; 1311; -.
DR   NextBio; 35472801; -.
DR   PMAP-CutDB; P49747; -.
DR   PRO; PR:P49747; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; P49747; -.
DR   CleanEx; HS_COMP; -.
DR   ExpressionAtlas; P49747; baseline and differential.
DR   Genevisible; P49747; HS.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0005578; C:proteinaceous extracellular matrix; TAS:ProtInc.
DR   GO; GO:0005509; F:calcium ion binding; IDA:UniProtKB.
DR   GO; GO:0005518; F:collagen binding; IDA:UniProtKB.
DR   GO; GO:0005201; F:extracellular matrix structural constituent; TAS:ProtInc.
DR   GO; GO:0043395; F:heparan sulfate proteoglycan binding; IDA:UniProtKB.
DR   GO; GO:0008201; F:heparin binding; IDA:UniProtKB.
DR   GO; GO:0002020; F:protease binding; IPI:BHF-UCL.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0003417; P:growth plate cartilage development; IEA:Ensembl.
DR   GO; GO:0060173; P:limb development; IDA:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0009887; P:organ morphogenesis; TAS:ProtInc.
DR   GO; GO:0001501; P:skeletal system development; TAS:ProtInc.
DR   Gene3D; 2.60.120.200; -; 1.
DR   Gene3D; 4.10.1080.10; -; 2.
DR   InterPro; IPR013320; ConA-like_dom.
DR   InterPro; IPR001881; EGF-like_Ca-bd_dom.
DR   InterPro; IPR013032; EGF-like_CS.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR018097; EGF_Ca-bd_CS.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR024665; Thbs/COMP_coiled-coil.
DR   InterPro; IPR003367; Thrombospondin_3-like_rpt.
DR   InterPro; IPR017897; Thrombospondin_3_rpt.
DR   InterPro; IPR008859; Thrombospondin_C.
DR   InterPro; IPR028974; TSP_type-3_rpt.
DR   Pfam; PF11598; COMP; 1.
DR   Pfam; PF07645; EGF_CA; 2.
DR   Pfam; PF02412; TSP_3; 6.
DR   Pfam; PF05735; TSP_C; 1.
DR   SMART; SM00181; EGF; 2.
DR   SMART; SM00179; EGF_CA; 2.
DR   SUPFAM; SSF103647; SSF103647; 3.
DR   SUPFAM; SSF49899; SSF49899; 1.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   PROSITE; PS01186; EGF_2; 1.
DR   PROSITE; PS50026; EGF_3; 3.
DR   PROSITE; PS01187; EGF_CA; 2.
DR   PROSITE; PS51234; TSP3; 8.
DR   PROSITE; PS51236; TSP_CTER; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; Calcium; Cell adhesion;
KW   Complete proteome; Direct protein sequencing; Disease mutation;
KW   Disulfide bond; Dwarfism; EGF-like domain; Extracellular matrix;
KW   Glycoprotein; Heparin-binding; Polymorphism; Reference proteome;
KW   Repeat; Secreted; Signal.
FT   SIGNAL        1     20       {ECO:0000255}.
FT   CHAIN        21    757       Cartilage oligomeric matrix protein.
FT                                /FTId=PRO_0000035857.
FT   DOMAIN       87    126       EGF-like 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      127    179       EGF-like 2; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      180    222       EGF-like 3; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      225    267       EGF-like 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   REPEAT      268    300       TSP type-3 1.
FT   REPEAT      301    336       TSP type-3 2.
FT   REPEAT      337    359       TSP type-3 3.
FT   REPEAT      360    395       TSP type-3 4.
FT   REPEAT      396    418       TSP type-3 5.
FT   REPEAT      419    456       TSP type-3 6.
FT   REPEAT      457    492       TSP type-3 7.
FT   REPEAT      493    528       TSP type-3 8.
FT   DOMAIN      532    746       TSP C-terminal. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00635}.
FT   REGION       22     86       COMP N-terminal.
FT   REGION      527    757       Mediates cell survival and induction of
FT                                the IAP family of survival proteins.
FT   MOTIF       367    369       Cell attachment site. {ECO:0000255}.
FT   CARBOHYD    121    121       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    742    742       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19276170}.
FT   DISULFID     69     69       Interchain.
FT                                {ECO:0000305|PubMed:19276170}.
FT   DISULFID     72     72       Interchain.
FT                                {ECO:0000305|PubMed:19276170}.
FT   DISULFID     91    102       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID     96    111       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    114    125       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    131    142       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    136    151       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    154    178       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    184    197       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    191    206       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    209    221       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    229    243       {ECO:0000255|PROSITE-ProRule:PRU00076,
FT                                ECO:0000269|PubMed:19276170}.
FT   DISULFID    237    253       {ECO:0000255|PROSITE-ProRule:PRU00076,
FT                                ECO:0000269|PubMed:19276170}.
FT   DISULFID    255    266       {ECO:0000255|PROSITE-ProRule:PRU00076,
FT                                ECO:0000269|PubMed:19276170}.
FT   DISULFID    282    287       {ECO:0000255|PROSITE-ProRule:PRU00076,
FT                                ECO:0000269|PubMed:19276170}.
FT   DISULFID    292    312       {ECO:0000255|PROSITE-ProRule:PRU00076,
FT                                ECO:0000269|PubMed:19276170}.
FT   DISULFID    328    348       {ECO:0000255|PROSITE-ProRule:PRU00076,
FT                                ECO:0000269|PubMed:19276170}.
FT   DISULFID    351    371       {ECO:0000255|PROSITE-ProRule:PRU00076,
FT                                ECO:0000269|PubMed:19276170}.
FT   DISULFID    387    407       {ECO:0000255|PROSITE-ProRule:PRU00076,
FT                                ECO:0000269|PubMed:19276170}.
FT   DISULFID    410    430       {ECO:0000255|PROSITE-ProRule:PRU00076,
FT                                ECO:0000269|PubMed:19276170}.
FT   DISULFID    448    468       {ECO:0000255|PROSITE-ProRule:PRU00076,
FT                                ECO:0000269|PubMed:19276170}.
FT   DISULFID    484    504       {ECO:0000255|PROSITE-ProRule:PRU00076,
FT                                ECO:0000269|PubMed:19276170}.
FT   DISULFID    520    741       {ECO:0000255|PROSITE-ProRule:PRU00076,
FT                                ECO:0000269|PubMed:19276170}.
FT   VAR_SEQ     129    181       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_055758.
FT   VARIANT      50     50       E -> D. {ECO:0000269|PubMed:7713493,
FT                                ECO:0000269|Ref.2}.
FT                                /FTId=VAR_016254.
FT   VARIANT      51     51       L -> W. {ECO:0000269|PubMed:7713493,
FT                                ECO:0000269|Ref.2}.
FT                                /FTId=VAR_016255.
FT   VARIANT     109    109       A -> G. {ECO:0000269|PubMed:7713493,
FT                                ECO:0000269|Ref.2}.
FT                                /FTId=VAR_016257.
FT   VARIANT     167    167       G -> E (in EDM1).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066789.
FT   VARIANT     224    224       R -> G. {ECO:0000269|PubMed:7713493,
FT                                ECO:0000269|Ref.2}.
FT                                /FTId=VAR_016258.
FT   VARIANT     234    234       P -> S (in PSACH).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066790.
FT   VARIANT     276    276       P -> R (in EDM1).
FT                                {ECO:0000269|PubMed:11565064,
FT                                ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_026239.
FT   VARIANT     285    285       R -> P. {ECO:0000269|PubMed:7713493,
FT                                ECO:0000269|Ref.2}.
FT                                /FTId=VAR_016261.
FT   VARIANT     290    290       D -> G (in PSACH).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066791.
FT   VARIANT     290    290       D -> N (in PSACH; mild form).
FT                                /FTId=VAR_007614.
FT   VARIANT     298    298       S -> L (in EDM1; phenotypic features
FT                                overlapping with mild PSACH).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066792.
FT   VARIANT     299    299       G -> R (in PSACH).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_007615.
FT   VARIANT     311    311       A -> D (in EDM1).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066793.
FT   VARIANT     317    317       D -> G (in EDM1; atypical form).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066794.
FT   VARIANT     326    326       D -> G (in EDM1).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066795.
FT   VARIANT     326    326       D -> Y (in PSACH).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066796.
FT   VARIANT     328    328       C -> R (in PSACH; mild form).
FT                                {ECO:0000269|PubMed:7670472,
FT                                ECO:0000269|PubMed:9452026}.
FT                                /FTId=VAR_007616.
FT   VARIANT     341    342       Missing (in PSACH).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066797.
FT   VARIANT     342    342       D -> Y (in EDM1; Fairbank type).
FT                                {ECO:0000269|PubMed:7670472,
FT                                ECO:0000269|PubMed:9452026}.
FT                                /FTId=VAR_007617.
FT   VARIANT     348    348       C -> F (in EDM1).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066798.
FT   VARIANT     348    348       C -> R (in PSACH).
FT                                {ECO:0000269|PubMed:11746045}.
FT                                /FTId=VAR_017102.
FT   VARIANT     349    349       D -> V (in PSACH; mild form).
FT                                /FTId=VAR_007618.
FT   VARIANT     350    372       Missing (in PSACH).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066799.
FT   VARIANT     361    361       D -> V (in EDM1; Fairbank type).
FT                                /FTId=VAR_007619.
FT   VARIANT     361    361       D -> Y (in EDM1; binds less calcium).
FT                                {ECO:0000269|PubMed:11084047,
FT                                ECO:0000269|PubMed:9452026}.
FT                                /FTId=VAR_007620.
FT   VARIANT     367    368       Missing (in EDM1).
FT                                {ECO:0000269|PubMed:9452026}.
FT                                /FTId=VAR_007621.
FT   VARIANT     371    371       C -> S (in EDM1; Fairbank type).
FT                                {ECO:0000269|PubMed:21922596,
FT                                ECO:0000269|PubMed:9184241}.
FT                                /FTId=VAR_007622.
FT   VARIANT     371    371       C -> Y (in EDM1).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066800.
FT   VARIANT     372    372       Missing (in PSACH).
FT                                {ECO:0000269|PubMed:9452026}.
FT                                /FTId=VAR_007623.
FT   VARIANT     374    374       D -> N (in EDM1).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066801.
FT   VARIANT     374    374       Missing (in PSACH; mild form).
FT                                /FTId=VAR_007624.
FT   VARIANT     376    376       D -> N (in EDM1).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066802.
FT   VARIANT     378    378       D -> V (in PSACH).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066803.
FT   VARIANT     381    381       R -> C (in dbSNP:rs3179763).
FT                                /FTId=VAR_046796.
FT   VARIANT     385    385       D -> N (in EDM1; atypical form).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066804.
FT   VARIANT     385    385       D -> Y (in EDM1; atypical form).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066805.
FT   VARIANT     385    385       Missing (in EDM1).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066806.
FT   VARIANT     387    387       C -> G (in PSACH; mild form).
FT                                /FTId=VAR_007625.
FT   VARIANT     387    387       C -> R (in PSACH).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066807.
FT   VARIANT     391    394       PNSD -> V (in PSACH).
FT                                {ECO:0000269|PubMed:9452026}.
FT                                /FTId=VAR_007626.
FT   VARIANT     397    397       D -> H (in EDM1).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066808.
FT   VARIANT     402    404       GIG -> VC (in PSACH).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066809.
FT   VARIANT     404    404       G -> R (in EDM1).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066810.
FT   VARIANT     408    408       D -> Y (in EDM1).
FT                                {ECO:0000269|PubMed:9452026}.
FT                                /FTId=VAR_007627.
FT   VARIANT     410    410       C -> Y (in EDM1; phenotype overlapping
FT                                with mild PSACH).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066811.
FT   VARIANT     415    415       N -> K (in EDM1).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066812.
FT   VARIANT     420    420       D -> A (in EDM1).
FT                                {ECO:0000269|PubMed:11565064}.
FT                                /FTId=VAR_026240.
FT   VARIANT     427    427       G -> E (in EDM1).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066813.
FT   VARIANT     430    432       CDS -> LWC (in EDM1).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066814.
FT   VARIANT     440    440       G -> E (in PSACH; mild form).
FT                                /FTId=VAR_007628.
FT   VARIANT     440    440       G -> R (in PSACH).
FT                                {ECO:0000269|PubMed:21922596,
FT                                ECO:0000269|PubMed:9452026}.
FT                                /FTId=VAR_007629.
FT   VARIANT     446    446       D -> N (in PSACH).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066815.
FT   VARIANT     448    448       C -> S (in PSACH).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066816.
FT   VARIANT     453    453       N -> S (in EDM1; Fairbank type;
FT                                dbSNP:rs28936668).
FT                                {ECO:0000269|PubMed:9463320}.
FT                                /FTId=VAR_007630.
FT   VARIANT     457    457       Missing (in EDM1).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066817.
FT   VARIANT     459    459       Missing (in PSACH; severe form).
FT                                {ECO:0000269|PubMed:7670471,
FT                                ECO:0000269|PubMed:9452026}.
FT                                /FTId=VAR_007631.
FT   VARIANT     468    468       C -> Y (in PSACH; severe form).
FT                                {ECO:0000269|PubMed:7670471,
FT                                ECO:0000269|PubMed:9452026}.
FT                                /FTId=VAR_007632.
FT   VARIANT     469    469       Missing (in PSACH; severe form; MUT3
FT                                mutant; most common mutation; binds less
FT                                calcium and causes misfolding of the
FT                                protein; greatly reduced interaction with
FT                                ACAN; reduced interaction with collagen).
FT                                {ECO:0000269|PubMed:10852928,
FT                                ECO:0000269|PubMed:11084047,
FT                                ECO:0000269|PubMed:9452026}.
FT                                /FTId=VAR_007633.
FT   VARIANT     472    472       D -> Y (in PSACH; severe form).
FT                                {ECO:0000269|PubMed:7670471,
FT                                ECO:0000269|PubMed:9452026}.
FT                                /FTId=VAR_007634.
FT   VARIANT     473    473       D -> DD (in EDM1).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066818.
FT   VARIANT     473    473       D -> G (in PSACH; severe form;
FT                                dbSNP:rs28936669).
FT                                /FTId=VAR_007635.
FT   VARIANT     473    473       D -> H (in PSACH).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066819.
FT   VARIANT     473    473       Missing (in PSACH; severe form).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_007636.
FT   VARIANT     475    475       D -> N (in PSACH).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066820.
FT   VARIANT     482    482       D -> G (in PSACH).
FT                                {ECO:0000269|PubMed:21922596,
FT                                ECO:0000269|PubMed:9452063}.
FT                                /FTId=VAR_007637.
FT   VARIANT     501    501       G -> D (in EDM1).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066821.
FT   VARIANT     507    507       D -> G (in PSACH).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066822.
FT   VARIANT     511    511       D -> G (in PSACH).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066823.
FT   VARIANT     513    516       Missing (in PSACH; mild form).
FT                                {ECO:0000269|PubMed:9184241}.
FT                                /FTId=VAR_007638.
FT   VARIANT     515    515       D -> G (in PSACH).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066824.
FT   VARIANT     518    518       D -> N (in PSACH; mild form).
FT                                /FTId=VAR_007639.
FT   VARIANT     523    523       N -> K (in EDM1; Ribbing type).
FT                                {ECO:0000269|PubMed:21922596,
FT                                ECO:0000269|PubMed:9021009}.
FT                                /FTId=VAR_007640.
FT   VARIANT     529    529       T -> I (in PSACH).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066825.
FT   VARIANT     585    585       T -> M (in PSACH; mild form and EDM1).
FT                                {ECO:0000269|PubMed:11565064,
FT                                ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_007641.
FT   VARIANT     585    585       T -> R (in EDM1 and PSACH).
FT                                {ECO:0000269|PubMed:21922596,
FT                                ECO:0000269|PubMed:9463320}.
FT                                /FTId=VAR_007642.
FT   VARIANT     718    718       R -> P (in EDM1).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066826.
FT   VARIANT     718    718       R -> W (in EDM1; dbSNP:rs28936368).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066827.
FT   VARIANT     719    719       G -> D (in PSACH; severe).
FT                                {ECO:0000269|PubMed:11746044}.
FT                                /FTId=VAR_017103.
FT   VARIANT     719    719       G -> S (in PSACH).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066828.
FT   VARIANT     756    756       Q -> R (in a patient with multiple
FT                                epiphyseal dysplasia; dbSNP:rs61752496).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066829.
FT   CONFLICT    256    256       A -> R (in Ref. 1; AAA57253 and 2;
FT                                BAC53888). {ECO:0000305}.
FT   CONFLICT    340    340       D -> Y (in Ref. 7; AAB35270).
FT                                {ECO:0000305}.
FT   STRAND      232    234       {ECO:0000244|PDB:3FBY}.
FT   STRAND      241    245       {ECO:0000244|PDB:3FBY}.
FT   STRAND      251    255       {ECO:0000244|PDB:3FBY}.
FT   STRAND      259    265       {ECO:0000244|PDB:3FBY}.
FT   STRAND      272    274       {ECO:0000244|PDB:3FBY}.
FT   HELIX       285    287       {ECO:0000244|PDB:3FBY}.
FT   STRAND      291    295       {ECO:0000244|PDB:3FBY}.
FT   STRAND      306    308       {ECO:0000244|PDB:3FBY}.
FT   HELIX       310    312       {ECO:0000244|PDB:3FBY}.
FT   TURN        314    317       {ECO:0000244|PDB:3FBY}.
FT   STRAND      319    321       {ECO:0000244|PDB:3FBY}.
FT   HELIX       323    325       {ECO:0000244|PDB:3FBY}.
FT   STRAND      327    331       {ECO:0000244|PDB:3FBY}.
FT   STRAND      342    344       {ECO:0000244|PDB:3FBY}.
FT   HELIX       346    348       {ECO:0000244|PDB:3FBY}.
FT   STRAND      364    367       {ECO:0000244|PDB:3FBY}.
FT   HELIX       369    371       {ECO:0000244|PDB:3FBY}.
FT   STRAND      378    380       {ECO:0000244|PDB:3FBY}.
FT   STRAND      401    403       {ECO:0000244|PDB:3FBY}.
FT   HELIX       405    407       {ECO:0000244|PDB:3FBY}.
FT   STRAND      424    426       {ECO:0000244|PDB:3FBY}.
FT   TURN        428    430       {ECO:0000244|PDB:3FBY}.
FT   HELIX       443    445       {ECO:0000244|PDB:3FBY}.
FT   STRAND      462    464       {ECO:0000244|PDB:3FBY}.
FT   TURN        466    468       {ECO:0000244|PDB:3FBY}.
FT   STRAND      470    473       {ECO:0000244|PDB:3FBY}.
FT   STRAND      475    477       {ECO:0000244|PDB:3FBY}.
FT   HELIX       479    481       {ECO:0000244|PDB:3FBY}.
FT   STRAND      495    500       {ECO:0000244|PDB:3FBY}.
FT   TURN        503    506       {ECO:0000244|PDB:3FBY}.
FT   STRAND      511    513       {ECO:0000244|PDB:3FBY}.
FT   HELIX       515    517       {ECO:0000244|PDB:3FBY}.
FT   STRAND      532    540       {ECO:0000244|PDB:3FBY}.
FT   STRAND      551    553       {ECO:0000244|PDB:3FBY}.
FT   TURN        555    557       {ECO:0000244|PDB:3FBY}.
FT   STRAND      560    562       {ECO:0000244|PDB:3FBY}.
FT   STRAND      567    588       {ECO:0000244|PDB:3FBY}.
FT   STRAND      596    605       {ECO:0000244|PDB:3FBY}.
FT   STRAND      608    617       {ECO:0000244|PDB:3FBY}.
FT   STRAND      625    627       {ECO:0000244|PDB:3FBY}.
FT   STRAND      636    641       {ECO:0000244|PDB:3FBY}.
FT   HELIX       648    655       {ECO:0000244|PDB:3FBY}.
FT   STRAND      656    658       {ECO:0000244|PDB:3FBY}.
FT   TURN        661    663       {ECO:0000244|PDB:3FBY}.
FT   STRAND      664    669       {ECO:0000244|PDB:3FBY}.
FT   STRAND      681    689       {ECO:0000244|PDB:3FBY}.
FT   HELIX       690    692       {ECO:0000244|PDB:3FBY}.
FT   STRAND      694    701       {ECO:0000244|PDB:3FBY}.
FT   STRAND      704    708       {ECO:0000244|PDB:3FBY}.
FT   STRAND      716    728       {ECO:0000244|PDB:3FBY}.
FT   STRAND      732    741       {ECO:0000244|PDB:3FBY}.
FT   HELIX       748    754       {ECO:0000244|PDB:3FBY}.
SQ   SEQUENCE   757 AA;  82860 MW;  A0B73AADB39FBC7B CRC64;
     MVPDTACVLL LTLAALGASG QGQSPLGSDL GPQMLRELQE TNAALQDVRE LLRQQVREIT
     FLKNTVMECD ACGMQQSVRT GLPSVRPLLH CAPGFCFPGV ACIQTESGAR CGPCPAGFTG
     NGSHCTDVNE CNAHPCFPRV RCINTSPGFR CEACPPGYSG PTHQGVGLAF AKANKQVCTD
     INECETGQHN CVPNSVCINT RGSFQCGPCQ PGFVGDQASG CQRRAQRFCP DGSPSECHEH
     ADCVLERDGS RSCVCAVGWA GNGILCGRDT DLDGFPDEKL RCPERQCRKD NCVTVPNSGQ
     EDVDRDGIGD ACDPDADGDG VPNEKDNCPL VRNPDQRNTD EDKWGDACDN CRSQKNDDQK
     DTDQDGRGDA CDDDIDGDRI RNQADNCPRV PNSDQKDSDG DGIGDACDNC PQKSNPDQAD
     VDHDFVGDAC DSDQDQDGDG HQDSRDNCPT VPNSAQEDSD HDGQGDACDD DDDNDGVPDS
     RDNCRLVPNP GQEDADRDGV GDVCQDDFDA DKVVDKIDVC PENAEVTLTD FRAFQTVVLD
     PEGDAQIDPN WVVLNQGREI VQTMNSDPGL AVGYTAFNGV DFEGTFHVNT VTDDDYAGFI
     FGYQDSSSFY VVMWKQMEQT YWQANPFRAV AEPGIQLKAV KSSTGPGEQL RNALWHTGDT
     ESQVRLLWKD PRNVGWKDKK SYRWFLQHRP QVGYIRVRFY EGPELVADSN VVLDTTMRGG
     RLGVFCFSQE NIIWANLRYR CNDTIPEDYE THQLRQA
//
ID   MYP0_HUMAN              Reviewed;         248 AA.
AC   P25189; Q16072; Q5VTH4; Q92677; Q9BR67;
DT   01-MAY-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1992, sequence version 1.
DT   20-JAN-2016, entry version 185.
DE   RecName: Full=Myelin protein P0;
DE   AltName: Full=Myelin peripheral protein;
DE            Short=MPP;
DE   AltName: Full=Myelin protein zero;
DE   Flags: Precursor;
GN   Name=MPZ;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Fetal spinal cord;
RX   PubMed=1719967; DOI=10.1016/S0006-291X(05)81094-0;
RA   Hayasaka K., Nanao K., Tahara M., Sato W., Takada G., Miura M.,
RA   Uyemura K.;
RT   "Isolation and sequence determination of cDNA encoding the major
RT   structural protein of human peripheral myelin.";
RL   Biochem. Biophys. Res. Commun. 180:515-518(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), AND VARIANT
RP   CMT1B HIS-98.
RC   TISSUE=Spinal cord;
RX   PubMed=7688964; DOI=10.1006/bbrc.1993.1968;
RA   Hayasaka K., Ohnishi A., Takada G., Fukushima Y., Murai Y.;
RT   "Mutation of the myelin P0 gene in Charcot-Marie-Tooth neuropathy type
RT   1.";
RL   Biochem. Biophys. Res. Commun. 194:1317-1322(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=7509228; DOI=10.1093/hmg/2.12.2051;
RA   Pham-Dinh D., Fourbil Y., Blanquet F., Mattei M.-G., Roeckel N.,
RA   Latour P., Chazot G., Vandenberghe A., Dautigny A.;
RT   "The major peripheral myelin protein zero gene: structure and
RT   localization in the cluster of Fc gamma receptor genes on human
RT   chromosome 1q21.3-q23.";
RL   Hum. Mol. Genet. 2:2051-2054(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Pericardium;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-115 (ISOFORM 1), AND VARIANT CMT1B
RP   SER-63 DEL.
RX   PubMed=7693130; DOI=10.1038/ng0993-35;
RA   Kulkens T., Bolhuis P.A., Wolterman R.A., Kemp S., Te Nijenhuis S.,
RA   Valentijn L.J., Hensels G.W., Jennekens F.G., de Visser M.,
RA   Hoogendijk J.E., Baas F.;
RT   "Deletion of the serine 34 codon from the major peripheral myelin
RT   protein P0 gene in Charcot-Marie-Tooth disease type 1B.";
RL   Nat. Genet. 5:35-39(1993).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 24-248, AND VARIANT CMT1B
RP   GLU-134.
RX   PubMed=7530774; DOI=10.1136/jmg.31.10.811;
RA   Nelis E., Timmerman V., De Jonghe P., Muylle L., Martin J.-J.,
RA   Van Broeckhoven C.;
RT   "Linkage and mutation analysis in an extended family with Charcot-
RT   Marie-Tooth disease type 1B.";
RL   J. Med. Genet. 31:811-815(1994).
RN   [11]
RP   PARTIAL PROTEIN SEQUENCE (ISOFORM L-MPZ), ALTERNATIVE SPLICING, AND
RP   SUBCELLULAR LOCATION (ISOFORM L-MPZ).
RC   TISSUE=PNS;
RX   PubMed=22457349; DOI=10.1074/jbc.M111.314468;
RA   Yamaguchi Y., Hayashi A., Campagnoni C.W., Kimura A., Inuzuka T.,
RA   Baba H.;
RT   "L-MPZ, a novel isoform of myelin P0, is produced by stop codon
RT   readthrough.";
RL   J. Biol. Chem. 287:17765-17776(2012).
RN   [12]
RP   REVIEW ON CMT1B VARIANTS.
RX   PubMed=7762451;
RA   Roa B.B., Lupski J.R.;
RT   "Molecular genetics of Charcot-Marie-Tooth neuropathy.";
RL   Adv. Hum. Genet. 22:117-152(1994).
RN   [13]
RP   REVIEW ON CMT1B VARIANTS.
RX   PubMed=7518101; DOI=10.1016/0168-9525(94)90214-3;
RA   Patel P.I., Lupski J.R.;
RT   "Charcot-Marie-Tooth disease: a new paradigm for the mechanism of
RT   inherited disease.";
RL   Trends Genet. 10:128-133(1994).
RN   [14]
RP   REVIEW ON CMT1B AND DSS VARIANTS.
RX   PubMed=9888385;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:1<11::AID-HUMU2>3.0.CO;2-A;
RA   Nelis E., Haites N., van Broeckhoven C.;
RT   "Mutations in the peripheral myelin genes and associated genes in
RT   inherited peripheral neuropathies.";
RL   Hum. Mutat. 13:11-28(1999).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 30-150, SUBUNIT, AND
RP   DISULFIDE BOND.
RX   PubMed=21971831; DOI=10.1002/prot.23164;
RA   Liu Z., Wang Y., Yedidi R.S., Brunzelle J.S., Kovari I.A., Sohi J.,
RA   Kamholz J., Kovari L.C.;
RT   "Crystal structure of the extracellular domain of human myelin protein
RT   zero.";
RL   Proteins 80:307-313(2012).
RN   [16]
RP   VARIANT CMT1B MET-30.
RX   PubMed=7694726; DOI=10.1093/hmg/2.9.1369;
RA   Hayasaka K., Takada G., Ionasescu V.V.;
RT   "Mutation of the myelin P0 gene in Charcot-Marie-Tooth neuropathy type
RT   1B.";
RL   Hum. Mol. Genet. 2:1369-1372(1993).
RN   [17]
RP   VARIANT CMT1B CYS-82.
RX   PubMed=7505151;
RA   Himoro M., Yoshikawa H., Matsui T., Mitsui Y., Takahashi M., Kaido M.,
RA   Nishimura T., Sawaishi Y., Takada G., Hayasaka K.;
RT   "New mutation of the myelin P0 gene in a pedigree of Charcot-Marie-
RT   Tooth neuropathy 1.";
RL   Biochem. Mol. Biol. Int. 31:169-173(1993).
RN   [18]
RP   VARIANTS CMT1B GLU-90 AND GLU-96.
RX   PubMed=7693129; DOI=10.1038/ng0993-31;
RA   Hayasaka K., Himoro M., Sato W., Takada G., Uyemura K., Shimizu N.,
RA   Bird T.D., Conneally P.M., Chance P.F.;
RT   "Charcot-Marie-Tooth neuropathy type 1B is associated with mutations
RT   of the myelin P0 gene.";
RL   Nat. Genet. 5:31-34(1993).
RN   [19]
RP   VARIANTS CMT1B GLU-96 AND 216-THR DELINS GLU-ARG.
RX   PubMed=7504284; DOI=10.1073/pnas.90.22.10856;
RA   Su Y., Brooks D.G., Li L., Lepercq J., Trofatter J.A., Ravetch J.V.,
RA   Lebo R.V.;
RT   "Myelin protein zero gene mutated in Charcot-Marie-Tooth type 1B
RT   patients.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:10856-10860(1993).
RN   [20]
RP   VARIANTS DSS CYS-63 AND ARG-167.
RX   PubMed=7506095; DOI=10.1038/ng1193-266;
RA   Hayasaka K., Himoro M., Sawaishi Y., Nanao K., Takahashi T.,
RA   Takada G., Nicholson G.A., Ouvrier R.A., Tachi N.;
RT   "De novo mutation of the myelin P0 gene in Dejerine-Sottas disease
RT   (hereditary motor and sensory neuropathy type III).";
RL   Nat. Genet. 5:266-268(1993).
RN   [21]
RP   VARIANTS CMT1B LEU-78 AND ASN-134.
RX   PubMed=7527371; DOI=10.1007/BF00206959;
RA   Nelis E., Timmerman V., de Jonghe P., Vandenberghe A., Pham-Dinh D.,
RA   Dautigny A., Martin J.-J., van Broeckhoven C.;
RT   "Rapid screening of myelin genes in CMT1 patients by SSCP analysis:
RT   identification of new mutations and polymorphisms in the P0 gene.";
RL   Hum. Genet. 94:653-657(1994).
RN   [22]
RP   VARIANT CMT1B PHE-63.
RX   PubMed=8835320;
RA   Blanquet-Grossard F., Pham-Dinh D., Dautigny A., Latour P.,
RA   Bonnebouche C., Corbillon E., Chazot G., Vandenberghe A.;
RT   "Charcot-Marie-Tooth type 1B neuropathy: third mutation of serine 63
RT   codon in the major peripheral myelin glycoprotein PO gene.";
RL   Clin. Genet. 48:281-283(1995).
RN   [23]
RP   VARIANTS CMT1B LEU-78 AND CYS-101.
RX   PubMed=7550231; DOI=10.1002/humu.1380060110;
RA   Latour P., Blanquet F., Nelis E., Bonnebouche C., Chapon F.,
RA   Diraison P., Ollagnon E., Dautigny A., Pham-Dinh D., Chazot G.,
RA   Boucherat M., van Broeckhoven C., Vandenberghe A.;
RT   "Mutations in the myelin protein zero gene associated with Charcot-
RT   Marie-Tooth disease type 1B.";
RL   Hum. Mutat. 6:50-54(1995).
RN   [24]
RP   VARIANT DSS PHE-64 DEL.
RX   PubMed=8630052; DOI=10.1006/bbrc.1996.0705;
RA   Ikegami T., Nicholson G.A., Ikeda H., Ishida A., Johnston H., Wise G.,
RA   Ouvrier R.A., Hayasaka K.;
RT   "A novel homozygous mutation of the myelin Po gene producing Dejerine-
RT   Sottas disease (hereditary motor and sensory neuropathy type III).";
RL   Biochem. Biophys. Res. Commun. 222:107-110(1996).
RN   [25]
RP   VARIANTS CMT1B THR-135 AND SER-137.
RX   PubMed=8664899;
RX   DOI=10.1002/(SICI)1098-1004(1996)7:1<36::AID-HUMU5>3.0.CO;2-N;
RA   Roa B.B., Warner L.E., Garcia C.A., Russo D., Lovelace R.,
RA   Chance P.F., Lupski J.R.;
RT   "Myelin protein zero (MPZ) gene mutations in nonduplication type 1
RT   Charcot-Marie-Tooth disease.";
RL   Hum. Mutat. 7:36-45(1996).
RN   [26]
RP   VARIANT CMT1B SER-122.
RX   PubMed=8844219;
RX   DOI=10.1002/(SICI)1098-1004(1996)8:2<185::AID-HUMU13>3.0.CO;2-Z;
RA   Blanquet-Grossard F., Pham-Dinh D., Dautigny A., Latour P.,
RA   Bonnebouche C., Diraison P., Chapon F., Chazot G., Vandenberghe A.;
RT   "Charcot-Marie-Tooth type 1B neuropathy: a mutation at the single
RT   glycosylation site in the major peripheral myelin glycoprotein Po.";
RL   Hum. Mutat. 8:185-186(1996).
RN   [27]
RP   VARIANTS CMT1B/DSS ILE-34; CYS-98; HIS-98; ARG-130 AND LEU-135.
RX   PubMed=8797476; DOI=10.1212/WNL.47.3.761;
RA   Gabreeels-Festen A.A.W.M., Hoogendijk J.E., Meijerink P.H.,
RA   Gabreeels F.J.M., Bolhuis P.A., van Beersum S., Kulkens T., Nelis E.,
RA   Jennekens F.G., de Visser M., van Engelen B.G., van Broeckhoven C.,
RA   Mariman E.C.;
RT   "Two divergent types of nerve pathology in patients with different P0
RT   mutations in Charcot-Marie-Tooth disease.";
RL   Neurology 47:761-765(1996).
RN   [28]
RP   VARIANTS CMT1B CYS-98 AND SER-98, AND VARIANT DSS CYS-98.
RX   PubMed=8816708; DOI=10.1016/S0896-6273(00)80177-4;
RA   Warner L.E., Hilz M.J., Appel S.H., Killian J.M., Kolodry E.H.,
RA   Karpati G., Carpenter S., Watters G.V., Wheeler C., Witt D.,
RA   Bodell A., Nelis E., van Broeckhoven C., Lupski J.R.;
RT   "Clinical phenotypes of different MPZ (P0) mutations may include
RT   Charcot-Marie-Tooth type 1B, Dejerine-Sottas, and congenital
RT   hypomyelination.";
RL   Neuron 17:451-460(1996).
RN   [29]
RP   VARIANT CMT1B GLU-93.
RX   PubMed=9217235;
RX   DOI=10.1002/(SICI)1096-8628(19970808)71:2<246::AID-AJMG28>3.0.CO;2-D;
RA   Ikegami T., Ikeda H., Mitsui T., Hayasaka K., Ishii S.;
RT   "Novel mutation of the myelin Po gene in a pedigree with Charcot-
RT   Marie-Tooth disease type 1B.";
RL   Am. J. Med. Genet. 71:246-248(1997).
RN   [30]
RP   VARIANT CMT1B LEU-78, AND VARIANT DSS CYS-98.
RX   PubMed=9187667; DOI=10.1007/s004390050442;
RA   Bort S., Nelis E., Timmerman V., Sevilla T., Cruz-Martinez A.,
RA   Martinez F., Millan J.M., Arpa J., Vilchez J.J., Prieto F.,
RA   van Broeckhoven C., Palau F.;
RT   "Mutational analysis of the MPZ, PMP22 and Cx32 genes in patients of
RT   Spanish ancestry with Charcot-Marie-Tooth disease and hereditary
RT   neuropathy with liability to pressure palsies.";
RL   Hum. Genet. 99:746-754(1997).
RN   [31]
RP   VARIANT CMT1B ARG-81.
RX   PubMed=8990016;
RX   DOI=10.1002/(SICI)1098-1004(1997)9:1<74::AID-HUMU16>3.3.CO;2-Q;
RA   Sorour E., Macmillan J., Upadhyaya M.;
RT   "Novel mutation of the myelin P0 gene in a CMT1B family.";
RL   Hum. Mutat. 9:74-77(1997).
RN   [32]
RP   VARIANTS DSS THR-114; HIS-116 AND ASN-128.
RX   PubMed=9222756;
RX   DOI=10.1002/(SICI)1098-1004(1997)10:1<21::AID-HUMU3>3.0.CO;2-P;
RA   Warner L.E., Shohat M., Shorer Z., Lupski J.R.;
RT   "Multiple de novo MPZ (P0) point mutations in a sporadic Dejerine-
RT   Sottas case.";
RL   Hum. Mutat. 10:21-24(1997).
RN   [33]
RP   VARIANT DSS PHE-TYR-118 INS.
RX   PubMed=9452055;
RA   Ikegami T., Nicholson G.A., Ikeda H., Ishida A., Johnston H., Wise G.,
RA   Ouvrier R.A., Hayasaka K.;
RT   "De novo mutation of the myelin P0 gene in Dejerine-Sottas disease
RT   (hereditary motor and sensory neuropathy type III): two amino acid
RT   insertion after Asp 118.";
RL   Hum. Mutat. Suppl. 1:S103-S105(1998).
RN   [34]
RP   VARIANT CMT1B MET-124, AND VARIANT DSS 124-THR-PHE-125 DEL.
RX   PubMed=9452091;
RA   Schiavon F., Rampazzo A., Merlini L., Angelini C., Mostacciuolo M.L.;
RT   "Mutations of the same sequence of the myelin P0 gene causing two
RT   different phenotypes.";
RL   Hum. Mutat. Suppl. 1:S217-S219(1998).
RN   [35]
RP   VARIANTS CMT1B PHE-58; CYS-68; THR-112; LEU-132 AND ALA-167.
RX   PubMed=9452099;
RA   Sorour E., Upadhyaya M.;
RT   "Mutation analysis in Charcot-Marie-Tooth disease type 1 (CMT1).";
RL   Hum. Mutat. Suppl. 1:S242-S247(1998).
RN   [36]
RP   VARIANT CMT1B LEU-78, AND VARIANT DSS CYS-82.
RX   PubMed=9633821;
RX   DOI=10.1002/(SICI)1098-1004(1998)12:1<59::AID-HUMU9>3.0.CO;2-A;
RA   Silander K., Meretoja P., Juvonen V., Ignatius J., Pihko H.,
RA   Saarinen A., Wallden T., Herrgaard E., Aula P., Savontaus M.-L.;
RT   "Spectrum of mutations in Finnish patients with Charcot-Marie-Tooth
RT   disease and related neuropathies.";
RL   Hum. Mutat. 12:59-68(1998).
RN   [37]
RP   VARIANT CMT2I PHE-44.
RX   PubMed=9595994; DOI=10.1212/WNL.50.5.1397;
RA   Marrosu M.G., Vaccargiu S., Marrosu G., Vannelli A., Cianchetti C.,
RA   Muntoni F.;
RT   "Charcot-Marie-Tooth disease type 2 associated with mutation of the
RT   myelin protein zero gene.";
RL   Neurology 50:1397-1401(1998).
RN   [38]
RP   VARIANT ROULS LYS-131.
RX   PubMed=10553995;
RX   DOI=10.1002/1531-8249(199911)46:5<770::AID-ANA13>3.0.CO;2-U;
RA   Plante-Bordeneuve V., Guiochon-Mantel A., Lacroix C., Lapresle J.,
RA   Said G.;
RT   "The Roussy-Levy family: from the original description to the gene.";
RL   Ann. Neurol. 46:770-773(1999).
RN   [39]
RP   VARIANT CMT2J MET-124.
RX   PubMed=10071056; DOI=10.1093/brain/122.2.281;
RA   De Jonghe P., Timmerman V., Ceuterick C., Nelis E., De Vriendt E.,
RA   Lofgren A., Vercruyssen A., Verellen C., Van Maldergem L.,
RA   Martin J.-J., Van Broeckhoven C.;
RT   "The Thr124Met mutation in the peripheral myelin protein zero (MPZ)
RT   gene is associated with a clinically distinct Charcot-Marie-Tooth
RT   phenotype.";
RL   Brain 122:281-290(1999).
RN   [40]
RP   VARIANT CMT1B PRO-54.
RA   Bissar-Tadmouri N., Latour P., Gulsen-Parman Y., Deymeer F.,
RA   Serdaroglu P., Ozdemir C., Vandenberghe A.;
RT   "Novel mutations of the myelin P0 gene in two Charcot-Marie-Tooth type
RT   1 patients from Turkey.";
RL   Eur. J. Hum. Genet. Suppl. 7:116-116(1999).
RN   [41]
RP   VARIANT CMT2 MET-124.
RX   PubMed=10329755; DOI=10.1136/jnnp.66.6.779;
RA   Chapon F., Latour P., Diraison P., Schaeffer S., Vandenberghe A.;
RT   "Axonal phenotype of Charcot-Marie-Tooth disease associated with a
RT   mutation in the myelin protein zero gene.";
RL   J. Neurol. Neurosurg. Psych. 66:779-782(1999).
RN   [42]
RP   VARIANT CMTDID TYR-35.
RX   PubMed=10406984; DOI=10.1136/jnnp.67.2.174;
RA   Mastaglia F.L., Nowak K.J., Stell R., Phillips B.A., Edmondston J.E.,
RA   Dorosz S.M., Wilton S.D., Hallmayer J., Kakulas B.A., Laing N.G.;
RT   "Novel mutation in the myelin protein zero gene in a family with
RT   intermediate hereditary motor and sensory neuropathy.";
RL   J. Neurol. Neurosurg. Psych. 67:174-179(1999).
RN   [43]
RP   VARIANT CMT1B PHE-62.
RX   PubMed=10214757; DOI=10.1212/WNL.52.6.1271;
RA   Nakagawa M., Suehara M., Saito A., Takashima H., Umehara F., Saito M.,
RA   Kanzato N., Matsuzaki T., Takenaga S., Sakoda S., Izumo S., Osame M.;
RT   "A novel MPZ gene mutation in dominantly inherited neuropathy with
RT   focally folded myelin sheaths.";
RL   Neurology 52:1271-1275(1999).
RN   [44]
RP   VARIANT CMT1B ASN-109.
RX   PubMed=10545037; DOI=10.1016/S0960-8966(99)00031-0;
RA   Lagueny A., Latour P., Vital A., Rajabally Y., Le Masson G.,
RA   Ferrer X., Bernard I., Julien J., Vital C., Vandenberghe A.;
RT   "Peripheral myelin modification in CMT1B correlates with MPZ gene
RT   mutations.";
RL   Neuromuscul. Disord. 9:361-367(1999).
RN   [45]
RP   VARIANT CMT1B LEU-78.
RX   PubMed=10965800; DOI=10.1007/s004019900175;
RA   Fabrizi G.M., Taioli F., Cavallaro T., Rigatelli F., Simonati A.,
RA   Mariani G., Perrone P., Rizzuto N.;
RT   "Focally folded myelin in Charcot-Marie-Tooth neuropathy type 1B with
RT   Ser49Leu in the myelin protein zero.";
RL   Acta Neuropathol. 100:299-304(2000).
RN   [46]
RP   VARIANTS CMT2 GLY-61 AND CYS-119.
RX   PubMed=10764043;
RA   Senderek J., Hermanns B., Lehmann U., Bergmann C., Marx G., Kabus C.,
RA   Timmerman V., Stoltenburg-Didinger G., Schroder J.M.;
RT   "Charcot-Marie-Tooth neuropathy type 2 and P0 point mutations: two
RT   novel amino acid substitutions (Asp61Gly; Tyr119Cys) and a possible
RT   'hotspot' on Thr124Met.";
RL   Brain Pathol. 10:235-248(2000).
RN   [47]
RP   VARIANTS CMT1B HIS-98; GLY-134; GLU-134; THR-135; ASN-138 AND ASN-139.
RX   PubMed=10737979;
RX   DOI=10.1002/(SICI)1098-1004(200004)15:4<340::AID-HUMU6>3.3.CO;2-P;
RA   Mersiyanova I.V., Ismailov S.M., Polyakov A.V., Dadali E.L.,
RA   Fedotov V.P., Nelis E., Loefgren A., Timmerman V., Van Broeckhoven C.,
RA   Evgrafov O.V.;
RT   "Screening for mutations in the peripheral myelin genes PMP22, MPZ and
RT   Cx32 (GJB1) in Russian Charcot-Marie-Tooth neuropathy patients.";
RL   Hum. Mutat. 15:340-347(2000).
RN   [48]
RP   VARIANTS CMT PHE-32; CYS-68; MET-124 AND ARG-130.
RX   PubMed=10923043;
RX   DOI=10.1002/1098-1004(200008)16:2<177::AID-HUMU14>3.0.CO;2-5;
RA   Yoshihara T., Yamamoto M., Doyu M., Misu K., Hattori N., Hasegawa Y.,
RA   Mokuno K., Mitsuma T., Sobue G.;
RT   "Mutations in the peripheral myelin protein zero and connexin32 genes
RT   detected by non-isotopic RNase cleavage assay and their phenotypes in
RT   Japanese patients with Charcot-Marie-Tooth disease.";
RL   Hum. Mutat. 16:177-178(2000).
RN   [49]
RP   VARIANTS CMT2J VAL-75 AND MET-124.
RX   PubMed=11080237; DOI=10.1136/jnnp.69.6.806;
RA   Misu K., Yoshihara T., Shikama Y., Awaki E., Yamamoto M., Hattori N.,
RA   Hirayama M., Takegami T., Nakashima K., Sobue G.;
RT   "An axonal form of Charcot-Marie-Tooth disease showing distinctive
RT   features in association with mutations in the peripheral myelin
RT   protein zero gene (Thr124Met or Asp75Val).";
RL   J. Neurol. Neurosurg. Psych. 69:806-811(2000).
RN   [50]
RP   VARIANTS CMT1B PHE-63 AND MET-124, AND VARIANTS DSS CYS-98 AND
RP   124-THR-PHE-125 DEL.
RX   PubMed=11438991; DOI=10.1002/humu.1147;
RA   Mostacciuolo M.L., Righetti E., Zortea M., Bosello V., Schiavon F.,
RA   Vallo L., Merlini L., Siciliano G., Fabrizi G.M., Rizzuto N.,
RA   Milani M., Baratta S., Taroni F.;
RT   "Charcot-Marie-Tooth disease type I and related demyelinating
RT   neuropathies: mutation analysis in a large cohort of Italian
RT   families.";
RL   Hum. Mutat. 18:32-41(2001).
RN   [51]
RP   VARIANTS CMT1B PHE-51; LEU-78 AND HIS-98.
RX   PubMed=11437164; DOI=10.1007/s004150170183;
RA   Young P., Grote K., Kuhlenbaeumer G., Debus O., Kurlemann H.,
RA   Halfter H., Funke H., Ringelstein E.B., Stoegbauer F.;
RT   "Mutation analysis in Chariot-Marie Tooth disease type 1: point
RT   mutations in the MPZ gene and the GJB1 gene cause comparable
RT   phenotypic heterogeneity.";
RL   J. Neurol. 248:410-415(2001).
RN   [52]
RP   VARIANTS DSS VAL-42 DEL AND THR-221.
RX   PubMed=11596785; DOI=10.1007/s004150170096;
RA   Plante-Bordeneuve V., Parman Y., Guiochon-Mantel A., Alj Y.,
RA   Deymeer F., Serdaroglu P., Eraksoy M., Said G.;
RT   "The range of chronic demyelinating neuropathy of infancy: a clinico-
RT   pathological and genetic study of 15 unrelated cases.";
RL   J. Neurol. 248:795-803(2001).
RN   [53]
RP   VARIANT CMT1B GLU-103.
RX   PubMed=11445635; DOI=10.1212/WNL.57.1.101;
RA   Fabrizi G.M., Ferrarini M., Cavallaro T., Jarre L., Polo A.,
RA   Rizzuto N.;
RT   "A somatic and germline mosaic mutation in MPZ/P(0) mimics recessive
RT   inheritance of CMT1B.";
RL   Neurology 57:101-105(2001).
RN   [54]
RP   VARIANTS CMT1B LEU-78 AND CYS-82, VARIANTS CMT2I ASN-89; MET-92 AND
RP   MET-162, AND VARIANTS DSS CYS-123 AND GLU-136.
RX   PubMed=11835375; DOI=10.1002/ana.10089;
RA   Boerkoel C.F., Takashima H., Garcia C.A., Olney R.K., Johnson J.,
RA   Berry K., Russo P., Kennedy S., Teebi A.S., Scavina M., Williams L.L.,
RA   Mancias P., Butler I.J., Krajewski K., Shy M., Lupski J.R.;
RT   "Charcot-Marie-Tooth disease and related neuropathies: mutation
RT   distribution and genotype-phenotype correlation.";
RL   Ann. Neurol. 51:190-201(2002).
RN   [55]
RP   VARIANTS CMT1B SER-63 DEL; ILE-65; CYS-68; CYS-82; MET-124; ARG-163
RP   AND ARG-170, AND VARIANTS CMT2 VAL-75 AND ILE-113.
RX   PubMed=12402337; DOI=10.1002/humu.10134;
RA   Numakura C., Lin C., Ikegami T., Guldberg P., Hayasaka K.;
RT   "Molecular analysis in Japanese patients with Charcot-Marie-Tooth
RT   disease: DGGE analysis for PMP22, MPZ, and Cx32/GJB1 mutations.";
RL   Hum. Mutat. 20:392-398(2002).
RN   [56]
RP   VARIANT CMT1B HIS-98.
RX   PubMed=12221176; DOI=10.1212/WNL.59.5.767;
RA   Watanabe M., Yamamoto N., Ohkoshi N., Nagata H., Kohno Y., Hayashi A.,
RA   Tamaoka A., Shoji S.;
RT   "Corticosteroid-responsive asymmetric neuropathy with a myelin protein
RT   zero gene mutation.";
RL   Neurology 59:767-769(2002).
RN   [57]
RP   VARIANTS CMT TYR-81 AND PHE-113.
RX   PubMed=11801400; DOI=10.1016/S0960-8966(01)00281-4;
RA   Bienfait H.M.E., Baas F., Gabreeels-Festen A.A.W.M., Koelman J.H.T.M.,
RA   Langerhorst C.T., de Visser M.;
RT   "Two amino-acid substitutions in the myelin protein zero gene of a
RT   case of Charcot-Marie-Tooth disease associated with light-near
RT   dissociation.";
RL   Neuromuscul. Disord. 12:281-285(2002).
RN   [58]
RP   VARIANTS CMT1B THR-140; ARG-163 AND LYS-236 DEL.
RX   PubMed=12207932; DOI=10.1016/S0960-8966(02)00021-4;
RA   Street V.A., Meekins G., Lipe H.P., Seltzer W.K., Carter G.T.,
RA   Kraft G.H., Bird T.D.;
RT   "Charcot-Marie-Tooth neuropathy: clinical phenotypes of four novel
RT   mutations in the MPZ and Cx 32 genes.";
RL   Neuromuscul. Disord. 12:643-650(2002).
RN   [59]
RP   VARIANTS CMT TYR-35; PHE-62; SER-63 DEL; CYS-68; VAL-75; ARG-81;
RP   GLU-93; CYS-98; MET-124; ARG-130; PHE-146 AND ARG-167.
RX   PubMed=12477701; DOI=10.1093/brain/awg012;
RG   The study group for hereditary neuropathy in Japan;
RA   Hattori N., Yamamoto M., Yoshihara T., Koike H., Nakagawa M.,
RA   Yoshikawa H., Ohnishi A., Hayasaka K., Onodera O., Baba M., Yasuda H.,
RA   Saito T., Nakashima K., Kira J., Kaji R., Oka N., Sobue G.;
RT   "Demyelinating and axonal features of Charcot-Marie-Tooth disease with
RT   mutations of myelin-related proteins (PMP22, MPZ and Cx32): a
RT   clinicopathological study of 205 Japanese patients.";
RL   Brain 126:134-151(2003).
RN   [60]
RP   VARIANT CMT1B LEU-78, AND VARIANT DSS ASP-110.
RX   PubMed=12497641; DOI=10.1002/humu.9101;
RA   Huehne K., Benes V., Thiel C., Kraus C., Kress W., Hoeltzenbein M.,
RA   Ploner C.J., Kotzian J., Reis A., Rott H.D., Rautenstrauss B.W.;
RT   "Novel mutations in the Charcot-Marie-Tooth disease genes PMP22, MPZ,
RT   and GJB1.";
RL   Hum. Mutat. 21:100-100(2003).
RN   [61]
RP   VARIANT CMT1B TRP-78.
RX   PubMed=12707985; DOI=10.1002/mus.10344;
RA   Kakar R., Ma W., Dutra A., Seltzer W.K., Grewal R.P.;
RT   "Clinical and genetic analysis of CMT1B in a Nigerian family.";
RL   Muscle Nerve 27:628-630(2003).
RN   [62]
RP   VARIANT CMT1B SER-145.
RX   PubMed=12845552; DOI=10.1007/s10048-003-0153-0;
RA   Leal A., Berghoff C., Berghoff M., Del Valle G., Contreras C.,
RA   Montoya O., Hernandez E., Barrantes R., Schloetzer-Schrehardt U.,
RA   Neundoerfer B., Reis A., Rautenstrauss B., Heuss D.;
RT   "Charcot-Marie-Tooth disease: a novel Tyr145Ser mutation in the myelin
RT   protein zero (MPZ, P0) gene causes different phenotypes in homozygous
RT   and heterozygous carriers within one family.";
RL   Neurogenetics 4:191-197(2003).
RN   [63]
RP   VARIANTS CMT2I HIS-60 AND MET-62.
RX   PubMed=14638973; DOI=10.1212/01.WNL.0000094197.46109.75;
RA   Auer-Grumbach M., Strasser-Fuchs S., Robl T., Windpassinger C.,
RA   Wagner K.;
RT   "Late onset Charcot-Marie-Tooth 2 syndrome caused by two novel
RT   mutations in the MPZ gene.";
RL   Neurology 61:1435-1437(2003).
RN   [64]
RP   VARIANTS CMT1B PRO-39; PHE-44; CYS-50 DEL; HIS-98; CYS-123; ARG-130;
RP   THR-140 AND SER-227.
RX   PubMed=14711881; DOI=10.1093/brain/awh048;
RA   Shy M.E., Jani A., Krajewski K., Grandis M., Lewis R.A., Li J.,
RA   Shy R.R., Balsamo J., Lilien J., Garbern J.Y., Kamholz J.;
RT   "Phenotypic clustering in MPZ mutations.";
RL   Brain 127:371-384(2004).
RN   [65]
RP   VARIANT CMT2 LYS-56.
RX   PubMed=14871447; DOI=10.1111/j.1085-9489.2004.09101.x;
RA   Kochanski A., Kabzinska D., Nowakowski A., Drac H.,
RA   Hausmanowa-Petrusewicz I.;
RT   "An axonal form of Charcot-Marie-Tooth disease with a novel missense
RT   mutation in the myelin protein zero gene.";
RL   J. Peripher. Nerv. Syst. 9:1-2(2004).
RN   [66]
RP   VARIANTS CMT2I ASN-118 AND GLU-236.
RX   PubMed=15241803; DOI=10.1002/humu.9261;
RA   Choi B.-O., Lee M.S., Shin S.H., Hwang J.H., Choi K.-G., Kim W.-K.,
RA   Sunwoo I.N., Kim N.K., Chung K.W.;
RT   "Mutational analysis of PMP22, MPZ, GJB1, EGR2 and NEFL in Korean
RT   Charcot-Marie-Tooth neuropathy patients.";
RL   Hum. Mutat. 24:185-186(2004).
RN   [67]
RP   VARIANT CHN LYS-124.
RX   PubMed=15184631; DOI=10.1212/01.WNL.0000127606.93772.3A;
RA   Kochanski A., Drac H., Kabzinska D., Ryniewicz B.,
RA   Rowinska-Marcinska K., Nowakowski A., Hausmanowa-Petrusewicz I.;
RT   "A novel MPZ gene mutation in congenital neuropathy with
RT   hypomyelination.";
RL   Neurology 62:2122-2123(2004).
RN   [68]
RP   VARIANT CMT2J VAL-97.
RX   PubMed=15326256; DOI=10.1212/01.WNL.0000134605.61307.DE;
RA   Seeman P., Mazanec R., Huehne K., Suslikova P., Keller O.,
RA   Rautenstrauss B.;
RT   "Hearing loss as the first feature of late-onset axonal CMT disease
RT   due to a novel P0 mutation.";
RL   Neurology 63:733-735(2004).
RN   [69]
RP   VARIANT CMT1B TYR-224.
RX   PubMed=16488608; DOI=10.1016/j.nmd.2006.01.006;
RA   Fabrizi G.M., Pellegrini M., Angiari C., Cavallaro T., Morini A.,
RA   Taioli F., Cabrini I., Orrico D., Rizzuto N.;
RT   "Gene dosage sensitivity of a novel mutation in the intracellular
RT   domain of P0 associated with Charcot-Marie-Tooth disease type 1B.";
RL   Neuromuscul. Disord. 16:183-187(2006).
RN   [70]
RP   CHARACTERIZATION OF VARIANTS CMT1B 51-SER--TRP-57 DEL; PRO-39; ARG-81
RP   AND MET-124.
RX   PubMed=18337304; DOI=10.1093/hmg/ddn083;
RA   Grandis M., Vigo T., Passalacqua M., Jain M., Scazzola S.,
RA   La Padula V., Brucal M., Benvenuto F., Nobbio L., Cadoni A.,
RA   Mancardi G.L., Kamholz J., Shy M.E., Schenone A.;
RT   "Different cellular and molecular mechanisms for early and late-onset
RT   myelin protein zero mutations.";
RL   Hum. Mol. Genet. 17:1877-1889(2008).
RN   [71]
RP   VARIANT CMT2 MET-124.
RX   PubMed=15159512; DOI=10.1212/01.WNL.0000125287.98456.23;
RA   Baloh R.H., Jen J.C., Kim G., Baloh R.W.;
RT   "Chronic cough due to Thr124Met mutation in the peripheral myelin
RT   protein zero (MPZ gene).";
RL   Neurology 62:1905-1906(2004).
RN   [72]
RP   VARIANT CMT1B ALA-65.
RX   PubMed=15036333; DOI=10.1016/j.nmd.2003.12.001;
RA   Kochanski A., Drac H., Kabzinska D., Hausmanowa-Petrusewicz I.;
RT   "A novel mutation, Thr65Ala, in the MPZ gene in a patient with
RT   Charcot-Marie-Tooth type 1B disease with focally folded myelin.";
RL   Neuromuscul. Disord. 14:229-232(2004).
RN   [73]
RP   VARIANT CMT2J MET-124, AND INVOLVEMENT IN ADIE PUPIL.
RX   PubMed=16775239; DOI=10.1056/NEJMcpc069009;
RA   Triggs W.J., Brown R.H. Jr., Menkes D.L.;
RT   "Case records of the Massachusetts General Hospital. Case 18-2006. A
RT   57-year-old woman with numbness and weakness of the feet and legs.";
RL   N. Engl. J. Med. 354:2584-2592(2006).
CC   -!- FUNCTION: Creation of an extracellular membrane face which guides
CC       the wrapping process and ultimately compacts adjacent lamellae.
CC   -!- SUBUNIT: Homodimer and homotetramer.
CC       {ECO:0000305|PubMed:21971831}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein.
CC   -!- SUBCELLULAR LOCATION: Isoform L-MPZ: Myelin membrane
CC       {ECO:0000269|PubMed:22457349}; Single-pass type I membrane protein
CC       {ECO:0000269|PubMed:22457349}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P25189-1; Sequence=Displayed;
CC       Name=L-MPZ;
CC         IsoId=P25189-2; Sequence=VSP_045844;
CC         Note=Based on a naturally occurring readthrough transcript.
CC         Highly antigenic.;
CC   -!- TISSUE SPECIFICITY: Found only in peripheral nervous system
CC       Schwann cells.
CC   -!- PTM: N-glycosylated; contains sulfate-substituted glycan.
CC       {ECO:0000250}.
CC   -!- DISEASE: Charcot-Marie-Tooth disease 1B (CMT1B) [MIM:118200]: A
CC       dominant demyelinating form of Charcot-Marie-Tooth disease, a
CC       disorder of the peripheral nervous system, characterized by
CC       progressive weakness and atrophy, initially of the peroneal
CC       muscles and later of the distal muscles of the arms. Charcot-
CC       Marie-Tooth disease is classified in two main groups on the basis
CC       of electrophysiologic properties and histopathology: primary
CC       peripheral demyelinating neuropathies (designated CMT1 when they
CC       are dominantly inherited) and primary peripheral axonal
CC       neuropathies (CMT2). Demyelinating neuropathies are characterized
CC       by severely reduced nerve conduction velocities (less than 38
CC       m/sec), segmental demyelination and remyelination with onion bulb
CC       formations on nerve biopsy, slowly progressive distal muscle
CC       atrophy and weakness, absent deep tendon reflexes, and hollow
CC       feet. {ECO:0000269|PubMed:10214757, ECO:0000269|PubMed:10545037,
CC       ECO:0000269|PubMed:10737979, ECO:0000269|PubMed:10965800,
CC       ECO:0000269|PubMed:11437164, ECO:0000269|PubMed:11438991,
CC       ECO:0000269|PubMed:11445635, ECO:0000269|PubMed:11835375,
CC       ECO:0000269|PubMed:12207932, ECO:0000269|PubMed:12221176,
CC       ECO:0000269|PubMed:12402337, ECO:0000269|PubMed:12497641,
CC       ECO:0000269|PubMed:12707985, ECO:0000269|PubMed:12845552,
CC       ECO:0000269|PubMed:14711881, ECO:0000269|PubMed:15036333,
CC       ECO:0000269|PubMed:16488608, ECO:0000269|PubMed:7504284,
CC       ECO:0000269|PubMed:7505151, ECO:0000269|PubMed:7527371,
CC       ECO:0000269|PubMed:7530774, ECO:0000269|PubMed:7550231,
CC       ECO:0000269|PubMed:7688964, ECO:0000269|PubMed:7693129,
CC       ECO:0000269|PubMed:7693130, ECO:0000269|PubMed:7694726,
CC       ECO:0000269|PubMed:8664899, ECO:0000269|PubMed:8797476,
CC       ECO:0000269|PubMed:8816708, ECO:0000269|PubMed:8835320,
CC       ECO:0000269|PubMed:8844219, ECO:0000269|PubMed:8990016,
CC       ECO:0000269|PubMed:9187667, ECO:0000269|PubMed:9217235,
CC       ECO:0000269|PubMed:9452091, ECO:0000269|PubMed:9452099,
CC       ECO:0000269|PubMed:9633821, ECO:0000269|Ref.40}. Note=The disease
CC       is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Charcot-Marie-Tooth disease 2I (CMT2I) [MIM:607677]: A
CC       dominant axonal form of Charcot-Marie-Tooth disease, a disorder of
CC       the peripheral nervous system, characterized by progressive
CC       weakness and atrophy, initially of the peroneal muscles and later
CC       of the distal muscles of the arms. Charcot-Marie-Tooth disease is
CC       classified in two main groups on the basis of electrophysiologic
CC       properties and histopathology: primary peripheral demyelinating
CC       neuropathies (designated CMT1 when they are dominantly inherited)
CC       and primary peripheral axonal neuropathies (CMT2). Neuropathies of
CC       the CMT2 group are characterized by signs of axonal degeneration
CC       in the absence of obvious myelin alterations, normal or slightly
CC       reduced nerve conduction velocities, and progressive distal muscle
CC       weakness and atrophy. Nerve conduction velocities are normal or
CC       slightly reduced. {ECO:0000269|PubMed:11835375,
CC       ECO:0000269|PubMed:14638973, ECO:0000269|PubMed:15241803,
CC       ECO:0000269|PubMed:9595994}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Charcot-Marie-Tooth disease 2J (CMT2J) [MIM:607736]: A
CC       dominant axonal form of Charcot-Marie-Tooth disease, a disorder of
CC       the peripheral nervous system, characterized by progressive
CC       weakness and atrophy, initially of the peroneal muscles and later
CC       of the distal muscles of the arms. Charcot-Marie-Tooth disease is
CC       classified in two main groups on the basis of electrophysiologic
CC       properties and histopathology: primary peripheral demyelinating
CC       neuropathies (designated CMT1 when they are dominantly inherited)
CC       and primary peripheral axonal neuropathies (CMT2). Neuropathies of
CC       the CMT2 group are characterized by signs of axonal degeneration
CC       in the absence of obvious myelin alterations, normal or slightly
CC       reduced nerve conduction velocities, and progressive distal muscle
CC       weakness and atrophy. Nerve conduction velocities are normal or
CC       slightly reduced. Charcot-Marie-Tooth disease type 2J is
CC       characterized by the association of axonal peripheral neuropathy
CC       with hearing loss and pupillary abnormalities such as Adie pupil.
CC       {ECO:0000269|PubMed:10071056, ECO:0000269|PubMed:11080237,
CC       ECO:0000269|PubMed:15326256, ECO:0000269|PubMed:16775239}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Adie pupil (ADIEP) [MIM:103100]: A stationary, benign
CC       disorder characterized by tonic, sluggishly reacting pupil and
CC       hypoactive or absent tendon reflexes. Adie pupil is a
CC       characteristic of Charcot-Marie-Tooth disease type 2J.
CC       {ECO:0000269|PubMed:16775239}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Charcot-Marie-Tooth disease, dominant, intermediate type,
CC       D (CMTDID) [MIM:607791]: A form of Charcot-Marie-Tooth disease, a
CC       disorder of the peripheral nervous system, characterized by
CC       progressive weakness and atrophy, initially of the peroneal
CC       muscles and later of the distal muscles of the arms. The dominant
CC       intermediate type D is characterized by clinical and pathologic
CC       features intermediate between demyelinating and axonal peripheral
CC       neuropathies, and motor median nerve conduction velocities ranging
CC       from 25 to 45 m/sec. {ECO:0000269|PubMed:10406984}. Note=The
CC       disease may be caused by mutations affecting the gene represented
CC       in this entry.
CC   -!- DISEASE: Dejerine-Sottas syndrome (DSS) [MIM:145900]: A severe
CC       degenerating neuropathy of the demyelinating Charcot-Marie-Tooth
CC       disease category, with onset by age 2 years. Characterized by
CC       motor and sensory neuropathy with very slow nerve conduction
CC       velocities, increased cerebrospinal fluid protein concentrations,
CC       hypertrophic nerve changes, delayed age of walking as well as
CC       areflexia. There are both autosomal dominant and autosomal
CC       recessive forms of Dejerine-Sottas syndrome.
CC       {ECO:0000269|PubMed:11438991, ECO:0000269|PubMed:11596785,
CC       ECO:0000269|PubMed:11835375, ECO:0000269|PubMed:12497641,
CC       ECO:0000269|PubMed:7506095, ECO:0000269|PubMed:8630052,
CC       ECO:0000269|PubMed:8816708, ECO:0000269|PubMed:9187667,
CC       ECO:0000269|PubMed:9222756, ECO:0000269|PubMed:9452055,
CC       ECO:0000269|PubMed:9452091, ECO:0000269|PubMed:9633821}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Neuropathy, congenital hypomyelinating or amyelinating
CC       (CHN) [MIM:605253]: A severe degenerating neuropathy that results
CC       from a congenital impairment in myelin formation. It is clinically
CC       characterized by early onset of hypotonia, areflexia, distal
CC       muscle weakness, and very slow nerve conduction velocities (as low
CC       as 3m/s). Some patients manifest nearly complete absence of
CC       spontaneous limb movements, respiratory distress at birth, and
CC       complete absence of myelin shown by electron microscopy of
CC       peripheral nerves. Inheritance can be autosomal dominant or
CC       recessive. {ECO:0000269|PubMed:15184631}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Roussy-Levy syndrome (ROULS) [MIM:180800]: Autosomal
CC       dominant disorder that resembles Charcot-Marie-Tooth disease type
CC       1 in that it presents with foot deformity, weakness and atrophy of
CC       distal limb muscles, especially the peronei, and absent tendon
CC       reflexes. The phenotype differs, however, in that it includes
CC       static tremor of the upper limbs and gait ataxia.
CC       {ECO:0000269|PubMed:10553995}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the myelin P0 protein family.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 Ig-like V-type (immunoglobulin-like)
CC       domain. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH06491.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=AAP35411.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=BAA03540.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=BAG36330.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=CAH70270.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=EAW52606.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Inherited peripheral neuropathies mutation db;
CC       URL="http://www.molgen.ua.ac.be/CMTMutations/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D10537; BAA01395.1; -; mRNA.
DR   EMBL; D14720; BAA03540.1; ALT_INIT; Genomic_DNA.
DR   EMBL; L24893; AAA20656.1; -; Genomic_DNA.
DR   EMBL; L24894; AAA20656.1; JOINED; Genomic_DNA.
DR   EMBL; AK313555; BAG36330.1; ALT_INIT; mRNA.
DR   EMBL; BT006765; AAP35411.1; ALT_INIT; mRNA.
DR   EMBL; AL592295; CAH70270.1; ALT_INIT; Genomic_DNA.
DR   EMBL; CH471121; EAW52606.1; ALT_INIT; Genomic_DNA.
DR   EMBL; BC006491; AAH06491.1; ALT_INIT; mRNA.
DR   EMBL; S66705; AAB28708.1; -; mRNA.
DR   EMBL; U10018; AAA18981.1; -; Genomic_DNA.
DR   EMBL; U10017; AAA18981.1; JOINED; Genomic_DNA.
DR   CCDS; CCDS1229.2; -. [P25189-1]
DR   PIR; JH0252; JH0252.
DR   RefSeq; NP_000521.2; NM_000530.7. [P25189-1]
DR   RefSeq; NP_001302420.1; NM_001315491.1.
DR   UniGene; Hs.591486; -.
DR   PDB; 1N2P; Model; -; A=1-248.
DR   PDB; 3OAI; X-ray; 2.10 A; A/B=30-150.
DR   PDBsum; 1N2P; -.
DR   PDBsum; 3OAI; -.
DR   ProteinModelPortal; P25189; -.
DR   SMR; P25189; 24-150.
DR   BioGrid; 110499; 2.
DR   IntAct; P25189; 3.
DR   MINT; MINT-1390651; -.
DR   STRING; 9606.ENSP00000431538; -.
DR   PhosphoSite; P25189; -.
DR   BioMuta; MPZ; -.
DR   DMDM; 127721; -.
DR   MaxQB; P25189; -.
DR   PaxDb; P25189; -.
DR   PRIDE; P25189; -.
DR   DNASU; 4359; -.
DR   Ensembl; ENST00000463290; ENSP00000431538; ENSG00000158887. [P25189-1]
DR   Ensembl; ENST00000533357; ENSP00000432943; ENSG00000158887. [P25189-1]
DR   GeneID; 4359; -.
DR   KEGG; hsa:4359; -.
DR   UCSC; uc001gaf.4; human. [P25189-1]
DR   CTD; 4359; -.
DR   GeneCards; MPZ; -.
DR   GeneReviews; MPZ; -.
DR   HGNC; HGNC:7225; MPZ.
DR   MalaCards; MPZ; -.
DR   MIM; 103100; phenotype.
DR   MIM; 118200; phenotype.
DR   MIM; 145900; phenotype.
DR   MIM; 159440; gene.
DR   MIM; 180800; phenotype.
DR   MIM; 605253; phenotype.
DR   MIM; 607677; phenotype.
DR   MIM; 607736; phenotype.
DR   MIM; 607791; phenotype.
DR   neXtProt; NX_P25189; -.
DR   Orphanet; 99942; Autosomal dominant Charcot-Marie-Tooth disease type 2I.
DR   Orphanet; 99943; Autosomal dominant Charcot-Marie-Tooth disease type 2J.
DR   Orphanet; 100046; Autosomal dominant intermediate Charcot-Marie-Tooth disease type D.
DR   Orphanet; 324585; Autosomal dominant intermediate Charcot-Marie-Tooth disease with neuropathic pain.
DR   Orphanet; 101082; Charcot-Marie-Tooth disease type 1B.
DR   Orphanet; 64748; Dejerine-Sottas syndrome.
DR   Orphanet; 3115; Roussy-Levy syndrome.
DR   PharmGKB; PA30930; -.
DR   eggNOG; ENOG410IJG4; Eukaryota.
DR   eggNOG; ENOG4111R0Y; LUCA.
DR   GeneTree; ENSGT00640000091161; -.
DR   HOGENOM; HOG000232144; -.
DR   HOVERGEN; HBG096384; -.
DR   InParanoid; P25189; -.
DR   KO; K06770; -.
DR   OMA; YAMLDHS; -.
DR   OrthoDB; EOG7G1V80; -.
DR   PhylomeDB; P25189; -.
DR   TreeFam; TF331728; -.
DR   GeneWiki; Myelin_protein_zero; -.
DR   GenomeRNAi; 4359; -.
DR   NextBio; 17155; -.
DR   PRO; PR:P25189; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; P25189; -.
DR   CleanEx; HS_MPZ; -.
DR   ExpressionAtlas; P25189; baseline and differential.
DR   Genevisible; P25189; HS.
DR   GO; GO:0016323; C:basolateral plasma membrane; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005764; C:lysosome; IEA:Ensembl.
DR   GO; GO:0043209; C:myelin sheath; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; NAS:ProtInc.
DR   GO; GO:0005791; C:rough endoplasmic reticulum; IEA:Ensembl.
DR   GO; GO:0005198; F:structural molecule activity; NAS:ProtInc.
DR   GO; GO:0045217; P:cell-cell junction maintenance; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0007268; P:synaptic transmission; TAS:ProtInc.
DR   Gene3D; 2.60.40.10; -; 1.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013106; Ig_V-set.
DR   InterPro; IPR019566; Myelin-PO_C.
DR   InterPro; IPR000920; Myelin_P0-rel.
DR   InterPro; IPR019738; Myelin_P0_CS.
DR   InterPro; IPR029869; P0.
DR   PANTHER; PTHR13869; PTHR13869; 1.
DR   PANTHER; PTHR13869:SF7; PTHR13869:SF7; 1.
DR   Pfam; PF10570; Myelin-PO_C; 1.
DR   Pfam; PF07686; V-set; 1.
DR   PRINTS; PR00213; MYELINP0.
DR   SMART; SM00406; IGv; 1.
DR   SUPFAM; SSF48726; SSF48726; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00568; MYELIN_P0; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane;
KW   Charcot-Marie-Tooth disease; Complete proteome; Deafness;
KW   Dejerine-Sottas syndrome; Direct protein sequencing; Disease mutation;
KW   Disulfide bond; Glycoprotein; Immunoglobulin domain; Membrane;
KW   Neurodegeneration; Neuropathy; Phosphoprotein; Polymorphism;
KW   Reference proteome; Signal; Transmembrane; Transmembrane helix.
FT   SIGNAL        1     29
FT   CHAIN        30    248       Myelin protein P0.
FT                                /FTId=PRO_0000019300.
FT   TOPO_DOM     30    153       Extracellular. {ECO:0000255}.
FT   TRANSMEM    154    179       Helical. {ECO:0000255}.
FT   TOPO_DOM    180    248       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       30    143       Ig-like V-type.
FT   MOD_RES     210    210       Phosphoserine; by PKC. {ECO:0000250}.
FT   MOD_RES     226    226       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P27573}.
FT   MOD_RES     228    228       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P27573}.
FT   MOD_RES     233    233       Phosphoserine; by PKC. {ECO:0000250}.
FT   MOD_RES     243    243       Phosphoserine; by PKC. {ECO:0000250}.
FT   CARBOHYD    122    122       N-linked (GlcNAc...) (complex).
FT                                {ECO:0000250}.
FT   DISULFID     50    127       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:21971831}.
FT   VAR_SEQ     248    248       K -> KRLAGRAGDRGLGVESAKGPKVMVIEMELRKDEQSP
FT                                ELRPAVKSPSRTSLKNALKNMMGLNSDK (in isoform
FT                                L-MPZ). {ECO:0000305}.
FT                                /FTId=VSP_045844.
FT   VARIANT      30     30       I -> M (in CMT1B).
FT                                {ECO:0000269|PubMed:7694726}.
FT                                /FTId=VAR_004500.
FT   VARIANT      32     32       V -> F (in CMT1B; severe).
FT                                {ECO:0000269|PubMed:10923043}.
FT                                /FTId=VAR_004501.
FT   VARIANT      34     34       T -> I (in CMT1B).
FT                                {ECO:0000269|PubMed:8797476}.
FT                                /FTId=VAR_004502.
FT   VARIANT      35     35       D -> Y (in CMTDID).
FT                                {ECO:0000269|PubMed:10406984,
FT                                ECO:0000269|PubMed:12477701}.
FT                                /FTId=VAR_015971.
FT   VARIANT      39     39       H -> P (in CMT1B; slightly reduces
FT                                intercellular adhesion; does not affect
FT                                targeting to the cell membrane).
FT                                {ECO:0000269|PubMed:14711881,
FT                                ECO:0000269|PubMed:18337304}.
FT                                /FTId=VAR_054393.
FT   VARIANT      42     42       Missing (in DSS).
FT                                {ECO:0000269|PubMed:11596785}.
FT                                /FTId=VAR_031884.
FT   VARIANT      44     44       S -> F (in CMT2I and CMT1B).
FT                                {ECO:0000269|PubMed:14711881,
FT                                ECO:0000269|PubMed:9595994}.
FT                                /FTId=VAR_004503.
FT   VARIANT      50     50       Missing (in CMT1B).
FT                                {ECO:0000269|PubMed:14711881}.
FT                                /FTId=VAR_054394.
FT   VARIANT      51     57       Missing (in CMT1B; affects targeting to
FT                                the cell membrane; reduces intercellular
FT                                adhesion). {ECO:0000269|PubMed:18337304}.
FT                                /FTId=VAR_054395.
FT   VARIANT      51     51       S -> F (in CMT1B).
FT                                {ECO:0000269|PubMed:11437164}.
FT                                /FTId=VAR_029971.
FT   VARIANT      54     54       S -> C (in CMT1B; severe).
FT                                /FTId=VAR_004504.
FT   VARIANT      54     54       S -> P (in CMT1B). {ECO:0000269|Ref.40}.
FT                                /FTId=VAR_004505.
FT   VARIANT      56     56       E -> K (in CMT2).
FT                                {ECO:0000269|PubMed:14871447}.
FT                                /FTId=VAR_054396.
FT   VARIANT      58     58       V -> F (in CMT1B; moderate).
FT                                {ECO:0000269|PubMed:9452099}.
FT                                /FTId=VAR_004506.
FT   VARIANT      60     60       D -> H (in CMT2I).
FT                                {ECO:0000269|PubMed:14638973}.
FT                                /FTId=VAR_029972.
FT   VARIANT      61     61       D -> G (in CMT2; unclassified).
FT                                {ECO:0000269|PubMed:10764043}.
FT                                /FTId=VAR_031885.
FT   VARIANT      62     62       I -> F (in CMT1B).
FT                                {ECO:0000269|PubMed:10214757,
FT                                ECO:0000269|PubMed:12477701}.
FT                                /FTId=VAR_015972.
FT   VARIANT      62     62       I -> M (in CMT2I).
FT                                {ECO:0000269|PubMed:14638973}.
FT                                /FTId=VAR_029973.
FT   VARIANT      63     63       S -> C (in DSS).
FT                                {ECO:0000269|PubMed:7506095}.
FT                                /FTId=VAR_004508.
FT   VARIANT      63     63       S -> F (in CMT1B).
FT                                {ECO:0000269|PubMed:11438991,
FT                                ECO:0000269|PubMed:8835320}.
FT                                /FTId=VAR_004509.
FT   VARIANT      63     63       Missing (in CMT1B).
FT                                {ECO:0000269|PubMed:12402337,
FT                                ECO:0000269|PubMed:12477701,
FT                                ECO:0000269|PubMed:7693130}.
FT                                /FTId=VAR_004507.
FT   VARIANT      64     64       Missing (in CMT1B and DSS).
FT                                {ECO:0000269|PubMed:8630052}.
FT                                /FTId=VAR_004510.
FT   VARIANT      65     65       T -> A (in CMT1B).
FT                                {ECO:0000269|PubMed:15036333}.
FT                                /FTId=VAR_031886.
FT   VARIANT      65     65       T -> I (in CMT1B).
FT                                {ECO:0000269|PubMed:12402337}.
FT                                /FTId=VAR_029974.
FT   VARIANT      68     68       Y -> C (in CMT1B; severe/mild).
FT                                {ECO:0000269|PubMed:10923043,
FT                                ECO:0000269|PubMed:12402337,
FT                                ECO:0000269|PubMed:12477701,
FT                                ECO:0000269|PubMed:9452099}.
FT                                /FTId=VAR_004511.
FT   VARIANT      75     75       D -> V (in CMT2J).
FT                                {ECO:0000269|PubMed:11080237,
FT                                ECO:0000269|PubMed:12402337,
FT                                ECO:0000269|PubMed:12477701}.
FT                                /FTId=VAR_015973.
FT   VARIANT      78     78       S -> L (in CMT1B; severe).
FT                                {ECO:0000269|PubMed:10965800,
FT                                ECO:0000269|PubMed:11437164,
FT                                ECO:0000269|PubMed:11835375,
FT                                ECO:0000269|PubMed:12497641,
FT                                ECO:0000269|PubMed:7527371,
FT                                ECO:0000269|PubMed:7550231,
FT                                ECO:0000269|PubMed:9187667,
FT                                ECO:0000269|PubMed:9633821}.
FT                                /FTId=VAR_004512.
FT   VARIANT      78     78       S -> W (in CMT1B).
FT                                {ECO:0000269|PubMed:12707985}.
FT                                /FTId=VAR_031887.
FT   VARIANT      81     81       H -> R (in CMT1B; severe; reduces
FT                                intercellular adhesion; does not affect
FT                                targeting to the cell membrane).
FT                                {ECO:0000269|PubMed:12477701,
FT                                ECO:0000269|PubMed:18337304,
FT                                ECO:0000269|PubMed:8990016}.
FT                                /FTId=VAR_004513.
FT   VARIANT      81     81       H -> Y (in CMT; associated with F-113).
FT                                {ECO:0000269|PubMed:11801400}.
FT                                /FTId=VAR_031888.
FT   VARIANT      82     82       Y -> C (in CMT1B and DSS).
FT                                {ECO:0000269|PubMed:11835375,
FT                                ECO:0000269|PubMed:12402337,
FT                                ECO:0000269|PubMed:7505151,
FT                                ECO:0000269|PubMed:9633821}.
FT                                /FTId=VAR_004514.
FT   VARIANT      89     89       I -> N (in CMT2I; patient carrying also
FT                                Met-92 and Met-162).
FT                                {ECO:0000269|PubMed:11835375}.
FT                                /FTId=VAR_015974.
FT   VARIANT      90     90       D -> E (in CMT1B).
FT                                {ECO:0000269|PubMed:7693129}.
FT                                /FTId=VAR_004515.
FT   VARIANT      92     92       V -> M (in CMT2I; patient carrying also
FT                                Asn-89 and Met-162).
FT                                {ECO:0000269|PubMed:11835375}.
FT                                /FTId=VAR_015975.
FT   VARIANT      93     93       G -> E (in CMT1B).
FT                                {ECO:0000269|PubMed:12477701,
FT                                ECO:0000269|PubMed:9217235}.
FT                                /FTId=VAR_004516.
FT   VARIANT      96     96       K -> E (in CMT1B).
FT                                {ECO:0000269|PubMed:7504284,
FT                                ECO:0000269|PubMed:7693129}.
FT                                /FTId=VAR_004517.
FT   VARIANT      97     97       E -> V (in CMT2J).
FT                                {ECO:0000269|PubMed:15326256}.
FT                                /FTId=VAR_029975.
FT   VARIANT      98     98       R -> C (in CMT1B; severe and DSS).
FT                                {ECO:0000269|PubMed:11438991,
FT                                ECO:0000269|PubMed:12477701,
FT                                ECO:0000269|PubMed:8797476,
FT                                ECO:0000269|PubMed:8816708,
FT                                ECO:0000269|PubMed:9187667}.
FT                                /FTId=VAR_004518.
FT   VARIANT      98     98       R -> H (in CMT1B).
FT                                {ECO:0000269|PubMed:10737979,
FT                                ECO:0000269|PubMed:11437164,
FT                                ECO:0000269|PubMed:12221176,
FT                                ECO:0000269|PubMed:14711881,
FT                                ECO:0000269|PubMed:7688964,
FT                                ECO:0000269|PubMed:8797476}.
FT                                /FTId=VAR_004519.
FT   VARIANT      98     98       R -> P (in CMT1B).
FT                                /FTId=VAR_004520.
FT   VARIANT      98     98       R -> S (in CMT1B).
FT                                {ECO:0000269|PubMed:8816708}.
FT                                /FTId=VAR_004521.
FT   VARIANT      99     99       I -> T (in CMT1B).
FT                                /FTId=VAR_004522.
FT   VARIANT     101    101       W -> C (in CMT1B).
FT                                {ECO:0000269|PubMed:7550231}.
FT                                /FTId=VAR_004523.
FT   VARIANT     103    103       G -> E (in CMT1B).
FT                                {ECO:0000269|PubMed:11445635}.
FT                                /FTId=VAR_015976.
FT   VARIANT     109    109       D -> N (in CMT1B).
FT                                {ECO:0000269|PubMed:10545037}.
FT                                /FTId=VAR_031889.
FT   VARIANT     110    110       G -> D (in DSS).
FT                                {ECO:0000269|PubMed:12497641}.
FT                                /FTId=VAR_029976.
FT   VARIANT     112    112       I -> T (in CMT1B; severe).
FT                                {ECO:0000269|PubMed:9452099}.
FT                                /FTId=VAR_004524.
FT   VARIANT     113    113       V -> F (in CMT; unclassified; associated
FT                                with Y-81).
FT                                {ECO:0000269|PubMed:11801400}.
FT                                /FTId=VAR_031890.
FT   VARIANT     113    113       V -> I (in CMT2).
FT                                {ECO:0000269|PubMed:12402337}.
FT                                /FTId=VAR_029977.
FT   VARIANT     114    114       I -> T (in DSS; associated on the same
FT                                allele as His-116 and Asn-128 in one
FT                                patient). {ECO:0000269|PubMed:9222756}.
FT                                /FTId=VAR_004525.
FT   VARIANT     116    116       N -> H (in DSS; associated on the same
FT                                allele as Thr-114 and Asn-128 in one
FT                                patient). {ECO:0000269|PubMed:9222756}.
FT                                /FTId=VAR_004526.
FT   VARIANT     118    118       D -> DFY (in DSS).
FT                                {ECO:0000269|PubMed:9452055}.
FT                                /FTId=VAR_004527.
FT   VARIANT     118    118       D -> N (in CMT2I).
FT                                {ECO:0000269|PubMed:15241803}.
FT                                /FTId=VAR_021609.
FT   VARIANT     119    119       Y -> C (in CMT2; unclassified).
FT                                {ECO:0000269|PubMed:10764043}.
FT                                /FTId=VAR_031891.
FT   VARIANT     122    122       N -> S (in CMT1B; loss of glycosylation
FT                                site). {ECO:0000269|PubMed:8844219}.
FT                                /FTId=VAR_004528.
FT   VARIANT     123    123       G -> C (in DSS and CMT1B).
FT                                {ECO:0000269|PubMed:11835375,
FT                                ECO:0000269|PubMed:14711881}.
FT                                /FTId=VAR_015977.
FT   VARIANT     124    125       Missing (in DSS).
FT                                {ECO:0000269|PubMed:11438991,
FT                                ECO:0000269|PubMed:9452091}.
FT                                /FTId=VAR_004530.
FT   VARIANT     124    124       T -> K (in CHN).
FT                                {ECO:0000269|PubMed:15184631}.
FT                                /FTId=VAR_029978.
FT   VARIANT     124    124       T -> M (in CMT1B and CMT2J; CMTJ2
FT                                patients present Adie pupil; slightly
FT                                reduces intercellular adhesion; does not
FT                                affect targeting to the cell membrane;
FT                                affects glycosylation).
FT                                {ECO:0000269|PubMed:10071056,
FT                                ECO:0000269|PubMed:10329755,
FT                                ECO:0000269|PubMed:10923043,
FT                                ECO:0000269|PubMed:11080237,
FT                                ECO:0000269|PubMed:11438991,
FT                                ECO:0000269|PubMed:12402337,
FT                                ECO:0000269|PubMed:12477701,
FT                                ECO:0000269|PubMed:15159512,
FT                                ECO:0000269|PubMed:16775239,
FT                                ECO:0000269|PubMed:18337304,
FT                                ECO:0000269|PubMed:9452091}.
FT                                /FTId=VAR_004529.
FT   VARIANT     127    127       C -> Y (in DSS).
FT                                /FTId=VAR_004531.
FT   VARIANT     128    128       D -> E (in CMT1B).
FT                                /FTId=VAR_004532.
FT   VARIANT     128    128       D -> N (in DSS; associated on the same
FT                                allele as Thr-114 and His-116 in one
FT                                patient). {ECO:0000269|PubMed:9222756}.
FT                                /FTId=VAR_004533.
FT   VARIANT     130    130       K -> R (in CMT1B and DSS).
FT                                {ECO:0000269|PubMed:10923043,
FT                                ECO:0000269|PubMed:12477701,
FT                                ECO:0000269|PubMed:14711881,
FT                                ECO:0000269|PubMed:8797476}.
FT                                /FTId=VAR_004534.
FT   VARIANT     131    131       N -> K (in ROULS).
FT                                {ECO:0000269|PubMed:10553995}.
FT                                /FTId=VAR_015978.
FT   VARIANT     132    132       P -> L (in CMT1B; moderate).
FT                                {ECO:0000269|PubMed:9452099}.
FT                                /FTId=VAR_004535.
FT   VARIANT     134    134       D -> E (in CMT1B).
FT                                {ECO:0000269|PubMed:10737979,
FT                                ECO:0000269|PubMed:7530774}.
FT                                /FTId=VAR_004536.
FT   VARIANT     134    134       D -> G (in CMT1B).
FT                                {ECO:0000269|PubMed:10737979}.
FT                                /FTId=VAR_029979.
FT   VARIANT     134    134       D -> N (in CMT1B).
FT                                {ECO:0000269|PubMed:7527371}.
FT                                /FTId=VAR_004537.
FT   VARIANT     135    135       I -> L (in CMT1B and DSS).
FT                                {ECO:0000269|PubMed:8797476}.
FT                                /FTId=VAR_004538.
FT   VARIANT     135    135       I -> T (in CMT1B).
FT                                {ECO:0000269|PubMed:10737979,
FT                                ECO:0000269|PubMed:8664899}.
FT                                /FTId=VAR_004539.
FT   VARIANT     136    136       V -> E (in DSS).
FT                                {ECO:0000269|PubMed:11835375}.
FT                                /FTId=VAR_015979.
FT   VARIANT     137    137       G -> S (in CMT1B).
FT                                {ECO:0000269|PubMed:8664899}.
FT                                /FTId=VAR_004540.
FT   VARIANT     138    138       K -> N (in CMT1B).
FT                                {ECO:0000269|PubMed:10737979}.
FT                                /FTId=VAR_029980.
FT   VARIANT     139    139       T -> N (in CMT1B).
FT                                {ECO:0000269|PubMed:10737979}.
FT                                /FTId=VAR_029981.
FT   VARIANT     140    140       S -> T (in CMT1B).
FT                                {ECO:0000269|PubMed:12207932,
FT                                ECO:0000269|PubMed:14711881}.
FT                                /FTId=VAR_029982.
FT   VARIANT     143    143       T -> M (in CMT1B).
FT                                /FTId=VAR_004541.
FT   VARIANT     145    145       Y -> S (in CMT1B).
FT                                {ECO:0000269|PubMed:12845552}.
FT                                /FTId=VAR_029983.
FT   VARIANT     146    146       V -> F (in CMT1B).
FT                                {ECO:0000269|PubMed:12477701}.
FT                                /FTId=VAR_029984.
FT   VARIANT     162    162       I -> M (in CMT2I; patient carrying also
FT                                Asn-89 and Met-92).
FT                                {ECO:0000269|PubMed:11835375}.
FT                                /FTId=VAR_015980.
FT   VARIANT     163    163       G -> R (in CMT1B).
FT                                {ECO:0000269|PubMed:12207932,
FT                                ECO:0000269|PubMed:12402337}.
FT                                /FTId=VAR_004542.
FT   VARIANT     167    167       G -> A (in CMT1B and DSS; severe).
FT                                {ECO:0000269|PubMed:9452099}.
FT                                /FTId=VAR_004543.
FT   VARIANT     167    167       G -> R (in DSS and CMT).
FT                                {ECO:0000269|PubMed:12477701,
FT                                ECO:0000269|PubMed:7506095}.
FT                                /FTId=VAR_004544.
FT   VARIANT     170    170       L -> R (in CMT1B).
FT                                {ECO:0000269|PubMed:12402337}.
FT                                /FTId=VAR_029985.
FT   VARIANT     216    216       T -> ER (in CMT1B; referred to as
FT                                'T216ER').
FT                                /FTId=VAR_029986.
FT   VARIANT     221    221       A -> T (in DSS).
FT                                {ECO:0000269|PubMed:11596785}.
FT                                /FTId=VAR_031892.
FT   VARIANT     224    224       D -> Y (in CMT1B; also in two
FT                                asymptomatic individuals from the same
FT                                family). {ECO:0000269|PubMed:16488608}.
FT                                /FTId=VAR_054397.
FT   VARIANT     227    227       R -> S (in CMT1B).
FT                                {ECO:0000269|PubMed:14711881}.
FT                                /FTId=VAR_054398.
FT   VARIANT     236    236       K -> E (in CMT2I).
FT                                {ECO:0000269|PubMed:15241803}.
FT                                /FTId=VAR_021610.
FT   VARIANT     236    236       Missing (in CMT1B).
FT                                {ECO:0000269|PubMed:12207932}.
FT                                /FTId=VAR_029987.
FT   VARIANT     244    244       R -> L.
FT                                /FTId=VAR_004545.
FT   STRAND       36     41       {ECO:0000244|PDB:3OAI}.
FT   STRAND       46     48       {ECO:0000244|PDB:3OAI}.
FT   STRAND       63     70       {ECO:0000244|PDB:3OAI}.
FT   STRAND       77     83       {ECO:0000244|PDB:3OAI}.
FT   STRAND       86     89       {ECO:0000244|PDB:3OAI}.
FT   TURN         94     98       {ECO:0000244|PDB:3OAI}.
FT   STRAND       99    101       {ECO:0000244|PDB:3OAI}.
FT   HELIX       105    107       {ECO:0000244|PDB:3OAI}.
FT   STRAND      112    114       {ECO:0000244|PDB:3OAI}.
FT   HELIX       119    121       {ECO:0000244|PDB:3OAI}.
FT   STRAND      123    131       {ECO:0000244|PDB:3OAI}.
FT   STRAND      134    148       {ECO:0000244|PDB:3OAI}.
SQ   SEQUENCE   248 AA;  27555 MW;  A93F4744DACB0D5E CRC64;
     MAPGAPSSSP SPILAVLLFS SLVLSPAQAI VVYTDREVHG AVGSRVTLHC SFWSSEWVSD
     DISFTWRYQP EGGRDAISIF HYAKGQPYID EVGTFKERIQ WVGDPRWKDG SIVIHNLDYS
     DNGTFTCDVK NPPDIVGKTS QVTLYVFEKV PTRYGVVLGA VIGGVLGVVL LLLLLFYVVR
     YCWLRRQAAL QRRLSAMEKG KLHKPGKDAS KRGRQTPVLY AMLDHSRSTK AVSEKKAKGL
     GESRKDKK
//
ID   APOA4_HUMAN             Reviewed;         396 AA.
AC   P06727; A8MSL6; Q14CW8; Q6Q787;
DT   01-JAN-1988, integrated into UniProtKB/Swiss-Prot.
DT   07-MAR-2006, sequence version 3.
DT   17-FEB-2016, entry version 179.
DE   RecName: Full=Apolipoprotein A-IV;
DE            Short=Apo-AIV;
DE            Short=ApoA-IV;
DE   AltName: Full=Apolipoprotein A4;
DE   Flags: Precursor;
GN   Name=APOA4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT LYS-279.
RX   PubMed=3755616; DOI=10.1021/bi00361a034;
RA   Karathanasis S.K., Yunis I.;
RT   "Structure, evolution, and tissue-specific synthesis of human
RT   apolipoprotein AIV.";
RL   Biochemistry 25:3962-3970(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-279.
RX   PubMed=3095836; DOI=10.1073/pnas.83.22.8457;
RA   Karathanasis S.K., Oettgen P., Haddad I.A., Antonarakis S.E.;
RT   "Structure, evolution, and polymorphisms of the human apolipoprotein
RT   A4 gene (APOA4).";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:8457-8461(1986).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], POLYMORPHISM, AND VARIANT APOA-IV*2
RP   HIS-380.
RX   PubMed=3036793;
RA   Elshourbagy N.A., Walker D.W., Paik Y.K., Boguski M.S., Freeman M.,
RA   Gordon J.I., Taylor J.M.;
RT   "Structure and expression of the human apolipoprotein A-IV gene.";
RL   J. Biol. Chem. 262:7973-7981(1987).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Intestine;
RX   PubMed=2930771; DOI=10.1016/0005-2760(89)90292-0;
RA   Yang C., Gu Z.W., Xiong W., Rosseneu M., Yang H.X., Lee B.M.,
RA   Gotto A.M. Jr., Chan L.;
RT   "The primary structure of human apolipoprotein A-IV.";
RL   Biochim. Biophys. Acta 1002:231-237(1989).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS MET-13; HIS-77;
RP   SER-147; SER-161; SER-367 AND HIS-380.
RX   PubMed=15108119; DOI=10.1007/s00439-004-1106-x;
RA   Fullerton S.M., Buchanan A.V., Sonpar V.A., Taylor S.L., Smith J.D.,
RA   Carlson C.S., Salomaa V., Stengaard J.H., Boerwinkle E., Clark A.G.,
RA   Nickerson D.A., Weiss K.M.;
RT   "The effects of scale: variation in the APOA1/C3/A4/A5 gene cluster.";
RL   Hum. Genet. 115:36-56(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT SER-147.
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F.,
RA   Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E.,
RA   FitzGerald M.G., Jaffe D.B., LaButti K., Nicol R., Park H.-S.,
RA   Seaman C., Sougnez C., Yang X., Zimmer A.R., Zody M.C., Birren B.W.,
RA   Nusbaum C., Fujiyama A., Hattori M., Rogers J., Lander E.S.,
RA   Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, and Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 21-396, AND VARIANT APOA-IV*2 HIS-380.
RX   PubMed=3080432;
RA   Elshourbagy N.A., Walker D.W., Boguski M.S., Gordon J.I., Taylor J.M.;
RT   "The nucleotide and derived amino acid sequence of human
RT   apolipoprotein A-IV mRNA and the close linkage of its gene to the
RT   genes of apolipoproteins A-I and C-III.";
RL   J. Biol. Chem. 261:1998-2002(1986).
RN   [9]
RP   SIGNAL SEQUENCE CLEAVAGE SITE.
RX   PubMed=6706947;
RA   Gordon J.I., Bisgaier C.L., Sims H.F., Sachdev O.P., Glickman R.M.,
RA   Strauss A.W.;
RT   "Biosynthesis of human preapolipoprotein A-IV.";
RL   J. Biol. Chem. 259:468-474(1984).
RN   [10]
RP   REVIEW ON POLYMORPHISM.
RA   Lohse P., Brewer H.B. Jr.;
RT   "Genetic polymorphism of apolipoprotein A-IV.";
RL   Curr. Opin. Lipidol. 2:90-95(1991).
RN   [11]
RP   POLYMORPHISM, ALLELES APOA-IV*1 AND APOA-IV*2, AND VARIANT HIS-380.
RX   PubMed=2351649;
RA   Lohse P., Kindt M.R., Rader D.J., Brewer H.B. Jr.;
RT   "Genetic polymorphism of human plasma apolipoprotein A-IV is due to
RT   nucleotide substitutions in the apolipoprotein A-IV gene.";
RL   J. Biol. Chem. 265:10061-10064(1990).
RN   [12]
RP   POLYMORPHISM, ALLELES A-IV*0 AND A-IV*3, AND VARIANTS LYS-250 AND
RP   GLU-GLN-GLN-GLN-381 INS.
RX   PubMed=1973689;
RA   Lohse P., Kindt M.R., Rader D.J., Brewer H.B. Jr.;
RT   "Human plasma apolipoproteins A-IV-0 and A-IV-3. Molecular basis for
RT   two rare variants of apolipoprotein A-IV-1.";
RL   J. Biol. Chem. 265:12734-12739(1990).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 84-355, AND SUBUNIT.
RX   PubMed=22579246; DOI=10.1016/j.str.2012.02.020;
RA   Deng X., Morris J., Dressmen J., Tubb M.R., Tso P., Jerome W.G.,
RA   Davidson W.S., Thompson T.B.;
RT   "The structure of dimeric apolipoprotein A-IV and its mechanism of
RT   self-association.";
RL   Structure 20:767-779(2012).
RN   [15]
RP   VARIANT HIS-380.
RX   PubMed=2065039;
RA   Tenkanen H., Lukka M., Jauhiainen M., Metso J., Baumann M.,
RA   Peltonen L., Ehnholm C.;
RT   "The mutation causing the common apolipoprotein A-IV polymorphism is a
RT   glutamine to histidine substitution of amino acid 360.";
RL   Arterioscler. Thromb. 11:851-856(1991).
RN   [16]
RP   POLYMORPHISM, ALLELES A-IV*0; A-IV*1; A-IV*2 AND A-IV*3, AND VARIANTS
RP   LYS-185; GLU-187; SER-367 AND HIS-380.
RX   PubMed=1677358;
RA   Lohse P., Kindt M.R., Rader D.J., Brewer H.B. Jr.;
RT   "Three genetic variants of human plasma apolipoprotein A-IV: apoA-IV-
RT   1(Thr-347-->Ser), apoA-IV-0(Lys-167-->Glu,Gln-360-->His), and apoA-IV-
RT   3(Glu-165-->Lys).";
RL   J. Biol. Chem. 266:13513-13518(1991).
RN   [17]
RP   ERRATUM.
RA   Lohse P., Kindt M.R., Rader D.J., Brewer H.B. Jr.;
RL   J. Biol. Chem. 266:19866-19866(1991).
RN   [18]
RP   VARIANT MET-13.
RX   PubMed=1349197;
RA   von Eckardstein A., Funke H., Schulte M., Erren M., Schulte H.,
RA   Assmann G.;
RT   "Nonsynonymous polymorphic sites in the apolipoprotein (apo) A-IV gene
RT   are associated with changes in the concentration of apo B- and apo A-
RT   I-containing lipoproteins in a normal population.";
RL   Am. J. Hum. Genet. 50:1115-1128(1992).
RN   [19]
RP   VARIANT SER-147.
RX   PubMed=1737067; DOI=10.1016/0925-4439(92)90147-F;
RA   Tenkanen H., Koskinen P., Metso J., Baumann M., Lukka M.,
RA   Kauppinen-Makelin R., Kontula K., Taskinen M.R., Manttari M.,
RA   Manninen V., Ehnholm C.;
RT   "A novel polymorphism of apolipoprotein A-IV is the result of an
RT   asparagine to serine substitution at residue 127.";
RL   Biochim. Biophys. Acta 1138:27-33(1992).
RN   [20]
RP   POLYMORPHISM, ALLELE A-IV*5, AND VARIANT GLU-GLN-GLN-GLN-381 INS.
RX   PubMed=1487136; DOI=10.1002/gepi.1370090602;
RA   Kamboh M.I., Williams E.R., Law J.C., Aston C.E., Bunker C.H.,
RA   Ferrell R.E., Pollitzer W.S.;
RT   "Molecular basis of a unique African variant (A-IV 5) of human
RT   apolipoprotein A-IV and its significance in lipid metabolism.";
RL   Genet. Epidemiol. 9:379-388(1992).
RN   [21]
RP   VARIANTS BUDAPEST-2 LYS-44; BUDAPEST-1 CYS-305 AND SER-367.
RX   PubMed=7728150; DOI=10.1002/humu.1380050108;
RA   Menzel H.J., Dieplinger H., Sandholzer C., Karadi I., Utermann G.,
RA   Csaszar A.;
RT   "Apolipoprotein A-IV polymorphism in the Hungarian population: gene
RT   frequencies, effect on lipid levels, and sequence of two new
RT   variants.";
RL   Hum. Mutat. 5:58-65(1995).
RN   [22]
RP   VARIANTS SEATTLE-3 SER-161; SEATTLE-1 LEU-178 AND SEATTLE-2 GLN-264.
RX   PubMed=8956036;
RX   DOI=10.1002/(SICI)1098-1004(1996)8:4<319::AID-HUMU4>3.3.CO;2-T;
RA   Deeb S.S., Nevin D.N., Iwasaki L., Brunzell J.D.;
RT   "Two novel apolipoprotein A-IV variants in individuals with familial
RT   combined hyperlipidemia and diminished levels of lipoprotein lipase
RT   activity.";
RL   Hum. Mutat. 8:319-325(1996).
RN   [23]
RP   VARIANT HIS-380.
RX   PubMed=10391210; DOI=10.1038/10297;
RA   Halushka M.K., Fan J.-B., Bentley K., Hsie L., Shen N., Weder A.,
RA   Cooper R., Lipshutz R., Chakravarti A.;
RT   "Patterns of single-nucleotide polymorphisms in candidate genes for
RT   blood-pressure homeostasis.";
RL   Nat. Genet. 22:239-247(1999).
RN   [24]
RP   VARIANT [LARGE SCALE ANALYSIS] SER-147, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
CC   -!- FUNCTION: May have a role in chylomicrons and VLDL secretion and
CC       catabolism. Required for efficient activation of lipoprotein
CC       lipase by ApoC-II; potent activator of LCAT. Apoa-IV is a major
CC       component of HDL and chylomicrons.
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:22579246}.
CC   -!- INTERACTION:
CC       P20393:NR1D1; NbExp=3; IntAct=EBI-1222447, EBI-2811738;
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- TISSUE SPECIFICITY: Synthesized primarily in the intestine and
CC       secreted in plasma.
CC   -!- DOMAIN: Nine of the thirteen 22-amino acid tandem repeats (each
CC       22-mer is actually a tandem array of two, A and B, related 11-
CC       mers) occurring in this sequence are predicted to be highly alpha-
CC       helical, and many of these helices are amphipathic. They may
CC       therefore serve as lipid-binding domains with lecithin:cholesterol
CC       acyltransferase (LCAT) activating abilities.
CC   -!- PTM: Phosphorylation sites are present in the extracellular
CC       medium.
CC   -!- POLYMORPHISM: Eight alleles have been characterized (APOA-IV*0 to
CC       APOA-IV*7). APOA-IV*1 is the major allele (90%), APOA-IV*2 is also
CC       common (8%), the others are rare alleles. The sequence shown
CC       represents allele APOA-IV*1. {ECO:0000269|PubMed:1487136,
CC       ECO:0000269|PubMed:1677358, ECO:0000269|PubMed:1973689,
CC       ECO:0000269|PubMed:2351649, ECO:0000269|PubMed:3036793,
CC       ECO:0000269|Ref.10}.
CC   -!- SIMILARITY: Belongs to the apolipoprotein A1/A4/E family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=APOA4";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M13654; AAA51744.1; -; mRNA.
DR   EMBL; M14642; AAA51745.1; -; Genomic_DNA.
DR   EMBL; J02758; AAA96731.1; -; Genomic_DNA.
DR   EMBL; X13629; CAA31955.1; -; mRNA.
DR   EMBL; AY422950; AAQ91809.1; -; Genomic_DNA.
DR   EMBL; AY555191; AAS68228.1; -; Genomic_DNA.
DR   EMBL; AP006216; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC074764; AAH74764.1; -; mRNA.
DR   EMBL; BC113594; AAI13595.1; -; mRNA.
DR   EMBL; BC113596; AAI13597.1; -; mRNA.
DR   EMBL; M14566; AAA51748.1; -; mRNA.
DR   CCDS; CCDS31681.1; -.
DR   PIR; A94137; LPHUA4.
DR   UniGene; Hs.1247; -.
DR   PDB; 3S84; X-ray; 2.40 A; A/B=84-355.
DR   PDBsum; 3S84; -.
DR   ProteinModelPortal; P06727; -.
DR   SMR; P06727; 25-389.
DR   DIP; DIP-38333N; -.
DR   IntAct; P06727; 2.
DR   STRING; 9606.ENSP00000350425; -.
DR   PhosphoSite; P06727; -.
DR   DMDM; 93163358; -.
DR   DOSAC-COBS-2DPAGE; P06727; -.
DR   REPRODUCTION-2DPAGE; IPI00304273; -.
DR   SWISS-2DPAGE; P06727; -.
DR   MaxQB; P06727; -.
DR   PaxDb; P06727; -.
DR   PeptideAtlas; P06727; -.
DR   PRIDE; P06727; -.
DR   Ensembl; ENST00000357780; ENSP00000350425; ENSG00000110244.
DR   UCSC; uc001pps.1; human.
DR   GeneCards; APOA4; -.
DR   HGNC; HGNC:602; APOA4.
DR   HPA; CAB068250; -.
DR   HPA; CAB068251; -.
DR   HPA; CAB068252; -.
DR   HPA; HPA001352; -.
DR   HPA; HPA002549; -.
DR   MIM; 107690; gene.
DR   neXtProt; NX_P06727; -.
DR   eggNOG; ENOG410IKU1; Eukaryota.
DR   eggNOG; ENOG41119VI; LUCA.
DR   HOGENOM; HOG000037942; -.
DR   HOVERGEN; HBG105707; -.
DR   InParanoid; P06727; -.
DR   OrthoDB; EOG7K9K48; -.
DR   PhylomeDB; P06727; -.
DR   TreeFam; TF334458; -.
DR   Reactome; R-HSA-174800; Chylomicron-mediated lipid transport.
DR   Reactome; R-HSA-975634; Retinoid metabolism and transport.
DR   Reactome; R-HSA-977225; Amyloid fiber formation.
DR   PMAP-CutDB; A8MSL6; -.
DR   PRO; PR:P06727; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; P06727; -.
DR   CleanEx; HS_APOA4; -.
DR   Genevisible; P06727; HS.
DR   GO; GO:0072562; C:blood microparticle; IDA:UniProtKB.
DR   GO; GO:0042627; C:chylomicron; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005769; C:early endosome; TAS:Reactome.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; NAS:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0034364; C:high-density lipoprotein particle; IDA:BHF-UCL.
DR   GO; GO:0034361; C:very-low-density lipoprotein particle; IDA:BHF-UCL.
DR   GO; GO:0016209; F:antioxidant activity; IDA:HGNC.
DR   GO; GO:0015485; F:cholesterol binding; IBA:GO_Central.
DR   GO; GO:0017127; F:cholesterol transporter activity; IDA:BHF-UCL.
DR   GO; GO:0005507; F:copper ion binding; IDA:HGNC.
DR   GO; GO:0008289; F:lipid binding; IMP:BHF-UCL.
DR   GO; GO:0005319; F:lipid transporter activity; TAS:ProtInc.
DR   GO; GO:0031210; F:phosphatidylcholine binding; IDA:BHF-UCL.
DR   GO; GO:0060228; F:phosphatidylcholine-sterol O-acyltransferase activator activity; IDA:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:BHF-UCL.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0006695; P:cholesterol biosynthetic process; IBA:GO_Central.
DR   GO; GO:0033344; P:cholesterol efflux; IDA:BHF-UCL.
DR   GO; GO:0042632; P:cholesterol homeostasis; IDA:BHF-UCL.
DR   GO; GO:0008203; P:cholesterol metabolic process; IDA:BHF-UCL.
DR   GO; GO:0034378; P:chylomicron assembly; TAS:BHF-UCL.
DR   GO; GO:0034371; P:chylomicron remodeling; IC:BHF-UCL.
DR   GO; GO:0034380; P:high-density lipoprotein particle assembly; IBA:GO_Central.
DR   GO; GO:0034375; P:high-density lipoprotein particle remodeling; IC:BHF-UCL.
DR   GO; GO:0042744; P:hydrogen peroxide catabolic process; IDA:HGNC.
DR   GO; GO:0002227; P:innate immune response in mucosa; IDA:BHF-UCL.
DR   GO; GO:0007159; P:leukocyte cell-cell adhesion; IDA:BHF-UCL.
DR   GO; GO:0055088; P:lipid homeostasis; IDA:BHF-UCL.
DR   GO; GO:0006869; P:lipid transport; IDA:BHF-UCL.
DR   GO; GO:0042157; P:lipoprotein metabolic process; IBA:GO_Central.
DR   GO; GO:0044240; P:multicellular organismal lipid catabolic process; IDA:BHF-UCL.
DR   GO; GO:0034445; P:negative regulation of plasma lipoprotein particle oxidation; IDA:BHF-UCL.
DR   GO; GO:0031102; P:neuron projection regeneration; IBA:GO_Central.
DR   GO; GO:0046470; P:phosphatidylcholine metabolic process; IDA:BHF-UCL.
DR   GO; GO:0033700; P:phospholipid efflux; IDA:BHF-UCL.
DR   GO; GO:0007603; P:phototransduction, visible light; TAS:Reactome.
DR   GO; GO:0010873; P:positive regulation of cholesterol esterification; IDA:BHF-UCL.
DR   GO; GO:0045723; P:positive regulation of fatty acid biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0051006; P:positive regulation of lipoprotein lipase activity; IDA:BHF-UCL.
DR   GO; GO:0010898; P:positive regulation of triglyceride catabolic process; IDA:BHF-UCL.
DR   GO; GO:0065005; P:protein-lipid complex assembly; IMP:BHF-UCL.
DR   GO; GO:0032374; P:regulation of cholesterol transport; IDA:BHF-UCL.
DR   GO; GO:0030300; P:regulation of intestinal cholesterol absorption; IBA:GO_Central.
DR   GO; GO:0019430; P:removal of superoxide radicals; IDA:HGNC.
DR   GO; GO:0006982; P:response to lipid hydroperoxide; IDA:HGNC.
DR   GO; GO:0035634; P:response to stilbenoid; IEA:Ensembl.
DR   GO; GO:0001523; P:retinoid metabolic process; TAS:Reactome.
DR   GO; GO:0043691; P:reverse cholesterol transport; IDA:BHF-UCL.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0019433; P:triglyceride catabolic process; IBA:GO_Central.
DR   GO; GO:0070328; P:triglyceride homeostasis; IBA:GO_Central.
DR   GO; GO:0034372; P:very-low-density lipoprotein particle remodeling; IDA:BHF-UCL.
DR   InterPro; IPR000074; ApoA_E.
DR   Pfam; PF01442; Apolipoprotein; 3.
PE   1: Evidence at protein level;
KW   3D-structure; Chylomicron; Complete proteome; HDL; Lipid transport;
KW   Phosphoprotein; Polymorphism; Reference proteome; Repeat; Secreted;
KW   Signal; Transport.
FT   SIGNAL        1     20       {ECO:0000269|PubMed:6706947}.
FT   CHAIN        21    396       Apolipoprotein A-IV.
FT                                /FTId=PRO_0000001975.
FT   REPEAT       33     54       1.
FT   REPEAT       60     81       2.
FT   REPEAT       82    103       3.
FT   REPEAT      115    136       4.
FT   REPEAT      137    158       5.
FT   REPEAT      159    180       6.
FT   REPEAT      181    202       7.
FT   REPEAT      203    224       8.
FT   REPEAT      225    246       9.
FT   REPEAT      247    268       10.
FT   REPEAT      269    286       11.
FT   REPEAT      287    308       12.
FT   REPEAT      309    330       13.
FT   REGION       33    330       13 X 22 AA approximate tandem repeats.
FT   COMPBIAS    372    389       Gln/Glu-rich.
FT   VARIANT      13     13       V -> M (in allele APOA-IV*1D).
FT                                {ECO:0000269|PubMed:1349197,
FT                                ECO:0000269|PubMed:15108119}.
FT                                /FTId=VAR_000626.
FT   VARIANT      44     44       E -> K (in Budapest-2).
FT                                {ECO:0000269|PubMed:7728150}.
FT                                /FTId=VAR_000627.
FT   VARIANT      74     74       G -> S (in dbSNP:rs5102).
FT                                /FTId=VAR_014610.
FT   VARIANT      77     77       Q -> H. {ECO:0000269|PubMed:15108119}.
FT                                /FTId=VAR_025444.
FT   VARIANT     147    147       N -> S (in allele APOA-IV*1B;
FT                                dbSNP:rs5104).
FT                                {ECO:0000244|PubMed:24275569,
FT                                ECO:0000269|PubMed:15108119,
FT                                ECO:0000269|PubMed:16554811,
FT                                ECO:0000269|PubMed:1737067}.
FT                                /FTId=VAR_000628.
FT   VARIANT     161    161       A -> S (in Seattle-3).
FT                                {ECO:0000269|PubMed:15108119,
FT                                ECO:0000269|PubMed:8956036}.
FT                                /FTId=VAR_000629.
FT   VARIANT     178    178       S -> L (in Seattle-1; may contribute to
FT                                the development of familial combined
FT                                hyperlipidemia).
FT                                {ECO:0000269|PubMed:8956036}.
FT                                /FTId=VAR_000630.
FT   VARIANT     185    185       E -> K (in allele APOA-IV*3).
FT                                {ECO:0000269|PubMed:1677358}.
FT                                /FTId=VAR_000631.
FT   VARIANT     187    187       K -> E (in allele APOA-IV*0A; associated
FT                                with H-380).
FT                                {ECO:0000269|PubMed:1677358}.
FT                                /FTId=VAR_000632.
FT   VARIANT     250    250       E -> K (in allele APOA-IV*3A).
FT                                {ECO:0000269|PubMed:1973689}.
FT                                /FTId=VAR_000633.
FT   VARIANT     264    264       R -> Q (in Seattle-2; may contribute to
FT                                the development of familial combined
FT                                hyperlipidemia; dbSNP:rs2238008).
FT                                {ECO:0000269|PubMed:8956036}.
FT                                /FTId=VAR_000634.
FT   VARIANT     279    279       R -> K (in dbSNP:rs1042372).
FT                                {ECO:0000269|PubMed:3095836,
FT                                ECO:0000269|PubMed:3755616}.
FT                                /FTId=VAR_025443.
FT   VARIANT     305    305       R -> C (in Budapest-1).
FT                                {ECO:0000269|PubMed:7728150}.
FT                                /FTId=VAR_000635.
FT   VARIANT     307    307       V -> L (in dbSNP:rs5108).
FT                                /FTId=VAR_014611.
FT   VARIANT     367    367       T -> S (in allele APOA-IV*1A and allele
FT                                Budapest-1; dbSNP:rs675).
FT                                {ECO:0000269|PubMed:15108119,
FT                                ECO:0000269|PubMed:1677358,
FT                                ECO:0000269|PubMed:7728150}.
FT                                /FTId=VAR_000636.
FT   VARIANT     380    380       Q -> H (in allele APOA-IV*2 and allele
FT                                APOA-IV*0A; associated with E-187 in
FT                                allele APOA-IV*0A; dbSNP:rs5110).
FT                                {ECO:0000269|PubMed:10391210,
FT                                ECO:0000269|PubMed:15108119,
FT                                ECO:0000269|PubMed:1677358,
FT                                ECO:0000269|PubMed:2065039,
FT                                ECO:0000269|PubMed:2351649,
FT                                ECO:0000269|PubMed:3036793,
FT                                ECO:0000269|PubMed:3080432}.
FT                                /FTId=VAR_000637.
FT   VARIANT     381    381       Q -> QEQQQ (in allele APOA-IV*0 and
FT                                allele APOA-IV*5; allele APOA-IV*5 is
FT                                further defined by a silent nucleotide
FT                                substitution).
FT                                {ECO:0000269|PubMed:1487136}.
FT                                /FTId=VAR_000638.
FT   CONFLICT    158    160       TPY -> DPL (in Ref. 1; AAA51744 and 2;
FT                                AAA51745). {ECO:0000305}.
FT   CONFLICT    327    327       Q -> T (in Ref. 3; AAA96731 and 8;
FT                                AAA51748). {ECO:0000305}.
FT   HELIX        97    113       {ECO:0000244|PDB:3S84}.
FT   HELIX       114    116       {ECO:0000244|PDB:3S84}.
FT   HELIX       117    223       {ECO:0000244|PDB:3S84}.
FT   HELIX       224    226       {ECO:0000244|PDB:3S84}.
FT   HELIX       231    276       {ECO:0000244|PDB:3S84}.
FT   STRAND      278    280       {ECO:0000244|PDB:3S84}.
FT   HELIX       282    307       {ECO:0000244|PDB:3S84}.
FT   HELIX       310    329       {ECO:0000244|PDB:3S84}.
SQ   SEQUENCE   396 AA;  45399 MW;  193753196CA2FA4A CRC64;
     MFLKAVVLTL ALVAVAGARA EVSADQVATV MWDYFSQLSN NAKEAVEHLQ KSELTQQLNA
     LFQDKLGEVN TYAGDLQKKL VPFATELHER LAKDSEKLKE EIGKELEELR ARLLPHANEV
     SQKIGDNLRE LQQRLEPYAD QLRTQVNTQA EQLRRQLTPY AQRMERVLRE NADSLQASLR
     PHADELKAKI DQNVEELKGR LTPYADEFKV KIDQTVEELR RSLAPYAQDT QEKLNHQLEG
     LTFQMKKNAE ELKARISASA EELRQRLAPL AEDVRGNLRG NTEGLQKSLA ELGGHLDQQV
     EEFRRRVEPY GENFNKALVQ QMEQLRQKLG PHAGDVEGHL SFLEKDLRDK VNSFFSTFKE
     KESQDKTLSL PELEQQQEQQ QEQQQEQVQM LAPLES
//
ID   DQB1_HUMAN              Reviewed;         261 AA.
AC   P01920; A1KR27; A2RPH3; A4Q9R4; A4USG2; A4USG5; A6N8I7; A9YQA0;
AC   B0S7Y7; B1A0K6; B1GXI3; B3VLT3; B5BLN7; B7VU69; C0MQ34; C0MQ35;
AC   C8ZL52; C8ZLJ8; C8ZLJ9; C9DRQ3; O19708; O19713; O19724; O62861;
AC   O78046; O78221; O78223; O98034; O98201; P01917; P01918; P01919;
AC   P03992; P05537; P79482; P79526; P79544; P79551; Q08GC8; Q09035;
AC   Q0E4V9; Q1M312; Q29731; Q29877; Q29884; Q29915; Q29966; Q2P9N3;
AC   Q2QK85; Q30061; Q30075; Q30076; Q30080; Q30081; Q30082; Q30083;
AC   Q30084; Q30089; Q30095; Q31633; Q38I47; Q45UE3; Q4QZB5; Q53I44;
AC   Q564J6; Q5G841; Q5ISH1; Q5ISH3; Q5W1E1; Q5Y7G8; Q643R4; Q6B9X1;
AC   Q70VH8; Q7YP69; Q8HWH0; Q8MH58; Q8SNB4; Q8SND1; Q8SP70; Q8WMA3;
AC   Q9BD17; Q9MYH2; Q9TPA9; Q9XRY6; Q9XRY7; Q9XRZ2;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   02-MAR-2010, sequence version 2.
DT   20-JAN-2016, entry version 151.
DE   RecName: Full=HLA class II histocompatibility antigen, DQ beta 1 chain;
DE   AltName: Full=MHC class II antigen DQB1;
DE   Flags: Precursor;
GN   Name=HLA-DQB1; Synonyms=HLA-DQB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DQB1*02:01), AND NUCLEOTIDE
RP   SEQUENCE [MRNA] OF 33-261 (CLONE PII-BETA-2) (ALLELE DQB1*05:01).
RX   PubMed=6415003; DOI=10.1016/0198-8859(83)90087-3;
RA   Larhammar D., Andersson G., Andersson M., Bill P., Boehme J.,
RA   Claesson L., Denaro M., Emmoth E., Gustafsson K., Hammarling U.,
RA   Heldin E., Hyldig-Nielsen J.-J., Lind P., Schenning L., Servenius B.,
RA   Widmark E., Rask L., Peterson P.A.;
RT   "Molecular analysis of human class II transplantation antigens and
RT   their genes.";
RL   Hum. Immunol. 8:95-103(1983).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DQB1*02:01).
RX   PubMed=6954511; DOI=10.1073/pnas.79.12.3687;
RA   Larhammar D., Schenning L., Gustafsson K., Wiman K., Claesson L.,
RA   Rask L., Peterson P.A.;
RT   "Complete amino acid sequence of an HLA-DR antigen-like beta chain as
RT   predicted from the nucleotide sequence: similarities with
RT   immunoglobulins and HLA-A, -B, and -C antigens.";
RL   Proc. Natl. Acad. Sci. U.S.A. 79:3687-3691(1982).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE DQB1*03:02).
RX   PubMed=6316358; DOI=10.1073/pnas.80.23.7313;
RA   Larhammar D., Hyldig-Nielsen J.-J., Servenius B., Andersson G.,
RA   Rask L., Peterson P.A.;
RT   "Exon-intron organization and complete nucleotide sequence of a human
RT   major histocompatibility antigen DC beta gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 80:7313-7317(1983).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE DQB1*02:01).
RX   PubMed=6206493; DOI=10.1073/pnas.81.16.5199;
RA   Boss J.M., Strominger J.L.;
RT   "Cloning and sequence analysis of the human major histocompatibility
RT   complex gene DC-3 beta.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:5199-5203(1984).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DQB1*05:01).
RX   PubMed=2998758;
RA   Tonnelle C., Demars R., Long E.O.;
RT   "DO beta: a new beta chain gene in HLA-D with a distinct regulation of
RT   expression.";
RL   EMBO J. 4:2839-2847(1985).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DQB1*05:01).
RX   PubMed=2888727; DOI=10.1007/BF00346523;
RA   Turco E., Care A., Compagnone-Post P., Robinson C., Cascino I.,
RA   Trucco M.;
RT   "Allelic forms of the alpha- and beta-chain genes encoding DQw1-
RT   positive heterodimers.";
RL   Immunogenetics 26:282-290(1987).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE DQB1*03:02).
RX   PubMed=3036828;
RA   Jonsson A.-K., Hyldig-Nielsen J.-J., Servenius B., Larhammar D.,
RA   Andersson G., Joergensen F., Peterson P.A., Rask L.;
RT   "Class II genes of the human major histocompatibility complex.
RT   Comparisons of the DQ and DX alpha and beta genes.";
RL   J. Biol. Chem. 262:8767-8777(1987).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS VAL-15; SER-28; GLY-45;
RP   LEU-58; GLY-77; GLY-102 AND ARG-199.
RX   PubMed=3584986;
RA   Schiffenbauer J., Didier D.K., Klearman M., Rice K., Shuman S.,
RA   Tieber V.L., Kittlesen D.J., Schwartz B.D.;
RT   "Complete sequence of the HLA DQ alpha and DQ beta cDNA from a
RT   DR5/DQw3 cell line.";
RL   J. Immunol. 139:228-233(1987).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DQB1*06:02).
RX   PubMed=3259543; DOI=10.1007/BF00364432;
RA   Lock C.B., So A.K., Welsh K.I., Parkes J.D., Trowsdale J.;
RT   "MHC class II sequences of an HLA-DR2 narcoleptic.";
RL   Immunogenetics 27:449-455(1988).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DQB1*03:03).
RX   PubMed=2050393; DOI=10.1007/BF00216702;
RA   Giorda R., Turco E., Trucco M.;
RT   "Full length beta chain cDNAs of DQw9 and DQw8 molecules encode
RT   proteins that differ only at amino acid 57.";
RL   Immunogenetics 33:404-408(1991).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DQB1*06:12).
RX   PubMed=8988543; DOI=10.1111/j.1399-0039.1996.tb02674.x;
RA   Vilches C., Garcia-Pacheco J.M., de Pablo R., Puente S., Kreisler M.;
RT   "Complete coding region of the new HLA-DQB1*0612 allele, obtained by
RT   RT-PCR.";
RL   Tissue Antigens 48:589-592(1996).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE DQB1*02:01).
RX   PubMed=9271631; DOI=10.1007/s002510050295;
RA   Ellis M.C., Hetisimer A.H., Ruddy D.A., Hansen S.L., Kronmal G.S.,
RA   McClelland E., Quintana L., Drayna D.T., Aldrich M.S., Mignot E.;
RT   "HLA class II haplotype and sequence analysis support a role for DQ in
RT   narcolepsy.";
RL   Immunogenetics 46:410-417(1997).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELES DQB1*03:01 AND DQB1*03:03).
RX   PubMed=16140993; DOI=10.1101/gr.3554305;
RA   Raymond C.K., Kas A., Paddock M., Qiu R., Zhou Y., Subramanian S.,
RA   Chang J., Palmieri A., Haugen E., Kaul R., Olson M.V.;
RT   "Ancient haplotypes of the HLA Class II region.";
RL   Genome Res. 15:1250-1257(2005).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELES DQB1*03:01; DQB1*04:01 AND
RP   DQB1*05:02).
RA   Kim E., Lee E., Kwack K.;
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] (ALLELES DQB1*02:02;
RP   DQB1*03:01 AND DQB1*03:03).
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ALLELE DQB1*03:02).
RC   TISSUE=B-cell;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [17]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-126 (ALLELE DQB1*06:02).
RX   PubMed=2925231; DOI=10.1007/BF00373644;
RA   Hiraiwa A., Seyfried C.E., Nepom G.T., Milner E.C.;
RT   "Sequence analysis of HLA class II domains: characterization of the
RT   DQw3 family of DQB genes.";
RL   Immunogenetics 29:186-190(1989).
RN   [18]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 2-261 (ALLELE DQB1*03:01), AND
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 33-261 (ALLELE DQB1*03:09).
RA   White J.M., Baxter-Lowe L.A.;
RT   "Nucleotide Deletions in a DQB1*0301 variant.";
RL   Submitted (DEC-1996) to the EMBL/GenBank/DDBJ databases.
RN   [19]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 10-126 (ALLELE DQB1*06:02).
RX   PubMed=2494138; DOI=10.1016/0198-8859(89)90058-X;
RA   Uryu N., Maeda M., Nagata Y., Matsuki K., Juji T., Honda Y., Kawai J.,
RA   Ando A., Tsuji K., Inoko H.;
RT   "No difference in the nucleotide sequence of the DQ beta beta 1 domain
RT   between narcoleptic and healthy individuals with DR2,Dw2.";
RL   Hum. Immunol. 24:175-181(1989).
RN   [20]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 33-261 (ALLELE DQB1*04:02).
RX   PubMed=2777341; DOI=10.1007/BF02421214;
RA   Jonsson A.-K., Andersson L., Rask L.;
RT   "Complete sequences of DQA1 and DQB1 cDNA clones corresponding to the
RT   DQw4 specificity.";
RL   Immunogenetics 30:232-234(1989).
RN   [21]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 33-261 (ALLELES DQB1*03:03; DQB1*05:01;
RP   DQB1*05:03; DQB1*06:01; DQB1*06:02; DQB1*06:03 AND DQB1*06:04), AND
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 33-126 (ALLELE DQB1*03:01).
RX   PubMed=8929711; DOI=10.1111/j.1399-0039.1996.tb02512.x;
RA   Yasunaga S., Kimura A., Hamaguchi K., Ronningen K.S., Sasazuki T.;
RT   "Different contribution of HLA-DR and -DQ genes in susceptibility and
RT   resistance to insulin-dependent diabetes mellitus (IDDM).";
RL   Tissue Antigens 47:37-48(1996).
RN   [22]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 33-261 (ALLELE DQB1*03:10).
RX   PubMed=11098940; DOI=10.1034/j.1399-0039.2000.560412.x;
RA   Balas A., Santos S., Aviles M.J., Garcia-Sanchez F., Lillo R.,
RA   Vicario J.L.;
RT   "Identification by sequencing based typing and complete coding region
RT   analysis of three new HLA class II alleles: DRB3*0210, DRB3*0211 and
RT   DQB1*0310.";
RL   Tissue Antigens 56:380-384(2000).
RN   [23]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 33-261 (ALLELE DQB1*06:09).
RA   Yasunaga S.;
RL   Submitted (JAN-1996) to the EMBL/GenBank/DDBJ databases.
RN   [24]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 33-231 (ALLELES DQB1*03:04 AND
RP   DQB1*03:05).
RX   PubMed=7928445; DOI=10.1016/0198-8859(94)90060-4;
RA   Cucca F., Frau F., Lampis R., Floris M., Argiolas L., Macis D.,
RA   Cao A., De Virgiliis S., Congia M.;
RT   "HLA-DQB1*0305 and -DQB1*0304 alleles among Sardinians. Evolutionary
RT   and practical implications for oligotyping.";
RL   Hum. Immunol. 40:143-149(1994).
RN   [25]
RP   PROTEIN SEQUENCE OF 33-181 AND 200-230 (ALLELE DQB1*06:02).
RX   PubMed=6576979;
RA   Goetz H., Kratzin H., Thinnes F.P., Yang C.-Y., Kruse T., Pauly E.,
RA   Koelbel S., Egert G., Wernet P., Hilschmann N.;
RT   "Primary structure of human class II histocompatibility antigens 3rd
RT   communication. Amino acid sequence comparison between DR and DC
RT   subclass antigens derived from a lymphoblastoid B cell line homozygous
RT   at the HLA loci (HLA-A3,3; B7,7; Dw2,2; DR2,2: MT1,1; Dc1,1: MB1,1).";
RL   Hoppe-Seyler's Z. Physiol. Chem. 364:749-755(1983).
RN   [26]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 33-140 (ALLELE DQB1*06:05).
RX   PubMed=2212675;
RA   Lee K.W., Johnson A.H., Hurley C.K.;
RT   "Two divergent routes of evolution gave rise to the DRw13
RT   haplotypes.";
RL   J. Immunol. 145:3119-3125(1990).
RN   [27]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 33-126 (ALLELE DQB1*02:01).
RX   PubMed=3020127;
RA   Karr R.W., Gregersen P.K., Obata F., Goldberg D., Maccari J.,
RA   Alber C., Silver J.;
RT   "Analysis of DR-beta and DQ-beta chain cDNA clones from a DR7
RT   haplotype.";
RL   J. Immunol. 137:2886-2890(1986).
RN   [28]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 33-126 (ALLELE DQB1*06:22).
RX   PubMed=17868257; DOI=10.1111/j.1399-0039.2007.00927.x;
RA   Chang Y., Fan T.X., Santana Z., Day N.K.;
RT   "Identification of a novel allele HLA-DQB1*0622.";
RL   Tissue Antigens 70:442-444(2007).
RN   [29]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 33-122 (ALLELE DQB1*06:02).
RX   PubMed=2886427; DOI=10.1007/BF00345460;
RA   Lee B.S., Bell J.I., Rust N.A., McDevitt H.O.;
RT   "Structural and functional variability among DQ beta alleles of DR2
RT   subtypes.";
RL   Immunogenetics 26:85-91(1987).
RN   [30]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 33-107 (ALLELE DQB1*03:07).
RX   PubMed=9174147; DOI=10.1111/j.1399-0039.1997.tb02789.x;
RA   Thye T., Muntau B., Stelma F.F., Horstmann R.D.;
RT   "A novel allele, DQB1*0307, in a West African family.";
RL   Tissue Antigens 49:517-518(1997).
RN   [31]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 37-126 (ALLELE DQB1*06:18).
RX   PubMed=11782280; DOI=10.1034/j.1399-0039.2001.580409.x;
RA   Casamitjana N., Gil J., Campos E., Santos M., Nogues N., Ribera A.,
RA   Palou E.;
RT   "Identification of a novel HLA-DQB1*06 allele, DQB1*0618.";
RL   Tissue Antigens 58:269-271(2001).
RN   [32]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 37-126 (ALLELE DQB1*06:19).
RA   Bowman S., Diviney M., Dunckley H., Holdsworth R., Varney M.;
RT   "A new DQB1*0602 variant found in Australian Caucasian.";
RL   Submitted (MAR-2001) to the EMBL/GenBank/DDBJ databases.
RN   [33]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 37-121 (ALLELE DQB1*06:13).
RX   PubMed=9458130; DOI=10.1111/j.1399-0039.1997.tb02935.x;
RA   Hsu S.H., Robbins F.M., Modelo R.B., Brunner J., Flomenberg N.;
RT   "Identification of a new DQB1*0613 allele in a family.";
RL   Tissue Antigens 50:685-687(1997).
RN   [34]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-257 (ALLELE DQB1*06:36).
RC   TISSUE=Peripheral blood;
RA   Skrablin P.S., Richter R., Seidl C., Seifried E.;
RT   "New HLA-DQB1*06 allele found in a voluntary blood stem cell donor.";
RL   Submitted (MAR-2009) to the EMBL/GenBank/DDBJ databases.
RN   [35]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-220 (ALLELE DQB1*03:19).
RX   PubMed=17559588; DOI=10.1111/j.1399-0039.2007.00848.x;
RA   Witter K., Mautner J., Albert T., Zahn R., Kauke T.;
RT   "HLA-DQB1*0319, a novel HLA-DQB1 allele, shows strong haplotype
RT   association to HLA-DRB1*1102.";
RL   Tissue Antigens 70:73-75(2007).
RN   [36]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-220 (ALLELE DQB1*06:34).
RX   PubMed=18331527; DOI=10.1111/j.1399-0039.2008.01021.x;
RA   Witter K., Albert T., Zahn R., Kauke T.;
RT   "HLA-DQB1*0634, a novel DQB1 allele found by high-resolution HLA
RT   typing of a sibling pair for potential bone marrow transplantation.";
RL   Tissue Antigens 71:486-488(2008).
RN   [37]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-220 (ALLELE DQB1*03:21), AND
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-126 (ALLELES DQB1*02:05 AND
RP   DQB1*03:20).
RX   PubMed=18588576; DOI=10.1111/j.1399-0039.2008.01070.x;
RA   Lazaro A.M., Xiao Y., Masaberg C., Lebeck L., Ng J., Hurley C.K.,
RA   Posch P.E.;
RT   "Novel alleles at the HLA-DRB1 and -DQB1 loci.";
RL   Tissue Antigens 72:72-74(2008).
RN   [38]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-220 (ALLELE DQB1*03:22).
RC   TISSUE=Peripheral blood;
RX   PubMed=19254265; DOI=10.1111/j.1399-0039.2008.01201.x;
RA   Witter K., Lochmann E., Vecchiato C., Albert T., Zahn R., Kauke T.;
RT   "Sequence-based HLA high-resolution retyping of a bone marrow
RT   donor/recipient pair reveals the novel HLA allele DQB1*0322.";
RL   Tissue Antigens 73:283-285(2009).
RN   [39]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-220 (ALLELE DQB1*03:23).
RC   TISSUE=Peripheral blood;
RX   PubMed=19493242; DOI=10.1111/j.1399-0039.2009.01231.x;
RA   Wienzek S., Verboom M., Blasczyk R., Bein G., Horn P.A.;
RT   "DQB1*0323 is the result of a gene conversion event between a DQB1*06
RT   and a DQB1*030303 allele.";
RL   Tissue Antigens 73:624-625(2009).
RN   [40]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-220 (ALLELE DQB1*02:04).
RA   Gragg H., Cordovado S.K., Hendrix M.M., Mueller P.W.;
RT   "Identification of a novel HLA-DQB1*02 allele.";
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [41]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-220 (ALLELE DQB1*03:25).
RA   Thompson E.M., Mehdizadeh Kashi Z., Martin R.K.;
RT   "Homo sapiens novel MHC class II HLA-DQB1 gene HLA-DQB1*03 novel
RT   allele, exons 2 and 3.";
RL   Submitted (MAY-2008) to the EMBL/GenBank/DDBJ databases.
RN   [42]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-220 (ALLELE DQB1*03:24).
RA   Michaud C., Giannoli C., Favre Victoire I., Dubois V.;
RT   "A new HLA-DQB allele, identified by routine sequencing.";
RL   Submitted (DEC-2008) to the EMBL/GenBank/DDBJ databases.
RN   [43]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-220 (ALLELES DQB1*06:38 AND
RP   DQB1*06:39).
RC   TISSUE=Blood;
RA   Anholts J.D.H.;
RT   "New alleles found during routine SBT HLA typing.";
RL   Submitted (SEP-2009) to the EMBL/GenBank/DDBJ databases.
RN   [44]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-126 (ALLELE DQB1*06:10).
RX   PubMed=8896183; DOI=10.1111/j.1399-0039.1996.tb02633.x;
RA   Mersch G., Semana G., De Canck I., Jannes G., Rombout A., Sterker G.,
RA   Rossau R.;
RT   "Characterization of a new DQB1 allele (DQB1*0610) which differs from
RT   DQB1*0602 at the highly polymorphic 57-codon.";
RL   Tissue Antigens 48:217-220(1996).
RN   [45]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-126 (ALLELE DQB1*03:06).
RC   TISSUE=Blood;
RX   PubMed=8988541; DOI=10.1111/j.1399-0039.1996.tb02672.x;
RA   Saito S., Ota S., Hashizume K., Yamada E., Kaneshige T., Hashimoto M.,
RA   Oguchi H., Ishii E., Fukushima H.;
RT   "A new HLA-DQB1*0306 allele sharing motifs from DQB1*03032 and DQB1*04
RT   sequences.";
RL   Tissue Antigens 48:580-585(1996).
RN   [46]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-126 (ALLELE DQB1*03:11), AND
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 41-120 (ALLELE DQB1*06:20).
RX   PubMed=15361133; DOI=10.1111/j.1399-0039.2004.00307.x;
RA   Hogbin J.P., Greville W., Chapman G., Kennedy A., Velickovic Z.M.,
RA   Dunckley H.;
RT   "Identification of two novel HLA class II alleles, DQB1*0311 and
RT   DQB1*0620.";
RL   Tissue Antigens 64:515-517(2004).
RN   [47]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-126 (ALLELE DQB1*03:16).
RA   Chen D.-F., DeOliveira A., Peplinski S., Herczyk W., Reinsmoen N.L.;
RT   "A novel DQB1*03 allele revealed by rSSOP and identified by SBT.";
RL   Hum. Immunol. 66:30-30(2005).
RN   [48]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-126 (ALLELE DQB1*03:14).
RX   PubMed=15853909; DOI=10.1111/j.1399-0039.2005.00397.x;
RA   Gu H., Kimm K., Lee J.K., Oh B.;
RT   "Identification of a novel HLA-DQB1 allele, DQB1*0314, by sequence-
RT   based typing in the Korean population.";
RL   Tissue Antigens 65:503-504(2005).
RN   [49]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-126 (ALLELE DQB1*06:28).
RX   PubMed=17212715; DOI=10.1111/j.1399-0039.2006.00733.x;
RA   Witter K., Albert T., Zahn R., Kauke T.;
RT   "A novel HLA-DQB1*06 allele, DQB1*0628, found through routine
RT   sequence-based HLA typing and confirmation of DQB1*060302.";
RL   Tissue Antigens 69:102-103(2007).
RN   [50]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-126 (ALLELE DQB1*06:32).
RC   TISSUE=Blood;
RX   PubMed=17999653; DOI=10.1111/j.1399-0039.2007.00967.x;
RA   Emmerich F., Schonemann C., Diederich G., Horn P.A., Salama A.;
RT   "Identification of a novel HLA-DQB1 allele, HLA-DQB1*0632.";
RL   Tissue Antigens 71:94-95(2008).
RN   [51]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-126 (ALLELE DQB1*05:05).
RX   PubMed=19392794; DOI=10.1111/j.1399-0039.2009.01248.x;
RA   Giannoli C., Paturel L., Favre-Victoire I., Bera O., Dubois V.;
RT   "Two new HLA-DQB alleles routinely identified by sequence-based
RT   typing: DQB1*030103 and DQB1*0505.";
RL   Tissue Antigens 73:622-623(2009).
RN   [52]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-126 (ALLELE DQB1*02:03).
RA   Olerup O.H.;
RT   "A novel DQB1*02 allele.";
RL   Submitted (OCT-1995) to the EMBL/GenBank/DDBJ databases.
RN   [53]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-126 (ALLELE DQB1*03:05).
RA   Rugg J., Blanton M., Whitacre L., Balakrishnan K., Lebeer K.,
RA   Van Reybroeck G., Mersch G.;
RT   "Detection of a new DQB1 allele.";
RL   Submitted (NOV-1997) to the EMBL/GenBank/DDBJ databases.
RN   [54]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-126 (ALLELE DQB1*06:15).
RA   Shah A., Ross J., Chenery P., Holman R., Madrigal A., Little A.M.;
RT   "Two novel DQB1*06 alleles, identified by reverse line blot assay.";
RL   Submitted (OCT-1998) to the EMBL/GenBank/DDBJ databases.
RN   [55]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-126 (ALLELE DQB1*03:05).
RC   TISSUE=Peripheral blood;
RA   Moine A.;
RT   "A new variant form of the HLA DQB1*0305 allele.";
RL   Submitted (JAN-2001) to the EMBL/GenBank/DDBJ databases.
RN   [56]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-126 (ALLELE DQB1*03:12).
RA   Schwarz K., Zenz C.;
RT   "Homo sapiens HLA-DQB1*0312 allele, exon 2.";
RL   Submitted (JAN-2002) to the EMBL/GenBank/DDBJ databases.
RN   [57]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-126 (ALLELE DQB1*03:13).
RA   Wu J., Bassinger S., Williams T.M.;
RT   "Novel human HLA-DQB1 allele identified in potential bone marrow
RT   donors.";
RL   Submitted (FEB-2002) to the EMBL/GenBank/DDBJ databases.
RN   [58]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-126 (ALLELE DQB1*06:21).
RA   De Canck I.;
RT   "Identification of a new HLA-DQB1*06 allele by INNO-LiPA.";
RL   Submitted (DEC-2002) to the EMBL/GenBank/DDBJ databases.
RN   [59]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-126 (ALLELE DQB1*06:17).
RA   Bassinger S., Wu J., Zhang Q., Brinkema C., Smith A.G., Williams T.M.;
RT   "Novel DQB1*06 alleles.";
RL   Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.
RN   [60]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-126 (ALLELE DQB1*06:23).
RA   Hirv K., Krauss A., Mytilineos J.;
RT   "Characterization of a new HLA-DQB1 allele by direct sequencing.";
RL   Submitted (AUG-2004) to the EMBL/GenBank/DDBJ databases.
RN   [61]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-126 (ALLELE DQB1*03:15).
RC   TISSUE=Peripheral blood;
RA   Velickovic Z.M.;
RT   "Novel HLA-DQB1*03 allele.";
RL   Submitted (NOV-2004) to the EMBL/GenBank/DDBJ databases.
RN   [62]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-126 (ALLELE DQB1*06:24).
RA   Schranz P., Seelig R., Seelig H.P.;
RT   "A new HLA-DQB1 allele.";
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [63]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-126 (ALLELE DQB1*06:25).
RA   Watabe K., Hashimoto M.;
RT   "Homo sapiens HLA-DQ gene for MHC class2 antigen, partial cds, allele:
RT   HLA-DQB1*060401V.";
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [64]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-126 (ALLELE DQB1*03:17).
RA   Chu C.-C.;
RT   "A novel DQB1 allele found in Taiwan.";
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [65]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-126 (ALLELE DQB1*03:18).
RA   Hendrix M.M., Cordovado S.K., Mueller P.W.;
RT   "High resolution genotyping of HLA-DQB1 exon 2 and 3.";
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [66]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-126 (ALLELE DQB1*06:29).
RA   Horn P.A., Blasczyk R.;
RT   "A novel HLA-DRQ1*06 allele.";
RL   Submitted (SEP-2006) to the EMBL/GenBank/DDBJ databases.
RN   [67]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-126 (ALLELE DQB1*06:31).
RA   Nieberle I., Hirschmann D., Woelpl A.;
RT   "Identification of several new class I and II alleles in routine HLA-
RT   testing.";
RL   Submitted (JAN-2007) to the EMBL/GenBank/DDBJ databases.
RN   [68]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-126 (ALLELE DQB1*06:33).
RA   Yu M., Hall J.E., Hartman K.J., Caparelli E., Czech J., Smyth E.,
RA   Jennings L.;
RT   "A novel HLA-DQB1*06 allele identified by PCR-SBT in a caucasian NMDP
RT   donor.";
RL   Submitted (MAY-2007) to the EMBL/GenBank/DDBJ databases.
RN   [69]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-126 (ALLELE DQB1*04:03).
RA   Vigh A., Hirv K., Mytilineos J.;
RT   "Characterization of a new HLA-Cw*07 allele.";
RL   Submitted (JAN-2008) to the EMBL/GenBank/DDBJ databases.
RN   [70]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-126 (ALLELE DQB1*06:37).
RA   Fuerst D., Mytilineos J.;
RT   "A new variant of HLA-DQB1*06.";
RL   Submitted (JUL-2009) to the EMBL/GenBank/DDBJ databases.
RN   [71]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-126 (ALLELE DQB1*03:26).
RA   Yang K., Chen M.;
RT   "Novel DQB1*03 found in CAP test sample.";
RL   Submitted (SEP-2009) to the EMBL/GenBank/DDBJ databases.
RN   [72]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-122 (ALLELE DQB1*06:16).
RX   PubMed=10323344; DOI=10.1034/j.1399-0039.1999.530410.x;
RA   Luo M., Blanchard J., Maclean I., Brunham R.;
RT   "Identification of a novel DQB1 allele DBQ1*0616.";
RL   Tissue Antigens 53:381-382(1999).
RN   [73]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-115 (ALLELE DQB1*06:30).
RA   Rizzo M., Hurley C.K.;
RT   "Novel HLA-DQB1 allele.";
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [74]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 41-126 (ALLELE DQB1*06:14).
RC   TISSUE=Blood;
RX   PubMed=9802612; DOI=10.1111/j.1399-0039.1998.tb03047.x;
RA   Hashemi-tavoularis S., Ouellet S., Sengar D.P.S., Buyse I.M.;
RT   "A novel DRB3 allele (DRB3*0208), a new allelic variant of DRB1*1502
RT   (DRB1*15023) and two new DQB1 (DQB1*03012 and DQB1*0614) alleles.";
RL   Tissue Antigens 52:294-299(1998).
RN   [75]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 41-125 (ALLELE DQB1*06:11).
RX   PubMed=8896171; DOI=10.1111/j.1399-0039.1996.tb02621.x;
RA   Williams T.M., Bassinger S., Moehlenkamp C., Wu J., Montoya G.D.,
RA   Griffith B.B., McAuley J.D., Goldman S., Maurer D.H., Troup G.M.;
RT   "Strategy for distinguishing a new DQB1 allele (DQB1*0611) from the
RT   closely related DQB1*0602 allele via sequence specific PCR or direct
RT   DNA sequencing.";
RL   Tissue Antigens 48:143-147(1996).
RN   [76]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 41-125 (ALLELE DQB1*06:27).
RX   PubMed=16441489; DOI=10.1111/j.1399-0039.2006.00515.x;
RA   Brixner V., Mosebach M., Schmidt M., Hermann S., Seifried E.,
RA   Martin H., Seidl C.;
RT   "HLA-DRB1*0826 and HLA-DQB1*0627, two novel class II alleles
RT   identified in blood stem cell donors of Caucasian origin.";
RL   Tissue Antigens 67:160-162(2006).
RN   [77]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 41-122 (ALLELES DQB1*06:07 AND
RP   DQB1*06:08).
RA   Dinauer D.M., Hessner M.J.;
RL   Submitted (DEC-1998) to the EMBL/GenBank/DDBJ databases.
RN   [78]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 41-114 (ALLELE DQB1*05:04).
RX   PubMed=1440562; DOI=10.1111/j.1399-0039.1992.tb01958.x;
RA   Fenske T.S., Baxter-Lowe L.A.;
RT   "Two novel HLA-DQB1*06 alleles reveal additional heterogeneity of HLA-
RT   DQw1.";
RL   Tissue Antigens 40:49-52(1992).
RN   [79]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 53-109 (ALLELE DQB1*02:01).
RX   PubMed=2308943; DOI=10.1073/pnas.87.5.1835;
RA   Gyllensten U.B., Lashkari D., Erlich H.A.;
RT   "Allelic diversification at the class II DQB locus of the mammalian
RT   major histocompatibility complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:1835-1839(1990).
RN   [80]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 53-109 (ALLELES DQB1*02:01 AND
RP   DQB1*06:02).
RX   PubMed=2010218; DOI=10.1007/BF01719235;
RA   Bugawan T.L., Erlich H.A.;
RT   "Rapid typing of HLA-DQB1 DNA polymorphism using nonradioactive
RT   oligonucleotide probes and amplified DNA.";
RL   Immunogenetics 33:163-170(1991).
RN   [81]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 135-217 (ALLELE DQB1*02:01).
RX   PubMed=6952552; DOI=10.1111/j.1365-3083.1981.tb00603.x;
RA   Larhammar D., Wiman K., Schenning L., Claesson L., Gustafsson K.,
RA   Peterson P.A., Rask L.;
RT   "Evolutionary relationship between HLA-DR antigen beta-chains, HLA-A,
RT   B, C antigen subunits and immunoglobulin chains.";
RL   Scand. J. Immunol. 14:617-622(1981).
RN   [82]
RP   POLYMORPHISM.
RX   PubMed=18565458; DOI=10.1016/S1474-4422(08)70140-6;
RA   Bourgin P., Zeitzer J.M., Mignot E.;
RT   "CSF hypocretin-1 assessment in sleep and neurological disorders.";
RL   Lancet Neurol. 7:649-662(2008).
RN   [83]
RP   REVIEW.
RX   PubMed=8598037; DOI=10.1016/S0092-8674(00)81025-9;
RA   Cresswell P.;
RT   "Invariant chain structure and MHC class II function.";
RL   Cell 84:505-507(1996).
RN   [84]
RP   REVIEW.
RX   PubMed=11684289; DOI=10.1016/S0161-5890(01)00069-4;
RA   Villadangos J.A.;
RT   "Presentation of antigens by MHC class II molecules: getting the most
RT   out of them.";
RL   Mol. Immunol. 38:329-346(2001).
RN   [85]
RP   REVIEW.
RX   PubMed=18046453; DOI=10.1038/sj.emboj.7601945;
RA   Rocha N., Neefjes J.;
RT   "MHC class II molecules on the move for successful antigen
RT   presentation.";
RL   EMBO J. 27:1-5(2008).
RN   [86]
RP   REVIEW.
RX   PubMed=17241953; DOI=10.1016/j.immuni.2007.01.005;
RA   Menendez-Benito V., Neefjes J.;
RT   "Autophagy in MHC class II presentation: sampling from within.";
RL   Immunity 26:1-3(2007).
RN   [87]
RP   REVIEW.
RX   PubMed=19092054; DOI=10.1242/jcs.035089;
RA   Berger A.C., Roche P.A.;
RT   "MHC class II transport at a glance.";
RL   J. Cell Sci. 122:1-4(2009).
RN   [88]
RP   REVIEW.
RX   PubMed=19533806; DOI=10.3748/wjg.15.2855;
RA   Beswick E.J., Reyes V.E.;
RT   "CD74 in antigen presentation, inflammation, and cancers of the
RT   gastrointestinal tract.";
RL   World J. Gastroenterol. 15:2855-2861(2009).
RN   [89]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 35-224 OF HLA-DQA1/HLA-DQB1
RP   HETERODIMER IN COMPLEX WITH INS PEPTIDE, SUBUNIT, AND DISULFIDE BONDS.
RX   PubMed=11376336; DOI=10.1038/88694;
RA   Lee K.H., Wucherpfennig K.W., Wiley D.C.;
RT   "Structure of a human insulin peptide-HLA-DQ8 complex and
RT   susceptibility to type 1 diabetes.";
RL   Nat. Immunol. 2:501-507(2001).
RN   [90]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 35-231 OF HLA-DQA1/HLA-DQB1
RP   HETERODIMER (HLA-DQ0602) IN COMPLEX WITH HCRT PEPTIDE, POLYMORPHISM,
RP   SUBUNIT, AND DISULFIDE BONDS.
RX   PubMed=14769912; DOI=10.1073/pnas.0308458100;
RA   Siebold C., Hansen B.E., Wyer J.R., Harlos K., Esnouf R.E.,
RA   Svejgaard A., Bell J.I., Strominger J.L., Jones E.Y., Fugger L.;
RT   "Crystal structure of HLA-DQ0602 that protects against type 1 diabetes
RT   and confers strong susceptibility to narcolepsy.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:1999-2004(2004).
RN   [91]
RP   X-RAY CRYSTALLOGRAPHY (2.22 ANGSTROMS) OF 33-230 OF HLA-DQA1/HLA-DQB1
RP   HETERODIMER (DQ2) IN COMPLEX WITH TRITICUM AESTIVUM ALPHA/BETA-GLIADIN
RP   PEPTIDE, SUBUNIT, AND POLYMORPHISM.
RX   PubMed=15020763; DOI=10.1073/pnas.0306885101;
RA   Kim C.Y., Quarsten H., Bergseng E., Khosla C., Sollid L.M.;
RT   "Structural basis for HLA-DQ2-mediated presentation of gluten epitopes
RT   in celiac disease.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:4175-4179(2004).
RN   [92]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 33-224 OF HLA-DQA1/HLA-DQB1
RP   HETERODIMER IN COMPLEX WITH TRITICUM AESTIVUM ALPHA/BETA-GLIADIN
RP   PEPTIDE, POLYMORPHISM, SUBUNIT, AND DISULFIDE BONDS.
RX   PubMed=17629515; DOI=10.1016/j.immuni.2007.05.015;
RA   Henderson K.N., Tye-Din J.A., Reid H.H., Chen Z., Borg N.A.,
RA   Beissbarth T., Tatham A., Mannering S.I., Purcell A.W., Dudek N.L.,
RA   van Heel D.A., McCluskey J., Rossjohn J., Anderson R.P.;
RT   "A structural and immunological basis for the role of human leukocyte
RT   antigen DQ8 in celiac disease.";
RL   Immunity 27:23-34(2007).
RN   [93]
RP   VARIANT [LARGE SCALE ANALYSIS] ALA-172, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
CC   -!- FUNCTION: Binds peptides derived from antigens that access the
CC       endocytic route of antigen presenting cells (APC) and presents
CC       them on the cell surface for recognition by the CD4 T-cells. The
CC       peptide binding cleft accommodates peptides of 10-30 residues. The
CC       peptides presented by MHC class II molecules are generated mostly
CC       by degradation of proteins that access the endocytic route, where
CC       they are processed by lysosomal proteases and other hydrolases.
CC       Exogenous antigens that have been endocytosed by the APC are thus
CC       readily available for presentation via MHC II molecules, and for
CC       this reason this antigen presentation pathway is usually referred
CC       to as exogenous. As membrane proteins on their way to degradation
CC       in lysosomes as part of their normal turn-over are also contained
CC       in the endosomal/lysosomal compartments, exogenous antigens must
CC       compete with those derived from endogenous components. Autophagy
CC       is also a source of endogenous peptides, autophagosomes
CC       constitutively fuse with MHC class II loading compartments. In
CC       addition to APCs, other cells of the gastrointestinal tract, such
CC       as epithelial cells, express MHC class II molecules and CD74 and
CC       act as APCs, which is an unusual trait of the GI tract. To produce
CC       a MHC class II molecule that presents an antigen, three MHC class
CC       II molecules (heterodimers of an alpha and a beta chain) associate
CC       with a CD74 trimer in the ER to form a heterononamer. Soon after
CC       the entry of this complex into the endosomal/lysosomal system
CC       where antigen processing occurs, CD74 undergoes a sequential
CC       degradation by various proteases, including CTSS and CTSL, leaving
CC       a small fragment termed CLIP (class-II-associated invariant chain
CC       peptide). The removal of CLIP is facilitated by HLA-DM via direct
CC       binding to the alpha-beta-CLIP complex so that CLIP is released.
CC       HLA-DM stabilizes MHC class II molecules until primary high
CC       affinity antigenic peptides are bound. The MHC II molecule bound
CC       to a peptide is then transported to the cell membrane surface. In
CC       B-cells, the interaction between HLA-DM and MHC class II molecules
CC       is regulated by HLA-DO. Primary dendritic cells (DCs) also to
CC       express HLA-DO. Lysosomal microenvironment has been implicated in
CC       the regulation of antigen loading into MHC II molecules, increased
CC       acidification produces increased proteolysis and efficient peptide
CC       loading.
CC   -!- SUBUNIT: Heterodimer of an alpha and a beta subunit; also referred
CC       as MHC class II molecule. In the endoplasmic reticulum (ER) it
CC       forms a heterononamer; 3 MHC class II molecules bind to a CD74
CC       homotrimer (also known as invariant chain or HLA class II
CC       histocompatibility antigen gamma chain). In the
CC       endosomal/lysosomal system; CD74 undergoes sequential degradation
CC       by various proteases; leaving a small fragment termed CLIP on each
CC       MHC class II molecule. MHC class II molecule interacts with
CC       HLA_DM, and HLA_DO in B-cells, in order to release CLIP and
CC       facilitate the binding of antigenic peptides.
CC       {ECO:0000269|PubMed:11376336, ECO:0000269|PubMed:14769912,
CC       ECO:0000269|PubMed:15020763, ECO:0000269|PubMed:17629515}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein. Endoplasmic reticulum membrane; Single-pass type I
CC       membrane protein. Golgi apparatus, trans-Golgi network membrane;
CC       Single-pass type I membrane protein. Endosome membrane; Single-
CC       pass type I membrane protein. Lysosome membrane; Single-pass type
CC       I membrane protein. Note=The MHC class II complex transits through
CC       a number of intracellular compartments in the endocytic pathway
CC       until it reaches the cell membrane for antigen presentation.
CC   -!- POLYMORPHISM: The following alleles of HLA-DQB1 are known:
CC       DQB1*02:01, DQB1*02:02, DQB1*02:03, DQB1*02:04, DQB1*02:05,
CC       DQB1*03:01, DQB1*03:02, DQB1*03:03, DQB1*03:04, DQB1*03:05,
CC       DQB1*03:06, DQB1*03:07, DQB1*03:08, DQB1*03:09, DQB1*03:10,
CC       DQB1*03:11, DQB1*03:12, DQB1*03:13, DQB1*03:14, DQB1*03:15,
CC       DQB1*03:16, DQB1*03:17, DQB1*03:18, DQB1*03:19, DQB1*03:20,
CC       DQB1*03:21, DQB1*03:22, DQB1*03:23, DQB1*03:24, DQB1*03:25,
CC       DQB1*03:26, DQB1*04:01, DQB1*04:02, DQB1*04:03, DQB1*05:01,
CC       DQB1*05:02, DQB1*05:03, DQB1*05:04, DQB1*05:05, DQB1*06:01,
CC       DQB1*06:02, DQB1*06:03, DQB1*06:04, DQB1*06:05, DQB1*06:06,
CC       DQB1*06:07, DQB1*06:08, DQB1*06:09, DQB1*06:10, DQB1*06:11,
CC       DQB1*06:12, DQB1*06:13, DQB1*06:14, DQB1*06:15, DQB1*06:16,
CC       DQB1*06:17, DQB1*06:18, DQB1*06:19, DQB1*06:20, DQB1*06:21,
CC       DQB1*06:22, DQB1*06:23, DQB1*06:24, DQB1*06:25, DQB1*06:27,
CC       DQB1*06:28, DQB1*06:29, DQB1*06:30, DQB1*06:31, DQB1*06:32,
CC       DQB1*06:33, DQB1*06:34, DQB1*06:35, DQB1*06:36, DQB1*06:37,
CC       DQB1*06:38, and DQB1*06:39. The sequence shown is that of
CC       DQB1*03:01.
CC   -!- POLYMORPHISM: DQ2 (heterodimer of DQA1*05:01/DQB1*02:01) is
CC       associated with more than 90% of celiac disease patients. A
CC       minority displays DQ8 (heterodimer of DQA1*03/DQB1*03:02).
CC   -!- POLYMORPHISM: DQ0602 (heterodimer of DQA1*01:02/DQB1*06:02)
CC       confers dominant protection against type 1 diabetes (T1D) and
CC       strong susceptibility to narcolepsy. DQB1*06:02 has been found to
CC       be present in most of the narcolepsy patients. As well 98% of the
CC       patients with an HCRT deficiency are positive for DQB1*06:02.
CC   -!- SIMILARITY: Belongs to the MHC class II family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 Ig-like C1-type (immunoglobulin-like)
CC       domain. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC64403.2; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=CAJ57391.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=HLA-DQB1";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; K01499; AAA98746.1; -; Genomic_DNA.
DR   EMBL; K02405; AAA75521.1; -; Genomic_DNA.
DR   EMBL; X03068; CAA26872.1; -; mRNA.
DR   EMBL; M17564; AAA59765.1; -; mRNA.
DR   EMBL; M29613; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M29616; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M16996; AAA59770.1; -; mRNA.
DR   EMBL; M20432; AAA59769.1; -; mRNA.
DR   EMBL; M60028; AAA59755.1; -; mRNA.
DR   EMBL; X96420; CAA65280.1; -; mRNA.
DR   EMBL; U92032; AAB91991.1; -; Genomic_DNA.
DR   EMBL; AY663393; AAU87973.1; -; Genomic_DNA.
DR   EMBL; AY663394; AAU87977.1; -; Genomic_DNA.
DR   EMBL; AY663397; AAU87986.1; -; Genomic_DNA.
DR   EMBL; AY663409; AAU88017.1; -; Genomic_DNA.
DR   EMBL; AY663404; AAU88002.1; -; Genomic_DNA.
DR   EMBL; AY663410; AAU88020.1; -; Genomic_DNA.
DR   EMBL; AY663412; AAU88027.1; -; Genomic_DNA.
DR   EMBL; AY656681; AAV71028.1; -; mRNA.
DR   EMBL; AY656682; AAV71029.1; -; mRNA.
DR   EMBL; AY656683; AAV71030.1; -; mRNA.
DR   EMBL; BX927168; CAQ08747.1; -; Genomic_DNA.
DR   EMBL; CR753846; CAQ09755.1; -; Genomic_DNA.
DR   EMBL; CR933859; CAQ09239.1; -; Genomic_DNA.
DR   EMBL; BC012106; AAH12106.1; -; mRNA.
DR   EMBL; M25327; AAA59677.1; -; mRNA.
DR   EMBL; U66400; AAB51698.1; -; mRNA.
DR   EMBL; U83582; AAB41231.1; -; mRNA.
DR   EMBL; AH002887; AAA59762.1; -; Genomic_DNA.
DR   EMBL; M26042; AAA36270.1; -; mRNA.
DR   EMBL; M33907; AAA52672.1; -; mRNA.
DR   EMBL; L34096; AAC41964.1; -; mRNA.
DR   EMBL; L34098; AAC41966.1; -; mRNA.
DR   EMBL; L34101; AAC41969.1; -; mRNA.
DR   EMBL; L34103; AAC41971.1; -; mRNA.
DR   EMBL; L34104; AAC41972.1; -; mRNA.
DR   EMBL; L34105; AAC41973.1; -; mRNA.
DR   EMBL; L34106; AAC41974.1; -; mRNA.
DR   EMBL; L34107; AAC41975.1; -; mRNA.
DR   EMBL; AF195245; AAF28315.1; -; mRNA.
DR   EMBL; L42626; AAA85335.1; -; mRNA.
DR   EMBL; X76553; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; X76554; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; M59800; AAA64235.1; -; mRNA.
DR   EMBL; M14189; AAA36268.1; -; mRNA.
DR   EMBL; AY672649; AAT77952.1; -; Genomic_DNA.
DR   EMBL; M17207; AAA59697.1; -; mRNA.
DR   EMBL; Z49215; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AY026349; AAK01944.1; -; Genomic_DNA.
DR   EMBL; AF091305; AAC64403.2; ALT_SEQ; Genomic_DNA.
DR   EMBL; U77344; AAB19215.1; -; Genomic_DNA.
DR   EMBL; FN256435; CAX62164.1; -; Genomic_DNA.
DR   EMBL; FN256435; CAX62165.1; -; Genomic_DNA.
DR   EMBL; AM400970; CAL47037.1; -; Genomic_DNA.
DR   EMBL; AM421131; CAM07104.1; -; Genomic_DNA.
DR   EMBL; EF484936; ABO87661.1; -; Genomic_DNA.
DR   EMBL; EF484939; ABO87664.1; -; Genomic_DNA.
DR   EMBL; EU275158; ABY26531.1; -; Genomic_DNA.
DR   EMBL; AM944346; CAQ16179.1; -; Genomic_DNA.
DR   EMBL; FM200854; CAR31119.1; -; Genomic_DNA.
DR   EMBL; AH013029; AAP93137.1; -; Genomic_DNA.
DR   EMBL; EU770203; ACF16333.1; -; Genomic_DNA.
DR   EMBL; FM955320; CAW24712.1; -; Genomic_DNA.
DR   EMBL; FN552709; CBF35736.1; -; Genomic_DNA.
DR   EMBL; FN552710; CBF35739.1; -; Genomic_DNA.
DR   EMBL; X86327; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; D78569; BAA11413.1; -; Genomic_DNA.
DR   EMBL; AF439338; AAL35222.1; -; Genomic_DNA.
DR   EMBL; AF384556; AAM53072.1; -; Genomic_DNA.
DR   EMBL; DQ026226; AAY89656.1; -; Genomic_DNA.
DR   EMBL; AY762968; AAV97949.1; -; Genomic_DNA.
DR   EMBL; AM181332; CAJ57391.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AM691798; CAM88661.1; -; Genomic_DNA.
DR   EMBL; AM259942; CAJ90956.1; -; Genomic_DNA.
DR   EMBL; U39090; AAB02681.1; -; Genomic_DNA.
DR   EMBL; AJ003005; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AJ012156; CAA09929.1; -; Genomic_DNA.
DR   EMBL; AJ290396; CAC27418.1; -; Genomic_DNA.
DR   EMBL; AF469118; AAL77085.1; -; Genomic_DNA.
DR   EMBL; AF479569; AAM09472.1; -; Genomic_DNA.
DR   EMBL; AJ535315; CAD59445.2; -; Genomic_DNA.
DR   EMBL; AF181983; AAD54423.2; -; Genomic_DNA.
DR   EMBL; AY733062; AAU33811.1; -; Genomic_DNA.
DR   EMBL; AJ854065; CAH69441.1; -; Genomic_DNA.
DR   EMBL; AJ964903; CAI79639.1; -; Genomic_DNA.
DR   EMBL; AB211231; BAD95610.1; -; Genomic_DNA.
DR   EMBL; DQ114427; AAZ20753.1; -; Genomic_DNA.
DR   EMBL; DQ227421; ABB05231.1; -; Genomic_DNA.
DR   EMBL; AM403489; CAL48285.1; -; Genomic_DNA.
DR   EMBL; AM490069; CAM32717.1; -; Genomic_DNA.
DR   EMBL; EF622510; ABR24117.1; -; Genomic_DNA.
DR   EMBL; EU410617; ABZ89500.1; -; Genomic_DNA.
DR   EMBL; GQ422610; ACV66342.1; -; Genomic_DNA.
DR   EMBL; FN550110; CBE66554.1; -; Genomic_DNA.
DR   EMBL; AF087939; AAD39697.1; -; Genomic_DNA.
DR   EMBL; AY094140; AAM14401.1; -; Genomic_DNA.
DR   EMBL; AJ001257; CAA04631.1; -; Genomic_DNA.
DR   EMBL; U39086; AAA93181.1; -; Genomic_DNA.
DR   EMBL; AJ965439; CAI84643.1; -; Genomic_DNA.
DR   EMBL; AF112463; AAD23990.1; -; Genomic_DNA.
DR   EMBL; AF112464; AAD23991.1; -; Genomic_DNA.
DR   EMBL; M94773; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M65042; AAA36241.1; -; Genomic_DNA.
DR   EMBL; M25025; AAA59793.1; -; mRNA.
DR   PIR; A02234; HLHU1C.
DR   PIR; A35055; A35055.
DR   PIR; A94003; HLHUDB.
DR   PIR; B32527; B32527.
DR   PIR; B37044; B37044.
DR   PIR; C24669; HLHU2C.
DR   PIR; F30575; F30575.
DR   PIR; I54480; I54480.
DR   PIR; I68732; I68732.
DR   PIR; I72482; I72482.
DR   PIR; S46648; S46648.
DR   RefSeq; NP_001230891.1; NM_001243962.1.
DR   RefSeq; NP_002114.3; NM_002123.4.
DR   UniGene; Hs.409934; -.
DR   UniGene; Hs.534322; -.
DR   PDB; 1JK8; X-ray; 2.40 A; B=35-224.
DR   PDB; 1NBN; Model; -; B=35-224.
DR   PDB; 1S9V; X-ray; 2.22 A; B/E=33-230.
DR   PDB; 1UVQ; X-ray; 1.80 A; B=35-230.
DR   PDB; 2NNA; X-ray; 2.10 A; B=33-224.
DR   PDB; 4GG6; X-ray; 3.20 A; B/D=33-224.
DR   PDB; 4OZF; X-ray; 2.70 A; B=33-224.
DR   PDB; 4OZG; X-ray; 3.00 A; B/D=33-224.
DR   PDB; 4OZH; X-ray; 2.80 A; B/D=33-224.
DR   PDB; 4OZI; X-ray; 3.20 A; B/D=33-224.
DR   PDBsum; 1JK8; -.
DR   PDBsum; 1NBN; -.
DR   PDBsum; 1S9V; -.
DR   PDBsum; 1UVQ; -.
DR   PDBsum; 2NNA; -.
DR   PDBsum; 4GG6; -.
DR   PDBsum; 4OZF; -.
DR   PDBsum; 4OZG; -.
DR   PDBsum; 4OZH; -.
DR   PDBsum; 4OZI; -.
DR   ProteinModelPortal; P01920; -.
DR   SMR; P01920; 35-224.
DR   IntAct; P01920; 1.
DR   MINT; MINT-199658; -.
DR   iPTMnet; P01920; -.
DR   PhosphoSite; P01920; -.
DR   BioMuta; HLA-DQB1; -.
DR   DMDM; 290457643; -.
DR   MaxQB; P01920; -.
DR   PRIDE; P01920; -.
DR   DNASU; 3119; -.
DR   Ensembl; ENST00000399088; ENSP00000382038; ENSG00000231286.
DR   Ensembl; ENST00000413089; ENSP00000396539; ENSG00000231286.
DR   Ensembl; ENST00000416192; ENSP00000410107; ENSG00000233209.
DR   Ensembl; ENST00000419914; ENSP00000402865; ENSG00000225824.
DR   Ensembl; ENST00000422950; ENSP00000414079; ENSG00000233209.
DR   Ensembl; ENST00000424806; ENSP00000410330; ENSG00000225824.
DR   GeneID; 3119; -.
DR   UCSC; uc011hzw.2; human.
DR   CTD; 3119; -.
DR   GeneCards; HLA-DQB1; -.
DR   GeneReviews; HLA-DQB1; -.
DR   HGNC; HGNC:4944; HLA-DQB1.
DR   HPA; HPA013667; -.
DR   MalaCards; HLA-DQB1; -.
DR   MIM; 604305; gene.
DR   neXtProt; NX_P01920; -.
DR   Orphanet; 703; Bullous pemphigoid.
DR   Orphanet; 555; Celiac disease.
DR   Orphanet; 243377; Diabetes mellitus type 1.
DR   Orphanet; 930; Idiopathic achalasia.
DR   Orphanet; 802; Multiple sclerosis.
DR   Orphanet; 83465; Narcolepsy without cataplexy.
DR   Orphanet; 2073; Narcolepsy-cataplexy.
DR   PharmGKB; PA35068; -.
DR   HOVERGEN; HBG012730; -.
DR   InParanoid; P01920; -.
DR   PhylomeDB; P01920; -.
DR   Reactome; R-HSA-202424; Downstream TCR signaling.
DR   Reactome; R-HSA-202427; Phosphorylation of CD3 and TCR zeta chains.
DR   Reactome; R-HSA-202430; Translocation of ZAP-70 to Immunological synapse.
DR   Reactome; R-HSA-202433; Generation of second messenger molecules.
DR   Reactome; R-HSA-2132295; MHC class II antigen presentation.
DR   Reactome; R-HSA-389948; PD-1 signaling.
DR   Reactome; R-HSA-877300; Interferon gamma signaling.
DR   ChiTaRS; HLA-DQB1; human.
DR   EvolutionaryTrace; P01920; -.
DR   GeneWiki; HLA-DQB1; -.
DR   GenomeRNAi; 3119; -.
DR   NextBio; 20783717; -.
DR   PRO; PR:P01920; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   CleanEx; HS_HLA-DQB1; -.
DR   GO; GO:0030669; C:clathrin-coated endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0030666; C:endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0010008; C:endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0012507; C:ER to Golgi transport vesicle membrane; TAS:Reactome.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0071556; C:integral component of lumenal side of endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0005765; C:lysosomal membrane; TAS:Reactome.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0042613; C:MHC class II protein complex; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0032588; C:trans-Golgi network membrane; TAS:Reactome.
DR   GO; GO:0030658; C:transport vesicle membrane; TAS:Reactome.
DR   GO; GO:0032395; F:MHC class II receptor activity; NAS:UniProtKB.
DR   GO; GO:0042605; F:peptide antigen binding; ISS:UniProtKB.
DR   GO; GO:0019886; P:antigen processing and presentation of exogenous peptide antigen via MHC class II; TAS:Reactome.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0002455; P:humoral immune response mediated by circulating immunoglobulin; IDA:UniProtKB.
DR   GO; GO:0006955; P:immune response; NAS:UniProtKB.
DR   GO; GO:0002381; P:immunoglobulin production involved in immunoglobulin mediated immune response; IDA:UniProtKB.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0031295; P:T cell costimulation; TAS:Reactome.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; TAS:Reactome.
DR   Gene3D; 2.60.40.10; -; 1.
DR   Gene3D; 3.10.320.10; -; 1.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003006; Ig/MHC_CS.
DR   InterPro; IPR003597; Ig_C1-set.
DR   InterPro; IPR011162; MHC_I/II-like_Ag-recog.
DR   InterPro; IPR014745; MHC_II_a/b_N.
DR   InterPro; IPR000353; MHC_II_b_N.
DR   Pfam; PF07654; C1-set; 1.
DR   Pfam; PF00969; MHC_II_beta; 1.
DR   ProDom; PD000328; MHC_II_b_N; 1.
DR   SMART; SM00407; IGc1; 1.
DR   SMART; SM00921; MHC_II_beta; 1.
DR   SUPFAM; SSF48726; SSF48726; 1.
DR   SUPFAM; SSF54452; SSF54452; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00290; IG_MHC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Complete proteome;
KW   Direct protein sequencing; Disulfide bond; Endoplasmic reticulum;
KW   Endosome; Glycoprotein; Golgi apparatus; Immunity; Lysosome; Membrane;
KW   MHC II; Polymorphism; Reference proteome; Signal; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL        1     32       {ECO:0000269|PubMed:6576979}.
FT   CHAIN        33    261       HLA class II histocompatibility antigen,
FT                                DQ beta 1 chain.
FT                                /FTId=PRO_0000018989.
FT   TOPO_DOM     33    230       Extracellular. {ECO:0000255}.
FT   TRANSMEM    231    251       Helical. {ECO:0000255}.
FT   TOPO_DOM    252    261       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      129    217       Ig-like C1-type.
FT   REGION       33    126       Beta-1.
FT   REGION      127    220       Beta-2.
FT   REGION      221    230       Connecting peptide.
FT   CARBOHYD     51     51       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     47    111
FT   DISULFID    149    205
FT   VARIANT       6      6       A -> S (in allele DQB1*05:01 and allele
FT                                DQB1*05:02; dbSNP:rs1049056).
FT                                /FTId=VAR_056570.
FT   VARIANT      12     12       G -> D (in allele DQB1*05:01, allele
FT                                DQB1*05:02, allele DQB1*06:02 and allele
FT                                DQB1*06:12; dbSNP:rs1049057).
FT                                /FTId=VAR_062679.
FT   VARIANT      15     15       A -> V (in allele DQB1*03:02, allele
FT                                DQB1*03:03, allele DQB1*04:01, allele
FT                                DQB1*05:01, allele DQB1*05:02, allele
FT                                DQB1*06:02 and allele DQB1*06:12;
FT                                dbSNP:rs3189152).
FT                                {ECO:0000269|PubMed:3584986}.
FT                                /FTId=VAR_062680.
FT   VARIANT      23     23       A -> S (in allele DQB1*02:01 and allele
FT                                DQB1*02:02; dbSNP:rs3891176).
FT                                /FTId=VAR_062681.
FT   VARIANT      24     24       M -> I (in allele DQB1*05:01 and allele
FT                                DQB1*05:02; dbSNP:rs1049059).
FT                                /FTId=VAR_062682.
FT   VARIANT      27     27       T -> A (in allele DQB1*04:01).
FT                                /FTId=VAR_062683.
FT   VARIANT      27     27       T -> S (in allele DQB1*05:01, allele
FT                                DQB1*05:02, allele DQB1*06:02 and allele
FT                                DQB1*06:12; dbSNP:rs1049060).
FT                                /FTId=VAR_062684.
FT   VARIANT      28     28       P -> L (in allele DQB1*06:02 and allele
FT                                DQB1*06:12; dbSNP:rs1049062).
FT                                /FTId=VAR_062685.
FT   VARIANT      28     28       P -> S (in allele DQB1*05:01 and allele
FT                                DQB1*05:02).
FT                                {ECO:0000269|PubMed:3584986}.
FT                                /FTId=VAR_062686.
FT   VARIANT      29     29       V -> L (in allele DQB1*05:01, allele
FT                                DQB1*05:02, allele DQB1*06:02 and allele
FT                                DQB1*06:12; dbSNP:rs1130366).
FT                                /FTId=VAR_062687.
FT   VARIANT      35     35       S -> P (in allele DQB1*06:01).
FT                                /FTId=VAR_062688.
FT   VARIANT      41     41       Y -> F (in allele DQB1*04:01, allele
FT                                DQB1*04:02, allele DQB1*04:03, allele
FT                                DQB1*06:02, allele DQB1*06:10, allele
FT                                DQB1*06:13, allele DQB1*06:14, allele
FT                                DQB1*06:15, allele DQB1*06:16, allele
FT                                DQB1*06:19, allele DQB1*06:20, allele
FT                                DQB1*06:22, allele DQB1*06:23, allele
FT                                DQB1*06:24, allele DQB1*06:29, allele
FT                                DQB1*06:33 and allele DQB1*06:37;
FT                                dbSNP:rs9274407).
FT                                /FTId=VAR_062689.
FT   VARIANT      41     41       Y -> L (in allele DQB1*06:01 and allele
FT                                DQB1*06:35; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_062690.
FT   VARIANT      43     43       F -> L (in allele DQB1*06:33;
FT                                dbSNP:rs56173496).
FT                                /FTId=VAR_062691.
FT   VARIANT      45     45       A -> G (in allele DQB1*02:01, allele
FT                                DQB1*02:02, allele DQB1*02:03, allele
FT                                DQB1*02:04, allele DQB1*02:05, allele
FT                                DQB1*03:02, allele DQB1*03:03, allele
FT                                DQB1*03:05, allele DQB1*03:06, allele
FT                                DQB1*03:07, allele DQB1*03:08, allele
FT                                DQB1*03:11, allele DQB1*03:15, allele
FT                                DQB1*03:17, allele DQB1*03:18, allele
FT                                DQB1*03:20, allele DQB1*03:23, allele
FT                                DQB1*03:25, allele DQB1*03:26, allele
FT                                DQB1*04:01, allele DQB1*04:02, allele
FT                                DQB1*04:03, allele DQB1*05:01, allele
FT                                DQB1*05:02, allele DQB1*05:03, allele
FT                                DQB1*05:04, allele DQB1*05:05, allele
FT                                DQB1*06:02, allele DQB1*06:03, allele
FT                                DQB1*06:04, allele DQB1*06:05, allele
FT                                DQB1*06:07, allele DQB1*06:08, allele
FT                                DQB1*06:09, allele DQB1*06:10, allele
FT                                DQB1*06:11, allele DQB1*06:12, allele
FT                                DQB1*06:13, allele DQB1*06:14, allele
FT                                DQB1*06:15, allele DQB1*06:16, allele
FT                                DQB1*06:17, allele DQB1*06:18, allele
FT                                DQB1*06:19, allele DQB1*06:20, allele
FT                                DQB1*06:21, allele DQB1*06:22, allele
FT                                DQB1*06:23, allele DQB1*06:24, allele
FT                                DQB1*06:25, allele DQB1*06:27, allele
FT                                DQB1*06:28, allele DQB1*06:29, allele
FT                                DQB1*06:30, allele DQB1*06:31, allele
FT                                DQB1*06:32, allele DQB1*06:33, allele
FT                                DQB1*06:34, allele DQB1*06:36, allele
FT                                DQB1*06:37, allele DQB1*06:38 and allele
FT                                DQB1*06:39; dbSNP:rs1130375).
FT                                {ECO:0000269|PubMed:3584986}.
FT                                /FTId=VAR_061472.
FT   VARIANT      46     46       M -> L (in allele DQB1*03:11, allele
FT                                DQB1*03:26, allele DQB1*05:01, allele
FT                                DQB1*05:02, allele DQB1*05:03, allele
FT                                DQB1*05:04, allele DQB1*05:05, allele
FT                                DQB1*06:05, allele DQB1*06:20 and allele
FT                                DQB1*06:31; dbSNP:rs1130368).
FT                                /FTId=VAR_061473.
FT   VARIANT      55     55       R -> L (in allele DQB1*04:01;
FT                                dbSNP:rs41540813).
FT                                /FTId=VAR_062692.
FT   VARIANT      58     58       Y -> G (in allele DQB1*03:05, allele
FT                                DQB1*03:17, allele DQB1*04:01, allele
FT                                DQB1*04:02, allele DQB1*05:01, allele
FT                                DQB1*05:02, allele DQB1*05:03, allele
FT                                DQB1*05:04, allele DQB1*05:05 and allele
FT                                DQB1*06:23; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_062693.
FT   VARIANT      58     58       Y -> L (in allele DQB1*02:01, allele
FT                                DQB1*02:02, allele DQB1*02:03, allele
FT                                DQB1*02:04, allele DQB1*02:05, allele
FT                                DQB1*03:02, allele DQB1*03:03, allele
FT                                DQB1*03:06, allele DQB1*03:07, allele
FT                                DQB1*03:08, allele DQB1*03:11, allele
FT                                DQB1*03:12, allele DQB1*03:15, allele
FT                                DQB1*03:18, allele DQB1*03:20, allele
FT                                DQB1*03:23, allele DQB1*03:25, allele
FT                                DQB1*03:26, allele DQB1*04:03, allele
FT                                DQB1*06:02, allele DQB1*06:03, allele
FT                                DQB1*06:04, allele DQB1*06:05, allele
FT                                DQB1*06:06, allele DQB1*06:07, allele
FT                                DQB1*06:08, allele DQB1*06:09, allele
FT                                DQB1*06:10, allele DQB1*06:11, allele
FT                                DQB1*06:12, allele DQB1*06:13, allele
FT                                DQB1*06:14, allele DQB1*06:15, allele
FT                                DQB1*06:16, allele DQB1*06:17, allele
FT                                DQB1*06:18, allele DQB1*06:19, allele
FT                                DQB1*06:20, allele DQB1*06:21, allele
FT                                DQB1*06:22, allele DQB1*06:24, allele
FT                                DQB1*06:25, allele DQB1*06:27, allele
FT                                DQB1*06:28, allele DQB1*06:29, allele
FT                                DQB1*06:30, allele DQB1*06:31, allele
FT                                DQB1*06:32, allele DQB1*06:33, allele
FT                                DQB1*06:34, allele DQB1*06:36, allele
FT                                DQB1*06:37, allele DQB1*06:38 and allele
FT                                DQB1*06:39; requires 2 nucleotide
FT                                substitutions).
FT                                {ECO:0000269|PubMed:3584986}.
FT                                /FTId=VAR_062694.
FT   VARIANT      59     59       V -> L (in allele DQB1*03:18;
FT                                dbSNP:rs41563539).
FT                                /FTId=VAR_062695.
FT   VARIANT      60     60       T -> S (in allele DQB1*02:01, allele
FT                                DQB1*02:02, allele DQB1*02:03, allele
FT                                DQB1*02:04 and allele DQB1*02:05;
FT                                dbSNP:rs9274405).
FT                                /FTId=VAR_062696.
FT   VARIANT      62     62       Y -> H (in allele DQB1*05:01, allele
FT                                DQB1*05:02, allele DQB1*05:03, allele
FT                                DQB1*05:05, allele DQB1*06:03, allele
FT                                DQB1*06:04, allele DQB1*06:07, allele
FT                                DQB1*06:08, allele DQB1*06:14, allele
FT                                DQB1*06:17, allele DQB1*06:21, allele
FT                                DQB1*06:25, allele DQB1*06:27, allele
FT                                DQB1*06:28, allele DQB1*06:30, allele
FT                                DQB1*06:31, allele DQB1*06:32, allele
FT                                DQB1*06:34, allele DQB1*06:36, allele
FT                                DQB1*06:38 and allele DQB1*06:39).
FT                                /FTId=VAR_062697.
FT   VARIANT      62     62       Y -> S (in allele DQB1*02:01, allele
FT                                DQB1*02:02, allele DQB1*02:03, allele
FT                                DQB1*02:04 and allele DQB1*02:05).
FT                                /FTId=VAR_062698.
FT   VARIANT      69     69       Y -> D (in allele DQB1*06:01 and allele
FT                                DQB1*06:35; dbSNP:rs1130370).
FT                                /FTId=VAR_062699.
FT   VARIANT      69     69       Y -> I (in allele DQB1*02:01, allele
FT                                DQB1*02:02, allele DQB1*02:03, allele
FT                                DQB1*02:04 and allele DQB1*02:05;
FT                                requires 2 nucleotide substitutions).
FT                                /FTId=VAR_062700.
FT   VARIANT      70     70       A -> T (in allele DQB1*03:20;
FT                                dbSNP:rs45519640).
FT                                /FTId=VAR_062701.
FT   VARIANT      70     70       A -> V (in allele DQB1*02:01, allele
FT                                DQB1*02:02, allele DQB1*02:03, allele
FT                                DQB1*02:04, allele DQB1*02:05, allele
FT                                DQB1*05:01, allele DQB1*05:02, allele
FT                                DQB1*05:03, allele DQB1*05:04, allele
FT                                DQB1*06:01, allele DQB1*06:28 and allele
FT                                DQB1*06:35; dbSNP:rs1063318).
FT                                /FTId=VAR_062702.
FT   VARIANT      77     77       E -> G (in allele DQB1*02:01, allele
FT                                DQB1*02:02, allele DQB1*02:03, allele
FT                                DQB1*02:04, allele DQB1*02:05, allele
FT                                DQB1*03:02, allele DQB1*03:03, allele
FT                                DQB1*03:05, allele DQB1*03:06, allele
FT                                DQB1*03:07, allele DQB1*03:08, allele
FT                                DQB1*03:10, allele DQB1*03:11, allele
FT                                DQB1*03:12, allele DQB1*03:14, allele
FT                                DQB1*03:15, allele DQB1*03:17, allele
FT                                DQB1*03:18, allele DQB1*03:20, allele
FT                                DQB1*03:23, allele DQB1*03:25, allele
FT                                DQB1*03:26, allele DQB1*04:01, allele
FT                                DQB1*04:02, allele DQB1*04:03, allele
FT                                DQB1*05:01, allele DQB1*05:02, allele
FT                                DQB1*05:03, allele DQB1*05:04, allele
FT                                DQB1*05:05, allele DQB1*06:01, allele
FT                                DQB1*06:02, allele DQB1*06:03, allele
FT                                DQB1*06:04, allele DQB1*06:05, allele
FT                                DQB1*06:06, allele DQB1*06:07, allele
FT                                DQB1*06:08, allele DQB1*06:09, allele
FT                                DQB1*06:10, allele DQB1*06:11, allele
FT                                DQB1*06:12, allele DQB1*06:13, allele
FT                                DQB1*06:14, allele DQB1*06:15, allele
FT                                DQB1*06:16, allele DQB1*06:17, allele
FT                                DQB1*06:18, allele DQB1*06:19, allele
FT                                DQB1*06:20, allele DQB1*06:21, allele
FT                                DQB1*06:22, allele DQB1*06:23, allele
FT                                DQB1*06:24, allele DQB1*06:25, allele
FT                                DQB1*06:27, allele DQB1*06:28, allele
FT                                DQB1*06:29, allele DQB1*06:30, allele
FT                                DQB1*06:31, allele DQB1*06:32, allele
FT                                DQB1*06:33, allele DQB1*06:34, allele
FT                                DQB1*06:36, allele DQB1*06:37, allele
FT                                DQB1*06:38 and allele DQB1*06:39;
FT                                dbSNP:rs1049083).
FT                                {ECO:0000269|PubMed:3584986}.
FT                                /FTId=VAR_062703.
FT   VARIANT      78     78       V -> E (in allele DQB1*02:01, allele
FT                                DQB1*02:02, allele DQB1*02:03, allele
FT                                DQB1*02:04 and allele DQB1*02:05;
FT                                dbSNP:rs9274398).
FT                                /FTId=VAR_062704.
FT   VARIANT      79     79       Y -> F (in allele DQB1*02:01, allele
FT                                DQB1*02:02, allele DQB1*02:03, allele
FT                                DQB1*02:04 and allele DQB1*02:05;
FT                                dbSNP:rs9274397).
FT                                /FTId=VAR_062705.
FT   VARIANT      81     81       A -> V (in allele DQB1*03:07;
FT                                dbSNP:rs41558214).
FT                                /FTId=VAR_062706.
FT   VARIANT      84     84       P -> L (in allele DQB1*02:01, allele
FT                                DQB1*02:02, allele DQB1*02:03, allele
FT                                DQB1*02:04 and allele DQB1*02:05;
FT                                dbSNP:rs9274395).
FT                                /FTId=VAR_062707.
FT   VARIANT      85     85       L -> Q (in allele DQB1*03:23, allele
FT                                DQB1*05:01, allele DQB1*05:02, allele
FT                                DQB1*05:03, allele DQB1*05:04, allele
FT                                DQB1*05:05, allele DQB1*06:01, allele
FT                                DQB1*06:02, allele DQB1*06:03, allele
FT                                DQB1*06:04, allele DQB1*06:05, allele
FT                                DQB1*06:06, allele DQB1*06:07, allele
FT                                DQB1*06:08, allele DQB1*06:09, allele
FT                                DQB1*06:10, allele DQB1*06:11, allele
FT                                DQB1*06:12, allele DQB1*06:13, allele
FT                                DQB1*06:14, allele DQB1*06:15, allele
FT                                DQB1*06:16, allele DQB1*06:17, allele
FT                                DQB1*06:18, allele DQB1*06:20, allele
FT                                DQB1*06:22, allele DQB1*06:21, allele
FT                                DQB1*06:23, allele DQB1*06:24, allele
FT                                DQB1*06:25, allele DQB1*06:27, allele
FT                                DQB1*06:28, allele DQB1*06:29, allele
FT                                DQB1*06:30, allele DQB1*06:31, allele
FT                                DQB1*06:32, allele DQB1*06:33, allele
FT                                DQB1*06:34, allele DQB1*06:36, allele
FT                                DQB1*06:37, allele DQB1*06:38 and allele
FT                                DQB1*06:39; dbSNP:rs1140313).
FT                                /FTId=VAR_062708.
FT   VARIANT      87     87       P -> L (in allele DQB1*02:01, allele
FT                                DQB1*02:02, allele DQB1*02:03, allele
FT                                DQB1*02:04 and allele DQB1*02:05).
FT                                /FTId=VAR_062709.
FT   VARIANT      87     87       P -> Q (in allele DQB1*03:16).
FT                                /FTId=VAR_062710.
FT   VARIANT      87     87       P -> R (in allele DQB1*03:23, allele
FT                                DQB1*03:25, allele DQB1*04:01, allele
FT                                DQB1*04:02, allele DQB1*04:03, allele
FT                                DQB1*05:01, allele DQB1*05:02, allele
FT                                DQB1*05:03, allele DQB1*05:04, allele
FT                                DQB1*05:05, allele DQB1*06:01, allele
FT                                DQB1*06:02, allele DQB1*06:03, allele
FT                                DQB1*06:04, allele DQB1*06:05, allele
FT                                DQB1*06:06, allele DQB1*06:07, allele
FT                                DQB1*06:08, allele DQB1*06:09, allele
FT                                DQB1*06:10, allele DQB1*06:11, allele
FT                                DQB1*06:12, allele DQB1*06:13, allele
FT                                DQB1*06:14, allele DQB1*06:15, allele
FT                                DQB1*06:16, allele DQB1*06:17, allele
FT                                DQB1*06:18, allele DQB1*06:19, allele
FT                                DQB1*06:20, allele DQB1*06:21, allele
FT                                DQB1*06:22, allele DQB1*06:23, allele
FT                                DQB1*06:24, allele DQB1*06:25, allele
FT                                DQB1*06:27, allele DQB1*06:28, allele
FT                                DQB1*06:30, allele DQB1*06:31, allele
FT                                DQB1*06:32, allele DQB1*06:33, allele
FT                                DQB1*06:34, allele DQB1*06:35, allele
FT                                DQB1*06:36, allele DQB1*06:37, allele
FT                                DQB1*06:38 and allele DQB1*06:39;
FT                                dbSNP:rs1130380).
FT                                /FTId=VAR_062711.
FT   VARIANT      88     88       P -> L (in allele DQB1*03:25, allele
FT                                DQB1*04:01, allele DQB1*04:02 and allele
FT                                DQB1*04:03; dbSNP:rs1130381).
FT                                /FTId=VAR_062712.
FT   VARIANT      89     89       D -> A (in allele DQB1*02:01, allele
FT                                DQB1*02:02, allele DQB1*02:04, allele
FT                                DQB1*02:05, allele DQB1*03:02, allele
FT                                DQB1*03:04, allele DQB1*03:05, allele
FT                                DQB1*03:07, allele DQB1*03:08, allele
FT                                DQB1*03:11, allele DQB1*03:14, allele
FT                                DQB1*03:18 and allele DQB1*06:29;
FT                                dbSNP:rs1071637).
FT                                /FTId=VAR_062713.
FT   VARIANT      89     89       D -> S (in allele DQB1*05:02, allele
FT                                DQB1*05:04, allele DQB1*05:05, allele
FT                                DQB1*06:10 and allele DQB1*06:25;
FT                                requires 2 nucleotide substitutions).
FT                                /FTId=VAR_062714.
FT   VARIANT      89     89       D -> V (in allele DQB1*05:01, allele
FT                                DQB1*06:04, allele DQB1*06:05, allele
FT                                DQB1*06:06, allele DQB1*06:08, allele
FT                                DQB1*06:09, allele DQB1*06:12, allele
FT                                DQB1*06:13, allele DQB1*06:17, allele
FT                                DQB1*06:18, allele DQB1*06:21, allele
FT                                DQB1*06:22, allele DQB1*06:27, allele
FT                                DQB1*06:34, allele DQB1*06:36, allele
FT                                DQB1*06:38 and allele DQB1*06:39).
FT                                /FTId=VAR_062715.
FT   VARIANT      92     92       Y -> N (in allele DQB1*06:16).
FT                                /FTId=VAR_062716.
FT   VARIANT      94     94       N -> K (in allele DQB1*06:37).
FT                                /FTId=VAR_062717.
FT   VARIANT      95     95       S -> R (in allele DQB1*03:15).
FT                                /FTId=VAR_062718.
FT   VARIANT      98     98       E -> D (in allele DQB1*02:01, allele
FT                                DQB1*02:02, allele DQB1*02:03, allele
FT                                DQB1*02:04, allele DQB1*02:05, allele
FT                                DQB1*03:06, allele DQB1*03:25, allele
FT                                DQB1*04:01, allele DQB1*04:02, allele
FT                                DQB1*04:03, allele DQB1*05:04, allele
FT                                DQB1*06:01 and allele DQB1*06:35;
FT                                dbSNP:rs9274390).
FT                                /FTId=VAR_062719.
FT   VARIANT      99     99       V -> D (in allele DQB1*03:13).
FT                                /FTId=VAR_062720.
FT   VARIANT      99     99       V -> I (in allele DQB1*02:01, allele
FT                                DQB1*02:02, allele DQB1*02:03, allele
FT                                DQB1*02:04, allele DQB1*02:05, allele
FT                                DQB1*03:06, allele DQB1*03:25, allele
FT                                DQB1*04:01, allele DQB1*04:02, allele
FT                                DQB1*04:03, allele DQB1*05:04, allele
FT                                DQB1*06:01 and allele DQB1*06:35).
FT                                /FTId=VAR_062721.
FT   VARIANT     102    102       R -> E (in allele DQB1*03:06, allele
FT                                DQB1*03:25, allele DQB1*04:01, allele
FT                                DQB1*04:02, allele DQB1*04:03 and allele
FT                                DQB1*05:04; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_062722.
FT   VARIANT     102    102       R -> G (in allele DQB1*03:08, allele
FT                                DQB1*05:01, allele DQB1*05:02, allele
FT                                DQB1*05:03, allele DQB1*05:05, allele
FT                                DQB1*06:02, allele DQB1*06:03, allele
FT                                DQB1*06:08, allele DQB1*06:10, allele
FT                                DQB1*06:11, allele DQB1*06:12, allele
FT                                DQB1*06:13, allele DQB1*06:14, allele
FT                                DQB1*06:16, allele DQB1*06:17, allele
FT                                DQB1*06:19, allele DQB1*06:20, allele
FT                                DQB1*06:21, allele DQB1*06:23, allele
FT                                DQB1*06:24, allele DQB1*06:28, allele
FT                                DQB1*06:29, allele DQB1*06:30, allele
FT                                DQB1*06:31 and allele DQB1*06:33;
FT                                dbSNP:rs1130386).
FT                                {ECO:0000269|PubMed:3584986}.
FT                                /FTId=VAR_062723.
FT   VARIANT     103    103       T -> A (in allele DQB1*05:01, allele
FT                                DQB1*05:02, allele DQB1*05:03, allele
FT                                DQB1*05:05, allele DQB1*06:17, allele
FT                                DQB1*06:24 and allele DQB1*06:30).
FT                                /FTId=VAR_062724.
FT   VARIANT     103    103       T -> D (in allele DQB1*03:06, allele
FT                                DQB1*03:25, allele DQB1*04:01, allele
FT                                DQB1*04:02, allele DQB1*04:03 and allele
FT                                DQB1*05:04; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_062725.
FT   VARIANT     103    103       T -> K (in allele DQB1*02:01, allele
FT                                DQB1*02:02, allele DQB1*02:03, allele
FT                                DQB1*02:04 and allele DQB1*02:05).
FT                                /FTId=VAR_062726.
FT   VARIANT     106    106       E -> A (in allele DQB1*02:01, allele
FT                                DQB1*02:02, allele DQB1*02:03, allele
FT                                DQB1*02:04, allele DQB1*02:05 and allele
FT                                DQB1*06:06; dbSNP:rs1130387).
FT                                /FTId=VAR_062727.
FT   VARIANT     106    106       E -> S (in allele DQB1*03:06, allele
FT                                DQB1*03:25, allele DQB1*04:01, allele
FT                                DQB1*04:02, allele DQB1*04:03, allele
FT                                DQB1*05:01, allele DQB1*05:02, allele
FT                                DQB1*05:03, allele DQB1*05:04 and allele
FT                                DQB1*05:05; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_062728.
FT   VARIANT     107    107       L -> V (in allele DQB1*02:01, allele
FT                                DQB1*02:02, allele DQB1*02:03, allele
FT                                DQB1*02:04, allele DQB1*02:05, allele
FT                                DQB1*03:06, allele DQB1*03:25, allele
FT                                DQB1*04:01, allele DQB1*04:02, allele
FT                                DQB1*04:03, allele DQB1*05:01, allele
FT                                DQB1*05:02, allele DQB1*05:03, allele
FT                                DQB1*05:04, allele DQB1*05:05 and allele
FT                                DQB1*06:06; dbSNP:rs9274384).
FT                                /FTId=VAR_062729.
FT   VARIANT     109    109       T -> R (in allele DQB1*02:01, allele
FT                                DQB1*02:02, allele DQB1*02:03, allele
FT                                DQB1*02:04, allele DQB1*05:01, allele
FT                                DQB1*05:02, allele DQB1*05:03, allele
FT                                DQB1*05:04, allele DQB1*05:05 and allele
FT                                DQB1*06:06; dbSNP:rs1130392).
FT                                /FTId=VAR_062730.
FT   VARIANT     116    116       Q -> E (in allele DQB1*05:01, allele
FT                                DQB1*05:02, allele DQB1*05:03, allele
FT                                DQB1*05:05, allele DQB1*06:01, allele
FT                                DQB1*06:02, allele DQB1*06:03, allele
FT                                DQB1*06:04, allele DQB1*06:05, allele
FT                                DQB1*06:07, allele DQB1*06:08, allele
FT                                DQB1*06:09, allele DQB1*06:10, allele
FT                                DQB1*06:11, allele DQB1*06:12, allele
FT                                DQB1*06:13, allele DQB1*06:14, allele
FT                                DQB1*06:15, allele DQB1*06:16, allele
FT                                DQB1*06:17, allele DQB1*06:18, allele
FT                                DQB1*06:19, allele DQB1*06:20, allele
FT                                DQB1*06:21, allele DQB1*06:22, allele
FT                                DQB1*06:23, allele DQB1*06:24, allele
FT                                DQB1*06:25, allele DQB1*06:27, allele
FT                                DQB1*06:28, allele DQB1*06:29, allele
FT                                DQB1*06:30, allele DQB1*06:31, allele
FT                                DQB1*06:32, allele DQB1*06:33, allele
FT                                DQB1*06:34, allele DQB1*06:35, allele
FT                                DQB1*06:36, allele DQB1*06:37, allele
FT                                DQB1*06:38, allele DQB1*06:39;
FT                                dbSNP:rs1140316).
FT                                /FTId=VAR_062731.
FT   VARIANT     117    117       L -> V (in allele DQB1*05:01, allele
FT                                DQB1*05:02, allele DQB1*05:03, allele
FT                                DQB1*05:05, allele DQB1*06:01, allele
FT                                DQB1*06:02, allele DQB1*06:03, allele
FT                                DQB1*06:04, allele DQB1*06:05, allele
FT                                DQB1*06:07, allele DQB1*06:08, allele
FT                                DQB1*06:09, allele DQB1*06:10, allele
FT                                DQB1*06:11, allele DQB1*06:12, allele
FT                                DQB1*06:13, allele DQB1*06:14, allele
FT                                DQB1*06:15, allele DQB1*06:16, allele
FT                                DQB1*06:17, allele DQB1*06:18, allele
FT                                DQB1*06:19, allele DQB1*06:20, allele
FT                                DQB1*06:21, allele DQB1*06:22, allele
FT                                DQB1*06:23, allele DQB1*06:24, allele
FT                                DQB1*06:25, allele DQB1*06:27, allele
FT                                DQB1*06:28, allele DQB1*06:29, allele
FT                                DQB1*06:30, allele DQB1*06:31, allele
FT                                DQB1*06:32, allele DQB1*06:33, allele
FT                                DQB1*06:34, allele DQB1*06:35, allele
FT                                DQB1*06:36, allele DQB1*06:37, allele
FT                                DQB1*06:38 and allele DQB1*06:39;
FT                                dbSNP:rs1140317).
FT                                /FTId=VAR_062732.
FT   VARIANT     118    118       E -> A (in allele DQB1*05:01, allele
FT                                DQB1*05:02, allele DQB1*05:03, allele
FT                                DQB1*05:05, allele DQB1*06:01, allele
FT                                DQB1*06:02, allele DQB1*06:03, allele
FT                                DQB1*06:08, allele DQB1*06:10, allele
FT                                DQB1*06:11, allele DQB1*06:13, allele
FT                                DQB1*06:14, allele DQB1*06:16, allele
FT                                DQB1*06:18, allele DQB1*06:19, allele
FT                                DQB1*06:20, allele DQB1*06:23, allele
FT                                DQB1*06:24, allele DQB1*06:27, allele
FT                                DQB1*06:28, allele DQB1*06:29, allele
FT                                DQB1*06:30, allele DQB1*06:31, allele
FT                                DQB1*06:32, allele DQB1*06:33, allele
FT                                DQB1*06:35 and allele DQB1*06:37).
FT                                /FTId=VAR_062733.
FT   VARIANT     118    118       E -> G (in allele DQB1*06:04, allele
FT                                DQB1*06:05, allele DQB1*06:07, allele
FT                                DQB1*06:09, allele DQB1*06:12, allele
FT                                DQB1*06:15, allele DQB1*06:17, allele
FT                                DQB1*06:21, allele DQB1*06:22, allele
FT                                DQB1*06:25, allele DQB1*06:34, allele
FT                                DQB1*06:36, allele DQB1*06:38 and allele
FT                                DQB1*06:39).
FT                                /FTId=VAR_062734.
FT   VARIANT     119    119       L -> F (in allele DQB1*06:01, allele
FT                                DQB1*06:02, allele DQB1*06:03, allele
FT                                DQB1*06:08, allele DQB1*06:10, allele
FT                                DQB1*06:11, allele DQB1*06:13, allele
FT                                DQB1*06:14, allele DQB1*06:16, allele
FT                                DQB1*06:18, allele DQB1*06:19, allele
FT                                DQB1*06:20, allele DQB1*06:23, allele
FT                                DQB1*06:24, allele DQB1*06:27, allele
FT                                DQB1*06:28, allele DQB1*06:29, allele
FT                                DQB1*06:30, allele DQB1*06:31, allele
FT                                DQB1*06:32, allele DQB1*06:33, allele
FT                                DQB1*06:35 and allele DQB1*06:37;
FT                                dbSNP:rs9274379).
FT                                /FTId=VAR_062735.
FT   VARIANT     119    119       L -> Y (in allele DQB1*05:01, allele
FT                                DQB1*05:02, allele DQB1*05:03, allele
FT                                DQB1*05:05, allele DQB1*06:04, allele
FT                                DQB1*06:05, allele DQB1*06:07, allele
FT                                DQB1*06:09, allele DQB1*06:12, allele
FT                                DQB1*06:15, allele DQB1*06:17, allele
FT                                DQB1*06:21, allele DQB1*06:22, allele
FT                                DQB1*06:25, allele DQB1*06:34, allele
FT                                DQB1*06:36, allele DQB1*06:38 and allele
FT                                DQB1*06:39; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_062736.
FT   VARIANT     121    121       T -> G (in allele DQB1*05:01, allele
FT                                DQB1*05:02, allele DQB1*05:03, allele
FT                                DQB1*05:05, allele DQB1*06:01, allele
FT                                DQB1*06:02, allele DQB1*06:03, allele
FT                                DQB1*06:04, allele DQB1*06:05, allele
FT                                DQB1*06:07, allele DQB1*06:08, allele
FT                                DQB1*06:09, allele DQB1*06:10, allele
FT                                DQB1*06:11, allele DQB1*06:12, allele
FT                                DQB1*06:13, allele DQB1*06:14, allele
FT                                DQB1*06:15, allele DQB1*06:16, allele
FT                                DQB1*06:17, allele DQB1*06:18, allele
FT                                DQB1*06:19, allele DQB1*06:21, allele
FT                                DQB1*06:22, allele DQB1*06:23, allele
FT                                DQB1*06:24, allele DQB1*06:25, allele
FT                                DQB1*06:27, allele DQB1*06:28, allele
FT                                DQB1*06:29, allele DQB1*06:30, allele
FT                                DQB1*06:31, allele DQB1*06:32, allele
FT                                DQB1*06:33, allele DQB1*06:34, allele
FT                                DQB1*06:35, allele DQB1*06:36, allele
FT                                DQB1*06:37, allele DQB1*06:38 and allele
FT                                DQB1*06:39; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_062737.
FT   VARIANT     122    122       T -> I (in allele DQB1*05:01, allele
FT                                DQB1*05:02, allele DQB1*05:03, allele
FT                                DQB1*05:05, allele DQB1*06:01, allele
FT                                DQB1*06:02, allele DQB1*06:03, allele
FT                                DQB1*06:04, allele DQB1*06:05, allele
FT                                DQB1*06:07, allele DQB1*06:08, allele
FT                                DQB1*06:09, allele DQB1*06:10, allele
FT                                DQB1*06:11, allele DQB1*06:12, allele
FT                                DQB1*06:14, allele DQB1*06:15, allele
FT                                DQB1*06:16, allele DQB1*06:17, allele
FT                                DQB1*06:18, allele DQB1*06:19, allele
FT                                DQB1*06:21, allele DQB1*06:22, allele
FT                                DQB1*06:23, allele DQB1*06:24, allele
FT                                DQB1*06:25, allele DQB1*06:27, allele
FT                                DQB1*06:28, allele DQB1*06:29, allele
FT                                DQB1*06:30, allele DQB1*06:31, allele
FT                                DQB1*06:32, allele DQB1*06:33, allele
FT                                DQB1*06:34, allele DQB1*06:35, allele
FT                                DQB1*06:36, allele DQB1*06:37, allele
FT                                DQB1*06:38 and allele DQB1*06:39;
FT                                dbSNP:rs1140320).
FT                                /FTId=VAR_062738.
FT   VARIANT     148    148       V -> I (in allele DQB1*05:01, allele
FT                                DQB1*05:02 and allele DQB1*05:03;
FT                                dbSNP:rs1049100).
FT                                /FTId=VAR_056571.
FT   VARIANT     157    157       A -> G (in allele DQB1*06:01, allele
FT                                DQB1*06:02, allele DQB1*06:03, allele
FT                                DQB1*06:04, allele DQB1*06:09, allele
FT                                DQB1*06:12, allele DQB1*06:34, allele
FT                                DQB1*06:36, allele DQB1*06:38 and allele
FT                                DQB1*06:39).
FT                                /FTId=VAR_062739.
FT   VARIANT     157    157       A -> S (in allele DQB1*05:01, allele
FT                                DQB1*05:02 and allele DQB1*05:03).
FT                                /FTId=VAR_062740.
FT   VARIANT     158    158       Q -> H (in allele DQB1*05:02).
FT                                /FTId=VAR_062741.
FT   VARIANT     162    162       R -> Q (in allele DQB1*03:22, allele
FT                                DQB1*06:04, allele DQB1*06:09, allele
FT                                DQB1*06:12, allele DQB1*06:34, allele
FT                                DQB1*06:36 and allele DQB1*06:38).
FT                                /FTId=VAR_062742.
FT   VARIANT     165    165       R -> Q (in allele DQB1*06:38).
FT                                /FTId=VAR_062744.
FT   VARIANT     165    165       R -> W (in allele DQB1*03:21).
FT                                /FTId=VAR_062743.
FT   VARIANT     167    167       D -> G (in allele DQB1*02:02).
FT                                /FTId=VAR_062745.
FT   VARIANT     168    168       Q -> E (in allele DQB1*02:04).
FT                                /FTId=VAR_062746.
FT   VARIANT     172    172       T -> A (in allele DQB1*02:01, allele
FT                                DQB1*02:02, allele DQB1*02:04, allele
FT                                DQB1*05:01, allele DQB1*05:02, allele
FT                                DQB1*05:03, allele DQB1*06:01, allele
FT                                DQB1*06:02, allele DQB1*06:03, allele
FT                                DQB1*06:04, allele DQB1*06:09, allele
FT                                DQB1*06:12, allele DQB1*06:34, allele
FT                                DQB1*06:36, allele DQB1*06:38 and allele
FT                                DQB1*06:39; dbSNP:rs1063323).
FT                                {ECO:0000244|PubMed:21269460}.
FT                                /FTId=VAR_062747.
FT   VARIANT     194    194       E -> D (in dbSNP:rs9273952).
FT                                /FTId=VAR_056572.
FT   VARIANT     197    197       P -> L (in dbSNP:rs9273948).
FT                                /FTId=VAR_059522.
FT   VARIANT     199    199       H -> R (in allele DQB1*02:01, allele
FT                                DQB1*02:02, allele DQB1*02:04, allele
FT                                DQB1*03:02, allele DQB1*03:03, allele
FT                                DQB1*03:05, allele DQB1*03:23, allele
FT                                DQB1*03:25, allele DQB1*04:01, allele
FT                                DQB1*04:02, allele DQB1*05:01, allele
FT                                DQB1*05:02, allele DQB1*05:03, allele
FT                                DQB1*06:02, allele DQB1*06:03, allele
FT                                DQB1*06:04, allele DQB1*06:09, allele
FT                                DQB1*06:12, allele DQB1*06:34, allele
FT                                DQB1*06:36, allele DQB1*06:38 and allele
FT                                DQB1*06:39).
FT                                {ECO:0000269|PubMed:3584986}.
FT                                /FTId=VAR_062748.
FT   VARIANT     200    201       GD -> A (in allele DQB1*03:09).
FT                                /FTId=VAR_062749.
FT   VARIANT     202    202       V -> I (in allele DQB1*03:24).
FT                                /FTId=VAR_062750.
FT   VARIANT     214    214       N -> S (in allele DQB1*02:01, allele
FT                                DQB1*02:02, allele DQB1*02:04, allele
FT                                DQB1*05:01, allele DQB1*05:02, allele
FT                                DQB1*05:03, allele DQB1*06:01, allele
FT                                DQB1*06:02, allele DQB1*06:03, allele
FT                                DQB1*06:04, allele DQB1*06:09, allele
FT                                DQB1*06:12, allele DQB1*06:34, allele
FT                                DQB1*06:36, allele DQB1*06:38 and allele
FT                                DQB1*06:39).
FT                                /FTId=VAR_062751.
FT   VARIANT     217    217       T -> I (in allele DQB1*03:02, allele
FT                                DQB1*03:03, allele DQB1*03:05, allele
FT                                DQB1*03:19, allele DQB1*03:25, allele
FT                                DQB1*04:01 and allele DQB1*04:02).
FT                                /FTId=VAR_062752.
FT   VARIANT     218    218       V -> A (in allele DQB1*06:36).
FT                                /FTId=VAR_062753.
FT   VARIANT     229    229       S -> N (in allele DQB1*06:01).
FT                                /FTId=VAR_062754.
FT   VARIANT     235    235       I -> V (in allele DQB1*05:01, allele
FT                                DQB1*05:02, allele DQB1*05:03, allele
FT                                DQB1*06:02, allele DQB1*06:03, allele
FT                                DQB1*06:04, allele DQB1*06:09, allele
FT                                DQB1*06:12 and allele DQB1*06:36).
FT                                /FTId=VAR_062755.
FT   VARIANT     252    252       H -> R (in allele DQB1*05:01, allele
FT                                DQB1*05:02, allele DQB1*05:03, allele
FT                                DQB1*06:01, allele DQB1*06:02, allele
FT                                DQB1*06:03, allele DQB1*06:04, allele
FT                                DQB1*06:09, allele DQB1*06:12 and allele
FT                                DQB1*06:36; dbSNP:rs1140342).
FT                                /FTId=VAR_062756.
FT   VARIANT     253    253       H -> Q (in allele DQB1*05:01, allele
FT                                DQB1*05:02, allele DQB1*05:03, allele
FT                                DQB1*06:01, allele DQB1*06:02, allele
FT                                DQB1*06:03, allele DQB1*06:04, allele
FT                                DQB1*06:09, allele DQB1*06:12 and allele
FT                                DQB1*06:36).
FT                                /FTId=VAR_062757.
FT   VARIANT     256    256       Q -> R (in allele DQB1*05:01, allele
FT                                DQB1*05:02 and allele DQB1*05:03;
FT                                dbSNP:rs1130432).
FT                                /FTId=VAR_061474.
FT   CONFLICT    111    111       C -> S (in Ref. 71; AAD39697).
FT                                {ECO:0000305}.
FT   CONFLICT    113    113       H -> Q (in Ref. 22; AAF28315).
FT                                {ECO:0000305}.
FT   CONFLICT    173    173       G -> A (in Ref. 24; X76553/X76554).
FT                                {ECO:0000305}.
FT   CONFLICT    214    214       N -> T (in Ref. 8; AAA59770).
FT                                {ECO:0000305}.
FT   STRAND       40     50       {ECO:0000244|PDB:1UVQ}.
FT   TURN         51     54       {ECO:0000244|PDB:1UVQ}.
FT   STRAND       55     64       {ECO:0000244|PDB:1UVQ}.
FT   STRAND       67     73       {ECO:0000244|PDB:1UVQ}.
FT   TURN         74     76       {ECO:0000244|PDB:1UVQ}.
FT   STRAND       78     83       {ECO:0000244|PDB:1UVQ}.
FT   HELIX        84     86       {ECO:0000244|PDB:1UVQ}.
FT   HELIX        87     94       {ECO:0000244|PDB:1UVQ}.
FT   HELIX        97    109       {ECO:0000244|PDB:1UVQ}.
FT   HELIX       111    117       {ECO:0000244|PDB:1UVQ}.
FT   HELIX       119    122       {ECO:0000244|PDB:1UVQ}.
FT   STRAND      130    135       {ECO:0000244|PDB:1UVQ}.
FT   STRAND      141    144       {ECO:0000244|PDB:1JK8}.
FT   STRAND      146    157       {ECO:0000244|PDB:1UVQ}.
FT   STRAND      160    165       {ECO:0000244|PDB:1UVQ}.
FT   STRAND      168    170       {ECO:0000244|PDB:1UVQ}.
FT   STRAND      174    176       {ECO:0000244|PDB:1UVQ}.
FT   STRAND      183    185       {ECO:0000244|PDB:1UVQ}.
FT   STRAND      187    194       {ECO:0000244|PDB:1UVQ}.
FT   STRAND      203    208       {ECO:0000244|PDB:1UVQ}.
FT   STRAND      216    220       {ECO:0000244|PDB:1UVQ}.
SQ   SEQUENCE   261 AA;  29991 MW;  79B1E571A628CF96 CRC64;
     MSWKKALRIP GGLRAATVTL MLAMLSTPVA EGRDSPEDFV YQFKAMCYFT NGTERVRYVT
     RYIYNREEYA RFDSDVEVYR AVTPLGPPDA EYWNSQKEVL ERTRAELDTV CRHNYQLELR
     TTLQRRVEPT VTISPSRTEA LNHHNLLVCS VTDFYPAQIK VRWFRNDQEE TTGVVSTPLI
     RNGDWTFQIL VMLEMTPQHG DVYTCHVEHP SLQNPITVEW RAQSESAQSK MLSGIGGFVL
     GLIFLGLGLI IHHRSQKGLL H
//
ID   A1AT_HUMAN              Reviewed;         418 AA.
AC   P01009; A6PX14; B2RDQ8; Q0PVP5; Q13672; Q53XB8; Q5U0M1; Q7M4R2;
AC   Q86U18; Q86U19; Q96BF9; Q96ES1; Q9P1P0; Q9UCE6; Q9UCM3;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 3.
DT   17-FEB-2016, entry version 225.
DE   RecName: Full=Alpha-1-antitrypsin;
DE   AltName: Full=Alpha-1 protease inhibitor;
DE   AltName: Full=Alpha-1-antiproteinase;
DE   AltName: Full=Serpin A1;
DE   Contains:
DE     RecName: Full=Short peptide from AAT;
DE              Short=SPAAT;
DE   Flags: Precursor;
GN   Name=SERPINA1; Synonyms=AAT, PI; ORFNames=PRO0684, PRO2209;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=6319097; DOI=10.1089/dna.1983.2.255;
RA   Bollen A., Herzog A., Cravador A., Herion P., Chuchana P.,
RA   van der Straten A., Loriau R., Jacobs P., van Elsen A.;
RT   "Cloning and expression in Escherichia coli of full-length
RT   complementary DNA coding for human alpha 1-antitrypsin.";
RL   DNA 2:255-264(1983).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=6093867; DOI=10.1021/bi00316a003;
RA   Long G.L., Chandra T., Woo S.L.C., Davie E.W., Kurachi K.;
RT   "Complete sequence of the cDNA for human alpha 1-antitrypsin and the
RT   gene for the S variant.";
RL   Biochemistry 23:4828-4837(1984).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND MUTAGENESIS OF MET-382.
RX   PubMed=6387509; DOI=10.1038/312077a0;
RA   Rosenberg S., Barr P.J., Najarian R.C., Hallewell R.A.;
RT   "Synthesis in yeast of a functional oxidation-resistant mutant of
RT   human alpha-antitrypsin.";
RL   Nature 312:77-80(1984).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2985281; DOI=10.1016/S0092-8674(85)80026-X;
RA   Ciliberto G., Dente L., Cortese R.;
RT   "Cell-specific expression of a transfected human alpha 1-antitrypsin
RT   gene.";
RL   Cell 41:531-540(1985).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND CHARACTERIZATION OF VARIANT Z.
RX   PubMed=3491072;
RA   Nukiwa T., Satoh K., Brantly M.L., Ogushi F., Fells G.A., Courtney M.,
RA   Crystal R.G.;
RT   "Identification of a second mutation in the protein-coding sequence of
RT   the Z type alpha 1-antitrypsin gene.";
RL   J. Biol. Chem. 261:15989-15994(1986).
RN   [6]
RP   ERRATUM.
RA   Nukiwa T., Satoh K., Brantly M.L., Ogushi F., Fells G.A., Courtney M.,
RA   Crystal R.G.;
RL   J. Biol. Chem. 262:10412-10412(1987).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS ALA-237 AND
RP   ASP-400.
RC   TISSUE=Liver;
RX   PubMed=17650587;
RA   Shasany A.K., Shukla A.K., Darokar M.P., Saraiya M., Chaturvedi N.,
RA   Tewari L., Khanuja S.P.;
RT   "An alpha-1 antitrypsin genetic variant from India.";
RL   Indian J. Biochem. Biophys. 44:176-178(2007).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS TRP-172; ALA-237 AND
RP   LYS-366.
RC   TISSUE=Lymphocyte;
RA   Balduyck M., Porchet N., Aubert J.-P., Zerimech F., Douchain F.,
RA   Verchain S.;
RT   "Characterization of a new variant of alpha1 antitrypsin M Lille
RT   (p.Gly148Trp).";
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Fetal liver;
RA   Zhang C., Yu Y., Zhang S., Ouyang S., Luo L., Wei H., Zhou G.,
RA   Zhou W., Bi J., Zhang Y., Liu M., He F.;
RT   "Functional prediction of the coding sequences of 32 new genes deduced
RT   by analysis of cDNA clones from human fetal liver.";
RL   Submitted (DEC-1998) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3).
RC   TISSUE=Fetal liver, and Placenta;
RA   Li W.B., Gruber C., Jessee J., Polayes D.;
RT   "Full-length cDNA libraries and normalization.";
RL   Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Synovium;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   ALA-237.
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Colon, and Ovary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-67; 196-255 AND 387-418.
RX   PubMed=6979715; DOI=10.1038/297655a0;
RA   Leicht M., Long G.L., Chandra T., Kurachi K., Kidd V.J., Mace M. Jr.,
RA   Davie E.W., Woo S.L.C.;
RT   "Sequence homology and structural comparison between the chromosomal
RT   human alpha 1-antitrypsin and chicken ovalbumin genes.";
RL   Nature 297:655-659(1982).
RN   [15]
RP   PRELIMINARY PROTEIN SEQUENCE OF 25-418 (ISOFORM 1).
RA   Chan S.K.;
RT   "The covalent structure of human alpha1-protease inhibitor.";
RL   Fed. Proc. 41:1016-1016(1982).
RN   [16]
RP   PROTEIN SEQUENCE OF 25-418 (ISOFORM 1).
RX   PubMed=7045697; DOI=10.1038/298329a0;
RA   Carrell R.W., Jeppsson J.-O., Laurell C.-B., Brennan S.O., Owen M.C.,
RA   Vaughan L., Boswell D.R.;
RT   "Structure and variation of human alpha 1-antitrypsin.";
RL   Nature 298:329-334(1982).
RN   [17]
RP   PROTEIN SEQUENCE OF 25-418 (ISOFORM 1), VARIANTS ABERRANT FORM
RP   190-GLY--ARG-198 AND VAL-288, AND FUNCTION.
RC   TISSUE=Blood;
RA   Sinha A.K., Girish G.V.;
RT   "Appearance of an aberrant form of alpha-antitrypsin in the
RT   circulation of chronic cigarette smokers and its effect on the insulin
RT   induced NO synthesis in blood platelets.";
RL   Submitted (AUG-2007) to UniProtKB.
RN   [18]
RP   PROTEIN SEQUENCE OF 25-39, AND FUNCTION.
RC   TISSUE=Ascites;
RX   PubMed=1906855; DOI=10.1111/j.1349-7006.1991.tb01905.x;
RA   Tanaka N., Sekiya S., Takamizawa H., Kato N., Moriyama Y.,
RA   Fujimura S.;
RT   "Characterization of a 54 kDa, alpha 1-antitrypsin-like protein
RT   isolated from ascitic fluid of an endometrial cancer patient.";
RL   Jpn. J. Cancer Res. 82:693-700(1991).
RN   [19]
RP   PROTEIN SEQUENCE OF 30-48 AND 248-257 (ISOFORMS 1/2/3), GLYCOSYLATION
RP   AT ASN-70; ASN-107 AND ASN-271, STRUCTURE OF CARBOHYDRATES,
RP   CYSTEINE-BINDING, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=16622833; DOI=10.1002/pmic.200500751;
RA   Kolarich D., Weber A., Turecek P.L., Schwarz H.P., Altmann F.;
RT   "Comprehensive glyco-proteomic analysis of human alpha1-antitrypsin
RT   and its charge isoforms.";
RL   Proteomics 6:3369-3380(2006).
RN   [20]
RP   PROTEIN SEQUENCE OF 47-66.
RC   TISSUE=Urine;
RX   PubMed=8323530; DOI=10.1006/bbrc.1993.1731;
RA   Umekawa T., Kohri K., Amasaki N., Yamate T., Yoshida K., Yamamoto K.,
RA   Suzuki Y., Sinohara H., Kurita T.;
RT   "Sequencing of a urinary stone protein, identical to alpha-one
RT   antitrypsin, which lacks 22 amino acids.";
RL   Biochem. Biophys. Res. Commun. 193:1049-1053(1993).
RN   [21]
RP   PROTEIN SEQUENCE OF 50-63 AND 161-178 (ISOFORMS 1/2/3), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Brain, and Cajal-Retzius cell;
RA   Lubec G., Afjehi-Sadat L.;
RL   Submitted (MAR-2007) to UniProtKB.
RN   [22]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 292-418 (ISOFORM 1).
RX   PubMed=3876243; DOI=10.1016/0014-5793(85)81056-5;
RA   Riley J.H., Bathurst I.C., Edbrooke M.R., Carrell R.W., Craig R.K.;
RT   "Alpha 1-antitrypsin and serum albumin mRNA accumulation in normal,
RT   acute phase and ZZ human liver.";
RL   FEBS Lett. 189:361-366(1985).
RN   [23]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 350-418 (ISOFORM 1).
RX   PubMed=7031661; DOI=10.1073/pnas.78.11.6826;
RA   Kurachi K., Chandra T., Friezner Degen S.J., White T.T.,
RA   Marchioro T.L., Woo S.L.C., Davie E.W.;
RT   "Cloning and sequence of cDNA coding for alpha 1-antitrypsin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 78:6826-6830(1981).
RN   [24]
RP   PROTEIN SEQUENCE OF 375-414, IDENTIFICATION OF SPAAT, FUNCTION, AND
RP   SUBCELLULAR LOCATION.
RC   TISSUE=Placenta;
RX   PubMed=1406456;
RA   Niemann M.A., Narkates A.J., Miller E.J.;
RT   "Isolation and serine protease inhibitory activity of the 44-residue,
RT   C-terminal fragment of alpha 1-antitrypsin from human placenta.";
RL   Matrix 12:233-241(1992).
RN   [25]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 387-418 (ISOFORM 1).
RX   PubMed=3873938;
RA   Coutelle C., Speer A., Rogers J., Kalsheker N., Humphries S.,
RA   Williamson R.;
RT   "Construction and partial characterization of a human liver cDNA
RT   library.";
RL   Biomed. Biochim. Acta 44:421-431(1985).
RN   [26]
RP   GLYCOSYLATION AT ASN-70 AND ASN-271.
RX   PubMed=12754519; DOI=10.1038/nbt827;
RA   Zhang H., Li X.-J., Martin D.B., Aebersold R.;
RT   "Identification and quantification of N-linked glycoproteins using
RT   hydrazide chemistry, stable isotope labeling and mass spectrometry.";
RL   Nat. Biotechnol. 21:660-666(2003).
RN   [27]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-70 AND ASN-271.
RC   TISSUE=Bile;
RX   PubMed=15084671; DOI=10.1074/mcp.M400015-MCP200;
RA   Kristiansen T.Z., Bunkenborg J., Gronborg M., Molina H.,
RA   Thuluvath P.J., Argani P., Goggins M.G., Maitra A., Pandey A.;
RT   "A proteomic analysis of human bile.";
RL   Mol. Cell. Proteomics 3:715-728(2004).
RN   [28]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-70 AND ASN-271.
RC   TISSUE=Plasma;
RX   PubMed=14760718; DOI=10.1002/pmic.200300556;
RA   Bunkenborg J., Pilch B.J., Podtelejnikov A.V., Wisniewski J.R.;
RT   "Screening for N-glycosylated proteins by liquid chromatography mass
RT   spectrometry.";
RL   Proteomics 4:454-465(2004).
RN   [29]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-70; ASN-107 AND ASN-271.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [30]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-70.
RC   TISSUE=Platelet;
RX   PubMed=16263699; DOI=10.1074/mcp.M500324-MCP200;
RA   Lewandrowski U., Moebius J., Walter U., Sickmann A.;
RT   "Elucidation of N-glycosylation sites on human platelet proteins: a
RT   glycoproteomic approach.";
RL   Mol. Cell. Proteomics 5:226-233(2006).
RN   [31]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-70; ASN-107 AND ASN-271.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [32]
RP   GLYCOSYLATION AT ASN-107 AND ASN-271.
RX   PubMed=19139490; DOI=10.1074/mcp.M800504-MCP200;
RA   Jia W., Lu Z., Fu Y., Wang H.P., Wang L.H., Chi H., Yuan Z.F.,
RA   Zheng Z.B., Song L.N., Han H.H., Liang Y.M., Wang J.L., Cai Y.,
RA   Zhang Y.K., Deng Y.L., Ying W.T., He S.M., Qian X.H.;
RT   "A strategy for precise and large scale identification of core
RT   fucosylated glycoproteins.";
RL   Mol. Cell. Proteomics 8:913-923(2009).
RN   [33]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-70; ASN-107 AND ASN-271,
RP   AND STRUCTURE OF CARBOHYDRATES.
RC   TISSUE=Cerebrospinal fluid;
RX   PubMed=19838169; DOI=10.1038/nmeth.1392;
RA   Nilsson J., Rueetschi U., Halim A., Hesse C., Carlsohn E.,
RA   Brinkmalm G., Larson G.;
RT   "Enrichment of glycopeptides for glycan structure and attachment site
RT   identification.";
RL   Nat. Methods 6:809-811(2009).
RN   [34]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [35]
RP   GLYCOSYLATION AT ASN-70 AND ASN-271, STRUCTURE OF CARBOHYDRATES, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=22171320; DOI=10.1074/mcp.M111.013649;
RA   Halim A., Nilsson J., Ruetschi U., Hesse C., Larson G.;
RT   "Human urinary glycoproteomics; attachment site specific analysis of
RT   N-and O-linked glycosylations by CID and ECD.";
RL   Mol. Cell. Proteomics 0:0-0(2011).
RN   [36]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-383, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [37]
RP   PHOSPHORYLATION AT SER-38.
RX   PubMed=26091039; DOI=10.1016/j.cell.2015.05.028;
RA   Tagliabracci V.S., Wiley S.E., Guo X., Kinch L.N., Durrant E., Wen J.,
RA   Xiao J., Cui J., Nguyen K.B., Engel J.L., Coon J.J., Grishin N.,
RA   Pinna L.A., Pagliarini D.J., Dixon J.E.;
RT   "A single kinase generates the majority of the secreted
RT   phosphoproteome.";
RL   Cell 161:1619-1632(2015).
RN   [38]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS).
RX   PubMed=6332197; DOI=10.1016/0022-2836(84)90298-5;
RA   Loebermann H., Tokuoka R., Deisenhofer J., Huber R.;
RT   "Human alpha 1-proteinase inhibitor. Crystal structure analysis of two
RT   crystal modifications, molecular model and preliminary analysis of the
RT   implications for function.";
RL   J. Mol. Biol. 177:531-556(1984).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS).
RX   PubMed=2785270; DOI=10.1093/protein/2.6.407;
RA   Engh R., Loebermann H., Schneider M., Wiegand G., Huber R.,
RA   Laurell C.-B.;
RT   "The S variant of human alpha 1-antitrypsin, structure and
RT   implications for function and metabolism.";
RL   Protein Eng. 2:407-415(1989).
RN   [41]
RP   X-RAY CRYSTALLOGRAPHY (3.46 ANGSTROMS) OF 25-418.
RX   PubMed=8543039; DOI=10.1016/0014-5793(95)01331-8;
RA   Song H.K., Lee K.N., Kwon K.-S., Yu M.-H., Suh S.W.;
RT   "Crystal structure of an uncleaved alpha 1-antitrypsin reveals the
RT   conformation of its inhibitory reactive loop.";
RL   FEBS Lett. 377:150-154(1995).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 26-418.
RX   PubMed=8756325; DOI=10.1038/nsb0896-676;
RA   Elliott P.R., Lomas D.A., Carrell R.W., Abrahams J.P.;
RT   "Inhibitory conformation of the reactive loop of alpha 1-
RT   antitrypsin.";
RL   Nat. Struct. Biol. 3:676-681(1996).
RN   [43]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 45-418.
RX   PubMed=8939743; DOI=10.1016/S0969-2126(96)00126-8;
RA   Ryu S.-E., Choi H.-J., Kwon K.-S., Lee K.N., Yu M.-H.;
RT   "The native strains in the hydrophobic core and flexible reactive loop
RT   of a serine protease inhibitor: crystal structure of an uncleaved
RT   alpha1-antitrypsin at 2.7 A.";
RL   Structure 4:1181-1192(1996).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 26-418.
RX   PubMed=9466920; DOI=10.1006/jmbi.1997.1458;
RA   Elliott P.R., Abrahams J.P., Lomas D.A.;
RT   "Wild-type alpha 1-antitrypsin is in the canonical inhibitory
RT   conformation.";
RL   J. Mol. Biol. 275:419-425(1998).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 48-418 IN COMPLEX WITH BOVINE
RP   TRYPSIN.
RX   PubMed=11057674; DOI=10.1038/35038119;
RA   Huntington J.A., Read R.J., Carrell R.W.;
RT   "Structure of a serpin-protease complex shows inhibition by
RT   deformation.";
RL   Nature 407:923-926(2000).
RN   [46]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 44-418.
RX   PubMed=10716194; DOI=10.1110/ps.9.2.417;
RA   Dunstone M.A., Dai W., Whisstock J.C., Rossjohn J., Pike R.N.,
RA   Feil S.C., Le Bonniec B.F., Parker M.W., Bottomley S.P.;
RT   "Cleaved antitrypsin polymers at atomic resolution.";
RL   Protein Sci. 9:417-420(2000).
RN   [47]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS).
RX   PubMed=10933492; DOI=10.1110/ps.9.7.1274;
RA   Elliott P.R., Pei X.Y., Dafforn T.R., Lomas D.A.;
RT   "Topography of a 2.0 A structure of alpha1-antitrypsin reveals targets
RT   for rational drug design to prevent conformational disease.";
RL   Protein Sci. 9:1274-1281(2000).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 25-418.
RX   PubMed=11178897; DOI=10.1006/jmbi.2000.4357;
RA   Kim S.-J., Woo J.-R., Seo E.J., Yu M.-H., Ryu S.-E.;
RT   "A 2.1 A resolution structure of an uncleaved alpha(1)-antitrypsin
RT   shows variability of the reactive center and other loops.";
RL   J. Mol. Biol. 306:109-119(2001).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 25-418.
RX   PubMed=12244055; DOI=10.1074/jbc.M207682200;
RA   Im H., Woo M.-S., Hwang K.Y., Yu M.-H.;
RT   "Interactions causing the kinetic trap in serpin protein folding.";
RL   J. Biol. Chem. 277:46347-46354(2002).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 26-418 OF VARIANT PITTSBURGH
RP   ARG-382.
RX   PubMed=12860985; DOI=10.1074/jbc.M305195200;
RA   Dementiev A., Simonovic M., Volz K., Gettins P.G.;
RT   "Canonical inhibitor-like interactions explain reactivity of alpha1-
RT   proteinase inhibitor Pittsburgh and antithrombin with proteinases.";
RL   J. Biol. Chem. 278:37881-37887(2003).
RN   [51]
RP   REVIEW.
RX   PubMed=2669992; DOI=10.1007/BF01115992;
RA   Kalsheker N.;
RT   "Alpha 1-antitrypsin: structure, function and molecular biology of the
RT   gene.";
RL   Biosci. Rep. 9:129-138(1989).
RN   [52]
RP   REVIEW.
RX   PubMed=1859394; DOI=10.1002/bies.950130404;
RA   Wu Y., Foreman R.C.;
RT   "The molecular genetics of alpha 1 antitrypsin deficiency.";
RL   Bioessays 13:163-169(1991).
RN   [53]
RP   CHARACTERIZATION OF VARIANT M2, AND POLYMORPHISM.
RX   PubMed=2901226;
RA   Nukiwa T., Brantly M.L., Ogushi F., Fells G.A., Crystal R.G.;
RT   "Characterization of the gene and protein of the common alpha 1-
RT   antitrypsin normal M2 allele.";
RL   Am. J. Hum. Genet. 43:322-330(1988).
RN   [54]
RP   VARIANT M3 ASP-400.
RX   PubMed=2394452; DOI=10.1007/BF00206766;
RA   Graham A., Hayes K., Weidinger S., Newton C.R., Markham A.F.,
RA   Kalsheker N.A.;
RT   "Characterisation of the alpha-1-antitrypsin M3 gene, a normal
RT   variant.";
RL   Hum. Genet. 85:381-382(1990).
RN   [55]
RP   VARIANT F CYS-247.
RX   PubMed=2035534;
RA   Okayama H., Brantly M., Holmes M., Crystal R.G.;
RT   "Characterization of the molecular basis of the alpha 1-antitrypsin F
RT   allele.";
RL   Am. J. Hum. Genet. 48:1154-1158(1991).
RN   [56]
RP   VARIANT M-HEERLEN LEU-393.
RX   PubMed=2784123; DOI=10.1007/BF00279001;
RA   Hofker M.H., Nukiwa T., van Paassen H.M.B., Nelen M., Kramps J.A.,
RA   Klasen E.C., Frants R.R., Crystal R.G.;
RT   "A Pro-->Leu substitution in codon 369 of the alpha-1-antitrypsin
RT   deficiency variant PI M-Heerlen.";
RL   Hum. Genet. 81:264-268(1989).
RN   [57]
RP   VARIANT M-MALTON PHE-75 DEL.
RX   PubMed=2786335;
RA   Fraizer G.C., Harrold T.R., Hofker M.H., Cox D.W.;
RT   "In-frame single codon deletion in the M-Malton deficiency allele of
RT   alpha 1-antitrypsin.";
RL   Am. J. Hum. Genet. 44:894-902(1989).
RN   [58]
RP   VARIANT M-MINERAL SPRINGS GLU-91.
RX   PubMed=1967187;
RA   Curiel D.T., Vogelmeier C., Hubbard R.C., Stier L.E., Crystal R.G.;
RT   "Molecular basis of alpha 1-antitrypsin deficiency and emphysema
RT   associated with the alpha 1-antitrypsin M-Mineral springs allele.";
RL   Mol. Cell. Biol. 10:47-56(1990).
RN   [59]
RP   VARIANT M-NICHINAN PHE-75 DEL.
RX   PubMed=2309708;
RA   Matsunaga E., Shiokawa S., Nakamura H., Maruyama T., Tsuda K.,
RA   Fukumaki Y.;
RT   "Molecular analysis of the gene of the alpha 1-antitrypsin deficiency
RT   variant, M-Nichinan.";
RL   Am. J. Hum. Genet. 46:602-612(1990).
RN   [60]
RP   VARIANT M-PROCIDA PRO-65.
RX   PubMed=3262617;
RA   Takahashi H., Nukiwa T., Satoh K., Ogushi F., Brantly M., Fells G.,
RA   Stier L., Courtney M., Crystal R.G.;
RT   "Characterization of the gene and protein of the alpha 1-antitrypsin
RT   'deficiency' allele M-Procida.";
RL   J. Biol. Chem. 263:15528-15534(1988).
RN   [61]
RP   VARIANT P-DUARTE VAL-280.
RX   PubMed=8364590; DOI=10.1002/humu.1380020311;
RA   Hildesheim J., Kinsley G., Bissell M., Pierce J., Brantly M.;
RT   "Genetic diversity from a limited repertoire of mutations on different
RT   common allelic backgrounds: alpha 1-antitrypsin deficiency variant P-
RT   Duarte.";
RL   Hum. Mutat. 2:221-228(1993).
RN   [62]
RP   INVOLVEMENT OF VARIANT PITTSBURGH ARG-382 IN BLEEDING DIATHESIS.
RX   PubMed=6604220; DOI=10.1056/NEJM198309223091203;
RA   Owen M.C., Brennan S.O., Lewis J.H., Carrell R.W.;
RT   "Mutation of antitrypsin to antithrombin. Alpha 1-antitrypsin
RT   Pittsburgh (358 Met leads to Arg), a fatal bleeding disorder.";
RL   N. Engl. J. Med. 309:694-698(1983).
RN   [63]
RP   INVOLVEMENT IN A1ATD, AND VARIANT S-IIYAMA PHE-77.
RX   PubMed=1905728;
RA   Seyama K., Nukiwa T., Takabe K., Takahashi H., Miyake K., Kira S.;
RT   "Siiyama (serine 53 (TCC) to phenylalanine 53 (TTC)). A new alpha 1-
RT   antitrypsin-deficient variant with mutation on a predicted conserved
RT   residue of the serpin backbone.";
RL   J. Biol. Chem. 266:12627-12632(1991).
RN   [64]
RP   VARIANT V-MUNICH ALA-26.
RX   PubMed=2316526;
RA   Holmes M.D., Brantly M.L., Curiel D.T., Weidinger S., Crystal R.G.;
RT   "Characterization of the normal alpha 1-antitrypsin allele V-Munich: a
RT   variant associated with a unique protein isoelectric focusing
RT   pattern.";
RL   Am. J. Hum. Genet. 46:810-816(1990).
RN   [65]
RP   INVOLVEMENT IN A1ATD, AND VARIANT W-BETHESDA THR-360.
RX   PubMed=2390072; DOI=10.1016/0006-291X(90)90493-7;
RA   Holmes M.D., Brantly M.L., Fells G.A., Crystal R.G.;
RT   "Alpha 1-antitrypsin W-Bethesda: molecular basis of an unusual alpha
RT   1-antitrypsin deficiency variant.";
RL   Biochem. Biophys. Res. Commun. 170:1013-1020(1990).
RN   [66]
RP   VARIANT Z-AUGSBURG LYS-366.
RX   PubMed=2339709;
RA   Faber J.-P., Weidinger S., Olek K.;
RT   "Sequence data of the rare deficient alpha 1-antitrypsin variant PI
RT   Zaugsburg.";
RL   Am. J. Hum. Genet. 46:1158-1162(1990).
RN   [67]
RP   INVOLVEMENT IN A1ATD, AND VARIANTS Z-WREXHAM LEU-4 AND Q0-NEWPORT
RP   SER-139.
RX   PubMed=2227940; DOI=10.1007/BF00194233;
RA   Graham A., Kalsheker N.A., Bamforth F.J., Newton C.R., Markham A.F.;
RT   "Molecular characterisation of two alpha-1-antitrypsin deficiency
RT   variants: proteinase inhibitor (Pi) Null(Newport) (Gly115-->Ser) and
RT   (Pi) Z Wrexham (Ser-19-->Leu).";
RL   Hum. Genet. 85:537-540(1990).
RN   [68]
RP   VARIANTS P-CARDIFF VAL-280; I CYS-63 AND M-MALTON PHE-75 DEL.
RX   PubMed=2606478; DOI=10.1007/BF00210671;
RA   Graham A., Kalsheker N.A., Newton C.R., Bamforth F.J., Powell S.J.,
RA   Markham A.F.;
RT   "Molecular characterisation of three alpha-1-antitrypsin deficiency
RT   variants: proteinase inhibitor (Pi) nullcardiff (Asp256-->Val); PiM-
RT   Malton (Phe51-->deletion) and PiI (Arg39-->Cys).";
RL   Hum. Genet. 84:55-58(1989).
RN   [69]
RP   VARIANT QO-LUDWIGSHAFEN ASN-116.
RX   PubMed=2254451; DOI=10.1172/JCI114919;
RA   Fraizer G.C., Siewertsen M.A., Hofker M.H., Brubacher M.G., Cox D.W.;
RT   "A null deficiency allele of alpha 1-antitrypsin, QO-Ludwigshafen,
RT   with altered tertiary structure.";
RL   J. Clin. Invest. 86:1878-1884(1990).
RN   [70]
RP   VARIANTS.
RX   PubMed=7977369;
RA   Faber J.-P., Poller W., Weidinger S., Kirchgesser M., Schwaab R.,
RA   Bidlingmaier F., Olek K.;
RT   "Identification and DNA sequence analysis of 15 new alpha 1-
RT   antitrypsin variants, including two PI*Q0 alleles and one deficient
RT   PI*M allele.";
RL   Am. J. Hum. Genet. 55:1113-1121(1994).
RN   [71]
RP   VARIANT Z-BRISTOL MET-109.
RX   PubMed=9459000; DOI=10.1017/S0003480097006404;
RA   Lovegrove J.U., Jeremiah S., Gillett G.T., Temple I.K., Povey S.,
RA   Whitehouse D.B.;
RT   "A new alpha 1-antitrypsin mutation, Thr-Met 85, (PI ZBristol)
RT   associated with novel electrophoretic properties.";
RL   Ann. Hum. Genet. 61:385-391(1997).
RN   [72]
RP   VARIANTS Y-BARCELONA VAL-280 AND HIS-415.
RX   PubMed=10651487;
RA   Jardi R., Rodriguez F., Miravitlles M., Vidal R., Cotrina M., Quer J.,
RA   Pascual C., Weidinger S.;
RT   "Identification and molecular characterization of the new alpha-1-
RT   antitrypsin deficient allele PI YBarcelona (Asp256Val and
RT   Pro391His).";
RL   Hum. Mutat. 12:213-213(1998).
RN   [73]
RP   VARIANT SAO TOME HIS-386.
RA   Seixas S., Trovoada M.J., Santos M.T., Rocha J.;
RT   "A novel alpha-1-antitrypsin P362H variant found in a population
RT   sample from Sao Tome e Principe (Gulf of Guinea, West Africa).";
RL   Hum. Mutat. 13:414-414(1999).
RN   [74]
RP   VARIANT BASQUE ARG-305 DEL.
RX   PubMed=10612848;
RX   DOI=10.1002/(SICI)1098-1004(200001)15:1<121::AID-HUMU37>3.0.CO;2-U;
RA   Seixas S., Garcia O., Amorim A., Rocha J.;
RT   "A novel alpha-1-antitrypsin r281del variant found in a population
RT   sample from the Basque country.";
RL   Hum. Mutat. 15:121-122(2000).
RN   [75]
RP   VARIANTS Z ALA-237 AND LYS-366, VARIANT S VAL-288, SUBCELLULAR
RP   LOCATION, TISSUE SPECIFICITY, GLYCOSYLATION, AND INTERACTION WITH CANX
RP   AND PDIA3.
RX   PubMed=23826168; DOI=10.1371/journal.pone.0066889;
RA   Marques P.I., Ferreira Z., Martins M., Figueiredo J., Silva D.I.,
RA   Castro P., Morales-Hojas R., Simoes-Correia J., Seixas S.;
RT   "SERPINA2 is a novel gene with a divergent function from SERPINA1.";
RL   PLoS ONE 8:E66889-E66889(2013).
CC   -!- FUNCTION: Inhibitor of serine proteases. Its primary target is
CC       elastase, but it also has a moderate affinity for plasmin and
CC       thrombin. Irreversibly inhibits trypsin, chymotrypsin and
CC       plasminogen activator. The aberrant form inhibits insulin-induced
CC       NO synthesis in platelets, decreases coagulation time and has
CC       proteolytic activity against insulin and plasmin.
CC   -!- FUNCTION: Short peptide from AAT: reversible chymotrypsin
CC       inhibitor. It also inhibits elastase, but not trypsin. Its major
CC       physiological function is the protection of the lower respiratory
CC       tract against proteolytic destruction by human leukocyte elastase
CC       (HLE).
CC   -!- SUBUNIT: The variants S and Z interact with CANX AND PDIA3.
CC       {ECO:0000269|PubMed:11057674}.
CC   -!- INTERACTION:
CC       Self; NbExp=5; IntAct=EBI-986224, EBI-986224;
CC       P00760:- (xeno); NbExp=5; IntAct=EBI-986224, EBI-986385;
CC       P00772:CELA1 (xeno); NbExp=2; IntAct=EBI-986224, EBI-986248;
CC       P71213:espB (xeno); NbExp=3; IntAct=EBI-986224, EBI-2615322;
CC       P43307:SSR1; NbExp=4; IntAct=EBI-986224, EBI-714168;
CC   -!- SUBCELLULAR LOCATION: Secreted. Endoplasmic reticulum. Note=The S
CC       and Z allele are not secreted effectively and accumulate
CC       intracellularly in the endoplasmic reticulum.
CC   -!- SUBCELLULAR LOCATION: Short peptide from AAT: Secreted,
CC       extracellular space, extracellular matrix.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P01009-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P01009-2; Sequence=VSP_028889;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=P01009-3; Sequence=VSP_028890;
CC         Note=No experimental confirmation available. May be produced at
CC         very low levels due to a premature stop codon in the mRNA,
CC         leading to nonsense-mediated mRNA decay.;
CC   -!- TISSUE SPECIFICITY: Ubiquitous. Expressed in leukocytes and
CC       plasma. {ECO:0000269|PubMed:23826168}.
CC   -!- DOMAIN: The reactive center loop (RCL) extends out from the body
CC       of the protein and directs binding to the target protease. The
CC       protease cleaves the serpin at the reactive site within the RCL,
CC       establishing a covalent linkage between the carboxyl group of the
CC       serpin reactive site and the serine hydroxyl of the protease. The
CC       resulting inactive serpin-protease complex is highly stable.
CC   -!- PTM: N-glycosylated. Differential glycosylation produces a number
CC       of isoforms. N-linked glycan at Asn-107 is alternatively di-
CC       antennary, tri-antennary or tetra-antennary. The glycan at Asn-70
CC       is di-antennary with trace amounts of tri-antennary. Glycan at
CC       Asn-271 is exclusively di-antennary. Structure of glycans at Asn-
CC       70 and Asn-271 is Hex5HexNAc4. The structure of the antennae is
CC       Neu5Ac(alpha1-6)Gal(beta1-4)GlcNAc attached to the core structure
CC       Man(alpha1-6)[Man(alpha1-3)]Man(beta1-4)GlcNAc(beta1-4)GlcNAc.
CC       Some antennae are fucosylated, which forms a Lewis-X determinant.
CC       {ECO:0000269|PubMed:12754519, ECO:0000269|PubMed:14760718,
CC       ECO:0000269|PubMed:15084671, ECO:0000269|PubMed:16263699,
CC       ECO:0000269|PubMed:16335952, ECO:0000269|PubMed:16622833,
CC       ECO:0000269|PubMed:19139490, ECO:0000269|PubMed:19159218,
CC       ECO:0000269|PubMed:19838169, ECO:0000269|PubMed:22171320,
CC       ECO:0000269|PubMed:23826168}.
CC   -!- PTM: Proteolytic processing may yield the truncated form that
CC       ranges from Asp-30 to Lys-418.
CC   -!- POLYMORPHISM: The sequence shown is that of the M1V allele which
CC       is the most common form of PI (44 to 49%). Other frequent alleles
CC       are: M1A 20 to 23%; M2 10 to 11%; M3 14 to 19%.
CC       {ECO:0000269|PubMed:2901226}.
CC   -!- DISEASE: Alpha-1-antitrypsin deficiency (A1ATD) [MIM:613490]: A
CC       disorder whose most common manifestation is emphysema, which
CC       becomes evident by the third to fourth decade. A less common
CC       manifestation of the deficiency is liver disease, which occurs in
CC       children and adults, and may result in cirrhosis and liver
CC       failure. Environmental factors, particularly cigarette smoking,
CC       greatly increase the risk of emphysema at an earlier age.
CC       {ECO:0000269|PubMed:1905728, ECO:0000269|PubMed:2227940,
CC       ECO:0000269|PubMed:2390072}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: The aberrant form is found in the plasma of chronic
CC       smokers, and persists after smoking is ceased. It can still be
CC       found ten years after smoking has ceased.
CC   -!- SIMILARITY: Belongs to the serpin family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAD62334.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC       Sequence=CAD62585.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Alpha-1 antitrypsin entry;
CC       URL="https://en.wikipedia.org/wiki/Alpha_1-antitrypsin";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; K01396; AAB59375.1; -; mRNA.
DR   EMBL; K02212; AAB59495.1; -; Genomic_DNA.
DR   EMBL; X01683; CAA25838.1; -; mRNA.
DR   EMBL; M11465; AAA51546.1; -; mRNA.
DR   EMBL; J02619; AAA51547.1; -; Genomic_DNA.
DR   EMBL; DQ682455; ABG73380.1; -; mRNA.
DR   EMBL; AM048838; CAJ15161.1; -; Genomic_DNA.
DR   EMBL; AF113676; AAF29581.1; -; mRNA.
DR   EMBL; AF130068; AAG35496.1; -; mRNA.
DR   EMBL; BX161449; CAD61914.1; -; mRNA.
DR   EMBL; BX247968; CAD62306.1; -; mRNA.
DR   EMBL; BX248002; CAD62334.1; ALT_INIT; mRNA.
DR   EMBL; BX248257; CAD62585.1; ALT_INIT; mRNA.
DR   EMBL; AK315637; BAG38005.1; -; mRNA.
DR   EMBL; BT019455; AAV38262.1; -; mRNA.
DR   EMBL; BC011991; AAH11991.1; -; mRNA.
DR   EMBL; BC015642; AAH15642.1; -; mRNA.
DR   EMBL; J00064; AAB59369.1; -; Genomic_DNA.
DR   EMBL; J00066; AAB59370.1; -; Genomic_DNA.
DR   EMBL; J00065; AAB59370.1; JOINED; Genomic_DNA.
DR   EMBL; J00067; AAB59371.1; -; Genomic_DNA.
DR   EMBL; X02920; CAA26677.1; -; mRNA.
DR   EMBL; V00496; CAA23755.1; -; mRNA.
DR   EMBL; M26123; AAA51545.1; -; mRNA.
DR   CCDS; CCDS9925.1; -. [P01009-1]
DR   PIR; A21853; ITHU.
DR   PIR; A61391; A61391.
DR   RefSeq; NP_000286.3; NM_000295.4. [P01009-1]
DR   RefSeq; NP_001002235.1; NM_001002235.2. [P01009-1]
DR   RefSeq; NP_001002236.1; NM_001002236.2. [P01009-1]
DR   RefSeq; NP_001121172.1; NM_001127700.1. [P01009-1]
DR   RefSeq; NP_001121173.1; NM_001127701.1. [P01009-1]
DR   RefSeq; NP_001121174.1; NM_001127702.1. [P01009-1]
DR   RefSeq; NP_001121175.1; NM_001127703.1. [P01009-1]
DR   RefSeq; NP_001121176.1; NM_001127704.1. [P01009-1]
DR   RefSeq; NP_001121177.1; NM_001127705.1. [P01009-1]
DR   RefSeq; NP_001121178.1; NM_001127706.1. [P01009-1]
DR   RefSeq; NP_001121179.1; NM_001127707.1. [P01009-1]
DR   UniGene; Hs.525557; -.
DR   PDB; 1ATU; X-ray; 2.70 A; A=45-418.
DR   PDB; 1D5S; X-ray; 3.00 A; A=44-377, B=378-418.
DR   PDB; 1EZX; X-ray; 2.60 A; A=48-382, B=383-418.
DR   PDB; 1HP7; X-ray; 2.10 A; A=25-418.
DR   PDB; 1IZ2; X-ray; 2.20 A; A=25-418.
DR   PDB; 1KCT; X-ray; 3.46 A; A=25-418.
DR   PDB; 1OO8; X-ray; 2.65 A; A=26-418.
DR   PDB; 1OPH; X-ray; 2.30 A; A=26-418.
DR   PDB; 1PSI; X-ray; 2.92 A; A=26-418.
DR   PDB; 1QLP; X-ray; 2.00 A; A=26-418.
DR   PDB; 1QMB; X-ray; 2.60 A; A=49-376, B=377-418.
DR   PDB; 2D26; X-ray; 3.30 A; A=25-382, B=383-418.
DR   PDB; 2QUG; X-ray; 2.00 A; A=25-418.
DR   PDB; 3CWL; X-ray; 2.44 A; A=25-418.
DR   PDB; 3CWM; X-ray; 2.51 A; A=25-418.
DR   PDB; 3DRM; X-ray; 2.20 A; A=26-418.
DR   PDB; 3DRU; X-ray; 3.20 A; A/B/C=26-418.
DR   PDB; 3NDD; X-ray; 1.50 A; A=46-382, B=383-418.
DR   PDB; 3NDF; X-ray; 2.70 A; A=46-382, B=383-418.
DR   PDB; 3NE4; X-ray; 1.81 A; A=48-418.
DR   PDB; 3T1P; X-ray; 3.90 A; A=48-418.
DR   PDB; 4PYW; X-ray; 1.91 A; A=26-418.
DR   PDB; 7API; X-ray; 3.00 A; A=36-382, B=383-418.
DR   PDB; 8API; X-ray; 3.10 A; A=36-382, B=383-418.
DR   PDB; 9API; X-ray; 3.00 A; A=36-382, B=383-418.
DR   PDBsum; 1ATU; -.
DR   PDBsum; 1D5S; -.
DR   PDBsum; 1EZX; -.
DR   PDBsum; 1HP7; -.
DR   PDBsum; 1IZ2; -.
DR   PDBsum; 1KCT; -.
DR   PDBsum; 1OO8; -.
DR   PDBsum; 1OPH; -.
DR   PDBsum; 1PSI; -.
DR   PDBsum; 1QLP; -.
DR   PDBsum; 1QMB; -.
DR   PDBsum; 2D26; -.
DR   PDBsum; 2QUG; -.
DR   PDBsum; 3CWL; -.
DR   PDBsum; 3CWM; -.
DR   PDBsum; 3DRM; -.
DR   PDBsum; 3DRU; -.
DR   PDBsum; 3NDD; -.
DR   PDBsum; 3NDF; -.
DR   PDBsum; 3NE4; -.
DR   PDBsum; 3T1P; -.
DR   PDBsum; 4PYW; -.
DR   PDBsum; 7API; -.
DR   PDBsum; 8API; -.
DR   PDBsum; 9API; -.
DR   ProteinModelPortal; P01009; -.
DR   SMR; P01009; 48-417.
DR   BioGrid; 111283; 37.
DR   DIP; DIP-35493N; -.
DR   IntAct; P01009; 20.
DR   MINT; MINT-365327; -.
DR   STRING; 9606.ENSP00000348068; -.
DR   MEROPS; I04.001; -.
DR   iPTMnet; P01009; -.
DR   PhosphoSite; P01009; -.
DR   UniCarbKB; P01009; -.
DR   BioMuta; SERPINA1; -.
DR   DMDM; 1703025; -.
DR   DOSAC-COBS-2DPAGE; P01009; -.
DR   OGP; P01009; -.
DR   REPRODUCTION-2DPAGE; IPI00553177; -.
DR   REPRODUCTION-2DPAGE; P01009; -.
DR   SWISS-2DPAGE; P01009; -.
DR   UCD-2DPAGE; P01009; -.
DR   MaxQB; P01009; -.
DR   PaxDb; P01009; -.
DR   PRIDE; P01009; -.
DR   DNASU; 5265; -.
DR   Ensembl; ENST00000355814; ENSP00000348068; ENSG00000197249. [P01009-1]
DR   Ensembl; ENST00000393087; ENSP00000376802; ENSG00000197249. [P01009-1]
DR   Ensembl; ENST00000393088; ENSP00000376803; ENSG00000197249. [P01009-1]
DR   Ensembl; ENST00000402629; ENSP00000386094; ENSG00000197249. [P01009-2]
DR   Ensembl; ENST00000404814; ENSP00000385960; ENSG00000197249. [P01009-1]
DR   Ensembl; ENST00000437397; ENSP00000408474; ENSG00000197249. [P01009-1]
DR   Ensembl; ENST00000440909; ENSP00000390299; ENSG00000197249. [P01009-1]
DR   Ensembl; ENST00000448921; ENSP00000416066; ENSG00000197249. [P01009-1]
DR   Ensembl; ENST00000449399; ENSP00000416354; ENSG00000197249. [P01009-1]
DR   Ensembl; ENST00000489769; ENSP00000451525; ENSG00000197249. [P01009-3]
DR   GeneID; 5265; -.
DR   KEGG; hsa:5265; -.
DR   UCSC; uc001ycx.4; human. [P01009-1]
DR   UCSC; uc001yda.1; human. [P01009-2]
DR   CTD; 5265; -.
DR   GeneCards; SERPINA1; -.
DR   GeneReviews; SERPINA1; -.
DR   HGNC; HGNC:8941; SERPINA1.
DR   HPA; CAB013211; -.
DR   HPA; CAB016648; -.
DR   HPA; CAB073396; -.
DR   HPA; HPA000927; -.
DR   HPA; HPA001292; -.
DR   MalaCards; SERPINA1; -.
DR   MIM; 107400; gene.
DR   MIM; 613490; phenotype.
DR   neXtProt; NX_P01009; -.
DR   Orphanet; 60; Alpha-1-antitrypsin deficiency.
DR   Orphanet; 178396; Hemorrhagic disease due to alpha-1-antitrypsin Pittsburgh mutation.
DR   PharmGKB; PA35509; -.
DR   eggNOG; KOG2392; Eukaryota.
DR   eggNOG; COG4826; LUCA.
DR   GeneTree; ENSGT00760000118839; -.
DR   HOVERGEN; HBG005957; -.
DR   InParanoid; P01009; -.
DR   KO; K03984; -.
DR   OMA; NITEMSE; -.
DR   OrthoDB; EOG7QC7W9; -.
DR   PhylomeDB; P01009; -.
DR   TreeFam; TF343201; -.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-204005; COPII (Coat Protein 2) Mediated Vesicle Transport.
DR   Reactome; R-HSA-5694530; Cargo concentration in the ER.
DR   ChiTaRS; SERPINA1; human.
DR   EvolutionaryTrace; P01009; -.
DR   GeneWiki; Alpha_1-antitrypsin; -.
DR   GenomeRNAi; 5265; -.
DR   NextBio; 20336; -.
DR   PMAP-CutDB; P01009; -.
DR   PRO; PR:P01009; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   Bgee; P01009; -.
DR   ExpressionAtlas; P01009; baseline and differential.
DR   Genevisible; P01009; HS.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0033116; C:endoplasmic reticulum-Golgi intermediate compartment membrane; TAS:Reactome.
DR   GO; GO:0030134; C:ER to Golgi transport vesicle; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; NAS:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0000139; C:Golgi membrane; TAS:GOC.
DR   GO; GO:0031093; C:platelet alpha granule lumen; TAS:Reactome.
DR   GO; GO:0005578; C:proteinaceous extracellular matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0001948; F:glycoprotein binding; IPI:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0002020; F:protease binding; IPI:UniProtKB.
DR   GO; GO:0004867; F:serine-type endopeptidase inhibitor activity; NAS:UniProtKB.
DR   GO; GO:0006953; P:acute-phase response; IEA:UniProtKB-KW.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0048208; P:COPII vesicle coating; TAS:Reactome.
DR   GO; GO:0006888; P:ER to Golgi vesicle-mediated transport; TAS:Reactome.
DR   GO; GO:0061024; P:membrane organization; TAS:Reactome.
DR   GO; GO:0010951; P:negative regulation of endopeptidase activity; IDA:GOC.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   GO; GO:0043687; P:post-translational protein modification; TAS:Reactome.
DR   GO; GO:0018279; P:protein N-linked glycosylation via asparagine; TAS:Reactome.
DR   InterPro; IPR023795; Serpin_CS.
DR   InterPro; IPR023796; Serpin_dom.
DR   InterPro; IPR000215; Serpin_fam.
DR   PANTHER; PTHR11461; PTHR11461; 1.
DR   Pfam; PF00079; Serpin; 1.
DR   SMART; SM00093; SERPIN; 1.
DR   SUPFAM; SSF56574; SSF56574; 1.
DR   PROSITE; PS00284; SERPIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acute phase; Alternative splicing; Blood coagulation;
KW   Complete proteome; Direct protein sequencing; Endoplasmic reticulum;
KW   Extracellular matrix; Glycoprotein; Hemostasis; Phosphoprotein;
KW   Polymorphism; Protease inhibitor; Reference proteome; Secreted;
KW   Serine protease inhibitor; Signal.
FT   SIGNAL        1     24       {ECO:0000269|PubMed:1906855}.
FT   CHAIN        25    418       Alpha-1-antitrypsin.
FT                                {ECO:0000269|PubMed:6093867}.
FT                                /FTId=PRO_0000032377.
FT   PEPTIDE     375    418       Short peptide from AAT.
FT                                /FTId=PRO_0000364030.
FT   REGION      368    392       RCL.
FT   SITE        382    383       Reactive bond.
FT   MOD_RES      38     38       Phosphoserine; by FAM20C.
FT                                {ECO:0000269|PubMed:26091039}.
FT   MOD_RES     256    256       S-cysteinyl cysteine.
FT   MOD_RES     383    383       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   CARBOHYD     70     70       N-linked (GlcNAc...) (complex).
FT                                {ECO:0000269|PubMed:12754519,
FT                                ECO:0000269|PubMed:14760718,
FT                                ECO:0000269|PubMed:15084671,
FT                                ECO:0000269|PubMed:16263699,
FT                                ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:16622833,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:19838169,
FT                                ECO:0000269|PubMed:22171320}.
FT   CARBOHYD    107    107       N-linked (GlcNAc...) (complex).
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:16622833,
FT                                ECO:0000269|PubMed:19139490,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:19838169}.
FT   CARBOHYD    271    271       N-linked (GlcNAc...) (complex).
FT                                {ECO:0000269|PubMed:12754519,
FT                                ECO:0000269|PubMed:14760718,
FT                                ECO:0000269|PubMed:15084671,
FT                                ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:16622833,
FT                                ECO:0000269|PubMed:19139490,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:19838169,
FT                                ECO:0000269|PubMed:22171320}.
FT   VAR_SEQ     307    418       Missing (in isoform 3).
FT                                {ECO:0000303|Ref.10}.
FT                                /FTId=VSP_028890.
FT   VAR_SEQ     356    418       AVHKAVLTIDEKGTEAAGAMFLEAIPMSIPPEVKFNKPFVF
FT                                LMIEQNTKSPLFMGKVVNPTQK -> VRSP (in
FT                                isoform 2). {ECO:0000303|Ref.10}.
FT                                /FTId=VSP_028889.
FT   VARIANT       4      4       S -> L (in Z-Wrexham).
FT                                {ECO:0000269|PubMed:2227940}.
FT                                /FTId=VAR_006978.
FT   VARIANT      26     26       D -> A (in V-Munich).
FT                                {ECO:0000269|PubMed:2316526}.
FT                                /FTId=VAR_006979.
FT   VARIANT      37     37       T -> A (in dbSNP:rs11558262).
FT                                /FTId=VAR_051938.
FT   VARIANT      58     58       A -> T (in M5-Karlsruhe).
FT                                /FTId=VAR_006980.
FT   VARIANT      63     63       R -> C (in I; dbSNP:rs28931570).
FT                                {ECO:0000269|PubMed:2606478}.
FT                                /FTId=VAR_006981.
FT   VARIANT      65     65       L -> P (in M-Procida; dbSNP:rs28931569).
FT                                {ECO:0000269|PubMed:3262617}.
FT                                /FTId=VAR_006982.
FT   VARIANT      69     69       S -> F (in M6-Bonn).
FT                                /FTId=VAR_006983.
FT   VARIANT      75     75       Missing (in M-Malton, M-Nichinan and M-
FT                                Palermo; associated with very low serum
FT                                levels of AAT; homozygosity for allele M-
FT                                Malton may be associated with a risk for
FT                                chronic emphysema or infantile liver
FT                                cirrhosis). {ECO:0000269|PubMed:2309708,
FT                                ECO:0000269|PubMed:2606478,
FT                                ECO:0000269|PubMed:2786335}.
FT                                /FTId=VAR_006984.
FT   VARIANT      77     77       S -> F (in S-Iiyama; dbSNP:rs55819880).
FT                                {ECO:0000269|PubMed:1905728}.
FT                                /FTId=VAR_006985.
FT   VARIANT      84     84       A -> T (in M6-Passau).
FT                                /FTId=VAR_006986.
FT   VARIANT      91     91       G -> E (in M-Mineral springs; causes
FT                                reduced AAT secretion; dbSNP:rs28931568).
FT                                {ECO:0000269|PubMed:1967187}.
FT                                /FTId=VAR_006987.
FT   VARIANT      92     92       T -> I (in QO-Lisbon; deficient AAT with
FT                                very low serum levels).
FT                                /FTId=VAR_006988.
FT   VARIANT     109    109       T -> M (in Z-Bristol; deficient AA;
FT                                disrupts the N-glycosylation site N-107).
FT                                {ECO:0000269|PubMed:9459000}.
FT                                /FTId=VAR_011620.
FT   VARIANT     112    112       P -> T (in M5-Berlin).
FT                                /FTId=VAR_006989.
FT   VARIANT     116    116       I -> N (in QO-Ludwigshafen;
FT                                dbSNP:rs28931572).
FT                                {ECO:0000269|PubMed:2254451}.
FT                                /FTId=VAR_006990.
FT   VARIANT     125    125       R -> H (in M2; associated with D-400;
FT                                dbSNP:rs709932).
FT                                /FTId=VAR_006991.
FT   VARIANT     139    139       G -> S (in QO-Newport; dbSNP:rs11558261).
FT                                {ECO:0000269|PubMed:2227940}.
FT                                /FTId=VAR_006992.
FT   VARIANT     172    172       G -> R (in V and M-Nichinan).
FT                                /FTId=VAR_006993.
FT   VARIANT     172    172       G -> W (in M2-Obernburg).
FT                                {ECO:0000269|Ref.8}.
FT                                /FTId=VAR_006994.
FT   VARIANT     180    180       Q -> E (in L-Frankfurt).
FT                                /FTId=VAR_006995.
FT   VARIANT     190    198       QGKIVDLVK -> GFQNAILVR (in Aberrant
FT                                form).
FT                                /FTId=VAR_036746.
FT   VARIANT     228    228       E -> K (in X).
FT                                /FTId=VAR_006996.
FT   VARIANT     237    237       V -> A (in M1A and Z; associated with K-
FT                                366 in Z; dbSNP:rs6647).
FT                                {ECO:0000269|PubMed:17650587,
FT                                ECO:0000269|PubMed:23826168,
FT                                ECO:0000269|Ref.12, ECO:0000269|Ref.8}.
FT                                /FTId=VAR_006997.
FT   VARIANT     247    247       R -> C (in F; dbSNP:rs28929470).
FT                                {ECO:0000269|PubMed:2035534}.
FT                                /FTId=VAR_006998.
FT   VARIANT     280    280       D -> V (in P-Duarte/P-Cardiff/P-Lowell;
FT                                associated with H-415 in Y-Barcelona;
FT                                dbSNP:rs28929472).
FT                                {ECO:0000269|PubMed:10651487,
FT                                ECO:0000269|PubMed:2606478,
FT                                ECO:0000269|PubMed:8364590}.
FT                                /FTId=VAR_006999.
FT   VARIANT     288    288       E -> V (in S and T; dbSNP:rs17580).
FT                                {ECO:0000269|PubMed:23826168,
FT                                ECO:0000269|Ref.17}.
FT                                /FTId=VAR_007000.
FT   VARIANT     305    305       Missing (in Basque).
FT                                {ECO:0000269|PubMed:10612848}.
FT                                /FTId=VAR_009216.
FT   VARIANT     354    354       S -> F (in S-Munich).
FT                                /FTId=VAR_007001.
FT   VARIANT     360    360       A -> T (in W-Bethesda; dbSNP:rs1802959).
FT                                {ECO:0000269|PubMed:2390072}.
FT                                /FTId=VAR_007002.
FT   VARIANT     365    365       D -> N (in P-St.Albans/P-Donauwoerth).
FT                                /FTId=VAR_007003.
FT   VARIANT     366    366       E -> K (in Z/Z-Augsburg/Z-Tun; associated
FT                                with A-237 in Z; dbSNP:rs28929474).
FT                                {ECO:0000269|PubMed:2339709,
FT                                ECO:0000269|PubMed:23826168,
FT                                ECO:0000269|Ref.8}.
FT                                /FTId=VAR_007004.
FT   VARIANT     382    382       M -> R (in Pittsburgh; has antithrombin
FT                                activity; causes fatal bleeding
FT                                diathesis).
FT                                {ECO:0000269|PubMed:12860985}.
FT                                /FTId=VAR_007005.
FT   VARIANT     386    386       P -> H (in Sao Tome).
FT                                {ECO:0000269|Ref.73}.
FT                                /FTId=VAR_007006.
FT   VARIANT     386    386       P -> T (in L-Offenbach).
FT                                /FTId=VAR_007007.
FT   VARIANT     387    387       E -> K (in Christchurch;
FT                                dbSNP:rs121912712).
FT                                /FTId=VAR_007008.
FT   VARIANT     393    393       P -> L (in M-Heerlen).
FT                                {ECO:0000269|PubMed:2784123}.
FT                                /FTId=VAR_007009.
FT   VARIANT     400    400       E -> D (in M2 and M3; associated with H-
FT                                125 in M2; dbSNP:rs1303).
FT                                {ECO:0000269|PubMed:17650587,
FT                                ECO:0000269|PubMed:2394452}.
FT                                /FTId=VAR_007010.
FT   VARIANT     415    415       P -> H (in Y-Barcelona; associated with
FT                                V-280). {ECO:0000269|PubMed:10651487}.
FT                                /FTId=VAR_007011.
FT   MUTAGEN     382    382       M->V: Oxidation-resistant inhibitor of
FT                                therapeutic importance.
FT                                {ECO:0000269|PubMed:6387509}.
FT   CONFLICT     12     12       Missing (in Ref. 4; AAA51546).
FT                                {ECO:0000305}.
FT   CONFLICT     23     23       L -> P (in Ref. 11; BAG38005).
FT                                {ECO:0000305}.
FT   CONFLICT     26     26       D -> H (in Ref. 18; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT     39     39       H -> L (in Ref. 18; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT     61     61       L -> P (in Ref. 9; AAF29581).
FT                                {ECO:0000305}.
FT   CONFLICT     96     96       T -> A (in Ref. 7; ABG73380).
FT                                {ECO:0000305}.
FT   CONFLICT    139    140       GN -> DG (in Ref. 1; AAB59375).
FT                                {ECO:0000305}.
FT   CONFLICT    174    174       T -> H (in Ref. 4; AAA51546).
FT                                {ECO:0000305}.
FT   CONFLICT    229    229       E -> D (in Ref. 4; AAA51546).
FT                                {ECO:0000305}.
FT   CONFLICT    273    273       T -> N (in Ref. 1; AAB59375).
FT                                {ECO:0000305}.
FT   CONFLICT    280    280       D -> G (in Ref. 7; ABG73380).
FT                                {ECO:0000305}.
FT   CONFLICT    326    326       V -> I (in Ref. 3; CAA25838).
FT                                {ECO:0000305}.
FT   CONFLICT    410    410       G -> L (in Ref. 24; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    414    414       N -> S (in Ref. 24; AA sequence).
FT                                {ECO:0000305}.
FT   TURN         48     50       {ECO:0000244|PDB:1HP7}.
FT   HELIX        51     68       {ECO:0000244|PDB:3NDD}.
FT   STRAND       70     72       {ECO:0000244|PDB:3NE4}.
FT   STRAND       74     76       {ECO:0000244|PDB:3NDD}.
FT   HELIX        78     89       {ECO:0000244|PDB:3NDD}.
FT   HELIX        94    103       {ECO:0000244|PDB:3NDD}.
FT   TURN        108    110       {ECO:0000244|PDB:3NDD}.
FT   HELIX       113    127       {ECO:0000244|PDB:3NDD}.
FT   STRAND      135    145       {ECO:0000244|PDB:3NDD}.
FT   STRAND      146    148       {ECO:0000244|PDB:1ATU}.
FT   HELIX       152    162       {ECO:0000244|PDB:3NDD}.
FT   STRAND      164    169       {ECO:0000244|PDB:3NDD}.
FT   STRAND      171    173       {ECO:0000244|PDB:1ATU}.
FT   HELIX       174    188       {ECO:0000244|PDB:3NDD}.
FT   TURN        189    191       {ECO:0000244|PDB:3NDD}.
FT   STRAND      206    220       {ECO:0000244|PDB:3NDD}.
FT   HELIX       224    226       {ECO:0000244|PDB:3NDD}.
FT   STRAND      228    235       {ECO:0000244|PDB:3NDD}.
FT   STRAND      238    256       {ECO:0000244|PDB:3NDD}.
FT   TURN        257    260       {ECO:0000244|PDB:3NDD}.
FT   STRAND      261    279       {ECO:0000244|PDB:3NDD}.
FT   STRAND      280    282       {ECO:0000244|PDB:1ATU}.
FT   HELIX       284    290       {ECO:0000244|PDB:3NDD}.
FT   HELIX       293    301       {ECO:0000244|PDB:3NDD}.
FT   STRAND      306    313       {ECO:0000244|PDB:3NDD}.
FT   STRAND      315    322       {ECO:0000244|PDB:3NDD}.
FT   HELIX       324    329       {ECO:0000244|PDB:3NDD}.
FT   HELIX       334    336       {ECO:0000244|PDB:3NDD}.
FT   TURN        337    339       {ECO:0000244|PDB:1QMB}.
FT   TURN        343    345       {ECO:0000244|PDB:3NDD}.
FT   STRAND      347    349       {ECO:0000244|PDB:3NDD}.
FT   STRAND      351    364       {ECO:0000244|PDB:3NDD}.
FT   STRAND      366    381       {ECO:0000244|PDB:3NDD}.
FT   STRAND      387    389       {ECO:0000244|PDB:3NDD}.
FT   STRAND      394    400       {ECO:0000244|PDB:3NDD}.
FT   TURN        401    403       {ECO:0000244|PDB:3NDD}.
FT   STRAND      406    414       {ECO:0000244|PDB:3NDD}.
SQ   SEQUENCE   418 AA;  46737 MW;  7016555F273B7F16 CRC64;
     MPSSVSWGIL LLAGLCCLVP VSLAEDPQGD AAQKTDTSHH DQDHPTFNKI TPNLAEFAFS
     LYRQLAHQSN STNIFFSPVS IATAFAMLSL GTKADTHDEI LEGLNFNLTE IPEAQIHEGF
     QELLRTLNQP DSQLQLTTGN GLFLSEGLKL VDKFLEDVKK LYHSEAFTVN FGDTEEAKKQ
     INDYVEKGTQ GKIVDLVKEL DRDTVFALVN YIFFKGKWER PFEVKDTEEE DFHVDQVTTV
     KVPMMKRLGM FNIQHCKKLS SWVLLMKYLG NATAIFFLPD EGKLQHLENE LTHDIITKFL
     ENEDRRSASL HLPKLSITGT YDLKSVLGQL GITKVFSNGA DLSGVTEEAP LKLSKAVHKA
     VLTIDEKGTE AAGAMFLEAI PMSIPPEVKF NKPFVFLMIE QNTKSPLFMG KVVNPTQK
//
ID   TGFB2_RAT               Reviewed;         442 AA.
AC   Q07257; Q63574; Q9QW26; Q9R281; Q9R298; Q9R2B8; Q9WUQ8;
DT   01-OCT-1994, integrated into UniProtKB/Swiss-Prot.
DT   15-MAY-2002, sequence version 2.
DT   17-FEB-2016, entry version 134.
DE   RecName: Full=Transforming growth factor beta-2;
DE            Short=TGF-beta-2;
DE   Contains:
DE     RecName: Full=Latency-associated peptide;
DE              Short=LAP;
DE   Flags: Precursor;
GN   Name=Tgfb2;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS TGF-BETA2A AND TGF-BETA2B),
RP   TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, AND INDUCTION.
RC   STRAIN=Wistar; TISSUE=Muscle;
RX   PubMed=10899565; DOI=10.1016/S0304-419X(00)00012-3;
RA   Koishi K., Dalzell K.G., McLennan I.S.;
RT   "The expression and structure of TGF-beta2 transcripts in rat
RT   muscles.";
RL   Biochim. Biophys. Acta 1492:311-319(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TGF-BETA2A).
RC   STRAIN=Wistar;
RX   PubMed=11014222; DOI=10.1210/en.141.10.3679;
RA   Konrad L., Albrecht M., Renneberg H., Aumuller G.;
RT   "Transforming growth factor-beta2 mediates mesenchymal-epithelial
RT   interactions of testicular somatic cells.";
RL   Endocrinology 141:3679-3686(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TGF-BETA2A).
RA   Plisov S.Y., Ivanov S.V., Plisova T.M., Lerman M., Perantoni A.O.;
RT   "Rat transforming growth factor-beta2, complete coding sequence.";
RL   Submitted (MAR-1999) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 278-348.
RX   PubMed=8509457; DOI=10.1083/jcb.121.6.1397;
RA   McKinnon R.D., Piras G., Ida J., Dubois-Dalq M.;
RT   "A role for TGF-beta in oligodendrocyte differentiation.";
RL   J. Cell Biol. 121:1397-1407(1993).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 366-441.
RC   STRAIN=Sprague-Dawley; TISSUE=Heart;
RX   PubMed=8486763; DOI=10.1172/JCI116412;
RA   Nishida M., Springhorn J.P., Kelly R.A., Smith T.W.;
RT   "Cell-cell signaling between adult rat ventricular myocytes and
RT   cardiac microvascular endothelial cells in heterotypic primary
RT   culture.";
RL   J. Clin. Invest. 91:1934-1941(1993).
CC   -!- FUNCTION: TGF-beta 2 has suppressive effects on interleukin-2
CC       dependent T-cell growth.
CC   -!- SUBUNIT: Homodimer; disulfide-linked. Heterodimers with TGFB1 and
CC       with TGFB3 have been found in bone. Interacts with ASPN and the
CC       serine proteases, HTRA1 and HTRA3. Latency-associated peptide
CC       interacts with NREP; the interaction results in a decrease in
CC       TGFB2 autoinduction. Interacts with MFAP5 (By similarity).
CC       {ECO:0000250|UniProtKB:P27090, ECO:0000250|UniProtKB:P61812}.
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=TGF-beta2B;
CC         IsoId=Q07257-1; Sequence=Displayed;
CC       Name=TGF-beta2A;
CC         IsoId=Q07257-2; Sequence=VSP_006418, VSP_006419;
CC   -!- TISSUE SPECIFICITY: Isoform TGF-beta2B expressed in the aorta,
CC       primary bronchus, uterus, heart, skeletal muscle, sciatic nerve
CC       and spinal cord but not in the intestine.
CC       {ECO:0000269|PubMed:10899565}.
CC   -!- DEVELOPMENTAL STAGE: High expression at E14. Sharp decline in
CC       expression between E16 and E18. Absent in adulthood.
CC       {ECO:0000269|PubMed:10899565}.
CC   -!- INDUCTION: Both isoforms down-regulated during muscle development.
CC       Up-regulated after denervation. {ECO:0000269|PubMed:10899565}.
CC   -!- PTM: The precursor is cleaved into mature TGF-beta-2 and LAP,
CC       which remains non-covalently linked to mature TGF-beta-2 rendering
CC       it inactive. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the TGF-beta family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF153012; AAD34159.1; -; mRNA.
DR   EMBL; AF153013; AAD34160.1; -; mRNA.
DR   EMBL; AJ132718; CAB42003.1; -; mRNA.
DR   EMBL; AF135598; AAD24484.1; -; mRNA.
DR   EMBL; X71904; CAA50723.1; -; mRNA.
DR   EMBL; M96643; AAA88514.1; ALT_SEQ; mRNA.
DR   PIR; A40699; A40699.
DR   RefSeq; NP_112393.1; NM_031131.1. [Q07257-1]
DR   RefSeq; XP_006250510.1; XM_006250448.2. [Q07257-2]
DR   UniGene; Rn.24539; -.
DR   ProteinModelPortal; Q07257; -.
DR   SMR; Q07257; 331-442.
DR   STRING; 10116.ENSRNOP00000003313; -.
DR   PaxDb; Q07257; -.
DR   Ensembl; ENSRNOT00000087023; ENSRNOP00000074059; ENSRNOG00000002418. [Q07257-2]
DR   GeneID; 81809; -.
DR   KEGG; rno:81809; -.
DR   UCSC; RGD:70491; rat. [Q07257-1]
DR   CTD; 7042; -.
DR   RGD; 70491; Tgfb2.
DR   eggNOG; KOG3900; Eukaryota.
DR   eggNOG; ENOG410XT8Z; LUCA.
DR   GeneTree; ENSGT00760000119112; -.
DR   HOVERGEN; HBG074115; -.
DR   InParanoid; Q07257; -.
DR   KO; K13376; -.
DR   PhylomeDB; Q07257; -.
DR   NextBio; 615687; -.
DR   PRO; PR:Q07257; -.
DR   Proteomes; UP000002494; Chromosome 13.
DR   ExpressionAtlas; Q07257; baseline and differential.
DR   GO; GO:0030424; C:axon; ISS:UniProtKB.
DR   GO; GO:0005604; C:basement membrane; IDA:RGD.
DR   GO; GO:0009986; C:cell surface; IDA:RGD.
DR   GO; GO:0005737; C:cytoplasm; IDA:RGD.
DR   GO; GO:0031012; C:extracellular matrix; ISS:AgBase.
DR   GO; GO:0005576; C:extracellular region; ISS:AgBase.
DR   GO; GO:0005615; C:extracellular space; IDA:RGD.
DR   GO; GO:0005622; C:intracellular; ISS:GOC.
DR   GO; GO:0043025; C:neuronal cell body; ISS:UniProtKB.
DR   GO; GO:0030141; C:secretory granule; IDA:RGD.
DR   GO; GO:0005802; C:trans-Golgi network; IDA:RGD.
DR   GO; GO:0001540; F:beta-amyloid binding; ISS:AgBase.
DR   GO; GO:0005125; F:cytokine activity; IBA:GO_Central.
DR   GO; GO:0046982; F:protein heterodimerization activity; IDA:RGD.
DR   GO; GO:0042803; F:protein homodimerization activity; ISS:AgBase.
DR   GO; GO:0047485; F:protein N-terminus binding; IMP:RGD.
DR   GO; GO:0005102; F:receptor binding; ISS:AgBase.
DR   GO; GO:0004702; F:receptor signaling protein serine/threonine kinase activity; ISS:AgBase.
DR   GO; GO:0005160; F:transforming growth factor beta receptor binding; ISS:AgBase.
DR   GO; GO:0005114; F:type II transforming growth factor beta receptor binding; ISS:AgBase.
DR   GO; GO:0034714; F:type III transforming growth factor beta receptor binding; ISS:AgBase.
DR   GO; GO:0032147; P:activation of protein kinase activity; ISS:AgBase.
DR   GO; GO:0007568; P:aging; IEP:RGD.
DR   GO; GO:0060317; P:cardiac epithelial to mesenchymal transition; ISS:AgBase.
DR   GO; GO:0060038; P:cardiac muscle cell proliferation; ISS:AgBase.
DR   GO; GO:0010002; P:cardioblast differentiation; ISS:AgBase.
DR   GO; GO:0042637; P:catagen; ISS:UniProtKB.
DR   GO; GO:0007050; P:cell cycle arrest; ISS:AgBase.
DR   GO; GO:0008219; P:cell death; ISS:AgBase.
DR   GO; GO:0048468; P:cell development; IBA:GO_Central.
DR   GO; GO:0016049; P:cell growth; IEA:InterPro.
DR   GO; GO:0016477; P:cell migration; ISS:AgBase.
DR   GO; GO:0000902; P:cell morphogenesis; ISS:AgBase.
DR   GO; GO:0045216; P:cell-cell junction organization; ISS:AgBase.
DR   GO; GO:0030199; P:collagen fibril organization; ISS:AgBase.
DR   GO; GO:0048565; P:digestive tract development; IEP:RGD.
DR   GO; GO:0042416; P:dopamine biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0048566; P:embryonic digestive tract development; ISS:AgBase.
DR   GO; GO:0048702; P:embryonic neurocranium morphogenesis; IDA:RGD.
DR   GO; GO:0001837; P:epithelial to mesenchymal transition; ISS:AgBase.
DR   GO; GO:0097191; P:extrinsic apoptotic signaling pathway; ISS:AgBase.
DR   GO; GO:0001654; P:eye development; ISS:AgBase.
DR   GO; GO:0007565; P:female pregnancy; IEP:RGD.
DR   GO; GO:0060364; P:frontal suture morphogenesis; IEP:RGD.
DR   GO; GO:0008347; P:glial cell migration; ISS:AgBase.
DR   GO; GO:0001942; P:hair follicle development; ISS:AgBase.
DR   GO; GO:0031069; P:hair follicle morphogenesis; ISS:UniProtKB.
DR   GO; GO:0007507; P:heart development; ISS:AgBase.
DR   GO; GO:0003007; P:heart morphogenesis; ISS:AgBase.
DR   GO; GO:0030097; P:hemopoiesis; ISS:UniProtKB.
DR   GO; GO:0030902; P:hindbrain development; IEP:RGD.
DR   GO; GO:0048839; P:inner ear development; IEP:RGD.
DR   GO; GO:0001822; P:kidney development; IEP:RGD.
DR   GO; GO:0030324; P:lung development; TAS:RGD.
DR   GO; GO:0010693; P:negative regulation of alkaline phosphatase activity; ISS:AgBase.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:RGD.
DR   GO; GO:0030308; P:negative regulation of cell growth; ISS:AgBase.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; ISS:AgBase.
DR   GO; GO:0050680; P:negative regulation of epithelial cell proliferation; ISS:AgBase.
DR   GO; GO:0050777; P:negative regulation of immune response; IDA:RGD.
DR   GO; GO:0010936; P:negative regulation of macrophage cytokine production; ISS:AgBase.
DR   GO; GO:0051280; P:negative regulation of release of sequestered calcium ion into cytosol; IDA:RGD.
DR   GO; GO:0048666; P:neuron development; ISS:UniProtKB.
DR   GO; GO:0030593; P:neutrophil chemotaxis; ISS:UniProtKB.
DR   GO; GO:0031016; P:pancreas development; IEP:RGD.
DR   GO; GO:0060389; P:pathway-restricted SMAD protein phosphorylation; ISS:AgBase.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IMP:RGD.
DR   GO; GO:0051891; P:positive regulation of cardioblast differentiation; ISS:AgBase.
DR   GO; GO:0051795; P:positive regulation of catagen; ISS:AgBase.
DR   GO; GO:0033630; P:positive regulation of cell adhesion mediated by integrin; ISS:AgBase.
DR   GO; GO:0045787; P:positive regulation of cell cycle; ISS:UniProtKB.
DR   GO; GO:0051781; P:positive regulation of cell division; IEA:UniProtKB-KW.
DR   GO; GO:0030307; P:positive regulation of cell growth; ISS:AgBase.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:RGD.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; ISS:AgBase.
DR   GO; GO:0010634; P:positive regulation of epithelial cell migration; ISS:AgBase.
DR   GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; ISS:AgBase.
DR   GO; GO:0045823; P:positive regulation of heart contraction; ISS:AgBase.
DR   GO; GO:0050778; P:positive regulation of immune response; ISS:UniProtKB.
DR   GO; GO:0045726; P:positive regulation of integrin biosynthetic process; ISS:AgBase.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; ISS:AgBase.
DR   GO; GO:0045778; P:positive regulation of ossification; ISS:AgBase.
DR   GO; GO:0010862; P:positive regulation of pathway-restricted SMAD protein phosphorylation; IBA:GO_Central.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; ISS:AgBase.
DR   GO; GO:0050714; P:positive regulation of protein secretion; ISS:AgBase.
DR   GO; GO:0032874; P:positive regulation of stress-activated MAPK cascade; ISS:AgBase.
DR   GO; GO:0006468; P:protein phosphorylation; ISS:AgBase.
DR   GO; GO:0001558; P:regulation of cell growth; TAS:RGD.
DR   GO; GO:0042127; P:regulation of cell proliferation; TAS:RGD.
DR   GO; GO:0043408; P:regulation of MAPK cascade; IBA:GO_Central.
DR   GO; GO:0032909; P:regulation of transforming growth factor beta2 production; ISS:AgBase.
DR   GO; GO:0009409; P:response to cold; IEP:RGD.
DR   GO; GO:0034097; P:response to cytokine; IEP:RGD.
DR   GO; GO:0042493; P:response to drug; IEP:RGD.
DR   GO; GO:0032355; P:response to estradiol; IEP:RGD.
DR   GO; GO:0043627; P:response to estrogen; IDA:RGD.
DR   GO; GO:0001666; P:response to hypoxia; ISS:UniProtKB.
DR   GO; GO:0034616; P:response to laminar fluid shear stress; IEP:RGD.
DR   GO; GO:0010243; P:response to organonitrogen compound; IEP:RGD.
DR   GO; GO:0032570; P:response to progesterone; ISS:AgBase.
DR   GO; GO:0009314; P:response to radiation; IEP:RGD.
DR   GO; GO:0032526; P:response to retinoic acid; IEP:RGD.
DR   GO; GO:0033280; P:response to vitamin D; IEP:RGD.
DR   GO; GO:0009611; P:response to wounding; ISS:AgBase.
DR   GO; GO:0007435; P:salivary gland morphogenesis; ISS:AgBase.
DR   GO; GO:0023014; P:signal transduction by protein phosphorylation; ISS:AgBase.
DR   GO; GO:0007519; P:skeletal muscle tissue development; IEP:RGD.
DR   GO; GO:0007184; P:SMAD protein import into nucleus; ISS:AgBase.
DR   GO; GO:0060395; P:SMAD protein signal transduction; IBA:GO_Central.
DR   GO; GO:0048103; P:somatic stem cell division; ISS:UniProtKB.
DR   GO; GO:0030878; P:thyroid gland development; IEP:RGD.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; ISS:AgBase.
DR   GO; GO:0042060; P:wound healing; ISS:UniProtKB.
DR   Gene3D; 2.10.90.10; -; 1.
DR   InterPro; IPR029034; Cystine-knot_cytokine.
DR   InterPro; IPR001839; TGF-b_C.
DR   InterPro; IPR001111; TGF-b_N.
DR   InterPro; IPR016319; TGF-beta.
DR   InterPro; IPR015615; TGF-beta-rel.
DR   InterPro; IPR003940; TGFb2.
DR   InterPro; IPR017948; TGFb_CS.
DR   PANTHER; PTHR11848; PTHR11848; 3.
DR   PANTHER; PTHR11848:SF141; PTHR11848:SF141; 3.
DR   Pfam; PF00019; TGF_beta; 1.
DR   Pfam; PF00688; TGFb_propeptide; 1.
DR   PIRSF; PIRSF001787; TGF-beta; 1.
DR   PRINTS; PR01423; TGFBETA.
DR   PRINTS; PR01425; TGFBETA2.
DR   SMART; SM00204; TGFB; 1.
DR   SUPFAM; SSF57501; SSF57501; 1.
DR   PROSITE; PS00250; TGF_BETA_1; 1.
DR   PROSITE; PS51362; TGF_BETA_2; 1.
PE   2: Evidence at transcript level;
KW   Alternative splicing; Cleavage on pair of basic residues;
KW   Complete proteome; Disulfide bond; Glycoprotein; Growth factor;
KW   Mitogen; Reference proteome; Secreted; Signal.
FT   SIGNAL        1     20       {ECO:0000255}.
FT   CHAIN        21    330       Latency-associated peptide.
FT                                /FTId=PRO_0000033790.
FT   CHAIN       331    442       Transforming growth factor beta-2.
FT                                /FTId=PRO_0000033791.
FT   CARBOHYD     72     72       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    168    168       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    269    269       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    337    346       {ECO:0000250}.
FT   DISULFID    345    408       {ECO:0000250}.
FT   DISULFID    374    439       {ECO:0000250}.
FT   DISULFID    378    441       {ECO:0000250}.
FT   DISULFID    407    407       Interchain. {ECO:0000250}.
FT   VAR_SEQ     116    143       Missing (in isoform TGF-beta2A).
FT                                {ECO:0000303|PubMed:10899565,
FT                                ECO:0000303|PubMed:11014222,
FT                                ECO:0000303|Ref.3}.
FT                                /FTId=VSP_006418.
FT   VAR_SEQ     144    144       D -> N (in isoform TGF-beta2A).
FT                                {ECO:0000303|PubMed:10899565,
FT                                ECO:0000303|PubMed:11014222,
FT                                ECO:0000303|Ref.3}.
FT                                /FTId=VSP_006419.
FT   CONFLICT     99     99       Y -> C (in Ref. 2; CAB42003).
FT                                {ECO:0000305}.
FT   CONFLICT    310    310       L -> P (in Ref. 3; AAD24484).
FT                                {ECO:0000305}.
FT   CONFLICT    343    343       D -> H (in Ref. 2; CAB42003 and 4;
FT                                CAA50723). {ECO:0000305}.
SQ   SEQUENCE   442 AA;  50534 MW;  69C81A19CE06C253 CRC64;
     MHYCVLRTFL LLHLVPVALS LSTCSTLDMD QFMRKRIEAI RGQILSKLKL TSPPEDYPEP
     DEVPPEVISI YNSTRDLLQE KASRRAAACE RERSDEEYYA KEVYKIDMPS HFPSETVCPV
     VTTSSGSVGS FCSIQSQVLC GYLDAIPPTF YRPYFRIVRF DVSTMEKNAS NLVKAEFRVF
     RLQNPKARVA EQRIELYQIL KSKDLTSPTQ RYIDSKVVKT RAEGEWLSFD VTDAVHEWLH
     HKDRNLGFKI SLHCPCCTFI PSNNYIIPNK SQELEARFAG IDGTSTYASG DQKTIKSTRK
     KSSGKTPHLL LMLLPSYRLE SQQSSRRRKR ALDAAYCFRN VQDNCCLRPL YIDFKRDLGW
     KWIHEPKGYN ANFCAGACPY LWSSDTQHTK VLSLYNTINP EASASPCCVS QDLEPLTILY
     YIGNTPKIEQ LSNMIVKSCK CS
//
ID   PGH2_MOUSE              Reviewed;         604 AA.
AC   Q05769; Q543K3;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 1.
DT   20-JAN-2016, entry version 174.
DE   RecName: Full=Prostaglandin G/H synthase 2;
DE            EC=1.14.99.1;
DE   AltName: Full=Cyclooxygenase-2;
DE            Short=COX-2;
DE   AltName: Full=Glucocorticoid-regulated inflammatory cyclooxygenase;
DE   AltName: Full=Gripghs;
DE   AltName: Full=Macrophage activation-associated marker protein P71/73;
DE   AltName: Full=PES-2;
DE   AltName: Full=PHS II;
DE   AltName: Full=Prostaglandin H2 synthase 2;
DE            Short=PGH synthase 2;
DE            Short=PGHS-2;
DE   AltName: Full=Prostaglandin-endoperoxide synthase 2;
DE   AltName: Full=TIS10 protein;
DE   Flags: Precursor;
GN   Name=Ptgs2; Synonyms=Cox-2, Cox2, Pghs-b, Tis10;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=SWR/J;
RX   PubMed=1712772;
RA   Kujubu D.A., Fletcher B.S., Varnum B.C., Lim R.W., Herschman H.R.;
RT   "TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3
RT   cells, encodes a novel prostaglandin synthase/cyclooxygenase
RT   homologue.";
RL   J. Biol. Chem. 266:12866-12872(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=1339449;
RA   Fletcher B.S., Kujubu D.A., Perrin D.M., Herschman H.R.;
RT   "Structure of the mitogen-inducible TIS10 gene and demonstration that
RT   the TIS10-encoded protein is a functional prostaglandin G/H
RT   synthase.";
RL   J. Biol. Chem. 267:4338-4344(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=1419907;
RA   Ryseck R.-P., Raynoschek C., Macdonald-Bravo H., Dorfman K.,
RA   Mattei M.-G., Bravo R.;
RT   "Identification of an immediate early gene, pghs-B, whose protein
RT   product has prostaglandin synthase/cyclooxygenase activity.";
RL   Cell Growth Differ. 3:443-450(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=1594589; DOI=10.1073/pnas.89.11.4888;
RA   O'Banion M.K., Winn V.D., Young D.A.;
RT   "cDNA cloning and functional activity of a glucocorticoid-regulated
RT   inflammatory cyclooxygenase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:4888-4892(1992).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J, and NOD;
RC   TISSUE=Hippocampus, Mammary gland, and Spleen;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M.,
RA   Davis M.J., Wilming L.G., Aidinis V., Allen J.E.,
RA   Ambesi-Impiombato A., Apweiler R., Aturaliya R.N., Bailey T.L.,
RA   Bansal M., Baxter L., Beisel K.W., Bersano T., Bono H., Chalk A.M.,
RA   Chiu K.P., Choudhary V., Christoffels A., Clutterbuck D.R.,
RA   Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., Della Gatta G.,
RA   di Bernardo D., Down T., Engstrom P., Fagiolini M., Faulkner G.,
RA   Fletcher C.F., Fukushima T., Furuno M., Futaki S., Gariboldi M.,
RA   Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N.,
RA   Hill D., Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T.,
RA   Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H.,
RA   Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K.,
RA   Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J.,
RA   Liuni S., McWilliam S., Madan Babu M., Madera M., Marchionni L.,
RA   Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K.,
RA   Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P.,
RA   Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O.,
RA   Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., Pesole G.,
RA   Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., Ringwald M.,
RA   Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B.,
RA   Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K.,
RA   Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A.,
RA   Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K.,
RA   Yamanishi H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C.,
RA   Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J.,
RA   Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y.,
RA   Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T.,
RA   Iida J., Imamura K., Itoh M., Kato T., Kawaji H., Kawagashira N.,
RA   Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N.,
RA   Nishio T., Okada M., Plessy C., Shibata K., Shiraki T., Suzuki S.,
RA   Tagami M., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J.,
RA   Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Adams M.D., Myers E.W., Smith H.O., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 281-360.
RX   PubMed=1744122;
RA   O'Banion M.K., Sadowski H.B., Winn V., Young D.A.;
RT   "A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a
RT   cyclooxygenase-related protein.";
RL   J. Biol. Chem. 266:23261-23267(1991).
RN   [8]
RP   PARTIAL PROTEIN SEQUENCE.
RX   PubMed=8482922;
RA   Phillips T.A., Kujubu D.A., Mackay R.J., Herschman H.R., Russell S.W.,
RA   Pace J.L.;
RT   "The mouse macrophage activation-associated marker protein, p71/73, is
RT   an inducible prostaglandin endoperoxide synthase (cyclooxygenase).";
RL   J. Leukoc. Biol. 53:411-419(1993).
RN   [9]
RP   GLYCOSYLATION AT ASN-53; ASN-130; ASN-396 AND ASN-580, AND ABSENCE OF
RP   GLYCOSYLATION AT ASN-592.
RX   PubMed=8349699;
RA   Otto J.C., Dewitt D.L., Smith W.L.;
RT   "N-glycosylation of prostaglandin endoperoxide synthases-1 and -2 and
RT   their orientations in the endoplasmic reticulum.";
RL   J. Biol. Chem. 268:18234-18242(1993).
RN   [10]
RP   FUNCTION IN INTESTINAL WOUND REPAIR, TISSUE SPECIFICITY, DEVELOPMENTAL
RP   STAGE, AND DISRUPTION PHENOTYPE.
RX   PubMed=22465430; DOI=10.1053/j.gastro.2012.03.037;
RA   Manieri N.A., Drylewicz M.R., Miyoshi H., Stappenbeck T.S.;
RT   "Igf2bp1 is required for full induction of Ptgs2 mRNA in colonic
RT   mesenchymal stem cells in mice.";
RL   Gastroenterology 143:110-121(2012).
RN   [11]
RP   REVIEW ON FUNCTION; TISSUE SPECIFICITY AND INHIBITION BY NSAIDS.
RX   PubMed=10966456; DOI=10.1146/annurev.biochem.69.1.145;
RA   Smith W.L., DeWitt D.L., Garavito R.M.;
RT   "Cyclooxygenases: structural, cellular, and molecular biology.";
RL   Annu. Rev. Biochem. 69:145-182(2000).
RN   [12]
RP   REVIEW ON FUNCTION; INHIBITION BY ASPIRIN AND INVOLVEMENT IN
RP   COLORECTAL CANCER.
RX   PubMed=24605250; DOI=10.4292/wjgpt.v5.i1.40;
RA   Sostres C., Gargallo C.J., Lanas A.;
RT   "Aspirin, cyclooxygenase inhibition and colorectal cancer.";
RL   World J. Gastrointest. Pharmacol. Ther. 5:40-49(2014).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) IN COMPLEX WITH
RP   (S)-FLURBIPROFEN; INDOMETHACIN; HEME AND
RP   1-PHENYLSULFONAMIDE-3-TRIFLUOROMETHYL-5-PARABROMOPHENYLPYRAZOLE,
RP   COFACTOR, AND GLYCOSYLATION AT ASN-53; ASN-130 AND ASN-396.
RX   PubMed=8967954; DOI=10.1038/384644a0;
RA   Kurumbail R.G., Stevens A.M., Gierse J.K., McDonald J.J.,
RA   Stegeman R.A., Pay J.Y., Gildehaus D., Miyashiro J.M., Penning T.D.,
RA   Seibert K., Isakson P.C., Stallings W.C.;
RT   "Structural basis for selective inhibition of cyclooxygenase-2 by
RT   anti-inflammatory agents.";
RL   Nature 384:644-648(1996).
RN   [14]
RP   ERRATUM.
RA   Kurumbail R.G., Stevens A.M., Gierse J.K., McDonald J.J.,
RA   Stegeman R.A., Pay J.Y., Gildehaus D., Miyashiro J.M., Penning T.D.,
RA   Seibert K., Isakson P.C., Stallings W.C.;
RL   Nature 385:555-555(1997).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 18-569 IN COMPLEX WITH
RP   ARACHIDONIC ACID, AND GLYCOSYLATION AT ASN-53; ASN-130 AND ASN-396.
RX   PubMed=10811226; DOI=10.1038/35011103;
RA   Kiefer J.R., Pawlitz J.L., Moreland K.T., Stegeman R.A., Hood W.F.,
RA   Gierse J.K., Stevens A.M., Goodwin D.C., Rowlinson S.W., Marnett L.J.,
RA   Stallings W.C., Kurumbail R.G.;
RT   "Structural insights into the stereochemistry of the cyclooxygenase
RT   reaction.";
RL   Nature 405:97-101(2000).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) IN COMPLEX WITH HEME AND
RP   DICLOFENAC, CATALYTIC ACTIVITY, FUNCTION, COFACTOR, DISULFIDE BONDS,
RP   ENZYME REGULATION, AND GLYCOSYLATION AT ASN-53; ASN-130 AND ASN-396.
RX   PubMed=12925531; DOI=10.1074/jbc.M305481200;
RA   Rowlinson S.W., Kiefer J.R., Prusakiewicz J.J., Pawlitz J.L.,
RA   Kozak K.R., Kalgutkar A.S., Stallings W.C., Kurumbail R.G.,
RA   Marnett L.J.;
RT   "A novel mechanism of cyclooxygenase-2 inhibition involving
RT   interactions with Ser-530 and Tyr-385.";
RL   J. Biol. Chem. 278:45763-45769(2003).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 20-604 IN COMPLEX WITH HEME;
RP   ACRYLIC ACID; ARACHIDONIC ACID AND DOCOSAHEXAENOIC ACID, CATALYTIC
RP   ACTIVITY, ACTIVE SITE, SUBUNIT, COFACTOR, FUNCTION, DISULFIDE BONDS,
RP   MUTAGENESIS OF LEU-517 AND ASN-580, AND GLYCOSYLATION AT ASN-53;
RP   ASN-130; ASN-396 AND ASN-580.
RX   PubMed=20463020; DOI=10.1074/jbc.M110.119867;
RA   Vecchio A.J., Simmons D.M., Malkowski M.G.;
RT   "Structural basis of fatty acid substrate binding to cyclooxygenase-
RT   2.";
RL   J. Biol. Chem. 285:22152-22163(2010).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (1.73 ANGSTROMS) OF 18-604 IN COMPLEXES WITH
RP   HEME AND NAPROXEN ANALOGS, FUNCTION, CATALYTIC ACTIVITY, ENZYME
RP   REGULATION, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-53; ASN-130 AND
RP   ASN-396.
RX   PubMed=20810665; DOI=10.1074/jbc.M110.162982;
RA   Duggan K.C., Walters M.J., Musee J., Harp J.M., Kiefer J.R.,
RA   Oates J.A., Marnett L.J.;
RT   "Molecular basis for cyclooxygenase inhibition by the non-steroidal
RT   anti-inflammatory drug naproxen.";
RL   J. Biol. Chem. 285:34950-34959(2010).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 20-599 IN COMPLEX WITH HEME;
RP   ACRYLIC ACID AND ARACHIDONIC ACID, FUNCTION, CATALYTIC ACTIVITY, AND
RP   GLYCOSYLATION AT ASN-53; ASN-130 AND ASN-396.
RX   PubMed=21489986; DOI=10.1074/jbc.M111.230367;
RA   Vecchio A.J., Malkowski M.G.;
RT   "The structural basis of endocannabinoid oxygenation by
RT   cyclooxygenase-2.";
RL   J. Biol. Chem. 286:20736-20745(2011).
CC   -!- FUNCTION: Converts arachidonate to prostaglandin H2 (PGH2), a
CC       committed step in prostanoid synthesis. Constitutively expressed
CC       in some tissues in physiological conditions, such as the
CC       endothelium, kidney and brain, and in pathological conditions,
CC       such as in cancer. PTGS2 is responsible for production of
CC       inflammatory prostaglandins. Up-regulation of PTGS2 is also
CC       associated with increased cell adhesion, phenotypic changes,
CC       resistance to apoptosis and tumor angiogenesis. In cancer cells,
CC       PTGS2 is a key step in the production of prostaglandin E2 (PGE2),
CC       which plays important roles in modulating motility, proliferation
CC       and resistance to apoptosis. {ECO:0000269|PubMed:12925531,
CC       ECO:0000269|PubMed:20463020, ECO:0000269|PubMed:20810665,
CC       ECO:0000269|PubMed:21489986, ECO:0000269|PubMed:22465430}.
CC   -!- CATALYTIC ACTIVITY: Arachidonate + AH(2) + 2 O(2) = prostaglandin
CC       H(2) + A + H(2)O. {ECO:0000269|PubMed:12925531,
CC       ECO:0000269|PubMed:20463020, ECO:0000269|PubMed:20810665,
CC       ECO:0000269|PubMed:21489986}.
CC   -!- COFACTOR:
CC       Name=heme b; Xref=ChEBI:CHEBI:60344;
CC         Evidence={ECO:0000269|PubMed:12925531,
CC         ECO:0000269|PubMed:20463020, ECO:0000269|PubMed:8967954};
CC       Note=Binds 1 heme b (iron(II)-protoporphyrin IX) group per
CC       subunit. {ECO:0000269|PubMed:12925531,
CC       ECO:0000269|PubMed:20463020, ECO:0000269|PubMed:8967954};
CC   -!- ENZYME REGULATION: Inhibited by the nonsteroidal anti-inflammatory
CC       drugs aspirin, naproxen, diclofenac, meclofenamic acid,
CC       indomethacin and their analogs. {ECO:0000269|PubMed:12925531,
CC       ECO:0000269|PubMed:20810665}.
CC   -!- PATHWAY: Lipid metabolism; prostaglandin biosynthesis.
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:10811226,
CC       ECO:0000269|PubMed:12925531, ECO:0000269|PubMed:20463020,
CC       ECO:0000269|PubMed:21489986, ECO:0000269|PubMed:8967954}.
CC   -!- SUBCELLULAR LOCATION: Microsome membrane; Peripheral membrane
CC       protein. Endoplasmic reticulum membrane; Peripheral membrane
CC       protein.
CC   -!- TISSUE SPECIFICITY: Following colon injury, expressed in the wound
CC       bed mesenchyme during the first phase of repair, probably by
CC       colonic mesenchymal stem cells (at protein level).
CC       {ECO:0000269|PubMed:22465430}.
CC   -!- DEVELOPMENTAL STAGE: During colonic wound repair, highly up-
CC       regulated (more than 1600-fold) in the mesenchyme of the wound bed
CC       2 days after injury as compared to uninjured mucosa. Further
CC       increase in expression is observed at day 4 following injury
CC       (close to 2200-fold). Down-regulated at day 6 (only 93-fold
CC       increase as compared to uninjured mucosa).
CC       {ECO:0000269|PubMed:22465430}.
CC   -!- INDUCTION: By cytokines and mitogens.
CC   -!- PTM: S-nitrosylation by NOS2 (iNOS) activates enzyme activity. S-
CC       nitrosylation may take place on different Cys residues in addition
CC       to Cys-526 (By similarity). {ECO:0000250}.
CC   -!- DISRUPTION PHENOTYPE: Mutant mice exhibit defects in colonic
CC       mucosal wound repair. {ECO:0000269|PubMed:22465430}.
CC   -!- MISCELLANEOUS: The conversion of arachidonate to prostaglandin H2
CC       is a 2 step reaction: a cyclooxygenase (COX) reaction which
CC       converts arachidonate to prostaglandin G2 (PGG2) and a peroxidase
CC       reaction in which PGG2 is reduced to prostaglandin H2 (PGH2). The
CC       cyclooxygenase reaction occurs in a hydrophobic channel in the
CC       core of the enzyme. The peroxidase reaction occurs at a heme-
CC       containing active site located near the protein surface. The
CC       nonsteroidal anti-inflammatory drugs (NSAIDs) binding site
CC       corresponds to the cyclooxygenase active site.
CC   -!- MISCELLANEOUS: Conversion of arachidonate to prostaglandin H2 is
CC       mediated by 2 different isozymes: the constitutive PTGS1 and the
CC       inducible PTGS2. PGHS1 is expressed constitutively and generally
CC       produces prostanoids acutely in response to hormonal stimuli to
CC       fine-tune physiological processes requiring instantaneous,
CC       continuous regulation (e.g. hemostasis). PGHS2 is inducible and
CC       typically produces prostanoids that mediate responses to
CC       physiological stresses such as infection and inflammation.
CC   -!- MISCELLANEOUS: PTGS1 and PTGS2 are the targets of nonsteroidal
CC       anti-inflammatory drugs (NSAIDs) including aspirin and ibuprofen.
CC       Aspirin is able to produce an irreversible inactivation of the
CC       enzyme through a serine acetylation. Inhibition of the PGHSs with
CC       NSAIDs acutely reduces inflammation, pain, and fever, and long-
CC       term use of these drugs reduces fatal thrombotic events, as well
CC       as the development of colon cancer and Alzheimer's disease. PTGS2
CC       is the principal isozyme responsible for production of
CC       inflammatory prostaglandins. New generation PTGSs inhibitors
CC       strive to be selective for PTGS2, to avoid side effects such as
CC       gastrointestinal complications and ulceration.
CC   -!- SIMILARITY: Belongs to the prostaglandin G/H synthase family.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 EGF-like domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00076}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M64291; AAA39924.1; -; mRNA.
DR   EMBL; M94967; AAA39918.1; -; mRNA.
DR   EMBL; M82866; AAA40448.1; -; Genomic_DNA.
DR   EMBL; M82862; AAA40448.1; JOINED; Genomic_DNA.
DR   EMBL; M82863; AAA40448.1; JOINED; Genomic_DNA.
DR   EMBL; M82864; AAA40448.1; JOINED; Genomic_DNA.
DR   EMBL; M82865; AAA40448.1; JOINED; Genomic_DNA.
DR   EMBL; M88242; AAA37740.1; -; mRNA.
DR   EMBL; AK049923; BAC33986.1; -; mRNA.
DR   EMBL; AK144956; BAE26154.1; -; mRNA.
DR   EMBL; AK166221; BAE38639.1; -; mRNA.
DR   EMBL; AK172161; BAE42855.1; -; mRNA.
DR   EMBL; CH466520; EDL39487.1; -; Genomic_DNA.
DR   CCDS; CCDS15353.1; -.
DR   PIR; A49010; A49010.
DR   RefSeq; NP_035328.2; NM_011198.4.
DR   UniGene; Mm.292547; -.
DR   PDB; 1CVU; X-ray; 2.40 A; A/B=18-569.
DR   PDB; 1CX2; X-ray; 3.00 A; A/B/C/D=18-604.
DR   PDB; 1DCX; Model; -; A/B=18-569.
DR   PDB; 1DD0; Model; -; A/B=18-569.
DR   PDB; 1DDX; X-ray; 3.00 A; A/B/C/D=18-569.
DR   PDB; 1PXX; X-ray; 2.90 A; A/B/C/D=1-604.
DR   PDB; 3HS5; X-ray; 2.10 A; A/B=20-604.
DR   PDB; 3HS6; X-ray; 2.40 A; A/B=20-604.
DR   PDB; 3HS7; X-ray; 2.65 A; A/B=20-604.
DR   PDB; 3KRK; X-ray; 2.40 A; A/B=20-604.
DR   PDB; 3LN0; X-ray; 2.20 A; A/B/C/D=18-604.
DR   PDB; 3LN1; X-ray; 2.40 A; A/B/C/D=18-604.
DR   PDB; 3MDL; X-ray; 2.20 A; A/B=20-599.
DR   PDB; 3MQE; X-ray; 2.80 A; A/B/C/D=18-604.
DR   PDB; 3NT1; X-ray; 1.73 A; A/B=18-604.
DR   PDB; 3NTB; X-ray; 2.27 A; A/B/C/D=18-604.
DR   PDB; 3NTG; X-ray; 2.19 A; A/B/C/D=18-569.
DR   PDB; 3OLT; X-ray; 2.45 A; A/B=20-604.
DR   PDB; 3OLU; X-ray; 2.35 A; A/B=20-604.
DR   PDB; 3PGH; X-ray; 2.50 A; A/B/C/D=18-604.
DR   PDB; 3Q7D; X-ray; 2.40 A; A/B=18-604.
DR   PDB; 3QH0; X-ray; 2.10 A; A/B=1-604.
DR   PDB; 3QMO; X-ray; 3.00 A; A/B=1-604.
DR   PDB; 3RR3; X-ray; 2.84 A; A/B/C/D=18-577.
DR   PDB; 3TZI; X-ray; 2.15 A; A/B=20-604.
DR   PDB; 4COX; X-ray; 2.90 A; A/B/C/D=18-604.
DR   PDB; 4E1G; X-ray; 2.10 A; A/B=1-604.
DR   PDB; 4FM5; X-ray; 2.81 A; A/B/C/D=1-604.
DR   PDB; 4M10; X-ray; 2.01 A; A/B/C/D=18-604.
DR   PDB; 4M11; X-ray; 2.45 A; A/B/C/D=18-569.
DR   PDB; 4OTJ; X-ray; 2.11 A; A/B/C/D=18-604.
DR   PDB; 4OTY; X-ray; 2.35 A; A/B=18-604.
DR   PDB; 4PH9; X-ray; 1.81 A; A/B=20-568.
DR   PDB; 4RRW; X-ray; 2.57 A; A/B/C/D=18-604.
DR   PDB; 4RRX; X-ray; 2.78 A; A/B=18-604.
DR   PDB; 4RRY; X-ray; 2.43 A; A/B/C/D=18-604.
DR   PDB; 4RRZ; X-ray; 2.57 A; A/B/C/D=18-604.
DR   PDB; 4RS0; X-ray; 2.81 A; A=18-604.
DR   PDB; 4RUT; X-ray; 2.16 A; A/B/C/D=18-604.
DR   PDB; 4Z0L; X-ray; 2.29 A; A/B/C/D=18-604.
DR   PDB; 5COX; X-ray; 3.00 A; A/B/C/D=18-604.
DR   PDB; 6COX; X-ray; 2.80 A; A/B=18-604.
DR   PDBsum; 1CVU; -.
DR   PDBsum; 1CX2; -.
DR   PDBsum; 1DCX; -.
DR   PDBsum; 1DD0; -.
DR   PDBsum; 1DDX; -.
DR   PDBsum; 1PXX; -.
DR   PDBsum; 3HS5; -.
DR   PDBsum; 3HS6; -.
DR   PDBsum; 3HS7; -.
DR   PDBsum; 3KRK; -.
DR   PDBsum; 3LN0; -.
DR   PDBsum; 3LN1; -.
DR   PDBsum; 3MDL; -.
DR   PDBsum; 3MQE; -.
DR   PDBsum; 3NT1; -.
DR   PDBsum; 3NTB; -.
DR   PDBsum; 3NTG; -.
DR   PDBsum; 3OLT; -.
DR   PDBsum; 3OLU; -.
DR   PDBsum; 3PGH; -.
DR   PDBsum; 3Q7D; -.
DR   PDBsum; 3QH0; -.
DR   PDBsum; 3QMO; -.
DR   PDBsum; 3RR3; -.
DR   PDBsum; 3TZI; -.
DR   PDBsum; 4COX; -.
DR   PDBsum; 4E1G; -.
DR   PDBsum; 4FM5; -.
DR   PDBsum; 4M10; -.
DR   PDBsum; 4M11; -.
DR   PDBsum; 4OTJ; -.
DR   PDBsum; 4OTY; -.
DR   PDBsum; 4PH9; -.
DR   PDBsum; 4RRW; -.
DR   PDBsum; 4RRX; -.
DR   PDBsum; 4RRY; -.
DR   PDBsum; 4RRZ; -.
DR   PDBsum; 4RS0; -.
DR   PDBsum; 4RUT; -.
DR   PDBsum; 4Z0L; -.
DR   PDBsum; 5COX; -.
DR   PDBsum; 6COX; -.
DR   ProteinModelPortal; Q05769; -.
DR   SMR; Q05769; 18-569.
DR   BioGrid; 202463; 5.
DR   DIP; DIP-31082N; -.
DR   IntAct; Q05769; 1.
DR   STRING; 10090.ENSMUSP00000035065; -.
DR   BindingDB; Q05769; -.
DR   ChEMBL; CHEMBL4321; -.
DR   SwissLipids; SLP:000001129; -.
DR   PeroxiBase; 3360; MmPGHS02.
DR   iPTMnet; Q05769; -.
DR   PhosphoSite; Q05769; -.
DR   UniCarbKB; Q05769; -.
DR   MaxQB; Q05769; -.
DR   PaxDb; Q05769; -.
DR   PRIDE; Q05769; -.
DR   Ensembl; ENSMUST00000035065; ENSMUSP00000035065; ENSMUSG00000032487.
DR   GeneID; 19225; -.
DR   KEGG; mmu:19225; -.
DR   UCSC; uc007cxv.1; mouse.
DR   CTD; 5743; -.
DR   MGI; MGI:97798; Ptgs2.
DR   eggNOG; KOG2408; Eukaryota.
DR   eggNOG; ENOG410XPZ3; LUCA.
DR   GeneTree; ENSGT00390000010743; -.
DR   HOGENOM; HOG000013149; -.
DR   HOVERGEN; HBG000366; -.
DR   InParanoid; Q05769; -.
DR   KO; K11987; -.
DR   OMA; CNNVKGC; -.
DR   OrthoDB; EOG7RFTHC; -.
DR   PhylomeDB; Q05769; -.
DR   TreeFam; TF329675; -.
DR   BRENDA; 1.14.99.1; 3474.
DR   Reactome; R-MMU-197264; Nicotinamide salvaging.
DR   Reactome; R-MMU-2142770; Synthesis of 15-eicosatetraenoic acid derivatives.
DR   Reactome; R-MMU-2162123; Synthesis of Prostaglandins (PG) and Thromboxanes (TX).
DR   UniPathway; UPA00662; -.
DR   EvolutionaryTrace; Q05769; -.
DR   NextBio; 296012; -.
DR   PRO; PR:Q05769; -.
DR   Proteomes; UP000000589; Chromosome 1.
DR   Bgee; Q05769; -.
DR   CleanEx; MM_PTGS2; -.
DR   ExpressionAtlas; Q05769; baseline and differential.
DR   Genevisible; Q05769; MM.
DR   GO; GO:0005901; C:caveola; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:MGI.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISO:MGI.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0043005; C:neuron projection; IDA:MGI.
DR   GO; GO:0043234; C:protein complex; IEA:Ensembl.
DR   GO; GO:0019899; F:enzyme binding; ISO:MGI.
DR   GO; GO:0020037; F:heme binding; IDA:UniProtKB.
DR   GO; GO:0008289; F:lipid binding; IEA:Ensembl.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0016702; F:oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen; IEA:Ensembl.
DR   GO; GO:0004601; F:peroxidase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004666; F:prostaglandin-endoperoxide synthase activity; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0001525; P:angiogenesis; IEA:Ensembl.
DR   GO; GO:0030282; P:bone mineralization; ISO:MGI.
DR   GO; GO:0050873; P:brown fat cell differentiation; IMP:BHF-UCL.
DR   GO; GO:0071318; P:cellular response to ATP; IEA:Ensembl.
DR   GO; GO:0071498; P:cellular response to fluid shear stress; IDA:MGI.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEA:Ensembl.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEA:Ensembl.
DR   GO; GO:0034644; P:cellular response to UV; IEA:Ensembl.
DR   GO; GO:0019371; P:cyclooxygenase pathway; IDA:UniProtKB.
DR   GO; GO:0046697; P:decidualization; IMP:MGI.
DR   GO; GO:0007566; P:embryo implantation; IMP:MGI.
DR   GO; GO:0042633; P:hair cycle; IEA:Ensembl.
DR   GO; GO:0006954; P:inflammatory response; IEA:Ensembl.
DR   GO; GO:0030216; P:keratinocyte differentiation; NAS:UniProtKB.
DR   GO; GO:0007612; P:learning; IEA:Ensembl.
DR   GO; GO:0035633; P:maintenance of blood-brain barrier; IEA:Ensembl.
DR   GO; GO:0007613; P:memory; IEA:Ensembl.
DR   GO; GO:0051926; P:negative regulation of calcium ion transport; IEA:Ensembl.
DR   GO; GO:0045786; P:negative regulation of cell cycle; IEA:Ensembl.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0045986; P:negative regulation of smooth muscle contraction; IEA:Ensembl.
DR   GO; GO:0032227; P:negative regulation of synaptic transmission, dopaminergic; IEA:Ensembl.
DR   GO; GO:0030728; P:ovulation; IEA:Ensembl.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0090336; P:positive regulation of brown fat cell differentiation; IMP:BHF-UCL.
DR   GO; GO:0090050; P:positive regulation of cell migration involved in sprouting angiogenesis; IEA:Ensembl.
DR   GO; GO:0031622; P:positive regulation of fever generation; IDA:BHF-UCL.
DR   GO; GO:0090271; P:positive regulation of fibroblast growth factor production; IEA:Ensembl.
DR   GO; GO:0042346; P:positive regulation of NF-kappaB import into nucleus; IEA:Ensembl.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IEA:Ensembl.
DR   GO; GO:0090362; P:positive regulation of platelet-derived growth factor production; IEA:Ensembl.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0045987; P:positive regulation of smooth muscle contraction; IEA:Ensembl.
DR   GO; GO:0031915; P:positive regulation of synaptic plasticity; IEA:Ensembl.
DR   GO; GO:0051968; P:positive regulation of synaptic transmission, glutamatergic; IEA:Ensembl.
DR   GO; GO:0071636; P:positive regulation of transforming growth factor beta production; IEA:Ensembl.
DR   GO; GO:0010575; P:positive regulation of vascular endothelial growth factor production; IEA:Ensembl.
DR   GO; GO:0045907; P:positive regulation of vasoconstriction; IEA:Ensembl.
DR   GO; GO:0001516; P:prostaglandin biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0008217; P:regulation of blood pressure; IMP:MGI.
DR   GO; GO:0042127; P:regulation of cell proliferation; IGI:MGI.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:0070542; P:response to fatty acid; IEA:Ensembl.
DR   GO; GO:0009750; P:response to fructose; IEA:Ensembl.
DR   GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0010226; P:response to lithium ion; IEA:Ensembl.
DR   GO; GO:0010042; P:response to manganese ion; IEA:Ensembl.
DR   GO; GO:0006979; P:response to oxidative stress; IEA:InterPro.
DR   GO; GO:0034612; P:response to tumor necrosis factor; IEA:Ensembl.
DR   GO; GO:0033280; P:response to vitamin D; IEA:Ensembl.
DR   GO; GO:0019233; P:sensory perception of pain; IEA:Ensembl.
DR   Gene3D; 1.10.640.10; -; 1.
DR   InterPro; IPR029576; COX-2.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR010255; Haem_peroxidase.
DR   InterPro; IPR019791; Haem_peroxidase_animal.
DR   PANTHER; PTHR11903:SF8; PTHR11903:SF8; 1.
DR   Pfam; PF03098; An_peroxidase; 1.
DR   Pfam; PF00008; EGF; 1.
DR   PRINTS; PR00457; ANPEROXIDASE.
DR   SMART; SM00181; EGF; 1.
DR   SUPFAM; SSF48113; SSF48113; 1.
DR   PROSITE; PS50026; EGF_3; 1.
DR   PROSITE; PS50292; PEROXIDASE_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Dioxygenase;
KW   Direct protein sequencing; Disulfide bond; Endoplasmic reticulum;
KW   Fatty acid biosynthesis; Fatty acid metabolism; Glycoprotein; Heme;
KW   Iron; Lipid biosynthesis; Lipid metabolism; Membrane; Metal-binding;
KW   Microsome; Oxidoreductase; Peroxidase; Prostaglandin biosynthesis;
KW   Prostaglandin metabolism; Reference proteome; S-nitrosylation; Signal.
FT   SIGNAL        1     17
FT   CHAIN        18    604       Prostaglandin G/H synthase 2.
FT                                /FTId=PRO_0000023876.
FT   DOMAIN       18     55       EGF-like. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   ACT_SITE    193    193       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00298,
FT                                ECO:0000269|PubMed:20463020}.
FT   ACT_SITE    371    371       For cyclooxygenase activity.
FT                                {ECO:0000269|PubMed:20463020}.
FT   METAL       374    374       Iron (heme axial ligand).
FT   BINDING     106    106       Substrate.
FT   BINDING     341    341       Substrate.
FT   BINDING     371    371       Substrate.
FT   SITE        516    516       Aspirin-acetylated serine.
FT   SITE        592    592       Not glycosylated.
FT   CARBOHYD     53     53       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:10811226,
FT                                ECO:0000269|PubMed:12925531,
FT                                ECO:0000269|PubMed:20463020,
FT                                ECO:0000269|PubMed:20810665,
FT                                ECO:0000269|PubMed:21489986,
FT                                ECO:0000269|PubMed:8349699,
FT                                ECO:0000269|PubMed:8967954}.
FT                                /FTId=CAR_000222.
FT   CARBOHYD    130    130       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:10811226,
FT                                ECO:0000269|PubMed:12925531,
FT                                ECO:0000269|PubMed:20463020,
FT                                ECO:0000269|PubMed:20810665,
FT                                ECO:0000269|PubMed:21489986,
FT                                ECO:0000269|PubMed:8349699,
FT                                ECO:0000269|PubMed:8967954}.
FT                                /FTId=CAR_000223.
FT   CARBOHYD    396    396       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:10811226,
FT                                ECO:0000269|PubMed:12925531,
FT                                ECO:0000269|PubMed:20463020,
FT                                ECO:0000269|PubMed:20810665,
FT                                ECO:0000269|PubMed:21489986,
FT                                ECO:0000269|PubMed:8349699,
FT                                ECO:0000269|PubMed:8967954}.
FT                                /FTId=CAR_000224.
FT   CARBOHYD    580    580       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:20463020,
FT                                ECO:0000269|PubMed:8349699}.
FT                                /FTId=CAR_000225.
FT   DISULFID     21     32
FT   DISULFID     22    145
FT   DISULFID     26     42
FT   DISULFID     44     54
FT   DISULFID    555    561
FT   MUTAGEN     517    517       L->A,F,P,T: Slightly reduced activity.
FT                                {ECO:0000269|PubMed:20463020}.
FT   MUTAGEN     580    580       N->A: Loss of glycosylation site.
FT                                {ECO:0000269|PubMed:20463020}.
FT   CONFLICT     98     98       I -> T (in Ref. 1; AAA39924).
FT                                {ECO:0000305}.
FT   CONFLICT    142    142       A -> R (in Ref. 3; AAA39918).
FT                                {ECO:0000305}.
FT   CONFLICT    301    301       I -> L (in Ref. 7; no nucleotide entry).
FT                                {ECO:0000305}.
FT   CONFLICT    585    585       H -> R (in Ref. 3; AAA39918).
FT                                {ECO:0000305}.
FT   TURN         20     23       {ECO:0000244|PDB:3NT1}.
FT   HELIX        27     29       {ECO:0000244|PDB:6COX}.
FT   STRAND       31     36       {ECO:0000244|PDB:3NT1}.
FT   STRAND       39     43       {ECO:0000244|PDB:3NT1}.
FT   STRAND       47     50       {ECO:0000244|PDB:3NT1}.
FT   TURN         51     54       {ECO:0000244|PDB:3NT1}.
FT   HELIX        59     67       {ECO:0000244|PDB:3NT1}.
FT   HELIX        71     78       {ECO:0000244|PDB:3NT1}.
FT   HELIX        82     89       {ECO:0000244|PDB:3NT1}.
FT   HELIX        92    107       {ECO:0000244|PDB:3NT1}.
FT   STRAND      116    119       {ECO:0000244|PDB:4RRX}.
FT   STRAND      120    122       {ECO:0000244|PDB:3NT1}.
FT   HELIX       125    129       {ECO:0000244|PDB:3NT1}.
FT   STRAND      131    133       {ECO:0000244|PDB:1DDX}.
FT   STRAND      135    138       {ECO:0000244|PDB:3NT1}.
FT   STRAND      145    147       {ECO:0000244|PDB:1DDX}.
FT   STRAND      150    153       {ECO:0000244|PDB:3NT1}.
FT   HELIX       160    167       {ECO:0000244|PDB:3NT1}.
FT   HELIX       182    192       {ECO:0000244|PDB:3NT1}.
FT   TURN        193    195       {ECO:0000244|PDB:3NT1}.
FT   TURN        200    202       {ECO:0000244|PDB:3NT1}.
FT   STRAND      206    208       {ECO:0000244|PDB:3NT1}.
FT   STRAND      213    215       {ECO:0000244|PDB:4PH9}.
FT   HELIX       217    220       {ECO:0000244|PDB:3NT1}.
FT   HELIX       224    230       {ECO:0000244|PDB:3NT1}.
FT   STRAND      241    243       {ECO:0000244|PDB:3NT1}.
FT   STRAND      246    248       {ECO:0000244|PDB:3NT1}.
FT   HELIX       252    255       {ECO:0000244|PDB:3NT1}.
FT   STRAND      263    265       {ECO:0000244|PDB:6COX}.
FT   HELIX       267    269       {ECO:0000244|PDB:3NT1}.
FT   TURN        276    279       {ECO:0000244|PDB:3NT1}.
FT   HELIX       282    305       {ECO:0000244|PDB:3NT1}.
FT   HELIX       311    332       {ECO:0000244|PDB:3NT1}.
FT   HELIX       334    339       {ECO:0000244|PDB:3NT1}.
FT   HELIX       349    352       {ECO:0000244|PDB:3NT1}.
FT   HELIX       365    370       {ECO:0000244|PDB:3NT1}.
FT   HELIX       374    376       {ECO:0000244|PDB:3NT1}.
FT   STRAND      379    383       {ECO:0000244|PDB:3NT1}.
FT   STRAND      386    388       {ECO:0000244|PDB:3NT1}.
FT   HELIX       390    393       {ECO:0000244|PDB:3NT1}.
FT   HELIX       398    414       {ECO:0000244|PDB:3NT1}.
FT   STRAND      420    424       {ECO:0000244|PDB:3NT1}.
FT   HELIX       428    430       {ECO:0000244|PDB:3NT1}.
FT   HELIX       431    443       {ECO:0000244|PDB:3NT1}.
FT   HELIX       449    455       {ECO:0000244|PDB:3NT1}.
FT   HELIX       464    468       {ECO:0000244|PDB:3NT1}.
FT   STRAND      469    471       {ECO:0000244|PDB:3NT1}.
FT   HELIX       472    481       {ECO:0000244|PDB:3NT1}.
FT   HELIX       484    486       {ECO:0000244|PDB:3NT1}.
FT   HELIX       489    495       {ECO:0000244|PDB:3NT1}.
FT   STRAND      503    505       {ECO:0000244|PDB:4PH9}.
FT   HELIX       506    521       {ECO:0000244|PDB:3NT1}.
FT   HELIX       524    526       {ECO:0000244|PDB:3NT1}.
FT   TURN        528    530       {ECO:0000244|PDB:3NT1}.
FT   HELIX       533    536       {ECO:0000244|PDB:3NT1}.
FT   HELIX       539    546       {ECO:0000244|PDB:3NT1}.
FT   HELIX       550    557       {ECO:0000244|PDB:3NT1}.
FT   STRAND      558    560       {ECO:0000244|PDB:3Q7D}.
SQ   SEQUENCE   604 AA;  69013 MW;  DFE1658295C92064 CRC64;
     MLFRAVLLCA ALGLSQAANP CCSNPCQNRG ECMSTGFDQY KCDCTRTGFY GENCTTPEFL
     TRIKLLLKPT PNTVHYILTH FKGVWNIVNN IPFLRSLIMK YVLTSRSYLI DSPPTYNVHY
     GYKSWEAFSN LSYYTRALPP VADDCPTPMG VKGNKELPDS KEVLEKVLLR REFIPDPQGS
     NMMFAFFAQH FTHQFFKTDH KRGPGFTRGL GHGVDLNHIY GETLDRQHKL RLFKDGKLKY
     QVIGGEVYPP TVKDTQVEMI YPPHIPENLQ FAVGQEVFGL VPGLMMYATI WLREHNRVCD
     ILKQEHPEWG DEQLFQTSRL ILIGETIKIV IEDYVQHLSG YHFKLKFDPE LLFNQQFQYQ
     NRIASEFNTL YHWHPLLPDT FNIEDQEYSF KQFLYNNSIL LEHGLTQFVE SFTRQIAGRV
     AGGRNVPIAV QAVAKASIDQ SREMKYQSLN EYRKRFSLKP YTSFEELTGE KEMAAELKAL
     YSDIDVMELY PALLVEKPRP DAIFGETMVE LGAPFSLKGL MGNPICSPQY WKPSTFGGEV
     GFKIINTASI QSLICNNVKG CPFTSFNVQD PQPTKTATIN ASASHSRLDD INPTVLIKRR
     STEL
//